PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	deCock, H; vanBlokland, S; Tommassen, J				deCock, H; vanBlokland, S; Tommassen, J			In vitro insertion and assembly of outer membrane protein PhoE of Escherichia coli K-12 into the outer membrane - Role of Triton X-100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMPF PORIN; INVITRO TRIMERIZATION; LIPOPOLYSACCHARIDE; ARCHITECTURE; PARTICLES; FUSION; GENE	The assembly of the in vitro synthesized outer membrane protein PhoE into purified outer membranes was investigated, The assembly appeared to be strongly stimulated by the presence of low amounts of Triton X-100 (optimal 0.08%, w/v). The role of Triton X-100 in the in vitro system was further examined. Pretreating outer membranes with Triton X-100 did not make the membranes competent for correct assembly, indicating that the detergent did not act on the membrane but at the protein level. PhoE became assembly-incompetent with a half-life of approximately 12 min and 90 s at 37 degrees C in the absence and presence, respectively, of 0.08% Triton X-100, Apparently, Triton X-100 induces an assembly-competent state in the PhoE protein with a very short half-life. Furthermore, the efficiency of correct assembly of PhoE was greatly reduced when outer membranes of deep rough lipopolysaccharide mutants were used, indicating an important role of lipopolysaccharides in the assembly of the porin.	UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS	Utrecht University	deCock, H (corresponding author), UNIV UTRECHT,BIOMEMBRANE INST,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.		de Cock, Hans/B-7790-2011; Tommassen, Jan/I-1690-2016	de Cock, Hans/0000-0002-8420-6764; Tommassen, Jan/0000-0001-7633-4945				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BOLLA JM, 1988, EMBO J, V7, P3595, DOI 10.1002/j.1460-2075.1988.tb03237.x; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DECOCK H, 1989, BIOCHIM BIOPHYS ACTA, V985, P313, DOI 10.1016/0005-2736(89)90418-5; DECOCK H, 1990, J BIOL CHEM, V265, P4646; DECOCK H, 1990, BIOCHIMIE, V72, P177, DOI 10.1016/0300-9084(90)90143-5; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DIEDRICH DL, 1990, J BACTERIOL, V172, P5307, DOI 10.1128/jb.172.9.5307-5311.1990; DIRIENZO JM, 1979, CELL, V17, P155, DOI 10.1016/0092-8674(79)90303-9; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; LAIRD MW, 1994, J BACTERIOL, V176, P2259, DOI 10.1128/JB.176.8.2259-2264.1994; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAGES JM, 1988, EUR J BIOCHEM, V176, P655, DOI 10.1111/j.1432-1033.1988.tb14327.x; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RIED J, 1988, J MOL BIOL, V263, P7753; SEN K, 1991, J BIOL CHEM, V266, P11295; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; TOMMASSEN J, 1984, J BACTERIOL, V157, P327, DOI 10.1128/JB.157.1.327-329.1984; TOMMASSEN J, 1981, J BACTERIOL, V147, P118, DOI 10.1128/JB.147.1.118-123.1981; VANALPHEN L, 1978, J BACTERIOL, V134, P1089, DOI 10.1128/JB.134.3.1089-1098.1978; VANALPHEN L, 1979, BIOCHIM BIOPHYS ACTA, V556, P233, DOI 10.1016/0005-2736(79)90045-2; VANALPHEN L, 1985, EUR J BIOCHEM, V147, P401; VANDERLEY P, 1986, J BACTERIOL, V168, P449, DOI 10.1128/jb.168.1.449-451.1986; VANDERLEY P, 1985, EUR J BIOCHEM, V147, P401; VANGELDER P, 1994, EUR J BIOCHEM, V226, P783; VERKLEIJ A, 1977, BIOCHIM BIOPHYS ACTA, V466, P269, DOI 10.1016/0005-2736(77)90224-3; VERKLEIJ AJ, 1976, BIOCHIM BIOPHYS ACTA, V426, P581, DOI 10.1016/0005-2736(76)90401-6; ZARDENETA G, 1994, ANAL BIOCHEM, V223, P1, DOI 10.1006/abio.1994.1537	35	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12885	12890		10.1074/jbc.271.22.12885	http://dx.doi.org/10.1074/jbc.271.22.12885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662743	hybrid			2022-12-27	WOS:A1996UN47400032
J	Okumura, K; Sakaguchi, G; Takagi, S; Naito, K; Mimori, T; Igarashi, H				Okumura, K; Sakaguchi, G; Takagi, S; Naito, K; Mimori, T; Igarashi, H			Sp1 family proteins recognize the U5 repressive element of the long terminal repeat of human T cell leukemia virus type I through binding to the CACCC core motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; KU-PROTEIN; RESPONSIVE ELEMENT; PROMOTER; DNA; HTLV; SITE; SEQUENCES; PHOSPHORYLATION	We have identified several nuclear proteins binding to the U5 repressive element (U5RE) at the U5 region of the human T cell leukemia virus type I (HTLV-I) long terminal repeat (LTR). In gel mobility shift assays with the U5RE DNA probe, Jurkat T cell nuclear proteins generated five different complexes, named U5RE binding protein complexes (U5RP)-A1, -A2, -A3, -B, and -C. Only U5RP-C was affected by pretreatment with an excess of poly(dI-dC) and was immunodepressed by anti-Ku/p80 antibodies, suggesting that U5RP-C is a nonspecific complex involving Ku antigen, UV cross-linking showed at least six nuclear proteins involved in the other complexes, including U5R9-A1, -A2, -A3, and -B. The sequence of the binding core element of these specific complexes, determined by competition assays and gel mobility shift assays using a series of the U5RE mutants, is CACCC which is identical to that for the Sp1 transcription factor. LTR with a mutant U5RE, which has no ability to bind with the nuclear proteins, showed stronger promoter activity than LTR with the wild U5RE, suggesting that the specific interaction of these U5RE-binding proteins might result in the U5-mediated repression. U5RP-A1 was supershifted by anti-Sp1 antibodies and U5RP-A2 and -B were supershifted by anti-Sp3 antibodies, suggesting that Sp1 or Sp3 is involved in U5RP-A1 or U5RP-A2 and -B, respectively. Although the other nuclear proteins remain to be characterized, these findings suggest that U5RE-binding proteins in U5RP-A1, -A2, -A3, and -B are involved in HTLV-I gene repression.	SHIONOGI INST MED SCI, SETTSU, OSAKA 566, JAPAN; KEIO UNIV, SCH MED, DEPT INTERNAL MED, DIV RHEUMATOL, TOKYO 160, JAPAN	Shionogi & Company Limited; Keio University								BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GARTENHAUS RB, 1991, BLOOD, V78, P2956; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KASHANCHI F, 1993, J VIROL, V67, P2894, DOI 10.1128/JVI.67.5.2894-2902.1993; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOEHIZUKI M, 1992, LANCET, V339, P1110; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NAKAMURA M, 1989, Virus Genes, V2, P147, DOI 10.1007/BF00315258; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NYBORG JK, 1990, J BIOL CHEM, V265, P8237; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; OSAME M, 1986, LANCET, V1, P1031; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12944	12950		10.1074/jbc.271.22.12944	http://dx.doi.org/10.1074/jbc.271.22.12944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662723	hybrid			2022-12-27	WOS:A1996UN47400042
J	Salzet, M; VergerBocquet, M; Bulet, P; Beauvillain, JC; Malecha, J				Salzet, M; VergerBocquet, M; Bulet, P; Beauvillain, JC; Malecha, J			Purification, sequence analysis, and cellular localization of a prodynorphin-derived peptide related to the alpha-Neo-endorphin in the rhynchobdellid leech Theromyzon tessulatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID-PEPTIDES; NERVOUS-SYSTEM; SUPRAESOPHAGEAL GANGLION; ERPOBDELLA-OCTOCULATA; MYTILUS-EDULIS; END-PRODUCTS; ENKEPHALINS; NEURONS; BRAIN; PROOPIOMELANOCORTIN	Cells immunoreactive to an antiserum specifically directed against vertebrate alpha-Neo-endorphin (alpha-NE) were detected in the internal wall of anterior and posterior suckers of the rhynchobdellid leech Theromyzon Tessulatum. These cells have morphological and ultrastructural characteristics close to the ''releasing gland cells'' of adhesive organs. The epitope recognized by anti-alpha-NE was contained in granules having a diameter of 0.2-0.3 mu m. Previous works involving the brain of this leech demonstrate the existence of similar to 14 neurons immunoreactive to the anti-alpha-NE. Following an extensive purification including high pressure gel permeation and reversed-phase high performance Liquid chromatography, epitopes contained in both suckers and central nervous system were isolated. Purity of the isolated peptides was controlled by capillary electrophoresis. Their sequences were determined by a combination of automated Edman degradation, electrospray mass spectrometry measurement, and coelution experiments in reversed-phase high performance liquid chromatography with synthetic alpha-NE. The results demonstrate that epitopes recognized by the anti-alpha-NE in the suckers and the central nervous system are identical to vertebrate alpha-NE (YGGFL-RKYPK). This finding constitutes the first biochemical characterization of a prodynorphin-derived peptide in invertebrates. Moreover the isolation of this peptide in the annelida establishes the very ancient phylogenetic origin of alpha-NE as well as its conservation in evolution.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9022, F-67084 STRASBOURG, FRANCE; INSERM, LAB NEUROENDOCRINOL & PHYSIOPATHOL NEURONALE, U422, F-59045 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)	Salzet, M (corresponding author), UNIV SCI & TECH LILLE FLANDRES ARTOIS, CTR BIOL CELLULAIRE, LAB PHYLOGENIE MOLEC ANNELIDES, DRED, F-59655 VILLENEUVE DASCQ, FRANCE.		Salzet, Michel/A-7675-2011; BULET, Philippe/C-8557-2014	Salzet, Michel/0000-0003-4318-0817; BULET, Philippe/0000-0001-9016-265X				BOER HH, 1985, PEPTIDES, V6, P459, DOI 10.1016/0196-9781(85)90414-0; BRINKHURST RO, 1989, HYDROBIOLOGIA, V180, P7, DOI 10.1007/BF00027533; DHAINAUTCOURTOIS N, 1986, NEUROCHEM INT, V8, P327, DOI 10.1016/0197-0186(86)90006-9; DORES RM, 1993, CELL PHYSIOL BIOCHEM, V3, P231, DOI 10.1159/000154686; DORES RM, 1992, GEN COMP ENDOCR, V88, P292, DOI 10.1016/0016-6480(92)90262-I; DORES RM, 1993, BRAIN BEHAV EVOLUT, V42, P69, DOI 10.1159/000114141; DORES RM, 1990, GEN COMP ENDOCR, V77, P489, DOI 10.1016/0016-6480(90)90241-D; DUVAUXMIRET O, 1992, ANN NY ACAD SCI, V650, P245; DUVAUXMIRET O, 1991, ADV NEUROIMMUNOL, V1, P41, DOI 10.1016/S0960-5428(06)80031-8; DUVAUXMIRET O, 1992, NEW BIOL, V2, P93; DUVE H, 1988, CELL TISSUE RES, V251, P399, DOI 10.1007/BF00215849; FALLON JH, 1990, HDB CHEM NEUROANATOM, V9, P1; FARNESI RM, 1981, J MORPHOL, V170, P195, DOI 10.1002/jmor.1051700206; FRANCESCHI C, 1992, J IMMUNOL RES-ITALY, V4, P53; GELDER SR, 1988, CAN J ZOOL, V66, P2057, DOI 10.1139/z88-303; GOLDSMITH LA, 1992, PHYSL BIOCH MOL BIOL; GUBLER U, 1987, MOL CLONING HORMONE, P229; HOGG N, 1983, J NEUROSCI RES, V9, P445, DOI 10.1002/jnr.490090410; HOLT PC, 1989, HYDROBIOLOGIA, V180, P1, DOI 10.1007/BF00027532; KREAM RM, 1980, J BIOL CHEM, V255, P9218; LAURENT V, 1995, NEUROSCI LETT, V190, P175, DOI 10.1016/0304-3940(95)11533-3; LEUNG MK, 1984, P NATL ACAD SCI-BIOL, V81, P955, DOI 10.1073/pnas.81.3.955; LUSCHEN W, 1991, P NATL ACAD SCI USA, V88, P8671, DOI 10.1073/pnas.88.19.8671; MALECHA J, 1989, CAN J ZOOL, V67, P636, DOI 10.1139/z89-091; MULLER KJ, 1981, NEUROBIOLOGY LEECH, P255; PATEY G, 1986, ANN ENDOCRINOL-PARIS, V47, P71; REUTER M, 1989, ARCH HISTOL CYTOL, V52, P253, DOI 10.1679/aohc.52.Suppl_253; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SALZET M, 1994, FEBS LETT, V348, P102, DOI 10.1016/0014-5793(94)00581-8; SALZET M, 1992, COMP BIOCHEM PHYS C, V102, P483, DOI 10.1016/0742-8413(92)90147-Y; SALZET M, 1993, BRAIN RES, V631, P247, DOI 10.1016/0006-8993(93)91542-Z; SALZET M, 1995, J BIOL CHEM, V270, P1575, DOI 10.1074/jbc.270.4.1575; SALZET M, 1995, FEBS LETT, V357, P187, DOI 10.1016/0014-5793(94)01358-8; SCHARRER B, 1990, AM ZOOL, V30, P887; SCHARRER B, 1994, NEUROPEPTIDES NEUROI; SEI CA, 1989, BRAIN RES, V479, P162, DOI 10.1016/0006-8993(89)91347-4; STEFANO GB, 1991, ADV NEUROIMMUNOL, V1, P71, DOI 10.1016/S0960-5428(06)80033-1; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P626, DOI 10.1073/pnas.86.2.626; STEFANO GB, 1982, CELL MOL NEUROBIOL, V2, P167, DOI 10.1007/BF00711145; STEFANO GB, 1992, CELL MOL NEUROBIOL, V12, P357, DOI 10.1007/BF00711538; STEWART RR, 1985, BRAIN RES, V332, P150, DOI 10.1016/0006-8993(85)90398-1; TYLER S, 1976, ZOOMORPHOLOGIE, V84, P1, DOI 10.1007/BF02568557; VERGERBOCQUET M, 1992, CAN J ZOOL, V70, P856, DOI 10.1139/z92-122; VERGERBOCQUET M, 1987, CELL TISSUE RES, V250, P63, DOI 10.1007/BF00214655; VERGERBOCQUET M, 1987, COMP ENDOCRINOL, V6, P195; VERGERBOCQUET M, 1988, COMP ENDOCRINOL LIFE, V7, P21; WEIGL AM, 1994, T AM MICROSC SOC, V113, P276, DOI 10.2307/3226623; WEISBLAT DA, 1980, DEV BIOL, V76, P58, DOI 10.1016/0012-1606(80)90362-0	48	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13191	13196		10.1074/jbc.271.22.13191	http://dx.doi.org/10.1074/jbc.271.22.13191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662671				2022-12-27	WOS:A1996UN47400077
J	Scholz, C; Zarnt, T; Kern, G; Lang, K; Burtscher, H; Fischer, G; Schmid, FX				Scholz, C; Zarnt, T; Kern, G; Lang, K; Burtscher, H; Fischer, G; Schmid, FX			Autocatalytic folding of the folding catalyst FKBP12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; BINDING-PROTEIN; IMMUNOSUPPRESSANT FK506; PROLINE ISOMERIZATION; COLLAGEN; DENATURATION; CYCLOPHILIN; RAPAMYCIN; RESIDUES	Prolyl isomerases are folding enzymes and thus have the potential to catalyze their own folding. We show here that the folding of cytosolic FKBP12 (FK 506 binding protein) is an autocatalytic process both for the mature protein and for a fusion protein with an aminoterminal extension of 16 residues. Native FKBP contains seven trans-prolyl peptide bonds, and the cis-to-trans isomerizations of some or all of them constitute the slow, rate-limiting events in folding. The rate of an autocatalytic reaction increases with reactant concentration, because the product catalyzes its own formation. Accordingly, the folding of the fusion protein was more than 10-fold accelerated when the protein concentration was increased from 0.05 mu M to 10 mu M. At high concentrations of both forms of FKBP12 autocatalysis was very efficient, and the observed folding rate seemed to approach the rate of the fast direct folding reaction of the protein molecules with the correct (all trans) peptidyl prolyl bond conformation.	UNIV BAYREUTH,BIOCHEM LAB,D-95440 BAYREUTH,GERMANY; MAX PLANCK GESELL,ARBEITSGRP ENZYMOL PEPTIDBINDUNG,D-06120 HALLE,GERMANY; BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,D-82377 PENZBERG,GERMANY	University of Bayreuth; Max Planck Society								BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DODGE RW, 1994, J PROTEIN CHEM, V13, P409, DOI 10.1007/BF01901697; EGAN DA, 1993, BIOCHEMISTRY-US, V32, P1920, DOI 10.1021/bi00059a006; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1992, J AM CHEM SOC, V114, P3464, DOI 10.1021/ja00035a046; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JULLIEN M, 1981, J MOL BIOL, V145, P265, DOI 10.1016/0022-2836(81)90343-0; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KREBS H, 1979, EUR J BIOCHEM, V100, P359, DOI 10.1111/j.1432-1033.1979.tb04178.x; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIN LN, 1988, BIOCHIM BIOPHYS ACTA, V956, P256, DOI 10.1016/0167-4838(88)90142-2; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; Pace C N, 1986, Methods Enzymol, V131, P266; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHMID F. X., 1986, ENZYME STRUCTURE L, P71; Schmid Franz X., 1992, P197; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; SCHMIDT B, 1995, FEBS LETT, V372, P169, DOI 10.1016/0014-5793(95)00951-5; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VEERARAGHAVAN S, 1994, BIOCHEMISTRY-US, V33, P687, DOI 10.1021/bi00169a009; VEERARAGHAVAN S, 1995, PROTEIN SCI S2, V4, P72; ZARNT T, 1995, BIOCHEM J, V305, P159, DOI 10.1042/bj3050159	47	14	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12703	12707		10.1074/jbc.271.22.12703	http://dx.doi.org/10.1074/jbc.271.22.12703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662669	hybrid			2022-12-27	WOS:A1996UN47400005
J	Gary, JD; Lin, WJ; Yang, MC; Herschman, HR; Clarke, S				Gary, JD; Lin, WJ; Yang, MC; Herschman, HR; Clarke, S			The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; RNA-BINDING PROTEINS; YEAST NSR1 PROTEIN; GENE DISRUPTION; NUCLEOLAR RNA; CYTOCHROME-C; BOVINE BRAIN; METHYLASE-I; HEAT-SHOCK; PURIFICATION	We have identified the major enzymatic activity responsible for the S-adenosyl-L-methionine-dependent methylation of arginine residues (EC 2.1.1.23) in proteins of the yeast Saccharomyces cerevisiae. The RMT1 (protein-arginine methyltransferase), formerly ODP1, gene product encodes a 348-residue polypeptide of 39.8 kDa that catalyzes both the N-G-mono- and N-G,N-G-asymmetric dimethylation of arginine residues in a variety of endogenous yeast polypeptides. A yeast strain in which the chromosomal RMT1 gene was disrupted is viable, but the level of N-G,N-G-[H-3]dimethylarginine residues detected in intact cells incubated with S-adenosyl-L-[methyl-H-3]methionine is reduced to less than 15% of the levels found in the parent strain, while the N-G-[H-3]monomethylarginine content is reduced to less than 30%. We show that soluble extract from parent cells, but not from mutant rmt1 cells, catalyzes the in vitro methylation of endogenous polypeptides of 55, 41, 38, 34, and 30 kDa. The hypomethylated form of these five polypeptides, as well as that of several others, can be mono- and asymmetrically dimethylated by incubating the mutant rmt1 extract with a purified, bacterially produced, glutathione S-transferase-RMT1 fusion protein and S-adenosyl-L-[methyl-H-3]methionine. This glutathione S-transferase-RMT1 fusion protein is also able to methylate a number of mammalian polypeptides including histones, recombinant heterogeneous ribonucleoprotein A1, cytochrome c, and myoglobin, but cannot methylate myelin basic protein. RMT1 appears to be a yeast homolog of a recently characterized mammalian protein-arginine methyltransferase whose activity may be modulated by mitotic stimulation of cells.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29797, GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMUR SG, 1986, J NEUROSCI RES, V16, P367, DOI 10.1002/jnr.490160204; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; ENOUF J, 1979, CANCER RES, V39, P4497; FAROOQUI JZ, 1985, J BIOL CHEM, V260, P537; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; GHOSH SK, 1990, BIOCHIM BIOPHYS ACTA, V1039, P142, DOI 10.1016/0167-4838(90)90179-J; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; GRANA X, 1995, ONCOGENE, V11, P211; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HRYCYNA CA, 1993, BIOCHEMISTRY-US, V32, P11293, DOI 10.1021/bi00093a005; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KARN J, 1977, J BIOL CHEM, V252, P7307; KIM S, 1990, PROTEIN METHYLATION, P77; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; KUJUBU DA, 1993, J NEUROSCI RES, V36, P58, DOI 10.1002/jnr.490360107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LIN WJ, 1996, IN PRESS J BIOL CHEM, V271; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LISCHWE MA, 1990, PROTEIN METHYLATION, P97; LIU Q, 1995, MOL CELL BIOL, V15, P2800; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MIYAKE M, 1973, J NEUROCHEM, V20, P859, DOI 10.1111/j.1471-4159.1973.tb00046.x; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; NAKAJIMA T, 1971, BIOCHIM BIOPHYS ACTA, V230, P212, DOI 10.1016/0304-4165(71)90206-6; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; PAIK WK, 1968, J BIOL CHEM, V243, P2108; PAIK WK, 1969, ARCH BIOCHEM BIOPHYS, V134, P632, DOI 10.1016/0003-9861(69)90327-0; PAIK WK, 1980, BIOCHEM BIOPH RES CO, V97, P8, DOI 10.1016/S0006-291X(80)80126-4; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; RAJPUROHIT R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P183, DOI 10.1016/0167-4838(92)90322-5; RAWAL N, 1992, BIOCHEM J, V287, P929, DOI 10.1042/bj2870929; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sambrook J., 2002, MOL CLONING LAB MANU; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VARNUM BC, 1994, J CELL PHYSIOL, V158, P205, DOI 10.1002/jcp.1041580125; WANG C, 1992, ARCH BIOCHEM BIOPHYS, V297, P169, DOI 10.1016/0003-9861(92)90656-H; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981; YOUNG PR, 1987, BIOCHEM BIOPH RES CO, V145, P1112, DOI 10.1016/0006-291X(87)91552-X	75	175	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12585	12594		10.1074/jbc.271.21.12585	http://dx.doi.org/10.1074/jbc.271.21.12585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647869	hybrid			2022-12-27	WOS:A1996UL66000071
J	Petersen, RB; Parchi, P; Richardson, SL; Urig, CB; Gambetti, P				Petersen, RB; Parchi, P; Richardson, SL; Urig, CB; Gambetti, P			Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; NEURO-BLASTOMA CELLS; LINKED OLIGOSACCHARIDES; NEUROBLASTOMA-CELLS; MOLECULAR-CLONING; SCRAPIE AGENT; MOUSE-BRAIN; GENE; CDNA; PRP	Prion diseases are thought to be caused by the conversion of the normal, or cellular, prion protein (PrPC) into an abnormal protease-resistant conformation (PrPres). There are three familial forms of human prion disease, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia (FFI) which are all expressed at advanced age despite the congenital presence of the mutant prion protein (PrPM). The cellular mechanisms that result in the age-dependent conversion of PrPM into PrPres and the unique phenotypes associated with each PrPM are unknown. FFI and a familial type of Creutzfeldt-Jakob disease (CJD(178)), share the D178N mutation in the PrP gene but have distinct phenotypes linked to codon 129, the site of a methionine/valine polymorphism (129M/V). We analyzed PrP processing in cells transfected with constructs reproducing the FFI and CJD(178) genotypes. The D178N mutation results in instability of the mutant PrP which is partially corrected by N-glycosylation. Hence, only the glycosylated forms of PrPM reach the cell surface whereas the unglycosylated form is degraded. The unglycosylated PrPM is also under-represented in the brain of FFI patients validating the cell model. These results offer new insight into the effect of the D178N mutation on the metabolism of the prion protein.			Petersen, RB (corresponding author), CASE WESTERN RESERVE UNIV,DEPT PATHOL,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106, USA.		Petersen, Robert/B-5075-2011; Parchi, Piero/L-9833-2015	Petersen, Robert/0000-0002-3154-0072; Parchi, Piero/0000-0002-9444-9524	NIA NIH HHS [AG-08992, AG-08155] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG008992, R37AG008155] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1988, P NATL ACAD SCI USA, V85, P4657, DOI 10.1073/pnas.85.13.4657; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FRA A, 1993, SUBCELLULAR BIOCH, V21; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HAMILTON JA, 1992, BIOCHIM BIOPHYS ACTA, V1139, P9, DOI 10.1016/0925-4439(92)90075-X; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENIKOFF S, 1987, GENETICS, V117, P711; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; NEARY K, 1991, J VIROL, V65, P1031, DOI 10.1128/JVI.65.2.1031-1034.1991; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, ANN NEUROL, V38, P21, DOI 10.1002/ana.410380107; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; ROBAKIS NK, 1986, P NATL ACAD SCI USA, V83, P6377, DOI 10.1073/pnas.83.17.6377; ROSS RA, 1983, J NATL CANCER I, V71, P741; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCOTT MRD, 1988, PROTEIN ENG, V2, P69, DOI 10.1093/protein/2.1.69; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333	41	125	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12661	12668		10.1074/jbc.271.21.12661	http://dx.doi.org/10.1074/jbc.271.21.12661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647879	hybrid			2022-12-27	WOS:A1996UL66000081
J	Sone, N; Tsuchiya, N; Inoue, M; Noguchi, S				Sone, N; Tsuchiya, N; Inoue, M; Noguchi, S			Bacillus stearothermophilus qcr operon encoding Rieske FeS protein, cytochrome b(6), and a novel-type cytochrome c(1) of quinol-cytochrome c reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM NOSTOC PCC-7906; THERMOPHILIC BACTERIUM PS3; IRON-SULFUR PROTEIN; NUCLEOTIDE-SEQUENCE; TERMINAL OXIDASES; BC1 COMPLEX; GENE; SUBTILIS; CLONING; CHLOROPLASTS	The qcr of Bacillus stearothermophilus K1041 encoding three subunits of the quinol-cytochrome c oxidoreductase (cytochrome reductase, b(6)c(1) complex) was cloned and sequenced. The gene (qcrA) for a Rieske FeS protein of 19,144 Da with 169 amino acid residues, and the gene (qcrC) for cytochrome c(1) of 27,342 Da with 250 amino acid residues were found at adjacent upstream and downstream sides of the previously reported qcrB (petB) for cytochrome b(6) of subunit 25,425 Da with 224 residues (Sone, N., Sawa, C., Sone, T., and Noguchi, S. (1995) J. Biol. Chem. 270, 10612-10617). The three structural genes for thermophilic Bacillus cytochrome reductase form a transcriptional unit. In the deduced amino acid sequence for the FeS protein, the domain including four cysteines and two histidines binding the 2Fe-2S cluster was conserved. Its N-terminal part more closely resembled the cyanobacteria-plastid type than the proteobacteria-mitochondria type when their sequences were compared. The amino acid sequence of cytochrome c(1) was not similar to either type; the thermophilic Bacillus cytochrome c(1) is composed of an N-terminal part corresponding to subunit IV with three membrane spanning segments, and a C-terminal part of cytochrome c reminiscent of cytochrome c-551 of thermophilic Bacillus. The subunit IV in the enzyme of cyanobacteria and plastids is the counterpart of C-terminal part of cytochrome b of proteobacteria and mitochondria. These characteristics indicate that Bacillus cytochrome b(6)c(1) complex is unique.			Sone, N (corresponding author), KYUSHU INST TECHNOL,DEPT BIOCHEM ENGN & SCI,680 KAWAZU,IIZUKA,FUKUOKA 820,JAPAN.							BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; DAVIDSON E, 1990, J MOL BIOL, V195, P23; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; FUJIWARA Y, 1993, BIOCHIM BIOPHYS ACTA, V1141, P213; GABELLINI N, 1988, J BIOENERG BIOMEMBR, V20, P59, DOI 10.1007/BF00762138; GARCIAHORSMAN JA, 1991, MOL MICROBIOL, V5, P197, DOI 10.1111/j.1365-2958.1991.tb01840.x; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HREGGVIDSSON GO, 1991, BIOCHIM BIOPHYS ACTA, V1058, P52, DOI 10.1016/S0005-2728(05)80268-3; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; KALLAS T, 1988, J BIOL CHEM, V263, P14334; KALLAS T, 1988, P NATL ACAD SCI USA, V85, P5794, DOI 10.1073/pnas.85.16.5794; KUTOH E, 1988, J BIOL CHEM, V263, P9020; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MAYES SR, 1991, PLANT MOL BIOL, V17, P289, DOI 10.1007/BF00039508; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; PRINCE RC, 1995, TRENDS BIOCHEM SCI, V20, P217, DOI 10.1016/S0968-0004(00)89018-0; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; ROCKE CD, 1987, CURR GENET, V17, P69; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SCHUTZ M, 1994, PHOTOSYNTH RES, V39, P163, DOI 10.1007/BF00029383; SHIGA Y, 1993, J BACTERIOL, V175, P7130, DOI 10.1128/JB.175.22.7130-7137.1993; SONE N, 1994, FEMS MICROBIOL LETT, V122, P203, DOI 10.1111/j.1574-6968.1994.tb07168.x; SONE N, 1987, J BIOL CHEM, V262, P15386; SONE N, 1991, J BIOCHEM-TOKYO, V110, P1016, DOI 10.1093/oxfordjournals.jbchem.a123671; SONE N, 1995, J BIOL CHEM, V270, P10612, DOI 10.1074/jbc.270.18.10612; SONE N, 1995, J BIOL CHEM, V270, P22076; SONE N, 1982, BIOCHIM BIOPHYS ACTA, V682, P216, DOI 10.1016/0005-2728(82)90101-3; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; USUI S, 1991, J BIOL CHEM, V266, P15644; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; VERBIST J, 1989, MOL GEN GENET, V219, P445, DOI 10.1007/BF00259618; VONWACHENFELDT C, 1990, J BIOL CHEM, V265, P13939; VONWACHENFELDT C, 1990, FEMS MICROBIOL LETT, V100, P91; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; YU J, 1995, J BACTERIOL, V177, P6751, DOI 10.1128/jb.177.23.6751-6760.1995	42	37	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12457	12462		10.1074/jbc.271.21.12457	http://dx.doi.org/10.1074/jbc.271.21.12457			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647852	hybrid			2022-12-27	WOS:A1996UL66000054
J	McCormick, SPA; Ng, JK; Veniant, M; Boren, J; Pierotti, V; Flynn, LM; Grass, DS; Connolly, A; Young, SG				McCormick, SPA; Ng, JK; Veniant, M; Boren, J; Pierotti, V; Flynn, LM; Grass, DS; Connolly, A; Young, SG			Transgenic mice that overexpress mouse apolipoprotein B - Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN	An 87-kilobase (kb) P1 bacteriophage clone (p649) spanning the mouse apolipoprotein (apo) B gene was used to generate transgenic mice that express high levels of mouse apoB. Plasma levels of apoB, low density lipoprotein cholesterol, and low density lipoprotein triglycerides were increased, and high density lipoprotein cholesterol levels were decreased in the transgenic mice, compared with nontransgenic littermate controls. Although p649 contained 33 kb of 5'-flanking sequences and 11 kb of 3'-flanking sequences, the tissue pattern of transgene expression was different from that of the endogenous apoB gene. RNA slot blots and RNase protection analysis indicated that the transgene was expressed in the liver but not in the intestine, whereas the endogenous apoB gene was expressed in both tissues. To confirm the absence of transgene expression in the intestine, the mouse apoB transgenic mice were mated with the apoB knockout mice, and transgenic mice that were homozygous for the apoB knockout mutation were obtained. Because of the absence of transgene expression in the intestine, those mice lacked all intestinal apoB synthesis, resulting in a marked accumulation of fats within the intestinal villus enterocytes. The current studies, along with prior studies of human apoB transgenic animals, strongly suggest that the DNA sequence element(s) controlling intestinal expression of the apoB gene is located many kilobases from the structural gene.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; DNX TRANSGEN,PRINCETON,NJ 08540	University of California System; University of California San Francisco; University of California System; University of California San Francisco	McCormick, SPA (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.			McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORSINI A, 1992, ATHEROSCLEROSIS, V93, P95, DOI 10.1016/0021-9150(92)90203-S; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MCCORMICK SPA, 1994, GENET ANAL TECH APPL, V11, P1588; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; SATO Y, 1993, J BIOL CHEM, V268, P17705; SCULLY RE, 1992, NEW ENGL J MED, V327, P628; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; Young Stephen G., 1994, Current Opinion in Lipidology, V5, P94, DOI 10.1097/00041433-199404000-00005	18	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11963	11970		10.1074/jbc.271.20.11963	http://dx.doi.org/10.1074/jbc.271.20.11963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662599	hybrid			2022-12-27	WOS:A1996UL25000059
J	Shen, HG; SosaPeinado, A; Mueller, DM				Shen, HG; SosaPeinado, A; Mueller, DM			Intragenic suppressors of P-loop mutations in the beta-subunit of the mitochondrial ATPase in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-RICH SEQUENCE; HIGH-EFFICIENCY TRANSFORMATION; BINDING CHANGE MECHANISM; COLI H+-ATPASE; ESCHERICHIA-COLI; CATALYTIC SITE; OXIDATIVE-PHOSPHORYLATION; DIRECTED MUTAGENESIS; SHUTTLE VECTORS; F1-ATPASE	Three intragenic second site suppressors, P353L, T237I, and L390F, were identified that suppressed two mutations in, and one adjacent to, the P-loop in the beta-subunit of the yeast F-1-ATPase. The crystal structure of bovine F-1-ATPase (Abrahams, J. P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628) shows that these suppressor residues are located in the nucleotide-binding domain. Specific hypotheses have been formulated that suggest the conformational coupling of the P-loop with the suppressor sites, P353L is in a ''catch'' region, which forms unique interactions with the gamma-subunit in the three different conformational states of the catalytic site. The identification of this suppressor mutation demonstrates genetically that the catch region is conformationally coupled to the P-loop. T237I is shown to interact with Lys-209, which occurs just after the P-loop. This suggests that this interaction changes the conformation of the P-loop to suppress the initial mutation, L390F interacts with Ala-181, which is adjacent to the P-loop, The mechanism of this suppression is suggested to occur through the interactions of L390F with Ala-181. These results identify critical interactions that modulate the structure of the P-loop and thus the biochemistry of the enzyme.	CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Chicago Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM44412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DREUSICKE D, 1988, J MOL BIOL, V203, P1021, DOI 10.1016/0022-2836(88)90126-X; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRABER P, 1992, J BIOENERG BIOMEMBR, V24, P493, DOI 10.1007/BF00762367; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; Leung DW, 1989, TECHNIQUE, V1, P11; Maniatis T., 1982, MOL CLONING; *MOL SIM INC, 1995, QUANTA VERSION 4 1 1; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RICHTER ML, 1995, IN PRESS ADV PHOTOSY; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHEN HG, 1994, J BIOL CHEM, V269, P9424; SIKORSKI RS, 1989, GENETICS, V122, P19; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; TODD RD, 1980, J BIOL CHEM, V255, P5461; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	41	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11844	11851		10.1074/jbc.271.20.11844	http://dx.doi.org/10.1074/jbc.271.20.11844			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662632	hybrid			2022-12-27	WOS:A1996UL25000043
J	LeRoy, C; Leduque, P; Dubois, PM; Saez, JM; Langlois, D				LeRoy, C; Leduque, P; Dubois, PM; Saez, JM; Langlois, D			Repression of transforming growth factor beta 1 protein by antisense oligonucleotide-induced increase of adrenal cell differentiated functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE ADRENOCORTICAL-CELLS; ANGIOTENSIN-II; GENE-EXPRESSION; RECEPTOR; OLIGODEOXYNUCLEOTIDES; INHIBITION; SEQUENCE; CLONING; INSULIN; FACTOR-BETA-1	Transforming growth factor beta 1 (TGF beta 1) is a potent inhibitor of several differentiated functions in bovine adrenal fasciculata cells (BAC). In addition, these cells express and secrete this factor. To determine whether this peptide plays an autocrine role in BAC, cells were transfected with 10 mu M unmodified sense (SON) or antisense (AON) oligonucleotide complementary to the translation initiation region of the TGF beta 1 mRNA in an attempt to inhibit TGF beta 1 protein synthesis. We investigated first, the cellular uptake, the stability, and the intracellular distribution of P-32-labeled TGF beta 1 AON and SON; and second, the effects of both oligonucleotides on BAC specific functions. We have demonstrated that in BAC, the TGF beta 1 AON uptake reached a plateau after 8 h of transfection (16% of the radioactivity added) and remained fairly constant for at least 24 h. In contrast, the uptake of TGF beta 1 SON reached a plateau after 2 h of transfection (8% of the radioactivity added), remained stable for only 3 h, and then declined. After 8 h of transfection, followed by 44 h of culture without oligonucleotides, the intracellular level of TGF beta 1 AON was still high with about 8% of the radioactivity added, whereas that of TGF beta 1 SON represented only 1.2%. Moreover, AON was present in the cytoplasmic and nuclear fractions, and it was hybridized in both compartments. However, TGF beta 1 SON was present mainly in the cytoplasmic fraction where it was not hybridized. Neither TGF beta 1 AON nor SON modified TGF beta 1 mRNA levels; however, TGF beta 1 AON, but not SON, caused the disappearance of TGF beta 1 immunoreactivity inside the cells. Finally, the steroidogenic responsiveness of BAC transfected with TGF beta 1 AON increased about 2-fold, and this was associated with a 2-fold increase of the mRNA levels of both cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase. Neither TGF beta 1 SON nor a scrambled oligonucleotide containing the same number of G nucleotides as TGF beta 1 AON had any effect on these parameters Thus, these studies demonstrate that TGF beta 1 has an autocrine inhibitory effect on BAC differentiated functions, an effect that can be overcome by TGF beta 1 AON.	HOP DEBROUSSE,INSERM,INRA,U418,F-69322 LYON 05,FRANCE; FAC MED LYON SUD,HISTOL LAB,F-69600 OULLINS,FRANCE	CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm)			Le Roy, Christine/N-3718-2017	Le Roy, Christine/0000-0003-3538-6487				AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; AVALLET O, 1994, ENDOCRINOLOGY, V134, P2079, DOI 10.1210/en.134.5.2079; BAERTSCHI AJ, 1994, MOL CELL ENDOCRINOL, V101, P15; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; BURT DW, 1992, DNA CELL BIOL, V11, P497, DOI 10.1089/dna.1992.11.497; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHET C, 1988, J BIOL CHEM, V263, P5707; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; CUMIN F, 1993, EUR J BIOCHEM, V212, P347, DOI 10.1111/j.1432-1033.1993.tb17668.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FEIGE JJ, 1991, ENDOCR RES, V17, P267, DOI 10.1080/07435809109027201; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; GAO WY, 1993, MOL PHARMACOL, V43, P45; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1994, M S-MED SCI, V10, P253, DOI 10.4267/10608/2604; HOTTA M, 1986, P NATL ACAD SCI USA, V83, P7795, DOI 10.1073/pnas.83.20.7795; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JAROSZEWSKI JW, 1991, ADV DRUG DELIVER REV, V6, P235, DOI 10.1016/0169-409X(91)90019-9; KHANNA A, 1994, BIOCHEM BIOPH RES CO, V204, P1061, DOI 10.1006/bbrc.1994.2570; LANGLOIS D, 1990, ENDOCRINOLOGY, V126, P1867, DOI 10.1210/endo-126-4-1867; LANGLOIS D, 1994, ENDOCRINOLOGY, V135, P480, DOI 10.1210/en.135.1.480; LANGLOIS D, 1992, COLLOQ INSE, V222, P61; LEONETTI JP, 1993, PROG NUCLEIC ACID RE, V44, P143, DOI 10.1016/S0079-6603(08)60219-6; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOATSSTAATS BM, 1993, MOL ENDOCRINOL, V7, P171, DOI 10.1210/me.7.2.171; MORISSON RS, 1991, J BIOL CHEM, V266, P15917; NAVILLE D, 1991, MOL CELL ENDOCRINOL, V75, P257, DOI 10.1016/0303-7207(91)90168-R; OUALI R, 1992, J STEROID BIOCHEM, V43, P271, DOI 10.1016/0960-0760(92)90161-B; PERRIN A, 1990, ENDOCRINOLOGY, V128, P357; RAINEY WE, 1990, ENDOCRINOLOGY, V127, P1910, DOI 10.1210/endo-127-4-1910; RAINEY WE, 1988, MOL CELL ENDOCRINOL, V60, P189, DOI 10.1016/0303-7207(88)90178-5; RAINEY WE, 1991, ENDOCR RES, V17, P281, DOI 10.1080/07435809109027202; RAINEY WE, 1989, J BIOL CHEM, V264, P21474; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; TEMSAMANI J, 1994, ANTISENSE RES DEV, V4, P35, DOI 10.1089/ard.1994.4.35; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11027	11033		10.1074/jbc.271.18.11027	http://dx.doi.org/10.1074/jbc.271.18.11027			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631925	hybrid			2022-12-27	WOS:A1996UJ34200093
J	Lussier, M; Sdicu, AM; Camirand, A; Bussey, H				Lussier, M; Sdicu, AM; Camirand, A; Bussey, H			Functional characterization of the YUR1, KTR1, and KTR2 genes as members of the yeast KRE2/MNT1 mannosyltransferase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; O-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; LINKED OLIGOSACCHARIDES; MEMBRANE-PROTEIN; OUTER CHAIN; ENCODES; LOCALIZATION; COMPARTMENT; PATHWAY	Eukaryotic glycan structures are progressively elaborated in the secretory pathway. Following the addition of a core N-linked carbohydrate in the endoplasmic reticulum, glycoproteins move to the Golgi complex where the elongation of O-linked sugar chains and processing of complex N-linked oligosaccharide structures take place. In order to better define how such post-translational modifications occur, we have been studying a yeast gene family in which at least one member, KRE2/MNT1, is involved in protein glycosylation. The family currently contains five other members: YUR1, KTR1, RTR2, KTR3 and KTR4 (Mallet, L., Bussereau, F., and Jacquet, M. (1994) Yeast 10, 819-831). All encode putative type II membrane proteins with a short cytoplasmic N terminus, a membrane-spanning region, and a highly conserved catalytic lumenal domain. Kre2p/Mnt1p is a alpha 1,2-mannosyltransferase involved in O- and N-linked glycosylation (Hausler, A., Ballou, L., Ballou, C. E., and Bobbins, P. W. (1992) Proc. Natl. Acad. Sci. U.S. A. 89, 6846-6850); however, the role of the other proteins has not yet been established. We have carried out a functional analysis of Ktr1p, Ktr2p, and Yur1p. By in vitro assays, Ktr1p, Ktr2p, and Yur1p have been shown to be mannosyltransferases but, in vivo, do not appear to be involved in O-glycosylation. Examination of the electrophoretic mobility of the N-linked modified protein invertase in null mutant strains indicates that Ktr1p, Ktr2p, and Yur1p are involved in N-linked glycosylation, possibly as redundant enzymes. As found with Kre2p (Hill, K., Boone, C., Goebl, M., Puccia, R., Sdicu, A.-M., and Bussey, H. (1992) Genetics 130, 273-283), Ktr1p, Ktr2p, and Yur1p also seem to be implicated in the glycosylation of cell wall mannoproteins, since yeast cells containing different gene disruptions become K1 killer toxin-resistant. Immunofluorescence microscopy reveals that like Kre2p; Ktr1p, Ktr2p and Yur1p are localized in the Golgi complex.	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA	McGill University								BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BROWN JL, 1993, MOL CELL BIOL, V13, P6346, DOI 10.1128/MCB.13.10.6346; BROWN JL, 1994, MOL GENETICS YEAST P, P217; BUSSEY H, 1991, MOL MICROBIOL, V5, P2339, DOI 10.1111/j.1365-2958.1991.tb02079.x; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; IKMMERVOLL T, 1995, YEAST, V11, P1345; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEHLE L, 1995, GLYCOPROTEINS, P1; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUSSEL P, 1988, BIOCHIMIE, V70, P1471, DOI 10.1016/0300-9084(88)90284-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	54	50	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11001	11008		10.1074/jbc.271.18.11001	http://dx.doi.org/10.1074/jbc.271.18.11001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631921	hybrid			2022-12-27	WOS:A1996UJ34200089
J	Wilson, AL; Erdman, RA; Maltese, WA				Wilson, AL; Erdman, RA; Maltese, WA			Association of Rab1B with GDP-dissociation inhibitor (GDI) is required for recycling but not initial membrane targeting of the Rab protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GERANYLGERANYL TRANSFERASE; SMG P25A; EXCHANGE PROTEIN; EFFECTOR DOMAIN; CDNA CLONING; COMPONENT-A; TRANSPORT; ENZYME; IDENTIFICATION	We have identified a Rab1B effector-domain mutant (D44N) that, when geranylgeranylated by Rab:geranylgeranyltransferase (GGTase II) in cell-free systems or intact cells, fails to form detectable complexes with GDP . dissociation inhibitors (GDIs). GDI-Rab complexes were collected on anti-FLAG affinity beads after incubating recombinant geranylgeranylated Rab1B with FLAG epitope-tagged GDI in vitro, or transiently coexpressing Myc-tagged Rab1B with FLAG-GDI-alpha or FLAG-GDI-2 in human embryonal kidney 293 cells. [H-3]Mevalonate labeling and immunoprecipitation studies confirmed that the inability of Myc-Rab1B(D44N) to associate with GDI in vivo was not due to failure of the mutant to undergo geranylgeranylation. Immunofluorescence localization and immunoblot analysis of subcellular fractions indicated that expressed Myc-Rab1B(D44N) efficiently delivered to intracellular membranes in 293 cells. This was confirmed when the fate of the prenylated pool of Rab1B(D44N) in 293 cells was traced by labeling the geranylgeranyl groups attached to the nascent protein with [H-3]mevalonate. However, in contrast to the prenylated Rab1B(WT), which was distributed in both the membrane and soluble fractions, the prenylated Rab1B(D44N) was completely absent from the cytosol. Overexpression of Myc-Rab1B(D44N) did not impair ER --> Golgi glycoprotein trafficking in 293 cells, which was assessed by monitoring the Golgi-dependent processing of coexpressed beta-amyloid precursor protein. The current findings suggest that nascent prenylated Rab1B can be delivered to intracellular membranes in intact cells without forming a stable complex with GDI, but that recycling of prenylated Rab1B to the cytosolic compartment is absolutely dependent on GDI interaction.	GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center					NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Higuchi R., 1989, PCR TECHNOLOGY, P61; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GP, 1993, J BIOL CHEM, V268, P24475; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILSON AL, 1993, J BIOL CHEM, V268, P14561; WILSON AL, 1994, METHOD ENZYMOL, V250, P79; YANG CZ, 1994, J BIOL CHEM, V269, P31891; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217	58	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10932	10940		10.1074/jbc.271.18.10932	http://dx.doi.org/10.1074/jbc.271.18.10932			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631911	hybrid			2022-12-27	WOS:A1996UJ34200079
J	Blocker, A; Severin, FF; Habermann, A; Hyman, AA; Griffiths, G; Burkhardt, JK				Blocker, A; Severin, FF; Habermann, A; Hyman, AA; Griffiths, G; Burkhardt, JK			Microtubule-associated protein-dependent binding of phagosomes to microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANOUS ORGANELLES INVIVO; ENDOCYTIC CARRIER VESICLES; CYTOPLASMIC DYNEIN; CULTURED-CELLS; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; LYSOSOMAL MOVEMENTS; TUBULAR LYSOSOMES; FUSION INVITRO; GOLGI ELEMENTS	In macrophages, phagosome movement is microtubule-dependent. Microtubules are a prerequisite for phagosome maturation because they facilitate interact-ions between phagosomes and organelles of the endocytic pathway. We have established an in vitro assay that measures the binding of purified phagosomes to microtubules. This binding depends on the presence of membrane proteins, most likely integral to the surface of phagosomes, and on macrophage cytosol. The cytosolic binding factor can interact with microtubules prior to the addition of phagosomes to the assay, suggesting that it is a microtubule-associated protein (MAP). Consistent with this, depletion of MAPs from the cytosol by microtubule affinity removes all binding activity. Microtubule motor proteins show no binding activity, whereas a crude MAP preparation is sufficient to support binding and to restore full binding activity to MAP-depleted cytosol. We show that the activating MAP factor is a heat-sensitive protein(s) that migrates at around 150 kDa by gel filtration.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Hyman, Anthony A/B-3917-2017; Severin, Fedor/AAD-5444-2019; Blocker, Ariel/Q-6617-2016; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Habermann, Anja/0000-0003-3686-9050; Severin, Fedor/0000-0001-6703-1256				ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BURKHARDT JK, 1993, J CELL SCI, V104, P151; BURKHARDT JK, 1995, IN PRESS ELECTROPHOR; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HART PD, 1983, J EXP MED, V158, P477, DOI 10.1084/jem.158.2.477; HART PD, 1987, J EXP MED, V166, P933, DOI 10.1084/jem.166.4.933; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JAHRAUS A, 1994, J CELL SCI, V107, P145; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KNAPP PE, 1990, J CELL SCI, V95, P433; KORNFELD S, 1989, ANN REV CELL BIOL, V98, P139; KREIS TE, 1989, EUR J CELL BIOL, V49, P128; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUZNETSOV SA, 1978, FEBS LETT, V95, P339, DOI 10.1016/0014-5793(78)81025-4; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONT F, 1994, NATURE, V372, P801; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LIN SXH, 1992, J CELL SCI, V101, P125; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MIZUNO M, 1994, J CELL SCI, V107, P1321; MORIN PJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P275, DOI 10.1016/0005-2736(93)90366-8; MULLER WA, 1980, J CELL BIOL, V86, P292, DOI 10.1083/jcb.86.1.292; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; Olmsted J. B., 1993, P115; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PITT A, 1992, METHOD ENZYMOL, V219, P21; PITT A, 1992, J BIOL CHEM, V267, P126; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Sandoval I. V., 1984, J CELL BIOL, V99, P113; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SEVERIN FF, 1991, FEBS LETT, V282, P65, DOI 10.1016/0014-5793(91)80445-9; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TOYOHARA A, 1989, J CELL SCI, V94, P143; URRUTIA R, 1993, METHOD CELL BIOL, V39, P253, DOI 10.1016/S0091-679X(08)60175-2; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walden Paul D., 1993, P111; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; WETZEL MG, 1969, J CELL BIOL, V43, P90, DOI 10.1083/jcb.43.1.90; YOUNG MR, 1990, EXP CELL RES, V190, P283, DOI 10.1016/0014-4827(90)90198-J; YU H, 1992, J BIOL CHEM, V267, P20457	77	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3803	3811						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631997				2022-12-27	WOS:A1996TV72400071
J	Mourey, RJ; Vega, QC; Campbell, JS; Wenderoth, MP; Hauschka, SD; Krebs, EG; Dixon, JE				Mourey, RJ; Vega, QC; Campbell, JS; Wenderoth, MP; Hauschka, SD; Krebs, EG; Dixon, JE			A novel cytoplasmic dual specificity protein tyrosine phosphatase implicated in muscle and neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAP KINASE; VACCINIA VIRUS; ACTIVATION; EXPRESSION; CASCADE; CLONING; ENCODES; CULTURE; 3CH134	Dual specificity protein tyrosine phosphatases (dsPTPs) are a subfamily of protein tyrosine phosphatases implicated in the regulation of mitogen-activated protein kinase (MAPK). In addition to hydrolyzing phosphotyrosine, dsPTPs can hydrolyze phosphoserine/threonine-containing substrates and have been shown to dephosphorylate activated MAPK. We have identified a novel dsPTP, rVH6, from rat hippocampus. rVH6 contains the conserved dsPTP active site sequence, VXVHCX(2)GX(2)RSX(5)AY(L/I)M, and exhibits phosphatase activity against activated MAPK. In PC12 cells, rVH6 mRNA is induced during nerve growth factor-mediated differentiation but not during insulin or epidermal growth factor mitogenic stimulation. In MM14 muscle cells, rVH6 mRNA is highly expressed in proliferating cells and declines rapidly during differentiation. rVH6 expression correlates with the inability of fibroblast growth factor to stimulate MAPK activity in proliferating but not in differentiating MM14 cells. rVH6 protein localizes to the cytoplasm and is the first dsPTP to be localized outside the nucleus. This novel subcellular localization may expose rVH6 to potential substrates that differ from nuclear dsPTPs substrates.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Campbell, Jean/0000-0002-9187-2204	NIAMS NIH HHS [2RO1-AR18860] Funding Source: Medline; NIDDK NIH HHS [2RO1-DK4258, 2RO1-DK18849] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CLEGG CH, 1987, J CELL BIOL, V105, P929; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MILLAR JBA, 1991, EMBO J, V10, P4302; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OAKLEY B, 1992, EXP NEUROL, V115, P50, DOI 10.1016/0014-4886(92)90220-K; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STONE RL, 1994, J BIOL CHEM, V269, P31323; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	55	109	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3795	3802						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631996				2022-12-27	WOS:A1996TV72400070
J	Street, JM; Evans, JE; Natowicz, MR				Street, JM; Evans, JE; Natowicz, MR			Glucuronic acid-conjugated dihydroxy fatty acids in the urine of patients with generalized peroxisomal disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; GAS-LIQUID-CHROMATOGRAPHY; RAT-LIVER PEROXISOMES; ZELLWEGER SYNDROME; ARACHIDONIC-ACID; BILE-ACIDS; BETA-OXIDATION; INBORN-ERRORS; METABOLISM; HYDROPEROXIDE	Urine extracts from children diagnosed with generalized peroxisomal disorders were screened by continuous flow-negative ion fast atom bombardment-mass spectrometry. In 45 of 60 children with generalized peroxisomal disorders, we observed one or more intense ions (m/z 489, 505, 461, and others) that are infrequently found in children with cholestatic liver disease or normal children. Compounds giving rise to these ions were isolated using reverse phase and anion exchange chromatography. After appropriate derivatization and/or methanolysis the compounds were analyzed using capillary gas chromatography-mass spectrometry. The major compounds were found to be 12,13-dihydroxy-9-octadecenoic acid and 9,10-dihydroxy-12-octadecenoic acid, with one of the hydroxyl groups in glycosidic linkage with glucuronic acid. Minor compounds were glucuronic acid conjugates of 9,10-dihydroxy-octadecanoic acid, and 12, 13-dihydroxy-6,9-, 15, 16-dihydroxy-9,12-, and 9,10-dihydroxy-12,15-octadecadienoic acids. A series of hexadecanoic, hexadecanoic, and hexadecadienoic acid glucuronides which appear to be beta-oxidation products of the C18 fatty acids were also observed, with the major species being 10,11-dihydroxy-7-hexadecenoic acid glucuronide, In all, 16 C16 and C18 dihydroxy fatty acids were identified by gas chromatography-mass spectrometry, A series of at least 11 trihydroxy fatty acids was also observed but not fully characterized. Measurement of these compounds may prove to be useful in the diagnosis of some peroxisomal disorders.	EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,MASS SPECTROMETRY FACIL,WALTHAM,MA 02254; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Street, JM (corresponding author), EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,DIV MED GENET,200 TRAPELO RD,WALTHAM,MA 02254, USA.		Street, Jackie/A-2016-2011	Street, Jackie/0000-0002-1033-4341	NICHD NIH HHS [HD05515] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD005515] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALME B, 1977, J LIPID RES, V18, P339; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; ANGERMULLER S, 1987, EUR J CELL BIOL, V45, P137; BJORKHEM I, 1984, BIOCHIM BIOPHYS ACTA, V795, P15, DOI 10.1016/0005-2760(84)90099-7; BJORKHEM I, 1982, J LIPID RES, V23, P1020; BROWN FR, 1993, AM J DIS CHILD, V147, P617, DOI 10.1001/archpedi.1993.02160300023015; CHANG C, 1991, ARCH BIOCHEM BIOPHYS, V285, P276, DOI 10.1016/0003-9861(91)90360-U; CLAYTON PT, 1987, EUR J PEDIATR, V146, P166, DOI 10.1007/BF02343226; DANKS DM, 1975, J PEDIATR-US, V86, P382, DOI 10.1016/S0022-3476(75)80967-X; DHAUNSI GS, 1993, MOL CELL BIOCHEM, V126, P25, DOI 10.1007/BF01772205; DICZFALUSY U, 1994, PROG LIPID RES, V33, P403, DOI 10.1016/0163-7827(94)90025-6; EVANS JE, 1993, BIOL MASS SPECTROM, V22, P331, DOI 10.1002/bms.1200220604; FAHLSTADIUS P, 1988, LIPIDS, V23, P1015; GUTIERREZ C, 1988, J LIPID RES, V29, P613; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HANSON RF, 1979, SCIENCE, V203, P1107, DOI 10.1126/science.424737; HAYAKAWA M, 1986, BIOCHEM BIOPH RES CO, V137, P424, DOI 10.1016/0006-291X(86)91227-1; HEYMANS HSA, 1983, NATURE, V306, P69, DOI 10.1038/306069a0; IMIGAWA T, 1982, J BIOCHEM-TOKYO, V92, P1109; KATO T, 1983, TETRAHEDRON LETT, V24, P4715, DOI 10.1016/S0040-4039(00)86236-X; KLEIMAN R, 1973, J AM OIL CHEM SOC, V50, P31, DOI 10.1007/BF02886864; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LILLINGTON JM, 1981, CLIN CHIM ACTA, V111, P91, DOI 10.1016/0009-8981(81)90425-3; MEAD JF, 1986, LIPIDS CHEM BIOCH NU, P82; MLAKAR A, 1994, BBA-LIPID LIPID MET, V1214, P209; MOSER AE, 1984, NEW ENGL J MED, V310, P1141, DOI 10.1056/NEJM198405033101802; MOSER HW, 1991, CLIN BIOCHEM, V24, P343, DOI 10.1016/0009-9120(91)80009-R; OLIW EH, 1983, BIOCHEM BIOPH RES CO, V111, P644, DOI 10.1016/0006-291X(83)90355-8; OLIW EH, 1983, J CHROMATOGR, V275, P245, DOI 10.1016/S0378-4347(00)84372-8; OLIW EH, 1982, J BIOL CHEM, V257, P3771; OSMUNDSEN H, 1985, BIOCHEM J, V230, P329, DOI 10.1042/bj2300329; Osmundsen H., 1987, PEROXISOMES BIOL MED, P152; OZAWA T, 1986, BIOCHEM BIOPH RES CO, V134, P1071, DOI 10.1016/0006-291X(86)90360-8; PITT JJ, 1993, CLIN CHIM ACTA, V223, P23, DOI 10.1016/0009-8981(93)90059-D; POULOS A, 1990, CLIN GENET, V37, P106; POULOS A, 1984, CLIN GENET, V26, P579; PRITCHARD KA, 1990, BIOCHEM BIOPH RES CO, V167, P137, DOI 10.1016/0006-291X(90)91741-A; ROCCHICCIOLI F, 1986, BIOMED ENVIRON MASS, V13, P315, DOI 10.1002/bms.1200130609; ROELS F, 1991, J INHERIT METAB DIS, V14, P853, DOI 10.1007/BF01800464; SAWAZAKI S, 1994, J NEUROCHEM, V62, P2437; SETCHELL KDR, 1987, SEMIN LIVER DIS, V7, P85, DOI 10.1055/s-2008-1040568; SPECTOR AA, 1985, J LIPID RES, V26, P1015; ULSAKER GA, 1984, ANALYST, V109, P967, DOI 10.1039/an9840900967; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANROLLINS M, 1984, J BIOL CHEM, V259, P5776; WEISS RH, 1987, ARCH BIOCHEM BIOPHYS, V252, P334, DOI 10.1016/0003-9861(87)90039-7; WIESNER DA, 1994, ANAL BIOCHEM, V217, P316, DOI 10.1006/abio.1994.1125	49	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3507	3516						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631955				2022-12-27	WOS:A1996TV72400029
J	Tsai, JC; Jain, M; Hsieh, CM; Lee, WS; Yoshizumi, M; Patterson, C; Perrella, MA; Cooke, C; Wang, H; Haber, E; Schlegel, R; Lee, ME				Tsai, JC; Jain, M; Hsieh, CM; Lee, WS; Yoshizumi, M; Patterson, C; Perrella, MA; Cooke, C; Wang, H; Haber, E; Schlegel, R; Lee, ME			Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; METAL-IONS; VITAMIN-C; KAPPA-B; DEATH; PROTOONCOGENE; TRANSCRIPTION; EXPRESSION; ACTIVATION	Pyrrolidinedithiocarbamate (PDTC) and N-acetylcysteine (NAG) have been used as antioxidants to prevent apoptosis in lymphocytes, neurons, and vascular endothelial cells, We report here that PDTC and NAC induce apoptosis in rat and human smooth muscle cells, In rat aortic smooth muscle cells, PDTC induced cell shrinkage, chromatin condensation, and DNA strand breaks consistent with apoptosis. In addition, overexpression of Bcl-2 suppressed vascular smooth muscle cell death caused by PDTC and NAG. The viability of rat aortic smooth muscle cells decreased within 3 h of treatment with PDTC and was reduced to 30% at 12 h. The effect of PDTC and NAC on smooth muscle cells was not species specific because PDTC and NAC both caused dose-dependent reductions in viability in rat and human aortic smooth muscle cells. In contrast, neither PDTC nor NAC reduced viability in human aortic endothelial cells. The use of antioxidants to induce apoptosis in vascular smooth muscle cells may help prevent their proliferation in arteriosclerotic lesions.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL,BALTIMORE,MD 21205	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA049749] Funding Source: NIH RePORTER; NCI NIH HHS [CA49749] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ARINAGA M, 1994, SCIENCE, V263, P754; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; COHEN JJ, 1994, J LAB CLIN MED, V124, P761; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JASJSEN YMW, 1993, LAB INVEST, V69, P261; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORSE NR, 1995, PROTOPLASMA, V184, P184; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; OLIVIER R, 1992, INT C AIDS, V8, P65; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; RAFF MC, 1994, SCIENCE, V264, P668, DOI 10.1126/science.8171317; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; ROEDERER M, 1993, PHARMACOLOGY, V46, P121, DOI 10.1159/000139037; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; Sambrook J, 1989, MOL CLONING LABORATO; SAMUNI A, 1983, EUR J BIOCHEM, V137, P119, DOI 10.1111/j.1432-1033.1983.tb07804.x; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIMIZU S, 1995, NATURE, V374, P81; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	50	203	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3667	3670						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631978				2022-12-27	WOS:A1996TV72400052
J	Willmott, N; Sethi, JK; Walseth, TF; Lee, HC; White, AM; Galione, A				Willmott, N; Sethi, JK; Walseth, TF; Lee, HC; White, AM; Galione, A			Nitric oxide-induced mobilization of intracellular calcium via the cyclic ADP-ribose signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; CGMP; ACTIVATION; CHANNEL; CELLS; FERTILIZATION; MECHANISMS	Cyclic adenosine diphosphate ribose (cADPR) is a potent endogenous calcium-mobilizing agent synthesized from beta-NAD(+) by ADP-ribosyl cyclases in sea urchin eggs and in several mammalian cells (Galione, A, and White, A (1994) Trends Cell Biol, 4, 431-436), Pharmacological studies suggest that cADPR is an endogenous modulator of Ca2+-induced Ca2+ release mediated by ryanodine-sensitive Ca2+ release channels, An unresolved question is whether cADPR can act as a Ca2+-mobilizing intracellular messenger, We show that exogenous application of nitric oxide (NO) mobilizes Ca2+ from intracellular stores in intact sea urchin eggs and that it releases Ca2+ and elevates cADPR levels in egg homogenates, 8-Amino-cADPR, a selective competitive antagonist of cADPR-mediated Ca2+ release, and nicotinamide, an inhibitor of ADP-ribosyl cyclase, inhibit the Ca2+-mobilizing actions of NO, while, heparin, a competitive antagonist of the inositol 1,4,5-trisphosphate receptor, did not affect NO-induced Ca2+ release, Since the Ca2+-mobilizing effects of NO can be mimicked by cGRIP, are inhibited by the cGMP-dependent-protein kinase inhibitor, R(p)-8-pCPT-cGMPS, and in egg homogenates show a requirement for the guanylyl cyclase substrate, GTP, we suggest a novel action of NO in mobilizing intracellular calcium from microsomal stores via a signaling pathway involving cGMP and cADPR, These results suggest that cADPR has the capacity to act as a Ca2+-mobilizing intracellular messenger.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Oxford; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Walseth, Timothy F/F-9518-2010; Lee, Hon Cheung/C-4329-2009; Sethi, Jaswinder K./B-1413-2008	Walseth, Timothy F/0000-0003-2558-7859; Sethi, Jaswinder K./0000-0003-4157-0475; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; AYABE T, 1995, DEVELOPMENT, V121, P2233; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY IB, 1993, MOL BIOL CELL, V4, P347, DOI 10.1091/mbc.4.3.347; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BUCK WR, 1992, EXP CELL RES, V202, P59, DOI 10.1016/0014-4827(92)90404-V; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DONNELLY LE, 1994, BIOCHEM PHARMACOL, V48, P1669, DOI 10.1016/0006-2952(94)90450-2; DOSHI M, 1985, EXP EYE RES, V41, P61, DOI 10.1016/0014-4835(85)90094-6; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KOHDA K, 1995, J NEUROPHYSIOL, V74, P2184, DOI 10.1152/jn.1995.74.5.2184; KONG SK, 1994, BIOCHEM BIOPH RES CO, V199, P234, DOI 10.1006/bbrc.1994.1219; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MONCADA S, 1991, PHARMACOL REV, V43, P109; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PUBLICOVER NG, 1993, P NATL ACAD SCI USA, V90, P2087, DOI 10.1073/pnas.90.5.2087; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; VINCENT SR, 1994, PROG NEUROBIOL, V42, P129, DOI 10.1016/0301-0082(94)90023-X; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WILLMOTT NJ, 1995, FEBS LETT, V371, P99, DOI 10.1016/0014-5793(95)00848-4; XU X, 1994, J BIOL CHEM, V269, P12645; YUE CP, 1995, DEVELOPMENT, V121, P2645	51	195	203	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3699	3705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631983				2022-12-27	WOS:A1996TV72400057
J	Durkin, ME; Gautam, M; Loechel, F; Sanes, JR; Merlie, JP; Albrechtsen, R; Wewer, UM				Durkin, ME; Gautam, M; Loechel, F; Sanes, JR; Merlie, JP; Albrechtsen, R; Wewer, UM			Structural organization of the human and mouse laminin beta 2 chain genes, and alternative splicing at the 5' end of the human transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN S-LAMININ; COLLAGEN-IV; NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; ADHESION MOLECULE; SYNAPTIC CLEFT; MESSENGER-RNAS; FACTOR AP-2; SEQUENCE; EXPRESSION	We have determined the structural organization of the human and mouse genes that encode the laminin beta 2 chain (s-laminin), an essential component of the basement membranes of the neuromuscular synapse and the kidney glomerulus. The human and mouse genes have a nearly identical exon-intron organization and are the smallest laminin chain genes characterized to date, due to the unusually small size of their introns, The laminin beta 2 chain genes of both species consist of 33 exons that span less than or equal to 12 kilobase pairs of genomic DNA. The exon-intron pattern of the laminin beta 2 chain gene is also highly similar to that of the human genes encoding the homologous laminin beta 1 and beta 3 chains. The putative promoter regions of the human and mouse laminin beta 2 chain genes have features characteristic of the promoters of genes that have a limited tissue expression. Considerable conservation of the intron sequences of the mouse and human genes was observed. The first intron of the human gene, located 1 base pair upstream of the translation start codon, contains a non-consensus 5' splice site, This intron was shown to be inefficiently spliced in humans, suggesting that post-transcriptional mechanisms may be involved in the regulation of laminin beta 2 chain gene expression.	UNIV COPENHAGEN, INST PATHOL ANAT, LAB MOLEC PATHOL, DK-2100 COPENHAGEN, DENMARK; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	University of Copenhagen; Washington University (WUSTL); Washington University (WUSTL)				Albrechtsen, Reidar/0000-0003-4180-1827				ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Engvall E, 1996, J CELL BIOCHEM, V61, P493; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HUNTER DD, 1992, J COMP NEUROL, V323, P238, DOI 10.1002/cne.903230208; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; OKANO R, 1992, BIOCHIM BIOPHYS ACTA, V1132, P49, DOI 10.1016/0167-4781(92)90051-Z; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PORTER BE, 1993, GENOMICS, V16, P278, DOI 10.1006/geno.1993.1178; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; PULKKINEN L, 1995, GENOMICS, V25, P192, DOI 10.1016/0888-7543(95)80125-6; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REING J, 1992, J BIOL CHEM, V267, P23143; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; Rohrbach DH, 1993, MOL CELLULAR ASPECTS; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SUGIMOTO M, 1994, P NATL ACAD SCI USA, V91, P11679, DOI 10.1073/pnas.91.24.11679; TANAKA S, 1993, J BIOL CHEM, V268, P8862; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAILLY J, 1994, GENOMICS, V21, P286, DOI 10.1006/geno.1994.1263; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEWER UM, 1995, NEUROLOGY, V45, P2099, DOI 10.1212/WNL.45.11.2099; WEWER UM, 1994, LAB INVEST, V71, P719; WEWER UM, 1994, GENOMICS, V24, P243, DOI 10.1006/geno.1994.1612; YAMADA H, 1995, LAB INVEST, V72, P715; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	70	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13407	13416		10.1074/jbc.271.23.13407	http://dx.doi.org/10.1074/jbc.271.23.13407			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662701	hybrid			2022-12-27	WOS:A1996UP38500018
J	Klebanow, ER; Poon, D; Zhou, S; Weil, PA				Klebanow, ER; Poon, D; Zhou, S; Weil, PA			Isolation and characterization of TAF25, an essential yeast gene that encodes an RNA polymerase II-specific TATA-binding protein-associated factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIIB; HUMAN ESTROGEN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; CLONED GENES; EXPRESSION; TBP; IDENTIFICATION; PURIFICATION; COMPONENTS; PROMOTERS	We describe the cloning and analysis of TAF25, a previously uncharacterized yeast gene that encodes a yeast TATA-binding protein-associated factor or yTAF or M(r) = 25,000. The gene encoding yTAF25 is a single copy essential gene, and the protein sequence deduced from TAF25 exhibits sequence similarity to a metazoan hTAF(II). The results for immunological studies confirm that yTAF25 is a subunit of a large multiprotein TATA-binding protein-yeast TATA-binding protein-associated factor complex that contains a subset of the total number of the yTAFs present in yeast cell extracts. Both genetic and biochemical analyses demonstrate that yTAF25 can interact directly with itself. Transcriptional data show that the activity of the multiprotein complex containing yTAF25 is RNA polymerase II-specific, thus indicating that TAF25 encodes a bona fide yeast RNA polymerase II TAF. Hence the protein encoded by TAF25 has been termed yTAF (II)25.	VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,BERKELEY,CA 94720	Vanderbilt University; Howard Hughes Medical Institute; University of California System; University of California Berkeley					NCI NIH HHS [CA09385] Funding Source: Medline; NIGMS NIH HHS [GM52461] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1991, Methods Enzymol, V194, P1; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOCKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KARNITZ L, 1989, MOL CELL BIOL, V9, P1929, DOI 10.1128/MCB.9.5.1929; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LIU HP, 1992, GENETICS, V132, P665; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P11938, DOI 10.1073/pnas.91.25.11938; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; POON D, 1993, J BIOL CHEM, V268, P5005; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROEDER SC, 1994, J BIOL CHEM, V269, P28335; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWAFFIELD J, 1995, NATURE, V374, P89; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	75	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13706	13715		10.1074/jbc.271.23.13706	http://dx.doi.org/10.1074/jbc.271.23.13706			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662725	hybrid			2022-12-27	WOS:A1996UP38500062
J	Shiraiwa, N; Inohara, N; Okada, S; Yuzaki, M; Shoji, S; Ohta, S				Shiraiwa, N; Inohara, N; Okada, S; Yuzaki, M; Shoji, S; Ohta, S			An additional form of rat Bcl-x, Bcl-x beta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-B-CELLS; PROTOONCOGENE BCL-2; SEQUENCE SIMILARITY; FOLLICULAR LYMPHOMA; DNA FRAGMENTATION; GENE; DEATH; EXPRESSION; SURVIVAL; PROTEIN	The bcl-2 oncogene product delays apoptotic cell death and prolongs the cell survival, We cloned two bcl-2-related cDNAs from a rat thymus cDNA library by low stringency hybridization with a rat bcl-2 fragment as a probe. One of these, designated bcl-x alpha, was a counterpart of the human bcl-x(L) reported previously as a bcl-2-related gene (Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, M., Nunez, G., and Thompson, C. B. (1993) Cell 74, 597-608). The other, designated bcl-x beta, was novel and found to be generated by an unspliced mRNA, whereas bcl-x alpha was generated from a spliced transcript. The splice junction exactly corresponded to that found in the bcl-2 gene. bcl-x beta was specifically expressed in cerebellum, heart, and thymus. When bcl-x beta directed by a strong promoter was introduced into an interleukin-3-dependent promyeloid cell line, FDC-P1, DNA fragmentation was observed even in the growing state in the presence of interleukin-3 although not in the control transfectants. This finding suggests that the rat bcl-x beta gene product promotes apoptosis in the promyeloid cells.	NIPPON MED COLL, INST GERONTOL, DIV BIOCHEM, NAKAHARA KU, KAWASAKI, KANAGAWA 211, JAPAN; JICHI MED SCH, DEPT BIOCHEM, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; UNIV TSUKUBA, INST MED, DEPT NEUROL, TSUKUBA, IBARAKI 305, JAPAN	Nippon Medical School; Jichi Medical University; University of Tsukuba			Yuzaki, Michisuke/K-5328-2013	Yuzaki, Michisuke/0000-0002-5750-3544				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BORZILLO GV, 1992, ONCOGENE, V7, P869; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; FANG W, 1994, J IMMUNOL, V153, P4388; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LIN EY, 1993, J IMMUNOL, V151, P1979; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	55	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13258	13265		10.1074/jbc.271.22.13258	http://dx.doi.org/10.1074/jbc.271.22.13258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662675	hybrid			2022-12-27	WOS:A1996UN47400088
J	Theopold, U; Samakovlis, C; ErdjumentBromage, H; Dillon, N; Axelsson, B; Schmidt, O; Tempst, P; Hultmark, D				Theopold, U; Samakovlis, C; ErdjumentBromage, H; Dillon, N; Axelsson, B; Schmidt, O; Tempst, P; Hultmark, D			Helix pomatia lectin, an inducer of Drosophila immune response, binds to hemomucin, a novel surface mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRICTOSIDINE SYNTHASE; RAUVOLFIA-SERPENTINA; T-CELLS; EXPRESSION; PROTEINS; SEQUENCE; GENE; CD43; ENHANCEMENT; LEUKOSIALIN	We describe the isolation and initial characterization of hemomucin, a novel Drosophila surface mucin that is likely to be involved in the induction of antibacterial effector molecules after binding a snail lectin (Helix pomatia A hemagglutinin). Two proteins of 100 and 220 kDa were purified from the membrane fraction of a Drosophila blood cell line using lectin columns. The two proteins are products of the same gene, as demonstrated by peptide sequencing. The corresponding cDNAs code for a product that contains an amino-terminal putative transmembrane domain, a domain related to the plant enzyme strictosidine synthase, and a mucin-like domain in the carboxyl-terminal part of the protein. The gene is expressed throughout development. In adult flies, high expression is found in hemocytes, in specialized regions of the gut, and in the ovary, where the protein is deposited onto the egg surface. In the gut, the mucin co-localizes with the peritrophic membrane. The cytogenetic location of the gene is on the third chromosome in the region 97F-98A.	UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT IMMUNOL, S-10691 STOCKHOLM, SWEDEN; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Stockholm University; Stockholm University; Memorial Sloan Kettering Cancer Center	Theopold, U (corresponding author), UNIV ADELAIDE, DEPT CROP PROTECT, WAITE CAMPUS, GLEN OSMOND, SA 5064, AUSTRALIA.		Theopold, Ulrich/P-7205-2015; Dillon, Natalie L/B-7168-2015; Hultmark, Dan/C-5058-2013	Theopold, Ulrich/0000-0002-1009-8254; Hultmark, Dan/0000-0002-6506-5855; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; AXELSSON B, 1978, EUR J IMMUNOL, V8, P757, DOI 10.1002/eji.1830081102; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; BIERER BE, 1988, IMMUNOL ALLERGY CLIN, V8, P51; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BRACHER D, 1992, ARCH BIOCHEM BIOPHYS, V294, P717, DOI 10.1016/0003-9861(92)90746-J; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CASTEELSJOSSON K, 1994, J BIOL CHEM, V269, P28569; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COCIANCICH S, 1994, PARASITOL TODAY, V10, P132, DOI 10.1016/0169-4758(94)90260-7; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DEMEREC M, 1950, BIOL DROSOPHILA, P425; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GEROMANOS S, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P143; Gupta Ayodhya P., 1991, P19; Harlow E., 1988, ANTIBODIES LAB MANUA; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; ISHIKAWA N, 1994, IMMUNOLOGY, V81, P480; KUTCHAN TM, 1988, FEBS LETT, V237, P40, DOI 10.1016/0014-5793(88)80167-4; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; MANTLE M, 1993, INFECT IMMUN, V61, P4131, DOI 10.1128/IAI.61.10.4131-4138.1993; NAPPI AJ, 1984, SCIENCE, V225, P1166, DOI 10.1126/science.6433482; NASSEL DR, 1985, NEUROSCIENCE, V15, P293, DOI 10.1016/0306-4522(85)90136-8; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RIZKI TM, 1983, SCIENCE, V220, P73, DOI 10.1126/science.6402819; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SHI BB, 1994, PARASITE IMMUNOL, V16, P553, DOI 10.1111/j.1365-3024.1994.tb00310.x; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; THEOPOLD U, 1995, MOL CELL BIOL, V15, P824; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; WICKER C, 1990, J BIOL CHEM, V265, P22493; YANO Y, 1994, BIOCHEM J, V299, P303, DOI 10.1042/bj2990303	53	84	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12708	12715		10.1074/jbc.271.22.12708	http://dx.doi.org/10.1074/jbc.271.22.12708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662683	hybrid			2022-12-27	WOS:A1996UN47400006
J	Shiffman, D; Brooks, EE; Brooks, AR; Chan, CS; Milner, PG				Shiffman, D; Brooks, EE; Brooks, AR; Chan, CS; Milner, PG			Characterization of the human cyclin-dependent kinase 2 gene - Promoter analysis and gene structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC2 GENE; CELL-CYCLE; PROTEIN-KINASES; EXPRESSION; TRANSCRIPTION	Cyclin-dependent kinase 2 is a serine/threonine protein kinase essential for progression of the mammalian cell cycle from G(1) to S phase, CDK2 mRNA has been shown to be induced by serum in several cultured cell types. Therefore, we set out to identify elements that regulate the transcription of the human CDK2 gene and to characterize its structure. This paper describes the cloning of a similar to 2.4-kilobase pair genomic DNA fragment from the upstream region of the human CDK2 gene, This fragment contains five transcription initiation sites within a 72-nucleotide stretch, A 200-base pair sub-fragment that confers 70% of maximal basal promoter activity was shown to contain two synergistically acting Sp1 sites. However, a much larger DNA fragment containing similar to 1.7 kilobase pairs of upstream sequence is required for induction of promoter activity following serum stimulation. The intron exon boundaries of seven exons in this gene were also identified, and this information will be useful for analyzing genomic abnormalities associated with CDK2.			Shiffman, D (corresponding author), CV THERAPEUT, 3172 PORTER DR, PALO ALTO, CA 94304 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; FUCHS R, 1994, COMPUT APPL BIOSCI, V10, P171; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRANA X, 1995, ONCOGENE, V11, P211; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERBER, 1994, ONCOGENE, V9, P2105; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; KU DH, 1993, J BIOL CHEM, V268, P2255; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; OCHMAN H, 1989, PCR TECHNOLOGY PRINC, P105; OLIVE M, 1994, GENE, V151, P81, DOI 10.1016/0378-1119(94)90635-1; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHIEFFER E, 1995, RESTENOSIS SUMMIT, V7, P23; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHIFFMAN D, 1993, J BACTERIOL, V175, P6767, DOI 10.1128/jb.175.21.6767-6774.1993; TANGUAY DA, 1994, MOL IMMUNOL, V31, P643, DOI 10.1016/0161-5890(94)90173-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	36	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12199	12204		10.1074/jbc.271.21.12199	http://dx.doi.org/10.1074/jbc.271.21.12199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647814	hybrid			2022-12-27	WOS:A1996UL66000016
J	Durante, W; Liao, L; Iftikhar, I; Cheng, K; Schafer, AI				Durante, W; Liao, L; Iftikhar, I; Cheng, K; Schafer, AI			Platelet-derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; ECOTROPIC RETROVIRUS RECEPTOR; POLYAMINE METABOLISM; ENDOTHELIAL-CELLS; HEPATOMA-CELLS; PUTRESCINE; MOUSE; ATHEROSCLEROSIS; IDENTIFICATION; PATHOGENESIS	Since recent studies demonstrated that platelet derived growth factor (PDGF) induces vascular smooth muscle cell (SMC) proliferation by stimulating polyamine synthesis, we examined whether the transcellular transport of L-ornithine, the cationic amino acid precursor of polyamines, could regulate the mitogenic response of PDGF. Treatment of SMC with PDGF stimulated DNA and putrescine synthesis, and this was enhanced further by increasing the extracellular concentration of L-ornithine. The potentiating effect of L-ornithine was reversed by the competitive inhibitor of cationic amino acid transport, methyl-L-arginine, or by preventing putrescine formation with alpha-difluoromethylornithine. Cationic amino acid uptake by SMC was Na+-independent and was mediated by both a high and low affinity carrier system. Treatment of SMC with PDGF initially (0-2 h) decreased basic amino acid transport, while longer exposures (6-24 h) progressively increased uptake. Kinetic studies indicated that PDGF-induced inhibition was associated with a decrease in affinity for cationic amino acids, while the stimulation was mediated by an increase in transport capacity. Endogenous PDGF released by collagen-activated platelets likewise up-regulated cationic amino acid transport in SMC. Reverse transcriptase-polymerase chain reaction detected the presence of mRNA encoding two distinct cationic amino acid transporter (CAT) proteins, CAT-1 and CAT-2B. Treatment of SMC with PDGF strongly induced the expression CAT-2B mRNA and modestly elevated the level of CAT-1 mRNA, These results demonstrate that PDGF-induced polyamine synthesis and SMC mitogenesis are dependent on the transcellular transport of L-ornithine. The capacity of PDGF to up-regulate the transport of L-ornithine by inducing the expression of the genes for CAT-1 and CAT-2B may modulate its mitogenic effect by providing SMC with the necessary intracellular precursor for polyamine biosynthesis.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), VET AFFAIRS MED CTR,BLDG 109,RM 116,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NHLBI NIH HHS [HL 36045] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BYUS CV, 1991, J CELL PHYSIOL, V149, P9, DOI 10.1002/jcp.1041490103; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J VIROL, V67, P2097, DOI 10.1128/JVI.67.4.2097-2102.1993; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; DURANTE W, 1994, BLOOD, V83, P1831; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GONZALEZ GG, 1991, CANCER RES, V51, P2932; Kakuda DK, 1993, TRANSGENE, V1, P91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; PEGG AE, 1988, CANCER RES, V48, P759; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; SESSA WC, 1990, P NATL ACAD SCI USA, V87, P8607, DOI 10.1073/pnas.87.21.8607; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WU VS, 1984, BIOCHIM BIOPHYS ACTA, V804, P89, DOI 10.1016/0167-4889(84)90102-2; ZIERLER RE, 1982, ARCH SURG-CHICAGO, V117, P1408	32	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11838	11843		10.1074/jbc.271.20.11838	http://dx.doi.org/10.1074/jbc.271.20.11838			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662668	hybrid			2022-12-27	WOS:A1996UL25000042
J	Luo, Y; Karpichev, IV; Kohanski, RA; Small, GM				Luo, Y; Karpichev, IV; Kohanski, RA; Small, GM			Purification, identification, and properties of a Saccharomyces cerevisiae oleate-activated upstream activating sequence-binding protein that is involved in the activation of POX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL CONTROL; GENE; PROLIFERATION; YEAST; OXIDASE; MUTANTS; GAL4; DNA	Peroxisomes have a central function in lipid metabolism, and it is well established that these organelles are inducible by many compounds including fatty acids. Peroxisomes are the sole site for the beta-oxidation of fatty acids in yeast. The first and rate limiting enzyme of this cycle is fatty acyl-CoA oxidase. The gene encoding this enzyme in Saccharomyces cerevisiae (POX1) undergoes a complex regulation that is dependent on the growth environment. When this yeast is grown in medium containing oleic acid as the main carbon source, peroxisomes are induced and POX1 expression is activated. When cells are grown in the presence of glucose, the expression of POX1 mRNA is repressed, whereas growth on a carbon source such as glycerol or raffinose causes derepression. This rigorous regulation is brought about by the complex interactions between trans-acting factors and cis-elements in the POX1 promoter. Previously, we characterized regulatory elements in the promoter region of POX1 that are involved in the repression and activation of this gene (Wang, T., Luo, Y., and Small, G. M. (1994) J. Biol. Chem. 269, 24480-24485). In this study we have purified and identified an oleate-activated transcription factor (Oaf1p) that binds to the activating sequence (UAS1) in the POX1 gene. The protein has a predicted molecular mass of approximately 118 kDa.	CUNY MT SINAI SCH MED,DEPT CELL BIOL ANAT,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								Ausubel FM, 1994, CURRENT PROTOCOLS MO; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; EINERHAND AWC, 1995, MOL CELL BIOL, V15, P3405; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FERNANDEZ J, 1995, TECH PROT CHEM, V6, P135, DOI 10.1016/S1080-8914(06)80019-0; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; STANWAY CA, 1995, CURR GENET, V27, P404, DOI 10.1007/BF00311208; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1994, J BIOL CHEM, V269, P24480; WANG TW, 1992, NUCLEIC ACIDS RES, V20, P3495, DOI 10.1093/nar/20.13.3495; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133	33	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12068	12075		10.1074/jbc.271.20.12068	http://dx.doi.org/10.1074/jbc.271.20.12068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662598	hybrid			2022-12-27	WOS:A1996UL25000073
J	ManzanoWinkler, B; Novina, CD; Roy, AL				ManzanoWinkler, B; Novina, CD; Roy, AL			TFII is required for transcription of the naturally TATA-less but initiator-containing V beta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; BINDING PROTEIN; COMPLEX; SPECIFICITY; SEQUENCE; USF	The proximal or core promoter of a typical eukaryotic protein coding gene comprises distinct elements, TATA and/or initiator (Inr). The existence of TATA or Inr at the core promoter suggests that the mechanism of transcription initiation mediated by these two genetic elements may be different. Accordingly, it has been demon strated that the transcriptional requirements for the TATA-containing, Inr-less (TATA(+)Inr(-)) promoters are different from the transcriptional requirements for the TATA-less, Inr-containing (TATA(-)Inr(+)) promoters. Although both types of promoters require the transcription initiation factor (TFIID) in addition to other common initiation factors, a TATA(-)Inr(+) promoter requires accessory component(s). Here we have employed in vitro analyses to address the transcription factor requirements for a TATA(-)Inr(+) promoter. We demonstrate that in addition to TFIID, a naturally occurring TATA(-)Inr(+-) promoter requires TFII-I, an Inr element-dependent transcription factor. Consistent with its Inr element-dependent activities, TFII-I is dispensable for a TATA(+)Inr(-) promoter. Furthermore, we demonstrate that both TFII-I and TFIID activities in nuclear extracts are temperature-sensitive. However, TFII-I is heat-inactivated at temperatures lower than that required to inactivate TFIID. Therefore, differential heat treatment of nuclear extracts provides an assay to discriminate between transcriptional requirements at TATA(+)Inr(-) and TATA(-)Inr(+) promoters.	TUFTS UNIV,SCH MED,DEPT PATHOL,DIV IMMUNOL,SACKLER SCH GRAD STUDIES,BOSTON,MA 02111	Tufts University								ANDERSON SJ, 1988, P NATL ACAD SCI USA, V85, P3551, DOI 10.1073/pnas.85.10.3551; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARACAMO J, 1991, P NATL ACAD SCI USA, V88, P8052; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P583; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1994, INDIAN J BIOCHEM BIO, V31, P14; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	30	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12076	12081		10.1074/jbc.271.20.12076	http://dx.doi.org/10.1074/jbc.271.20.12076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662630	hybrid			2022-12-27	WOS:A1996UL25000074
J	Myette, JR; Niles, EG				Myette, JR; Niles, EG			Domain structure of the vaccinia virus mRNA capping enzyme - Expression in Escherichia coli of a subdomain possessing the RNA 5'-triphosphatase and guanylyltransferase activities and a kinetic comparison to the full-size enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED TRYPTIC DIGESTION; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; GUANYLATE INTERMEDIATE; PURIFICATION; VIRIONS; SUBUNIT; TRANSCRIPTION; ASSOCIATION; POLYMERASE	The RNA 5'-triphosphatase, nucleoside triphosphate phosphohydrolase, and guanylyltransferase activities of the vaccinia virus mRNA capping enzyme were previously localized to an NH2-terminal 60-kDa domain of the D1R subunit. Measurement of the relative ATPase and guanylyltransferase activities remaining in D1R carboxyl-terminal deletion variants expressed in Escherichia coli BL21(DE3)plysS localizes the carboxyl terminus of the active domain to between amino acids 520 and 545. Failure to obtain a deletion mutant with the loss of one activity indicates that the catalysis of both reactions requires a common domain structure. Based on these results, a truncated D1R protein terminating at amino acid 545 was expressed in E. coli and purified to homogeneity. D1R(1-545) was found to be kinetically equivalent to the holoenzyme in regard to ATPase, RNA 5'-triphosphatase, and guanylyltransferase activities. Measurement of RNA binding by mobility shift and UV photo-cross-linking analyses also demonstrates the ability of this domain to bind RNA independent of the methyltransferase domain, comprised of the carboxyl terminus of D1R from amino acids 498-844 and the entire D12L subunit. RNA binding to D1R(1-545) is substantially weaker than binding to either the methyltransferase domain or the holoenzyme. Binding is inhibited by 5'-OH RNA and to a lesser extent by DNA oligonucleotides in a concentration dependent manner which correlates with the inhibition of RNA 5'-triphosphatase activity by these same oligonucleotides. We conclude that D1R(1-545) represents a functionally independent domain of the mRNA capping enzyme, fully competent in substrate binding and catalysis at both the triphosphatase and guanylyltransferase active sites.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214; SUNY BUFFALO,SCH MED & BIOMED SCI,CTR ADV MOL BIOL & IMMUNOL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1988, J VIROL, V63, P226; BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; ITOH N, 1987, J BIOL CHEM, V262, P1989; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V57, P314, DOI 10.1073/pnas.57.2.314; LUO Y, 1993, J BIOL CHEM, V268, P21253; MAO XD, 1994, J BIOL CHEM, V269, P24472; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; MOSS B, 1975, J BIOL CHEM, V250, P4722; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; NILES EG, 1994, BIOCHEMISTRY-US, V33, P9898, DOI 10.1021/bi00199a011; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YAGI Y, 1984, J BIOL CHEM, V259, P4695; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; [No title captured]	43	42	73	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11936	11944		10.1074/jbc.271.20.11936	http://dx.doi.org/10.1074/jbc.271.20.11936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662635	hybrid			2022-12-27	WOS:A1996UL25000056
J	Preece, G; Murphy, G; Ager, A				Preece, G; Murphy, G; Ager, A			Metalloproteinase-mediated regulation of L-selectin levels on leucocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; PROTEIN-KINASE-C; CELL-SURFACE; CHEMOTACTIC FACTORS; HOMING RECEPTOR; ADHESION; ACTIVATION; LYMPHOCYTES; INHIBITORS; INVIVO	Leucocyte (L)-selectin can be proteolytically cleaved in the membrane proximal extracellular region to yield a soluble fragment that contains the functional lectin and epidermal growth factor domains. A variety of stimuli are known to stimulate L-selectin shedding including chemoattractants, phorbol esters, and L-selectin cross-linking; however, the enzymes that regulate L-selectin expression are not characterized, In this study we have used phorbol ester to stimulate endoproteolytic release of L-selectin and identified a major role for a cell surface metalloproteinase (L-selectin sheddase) in this process. The hydroxamic acid based inhibitor of zinc-dependent matrix metalloproteinases Ro 31-9790 completely prevented shedding of cell surface L-selectin from leucocytes in mouse, rat, and man, L-selectin was susceptible to cleavage by known matrix metalloproteinases. Recombinant human fibroblast collagenase (MMP1) reduced the number of L-selectin-positive lymphocytes to a similar extent as phorbol ester activation, and stromelysin (MMP3) had a partial effect on L-selectin expression, Gelatinases A (MMP2) and B (MMP9) were without effect, Lymphocytes did not express fibroblast collagenase or stromelysin at the cell surface, and tissue inhibitor of metalloproteinases (TIMP) did not affect L-selectin levels, L-selectin sheddase was not detected in media harvested from phorbol ester stimulated lymphocytes and was only able to cleave L selectin in the cis but not the trans configuration. These results suggest that endoproteolytic release of L-selectin from the leucocyte surface is mediated by a metalloproteinase (L-selectin sheddase), which is distinguishable from known matrix metalloproteinases. Understanding the regulation of L-selectin sheddase will be critical for controlling leucocyte migration from the blood.	NATL INST MED RES,DIV CELLULAR IMMUNOL,LONDON NW7 1AA,ENGLAND; STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND	MRC National Institute for Medical Research				Ager, Ann/0000-0002-5763-8908				ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BAZIL V, 1994, J IMMUNOL, V152, P1314; BUHRER C, 1992, SCAND J IMMUNOL, V35, P107, DOI 10.1111/j.1365-3083.1992.tb02839.x; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Johnson W H, 1987, J Enzyme Inhib, V2, P1, DOI 10.3109/14756368709030352; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, BLOOD, V77, P2553; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, LEUKEMIA, V5, P300; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; UMEZAWA H, 1983, PROTEINASE INHIBITOR, P3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHANG LS, 1994, J IMMUNOL, V153, P3745	45	192	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11634	11640		10.1074/jbc.271.20.11634	http://dx.doi.org/10.1074/jbc.271.20.11634			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662605	hybrid			2022-12-27	WOS:A1996UL25000011
J	Wilson, MP; Majerus, PW				Wilson, MP; Majerus, PW			Isolation of inositol 1,3,4-trisphosphate 5/6-kinase, cDNA cloning, and expression of the recombinant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; RECEPTOR ACTIVATION; METABOLISM; PHOSPHORYLATION; PHOSPHATES; CELLS; 1,3,4,6-TETRAKISPHOSPHATE; TETRAKISPHOSPHATE; 1,3-BISPHOSPHATE; TRISPHOSPHATE	Inositol 1,3,4-trisphosphate 5/6-kinase was purified 12,900-fold from calf brain using chromatography on heparin-agarose and affinity elution with inositol hexakisphosphate. The final preparation contained proteins of 48 and 36-38 kDa. All of these proteins had the same amino-terminal sequence and were enzymatically active. The smaller species represent proteolysis products with carboxyl-terminal truncation. The K-m of the enzyme for inositol 1,3,4-trisphosphate was 80 nM with a V-max of 60 nmol of product/min/mg of protein. The amino acid sequence of the tryptic peptide HSKLLARPAG-GLVGERTCNAXP matched the protein sequence encoded by a human expressed sequence tag clone (GB T09063) at 16 of 22 residues. The expressed sequence tag clone was used to screen a human fetal brain cDNA library to obtain a cDNA clone of 1991 base pairs (bp) that predicts a protein of 46 kDa. The clone encodes the amino-terminal amino acid sequence obtained from the purified calf brain preparation, suggesting that it represents its human homologue. The cDNA was expressed as a fusion protein in Escherichia coli and was found to have inositol 1,3,4-trisphosphate 5/6-kinase activity. Remarkably, both the purified calf brain and recombinant proteins produced both inositol 1,3,4,6-tetrakisphosphate and inositol 1,3,4,5-tetrakisphosphate as products in a ratio of 2.3-5:1. This finding proves that a single kinase phosphorylates inositol in both the D5 and D6 positions. Northern blot analysis identified a transcript of 3.6 kilobases in all tissues with the highest levels in brain. The composite cDNA isolated contains 3054 bp with a poly(A) tail, suggesting that 500-600 bp of 5' sequence remains to be identified.			Wilson, MP (corresponding author), WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,660 S EUCLID,BOX 8125,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, T32HL007088, R37HL016634, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14147, HL 16634, HL 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLA T, 1987, J BIOL CHEM, V262, P9952; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BARON CB, 1995, J BIOL CHEM, V270, P20459, DOI 10.1074/jbc.270.35.20459; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUONO P, 1990, EUR J BIOCHEM, V192, P805, DOI 10.1111/j.1432-1033.1990.tb19294.x; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COCCO L, 1995, ADV ENZYME REGUL, V35, P23, DOI 10.1016/0065-2571(94)00004-M; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHES PJ, 1994, BBA-MOL CELL RES, V1223, P57, DOI 10.1016/0167-4889(94)90073-6; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	28	68	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11904	11910		10.1074/jbc.271.20.11904	http://dx.doi.org/10.1074/jbc.271.20.11904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662638	hybrid			2022-12-27	WOS:A1996UL25000052
J	deCarvalho, MGS; McCormack, AL; Olson, E; Ghomashchi, F; Gelb, MH; Yates, JR; Leslie, CC				deCarvalho, MGS; McCormack, AL; Olson, E; Ghomashchi, F; Gelb, MH; Yates, JR; Leslie, CC			Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A(2) expressed in insect cells and present in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; PRODUCT-CONTAINING VESICLES; PROTEIN-KINASE-C; MOBILIZING PHOSPHOLIPASE-A2; MACROPHAGES; ACTIVATION; ACID; LIPOPOLYSACCHARIDE; MEMBRANE; LINE	The phosphorylation sites on the human, 85-kDa cytosolic phospholipase A(2) (cPLA(2)) were identified using recombinant cPLA, expressed in Spodoptera frugiperda (Sf9) cells, Analysis by high performance liquid chromatography of tryptic digests of P-32-labeled recombinant cPLA(2) showed four major peaks of radiolabeled phosphopeptides. The phosphorylated residues were identified as Ser-437, Ser-454, Ser-505, and Ser-727 using mass spectrometry and automated Edman sequencing, Sf9 cells infected with recombinant virus expressing cPLA(2) exhibited a time-dependent release of arachidonic acid in response to the calcium ionophore A23187 or the protein phosphatase inhibitor okadaic acid, which was not observed in Sf9 cells infected with wild-type virus, Stimulation of Sf9 cells with A23187 and okadaic acid also increased the level of phosphorylation of cPLA(2). Okadaic acid, but not A23187, induced a gel shift of cPLA(2) and increased the level of phosphorylation of Ser-727 by 4.5-fold, whereas the level of phosphorylation of the other sites increased by 60% or less in response to both agonists, To determine whether the same sites on cPLA(2) were phosphorylated in mammalian cells, human monocytes were studied, Okadaic acid stimulation of monocytes induced a gel shift of cPLA(2), increased the release of arachidonic acid, and increased the level of phosphorylation of cPLA(2) on serine residues, Comparison of two-dimensional peptide maps of tryptic digests of P-32-labeled recombinant cPLA(2) and human monocyte cPLA(2) demonstrated that the same peptides on cPLA(2) were phosphorylated in mammalian cells as in insect cells. These results show that the Sf9-baculovirus expression system is useful for investigation of the phosphorylation sites on cPLA(2). The results also suggest that phosphorylation of the cPLA(2) by protein kinases other than mitogen-activated protein kinase may he important for the regulation of arachidonic acid release.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT CHEM & BIOCHEM, SEATTLE, WA 98195 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50040, P01 HL034303, HL34303] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULLAH K, 1995, BBA-GEN SUBJECTS, V1244, P157, DOI 10.1016/0304-4165(94)00218-M; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE GJ, 1993, J AM SOC MASS SPECTR, V4, P955, DOI 10.1016/1044-0305(93)80022-Q; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1986, BIOCHEM J, V236, P251, DOI 10.1042/bj2360251; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SVENSSON U, 1993, EUR J BIOCHEM, V213, P81, DOI 10.1111/j.1432-1033.1993.tb17736.x; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WATERMAN WH, 1995, BIOCHEM BIOPH RES CO, V209, P271, DOI 10.1006/bbrc.1995.1499; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; XU XX, 1994, J BIOL CHEM, V269, P31693; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; YATES JR, 1994, CELL BIOL LABORATORY, P380	44	153	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6987	6997		10.1074/jbc.271.12.6987	http://dx.doi.org/10.1074/jbc.271.12.6987			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636128	hybrid			2022-12-27	WOS:A1996UB15700063
J	Fox, JEB; Shattil, SJ; KinloughRathbone, RL; Richardson, M; Packham, MA; Sanan, DA				Fox, JEB; Shattil, SJ; KinloughRathbone, RL; Richardson, M; Packham, MA; Sanan, DA			The platelet cytoskeleton stabilizes the interaction between alpha(IIb)beta(3) and its ligand and induces selective movements of ligand-occupied integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; SUSPENSION-ACTIVATED PLATELETS; OPEN CANALICULAR SYSTEM; MEMBRANE SKELETON; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIN-FILAMENTS; COLLOIDAL GOLD; GPIIB-IIIA; DEPENDENT PHOSPHORYLATION	Previously, we showed that a subpopulation of the major platelet integrin, alpha(IIb)beta(3), co-sediments from detergent lysates with talin and other membrane skeleton proteins. Once alpha(IIb)beta(3) has bound adhesive ligand in a platelet aggregate, the detergent-insoluble alpha(IIb)beta(3) redistributes (along with the detergent-insoluble membrane skeleton proteins and a variety of signaling molecules) to a fraction that contains cytoplasmic actin filaments. Concomitantly, certain signaling molecules are activated, The present study shows that, in intact platelets, alpha(IIb)beta(3) forms clusters when occupied by ligand and is selectively moved into the open canalicular system; alpha(IIb)beta(3) that has not bound ligand remains diffusely distributed at the periphery of the cell. When cytoplasmic actin filaments are depolymerized by cytochalasins, the ability of alpha(IIb)beta(3) to bind ligand is decreased, and the movement of ligand-occupied alpha(IIb)beta(3) is prevented. Together with the previous findings, these results suggest that (i) membrane skeleton-associated alpha(IIb)beta(3) is selectively induced to bind ligand in activated platelets, (ii) ligand-induced transmembrane signaling causes an altered association of membrane skeleton-associated alpha(IIb)beta(3) with the cytoplasmic component of the cytoskeleton, (iii) ligand-induced cytoskeletal reorganizations stabilize the interaction between ligand and integrin, and (iv) ligand-occupancy triggers cytoskeletal reorganizations that result in selective movements of occupied ligand.	CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609; UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; MCMASTER UNIV,HAMILTON,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON,CANADA; QUEENS UNIV,KINGSTON,ON,CANADA; GLADSTONE INST,SAN FRANCISCO,CA 94141	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Pennsylvania; University of Pennsylvania; McMaster University; University of Toronto; Queens University - Canada; University of California System; University of California San Francisco; The J David Gladstone Institutes	Fox, JEB (corresponding author), CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL FF20,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, P01HL040387, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL-49888, HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; ALBRECHT RM, 1989, AM J ANAT, V185, P149, DOI 10.1002/aja.1001850208; ALBRECHT RM, 1994, PROC ANN MEET MSA, P1016; ALBRECHT RM, 1990, FIBRINOGEN, V4, P87; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; DANSCHER G, 1983, J HISTOCHEM CYTOCHEM, V31, P1394, DOI 10.1177/31.12.6631001; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; EPPELL SJ, 1995, BIOPHYS J, V68, P671, DOI 10.1016/S0006-3495(95)80228-6; ESCOLAR G, 1989, BLOOD, V74, P1983; ESCOLAR G, 1994, MICROSC RES TECHNIQ, V28, P308, DOI 10.1002/jemt.1070280407; ESCOLAR G, 1991, BLOOD CELLS, V17, P467; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1989, J BIOL CHEM, V264, P9520; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOFTUS JC, 1984, J CELL BIOL, V99, P822, DOI 10.1083/jcb.99.3.822; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARGUERIE GA, 1983, ANN NY ACAD SCI, V408, P556, DOI 10.1111/j.1749-6632.1983.tb23272.x; MARUYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V626, P494; OLIVER JA, 1987, SCANNING MICROSCOPY, V1, P745; OLORUNDARE OE, 1993, EUR J CELL BIOL, V60, P131; OLURANDARE OE, 1992, BLOOD, V79, P99; PEERSCHKE EI, 1980, THROMB HAEMOSTASIS, V43, P58; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; PEERSCHKE EIB, 1985, SEMIN HEMATOL, V22, P241; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMMONS SR, 1993, P 51 ANN M MICR SOC, P230; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SUZUKI H, 1988, BLOOD, V71, P1310; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WHITE JG, 1990, BRIT J HAEMATOL, V76, P108, DOI 10.1111/j.1365-2141.1990.tb07844.x; WHITE JG, 1990, BLOOD CELLS, V16, P43; WHITE JG, 1990, EUR J CELL BIOL, V52, P341; WHITE JG, 1990, ARTERIOSCLEROSIS, V10, P738, DOI 10.1161/01.ATV.10.5.738; ZHANG J, 1992, J BIOL CHEM, V267, P4686	60	72	73	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7004	7011		10.1074/jbc.271.12.7004	http://dx.doi.org/10.1074/jbc.271.12.7004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636130	hybrid			2022-12-27	WOS:A1996UB15700065
J	Kobayashi, K; Oka, K; Forte, T; Ishida, B; Teng, BB; IshimuraOka, K; Nakamuta, M; Chan, L				Kobayashi, K; Oka, K; Forte, T; Ishida, B; Teng, BB; IshimuraOka, K; Nakamuta, M; Chan, L			Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; PROTEIN; RNA; METABOLISM; CLEARANCE; TYPE-5	We have used the technique of adenovirus-mediated gene transfer to study the in vivo function of the very low density lipoprotein receptor (VLDLR) in low density lipoprotein receptor (VLDLR) knockout mice. We generated a replication-defective adenovirus (AdmVLDLR) containing mouse VLDLR cDNA driven by a cytomegalovirus promoter, Transduction of cultured Hepa (mouse hepatoma) cells and LDLR-deficient CHO-IdIA7 cells in vitro by the virus led to high-level expression of immunoreactive VLDLR proteins with molecular sizes of 143 kDa and 161 kDa, Digestion of the cell extract with the enzymes neuraminidase, N-glycanase, and O-glycanase resulted in the stepwise lowering of the apparent size of the 161-kDa species toward the 143-kDa species. LDLR (-/-) mice fed a 0.2% cholesterol diet were treated with a single intravenous injection of 3 x 10(9) plaque-forming units of AdmVLDLR, Control LDLR (-/-) mice received either phosphate-buffered saline or AdLacZ, a similar adenovirus containing the LacZ cDNA instead of mVLDLR cDNA. Comparison of the plasma lipids in the 3 groups of mice indicates that in the AdmVLDL animals, total cholesterol is reduced by similar to 50% at days 4 and 9 and returned toward control values on day 21. in these animals, there was also a similar to 30% reduction in plasma apolipoprotein (apo) E accompanied by a 90% fall in apoB-100 on day 4 of treatment, By FPLC analysis, the major reduction in plasma cholesterol in the AdmVLDL animals was accounted for by a marked reduction in the intermediate density lipoprotein/low density lipoprotein (IDL/LDL) fraction. Plasma VLDL, IDL/LDL, and HDL were isolated from the three groups of animals by ultracentrifugal flotation, In the AdmVLDLR animals, there was substantial loss (similar to 65%) of protein and cholesterol mainly in the IDL/LDL fraction on days 4 and 9, Nondenaturing gradient gel electrophoresis indicates a preferential loss of the IDL peak although the LDL peak was also reduced, When I-125-IDL was administered intravenously into animals on day 4, the AdmVLDLR animals cleared the I-125-IDL at a rate 5-10 times higher than the AdLacZ animals. We conclude that adenovirus-mediated transfer of the	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; USDA ARS,CHILDRENS NUTR RES CTR,HOUSTON,TX 77030; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Baylor College of Medicine			Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016512, P01HL018574, R01HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16512, HL-18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DIAS VC, 1988, CLIN CHEM, V34, P2322; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIDA BY, 1992, J LIPID RES, V33, P1073; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; KROCZEK RA, 1989, NUCLEIC ACIDS RES, V17, P9497, DOI 10.1093/nar/17.22.9497; LI J, 1995, J CLIN INVEST, V95, P768, DOI 10.1172/JCI117725; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TENG BB, 1994, J BIOL CHEM, V269, P29395; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	34	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6852	6860		10.1074/jbc.271.12.6852	http://dx.doi.org/10.1074/jbc.271.12.6852			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636110	hybrid			2022-12-27	WOS:A1996UB15700045
J	Nehrke, K; Hagen, FK; Tabak, LA				Nehrke, K; Hagen, FK; Tabak, LA			Charge distribution of flanking amino acids influences O-glycan acquisition in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; UDP-GALNAC; GLYCOSYLATION SITES; GLYCOPROTEINS; SPECIFICITY; SEQUENCES; PROTEINS; INVITRO; GOLGI; CELLS	The elements that regulate O-glycosylation are poorly understood, We have developed a novel in vivo system to analyze the role of flanking sequence on the modification of a single well characterized O-glycosylation site derived from human von Willebrand factor (PHMAQVTVGPGL), A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells, Glycosylated and non-glycosylated forms of the immunoprecipitated reporter were resolved electrophoretically and their relative amounts quantitated, Using mutational analysis we find that the glycosylation apparatus of COS7 cells can accommodate a broad range of changes in the flanking sequence without compromising glycosylation, but that the distribution of charged amino acids flanking the O-glycosylation site can have a profound influence on glycosylation with position -1 relative to the glycosylation site being particularly sensitive, A combination of acidic residues at positions -1 and +3 almost completely eliminates glycosylation of the reporter in both COS7 and MCF-7 cells. The overall density of charged amino acids is less important since substitution of acidic residues at position -2, +1, and +2 had no effect in the level of glycosylation observed.	UNIV ROCHESTER, SCH MED & DENT, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108, T32DE007202] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32 DE-07202, DE-08108] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHOU KC, 1995, PROTEINS, V21, P118, DOI 10.1002/prot.340210205; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; DRICKAMER K, 1983, J BIOL CHEM, V258, P2357; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HENLE KJ, 1990, J CELL SCI, V95, P555; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; OCONNELL BC, 1993, J DENT RES, V72, P1554, DOI 10.1177/00220345930720120401; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG WC, 1991, J BIOL CHEM, V266, P23185; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; YEO KT, 1985, J BIOL CHEM, V260, P7896	29	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7061	7065		10.1074/jbc.271.12.7061	http://dx.doi.org/10.1074/jbc.271.12.7061			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636138	hybrid			2022-12-27	WOS:A1996UB15700073
J	Reid, BG; Flynn, GC				Reid, BG; Flynn, GC			GroEL binds to and unfolds rhodanese posttranslationally	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; LIVER RHODANESE; SPECIFICITY; LYSOZYME; SYSTEMS; DNAK; BIP	The Escherichia coli chaperone GroEL is a member of a class of molecular chaperones that possesses a stacked double ring structure containing seven subunits per ring, with approximately 60-kDa subunits. It has been suggested that newly synthesized proteins may interact with a eukaryotic homolog of GroEL co-translationally, thereby sequestering the unfolded protein from other proteins in the cell. To test whether it is essential for GroEL to form a stable interaction with a nascent polypeptide co-translationally, we translated the well studied GroEL substrate rhodanese in bacterial and wheat germ translation extracts. We found that rhodanese formed stable complexes with GroEL solely posttranslationally. Upon binding to GroEL, the protease resistant N-terminal domain of rhodanese unfolds. This interaction with GroEL leads to productive folding of the full-length rhodanese. We conclude that GroEL is able to assist in the folding of newly synthesized proteins following release from the ribosome and that GroEL can unfold a trapped protein folding intermediate of rhodanese.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN BL, 1992, BIOCHEMISTRY-US, V31, P1464, DOI 10.1021/bi00120a025; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PJURA PE, 1990, BIOCHEMISTRY-US, V29, P2592, DOI 10.1021/bi00462a023; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHANG T, 1993, BIOCHEMISTRY-US, V32, P12311, DOI 10.1021/bi00097a006; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7212	7217		10.1074/jbc.271.12.7212	http://dx.doi.org/10.1074/jbc.271.12.7212			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636159	hybrid			2022-12-27	WOS:A1996UB15700094
J	Telen, MJ; Udani, M; Washington, MK; Levesque, MC; Lloyd, E; Rao, N				Telen, MJ; Udani, M; Washington, MK; Levesque, MC; Lloyd, E; Rao, N			A blood group-related polymorphism of CD44 abolishes a hyaluronan binding consensus sequence without preventing hyaluronan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; HUMAN-ERYTHROCYTE ANTIGENS; CELL-SURFACE GLYCOPROTEINS; IN(LU) GENE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; SPLICE VARIANTS; INB ANTIGEN; EXPRESSION; MOLECULE	CD44 is a widely expressed integral membrane protein that acts as a receptor for hyaluronan (HA) and is proposed to be important to cell-extracellular matrix interaction. The Indian (In) blood group antigens reside on CD44, and most individuals express the In-b antigen. Homozygosity for the In-a allele occurs as a rare event and is associated with production of alloantibody to the common In-b antigen after transfusion or pregnancy. The present study demonstrates that a single point mutation (G(252) --> C) causes an Arg(46) --> Pro substitution, which is responsible for the In-b/In-a polymorphism. Additional mutations were found in In(a+b-) cDNA but were not necessary to the antigenic phenotype as determined in site-directed mutagenesis studies, In studies using CD44 chimeric constructs, Arg(46) has previously been shown to be crucial for maintenance of HA-binding ability to a CD44 peptide. However, the present study demonstrates that the Arg(46) --> Pro substitution does not reduce HA binding to the intact CD44 protein, which contains two proposed extracellular HA-binding motifs. Down-regulation of HA binding to In(a+b-) CD44 by anti-CD44 monoclonal antibody (mAb) ligands, however, was weakened, although all mAbs tested bound In(a+b-) and In(a-b+) CD44 equally well. Competitive inhibition studies using human anti-In-b also showed that some mAbs that inhibit HA binding to CD44 may do so by interacting with a domain separate from, but affecting the structure of, the In-b epitope.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	Telen, MJ (corresponding author), DUKE UNIV, MED CTR, DEPT MED, 2615 DUMC, DURHAM, NC 27710 USA.			Telen, Marilyn/0000-0003-3809-1780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033572] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL33572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BRUCE LJ, 1995, BLOOD, V85, P541; CARTER WG, 1982, J BIOL CHEM, V257, P3249; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW FL, 1985, BLOOD, V66, P940; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DENNING SM, 1990, J IMMUNOL, V144, P7; DENNING SM, 1995, LEUCOCYTE TYPING, V5, P1713; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; FERGUSON DJ, 1988, TRANSFUSION, V28, P479, DOI 10.1046/j.1537-2995.1988.28588337342.x; GEE B, 1995, BLOOD S, V86, P137; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; HOFMANN M, 1991, CANCER RES, V51, P5292; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HUGHES EN, 1981, J BIOL CHEM, V256, P7023; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIO HX, J IMMUNOL, V155, P3938; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1993, J IMMUNOL, V151, P6490; LIAO HX, 1995, LEUCOCYTE TYPING, V5, P1735; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PICKER LJ, 1989, J IMMUNOL, V142, P2046; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SPRING FA, 1988, IMMUNOLOGY, V64, P37; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TELEN MJ, 1990, VOX SANG, V58, P118, DOI 10.1111/j.1423-0410.1990.tb02073.x; TELEN MJ, 1983, J CLIN INVEST, V71, P1878, DOI 10.1172/JCI110943; TELEN MJ, 1987, VOX SANG, V52, P236, DOI 10.1111/j.1423-0410.1987.tb03035.x; TELEN MJ, 1995, BLOOD, V85, P299; TELEN MJ, 1984, BLOOD, V64, P599; TELEN MJ, 1992, PROTEIN BLOOD GROUP, P70; TELEN MJ, 1995, LEUCOCYTE TYPING, V5, P1730; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERFAILLIE CM, 1994, BLOOD, V84, P1802; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	47	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7147	7153		10.1074/jbc.271.12.7147	http://dx.doi.org/10.1074/jbc.271.12.7147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636151	hybrid			2022-12-27	WOS:A1996UB15700086
J	Weber, E; Jilling, T; Kirk, KL				Weber, E; Jilling, T; Kirk, KL			Distinct functional properties of Rab3A and Rab3B in PC12 neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TARGET PROTEIN; ACTIVATING PROTEIN; ENDOCYTIC PATHWAY; SYNAPTIC VESICLES; SMG P25A; RABPHILIN-3A; ASSOCIATION; SENSITIVITY; EXOCYTOSIS	Rab3A and Rab3B are highly homologous monomeric GTPases that are putative regulators of exocytosis in those tissues in which they are expressed, We have characterized and directly compared the targeting and functional properties of these isoforms in PC12 neuroendocrine cells. Rab3A and Rab3B both targeted to norepinephrine (NE)-containing large dense core vesicles (LDCVs) when stably expressed in PC12 cells, as determined by immunofluorescence and membrane fractionation. Both Rab3 isoforms also bound to recombinant rabphilin-3A in a GTP-dependent manner. The membrane association of rabphilin-3A was modestly enhanced in Rab3B-expressing PC12 cells relative to Rab3A-overexpressing cells, In addition, overexpression of Rab3A modestly inhibited Ca2+-evoked NE release, whereas Rab3B and a GTP binding mutant (Rab3B N135I) markedly stimulated the efficiency of [H-3]NE secretion by PC12 cells (i.e. secretion normalized to total cell radioactivity). Expression of Rab3B and Rab3B N135I increased not only the efficiency of NE secretion but also the accumulation of [H-3]NE into LDCVs (i.e. the secretory cargo available for secretion). Neither of these effects was attributable to changes in the numbers of LDCVs nor the docking of LDCVs at the plasma membrane. Our results indicate that Rab3A and Rab3B have similar membrane targeting properties and are capable of interacting with the same putative downstream effector; i.e. rabphilin-3A. However, these isoforms are functionally distinct monomeric GTPases with Rab3B stimulating a late step in Ca2+-evoked secretion when expressed in PC12 cells.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				Jilling, Tamas/0000-0002-6200-3851	NIDDK NIH HHS [DK50830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DARCHEN F, 1995, J CELL SCI, V108, P1639; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; KONGSAMUT S, 1986, P NATL ACAD SCI USA, V83, P2243, DOI 10.1073/pnas.83.7.2243; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MACARA IG, 1994, TRENDS ENDOCRIN MET, V5, P267, DOI 10.1016/1043-2760(94)P3201-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WEI NM, 1995, AM J PHYSIOL-ENDOC M, V268, pE145, DOI 10.1152/ajpendo.1995.268.1.E145; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	45	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6963	6971		10.1074/jbc.271.12.6963	http://dx.doi.org/10.1074/jbc.271.12.6963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636125	hybrid			2022-12-27	WOS:A1996UB15700060
J	Davis, EC; Mecham, RP				Davis, EC; Mecham, RP			Selective degradation of accumulated secretory proteins in the endoplasmic reticulum - A possible clearance pathway for abnormal tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; BREFELDIN-A; CYSTEINE PROTEASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; INTRACELLULAR-TRANSPORT; ORGANELLE STRUCTURE; ELASTIN RECEPTOR; MEMBRANE-PROTEIN; APOLIPOPROTEIN-B; GOLGI PROTEINS	The specific pathway of tropoelastin secretion was investigated in fetal calf ligamentum nuchae (FCL) cells using brefeldin A (BFA) to disrupt the secretory pathway, Electron microscopic studies of BFA-treated FCL cells showed ultrastructural changes consistent with the reported effects of BFA on intracellular organelles. When FCL cells were labeled with [H-3]leucine in the presence of BFA, radiolabeled tropoelastin was not secreted, nor was there an intracellular accumulation of the protein, In contrast, fibronectin accumulated within the cells in the presence of BFA. Northern analysis of mRNA levels in FCL cells showed that the message for tropoelastin was unaffected by BFA treatment, Pulse chase experiments conducted in the presence of BFA demonstrated that the tropoelastin retained within the cells was rapidly degraded, Ammonium chloride, nocodazole, and cycloheximide had no effect on the degradation of tropoelastin, indicating that the degradation did not involve the endosome/lysosome pathway, movement via microtubules, or a short-lived protein, respectively. Incubation of FCL cells with BFA in the presence of N-acetyl-Leu-Leu-norleucinal, however, allowed tropoelastin to steadily accumulate in the cells, Cells pulsed in the presence of BFA alone showed that tropoelastin initially accumulates within the cells for approximately 1 h prior to being degraded, thus indicating that a critical threshold of tropoelastin must be reached before degradation can occur, Results from this study provide evidence for selective degradation of a soluble secreted protein by a cysteine protease following retention of the protein in the endoplasmic reticulum.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)	Davis, EC (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,BOX 8228,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Davis, Elaine/F-3449-2012		NHLBI NIH HHS [HL-53325, HL-41926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL041926, R01HL053325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; AMITAY R, 1992, J BIOL CHEM, V267, P20694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN KT, 1990, J BIOL CHEM, V265, P22004; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; COX BA, 1974, J BIOL CHEM, V249, P997; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DAGAGORDINI D, 1987, HISTOCHEM J, V19, P623, DOI 10.1007/BF01676168; DAMIANO V, 1984, COLLAGEN REL RES, V4, P153; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FRANC S, 1984, J HISTOCHEM CYTOCHEM, V32, P251, DOI 10.1177/32.2.6198356; FRISCH SM, 1985, MOL CELL BIOL, V5, P253, DOI 10.1128/MCB.5.1.253; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GROSSO L, 1988, BIOCHEM BIOPH RES CO, V151, P822; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; JAIN N, 1994, BIOCHEM J, V304, P61, DOI 10.1042/bj3040061; JAIN N, 1994, ARCH BIOCHEM BIOPHYS, V314, P23, DOI 10.1006/abbi.1994.1407; KARR SR, 1981, J BIOL CHEM, V256, P5946; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; LECUREUX LW, 1994, J CELL SCI, V107, P2635; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAGNER JA, 1988, ENDOCRINOLOGY, V122, P912, DOI 10.1210/endo-122-3-912; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1992, MATRIX, V12, P156, DOI 10.1016/S0934-8832(11)80057-0; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROY S, 1992, J BIOL CHEM, V267, P23151; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SATO R, 1990, J BIOL CHEM, V265, P11880; SAUNDERS NA, 1984, BIOCHEM J, V221, P333; THYBERG J, 1979, HISTOCHEM J, V11, P1, DOI 10.1007/BF01041263; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WRENN DS, 1986, BIOCHEMISTRY-US, V25, P5172, DOI 10.1021/bi00366a028	57	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3787	3794						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631995				2022-12-27	WOS:A1996TV72400069
J	Zhang, K; Sun, JL; Liu, NL; Wen, DZ; Chang, D; Thomason, A; Yoshinaga, SK				Zhang, K; Sun, JL; Liu, NL; Wen, DZ; Chang, D; Thomason, A; Yoshinaga, SK			Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU ONCOGENE; EXPRESSION; ANTIGEN; LIGAND; HER4/P180(ERBB4); OVEREXPRESSION; FIBROBLASTS; ACTIVATION; HEREGULIN; MEMBER	Members of the epidermal growth factor receptor (EGFR) subfamily of receptor protein tyrosine kinases have been implicated in the pathogenesis of various malignancies. The ability of one EGFR subfamily member to influence, or function synergistically with, another is likely to be a general feature of these receptors. To assess the role of receptor heterodimerization, we analyzed the ability of Neu differentiation factor (NDF) to induce cell growth and transformation of NIH 3T3 cells transfected with different combinations of the EGFR subfamily of receptors. NDF induced mitogenesis, but not transformation, of cells expressing either HER3 or HER4 alone. However, NDF-induced cell transformation was observed when either HER1 or HER2 was coexpressed with HER3 or HER4. In analogous receptor phosphorylation experiments, NDF-induced transphosphorylation appears to be correlated with synergistic transformation of NIH 3T3 cells. Interestingly, transphosphorylation between HER1 and HER4 can be stimulated by either EGF or NDF.	AMGEN CORP,THOUSAND OAKS,CA 91320	Amgen			Mieszkowska, Magdalena/O-6753-2017					ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Di Fiore P P, 1992, Cancer Treat Res, V61, P139; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; FAEGERSTAM LG, 1990, J MOL RECOGNIT, V3, P208; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARLOW E, 1988, PLAINVIEW; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KIM HH, 1994, J BIOL CHEM, V269, P24747; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Kohler G, 1992, Biotechnology, V24, P524; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KROIZMAN TS, 1992, J BIOL CHEM, V267, P8056; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; MALMBORG AC, 1992, SCAND J IMMUNOL, V35, P643, DOI 10.1111/j.1365-3083.1992.tb02970.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAJKUMAR T, 1994, BRIT J CANCER, V70, P459, DOI 10.1038/bjc.1994.328; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	44	195	207	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3884	3890						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632008				2022-12-27	WOS:A1996TV72400082
J	Axelson, M; Larsson, O				Axelson, M; Larsson, O			27-Hydroxylated low density lipoprotein (LDL) cholesterol can be converted to 7 alpha,27-dihydroxy-4-cholesten-3-one (cytosterone) before suppressing cholesterol production in normal human fibroblasts - Evidence that an altered metabolism of LDL cholesterol can underlie a defective feedback control in malignant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; OXYSTEROL-BINDING-PROTEIN; BILE-ACID PRECURSORS; CULTURED MOUSE CELLS; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; OXYGENATED STEROLS; BIOLOGICAL-ACTIVITIES; CYCLOSPORINE-A; INHIBITION; RECEPTOR	The formation of oxysterols in cultured human fibroblasts and their physiological roles as intracellular regulators of cholesterol production have been investigated. In the presence of low density lipoproteins (LDL), normal fibroblasts converted LDL cholesterol to 27-hydroxycholesterol, which was further metabolized to 7 alpha,27-dihydroxycholesterol, 7 alpha,27-dihydroxy-4-cholesten-3-one, and 7 alpha-hydroxy-3-oxo-4-cholestenoic acid. Autooxidation products of cholesterol contaminating the lipoproteins were also metabolized in the cells. 7 alpha-Hydroxycholesterol was converted to 7 alpha-hydroxy-3-cholesten-3-one prior to 27-hydroxylation and further oxidation to 7 alpha-hydroxy-3-oxo-4-cholestenoic acid. 7 beta-Hydroxycholesterol and 7-oxocholesterol were 27-hydroxylated and then oxidized to C-27-acids. Oxidation of the 7 beta-hydroxy group also occurred. 25-Hydroxycholesterol was 7 alpha-hydroxylated and further oxidized to 7 alpha,25-dihydroxy-4-cholesten-3-one. 25-Hydroxylation of sterols was observed only under specific conditions. In contrast, only small amounts of oxysterols were formed in virus-transformed human fibroblasts when incubated with lipoproteins. This was due to very low activities of the 27- and 7 alpha-hydroxylating enzymes. The rate of oxidation at C-3 was also decreased moderately. A defective suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase by LDL and autooxidation products of cholesterol observed in the transformed fibroblasts could be caused by the deficiencies of the sterol-metabolizing enzymes, since these cells responded normally to the sterol metabolites 7 alpha,27-dihydroxy-4-cholesten-3-one, 7 alpha,25-dihydroxy-4-cholesten-3-one, and 27-hydroxy-7-oxo-cholesterol. These metabolites, which all possessed an oxo group with a conjugated double bond in the steroid nucleus and a hydroxyl group in the side chain, did not seem to require further metabolism in order to be active. An impaired response to LDL was also seen in other human tumor cells, including breast carcinoma, colonic carcinoma, and malignant melanoma cells. Common to all the malignant cells was an intracellular shortage of 7 alpha,27-dihydroxy-4-cholesten-3-one caused by a decreased formation or an increased metabolism.	KAROLINSKA HOSP,DEPT TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	Axelson, M (corresponding author), KAROLINSKA HOSP,DEPT CLIN CHEM,S-17176 STOCKHOLM,SWEDEN.							ARUNACHALAM T, 1981, J ORG CHEM, V46, P2966, DOI 10.1021/jo00327a025; AXELSON M, 1995, J LIPID RES, V36, P290; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1991, J BIOL CHEM, V266, P17770; AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CAVENEE WK, 1981, J BIOL CHEM, V256, P2675; DAHLBACKSJOBERG H, 1993, BIOCHEM J, V293, P203, DOI 10.1042/bj2930203; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; EDWARDS PA, 1979, J LIPID RES, V20, P40; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIESER LF, 1967, REAGENTS ORGANIC SYN, P1059; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GUPTA A, 1986, J BIOL CHEM, V261, P8348; HWANG PL, 1991, BIOESSAYS, V13, P583, DOI 10.1002/bies.950131108; KANDUTSCH AA, 1980, J BIOL CHEM, V255, P813; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KIM HS, 1989, J LIPID RES, V30, P247; KUDO K, 1989, J LIPID RES, V30, P1097; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MICHELL A, 1978, CANCER RES, V38, P4474; Myant N., 2012, CHOLESTEROL METABOLI, DOI [10.1016/B978-0-12-512300-6.50007-7, DOI 10.1016/B978-0-12-512300-6.50007-7]; PAYNE DW, 1995, J BIOL CHEM, V270, P1888; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; POLSKY FI, 1973, J CLIN INVEST, V52, pA65; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SHODA J, 1993, HEPATOLOGY, V17, P395; SHODA J, 1993, STEROIDS, V58, P119, DOI 10.1016/0039-128X(93)90048-R; SIPERSTEIN M. D., 1970, Current Topics in Cell. Regulation, V2, P65; SIPERSTEIN MD, 1966, CANCER RES, V26, P7; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; WEINSTEIN DB, 1979, CIRCULATION, V59, P54; ZHANG J, 1995, BBA-LIPID LIPID MET, V1256, P353	47	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12724	12736		10.1074/jbc.271.22.12724	http://dx.doi.org/10.1074/jbc.271.22.12724			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662693	hybrid			2022-12-27	WOS:A1996UN47400008
J	Zhang, JZ; Redman, CM				Zhang, JZ; Redman, CM			Assembly and secretion of fibrinogen - Involvement of amino-terminal domains in dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; MOLECULAR-STRUCTURE; DISULFIDE BONDS; CELLS; IDENTIFICATION; MUTAGENESIS; EXPRESSION; EFFICIENT; VECTORS; CHAINS	Fibrinogen is a dimer with each half-molecule composed of three different chains (A alpha, B beta, gamma). Previous studies showed that amino-terminal disulfide bonds, as well as the disulfide rings that flank the ''coiled-coil'' region, are necessary for chain assembly and secretion (Zhang, J. Z., and Redman, C. M. (1994) J. Biol. Chem. 269, 652-658). We now determine whether other amino-terminal domains are involved in linking the half-molecules. Fibrinogen chains, with deletions at the amino terminus, were co-expressed in COS cells together with normal fibrinogen chains. Elimination of the first 8 amino acids of the B beta chain did not affect dimer assembly, but deletion of amino acid residues 9-72 had a small inhibitory effect on dimer formation. Deletion of the first 72 amino acids of the B beta chain further inhibited dimer formation and resulted in nearly equal amounts of half-molecule and dimeric fibrinogen being formed and secreted. Deletion of the first 80 residues, which includes the cysteine residues that form the amino-terminal disulfide ring, completely eliminated dimer formation, and only half-molecules were secreted. By contrast deletion of the first 41 amino acid residues of the A alpha chain or the first 15 residues of the gamma chain, which correspond to B beta Delta 1-72, did not affect chain assembly and secretion. However, co-expression of both A alpha Delta 1-41 and gamma Delta 1-15 with normal B beta, inhibited dimer formation. Taken together, these results indicate that in addition to disulfide bonds, noncovalent interactions of other amino-terminal amino acid residues in the three fibrinogen chains also participate in dimer formation.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU CY, 1985, J BIOL CHEM, V260, P4390; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; YU S, 1984, J BIOL CHEM, V259, P574; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	29	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12674	12680		10.1074/jbc.271.21.12674	http://dx.doi.org/10.1074/jbc.271.21.12674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647881	hybrid			2022-12-27	WOS:A1996UL66000083
J	Clementz, T; Bednarski, JJ; Raetz, CRH				Clementz, T; Bednarski, JJ; Raetz, CRH			Function of the htrB high temperature requirement gene of Escherichia coli in the acylation of lipid A - HtrB catalyzed incorporation of laurate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; PHOSPHATIDYLGLYCEROL-DEFICIENT MUTANT; DESORPTION MASS-SPECTROMETRY; NUCLEAR MAGNETIC-RESONANCE; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; NULL MUTATIONS; A PRECURSORS; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; STRUCTURAL DETERMINATION	By assaying lysates of Escherichia coli generated with the hybrid lambda bacteriophages of an ordered library (Kohara, Y., Akiyama, K., and Isono, K. (1987) Cell 50, 495-508), we identified two clones (lambda 232 and lambda 233) capable of overexpressing the lauroyl transferase that functions after 3-deoxy-D-manno-octulosonic acid (Kdo) addition in lipid A biosynthesis (Brozek, K. A., and Raetz, C. R. H. (1990) J. Biol. Chem. 265, 15410-15417). The E. coli DNA inserts in lambda 232 and lambda 233 suggested that a known gene (htrB) required for rapid growth above 33 degrees C might encode the lauroyl transferase. Using the intermediate (Kdo)(2)-lipid IVA as the laurate acceptor, extracts of strains with transposon insertions in htrB were found to contain no lauroyl transferase activity. Cells harboring hybrid htrB(+) plasmids overproduced transferase activity 100-200-fold. The overproduced transferase was solubilized with a non-ionic detergent and purified further by DEAE-Sepharose chromatography. With lauroyl acyl carrier protein as the donor, the purified enzyme rapidly incorporated one laurate residue into (Kdo)(2)-lipid IVA. The rate of laurate incorporation was reduced by several orders of magnitude when either one or both Kdos were absent in the acceptor. With a matched set of acyl-acyl carrier proteins, the enzyme incorporated laurate 3-8 times faster than decanoate or myristate, respectively. Transfer of palmitate, palmitoleate, or R-3-hydroxymyristate was very slow. Taken together with previous studies, our findings indicate that htrB encodes a key, late functioning acyltransferase of lipid A biosynthesis.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University			Bednarski, Jeff/GLN-6651-2022		NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Ausubel FM, 1988, MOL REPROD DEV; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BORODOVSKY M, 1994, TRENDS BIOCHEM SCI, V19, P309, DOI 10.1016/0968-0004(94)90067-1; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; CLEMENTZ T, 1995, FASEB J, V9, pA1311; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; DICKER IB, 1992, MOL MICROBIOL, V6, P817, DOI 10.1111/j.1365-2958.1992.tb01532.x; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MYERS KR, 1992, BIOCONJUGATE CHEM, V3, P540, DOI 10.1021/bc00018a013; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1996, IN PRESS ESCHERICHIA, V1; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROCK CO, 1979, J BIOL CHEM, V254, P7116; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P4245; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; WHITE KA, 1995, FASEB J, V9, pA1376; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	56	158	166	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12095	12102		10.1074/jbc.271.20.12095	http://dx.doi.org/10.1074/jbc.271.20.12095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662613	hybrid			2022-12-27	WOS:A1996UL25000077
J	Drakopoulou, E; ZinnJustin, S; Guenneugues, M; Gilquin, B; Menez, A; Vita, C				Drakopoulou, E; ZinnJustin, S; Guenneugues, M; Gilquin, B; Menez, A; Vita, C			Changing the structural context of a functional beta-hairpin - Synthesis and characterization of a chimera containing the curaremimetic loop of a snake toxin in the scorpion alpha/beta scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN DESIGN; K+ CHANNELS; 3-DIMENSIONAL STRUCTURE; H-1-NMR SPECTRA; HIGH-AFFINITY; CHARYBDOTOXIN; BINDING; SPECTROSCOPY; NEUROTOXIN	An approach to obtain new active proteins is the incorporation of all or a part of a well defined active site onto a natural structure acting as a structural scaffold. According to this strategy we tentatively engineered a new curaremimetic molecule by transferring the functional central loop of a snake toxin, sequence 26-37, sandwiched between two hairpins, onto the structurally similar beta-hairpin of the scorpion toxin charybdotoxin, stabilized by a short helix. The resulting chimeric molecule, only 31 amino acids long, was produced by solid phase synthesis, refolded, and purified to homogeneity. As shown by structural analysis performed by CD and NMR spectroscopy, the chimera maintained the expected alpha/beta fold characteristic of scorpion toxins and presented a remarkable structural stability. The chimera competitively displaces the snake curaremimetic toxin alpha from the acetylcholine receptor at 10(-5) M concentrations. Antibodies, elicited in rabbits against the chimera, recognize the parent snake toxin and prevent its binding to the acetylcholine receptor, thus neutralizing its toxic function. All these data demonstrate that the strategy of active site transfer to the charybdotoxin scaffold has general applications in the engineering of novel ligands for membrane receptors and in vaccine design.	CTR ETUD SACLAY,DEPT INGN ETUD PROT,CEA,F-91190 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BONTEMS F, 1992, BIOCHEMISTRY-US, V31, P7756, DOI 10.1021/bi00149a003; BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BOUGIS PE, 1986, BIOCHEMISTRY-US, V25, P7235, DOI 10.1021/bi00370a070; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHANG YH, 1990, P NATL ACAD SCI USA, V87, P2823, DOI 10.1073/pnas.87.7.2823; CHICHE L, 1993, PROTEIN ENG, V6, P675, DOI 10.1093/protein/6.7.675; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; Dauplais M, 1995, BIOCHEMISTRY-US, V34, P16563, DOI 10.1021/bi00051a004; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1995, CURR OPIN BIOTECH, V6, P460, DOI 10.1016/0958-1669(95)80076-X; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; FARID RS, 1994, BIOCHEM SOC T, V22, P689, DOI 10.1042/bst0220689; FERNANDEZ I, 1994, BIOCHEMISTRY-US, V33, P14256, DOI 10.1021/bi00251a038; FIELDS C G, 1991, Peptide Research, V4, P95; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; JOHNSON BA, 1992, BIOCHEMISTRY-US, V31, P8151, DOI 10.1021/bi00150a006; JOHNSON BA, 1994, BIOCHEMISTRY-US, V33, P15061, DOI 10.1021/bi00254a015; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOBSCONRAD S, 1993, J BIOL CHEM, V268, P25285; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEONETTI M, 1990, J IMMUNOL, V145, P4214; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MARTINEAU P, 1991, BIO-TECHNOL, V9, P170, DOI 10.1038/nbt0291-170; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MEUNIER S, 1993, BIOCHEMISTRY-US, V32, P11969, DOI 10.1021/bi00096a005; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; NEYTON J, 1991, J GEN PHYSIOL, V97, P641, DOI 10.1085/jgp.97.4.641; OZATO K, 1980, J IMMUNOL, V124, P533; PIERRET B, 1995, INT J PEPT PROT RES, V46, P471; PILLET L, 1993, J BIOL CHEM, V268, P909; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; RAINES RT, 1995, J BIOL CHEM, V270, P17180, DOI 10.1074/jbc.270.29.17180; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGAN L, 1991, CURR OPIN BIOTECH, V2, P544, DOI 10.1016/0958-1669(91)90079-K; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; SCHWEITZ H, 1989, FEBS LETT, V250, P519, DOI 10.1016/0014-5793(89)80788-4; SOBEL A, 1980, EUR J BIOCHEM, V110, P13, DOI 10.1111/j.1432-1033.1980.tb04838.x; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; SZARDENINGS M, 1995, PROTEIN ENG, V8, P45, DOI 10.1093/protein/8.1.45; TANAKA T, 1994, PROTEIN ENG, V7, P969, DOI 10.1093/protein/7.8.969; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; VASQUEZ J, 1989, J MED CHEM, V264, P20902; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; VITA C, 1993, EUR J BIOCHEM, V217, P157, DOI 10.1111/j.1432-1033.1993.tb18231.x; VITA C, 1993, PEPTIDES 1992, P641; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; WEBER M, 1974, MOL PHARMACOL, V10, P1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WITHRICH K, 1986, NMR PROTEIN NUCLEIC; WOLFSON AJ, 1993, BIOCHEMISTRY-US, V32, P5327, DOI 10.1021/bi00071a007; ZANETTI M, 1992, NATURE, V355, P476, DOI 10.1038/355476a0; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	75	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11979	11987		10.1074/jbc.271.20.11979	http://dx.doi.org/10.1074/jbc.271.20.11979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662609	hybrid			2022-12-27	WOS:A1996UL25000061
J	Laura, RP; Dizhoor, AM; Hurley, JB				Laura, RP; Dizhoor, AM; Hurley, JB			The membrane guanylyl cyclase, retinal guanylyl cyclase-1, is activated through its intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-REGULATORY MODULE; ADENINE-NUCLEOTIDES; RECEPTOR; PURIFICATION	Retinal guanylyl cyclase-1 (RetGC-1) is a membrane guanylyl cyclase found in photoreceptor outer segments. It consists of an apparent extracellular domain (ECD) linked by a single transmembrane segment to an intracellular domain (ICD). Guanylyl cyclase activating protein-2 (GCAP-2) is a Ca2+-binding protein that activates RetGC-1 in a Ca2+-sensitive manner. To establish whether GCAP-2 stimulates RetGC-1 through the ECD or ICD, we made deletion mutants lacking either the ECD or both the ECD and transmembrane domains (TMD) of RetGC-1, Recombinant wild type RetGC-1 and both deletion mutants were expressed in HEK 293 cells, and their sensitivities to GCAP-2, Ca2+, and ATP were compared. Our data demonstrate that both deletion mutants are regulated similarly to wild type RetGC-1 with indistinguishable EC(50) values for Ca2+ and similar K-1/2 values for activation by GCAP-2, This shows that GCAP-2 functions through the ICD of RetGC-1 and that removal of the ECD and TMD do not significantly alter regulation by these factors. Our data also show that ATP potentiates stimulation of guanylyl cyclase activity by GCAP-2 and that neither the ECD nor the TMD of RetGC-1 participate in its regulation by ATP.	UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY06641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P4; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1994, EUR J BIOCHEM, V222, P589, DOI 10.1111/j.1432-1033.1994.tb18901.x; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MARALA RB, 1991, FEBS LETT, V281, P73, DOI 10.1016/0014-5793(91)80361-6; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	36	115	116	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11646	11651		10.1074/jbc.271.20.11646	http://dx.doi.org/10.1074/jbc.271.20.11646			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662612	hybrid			2022-12-27	WOS:A1996UL25000013
J	Lee, SST; Buters, JTM; Pineau, T; FernandezSalguero, P; Gonzalez, FJ				Lee, SST; Buters, JTM; Pineau, T; FernandezSalguero, P; Gonzalez, FJ			Role of CYP2E1 in the hepatotoxicity of acetaminophen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED HEPATIC NECROSIS; PARA-BENZOQUINONE IMINE; RIBONUCLEIC-ACID; TREATED RABBITS; HUMAN-LIVER; IN-VITRO; ETHANOL; RAT; CYTOCHROME-P-450; METABOLISM	CYP2E1, a cytochrome P-450 that is well conserved across mammalian species, metabolizes ethanol and many low molecular weight toxins and cancer suspect agents. The cyp2e1 gene was isolated, and a mouse line that lacks expression of CYP2E1 was generated by homologous recombination in embryonic stem cells. Animals deficient in expression of the enzyme were fertile, developed normally, and exhibited no obvious phenotypic abnormalities, thus indicating that CYP2E1 has no critical role in mammalian development and physiology in the absence of external stimuli. When cyp2e1 knockout mice were challenged with the common analgesic acetaminophen, they were found to be considerably less sensitive to its hepatotoxic effects than wild-type animals, indicating that this P-450 is the principal enzyme responsible for the metabolic conversion of the drug to its active hepatotoxic metabolite.	NCI,MOLEC CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			BUTERS, JEROEN/AAF-6949-2020; Fernandez-Salguero, Pedro M./J-8437-2014; Buters, Jeroen T/G-5070-2011	Fernandez-Salguero, Pedro M./0000-0003-2839-5027; Buters, Jeroen/0000-0003-3581-5472				AOYAMA T, 1989, MOL CARCINOGEN, V1, P253, DOI 10.1002/mc.2940010408; BRADLEY A, 1987, TERATOCARCINOMA EMBR, P133; CASAZZA JP, 1984, J BIOL CHEM, V259, P231; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN MJ, 1991, OXIDATIVE DAMAGE REP, P726; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; GONZALEZ FJ, 1986, MOL CELL BIOL, V6, P2969, DOI 10.1128/MCB.6.8.2969; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HOGAN B, 1986, MANIPULATING MOUSE E; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KOOP DR, 1984, MOL PHARMACOL, V25, P494; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIEBER CS, 1970, J BIOL CHEM, V245, P2505; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; NAGATA K, 1987, J BIOL CHEM, V262, P2787; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; PETERSON FJ, 1980, LIFE SCI, V27, P1705, DOI 10.1016/0024-3205(80)90646-3; POTTER WZ, 1973, J PHARMACOL EXP THER, V187, P203; PRASAD JS, 1990, BIOCHEM PHARMACOL, V40, P1989, DOI 10.1016/0006-2952(90)90228-D; RAUCY JL, 1989, ARCH BIOCHEM BIOPHYS, V271, P270, DOI 10.1016/0003-9861(89)90278-6; SHAW S, 1983, DIGEST DIS SCI, V28, P585, DOI 10.1007/BF01299917; SNAWDER JE, 1994, PHARMACOGENETICS, V4, P43, DOI 10.1097/00008571-199402000-00006; SNAWDER JE, 1994, BIOCHEM BIOPH RES CO, V203, P532, DOI 10.1006/bbrc.1994.2215; SONG BJ, 1989, J BIOL CHEM, V264, P3568; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SONG BJ, 1987, MOL ENDOCRINOL, V1, P542, DOI 10.1210/mend-1-8-542; SONG BJ, 1995, DRUG ALCOHOL ABUSE R, V6, P227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YAMANO S, 1989, BIOCHEMISTRY-US, V28, P7340, DOI 10.1021/bi00444a029	42	476	486	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12063	12067		10.1074/jbc.271.20.12063	http://dx.doi.org/10.1074/jbc.271.20.12063			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662637	Green Submitted, hybrid			2022-12-27	WOS:A1996UL25000072
J	West, CM; ScottWard, T; Tengumnuay, P; vanderWel, H; Kozarov, E; Huynh, A				West, CM; ScottWard, T; Tengumnuay, P; vanderWel, H; Kozarov, E; Huynh, A			Purification and characterization of an alpha 1,2-L-fucosyltransferase, which modifies the cytosolic protein FP21, from the cytosol of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA NCI-H69 CELLS; T7 EXPRESSION SYSTEM; GDP-L-FUCOSE; CYTOPLASMIC PROTEINS; HUMAN SERUM; GLYCOSYLATION; ACID; OLIGOSACCHARIDES; TRANSFERASE; SEQUENCE	A novel fucosyltransferase (cFTase) activity has been enriched over 10(6)-fold from the cytosolic compartment of Dictyostelium based on transfer of [H-3]fucose from GDP-[H-3]fucose to Gal beta 1,3GlcNAc beta-paranitrophenyl (paranitrophenyl-lacto-N-bioside or pNP-LNB). The activity behaved as a single component during purification over DEAE-, phenyl-, Reactive Blue-4-, GDP-adipate-, GDP-hexanolamine-, and Superdex gel filtration resins. The purified activity possessed an apparent M(r) of 95 x 10(3), was Mg2+-dependent with a neutral pH optimum, and exhibited a K-m for GDP-fucose of 0.34 mu M, a K-m for pNP-LNB of 0.6 mM, and a V-max for pNP-LNB of 620 nmol/min/mg protein. SDS-polyacrylamide gel electrophoresis analysis of the Superdex elution profile identified a polypeptide with an apparent M(r) of 85 x 10(3), which coeluted with the cFTase activity and could be specifically photolabeled with the donor substrate inhibitor GDP-hexanolaminyl-azido-I-125-salicylate. Based on substate analogue studies, exoglycosidase digestions, and co-chromatography with fucosylated standards, the product of the reaction with pNP-LNB was Fuc alpha 1,2Gal beta 1,3GlcNAc beta-pNP. The cFTase preferred substrates with a Gal beta 1,3 linkage, and thus its acceptor substrate specificity resembles the human Secretor-type alpha 1,2-FTase. Afucosyl isoforms of the FP21 glycoprotein, GP21-I and GP21-II, were purified from the cytosol of a Dictyostelium mutant and found to be substrates for the cFTase, which exhibited an apparent K-m of 0.21 mu M and an apparent V-max of 460 nmol/min/mg protein toward GP21-II. The highly purified cFTase was inhibited by the reaction products Fuc alpha 1,2Gal beta 1,3GlcNAc beta-pNP and FP21-II. FP21-I and recombinant FP21 were not inhibitory, suggesting that acceptor substrate specificity is based primarily on carbohydrate recognition. A cytosolic location for this step of FP21 glycosylation is implied by the isolation of the cFTase from the cytosolic fraction, its high affinity for its substrates, and its failure to be detected in crude membrane preparations.			West, CM (corresponding author), UNIV FLORIDA, COLL MED, DEPT ANAT & CELL BIOL, GAINESVILLE, FL 32610 USA.				NIGMS NIH HHS [GM-37539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BEYER TA, 1980, J BIOL CHEM, V255, P5373; CHEN H, 1995, GENOMICS, V27, P389, DOI 10.1006/geno.1995.1068; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HASHIMOTO F, 1983, ANAL BIOCHEM, V129, P192, DOI 10.1016/0003-2697(83)90068-4; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOLMES EH, 1990, J BIOL CHEM, V265, P13150; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; KYPRIANOU P, 1990, GLYCOCONJUGATE J, V7, P573, DOI 10.1007/BF01189078; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1982, AM J HUM GENET, V34, P402; LU ZQ, 1995, VIROLOGY, V206, P339, DOI 10.1016/S0042-6822(95)80049-2; MUDGAPALLI A, 1994, J BIOL CHEM, V269, P11327; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NUNEZ HA, 1976, BIOCHEMISTRY-US, V15, P3843, DOI 10.1021/bi00662a030; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; REDDY GP, 1991, ANAL BIOCHEM, V198, P278, DOI 10.1016/0003-2697(91)90425-S; RODEN L, 1994, J BIOL CHEM, V269, P11509; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; THALMANN I, 1990, LARYNGOSCOPE, V100, P99; THALMANN I, 1993, HEARING RES, V64, P191, DOI 10.1016/0378-5955(93)90005-L; THURIN J, 1995, J BIOL CHEM, V270, P26577, DOI 10.1074/jbc.270.44.26577; VEYNA NA, 1994, J NEUROCHEM, V62, P456; WEIJER CJ, 1984, J CELL SCI, V70, P111; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAZAWA S, 1990, ANAL BIOCHEM, V187, P374, DOI 10.1016/0003-2697(90)90472-L; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	48	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12024	12035		10.1074/jbc.271.20.12024	http://dx.doi.org/10.1074/jbc.271.20.12024			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662604	hybrid			2022-12-27	WOS:A1996UL25000067
J	Wolosker, H; deSouza, DO; deMeis, L				Wolosker, H; deSouza, DO; deMeis, L			Regulation of glutamate transport into synaptic vesicles by chloride and proton gradient	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; FUNCTIONAL RECONSTITUTION; ENERGY-DEPENDENCE; H+-ATPASE; ACID; BIOENERGETICS	Glutamate uptake into synaptic vesicles is driven by an electrochemical proton gradient formed across the membrane by a vacuolar H+-ATPase. Chloride has a biphasic effect on glutamate transport, which it activates at low concentrations (2-8 mM) and inhibits at high concentrations (>20 mM). Stimulation with 4 mM chloride was due to an increase in the V-max of transport, whereas inhibition by high chloride concentrations was related to an increase in K-m to glutamate. Both stimulation and inhibition by Cl- were observed in the presence of A23187 or (NH4)(2)SO4, two substances that dissipate the proton gradient (Delta pH). With the use of these agents, we show that the transmembrane potential regulates the apparent affinity for glutamate, whereas the Delta pH antagonizes the effect of high chloride concentrations and is important for retaining glutamate inside the vesicles. Selective dissipation of Delta pH in the presence of chloride led to a significant glutamate efflux from the vesicles and promoted a decrease in the velocity of glutamate uptake. The H+-ATPase activity was stimulated when the Delta pH component was dissipated. Glutamate efflux induced by chloride was saturable, and half-maximal effect was attained in the presence of 30 mM Cl-. The results indicate that: (i) both transmembrane potential and Delta pH modulate the glutamate uptake at different levels and (ii) chloride affects glutamate transport by two different mechanisms. One is related to a change of the proportions between the transmembrane potential and the Delta pH components of the electrochemical proton gradient, and the other involves a direct interaction of the anion with the glutamate transporter.	UNIV FED RIO GRANDE SUL,INST BIOCIENCIAS,DEPT BIOQUIM,BR-90050 PORTO ALEGRE,RS,BRAZIL	Universidade Federal do Rio Grande do Sul	Wolosker, H (corresponding author), UNIV FED RIO DE JANEIRO,DEPT BIOQUIM MED,INST CIENCIAS BIOMED,CCS,CIDADE UNIVERSITARIA,BR-21941590 RIO JANEIRO,BRAZIL.			Wolosker, Herman/0000-0001-5508-9194				Alberts B. D., 1989, MOL BIOL CELL, P301; CIDON S, 1989, J BIOL CHEM, V264, P8281; DISBROW JK, 1982, BIOCHEM BIOPH RES CO, V108, P1221, DOI 10.1016/0006-291X(82)92130-1; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLOOR E, 1990, J NEUROCHEM, V55, P1663, DOI 10.1111/j.1471-4159.1990.tb04954.x; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; HELL JW, 1990, J BIOL CHEM, V265, P2111; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSON RG, 1976, J GEN PHYSIOL, V298, P1; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MCMAHON HT, 1991, BIOCHIM BIOPHYS ACTA, V1059, P243, DOI 10.1016/S0005-2728(05)80210-5; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; MORIYAMA Y, 1995, J BIOL CHEM, V270, P22314, DOI 10.1074/jbc.270.38.22314; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; Shepherd G. M., 1988, NEUROBIOLOGY; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TABB JS, 1992, J BIOL CHEM, V267, P15412; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603	27	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11726	11731		10.1074/jbc.271.20.11726	http://dx.doi.org/10.1074/jbc.271.20.11726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662610	hybrid			2022-12-27	WOS:A1996UL25000024
J	Aragones, J; LopezRodriquez, C; Corbi, A; delArco, PG; LopezCabrera, M; deLandazuri, MO; Redondo, JM				Aragones, J; LopezRodriquez, C; Corbi, A; delArco, PG; LopezCabrera, M; deLandazuri, MO; Redondo, JM			Dithiocarbamates trigger differentiation and induction of CD11c gene through AP-1 in the myeloid lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR KAPPA-B; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; C-JUN GENE; HUMAN-IMMUNODEFICIENCY-VIRUS; U937 CELLS; REGULATED EXPRESSION; TRANSCRIPTION FACTOR; OXIDATIVE STRESS	It has recently been shown that the alteration of the cell-redox status affects the transcription factor expression and activity. Dithiocarbamates (DTCs) are potent antioxidant agents that can switch the expression of genes dependent on the activation of the transcription factors AP-1 and NF kappa B. In this study, we show that these agents triggered the expression of genes involved in myeloid differentiation of the promonocytic U-937 cell line. DTCs promoted differentiation-associated changes that included the surface up-regulation of pa-integrins (CD11a-c/CD18), cell growth arrest concomitant with transferrin receptor (CD71) down modulation, induction of the nonspecific esterase enzyme, and a rapid drop in the mRNA levels of c-myc. A further analysis, focused on the molecular mechanisms leading 60 the activation of CD11c expression, revealed that the pyrrolidine derivative of DTC (PDTC) increased CD11c mRNA levels and augmented its gene promoter activity. Transfection experiments with reporter constructs harboring different promoter regions of CD11c gene, indicated the presence of a functional DTC-responsive region located between positions -160 and +40 of the promoter. Gel retardation assays revealed that the PDTC-induced DNA-protein complexes were restricted to members of the Fos and Jun families that bound to an AP-1 site located at position -60 from the transcription start site. A role for this site was confirmed by in vitro mutagenesis experiments that indicated the functional importance of this site for the CD11c gene transcriptional activation in response to PDTC. The effect of DTCs on myeloid cell differentiation supports a possible role for these agents in the therapy of some bone marrow-derived malignancies.	UNIV AUTONOMA MADRID, FAC CIENCIAS, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN; HOSP PRINCESA, SERV IMMUNOL, MADRID, SPAIN; HOSP PRINCESA, SERV BIOL MOL, MADRID, SPAIN; CSIC, INST LOPEZ NEYRA, GRANADA, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital de La Princesa; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			Lopez-Rodriguez, C/G-4482-2014; Corbi, Angel/B-7194-2011; Corbí, Angel L./ABC-8146-2020; Cabrera, Manuel López/AAA-5463-2019; Redondo, Juan Miguel/H-6351-2015; Gomez-del Arco, Pablo/L-2728-2013	Lopez-Rodriguez, C/0000-0002-2311-2406; Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Redondo, Juan Miguel/0000-0001-5779-9122; Gomez-del Arco, Pablo/0000-0001-6748-7157; Lopez Cabrera, Manuel/0000-0002-0976-9719; Aragones Lopez, Julian/0000-0002-0193-4679				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CABANAS C, 1990, EUR J BIOCHEM, V191, P599, DOI 10.1111/j.1432-1033.1990.tb19163.x; CABANAS C, 1989, EUR J IMMUNOL, V19, P1373, DOI 10.1002/eji.1830190804; COLLINS SJ, 1987, BLOOD, V70, P1233; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DELVA L, 1993, BLOOD, V82, P2175; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOOD TC, 1983, P NATL ACAD SCI USA, V80, P7538; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FERREIRA OC, 1991, EXP CELL RES, V193, P20, DOI 10.1016/0014-4827(91)90533-Z; GUERRERO JAL, 1989, IMMUNOLOGY, V66, P252; HASS R, 1989, EUR J CELL BIOL, V48, P282; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1988, J IMMUNOL, V140, P1393; LANG JM, 1985, LANCET, V2, P1066; LI Y, 1992, J BIOL CHEM, V267, P15097; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MINTA JO, 1985, AM J PATHOL, V119, P111; MUNOZ E, 1992, EUR J IMMUNOL, V22, P2101, DOI 10.1002/eji.1830220821; NUEDA A, 1995, CELL IMMUNOL, V164, P163, DOI 10.1006/cimm.1995.1157; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PEREZ C, 1994, CELL GROWTH DIFFER, V5, P949; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RALPH P, 1983, BLOOD, V62, P1169; REDONDO JM, 1991, MOL CELL BIOL, V11, P5671, DOI 10.1128/MCB.11.11.5671; RIUS C, 1990, EXP CELL RES, V188, P129, DOI 10.1016/0014-4827(90)90287-K; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHUTZE S, 1988, J IMMUNOL, V140, P3000; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUNDERMAN FW, 1967, AM J MED SCI, V254, P24, DOI 10.1097/00000441-196707000-00003; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	51	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10924	10931		10.1074/jbc.271.18.10924	http://dx.doi.org/10.1074/jbc.271.18.10924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631910				2022-12-27	WOS:A1996UJ34200078
J	Illenberger, S; Drewes, G; Trinczek, B; Biernat, J; Meyer, HE; Olmsted, JB; Mandelkow, EM; Mandelkow, E				Illenberger, S; Drewes, G; Trinczek, B; Biernat, J; Meyer, HE; Olmsted, JB; Mandelkow, EM; Mandelkow, E			Phosphorylation of microtubule-associated proteins MAP2 and MAP4 by the protein kinase p110(mark) - Phosphorylation sites and regulation of microtubule dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-LIKE STATE; TAU-PROTEIN; DEPENDENT KINASE; DOMAIN-STRUCTURE; BINDING DOMAINS; NERVOUS-SYSTEM; TUBULIN; BRAIN; DISEASE; IDENTIFICATION	The phosphorylation of microtubule-associated proteins (MAPs) is thought to be a key factor in the regulation of microtubule stability. We have shown recently that a novel protein kinase, termed p110 microtubule-affinity regulating kinase (''MARK''), phosphorylates microtubule-associated protein tau at the KXGS motifs in the region of internal repeats and causes the detach ment of tau from microtubules (Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., Meyer, H. E., Mandelkow, E.-M., and Mandelkow, E. (1995) J. Biol. Chem, 270, 7679-7688). Here we show that p110(mark) phosphorylates analogous KXGS sites in the microtubule binding domains of the neuronal MAP2 and the ubiquitous MAP4. Phosphorylation in vitro leads to the dissociation of MAP2 and MAP4 from microtubules and to a pronounced increase in dynamic instability, Thus the phosphorylation of the repeated motifs in the micro tubule binding domains of MAPs by p110(mark) might provide a mechanism for the regulation of microtubule dynamics in cells.	MAX PLANCK UNIT STRUCT MOLEC BIOL, D-22603 HAMBURG, GERMANY; RUHR UNIV BOCHUM, INST PHYSIOL CHEM, D-44780 BOCHUM, GERMANY; UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA	Max Planck Society; Ruhr University Bochum; University of Rochester				Drewes, Gerard/0000-0003-0575-6766				AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; AIZAWA H, 1991, J BIOL CHEM, V266, P9841; AIZAWA H, 1990, J BIOL CHEM, V265, P13849; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BERLING B, 1994, EUR J CELL BIOL, V64, P120; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BULINSKI JC, 1980, J CELL BIOL, V87, P802, DOI 10.1083/jcb.87.3.802; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHAPIN SJ, 1994, CELL MOTIL CYTOSKEL, V27, P133, DOI 10.1002/cm.970270205; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; CHAPIN SJ, 1991, J CELL SCI, V98, P27; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CORREAS I, 1992, J BIOL CHEM, V267, P15721; COUCHIE D, 1992, P NATL ACAD SCI USA, V89, P4378, DOI 10.1073/pnas.89.10.4378; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DOLL T, 1993, J CELL SCI, V106, P633; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FARUKI S, 1994, CELL MOTIL CYTOSKEL, V28, P108, DOI 10.1002/cm.970280203; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; KINDLER S, 1990, J BIOL CHEM, V265, P19679; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1992, J CELL SCI, V102, P227; LEHRICH RW, 1994, J BIOL CHEM, V269, P32446; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORI A, 1991, BIOCHEMISTRY-US, V30, P9341, DOI 10.1021/bi00102a029; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Olmsted JB, 1991, CURR OPIN CELL BIOL, V3, P52, DOI 10.1016/0955-0674(91)90165-U; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; PRYER NK, 1992, J CELL SCI, V103, P965; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SONG JS, 1995, J PROTEIN CHEM, V14, P95, DOI 10.1007/BF01888367; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VANDRE DD, 1991, J CELL SCI, V98, P577; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEST RR, 1991, J BIOL CHEM, V266, P21886; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	89	154	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10834	10843		10.1074/jbc.271.18.10834	http://dx.doi.org/10.1074/jbc.271.18.10834			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631898	hybrid			2022-12-27	WOS:A1996UJ34200066
J	Proweller, A; Butler, JS				Proweller, A; Butler, JS			Ribosomal association of poly(A)-binding protein in poly(A)-deficient Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; POLY(A) BINDING-PROTEIN; MESSENGER-RNA; POSSIBLE INVOLVEMENT; XENOPUS-LAEVIS; INITIATION; YEAST; GENE; IDENTIFICATION; TRANSLATION	Poly(A) binding protein, the most abundant eukaryotic mRNP protein, is known primarily for its association with polyadenylate tails of mRNA. In the yeast, Saccharomyces cerevisiae, this protein (Pabp) was found to be essential for viability and has been implicated in models featuring roles in mRNA stability and as an enhancer of translation initiation. Although the mechanism of action is unknown, it is thought to require an activity to bind poly(A) tails and an additional capacity for an interaction with 60 S ribosomal subunits, perhaps via ribosomal protein L46 (RpI46), We have found that a significant amount of Pabp in wild-type cells is not associated with polyribosome complexes. The remaining majority, which is found in these complexes, maintains its association even in yeast cells deficient in polyadenylated mRNA and/or RpI46, These observations suggest that Pabp may not require interaction with poly(A) tails during translation, Further treatment of polyribosome lysates with agents known to differentially disrupt components of polyribosomes indicated that Pabp may require contact with some RNA component of the polyribosome, which could be either non-poly(A)-rich sequences of the translated mRNA or possibly a component of the ribosome. These findings suggest that Pabp may possess the ability to bind to ribosomes independently of its interaction with poly(A), We discuss these conclusions with respect to current models suggesting a multifunctional binding capacity of Pabp.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA	University of Rochester					NIAID NIH HHS [5-T32-AI070362] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07356] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1986, J VIROL, V57, P614, DOI 10.1128/JVI.57.2.614-622.1986; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DRAWBRIDGE J, 1990, MOL CELL BIOL, V10, P3994, DOI 10.1128/MCB.10.8.3994; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; Jacobson A., 1995, TRANSLATIONAL CONTRO, P451; LEMAY G, 1986, ARCH BIOCHEM BIOPHYS, V249, P191, DOI 10.1016/0003-9861(86)90574-6; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TARUN ZS, 1995, GENE DEV, V9, P2997; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10859	10865		10.1074/jbc.271.18.10859	http://dx.doi.org/10.1074/jbc.271.18.10859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631901	hybrid			2022-12-27	WOS:A1996UJ34200069
J	MartinMoutot, N; Charvin, N; Leveque, C; Sato, K; Nishiki, T; Kozaki, S; Takahashi, M; Seagar, M				MartinMoutot, N; Charvin, N; Leveque, C; Sato, K; Nishiki, T; Kozaki, S; Takahashi, M; Seagar, M			Interaction of SNARE complexes with P/Q-type calcium channels in rat cerebellar synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT SYNAPSE; CA2+ CHANNELS; SYNAPTOTAGMIN; DOCKING; FUSION	P- and Q-type calcium channels, which trigger rapid neurotransmitter release at many mammalian synapses, are blocked by omega-conotoxin MVIIC. I-125-omega Conotoxin MVIIC binding to rat cerebellar synaptosomes was not displaced by omega-conotogins GVIA or MVIIA (K-i > 1 mu M), which are selective for N-type calcium channels. Solubilized I-125-omega-conotoxin MMIC receptors were specifically recognized by antibodies directed against alpha(1)A calcium channel subunits, proteins known to constitute a pore with P/Q-like channel properties, Antibodies against syntaxin 1, SNAP 25, and VAMP 2 (synaptobrevin) each immunoprecipitated a similar fraction (20-40%) of omega-conotoxin MVIIC receptors. Immunoprecipitation was not additive, suggesting that heterotrimeric (SNARE) complexes containing these three proteins interact with P/Q-type calcium channels. Immobilized monoclonal anti-syntaxin antibodies retained ru,A calcium channel subunits of 220, 180 and 160 kDa monitored by immunoblotting with site directed antibodies. Synaptotagmin was detected in channel-associated complexes; but not synaptophysin, Rab 3A nor rat cysteine string protein, Trimeric SNARE complexes are implicated in calcium-dependent exocytosis, a process thought to be regulated by synaptotagmin. Our results indicate that these proteins interact with P/Q-type calcium channels, which may optimize their location within domains of calcium influx.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV OSAKA PREFECTURE,DEPT VET SCI,OSAKA 593,JAPAN	Osaka Metropolitan University	MartinMoutot, N (corresponding author), FAC MED,INST JEAN ROCHE,INSERM,U374,SECT NORD,BLVD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.		leveque, christian/GVU-3567-2022	leveque, christian/0000-0003-2583-2148				ADLER EM, 1991, J NEUROSCI, V11, P1496; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; GRANTHAM CJ, 1994, NEUROPHARMACOLOGY, V33, P255, DOI 10.1016/0028-3908(94)90017-5; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARTINMOUTOT N, 1995, FEBS LETT, V366, P21, DOI 10.1016/0014-5793(95)00467-N; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TURNER TJ, 1995, NEUROPHARMACOLOGY, V34, P1469, DOI 10.1016/0028-3908(95)00133-Q; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	31	112	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6567	6570		10.1074/jbc.271.12.6567	http://dx.doi.org/10.1074/jbc.271.12.6567			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636067	hybrid			2022-12-27	WOS:A1996UB15700002
J	Nakahira, K; Shi, GY; Rhodes, KJ; Trimmer, JS				Nakahira, K; Shi, GY; Rhodes, KJ; Trimmer, JS			Selective interaction of voltage-gated K+ channel beta-subunits with alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; RAT-BRAIN; EXPRESSION; CLONING; CDNA	To begin to study the molecular bases that determine the selective interaction of the beta-subunits of voltage-gated K+ channels with alpha-subunits observed in situ, we have expressed these polypeptides in transfected mammalian cells. Analysis of the specificity of alpha/beta-subunit interaction indicates that both the Kv beta 1 and Kv beta 2 beta-subunits display robust and selective interaction with the five members of the Shaker-related (Kv1) alpha-subunit subfamily tested. The interaction of these beta-subunits with Kv1 alpha-subunits does not require the beta-subunit N-terminal domains. Thus, the previously observed failure of N-terminal mutants of Kv beta 1 to modulate inactivation kinetics of Kv1 family members is not simply due to a lack of subunit interaction. Interaction of these beta-subunits with members of two other subfamilies (Shab- and Shaw-related) could not be detected. Somewhat surprisingly, a member of the Shal-related subfamily was found to interact with beta-subunits; however, this interaction had biochemical characteristics distinct from the beta-subunit interaction with Kv1 family members. In an cases, Kv beta 1 and Kv beta 2 exhibited indistinguishable alpha-subunit selectivity. These studies point to a selective interaction between K+ channel alpha- and beta-subunits mediated through conserved domains in the respective subunits.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; WYETH AYERST RES,CENT NERVOUS SYST DIV,PEARL RIVER,NY 10965	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pfizer					NINDS NIH HHS [NS34383] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034383, R37NS034383] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; LENZ S, 1994, SYNAPSE, V18, P55, DOI 10.1002/syn.890180108; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; SHEN NV, 1993, NEURON, V11, P67; SHI GY, 1994, J BIOL CHEM, V269, P23204; STRONG M, 1993, MOL BIOL EVOL, V10, P221; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761	28	126	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7084	7089		10.1074/jbc.271.12.7084	http://dx.doi.org/10.1074/jbc.271.12.7084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636142	hybrid			2022-12-27	WOS:A1996UB15700077
J	Riewald, M; Morgenstern, KA; Schleef, RR				Riewald, M; Morgenstern, KA; Schleef, RR			Identification and characterization of the cytoplasmic antiproteinase (CAP) in human platelets - Evidence for the interaction of CAP with endogenous platelet proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; PROTEASE NEXIN-I; CELL-LINE; MOLECULAR CHARACTERIZATION; BINDING-SITES; MESSENGER-RNA; THROMBIN; COMPLEXES; PURIFICATION; POLYPEPTIDES	To define the presence and potential role of platelet-associated protease inhibitors, we initiated a study designed to characterize the platelet components that are responsible for the formation of two SDS-stable complexes of approximately 58 and 70 kDa initially observed following the incubation of I-125-thrombin and human platelets. We demonstrate that thermal-mediated unfolding of the 58-kDa complex between I-125-thrombin and a nonsecreted platelet protein leads to an apparent molecular mass of 70 kDa. This platelet component is functionally and immunologically indistinguishable from the cytoplasmic antiproteinase (CAP), also known as placental thrombin inhibitor, a recently cloned member of the ovalbumin family of intracellular serpins (serine proteinase inhibitors), CAP-specific mRNA and antigen were detected in human platelets, suggesting that CAP synthesis occurs concurrent with platelet development. Utilizing quantitative immunoblotting, CAP antigen was estimated at 1.014 +/- 0.181 mu g/10(9) nonstimulated platelets. After platelet activation with the calcium ionophore A23187, CAP antigen was detected in released microparticles at approximately 0.195 +/- 0.031 mu g/10(9) platelets and a fraction of platelet CAP was proteolytically modified. We provide evidence that these lower molecular mass species arise by cleavage of CAP at or near the reactive site loop. Most importantly, molecular sieving chromatography indicates the presence of an approximately 68-kDa SDS-labile complex between cleaved CAP and a cellular component in A23187-stimulated platelets, suggesting a physiological target of this intracellular serpin and a potential role for this inhibitor in regulating proteolytic activity that may be formed during platelet activation.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; UNIV NEW MEXICO, SCH MED, DEPT PATHOL, BLOOD SYST RES FDN LAB, ALBUQUERQUE, NM 87131 USA	Scripps Research Institute; University of New Mexico					NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NHLBI NIH HHS [HL45954, HL49563] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954, R01HL049563] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER JB, 1986, SEMIN THROMB HEMOST, V12, P216, DOI 10.1055/s-2007-1003554; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BENNETT WF, 1980, CELL, V22, P621, DOI 10.1016/0092-8674(80)90372-4; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BROWNE PC, 1988, ARCH BIOCHEM BIOPHYS, V265, P534, DOI 10.1016/0003-9861(88)90158-0; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; GEORGE JN, 1982, BLOOD, V60, P834; GREENBERG SM, 1988, BLOOD, V72, P1968; GRONKE RS, 1989, BLOOD, V73, P472; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; HARFENIST EJ, 1982, BLOOD, V59, P952; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; KIRSCHNER RJ, 1980, J BIOL CHEM, V255, P5468; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA KM, 1987, P NATL ACAD SCI USA, V84, P5620, DOI 10.1073/pnas.84.16.5620; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; MILLER JJ, 1988, BIOCHEM BIOPH RES CO, V151, P9, DOI 10.1016/0006-291X(88)90552-9; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shuman M A, 1981, Ann N Y Acad Sci, V370, P57, DOI 10.1111/j.1749-6632.1981.tb29721.x; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; TESSMER U, 1989, ELECTROPHORESIS, V10, P277, DOI 10.1002/elps.1150100414; YE RD, 1987, J BIOL CHEM, V262, P3728; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	41	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7160	7167		10.1074/jbc.271.12.7160	http://dx.doi.org/10.1074/jbc.271.12.7160			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636153	hybrid			2022-12-27	WOS:A1996UB15700088
J	Toukdarian, AE; Helinski, DR; Perri, S				Toukdarian, AE; Helinski, DR; Perri, S			The plasmid RK2 initiation protein binds to the origin of replication as a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE PLASMID-RK2; GRAM-NEGATIVE BACTERIA; DNA-BINDING; TRFA GENE; SEQUENCE REQUIREMENTS; NUCLEOTIDE-SEQUENCE; REGION; MAINTENANCE; MUTATIONS; DOMAINS	The TrfA protein encoded by the broad host range bacterial plasmid RK2 specifically binds to eight direct repeats (iterons) present at the plasmid replication origin to initiate DNA replication. purified TrfA protein is largely in the form of a dimer, and using a dimerization test system that involves the fusion of the amino-terminal domain of the lambda cI repressor protein to TrfA, we show that the TrfA protein forms dimers in vivo., Because of the high stability of the dimer form of TrfA, the formation of heterodimers between the wild-type and different sized TrfA proteins requires in vivo de novo folding of the primary protein sequence or in vitro denaturation and renaturation. The results of gel mobility shift assays using in vitro or in vivo formed heterodimers indicated that the TrfA protein binds to the iteron DNA as a monomer. Furthermore, when the monomeric and dimeric forms of TrfA are separated by gel filtration chromatography, only the protein in the chromatographic position of the monomeric form demonstrated significant DNA binding activity. These results indicate that only the monomer form of the TrfA protein is active for binding to the iterons at the RK2 replication origin.	UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arber W., 1983, LAMBDA, P433; BACKMAN K, 1978, CELL, V13, P65, DOI 10.1016/0092-8674(78)90138-1; BAILONE A, 1980, NUCLEIC ACIDS RES, V8, P2147, DOI 10.1093/nar/8.10.2147; BATTAGLIA PA, 1994, BIOCHEM BIOPH RES CO, V201, P701, DOI 10.1006/bbrc.1994.1757; BRENNER M, 1991, P NATL ACAD SCI USA, V88, P405, DOI 10.1073/pnas.88.2.405; BUNKER CA, 1995, NUCLEIC ACIDS RES, V23, P269, DOI 10.1093/nar/23.2.269; CEREGHINO JL, 1994, PLASMID, V31, P89, DOI 10.1006/plas.1994.1009; CEREGHINO JL, 1993, J BIOL CHEM, V268, P24926; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DASGUPTA S, 1993, J MOL BIOL, V232, P23, DOI 10.1006/jmbi.1993.1367; DURLAND RH, 1990, J BACTERIOL, V172, P3859, DOI 10.1128/jb.172.7.3859-3867.1990; DURLAND RH, 1990, J BACTERIOL, V172, P3849, DOI 10.1128/jb.172.7.3849-3858.1990; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; HARLOW E, 1988, ANTIBODIES LAB MANUA, P561; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAUGAN K, 1995, PLASMID, V33, P27, DOI 10.1006/plas.1995.1004; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KORNACKI JA, 1984, PLASMID, V11, P48, DOI 10.1016/0147-619X(84)90006-4; LARSEN MH, 1994, J BACTERIOL, V176, P5022, DOI 10.1128/jb.176.16.5022-5032.1994; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; MANEN D, 1994, MOL MICROBIOL, V11, P875, DOI 10.1111/j.1365-2958.1994.tb00366.x; MANEN D, 1992, P NATL ACAD SCI USA, V89, P8923, DOI 10.1073/pnas.89.19.8923; MARCHETTI A, 1995, J MOL BIOL, V248, P541, DOI 10.1006/jmbi.1995.0241; MASSON L, 1988, NUCLEIC ACIDS RES, V16, P413, DOI 10.1093/nar/16.2.413; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PERRI S, 1991, J BIOL CHEM, V266, P12536; PERRI S, 1993, J BIOL CHEM, V268, P3662; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SCHMIDHAUSER TJ, 1985, J BACTERIOL, V164, P446, DOI 10.1128/JB.164.1.446-455.1985; SHINGLER V, 1984, J MOL BIOL, V175, P229, DOI 10.1016/0022-2836(84)90346-2; SHINGLER V, 1989, BIOCHIM BIOPHYS ACTA, V1007, P301, DOI 10.1016/0167-4781(89)90152-8; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUGIURA S, 1990, J BIOCHEM-TOKYO, V107, P369, DOI 10.1093/oxfordjournals.jbchem.a123052; SWACK JA, 1987, J BACTERIOL, V169, P3737, DOI 10.1128/jb.169.8.3737-3742.1987; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P231; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VALLA S, 1991, PLASMID, V25, P131, DOI 10.1016/0147-619X(91)90025-R; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903	50	35	36	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7072	7078		10.1074/jbc.271.12.7072	http://dx.doi.org/10.1074/jbc.271.12.7072			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636140	hybrid			2022-12-27	WOS:A1996UB15700075
J	Mozzarelli, A; Bettati, S; Rivetti, C; Rossi, GL; Colotti, G; Chiancone, E				Mozzarelli, A; Bettati, S; Rivetti, C; Rossi, GL; Colotti, G; Chiancone, E			Cooperative oxygen binding to Scapharca inaequivalvis hemoglobin in the crystal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGANDED T-STATE; STRUCTURAL TRANSITIONS; TETRAMERIC HEMOGLOBINS; DIMERIC HEMOGLOBIN; SINGLE-CRYSTALS	Oxygen binding to homodimeric Scapharca inaequivalvis hemoglobin (HbI) crystals has been investigated by single-crystal polarized absorption microspectrophotometry. The saturation curve, characterized by a Hill coefficient n(H) = 1.45 and an oxygen pressure at half saturation p(50) = 4.8 torr, at 15 degrees C, shows that HbI in the crystalline state retains positive cooperativity in ligand binding. This finding will permit the correlation of the oxygen-linked conformational changes in the crystal with the expression of cooperativity. Polarized absorption spectra of deoxy-HbI, oxy-HbI, and oxidized HbI crystals indicate that oxygenation does not induce heme reorientation, whereas oxidation does. Lattice interactions prevent the dissociation of oxidized dimers that occurs in solution and stabilize an equilibrium distribution of pentacoordinate and hexacoordinate high spin species.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,CTR STUDIO BIOL MOLEC,I-00185 ROME,ITALY	Sapienza University Rome	Mozzarelli, A (corresponding author), UNIV PARMA,IST SCI BIOCHIM,I-43100 PARMA,ITALY.		Mozzarelli, Andrea/C-3615-2014; Colotti, Gianni/D-2015-2010; Bettati, Stefano/V-9975-2018; Colotti, Gianni/AAG-4918-2019	Mozzarelli, Andrea/0000-0003-3762-0062; Colotti, Gianni/0000-0002-9913-0635; Bettati, Stefano/0000-0001-6787-0594; Rivetti, Claudio/0000-0003-3775-6779				AHMED SA, 1987, BIOCHEMISTRY-US, V260, P5492; ANSARI A, 1993, BIOPHYS J, V64, P852, DOI 10.1016/S0006-3495(93)81446-2; BERNI R, 1977, J MOL BIOL, V110, P405, DOI 10.1016/S0022-2836(77)80079-X; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; DVORAK JA, 1971, EXP CELL RES, V68, P144, DOI 10.1016/0014-4827(71)90596-9; Eaton W A, 1981, Methods Enzymol, V76, P175; GOUAUX JE, 1989, P NATL ACAD SCI USA, V86, P845, DOI 10.1073/pnas.86.3.845; HAUROWITZ F, 1938, Z PHYSL CHEM, V234, P266; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; IKEDASAITO M, 1983, J MOL BIOL, V170, P1009, DOI 10.1016/S0022-2836(83)80200-9; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; KASVINSKY PJ, 1976, J BIOL CHEM, V251, P6852; KAVANAUGH JS, 1995, J MOL BIOL, V248, P136, DOI 10.1006/jmbi.1995.0207; KIRSTEN H, 1983, P NATL ACAD SCI-BIOL, V80, P1807, DOI 10.1073/pnas.80.7.1807; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; MAKINEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301, DOI 10.1146/annurev.bb.06.060177.001505; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOZZARELLI A, 1982, J BIOL CHEM, V257, P6739; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1953, ACTA CRYSTALLOGR, V6, P859, DOI 10.1107/S0365110X53002507; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P6411, DOI 10.1021/bi00076a014; ROSSI GL, 1992, PHILOS T R SOC A, V340, P191, DOI 10.1098/rsta.1992.0060; ROSSI GL, 1992, CURR OPIN STRUC BIOL, V2, P816; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; RUPLEY JA, 1969, STRUCTURE STABILITY, P291; SPAGNUOLO C, 1994, J BIOL CHEM, V269, P20441; VAS M, 1979, J BIOL CHEM, V254, P8480	36	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3627	3632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631972				2022-12-27	WOS:A1996TV72400046
J	Su, C; Oliw, EH				Su, C; Oliw, EH			Purification and characterization of linoleate 8-dioxygenase from the fungus Gaeumannomyces graminis as a novel hemoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; ACTIVE-SITE IRON; ASPERGILLUS-NIDULANS; ACID; METABOLITES; IDENTIFICATION; LIPOXYGENASES; BIOSYNTHESIS; OXYGENATION; INHIBITORS	The fungus Gaeumannomyces graminis, which causes the major root disease of wheat known as ''take-all,'' can metabolize linoleic acid to (8R)-hydroperoxylinoleic acid. The enzyme linoleate 8-dioxygenase abstracts hydrogen and introduces molecular oxygen in an antarafacial way at C-8. We have now purified the enzyme 1000-fold to a specific activity of 1.8 mu mol/min/mg of protein. Acetone powder of mycelia of G. graminis was subjected to extraction and ammonium sulfate precipitation with solubilization. The 8-dioxygenase was purified by hydrophobic interaction chromatography, size-exclusion chromatography, anion-exchange chromatography, and immobilized metal ion affinity chromatography. The active enzyme appeared to consist of four subunits since the active enzyme had an apparent molecular mass of 520 kDa determined by gel filtration, while SDS-polyacrylamide gel electrophoresis showed a protein band of 130 kDa. Spectroscopy indicated the presence of heme. The characteristic pyridine ferrohemochrome alpha-band was found at 557 nm and the beta-band at 525 nm. The purified protein showed an absorption maximum at 408 nm (gamma, Soret). The absorption maximum shifted to 429 nm after reduction with dithionite and to 421 nm after treatment of the reduced enzyme with carbon monoxide. BW A4C, a hydroxamic acid derivative, inhibited the enzyme by >90% at 10 mu M. The pH optimum was 7.2-7.4, the isoelectric point was 5.2 by chromatofocusing, and the K-m values were 8 mu M for linoleic acid and 30 mu M for oxygen. We conclude that linoleate 8-dioxygenase appears to be a tetrameric hemoprotein distinct from other fatty-acid dioxygenases.			Su, C (corresponding author), UPPSALA UNIV, BIOMED CTR, DEPT PHARMACEUT BIOSCI, DIV BIOCHEM PHARMACOL, BOX 591, S-75124 UPPSALA, SWEDEN.			Oliw, Ernst/0000-0002-7986-8130				ABELSON PH, 1995, SCIENCE, V269, P1027, DOI 10.1126/science.269.5227.1027; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; BRODOWSKY ID, 1993, BIOCHIM BIOPHYS ACTA, V1168, P68, DOI 10.1016/0005-2760(93)90267-D; BRODOWSKY ID, 1994, EUR J PHARMACOL, V254, P43, DOI 10.1016/0014-2999(94)90368-9; BRODOWSKY ID, 1994, ACTA U UPSAL, V123, P1; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; ELLIOTT WJ, 1986, J BIOL CHEM, V261, P6719; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEDS JM, 1993, J BIOL CHEM, V268, P17781; MAEZONO K, 1990, BIOCHEM BIOPH RES CO, V170, P176, DOI 10.1016/0006-291X(90)91256-R; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; MCMILLAN RM, 1992, TRENDS PHARMACOL SCI, V13, P323, DOI 10.1016/0165-6147(92)90100-K; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON MJ, 1991, J BIOL CHEM, V266, P8225; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V300, P434, DOI 10.1006/abbi.1993.1059; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PORTER DA, 1995, LIPIDS, V30, P277; SCHUTZ G, 1972, J BIOL CHEM, V247, P5327; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SU C, 1995, LIPIDS, V30, P43, DOI 10.1007/BF02537040; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; Webb E. C., 1992, ENZYME NOMENCLATURE; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	39	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14112	14118		10.1074/jbc.271.24.14112	http://dx.doi.org/10.1074/jbc.271.24.14112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662736	hybrid			2022-12-27	WOS:A1996UQ66000029
J	Herwald, H; Renne, T; Meijers, JCM; Chung, DW; Page, JD; Colman, RW; MullerEsterl, W				Herwald, H; Renne, T; Meijers, JCM; Chung, DW; Page, JD; Colman, RW; MullerEsterl, W			Mapping of the discontinuous kininogen binding site of prekallikrein - A distal binding segment is located in the heavy chain domain A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; HUMAN-PLASMA PREKALLIKREIN; BLOOD-COAGULATION FACTOR; 4 TANDEM REPEATS; FACTOR-XI; FUNCTIONAL-PROPERTIES; POLYACRYLAMIDE GELS; HAGEMAN-FACTOR; KALLIKREIN; PROTEINS	Prekallikrein, the precursor to the serine proteinase kallikrein, circulates in plasma in an equimolar complex with H-kininogen. The binding to H-kininogen is mediated by the kallikrein heavy chain consisting of four ''apple'' domains, A1-A4, which attaches to H-kininogen with high specificity and affinity (K-D = 83 nM). At least two distinct portions of the kallikrein heavy chain form this H-kininogen binding site: a proximal segment located in the NH2-terminal fragment of the heavy chain encompassing A1, and distal segment(s) located in COOH-terminal fragment spanning domains A2-A4. The proximal binding segment has been located to amino acid positions 56-86 of A1. To precisely map the distal binding segment, we have identified monoclonal antibodies directed to the COOH-terminal fragment which interfere with the H-kininogen-prekallikrein complex formation. Monoclonal antibody 13G11 binds to recombinant apple domain A4 but not to domain A3 of the prekallikrein heavy chain. Deletion mutagenesis of domain A4 narrowed down the target epitope of 13G11 to the center portion of domain A4, positions 284-331. Direct binding studies of H-kininogen to various domain A4 constructs revealed that the distal H-kininogen binding portion is located on a segment of 48 residues, which overlaps the 13G11 epitope. Hence the tight interaction of H-kininogen add prekallikrein is mediated by at least two separate sequence segments located in domains A1 and A4, respectively, of the prekallikrein heavy chain. The isolated distal binding segment significantly prolongs the partial thromboplastin time of reconstituted Williams plasma thus stressing the critical role of the prekallikrein-H-kininogen complex formation in the initiation of the endogenous blood coagulation cascade.	UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY; UNIV UTRECHT HOSP,DEPT HAEMATOL,3508 GA UTRECHT,NETHERLANDS; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140	Johannes Gutenberg University of Mainz; Utrecht University; Utrecht University Medical Center; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Meijers, J.C.M./S-5981-2019; Herwald, Heiko/AAN-3708-2021; Sessum, Rachel/F-7312-2015	Meijers, J.C.M./0000-0002-4198-6780; Herwald, Heiko/0000-0002-8111-2842; Sessum, Rachel/0000-0002-2444-7056; Renne, Thomas/0000-0003-4594-5975	NHLBI NIH HHS [HL16929] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, BLOOD, V85, P2078, DOI 10.1182/blood.V85.8.2078.bloodjournal8582078; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BERGER D, 1986, J BIOL CHEM, V261, P324; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COLMAN RW, 1985, BLOOD, V65, P311; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; HEERWALD H, 1995, J BIOL CHEM, V270, P14634; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1993, J BIOL CHEM, V268, P14527; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOCK J, 1990, J BIOL CHEM, V265, P12005; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JOHANNESSEN M, 1990, THROMB HAEMOSTASIS, V63, P54; KAPLAN AP, 1987, BLOOD, V70, P1; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MANDLE R, 1977, P NATL ACAD SCI USA, V73, P4179; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MEIJERS JCM, 1992, BLOOD, V79, P1435; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PAGE JD, 1994, ARCH BIOCHEM BIOPHYS, V314, P159, DOI 10.1006/abbi.1994.1424; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHAPIRA M, 1982, J CLIN INVEST, V69, P462, DOI 10.1172/JCI110470; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VELOSO D, 1987, BLOOD, V70, P1053; VOGEL R, 1990, J BIOL CHEM, V265, P12494; YOU JL, 1993, PEPTIDES, V14, P867, DOI 10.1016/0196-9781(93)90061-K	45	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13061	13067		10.1074/jbc.271.22.13061	http://dx.doi.org/10.1074/jbc.271.22.13061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662705	hybrid			2022-12-27	WOS:A1996UN47400059
J	Bakos, E; Hegedus, T; Hollo, Z; Welker, E; Tusnady, GE; Zaman, GJR; Flens, MJ; Varadi, A; Sarkadi, B				Bakos, E; Hegedus, T; Hollo, Z; Welker, E; Tusnady, GE; Zaman, GJR; Flens, MJ; Varadi, A; Sarkadi, B			Membrane topology and glycosylation of the human multidrug resistance-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MDR1 P-GLYCOPROTEIN; INSECT CELLS; GENE; ORIENTATION; EXPRESSION; HOMOLOGY; CDNA; SITE	The membrane topology of the human multidrug resistance-associated protein (MRP) was examined by flow cytometry phenotyping, immunoblotting, and limited proteolysis in drug-resistant human and baculovirus-infected insect cells, expressing either the glycosylated or the underglycosylated forms of this protein, Inhibition of N-linked glycosylation in human cells by tunicamycin did not inhibit the transport function or the antibody recognition of MRP, although its apparent molecular mass was reduced from 180 kDa to 150 kDa. Extracellular addition of trypsin or chymotrypsin had no effect either on the function or on the molecular mass of MRP, while in isolated membranes limited proteolysis produced three large membrane-bound fragments, These experiments and the alignment of the MRP sequence with the human cystic fibrosis transmembrane conductance regulator (CFTR) suggest that human MRP, similarly to CFTR, contains a tandem repeat of six transmembrane helices, each followed by a nucleotide binding domain, and that the C-terminal membrane-bound region is glycosylated. However, the N-terminal region of MRP contains an additional membrane-bound, glycosylated area with four or five transmembrane helices, which seems to be a characteristic feature of MRP-like ATP-binding cassette transporters.	NATL INST HAEMATOL & IMMUNOL, H-1113 BUDAPEST, HUNGARY; HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, H-1113 BUDAPEST, HUNGARY; NETHERLANDS CANC INST, 1080 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, 1080 HV AMSTERDAM, NETHERLANDS	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Netherlands Cancer Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER			Hegedus, Tamas/P-8625-2015; Sarkadi, Balazs/I-5024-2013; Welker, Ervin/AAC-6493-2022; Tusnády, Gábor E/A-3207-2009; Varadi, Andras/A-2055-2012; Tusnády, Gábor E./AAI-1136-2021	Hegedus, Tamas/0000-0002-5195-749X; Tusnády, Gábor E/0000-0001-8105-0285; Tusnády, Gábor E./0000-0001-8105-0285				CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1993, SCIENCE, V260, P879, DOI 10.1126/science.8098549; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FELLER N, 1995, FEBS LETT, V368, P385, DOI 10.1016/0014-5793(95)00677-2; FLENS MJ, 1994, CANCER RES, V54, P4557; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Homolya L, 1996, BRIT J CANCER, V73, P849, DOI 10.1038/bjc.1996.151; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	32	195	197	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12322	12326		10.1074/jbc.271.21.12322	http://dx.doi.org/10.1074/jbc.271.21.12322			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647833	hybrid			2022-12-27	WOS:A1996UL66000035
J	Bielawska, A; Greenberg, MS; Perry, D; Jayadev, S; Shayman, JA; McKay, C; Hannun, YA				Bielawska, A; Greenberg, MS; Perry, D; Jayadev, S; Shayman, JA; McKay, C; Hannun, YA			(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; D-ERYTHRO-SPHINGOSINE; D-THREO-SPHINGOSINE; CELL-FREE SYSTEM; GLUCOSYLCERAMIDE SYNTHASE; HL-60 CELLS; SPHINGOMYELIN METABOLISM; MEDIATED BIOLOGY; PHOSPHOLIPASE-D; L-SERINE	In this study, we have examined the cellular and biochemical activities of the ceramide analog (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-erythro-MAPP). Addition of 5 mu M D-e-MAPP to HL-60 human promyelocytic leukemia cells resulted in a concentration- and time-dependent growth suppression accompanied by an arrest in the G(0)/G(1) phase of the cell cycle; thus mimicking the action of exogenous ceramides. Its enantiomer L-e-MAPP was without effect. Two lines of evidence suggested that D-e-MAPP may not function as a direct analog of ceramide. First, D-e-MAPP possesses a stereochemical configuration opposite to that of D-erythro-ceramide. Second, D-e-MAPP failed to activate ceramide-activated protein phosphatase in vitro. Therefore, we examined if D-e-MAPP functioned indirectly by modulating endogenous ceramide levels. The addition of D-e-MAPP to cells, but not L-e-MAPP, caused a time- and concentration-dependent elevation in endogenous ceramide levels reaching greater than 3-fold over base-line following 24 h of treatment. Both D-e-MAPP and L-e-MAPP underwent similar uptake by HL-60 cells. D-e-MAPP was poorly metabolized, and remained intact in cells, whereas L-e-MAPP underwent a time- and concentration-dependent metabolism; primarily through N-deacylation. In vitro, L-e-MAPP was metabolized by alkaline ceramidase to an extent similar to that seen with C-16-ceramide, D-e-MAPP was not metabolized. Instead, D-e-MAPP inhibited alkaline ceramidase activity in vitro with an IC50 of 1-5 mu M. D-e-MAPP did not modulate the activity of other ceramide metabolizing enzymes in vitro or in cells, and it was a poor inhibitor of acid ceramidase (IC50 > 500 mu M). Finally, D-e-MAPP inhibited the metabolism of L-e-MAPP in cells. These studies demonstrate that D-e-MAPP functions as an inhibitor of alkaline ceramidase in vitro and in cells resulting in elevation in endogenous levels of ceramide with the consequent biologic effects of growth suppression and cell cycle arrest. These studies point to an important role for ceramidases in the regulation of endogenous levels of ceramide.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; UNIV MICHIGAN, MED CTR, DEPT MED, ANN ARBOR, MI 48109 USA	Duke University; Duke University; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45067] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CARTER HE, 1956, J BIOL CHEM, V221, P879; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHEN WW, 1981, ARCH BIOCHEM BIOPHYS, V208, P444, DOI 10.1016/0003-9861(81)90531-2; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GARNER P, 1988, J ORG CHEM, V53, P4395, DOI 10.1021/jo00253a039; GATT S, 1969, METHOD ENZYMOL, V14, P139; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KISS Z, 1992, BIOCHIM BIOPHYS ACTA, V1124, P300, DOI 10.1016/0005-2760(92)90143-J; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; SPIEGEL S, 1994, BREAST CANCER RES TR, V31, P337, DOI 10.1007/BF00666166; STOFFEL W, 1973, CHEM PHYS LIPIDS, V11, P318, DOI 10.1016/0009-3084(73)90068-6; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WANG E, 1991, J BIOL CHEM, V266, P14486; WERTZ PW, 1990, FEBS LETT, V268, P110, DOI 10.1016/0014-5793(90)80985-R; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	69	185	202	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12646	12654		10.1074/jbc.271.21.12646	http://dx.doi.org/10.1074/jbc.271.21.12646			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647877	hybrid			2022-12-27	WOS:A1996UL66000079
J	Drake, FH; Dodds, RA; James, IE; Connor, JR; Debouck, C; Richardson, S; LeeRykaczewski, E; Coleman, L; Rieman, D; Barthlow, R; Hastings, G; Gowen, M				Drake, FH; Dodds, RA; James, IE; Connor, JR; Debouck, C; Richardson, S; LeeRykaczewski, E; Coleman, L; Rieman, D; Barthlow, R; Hastings, G; Gowen, M			Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITOR; BONE-RESORPTION; RAT OSTEOCLAST; LOCALIZATION	Random high throughput sequencing of a human osteoclast cDNA library was employed to identify novel osteoclast-expressed genes. Of the 5475 ESTs obtained, approximately 4% encoded cathepsin K, a novel cysteine protease homologous to cathepsins S and L; ESTs for other cathepsins were rare. In addition, ESTs for cathepsin K were absent or at low frequency in cDNA libraries from numerous other tissues and cells. In situ hybridization in osteoclastoma and osteophyte confirmed that cathepsin K mRNA was highly expressed selectively in osteoclasts; cathepsins S, L, and B were not detectable. Cathepsin K was not detected by in situ hybridization in a panel of other tissues. Western blot of human osteoclastoma or fetal rat humerus demonstrated bands of 38 and 27 kDa, consistent with sizes predicted for pro- and mature cathepsin K. Immunolocalization in osteoclastoma and osteophyte showed intense punctate staining of cathepsin K exclusively in osteoclasts, with a polar distribution that was more intense at the bone surface. The abundant expression of cathepsin K selectively in osteoclasts strongly suggests that it plays a specialized role in bone resorption. Furthermore, the data suggest that random sequencing of ESTs from cDNA libraries is a valuable approach for identifying novel cell-selective genes.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc	Drake, FH (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Baron Roland, 1993, P3; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DODDS RA, 1994, J HISTOCHEM CYTOCHEM, V42, P599, DOI 10.1177/42.5.8157931; Drake FH, 1994, J BONE MINER RES, V9, pS177; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; GOTO T, 1992, HISTOCHEMISTRY, V97, P13, DOI 10.1007/BF00271276; GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829; GOTO T, 1993, HISTOCHEMISTRY, V99, P411, DOI 10.1007/BF00717054; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KREMER M, 1995, J CELL BIOCHEM, V57, P271, DOI 10.1002/jcb.240570211; LERNER UH, 1992, J BONE MINER RES, V7, P433; Li Y. P., 1994, Molecular Biology of the Cell, V5, p335A; LI YP, 1995, J BONE MINER RES, V10, P1197; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; OHSAWA Y, 1993, J HISTOCHEM CYTOCHEM, V41, P1075, DOI 10.1177/41.7.8515049; PAGE AE, 1992, BIOCHIM BIOPHYS ACTA, V1116, P57, DOI 10.1016/0304-4165(92)90128-H; RIFKIN BR, 1991, BIOCHEM BIOPH RES CO, V179, P63, DOI 10.1016/0006-291X(91)91334-9; SANNES PL, 1986, J HISTOCHEM CYTOCHEM, V34, P983, DOI 10.1177/34.8.3016074; SASAKI T, 1993, CELL TISSUE RES, V271, P177, DOI 10.1007/BF00297556; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; TAGAMI K, 1994, FEBS LETT, V342, P308, DOI 10.1016/0014-5793(94)80522-9; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VANNOORDEN CJF, 1989, J HISTOCHEM CYTOCHEM, V37, P617, DOI 10.1177/37.5.2703699; ZELLER R, 1991, CURRENT PROTOCOLS MO	34	599	638	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12511	12516		10.1074/jbc.271.21.12511	http://dx.doi.org/10.1074/jbc.271.21.12511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647859	hybrid			2022-12-27	WOS:A1996UL66000061
J	Ghislain, JJ; Fish, EN				Ghislain, JJ; Fish, EN			Application of genomic DNA affinity chromatography identifies multiple interferon-alpha-regulated Stat2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; GROWTH-FACTOR; CELL-LINE; GENE; ELEMENT; ISGF3; POLYPEPTIDE; ACTIVATION	Interferon-alpha (IFN-alpha)-induced signal transduction is mediated by the phosphorylation-activation of the signal transducer and activator of transcription (STAT) proteins Stat1, Stat2, and Stat3. Previous studies have shown that these activated STATs dimerize to form four distinct STAT complexes which translocate to the nucleus and activates transcription by binding to specific promoter elements. The interferon-stimulated gene factor-3 (ISGF3) consists of Stat2 and Stat1 heterodimers in association with a DNA binding protein, p48, that binds to the interferon stimulated response element. Homo- and heterodimers of Stat1 and Stat3 bind to the palindromic interferon response element (pIRE). In this report we demonstrate the utility of a biochemical procedure that we have developed, based on genomic DNA affinity chromatography, for the identification of IFN-alpha-induced STAT complexes. Using this approach, we identified ISGF3-independent Stat2 containing STAT complexes. Results from the analysis of Stat2 complexes in the electrophoretic mobility shift assay were consistent with genomic DNA affinity chromatography results and identified a Stat2:1 complex that binds with low affinity to the pIRE of the interferon regulatory factor-1 gene. Immunoprecipitation studies of Stat2 revealed an IFN-alpha dependent co-precipitation of both Stat1 and Stat3. Taken together, our results suggest that IFN-alpha activates, in addition to ISGF3, other Stat2-containing STAT complexes, one of which binds to an element related to the interferon regulatory factor-1 pIRE.	UNIV TORONTO,DEPT MICROBIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUILLE MJ, 1994, EUR J BIOCHEM, V219, P547, DOI 10.1111/j.1432-1033.1994.tb19970.x; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RAZ R, 1994, J BIOL CHEM, V269, P24391; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	43	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12408	12413		10.1074/jbc.271.21.12408	http://dx.doi.org/10.1074/jbc.271.21.12408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647845	hybrid			2022-12-27	WOS:A1996UL66000047
J	Maiyar, AC; Huang, AJ; Phu, PT; Cha, HH; Firestone, GL				Maiyar, AC; Huang, AJ; Phu, PT; Cha, HH; Firestone, GL			p53 stimulates promoter activity of the sgk serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; TUMOR-SUPPRESSOR; DNA-BINDING; EXPRESSION; TRANSCRIPTION; SEQUENCE; IDENTIFICATION; DIFFERENTIATION; COMPLEXES	sgk is a novel member of the serine/threonine protein kinase gene family that is transcriptionally regulated by serum and glucocorticoids in mammary epithelial cells. To functionally determine if the sgk promoter is regulated by the p53 tumor suppressor protein in mammary cells, a series of sgk promoter fragments with 5'-deletions were linked to the bacterial chloramphenicol acetyltransferase gene (sgk-CAT) and transiently cotransfected into nontumorigenic NMuMG or transformed Con8Hd6 mammary epithelial cells with p53 expression plasmids. Wild-type p53, but not mutant p53, strongly stimulated sgk promoter activity in both mammary epithelial cell lines. These effects were mediated by specific regions within the sgk promoter containing p53 DNA-binding sites. The sgk p53 sequence at -1380 to -1345 (site IV) was sufficient to confer p53-dependent transactivation to a heterologous promoter, and p53 was capable of binding to this sequence in vitro as assessed by gel shift analysis. In the nontumorigenic NMuMG epithelial cell line, cotransfection of wild-type p53 strongly stimulated the activities of both the sgk promoter and the well characterized p53-responsive p21/Waf1 promoter, whereas in Rat a fibroblasts, wild-type p53 repressed the basal activities of both promoters, revealing that sgk and p21/Waf1 are similarly regulated in a cell type-specific manner. Taken together, these results demonstrate that sgk is a new transcriptional target of p53 in mammary epithelial cells and represent the first example of a hormone-regulated protein kinase gene with a functionally defined p53 promoter recognition element.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-05388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB SP, 1994, ONCOGENE, V9, P1341; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JUVEN T, 1993, ONCOGENE, V8, P3411; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OWENS RB, 1974, J NATL CANCER I, V52, P1375, DOI 10.1093/jnci/52.4.1375; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	83	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12414	12422		10.1074/jbc.271.21.12414	http://dx.doi.org/10.1074/jbc.271.21.12414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647846	hybrid			2022-12-27	WOS:A1996UL66000048
J	Tolkatchev, D; Yu, L; Yu, CA				Tolkatchev, D; Yu, L; Yu, CA			Potential induced redox reactions in mitochondrial and bacterial cytochrome b-c(1) complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; ENERGY TRANSDUCTION; RESPIRATORY-CHAIN; C REDUCTASE; PHOSPHOLIPIDS; CHEMILUMINESCENCE; OXIDOREDUCTASE; RECONSTITUTION; ORGANIZATION	Purified cytochrome b-c(1) complexes from beef heart mitochondria and Rhodobacter sphaeroides were reconstituted into potassium-loaded asolectin liposomes for studies of the energy-dependent electron transfer reactions within the complexes, Both complexes in a ubiquinone-sufficient state exhibit antimycin-sensitive reduction of cytochromes b (both low and high potential ones) upon induction of a diffusion potential by valinomycin in the presence of ascorbate. Addition of N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) to the ascorbate-reduced potassium-loaded asolectin proteoliposomes resulted in reduction of cytochrome b(562). Upon addition of valinomycin, the induced diffusion potential caused a partial reoxidation of cytochrome b(562) and partial reduction of cytochrome b(566) in beef heart cytochrome b-c(1) complex in the presence of antimycin and/or myxothiazol. Surprisingly, when ubiquinone-depleted beef heart cytochrome b-c(1) complex liposomes were treated under the same conditions, no cytochrome b(566) reduction was observed but only the oxidation of cytochrome b(562), and the oxidation was not oxygen-dependent. We explain this effect by b(566), iron-sulfur protein short-circuiting under these conditions, assuming that both antimycin and myxothiazol markedly affect subunit b conformation, The electrochemical midpoint potential of heme b(566) appears to be significantly higher than that of heme b(562) in the presence of myxothiazol, which cannot be accounted for only by the potential-driven electron transfer between these two hemes plus the shift in chemical midpoint potentials caused by myxothiazol. A model for energy coupling consistent with structural findings by Ohnishi et al. (Ohnishi, T., Schagger, H., Meinhardt, S. W., LoBrutto, R., Link, T. A., and von Jagow, G. (1989) J. Biol. Chem. 264, 735-744) is presented. This model is a compromise between pure ''redox-loop'' and pure ''proton-pump'' mechanisms. Reoxidation of high potential heme b is observed in an antimycin or antimycin plus myxothiazol-inhibited, ascorbate plus TMPD-prereduced R. sphaeroides b-c(1) complex, upon membrane potential development, suggesting that a similar electron transfer mechanism is also operating in the bacterial complex.			Tolkatchev, D (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,STILLWATER,OK 74078, USA.		Tolkatchev, Dmitri/B-7631-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATTIE DS, 1982, J BIOL CHEM, V257, P4745; GOPHER A, 1980, J BIOENERG BIOMEMBR, V12, P349, DOI 10.1007/BF00748764; GUTWENIGER H, 1977, BIOCHIM BIOPHYS ACTA, V459, P216, DOI 10.1016/0005-2728(77)90023-8; GWAK SH, 1986, BIOCHEMISTRY-US, V25, P7675, DOI 10.1021/bi00371a059; KAMENSKY Y, 1985, FEBS LETT, V181, P95, DOI 10.1016/0014-5793(85)81120-0; KAMENSKY YA, 1979, DOKL AKAD NAUK SSSR, V249, P994; KONSTANTINOV AA, 1990, BIOCHIM BIOPHYS ACTA, V1018, P138, DOI 10.1016/0005-2728(90)90234-U; KONSTANTINOV AA, 1981, CHEMIOSMOTIC PROTON, P123; KONSTANTINOV AA, 1988, CYTOCHROME SYSTEMS M, P751; KUNZ WS, 1984, FEBS LETT, V172, P261, DOI 10.1016/0014-5793(84)81137-0; KUNZ WS, 1983, FEBS LETT, V155, P237, DOI 10.1016/0014-5793(82)80611-X; LEUNG KH, 1975, J BIOL CHEM, V250, P8467; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NAKANO M, 1990, METHOD ENZYMOL, V186, P585; NAKANO M, 1990, METHOD ENZYMOL, V186, P227; NELSON BD, 1974, BIOCHIM BIOPHYS ACTA, V357, P358, DOI 10.1016/0005-2728(74)90025-5; OHNISHI T, 1989, J BIOL CHEM, V264, P735; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; WEST IC, 1988, BIOCHIM BIOPHYS ACTA, V933, P35, DOI 10.1016/0005-2728(88)90053-9; WEST IC, 1988, CHTOCHROME SYSTEMS M, P679; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; YU CA, 1987, BIOENERGETICS STRUCT, P81; YU L, 1984, J BIOL CHEM, V259, P5752	32	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12356	12363		10.1074/jbc.271.21.12356	http://dx.doi.org/10.1074/jbc.271.21.12356			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647838	hybrid			2022-12-27	WOS:A1996UL66000040
J	Yang, TP; Agellon, LB; Walsh, A; Breslow, JL; Tall, AR				Yang, TP; Agellon, LB; Walsh, A; Breslow, JL; Tall, AR			Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice - Exon exclusion modulates gene expression in response to dietary or developmental change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; MESSENGER-RNA; APOLIPOPROTEIN-E; HUMAN-PLASMA; INHIBITION; HYPERCHOLESTEROLEMIA; MECHANISM	The plasma cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl ester from high density lipoprotein to other lipoproteins. The human CETP gene produces two forms of mRNA, with or without exon 9 (E9)-derived sequences. To study the function and regulation of alternative splicing of the CETP gene, transgenic mice were prepared 1) with the metallothionein (mT) promoter driving an E9-deleted construct (mT.CETP(-E9) transgene), and 2) with the natural flanking regions (NFR) controlling expression of genomic sequences which permit alternative splicing of E9 (NFR.CETP(+/-E9) transgene). With zinc induction, the mT.CETP(-E9) transgene gave rise to abundant E9-deleted CETP mRNA in liver and small intestine, but only relatively small amounts of E9-deleted protein were found in plasma. The E9-deleted form of CETP was inactive in lipid transfer and produced no changes in plasma lipoprotein profile. The NFR.CETP(+/-E9) transgene gave rise to full-length (FL) and E9-deleted forms of CETP mRNA in liver and spleen. In response to hypercholesterolemia induced by diet and breeding into an apoE gene knock-out background, the FL CETP mRNA was induced more than the E9-deleted mRNA, resulting in a 2-fold increase in ratio of FL/E9-deleted mRNA. The expression of CETP mRNA was found to be developmentally regulated. In NFR.CETP(+/-E9) transgenic mice CETP mRNA levels were markedly increased in the liver and small intestine in the perinatal period and decreased in adult mice, whereas CETP mRNA in the spleen was low in perinatal mice and increased in adults. The developmental increase in CETP mRNA in the liver and spleen was preceded by an increased ratio of FL/E9-deleted forms. Thus, the E9-deleted mRNA appears to be poorly translated and/or secreted, and the cognate protein is inactive in lipid transfer and lipoprotein metabolism. CETP gene expression was found to be highly regulated in a tissue-specific fashion during development. Increased CETP gene expression during development or in response to hypercholesterolemia is associated with preferential accumulation of the full-length CETP mRNA.	COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,LAB BIOCHEM GENET,NEW YORK,NY 10021	Columbia University; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BARTER P, 1994, CLIN EXP PHARMACOL P, V21, P663, DOI 10.1111/j.1440-1681.1994.tb02569.x; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; DECKELBAUM RJ, 1986, J BIOL CHEM, V261, P5201; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HESLER CB, 1988, J BIOL CHEM, V263, P5020; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1993, J BIOL CHEM, V268, P27406; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QUINET E, 1993, J BIOL CHEM, V268, P16891; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL A, 1986, J CLIN INVEST, V77, P1163, DOI 10.1172/JCI112417; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHONG S, 1996, IN PRESS J CLIN INVE	25	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12603	12609		10.1074/jbc.271.21.12603	http://dx.doi.org/10.1074/jbc.271.21.12603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647871	hybrid			2022-12-27	WOS:A1996UL66000073
J	Heath, RJ; Rock, CO				Heath, RJ; Rock, CO			Inhibition of beta-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; COENZYME-A; INVIVO	beta-Ketoacyl-acyl carrier protein (ACP) synthase III (the fabH gene product) condenses acetyl-CoA with malonyl-ACP to initiate fatty acid biosynthesis in the dissociated, type II fatty acid synthase systems typified by Escherichia coli. The accumulation of malonyl-acyl carrier protein (ACP) following the inhibition of a reconstituted fatty acid synthase system by acyl-ACP implicated synthase III (FabH) as a target for acyl-ACP regulation (Heath, R. J., and Rock, C. O. (1996) J. Biol. Chem. 271, 1833-1836); therefore, the FabH protein was purified and its biochemical and regulatory properties examined. FabH exhibited a K-m of 40 mu M for acetyl-CoA and 5 mu M for malonyl-ACP. FabH also accepted other acyl-CoAs as primers with the rank order of activity being acetyl-CoA approximate to propionyl-CoA much greater than butyryl-CoA. FabH utilized neither hexanoyl-CoA nor octanoyl-CoA. Acyl-ACPs suppressed FabH activity, and their potency increased with increasing acyl chain length between 12 and 20 carbon atoms. Nonesterified ACP was not an inhibitor. Acyl-ACP inhibition kinetics were mixed with respect to acetyl-CoA, but were competitive with malonyl-ACP, indicating that acyl-ACPs decrease FabH activity by binding to either the free enzyme or the acyl-enzyme intermediate. These data support the concept that the inhibition of chain initiation at the beta-ketoacyl-ACP synthase III step contributes to the attenuation of fatty acid biosynthesis by acyl-ACP.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; DORMANN P, 1995, ARCH BIOCHEM BIOPHYS, V316, P612, DOI 10.1006/abbi.1995.1081; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; INGRAM LO, 1977, J BACTERIOL, V131, P1023, DOI 10.1128/JB.131.3.1023-1025.1977; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; MAGNUSON K, 1995, J BACTERIOL, V177, P3593, DOI 10.1128/jb.177.12.3593-3595.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; OHLROGGE J, 1995, ARCH BIOCHEM BIOPHYS, V317, P185, DOI 10.1006/abbi.1995.1152; PETTY KJ, 1994, CURRENT PROTOCOLS MO; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994	31	182	214	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10996	11000		10.1074/jbc.271.18.10996	http://dx.doi.org/10.1074/jbc.271.18.10996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631920	hybrid			2022-12-27	WOS:A1996UJ34200088
J	Bird, GSJ; Putney, JW				Bird, GSJ; Putney, JW			Effect of inositol 1,3,4,5-tetrakisphosphate on inositol trisphosphate-activated Ca2+ signaling in mouse lacrimal acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER; ENTRY; CA-2+	In mouse lacrimal acinar cells, microinjection of the metabolically stable analog of inositol 1,4,5-trisphosphate, inositol 2,4,5-trisphosphate ((2,4,5)IP3), stimulated both intracellular Ca2+ mobilization and Ca2+ entry. Microinjection of inositol 1,3,4,5-tetrakisphosphate ((1,3,4,5)IP4), the inositol 1,4,5-trisphosphate-3-kinase product, was ineffective at mobilizing intracellular Ca2+ or activating Ca2+ entry. In lacrimal cells previously microinjected with submaximal levels of (2,4,5)IP3, the subsequent microinjection of low to moderate concentrations of (1,3,4,5)IP4 did not result in additional release of intracellular Ca2+, nor did it potentiate the Ca2+ entry phase attributable to (2,4,5)IP3. However, as previously demonstrated (Bird, G. S. J., Rossier, M. F., Hughes, A. R., Shears, S. B., Armstrong, D. L., and Putney, J. W., Jr. (1991) Nature 352, 162-165), additional injections of (2,4,5)IP3 induced further mobilization of intracellular Ca2+ and increased the elevated and sustained Ca2+ entry phase. Introduction of high concentrations of (1,3,4,5)IP4 appeared to inhibit or block the (2,4,5)IP3-induced Ca2+ entry phase. These results were consistent with the observed effect of (1,3,4,5)IP4 in permeabilized lacrimal cells, where (1,3,4,5)IP4 did not release cellular Ca-45(2+) but at high concentrations inhibited the ability of submaximal concentrations of (2,4,5)IP3 to release Ca-45(2+). Likewise, injection of a high concentration of (1,3,4,5)IP4 prior to injection of (2,4,5)IP3 blocked both release and influx of Ca2+. The inhibitory action of (1,3,4,5)IP4 on Ca2+ signaling observed in intact cells occurred at concentrations that might be obtained in agonist-stimulated cells. However, in permeabilized cells, (1,3,4,5)IP4 inhibited Ca2+ mobilization at concentrations exceeding those likely to occur in agonist-stimulated cells. These results suggest that physiologically relevant levels of (1,3,4,5)IP4, in the cell cytoplasm do not release Ca2+, nor do they potentiate inositol trisphosphate-induced Ca2+ entry across the plasma membrane. Rather, the possibility is raised that (1,3,4,5)IP4 or one of its metabolites could function as a negative feedback on Ca2+ mobilization by inhibiting inositol 1,4,5-trisphosphate-induced Ca2+ release.			Bird, GSJ (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, NIH, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1991, NATURE, V352, P115, DOI 10.1038/352115a0; IRVINE RF, 1993, CURR BIOL, V3, P540, DOI 10.1016/0960-9822(93)90052-P; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SMITH PM, 1992, BIOCHEM J, V283, P27, DOI 10.1042/bj2830027; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; WILCOX RA, 1993, MOL PHARMACOL, V44, P810; WILCOX RA, 1994, SIGNAL ACTIVATED PHO, P190	24	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6766	6770		10.1074/jbc.271.12.6766	http://dx.doi.org/10.1074/jbc.271.12.6766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636098	hybrid			2022-12-27	WOS:A1996UB15700033
J	Dunphy, JT; Greentree, WK; Manahan, CL; Linder, ME				Dunphy, JT; Greentree, WK; Manahan, CL; Linder, ME			G-protein palmitoyltransferase activity is enriched in plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-GAMMA; AMINO TERMINUS; PALMITOYLATION; RECEPTOR; AFFINITY	Heterotrimeric G proteins are covalently modified by lipids. Myristoylation of G-protein alpha subunits and prenylation of gamma subunits are stable modifications. In contrast, palmitoylation of a subunits is dynamic and thus has the potential for regulating protein function. Indeed, receptor activation of G(s) increases palmitate turnover on the alpha subunit, presumably by stimulating deacylation. The enzymes that catalyze reversible palmitoylation of G-protein alpha subunits have not been characterized. Here we report the identification of a palmitoyl-CoA:protein S-palmitoyltransferase activity that acylates G-protein alpha subunits in vitro. Palmitoyltransferase activity is membrane-associated and requires detergent for solubilization. The preferred G-protein substrate for the enzyme activity is the alpha subunit in the context of the heterotrimer. Both myristoylated and nonmyristoylated G-protein a subunits are recognized as substrates. The palmitoyltransferase activity demonstrates a modest preference for palmitoyl-Coa over other fatty acyl-CoA substrates. Palmitoyltransferase activity is high in plasma membrane and present at low or undetectable levels in Golgi, endoplasmic reticulum, and mitochondria of rat liver. The subcellular localization of this enzyme activity is consistent with a role for regulated cycles of acylation and deacylation accompanying activation of G-protein signal transduction pathways.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07067, GM50556] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Fleischer S, 1974, Methods Enzymol, V31, P6; GUITIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HALLAK H, 1994, J BIOL CHEM, V269, P7413; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NAVON S, 1987, J BIOL CHEM, V262, P15476; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; SCHMIDT MFG, 1989, BIOCHEM SOC T, V17, P625, DOI 10.1042/bst0170625; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	44	151	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7154	7159		10.1074/jbc.271.12.7154	http://dx.doi.org/10.1074/jbc.271.12.7154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636152	hybrid			2022-12-27	WOS:A1996UB15700087
J	Wang, XY; Dumont, ME; Sherman, F				Wang, XY; Dumont, ME; Sherman, F			Sequence requirements for mitochondrial import of yeast cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN APOCYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; HEME LYASE; NEUROSPORA-CRASSA; MODEL MEMBRANES; ISO-1-CYTOCHROME-C; GENE; APOISO-1-CYTOCHROME-C; TRANSLOCATION; MUTAGENESIS	Apocytochrome c is synthesized in the cytoplasm, transported to the mitochondrial intermembrane space, and subsequently covalently attached to heme in a reaction catalyzed by the enzyme cytochrome c heme lyase. We have investigated the amino acid sequences in cytochrome c which are required for mitochondrial import, using a systematic: series of site-directed alterations of the CYC7-H3 gene which encodes iso-2-cytochrome c in the yeast Saccharomyces cerevisiae. Import of the altered apocytochromes c was assayed in yeast strains that overexpressed cytochrome c heme lyase. Under these conditions, there was efficient mitochondrial accumulation of forms of apocytochrome c which are incapable of having heme covalently attached. In fact, all apocytochromes c containing deletions located to the carboxyl-terminal side of His(27) efficiently accumulated in the mitochondria of strains overexpressing heme lyase, even though all but one of these deletion-containing proteins were incapable of heme attachment. A minimum length of polypeptide chain at the extreme amino terminus of cytochrome c, rather than any specific sequence element in this region, appears to be required for efficient mitochondrial import. Certain amino acid substitutions in the region extending from Gly(15) to Leu(18), at residue Phe(19) and at residue His(27), lead to reduced mitochondrial import of apocytochrome c, resulting from stalling of the altered apocytochrome c in partially imported states.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester					NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULD DS, 1991, BIOCHEMISTRY-US, V30, P8684, DOI 10.1021/bi00099a028; BABUL J, 1972, BIOCHEMISTRY-US, V11, P1195, DOI 10.1021/bi00757a013; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOWNIE JA, 1977, J MOL BIOL, V113, P369, DOI 10.1016/0022-2836(77)90147-4; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, IN PRESS ADV MOL CEL, V43; FETROW JS, 1989, PROTEINS, V6, P372, DOI 10.1002/prot.340060404; FISHER WR, 1973, J BIOL CHEM, V248, P3188; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HAMPSEY DM, 1988, FEBS LETT, V231, P275, DOI 10.1016/0014-5793(88)80834-2; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENNIG B, 1981, EUR J BIOCHEM, V121, P203, DOI 10.1111/j.1432-1033.1981.tb06450.x; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JORDI W, 1989, BIOCHEMISTRY-US, V28, P8998, DOI 10.1021/bi00449a007; JORDI W, 1989, J BIOL CHEM, V264, P2292; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Maniatis T, 1989, MOL CLONING; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MCKIMMBRESCHKIN JL, 1990, J IMMUNOL METHODS, V135, P277, DOI 10.1016/0022-1759(90)90282-Z; MCKNIGHT GL, 1981, CELL, V25, P409, DOI 10.1016/0092-8674(81)90059-3; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P116; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NYE SH, 1990, MOL CELL BIOL, V10, P5763, DOI 10.1128/MCB.10.11.5763; NYE SH, 1990, MOL CELL BIOL, V10, P5753, DOI 10.1128/MCB.10.11.5753; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SHERMAN F, 1966, P NATL ACAD SCI USA, V55, P1498, DOI 10.1073/pnas.55.6.1498; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1975, GENETICS, V81, P51; SHERMAN F, 1974, GENETICS, V77, P255; SHERMAN F, 1973, BIOCH GENE EXPRESSIO, P56; SHERMAN F, 1987, METHODS YEAST GENETI; SPRINKLE JR, 1990, P NATL ACAD SCI USA, V87, P5729, DOI 10.1073/pnas.87.15.5729; STUART RA, 1987, EMBO J, V6, P2131, DOI 10.1002/j.1460-2075.1987.tb02480.x; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VELOSO D, 1984, J BIOL CHEM, V259, P6067; ZHOU LX, 1988, BIOCHIM BIOPHYS ACTA, V942, P115	54	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6594	6604		10.1074/jbc.271.12.6594	http://dx.doi.org/10.1074/jbc.271.12.6594			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636074	hybrid			2022-12-27	WOS:A1996UB15700009
J	Desrosiers, MG; Gately, LJ; Gambel, AM; Menick, DR				Desrosiers, MG; Gately, LJ; Gambel, AM; Menick, DR			Purification and characterization of the Ca2+-ATPase of Flavobacterium odoratum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING KDP-ATPASE; SARCOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; MEMBRANE-VESICLES; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; RECONSTITUTION; CA-2+-ATPASE; HYDROLYSIS; CALMODULIN	The P-type Ca2+-ATPase from Flavobacterium odoratum has been purified to homogeneity and characterized. Inside-out membrane vesicles were extracted with C(12)E(8), followed by ammonium sulfate fractionation, centrifugation through two successive 32-48% glycerol gradients, and DE52 ion exchange chromatography. The purified Ca2+-ATPase consists of a single polypeptide. It migrates electrophoretically with an apparent molecular mass of 60,000 Da, consistent with the phosphorylation pattern originally reported in membrane vesicles. This single polypeptide is functional and capable of calcium-dependent vanadate-sensitive ATP hydrolysis and of forward and reverse phosphorylation. Maximum hydrolysis activity occurs at pH 8.0, with a specific activity of similar to 75 mu mol of ATP hydrolyzed min(-1) mg(-1) protein. The purified Ca2+-ATPase has an apparent K-m for calcium of 1.5 mu M and for ATP of 90 mu M. Vanadate strongly inhibits the activity with an IC50 of 0.6 mu M. The prokaryotic Ca2+-ATPase is insensitive to the SR Ca2+-ATPase inhibitors fluorescein isothiocyanate, thapsigargin, and cyclopiazonic acid. It is rapidly phosphorylated by [gamma-P-32]ATP in a calcium-dependent vanadate-inhibited manner and can be phosphorylated by P-i in both the presence and absence of calcium.	MED UNIV S CAROLINA, DIV CARDIOL, DEPT MED, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT BIOCHEM & MOLEC BIOL, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, CHARLESTON, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					PHS HHS [R01 44202] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P5596; BERKELMAN T, 1994, J BACTERIOL, V176, P4430, DOI 10.1128/jb.176.14.4430-4436.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1981, J BIOL CHEM, V256, P3263; DEES SB, 1986, J CLIN MICROBIOL, V23, P267, DOI 10.1128/JCM.23.2.267-273.1986; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GAMBEL AM, 1992, J BIOL CHEM, V267, P15923; GAMBEL AM, 1993, J BIOL CHEM, V268, P20590; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKAU W, 1983, BIOCH BOPHYS ACTA, V773, P124; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MENICK DR, 1992, ANN NY ACAD SCI, V671, P427, DOI 10.1111/j.1749-6632.1992.tb43819.x; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NELSON N, 1980, METHOD ENZYMOL, V69, P301; NIGGLI V, 1981, J BIOL CHEM, V256, P395; PANET R, 1971, J BIOL CHEM, V246, P7349; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; ROSEN BP, 1987, BIOCHIM BIOPHYS ACTA, V906, P101, DOI 10.1016/0304-4157(87)90007-4; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; SIEBERS A, 1988, METHOD ENZYMOL, V157, P668; Silhavy T. J., 1984, EXPT GENE FUSIONS; TRUMBLE WR, 1981, J BIOL CHEM, V256, P7101; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; YU X, 1994, J BIOL CHEM, V269, P16656	34	17	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3945	3951						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632017				2022-12-27	WOS:A1996TV72400091
J	KonKozlowski, M; Pani, G; Pawson, T; Siminovitch, KA				KonKozlowski, M; Pani, G; Pawson, T; Siminovitch, KA			The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTH-EATEN MICE; PROTOONCOGENE PRODUCT; SH2 DOMAIN; SACCHAROMYCES-CEREVISIAE; EXCHANGE FACTOR; PROTEIN; RECEPTOR; GENE; PHOSPHORYLATION; EXPRESSION	The association of the murine motheaten phenotype of severe hemopoietic dysregulation with loss of PTP1C tyrosine phosphatase activity indicates a critical role for this SH2 domain-containing phosphotyrosine phosphatase in the regulation of hemopoietic cell growth and differentiation. To explore the molecular basis for PTP1C effects on hematopoiesis, we have investigated the possibility that this enzyme interacts with the product of the Vav proto-oncogene, a putative guanine nucleotide exchange factor expressed exclusively in hemopoietic cells. Our data indicate that PTP1C physically associates with Vav in murine spleen cells and in EL4 T lymphoma and P815 mastocytoma cells, and that this interaction is increased following mitogenic stimulation and the induction of both PTP1C and Vav tyrosine phosphorylation. The results also reveal tyrosine phosphatase activity to be present in Vav immunoprecipitates from stimulated splenic and P815 cells and suggest that a major portion of total cellular PTP1C catalytic activity is associated with Vav. As Vav-associated tyrosine phosphatase activity was not detected in PTP1C deficient motheaten splenic cells, it appears that PTP1C accounts for most, if not all, Vav coprecipitable tyrosine phosphatase activity in normal cells. The data also demonstrate the capacity of the Vav SH2 domain alone to bind to PTP1C in activated P815 cells, but suggest a role for the two Vav SH3 domains in enhancing this interaction. In addition, the results reveal PTP1C association with two other molecules implicated in Ras activation, the Grb2 adaptor protein and mSos1, a GTP/GDP exchanger for Ras. PTP1C therefore has the capacity to bind and potentially modulate various signaling effecters involved in activation of Ras or Ras-related proteins, and, accordingly, regulation of Ras activation represents a possible mechanism whereby PTP1C influences hemopoietic cellular responses.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	KonKozlowski, M (corresponding author), DEPT HLTH & WELF, BUR DRUG RES, DIV LIFE SCI, TUNNEYS PASTURE, OTTAWA, ON K1A 0L2, CANADA.		Pawson, Tony J/E-4578-2013; Pani, Giovambattista/AAB-1446-2019; Siminovitch, Katherine/K-1475-2013	Pani, Giovambattista/0000-0001-7133-8728				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; OKADA M, 1993, J BIOL CHEM, V268, P18070; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3856	3862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632004				2022-12-27	WOS:A1996TV72400078
J	Weaver, CD; Yao, TL; Powers, AC; Verdoorn, TA				Weaver, CD; Yao, TL; Powers, AC; Verdoorn, TA			Differential expression of glutamate receptor subtypes in rat pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURSTING ELECTRICAL-ACTIVITY; GLUCAGON-SECRETION; AMPA SUBTYPE; BETA-CELLS; KAINATE; CHANNELS; SUBUNITS; BRAIN; ACID; OSCILLATIONS	Immunocytochemistry was carried out on sections of rat pancreas to localize the expression of glutamate receptor subunits and the major pancreatic peptide hormones. Glutamate receptor expression was concentrated in pancreatic islets, and each islet cell type expressed different neuronal glutamate receptors of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainate classes. AMPA receptor subunits were expressed in alpha, beta, and pancreatic polypeptide cells, whereas kainate receptors were found predominantly in alpha and delta cells. Patch clamp electrophysiology was used to measure the functional properties of islet cell glutamate receptors, L-glutamate and other glutamate receptor agonists evoked currents in islet cells that were blocked by the selective AMPA receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione and potentiated by cyclothiazide in a manner indistinguishable from that of neuronal AMPA receptors. Activation of islet cell AMPA receptors produced steady-state cation currents that depolarized the cells an average of 20.7 +/- 5.4 mV (n = 6), Currents mediated by functional kainate receptors were also observed in a line of transformed pancreatic alpha cells, Thus, L-glutamate probably regulates islet physiology via actions at both AMPA and kainate receptor classes, The pattern of receptor expression suggests that glutamate receptor activation may have multiple, complex consequences for islet physiology.	VANDERBILT UNIV,DEPT PHARMACOL,SCH MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DIV ENDOCRINOL,SCH MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NINDS NIH HHS [NS 09788, R01 NS 30945] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009788, R01NS030945] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BOXALL AR, 1995, NEUROCHEM RES, V20, P605, DOI 10.1007/BF01694543; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; GILON P, 1992, J BIOL CHEM, V267, P20713; GONOI T, 1994, J BIOL CHEM, V269, P16989; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LONGO EA, 1991, J BIOL CHEM, V266, P9314; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; PETRALIA RS, 1994, J NEUROSCI, V14, P667; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RORSMAN P, 1991, BIOCHEM PHARMACOL, V41, P1783, DOI 10.1016/0006-2952(91)90116-M; SANCHEZANDRES JV, 1995, J PHYSIOL-LONDON, V486, P223, DOI 10.1113/jphysiol.1995.sp020804; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SCHOEPFER R, 1994, PROG NEUROBIOL, V42, P353, DOI 10.1016/0301-0082(94)90076-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMER B, 1992, EMBO J, V11, P1651, DOI 10.1002/j.1460-2075.1992.tb05211.x; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; VINCENT SR, 1983, NEUROENDOCRINOLOGY, V36, P197, DOI 10.1159/000123456; VONBLANKENFELD G, 1995, PFLUG ARCH EUR J PHY, V430, P381, DOI 10.1007/BF00373913; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WONG LA, 1993, MOL PHARMACOL, V44, P504	45	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12977	12984		10.1074/jbc.271.22.12977	http://dx.doi.org/10.1074/jbc.271.22.12977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662728	hybrid			2022-12-27	WOS:A1996UN47400047
J	Fox, JC; Shanley, JR				Fox, JC; Shanley, JR			Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; EXTRACELLULAR-MATRIX; DNA-SYNTHESIS; TRANSFORMATION; PROLIFERATION; EXPRESSION; FGF; SIGNAL; DEATH; COMPLEMENTARY	Basic fibroblast growth factor (bFGF), a potent mitogen for many cell types, is expressed by vascular smooth muscle cells and plays a prominent role in the proliferative response to vascular injury. Basic FGF has also been implicated as a survival factor for a variety of quiescent or terminally differentiated cells. Autocrine mechanisms could potentially mediate both proliferation and cell survival. To probe such autocrine pathways, endogenous bFGF production was inhibited in cultured rat vascular smooth muscle cells by the expression of antisense bFGF RNA. Inhibition of endogenous bFGF production induced apoptosis in these cells independent of proliferation, and apoptosis could be prevented by exogenous bFGF but not serum or epidermal growth factor. The induction of apoptosis was associated with an inappropriate entry into S phase. These data demonstrate that interruption of autocrine bFGF signaling results in apoptosis of vascular smooth muscle cells, and that the mechanism involves disruption of normal cell cycle regulation.			Fox, JC (corresponding author), UNIV PENN,DEPT MED,STELLAR CHANCE LABS 809C,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026831, R01HL026831, K08HL002939] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26831, HL02939] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BLAM SB, 1988, ONCOGENE, V3, P129; BLOTTNER D, 1992, EXP NEUROL, V118, P35, DOI 10.1016/0014-4886(92)90020-Q; Brigstock DR, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011009; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHO A, 1995, CIRC RES, V76, P168, DOI 10.1161/01.RES.76.2.168; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOX JC, 1994, MOL CELL BIOL, V14, P4244, DOI 10.1128/MCB.14.6.4244; FRENCH BA, 1994, CIRCULATION, V90, P2402, DOI 10.1161/01.CIR.90.5.2402; FUKS Z, 1994, CANCER RES, V54, P2582; GENG YJ, 1995, AM J PATHOL, V147, P251; GOSPODAROWICZ D, 1988, EUR J CELL BIOL, V46, P144; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOUIS JC, 1993, EUR J NEUROSCI, V5, P1610, DOI 10.1111/j.1460-9568.1993.tb00230.x; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; OLSON NE, 1992, AM J PATHOL, V140, P1017; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; SHULDINER AR, 1993, PCR PROTOCOLS CURREN, P169; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SUGI Y, 1993, DEV BIOL, V157, P28, DOI 10.1006/dbio.1993.1109; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TERRELL GE, 1991, MATRIX, V11, P108, DOI 10.1016/S0934-8832(11)80214-3; UNSICKER K, 1992, DEV BRAIN RES, V65, P285, DOI 10.1016/0165-3806(92)90191-X; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YASUDA T, 1995, J NEUROSCI RES, V40, P306, DOI 10.1002/jnr.490400304; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	53	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12578	12584		10.1074/jbc.271.21.12578	http://dx.doi.org/10.1074/jbc.271.21.12578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647868	hybrid			2022-12-27	WOS:A1996UL66000070
J	Hurme, R; Berndt, KD; Namork, E; Rhen, M				Hurme, R; Berndt, KD; Namork, E; Rhen, M			DNA binding exerted by a bacterial gene regulator with an extensive coiled-coil domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTORS; VIRULENCE PLASMID; PROTEIN; DESIGN	Although quite common in the eukaryotic cell, bacterial proteins with an extensive coiled-coil domain are still relatively rare. One of the few thus far documented examples, TlpA from Salmonella typhimurium, is characterized by a remarkably long (250 amino acids) alpha-helical coiled-coil domain. Herein, we demonstrate that TlpA is a novel, sequence-specific DNA-binding protein. Several tlpA deletion mutants have been constructed, and their corresponding protein products were purified and tested for DNA binding. Two of the mutant proteins were shown to be deficient in DNA binding. Both mutants were analyzed by circular dichroism and electron microscopy, supporting the notion that mutant proteins were largely intact despite lacking the amino acid residues necessary for DNA binding. In vivo studies with transcriptional tlpA-lacZ fusions demonstrated that TlpA acts as a repressor. Using the repressor phenotype as a readout, the chain exchange previously described in vitro could also be confirmed in vivo. We believe the coiled-coil domain acts not only as a dimerization interface but could also serve a role as a flexible modulator of the protein-DNA interaction.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; NATL INST PUBL HLTH,ELECTRON MICROSCOPE UNIT,N-0403 TORSHOV,OSLO,NORWAY	Karolinska Institutet	Hurme, R (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,BOX 280,S-17177 STOCKHOLM,SWEDEN.		Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CAREY J, 1991, METHOD ENZYMOL, V208, P103; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FOSTER JW, 1995, ANNU REV MICROBIOL, V49, P145, DOI 10.1146/annurev.micro.49.1.145; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; HURME R, 1994, J BIOL CHEM, V269, P10675; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KOSKI P, 1992, J BIOL CHEM, V267, P12258; LEVCHENKO I, 1994, GENE, V145, P65, DOI 10.1016/0378-1119(94)90323-9; LUPAS A, 1995, J MOL BIOL, V248, P180, DOI 10.1006/jmbi.1995.0210; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MILLER JH, 1972, EXPT MOL GENETICS, P325; MORA R, 1988, ANAL BIOCHEM, V172, P368, DOI 10.1016/0003-2697(88)90457-5; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NOONAN B, 1995, MOL MICROBIOL, V17, P379, DOI 10.1111/j.1365-2958.1995.mmi_17020379.x; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; RHEN M, 1993, MOL MICROBIOL, V10, P45, DOI 10.1111/j.1365-2958.1993.tb00902.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9	31	37	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12626	12631		10.1074/jbc.271.21.12626	http://dx.doi.org/10.1074/jbc.271.21.12626			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647874	hybrid			2022-12-27	WOS:A1996UL66000076
J	Segade, F; Hurle, B; Claudio, E; Ramos, S; Lazo, PS				Segade, F; Hurle, B; Claudio, E; Ramos, S; Lazo, PS			Identification of an additional member of the cytochrome c oxidase subunit VIIa family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN COMPONENTS; NUCLEOTIDE-SEQUENCE; TRANSCRIPT LEVELS; THYROID-HORMONE; 2 ISOFORMS; CDNA; PURIFICATION; SEPARATION; EXPRESSION; SKELETAL	We report the cloning, nucleotide sequence, evolutionary analysis, and intracellular localization of SIG81, a silica-induced cDNA from mouse macrophages. The cDNA encodes a 111-amino acid protein with extensive sequence identity with members of the mammalian cytochrome c oxidase subunit VIIa (COX7a) family. A human SIG81 sequence >80% identical with the mouse cDNA was deduced from homologous sequences in the human expressed tags data base. The deduced aminoterminal region shows features common to mitochondrial targeting sequences. A phylogenetic analysis of the carboxyl-terminal domain homologous to COX7a identifies SIG81 as a divergent member of the family with an ancient origin. Southern blot analysis showed that the mouse genome contains two to three copies of the SIG81 gene. Northern blot analysis revealed that the SIG81 transcript is approximately 1 kb and expressed in every tissue tested, with higher levels of expression observed in kidney and liver. Antibodies raised against a glutathione S-transferase SIG81 fusion protein detected a 13.5-kDa protein that co-fractionates with mitochondrial localized enzymatic activity. Taken together, our data suggest that SIG81 is a novel member of the COX7a family that is constitutively expressed in mouse cells.	UNIV OVIEDO, DEPT BIOQUIM & BIOL MOLEC, E-33006 OVIEDO, SPAIN	University of Oviedo			Lazo, Pranvera/I-5299-2019; Lazo, Pedro/C-4087-2008	Lazo, Pranvera/0000-0002-7202-4058; Lazo, Pedro/0000-0002-1278-6878				ANTHONY G, 1990, FEBS LETT, V277, P97, DOI 10.1016/0014-5793(90)80817-3; ARNAUDO E, 1992, GENE, V119, P299, DOI 10.1016/0378-1119(92)90287-Y; BLAHOS J, 1995, J BIOL CHEM, V270, P20285, DOI 10.1074/jbc.270.35.20285; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPITANIO N, 1994, BIOCHEMISTRY-US, V33, P12521, DOI 10.1021/bi00207a020; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRZANOWSKALIGHTOWLERS ZMA, 1993, BIOCHEM BIOPH RES CO, V196, P328, DOI 10.1006/bbrc.1993.2252; CLAUDIO E, 1995, AM J RESP CELL MOL, V13, P547, DOI 10.1165/ajrcmb.13.5.7576690; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDERS C, 1990, NUCLEIC ACIDS RES, V18, P7143, DOI 10.1093/nar/18.23.7143; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FREUD R, 1994, EUR J BIOCHEM, V221, P1111, DOI 10.1111/j.1432-1033.1994.tb18831.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KADENBACH B, 1991, J BIOENERG BIOMEMBR, V23, P321, DOI 10.1007/BF00762225; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; Kimura M., 1983, NEUTRAL THEORY MOL E; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEELAN RS, 1989, NUCLEIC ACIDS RES, V17, P6410, DOI 10.1093/nar/17.15.6410; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SEELAN RS, 1993, GENOMICS, V18, P527; SEGADE F, 1995, J IMMUNOL, V154, P2384; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; VANDENBOGERT C, 1992, BIOCHIM BIOPHYS ACTA, V1099, P118, DOI 10.1016/0005-2728(92)90207-I; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; VANKUILENBURG ABP, 1992, EUR J BIOCHEM, V203, P193	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12343	12349		10.1074/jbc.271.21.12343	http://dx.doi.org/10.1074/jbc.271.21.12343			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647836	hybrid			2022-12-27	WOS:A1996UL66000038
J	Bogdanov, M; Sun, JZ; Kaback, HR; Dowhan, W				Bogdanov, M; Sun, JZ; Kaback, HR; Dowhan, W			A phospholipid acts as a chaperone in assembly of a membrane transport protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC CARRIER PROTEIN; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PERMEASE; COMPONENTS; MUTANTS; SYSTEM; GENE	A mutant of Escherichia coli lacking phosphatidylethanolamine (PE) and a monoclonal antibody (mAb 4B1) directed against a conformationally sensitive epitope (4B1) of lactose permease were used to establish a novel role for a phospholipid in the assembly of a membrane protein, Epitope 4B1 is readily detectable in spheroplasts and right-side-out membrane vesicles from PE-containing but not from PE-deficient cells expressing lactose permease. Lactose permease from PE-containing membranes, but not from PE-deficient membranes, subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western blot analysis is also recognized by mAb 4B1, If total E. coli phospholipids or PE (but not phosphatidylcholine, phosphatidylglycerol, or cardiolipin) are blotted on nitrocellulose sheets (Eastern blot) prior to transfer of proteins from SDS-polyacrylamide gels, the permease from PE-deficient cells regains its recognition by mAb 4B1, Therefore, PE is required during assembly to form epitope 4B1, but, once formed, sufficient ''conformational memory'' is retained in the permease to either retain or reform this epitope in the absence of PE, Lactose permease lacking epitope 4B1 can be induced to form the epitope if partially denatured and then renatured in the presence of PE specifically, These results establish for the first time a role for PE as a molecular chaperone in the assembly of the lactose permease.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT PHYSIOL & MICROBIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MOLEC GENET,LOS ANGELES,CA 90024	University of Texas System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Bogdanov, Mikhail/J-3695-2017		NIGMS NIH HHS [GM20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CHEN CC, 1984, J BIOL CHEM, V259, P150; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; KABACK HR, 1994, J EXP BIOL, V196, P183; PAGE MGP, 1988, J BIOL CHEM, V263, P15897; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SEELIG J, 1993, NEW DEV LIPID PROTEI, P441; Seto-Young D, 1985, J MEMBRANE BIOL, V84, P256; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; THURMOND RL, 1991, BIOPHYS J, V59, P108, DOI 10.1016/S0006-3495(91)82203-2; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377	24	169	176	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11615	11618		10.1074/jbc.271.20.11615	http://dx.doi.org/10.1074/jbc.271.20.11615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662750	hybrid			2022-12-27	WOS:A1996UL25000006
J	Dayan, G; BaubichonCortay, H; Jault, JM; Cortay, JC; Deleage, G; DiPietro, A				Dayan, G; BaubichonCortay, H; Jault, JM; Cortay, JC; Deleage, G; DiPietro, A			Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein - Overexpression, purification, and role of cysteine 430	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFER MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS; ATPASE ACTIVITY; ENERGY-TRANSFER; CATALYTIC SITE; ALPHA-SUBUNIT; GENE; PROTEINS; HYDROLYSIS; BACTERIA	Varying length cDNAs encoding the N-terminal nucleotide-binding domain (NBD1) from mouse mdr1 P-glycoprotein were prepared on the basis of structure predictions. Corresponding recombinant proteins were overexpressed in Escherichia coli, and the shortest one containing amino acids 395-581 exhibited the highest solubility. Insertion of an N-terminal hexahistidine tag allowed domain purification by nickel-chelate affinity chromatography. NBD1 efficiently interacted with nucleotides. Fluorescence methods showed that ATP bound at millimolar concentrations and its 2',3'-O-(2,4,6-trinitrophenyl) derivative at micromolar concentrations, while the 2'(3')-N-methylanthraniloyl derivative had intermediate affinity. Photoaffinity labeling was achieved upon irradiation with 8-azido-ATP. The domain exhibited ATPase activity with a K-m for MgATP in the millimolar range, and ATP hydrolysis was competitively inhibited by micromolar 2',3'-O-(2,4,6-trinitrophenyl)-ATP. NBD1 contained a single cysteine residue, at position 430, that was derivatized with radiolabeled N-ethylmaleimide. Cysteine modification increased 6-fold the K-d for 2'(3')-N-methylanthraniloyl-ATP and prevented 8-azido-ATP photolabeling. ATPase activity was inhibited with a 5-fold increase in the K-m for MgATP. The results suggest that chemical modification of Cys-430 is involved in the N-ethylmaleimide inhibition of whole P-glycoprotein by altering substrate interaction.	UNIV LYON 1,LAB BIOCHIM STRUCTURALE & FONCT,INST BIOL & CHIMIE PROTEINES,UPR 412 CNRS,F-69367 LYON 07,FRANCE; UNIV LYON 1,MOLEC BIOL LAB,INST BIOL & CHIMIE PROTEINES,UPR 412 CNRS,F-69367 LYON 07,FRANCE; UNIV LYON 1,LAB CONFORMAT PROTEINES,INST BIOL & CHIMIE PROTEINES,UPR 412 CNRS,F-69367 LYON 07,FRANCE	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Deléage, Gilbert/F-7163-2010; jault, jean-michel/G-2086-2012	Deléage, Gilbert/0000-0003-1939-1614; jault, jean-michel/0000-0003-1743-2777; Cortay, Jean-Claude/0000-0003-3676-8436				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Boger J, 1986, 6 INT C IMM TOR, P250; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILDS S, 1995, CANCER RES, V55, P2029; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ERIKSSON S, 1993, J BIOL CHEM, V268, P1805; EVANS GL, 1995, J BIOENERG BIOMEMBR, V27, P43, DOI 10.1007/BF02110330; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; GERMANN UA, 1995, J BIOENERG BIOMEMBR, V27, P53, DOI 10.1007/BF02110331; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HAMADA H, 1988, CANCER RES, V48, P4936; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JAULT JM, 1993, J BIOL CHEM, V268, P20762; KO YH, 1993, J BIOL CHEM, V268, P24330; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGE P, 1995, M S-MED SCI, V11, P357, DOI 10.4267/10608/2215; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MULLER KM, 1994, J BIOL CHEM, V269, P14032; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; UEDA K, 1992, J BIOL CHEM, V267, P24248; ULLMAN B, 1995, J BIOENERG BIOMEMBR, V27, P77, DOI 10.1007/BF02110334; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	58	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11652	11658		10.1074/jbc.271.20.11652	http://dx.doi.org/10.1074/jbc.271.20.11652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662620	hybrid			2022-12-27	WOS:A1996UL25000014
J	Paradis, P; MacLellan, WR; Belaguli, NS; Schwartz, RJ; Schneider, MD				Paradis, P; MacLellan, WR; Belaguli, NS; Schwartz, RJ; Schneider, MD			Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; INDUCED CARDIAC-HYPERTROPHY; TRANSFORMING GROWTH-FACTOR; PROTO-ONCOGENE FAMILY; C-FOS GENE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR CHARACTERIZATION; PHYSICAL ASSOCIATION; EXPRESSION; JUN	''Fetal'' gene transcription, including activation of the skeletal alpha-actin (SkA) promoter, is provoked in cardiac myocytes by mechanical stress and trophic ligands. Induction of the promoter by transforming growth factor beta or norepinephrine requires serum response factor (SRF) and TEF-1; expression is inhibited by YY1. We and others postulated that immediate-early transcription factors might couple trophic signals to this fetal program. However, multiple Fos/Jun proteins exist, and the exact relationship between control by Fos/Jun versus SRF, TEF-1, and YY1 is unexplained. We therefore cotransfected ventricular myocytes with Fos, Jun, or JunB, and SkA reporter genes, SkA transcription was augmented by Jun, Fos/Jun, Fos/JunB, and Jun/JunB; Fos and JunB alone were neutral or inhibitory. Mutation of the SRF site, SRE1, impaired activation by Jun; YY1, TEF-1, and Sp1 sites were dispensable. SRE1 conferred Jun activation to a heterologous promoter, as did the c-fos SRE. Deletions of DNA binding, dimerization, or trans-activation domains of Jun and SRF abolished activation by Jun and synergy with SRF. Neither direct binding of Fos/Jun to SREs, nor physical interaction between Fos/Jun and SRF, was detected in mobility-shift assays. Thus, AP-1 factors activate a hypertrophy-associated gene via SRF, without detectable binding to the promoter or to SRF.	BAYLOR COLL MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007706, P01HL049953, R01HL047567] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07706, P01 HL49953, R01 HL47567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; AOYAGI T, 1993, J BIOL CHEM, V268, P27176; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRAND T, 1993, J MOL CELL CARDIOL, V25, P1325, DOI 10.1006/jmcc.1993.1145; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BROWN PH, 1993, ONCOGENE, V8, P877; CHEN CY, 1995, CIRCULATION, V92, P369; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CURRAN T, 1987, ONCOGENE, V2, P79; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KIM JH, 1994, J BIOL CHEM, V269, P13740; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1990, J BIOL CHEM, V265, P1556; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MACLELLAN WR, 1993, CIRC RES, V73, P783, DOI 10.1161/01.RES.73.5.783; MCBRIDE K, 1993, MOL CELL BIOL, V13, P600, DOI 10.1128/MCB.13.1.600; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; Ransone Lynn J., 1993, Gene Expression, V3, P37; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROSENZWEIG A, 1991, CIRCULATION, V84, P1256, DOI 10.1161/01.CIR.84.3.1256; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; TANAKA M, 1995, J AM COLL CARDIOL, V26, P85, DOI 10.1016/0735-1097(95)00145-P; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; WADE EJ, 1992, J VIROL, V66, P2407, DOI 10.1128/JVI.66.4.2407-2417.1992; ZACHOW KR, 1992, J VIROL, V66, P1659; ZHU H, 1994, J BIOL CHEM, V269, P3489	58	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10827	10833		10.1074/jbc.271.18.10827	http://dx.doi.org/10.1074/jbc.271.18.10827			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631897	hybrid			2022-12-27	WOS:A1996UJ34200065
J	Cui, YH; Midkiff, MA; Wang, Q; Calvo, JM				Cui, YH; Midkiff, MA; Wang, Q; Calvo, JM			The leucine-responsive regulatory protein (Lrp) from Escherichia coli - Stoichiometry and minimal requirements for binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL RESPONSE; SITES; TRANSCRIPTION; ILVIH	Lrp (Leucine-responsive regulatory protein) regulates the expression of a number of operons in Escherichia coli, A recent study of DNA sequences recognized by Lrp established the consensus as a 15-bp sequence, YAGHA-WATTWTDCTR (Y = C/T, H = ''not G,'' W = A/T, D = ''not C,'' R = A/G) (Cui, Y., Wang, Q,, Stormo, G, D,, and Calvo, J, M, (1995) J, Bacteriol, 177, 4872-4880). Here we report the stoichiometry of Lrp binding (an Lrp dimer binds to a single binding site) and studies that define the minimal length of DNA required for binding, A double-stranded 15 mer having a sequence that closely matches the consensus does not show measurable binding to Lrp, One or two base pairs of DNA flanking each end are not sufficient for binding, but constructs having 3-5 additional base pairs (21 mer) show relatively strong binding, Single-stranded flanking DNA also contributes to strong binding, The extent of the contribution to binding is dependent upon whether the single strand is on the left or right of the double stranded region and whether the polarity of the single-stranded DNA is 5' to 3' or 3' to 5'.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039496] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39496] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CHEN YF, 1992, P NATL ACAD SCI USA, V89, P5123, DOI 10.1073/pnas.89.11.5123; CUI YH, 1995, J BACTERIOL, V177, P4872, DOI 10.1128/jb.177.17.4872-4880.1995; FERRARIO M, 1995, J BACTERIOL, V177, P103, DOI 10.1128/jb.177.1.103-113.1995; GALLY DL, 1994, J BACTERIOL, V176, P5665, DOI 10.1128/JB.176.18.5665-5672.1994; GAZEAU M, 1994, J MOL BIOL, V241, P378, DOI 10.1006/jmbi.1994.1514; HAGER DA, 1980, ANAL BIOCHEM, V109, P87; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; NEWMAN EB, 1992, CELL, V68, P617, DOI 10.1016/0092-8674(92)90135-Y; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SVAREN J, 1987, NUCLEIC ACIDS RES, V15, P8739, DOI 10.1093/nar/15.21.8739; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	24	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6611	6617		10.1074/jbc.271.12.6611	http://dx.doi.org/10.1074/jbc.271.12.6611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636076				2022-12-27	WOS:A1996UB15700011
J	Harding, PA; Wang, XZ; Okada, S; Chen, WY; Wan, W; Kopchick, JJ				Harding, PA; Wang, XZ; Okada, S; Chen, WY; Wan, W; Kopchick, JJ			Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; TRANSGENIC MICE; 3T3-F442A PREADIPOCYTES; EXTRACELLULAR DOMAIN; PROTEIN-KINASES; RAT ADIPOCYTES; INSULIN-LIKE; PHOSPHORYLATION; CELLS; EXPRESSION	It has previously been shown that a human growth hormone (hGH) analog, hGH-G120R, acts as a GH antagonist (Chen, W. Y., might, D. C., Wagner, T. E., and Kopchick, J, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5061-5065; Chen, m. Y., White, M. E., Wagner, T. E., and Kopchick, J. J. (1991) Endocrinology 129, 1402-1408; Chen, W. Y., Chen, N-Y., Yun, J., Wang X. Z., Wagner, T. E., and Kopchick, J. J. (1994) J. Biol. Chem. 269, 15892-15897). In this study, we report the ability of hGH and hGH-G120R 60 be internalized by GH receptor expressing cells. Additionally, results of chemical cross-linking experiments revealed that both native hGH and hGH-G120R form complexes similar in size to that expected for hGH when bound to recombinant hGH-binding protein (bp). The molecular mass of the complex was determined to be approximately 280 kDa which is consistent with multiple receptors interacting with the ligand, The predominant radiolabeled band detected was a complex of approximately 140 kDa which probably represents one GH molecule bound to one GH receptor. The crosslinked complexes were not detected in the presence of excess unlabeled hGH or hGH-G120R and were not observed in cells which do not express detectable levels of GH receptors. Also, GH induced tyrosine phosphorylation of a complex of proteins of approximately 95 kDa in these cells whereas hGH-G120R did not. Thus, we have separated the hGH or hGH-G120R/GHR binding and internalization capabilities from the ability to stimulate tyrosine phosphorylation of intracellular proteins.	OHIO UNIV,EDISON BIOTECHNOL INST,PROGRAM MOLEC & CELLULAR BIOL,ATHENS,OH 45701; OHIO UNIV,DEPT BIOL SCI,ATHENS,OH 45701	University System of Ohio; Ohio University; University System of Ohio; Ohio University								ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARRAZONE P, 1980, J CELL BIOL, V87, P360; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CARTERSU C, 1984, J BIOL CHEM, V259, P1099; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOODMAN HM, 1986, HUMAN GROWTH HORMONE, P499; GORIN E, 1985, ENDOCRINOLOGY, V116, P1796, DOI 10.1210/endo-116-5-1796; GU TY, 1995, BIOTECHNOL BIOENG, V48, P520, DOI 10.1002/bit.260480515; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HARDING PA, 1994, MOL CELL ENDOCRINOL, V106, P171, DOI 10.1016/0303-7207(94)90200-3; HARDING PA, 1995, RECEPTOR, V5, P81; HIZUKA N, 1982, ENDOCRINOLOGY, V111, P1576, DOI 10.1210/endo-111-5-1576; HJALMARSON A, 1967, ACTA ENDOCRINOL-COP, V56, P347, DOI 10.1530/acta.0.0560347; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KOSTYO JL, 1973, HORM METAB RES, V5, P167, DOI 10.1055/s-0028-1093965; KOSTYO JL, 1974, HDB PHYSIOLOGY     2, V4, P187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MILMAN AE, 1950, ENDOCRINOLOGY, V47, P114, DOI 10.1210/endo-47-2-114; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; SWISLOCKI NI, 1970, ENDOCRINOLOGY, V87, P900, DOI 10.1210/endo-87-5-900; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; WANG X, 1993, P NATL ACAD SCI USA, V91, P1391; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG XZ, 1993, MOL CELL ENDOCRINOL, V94, P89, DOI 10.1016/0303-7207(93)90055-O; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; XU BC, 1995, RECEPTOR, V5, P105; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	48	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6708	6712		10.1074/jbc.271.12.6708	http://dx.doi.org/10.1074/jbc.271.12.6708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636090	hybrid			2022-12-27	WOS:A1996UB15700025
J	Nightingale, KP; Pruss, D; Wolffe, AP				Nightingale, KP; Pruss, D; Wolffe, AP			A single high affinity binding site for histone H1 in a nucleosome containing the Xenopus borealis 5 S ribosomal RNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; DNA; CHROMATIN; H-1; ORGANIZATION; INVITRO; PROTEIN; NUCLEI; CORE; H5	We have reconstituted nucleosomes containing the Xenopus borealis 5 S rRNA gene, a single histone octamer, and 1 or 2 molecules of histone H1. We determine that the 1st molecule of histone H1 to associate with the 5 S nucleosome binds with high affinity (K-D similar to 2 nM), and the 2nd molecule of H1 binds with a reduced affinity (K-D similar to 10 nM). This latter binding is comparable with the association of histone H1 with naked DNA. Neither molecule of histone al alters the helical periodicity of DNA in the nucleosome as revealed by hydroxyl radical cleavage. We conclude that although multiple molecules of histone H1 can associate with nucleosomal DNA, there is only a single high affinity binding site for histone H1 within the 5 S nucleosome.	NICHHD,NIH,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; EISENBERG H, 1981, J MOL BIOL, V150, P537, DOI 10.1016/0022-2836(81)90379-X; GLOTOV BO, 1978, FEBS LETT, V91, P149, DOI 10.1016/0014-5793(78)80037-4; GOODWIN GH, 1977, BIOCHEM J, V167, P485, DOI 10.1042/bj1670485; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1993, P ANTL ACAD SCI US, V90, P615; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; NELSON PP, 1979, J BIOL CHEM, V254, P1751; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; OLINS AL, 1977, MOL BIOL MAMMALIAN G, V1, P211; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SINGER DS, 1976, NUCLEIC ACIDS RES, V3, P2531, DOI 10.1093/nar/3.10.2531; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; TODD RD, 1979, J BIOL CHEM, V254, P3074; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; URBAN MK, 1980, CAN J BIOCHEM CELL B, V58, P726, DOI 10.1139/o80-102; van Holde K.E., 1988, CHROMATIN; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WEINTRAUB H, 1978, NUCLEIC ACIDS RES, V5, P1178; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P767, DOI 10.1093/nar/17.2.767; WOLFFE AP, 1993, METH MOL G, V2, P314	47	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7090	7094		10.1074/jbc.271.12.7090	http://dx.doi.org/10.1074/jbc.271.12.7090			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636143	hybrid			2022-12-27	WOS:A1996UB15700078
J	Tomiyama, T; Shoji, A; Kataoka, K; Suwa, Y; Asano, S; Kaneko, H; Endo, N				Tomiyama, T; Shoji, A; Kataoka, K; Suwa, Y; Asano, S; Kaneko, H; Endo, N			Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin - Its possible function as a hydroxyl radical scavenger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELDERLY LEPROSY PATIENTS; SENILE PLAQUES; PEPTIDE; BRAIN	Aggregation of physiologically produced soluble amyloid beta protein (A beta) to insoluble, neurotoxic fibrils is a crucial step in the pathogenesis of Alzheimer's disease. Aggregation studies with synthetic A beta 1-40 peptide by the thioflavin T fluorescence assay and electron microscopy and cytotoxicity assays using rat pheochromocytoma PC12 cells showed that an antibiotic, rifampicin, and its derivatives, which possess a naphthohydroquinone or naphthoquinone structure, inhibited A beta 1-40 aggregation and neurotoxicity in a concentration-dependent manner, Hydroquinone, p-benzoquinone, and 1,4-dihydroxynaphthalene, which represent partial structures of the aromatic chromophore of rifampicin derivatives, also inhibited A beta 1-40 aggregation and neurotoxicity at comparable molar concentrations to rifampicin. Electron spin resonance spectrometric analysis revealed that the inhibitory activities of those agents correlated with their radical-scavenging ability on hydroxyl free radical, which was shown to be generated in cell-free incubation of A beta 1-40 peptide. These results suggest that at least one mechanism of rifampicin-mediated inhibition of A beta aggregation and neurotoxicity involves scavenging of free radicals and that rifampicin an/or appropriate hydroxyl radical scavengers may have therapeutic potential for Alzheimer's disease.			Tomiyama, T (corresponding author), TEIJIN INST BIOMED RES,4-3-2 ASAHIGAOKA,HINO,TOKYO 191,JAPAN.							BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; DYRKS T, 1992, J BIOL CHEM, V267, P18210; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARBOUR JR, 1974, CAN J CHEM, V52, P3549, DOI 10.1139/v74-527; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KIMURA T, 1993, LANCET, V342, P1364, DOI 10.1016/0140-6736(93)92274-W; LAGERCRA.C, 1969, ACTA CHEM SCAND, V23, P811, DOI 10.3891/acta.chem.scand.23-0811; Lancini G, 1977, STRUCTURE ACTIVITY R, P531; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MINDERMANN T, 1993, J ANTIMICROB CHEMOTH, V31, P731, DOI 10.1093/jac/31.5.731; NAMBA Y, 1992, LANCET, V340, P978, DOI 10.1016/0140-6736(92)92870-L; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428	22	284	295	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6839	6844		10.1074/jbc.271.12.6839	http://dx.doi.org/10.1074/jbc.271.12.6839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636108	hybrid			2022-12-27	WOS:A1996UB15700043
J	Lee, MH; Mori, S; Raychaudhuri, P				Lee, MH; Mori, S; Raychaudhuri, P			trans-Activation by the hnRNP K protein involves an increase in RNA synthesis from the reporter genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BINDING PROTEIN; RIBONUCLEOPROTEINS; IDENTIFICATION; TRANSCRIPTION; DEFINITION; PARTICLES; SEQUENCES; CONTAINS; DOMAINS	The function of many of the pre-mRNA-binding proteins in mRNA biogenesis is unclear. We have analyzed the biochemical function of the hnRNP K protein by using a mouse cDNA clone. A previous study indicated that the expression of hnRNP K activates c-myc promoter in transient transfection assays. We show that the expression of hnRNP K results in a trans-activation of a variety of RNA polymerase II promoters; The trans-activation function depends on the sequences of hnRNP K that are also necessary for RNA binding. However, the RNA binding motifs are not sufficient for trans activation. We could identify a mutant that bound RNA in vitro but was impaired in its ability to trans-activate the reporter genes. The trans-activation was not a result of the stabilization of the reporter mRNA, because hnRNP K increased the steady-state level of the reporter mRNA without altering its decay rate. By doing nuclear run-on assays, we provide evidence that the hnRNP K protein trans-activates the reporter genes by increasing the level of transcription.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NCI NIH HHS [CA55279] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055279] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, EMBO J, V10, P3457; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HART RP, 1985, MOL CELL BIOL, V5, P2975, DOI 10.1128/MCB.5.11.2975; HUTCHISON N, 1985, CELL, V43, P471, DOI 10.1016/0092-8674(85)90177-1; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAY SK, 1992, MOL CELL BIOL, V12, P4327, DOI 10.1128/MCB.12.10.4327; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875	31	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3420	3427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631943				2022-12-27	WOS:A1996TV72400017
J	Skerjanc, IS; Truong, J; Filion, P; McBurney, MW				Skerjanc, IS; Truong, J; Filion, P; McBurney, MW			A splice variant of the ITF-2 transcript encodes a transcription factor that inhibits MyoD activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; MYOGENIC REGULATORY FACTORS; T-CELL LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; GENE FAMILY; MAMMALIAN-CELLS; PLASMID DNA; EXPRESSION; SEQUENCE	Proteins of the basic helix-loop-helix (bHLH) family are transcription factors that bind DNA containing the E box motif (CANNTG) found in the promoters of many muscle-specific genes. ITF-2 is a bHLH protein with widespread expression that is thought to form active heterodimers with MyoD, a muscle-specific bHLH transcription factor. We have isolated cDNAs derived from two alternatively spliced forms of mouse ITF-2, termed MITF-2A and -2B. These proteins differ in their N termini. Neither MITF-2A nor -2B transactivated the cardiac alpha-actin promoter, which contains an E box, when transfected into nonmuscle cells. In fact, MITF-2B inhibited MyoD activation of the cardiac alpha-actin promoter. This inhibitory activity required the N-terminal 83 amino acids since MITF-2A showed no inhibitory activity, and a mutant MITF-2B with deletion of the N-terminal 83 amino acids failed to inhibit MyoD-mediated transcriptional activation. MyoD activity was also inhibited by Id, a HLH protein, and this inhibition was reversed by the addition of excess E12 or MITF-2A. However, the inhibition of MyoD activity by MITF-2B was not reversed with E12 or MITF-2A. While Id is thought to inhibit MyoD by binding and sequestering potential dimerization partners, MITF-2B appears to inhibit MyoD activity by forming an inactive heterodimer with MyoD. Thus, differentially spliced transcripts of mouse ITF-2 encode different proteins that appear to dimerize with MyoD and activate or repress transcription.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1H 8L6,CANADA; OTTAWA REG CANC CTR,OTTAWA,ON K1H 8L6,CANADA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Skerjanc, IS (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,HLTH SCI BLDG,LONDON,ON N6A 5C1,CANADA.		Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ONTELL M, 1993, DEVELOPMENT, V117, P1435; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILBUR WJ, 1983, P NATL ACAD SCI USA, V56, P607; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	46	59	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3555	3561						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631961	hybrid			2022-12-27	WOS:A1996TV72400035
J	Tillman, JB; Dhahbi, JM; Mote, PL; Walford, RL; Spindler, SR				Tillman, JB; Dhahbi, JM; Mote, PL; Walford, RL; Spindler, SR			Dietary calorie restriction in mice induces carbamyl phosphate synthetase I gene transcription tissue specifically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PROTEIN-SYNTHESIS; MESSENGER-RNA LEVELS; UREA CYCLE ENZYMES; GROWTH FACTOR-I; RAT-LIVER; FOOD RESTRICTION; CARBAMOYLPHOSPHATE SYNTHETASE; MORRIS HEPATOMA-5123D; MITOCHONDRIAL ENZYME; HORMONAL-REGULATION	Dietary calorie restriction (CR) delays age-related physiologic changes, increases maximum life span, and reduces cancer incidence, Here, we present the novel finding that chronic reduction of dietary calories by 50% without changing the intake of dietary protein induced the activity of mouse hepatic carbamyl phosphate synthetase I (CpsI) 5-fold, In liver, CpsI protein, mRNA, and gene transcription were each stimulated by similar to 3-fold, Thus, CR increased both the rate of gene transcription and the specific activity of the enzyme. Short-term feeding studies demonstrated that higher cpsI expression was due to CR and not consumption of more dietary protein, Intestinal CpsI activity was stimulated 2-fold, while its mRNA level did not change, suggesting enzyme activity or translation efficiency was stimulated. CpsI catalyzes the conversion of metabolic ammonia to carbamyl phosphate, the rate-limiting step in urea biosynthesis, cpsI induction suggests there is a shift in the metabolism of calorie-restricted animals toward protein catabolism. CpsI induction likely facilitates metabolic detoxification of ammonia, a strong neurotoxin, Enhanced protein turnover and metabolic detoxification may extend life span. Physiologic similarities between calorie-restricted and hibernating animals suggest the effects of CR may be part of a spectrum of adaptive responses that include hibernation.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024	University of California System; University of California Riverside; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Tillman, John/0000-0003-2912-2370	NIA NIH HHS [AG00424] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; BALAGE M, 1990, HORM METAB RES, V22, P207, DOI 10.1055/s-2007-1004886; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CRAIK JD, 1979, BIOCHEM J, V182, P503, DOI 10.1042/bj1820503; DEGROOT CJ, 1984, BIOCHEM BIOPH RES CO, V124, P882, DOI 10.1016/0006-291X(84)91040-4; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARRIS SB, 1994, MECH AGEING DEV, V73, P209, DOI 10.1016/0047-6374(94)90053-1; HAYDEN JM, 1995, J ENDOCRINOL, V145, P397, DOI 10.1677/joe.0.1450397; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; Hochachka PW., 1987, METABOLIC ARREST CON; HURSTING SD, 1993, CANCER RES, V53, P2750; ISHIGAMI A, 1990, ARCH BIOCHEM BIOPHYS, V283, P362, DOI 10.1016/0003-9861(90)90655-I; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; JONES ME, 1965, ANNU REV BIOCHEM, V34, P381; KINGSLEY TR, 1991, J GERONTOL, V46, pB135, DOI 10.1093/geronj/46.4.B135; KITAGAWA Y, 1987, EUR J BIOCHEM, V167, P19, DOI 10.1111/j.1432-1033.1987.tb13299.x; KITAGAWA Y, 1985, BIOCHIM BIOPHYS ACTA, V825, P148, DOI 10.1016/0167-4781(85)90098-3; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361; KOIZUMI A, 1992, J NUTR, V122, P1446, DOI 10.1093/jn/122.7.1446; KOIZUMI A, 1989, AGE, V12, P93, DOI 10.1007/BF02432371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6; LIU RK, 1972, GERONTOLOGY, V18, P363, DOI 10.1159/000211944; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MARINEZRAMON A, 1990, J HISTOCHEM CYTOCHEM, V38, P371; MASORO EJ, 1989, J GERONTOL, V44, pB20, DOI 10.1093/geronj/44.1.B20; MASORO EJ, 1983, J NUTR, V113, P880, DOI 10.1093/jn/113.4.880; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOUSSEAU DD, 1994, P SOC EXP BIOL MED, V206, P329; Nuzum CT, 1976, UREA CYCLE, P325; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PALEKAR AG, 1985, ARCH BIOCHEM BIOPHYS, V237, P430, DOI 10.1016/0003-9861(85)90296-6; RAYMOND Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P111, DOI 10.1016/0005-2787(81)90033-2; ROZEN R, 1983, BIOCHIM BIOPHYS ACTA, V741, P47, DOI 10.1016/0167-4781(83)90008-8; RUGGERI BA, 1989, CANCER RES, V49, P4130; RYALL J, 1985, EUR J BIOCHEM, V152, P287, DOI 10.1111/j.1432-1033.1985.tb09196.x; RYALL J, 1984, J BIOL CHEM, V259, P9172; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; SCHIMKE RT, 1963, J BIOL CHEM, V238, P1021; SEILER N, 1993, NEUROCHEM RES, V18, P235, DOI 10.1007/BF00969079; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SPINDLER SR, 1990, J NUTR, V120, P1412, DOI 10.1093/jn/120.11.1412; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; SPINDLER SR, 1991, J GERONTOL, V46, pB233, DOI 10.1093/geronj/46.6.B233; STEINBERG RA, 1975, CELL, V5, P29, DOI 10.1016/0092-8674(75)90088-4; TAL M, 1990, J CLIN INVEST, V86, P986, DOI 10.1172/JCI114801; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TILLMAN JB, 1996, IN PRESS J NUTR; WALFORD RL, 1992, P NATL ACAD SCI USA, V89, P11533, DOI 10.1073/pnas.89.23.11533; WARD W, 1991, HEPATOLOGY, V14, P935, DOI 10.1002/hep.1840140529; WARD WF, 1988, J GERONTOL, V43, pB121, DOI 10.1093/geronj/43.5.B121; WARD WF, 1988, J GERONTOL, V43, pB50, DOI 10.1093/geronj/43.2.B50; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1988, RETARDATION AGING DI; WHITE BA, 1982, J BIOL CHEM, V257, P8569	63	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3500	3506						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631954	hybrid			2022-12-27	WOS:A1996TV72400028
J	Park, RK; Liu, YB; Durden, DL				Park, RK; Liu, YB; Durden, DL			A role for Shc, Grb2, and Raf-1 in Fc gamma RI signal relay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; NATURAL-KILLER CELLS; TYROSINE PHOSPHORYLATION; LYMPHOKINE GENES; PROTEIN-KINASES; CROSS-LINKING; NADPH OXIDASE; U937 CELLS; LINE U937; T-CELL	The activation of the serine/threonine kinase, Raf-1, serves to connect upstream protein tyrosine kinases to downstream signaling events. We previously reported that Fc gamma RI stimulation of interferon gamma-differentiated U937 cells (termed U937IF cells) induces a mobility shift in Erk2. Herein, we report that cross-linking of Fc gamma RI receptor in U937IF cells induces a marked tyrosine phosphorylation of Raf-1 (10-fold increase). Tyrosine phosphorylation of Raf-1 is induced by Fc gamma RI activation and not by PMA (1 mu g/ml), N-formyl-Met-Leu-Phe (1 mu M), calcium ionophore (1 mu M), thrombin (0.05 unit/ml), Fc gamma RII, or Fc gamma RIII stimulation. The kinetics of Raf-1 tyrosine phosphorylations is rapid, reaching peak levels 1-2 min after Fc gamma RI activation, and the tyrosine phosphorylation of Raf-1 precedes the activation of the respiratory burst. Fc gamma RI cross-linking induces the tyrosine phosphorylation of Shc; tyrosine-phosphorylated Shc bind to Grb2 forming a Shc-Grb2 complex. The data provide evidence that the Fc gamma RI receptor signals via the upstream activation of nonreceptor protein tyrosine kinases, which leads to the subsequent activation of RAs family GTPases and serine/threonine kinases, RAf-1 and mitogen-activated protein kinase.	CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, DIV HEMATOL ONCOL, NEIL BOGART MEM LABS, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California								ABO A, 1992, J BIOL CHEM, V267, P16767; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; BALDARI CT, 1995, ONCOGENE, V10, P1141; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1993, ONCOGENE, V8, P2031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CASSATELLA MA, 1989, J EXP MED, V169, P549, DOI 10.1084/jem.169.2.549; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; DURDEN DL, 1995, J IMMUNOL, V154, P4039; DURDEN DL, 1994, BLOOD, V84, P2102; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; FUKAMACHI H, 1993, INT ARCH ALLERGY IMM, V102, P15, DOI 10.1159/000236546; FUKAMACHI H, 1993, INT ARCH ALLER A IMM, V102, P25; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GABIG TG, 1995, BLOOD, V85, P811; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HUANG MM, 1992, J BIOL CHEM, V267, P5467; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P48; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NEL AE, 1990, J IMMUNOL, V145, P971; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PESADA J, 1992, SCIENCE, V255, P212; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8171; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; PULMIGLIA K, 1995, MOL CELL BIOL, V15, P398; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBERTS PJ, 1991, J IMMUNOL, V147, P3104; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS K, 1994, EUR J IMMUNOL, V24, P3031, DOI 10.1002/eji.1830241217	68	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13342	13348		10.1074/jbc.271.23.13342	http://dx.doi.org/10.1074/jbc.271.23.13342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662746	hybrid			2022-12-27	WOS:A1996UP38500009
J	Condie, R; Herring, A; Koh, WS; Lee, M; Kaminski, NE				Condie, R; Herring, A; Koh, WS; Lee, M; Kaminski, NE			Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDEPENDENT ANTIGENS; RESPONSE ELEMENT; MOLECULAR-BASIS; MESSENGER-RNA; CYCLIC-AMP; RECEPTOR; CAMP; CREB; TRANSCRIPTION	Cannabinoid receptors negatively regulate adenylate cyclase through a pertussis toxin-sensitive GTP-binding protein. In the present studies, signaling via the adenylate cyclase/cAMP pathway was investigated in the murine thymoma-derived T-cell line, EL4.IL-2. Northern analysis of EL4.IL-2 cells identified the presence of 4-kilobase CB2 but not CB1 receptor-subtype mRNA transcripts. Southern analysis of genomic DNA digests for the CB2 receptor demonstrated identical banding patterns for EL4.IL-2 cells and mouse-derived DNA, both of which were dissimilar to DNA isolated from rat, Treatment of EL4.IL-2 cells with either cannabinol or Delta(9)-THC disrupted the adenylate cyclase signaling cascade by inhibiting forskolin-stimulated cAMP accumulation which consequently led to a decrease in protein kinase A activity and the binding of transcription factors to a CRE consensus sequence. Likewise, an inhibition of phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced interleukin 2 (IL-2) protein secretion, which correlated to decreased IL-2 gene transcription, was induced by both cannabinol and Delta(9)-THC. Further, cannabinoid treatment also decreased PMA/ionomycin-induced nuclear factor binding to the AP-1 proximal site of the IL-2 promoter. Conversely, forskolin enhanced PMA/ionomycin-induced AP-1 binding. These findings suggest that inhibition of signal transduction via the adenylate cyclase/cAMP pathway induces T-cell dysfunction which leads to a diminution in IL-2 gene transcription.	MICHIGAN STATE UNIV,DEPT PHARMACOL & TOXICOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PATHOL,E LANSING,MI 48824	Michigan State University; Michigan State University					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009171, R01DA007908] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07908, DA09171] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSSON B, 1971, CELL IMMUNOL, V2, P411, DOI 10.1016/0008-8749(71)90052-9; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHSUED TM, 1976, J IMMUNOL, V116, P1579; CLAMAN HN, 1976, PROG ALLERGY, V16, P40; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; FRIEDMAN H, 1995, IMMUNOTOXICOLOGY IMM, P303; GERY I, 1972, J IMMUNOL, V108, P1088; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HADDEN JW, 1972, P NATL ACAD SCI USA, V69, P3024, DOI 10.1073/pnas.69.10.3024; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWLETT AC, 1988, MOL PHARMACOL, V33, P297; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KAMINSKI NE, 1994, BIOCHEM PHARMACOL, V48, P1899, DOI 10.1016/0006-2952(94)90588-6; KAMINSKI NE, 1995, IMMUNOTOXICOLOGY IMM, P349; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KLEIN TW, 1991, J TOXICOL ENV HEALTH, V32, P465, DOI 10.1080/15287399109531496; KOH WS, 1995, BIOCHEM BIOPH RES CO, V206, P703, DOI 10.1006/bbrc.1995.1099; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE KC, 1976, EUR J IMMUNOL, V6, P63, DOI 10.1002/eji.1830060114; LITTLE PJ, 1989, PHARMACOL BIOCHEM BE, V32, P661, DOI 10.1016/0091-3057(89)90014-2; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCGUIRE KL, 1987, EMBO J, V6, P939, DOI 10.1002/j.1460-2075.1987.tb04842.x; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MOLLER G, 1971, CELL IMMUNOL, V2, P309, DOI 10.1016/0008-8749(71)90065-7; MOSIER DE, 1968, P NATL ACAD SCI USA, V61, P542, DOI 10.1073/pnas.61.2.542; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NAKANO Y, 1993, LIFE SCI, V52, P41, DOI 10.1016/0024-3205(93)90287-D; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; Russell D H, 1978, Adv Cyclic Nucleotide Res, V9, P493; SCHATZ AR, 1993, IMMUNOPHARMACOLOGY, V26, P129, DOI 10.1016/0162-3109(93)90005-B; SCHATZ AR, 1992, LIFE SCI, V51, P25; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; THOMAS BF, 1992, J PHARMACOL EXP THER, V263, P1383; TSURUTA L, 1995, J IMMUNOL, V154, P5255; VANDENHEUVEL JP, 1994, CANCER RES, V54, P62; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68	69	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13175	13183		10.1074/jbc.271.22.13175	http://dx.doi.org/10.1074/jbc.271.22.13175			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662742	hybrid			2022-12-27	WOS:A1996UN47400075
J	Wuillemin, WA; Eldering, E; Citarella, F; deRuig, CP; tenCate, H; Hack, CE				Wuillemin, WA; Eldering, E; Citarella, F; deRuig, CP; tenCate, H; Hack, CE			Modulation of contact system proteases by glycosaminoglycans - Selective enhancement of the inhibition of factor XIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; PLASMA THROMBOPLASTIN ANTECEDENT; MOLECULAR-WEIGHT KININOGEN; ACTIVATED HAGEMAN-FACTOR; FACTOR-XIIA; ANTITHROMBIN-III; KALLIKREIN-C1-INHIBITOR COMPLEXES; DEXTRAN SULFATE; CL-INHIBITOR; INACTIVATION	We investigated the influence of dextran sulfate, heparin, heparan sulfate, and dermatan sulfate on the inhibition of FXIa (where FXIa is activated factor XI, for example), FXIIa, and kallikrein by C1 inhibitor, alpha(1)-antitrypsin, alpha(2)-antiplasmin, and antithrombin III. The second-order rate constants for the inhibition of FXIa by C1 inhibitor, alpha(1)-antitrypsin, alpha(2)-antiplasmin, and antithrombin III, in the absence of glycosaminoglycans, were 1.8, 0.1, 0.43, and 0.32 x 10(3) M(-1) s(-1) respectively. The rate constants of the inactivation df FXIa by C1 inhibitor and by antithrombin III increased up to 117-fold in the presence of glycosaminoglycans. These data predicted that considering the plasma concentration of the inhibitors, C1 inhibitor would be the main inhibitor of FXIa in plasma in the presence of glycosaminoglycans. Results of experiments in which the formation of complexes between serine protease inhibitors and FXIa was studied in plasma agreed with this prediction. Glycosaminoglycans did not enhance the inhibition of alpha-FXIIa, beta-FXIIa, or kallikrein by C1 inhibitor. Thus, physiological glycosaminoglycans selectively enhance inhibition of FXIa without affecting the activity of FXIIa and kallikrein, suggesting that glycosaminoglycans may modulate the biological effects of contact activation, by inhibiting intrinsic coagulation without affecting the fibrinolytic potential of FXIIa/kallikrein.	UNIV AMSTERDAM,CENT LAB,NETHERLANDS RED CROSS BLOOD TRANSFUS SERV,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,CLIN & EXPTL IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY; UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & I,1066 CX AMSTERDAM,NETHERLANDS; SLOTERVAART HOSP,DEPT INTERNAL MED,1066 CX AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,1081 HV AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam; Sapienza University Rome; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER			Cate, Hugo ten/AAM-4000-2021; Levi, Marcel/AAZ-8559-2020					AUSPRUNK DH, 1981, AM J PATHOL, V103, P353; BEELER DL, 1986, BLOOD, V67, P1488; BODE W, 1994, FIBRINOLYSIS, V8, P161, DOI 10.1016/0268-9499(94)90714-5; BOUMA BN, 1983, BLOOD, V62, P1123; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DORS DM, 1992, THROMB HAEMOSTASIS, V67, P644; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; HARPEL PC, 1985, J BIOL CHEM, V260, P4257; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; KAPLAN AP, 1987, BLOOD, V70, P1; KITCHENS CS, 1991, SEMIN THROMB HEMOST, V17, P55, DOI 10.1055/s-2007-1002590; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOMIYAMA Y, 1988, THROMB RES, V50, P329, DOI 10.1016/0049-3848(88)90234-4; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P959, DOI 10.1021/bi00403a018; NUIJENS JH, 1988, BLOOD, V72, P1841; NUIJENS JH, 1987, THROMB HAEMOSTASIS, V58, P778; OSHIMA G, 1989, BIOL CHEM H-S, V370, P715, DOI 10.1515/bchm3.1989.370.2.715; PIXLEY R, 1983, BIOCHEMISTRY-US, V22, P4810, DOI 10.1021/bi00289a030; PIXLEY RA, 1987, ARCH BIOCHEM BIOPHYS, V256, P490, DOI 10.1016/0003-9861(87)90606-0; PIXLEY RA, 1985, J BIOL CHEM, V260, P1723; PIXLEY RA, 1986, FASEB J, V45, P1638; POOLE AR, 1986, BIOCHEM J, V236, P1; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RENT R, 1976, CLIN EXP IMMUNOL, V23, P264; ROSENBERG RD, 1986, CIBA FOUND S, V124, P47; SAITO H, 1977, BLOOD, V50, P377; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; SCHAPIRA M, 1981, BIOCHEMISTRY-US, V20, P2738, DOI 10.1021/bi00513a006; SCHAPIRA M, 1982, J CLIN INVEST, V69, P462, DOI 10.1172/JCI110470; SCHAPIRA M, 1987, SEMIN THROMB HEMOST, V13, P69, DOI 10.1055/s-2007-1003476; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SCOTT CF, 1989, BLOOD, V73, P1873; SIM RB, 1980, BIOCHIM BIOPHYS ACTA, V612, P433, DOI 10.1016/0005-2744(80)90126-6; SOONS H, 1987, BIOCHEMISTRY-US, V26, P4624, DOI 10.1021/bi00389a005; TANKERSLEY DL, 1983, BLOOD, V62, P448; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WUILLEMIN WA, 1995, BLOOD, V85, P1517, DOI 10.1182/blood.V85.6.1517.bloodjournal8561517	48	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12913	12918		10.1074/jbc.271.22.12913	http://dx.doi.org/10.1074/jbc.271.22.12913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662679	hybrid			2022-12-27	WOS:A1996UN47400037
J	Fagan, KA; Mahey, R; Cooper, DMF				Fagan, KA; Mahey, R; Cooper, DMF			Functional co-localization of transfected Ca2+-stimulable adenylyl cyclases with capacitative Ca2+ entry sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC SPINES; NCB-20 CELLS; CALCIUM; EXPRESSION; CALMODULIN; STIMULATION; INHIBITION; CLONING; PROTEIN	Three adenylyl cyclases (ACI, ACIII, and ACVIII) have been described, which are putatively Ca2+-stimulable, based on in vitro assays, However, it is not clear that these enzymes can be regulated by physiological rises in [Ca2+](i) when expressed in intact cells. Furthermore, it is not known whether transfected adenylyl cyclases might display the strict requirement for capacitative Ca2+ entry that is shown by the Ca2+-inhibitable ACVI, which is indigenous to C6-2B glioma cells (Chiono, M., Mahey, R., Tate, G., and Cooper, D. M. F. (1995) J. Biol. Chem. 270, 1149-1155). In the present study, ACI, ACIII, and ACVIII were heterologously expressed in HEK 293 cells, and conditions were devised that distinguished capacitative Ca2+ entry from both internal release and nonspecific elevation in [Ca2+](i) around the plasma membrane. Remarkably, not only were ACI and ACVIII largely insensitive to Ca2+ release from stores, but they were robustly stimulated only by capacitative Ca2+ entry and not at all by a substantial increase in [Ca2+](i) at the plasma membrane elicited by ionophore. (ACIII, reflecting its feeble in vitro sensitivity to Ca2+, was unaffected by any [Ca2+](i) rise.) These results suggest a quite unsuspected, essential association of Ca2+-sensitive adenylyl cyclases with capacitative Ca2+ entry sites, even when expressed heterologously.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM NEUROSCI, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AUGUSTINE GJ, 1991, ANN NY ACAD SCI, V635, P365, DOI 10.1111/j.1749-6632.1991.tb36505.x; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CARR DW, 1992, P NATL ACAD SCI USA, V89, P16816; CHEEK TR, 1989, J CELL SCI, V93, P211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; EVANS T, 1984, MOL PHARMACOL, V26, P395; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	37	146	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12438	12444		10.1074/jbc.271.21.12438	http://dx.doi.org/10.1074/jbc.271.21.12438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647849	hybrid			2022-12-27	WOS:A1996UL66000051
J	Ugi, S; Maegawa, H; Kashiwagi, A; Adachi, M; Olefsky, JM; Kikkawa, R				Ugi, S; Maegawa, H; Kashiwagi, A; Adachi, M; Olefsky, JM; Kikkawa, R			Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3'-kinase activity via modulation of phosphorylation of insulin receptor substrate-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; SIGNAL TRANSDUCTION; SH3 DOMAINS; CORKSCREW; 3-KINASE; SUBUNIT; KINASE; ASSOCIATION	To clarify the role of protein-tyrosine phosphatase (PTPase) containing Src homology 2 regions (SHPTP2) in insulin signaling, either wild-type or mutant SHPTP2 (Delta PTP; lacking full PTPase domain) was expressed in Rat 1 fibroblasts overexpressing human insulin receptors. In response to insulin, phosphorylation of insulin receptor substrate 1 (IRS-1), IRS-1-associated PTPase activities and phosphatidylinositol (PI) 3'-kinase activities were slightly enhanced in wild-type cells when compared with those in the parent cells transfected with hygromycin-resistant gene alone. In contrast, introduction of Delta PTP inhibited insulin-induced association of IRS 1 with endogenous SHPTP2 and impaired both insulin-stimulated phosphorylation of IRS-1 and activation of PI 3'-kinase. Furthermore, decreased content of p85 subunit of PI 3'-kinase was also found in mutant cells. Consistently, the insulin-stimulated mitogen-activated protein kinase activities and DNA synthesis were also enhanced in wild-type cells, but impaired in mutant cells. Thus, the interaction of SHPTP2 with IRS-1 may be associated with modulation of phosphorylation levels of IRS-1, resulting in the changes of PI 3'-kinase and mitogen-activated protein kinase activity. Furthermore, an impaired insulin signaling in mutant cells may be partly reflected in a decreased content of p85 protein of PI 3'-kinase.	SHIGA UNIV MED SCI,DEPT MED 3,OTSU,SHIGA 52021,JAPAN; SAPPORO MED COLL,DEPT MED 1,SAPPORO,HOKKAIDO 060,JAPAN; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	Shiga University of Medical Science; Sapporo Medical University; University of California System; University of California San Diego			Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISHER EH, 1991, SCIENCE, V253, P401; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKAMOTO M, 1993, BIOCHEM J, V290, P327, DOI 10.1042/bj2900327; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAKAGI Y, 1995, ATHEROSCLEROSIS, V113, P19, DOI 10.1016/0021-9150(94)05422-F; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	40	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12595	12602		10.1074/jbc.271.21.12595	http://dx.doi.org/10.1074/jbc.271.21.12595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647870	hybrid			2022-12-27	WOS:A1996UL66000072
J	vanHeerden, PS; Towers, GHN; Lewis, NG				vanHeerden, PS; Towers, GHN; Lewis, NG			Nitrogen metabolism in lignifying Pinus taeda cell cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; LEMNA-MINOR-L; AROGENATE DEHYDROGENASE; TYROSINE BIOSYNTHESIS; REGULATORY PROPERTIES; L-PHENYLALANINE; HIGHER-PLANTS; N-15; ASSIMILATION; GLUTAMINE	The primary metabolic fate of phenylalanine, following its deamination in plants, is conscription of its carbon skeleton for lignin, suberin, flavonoid, and related metabolite formation. Since this accounts for similar to 30-40% of all organic carbon, an effective means of recycling the liberated ammonium ion must be operative. In order to establish how this occurs, the uptake and metabolism of various N-15-labeled precursors (N-15-Phe, (NH4Cl)-N-15, N-15-Gln, and N-15-Glu) in lignifying Pinus taeda cell cultures was investigated, using a combination of high performance liquid chromatography, N-15 NMR, and gas chromatography-mass spectrometry analyses. It was found that the ammonium ion released during active phenylpropanoid metabolism was not made available for general amino acid/protein synthesis. Rather it was rapidly recycled back to regenerate phenylalanine, thereby providing an effective means of maintaining active phenylpropanoid metabolism with no additional nitrogen requirement. These results strongly suggest that, in lignifying cells, ammonium ion reassimilation is tightly compartmentalized.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University				Lewis, Norman/0000-0001-5742-032X				ALTENBURGER R, 1991, ARCH MICROBIOL, V156, P471, DOI 10.1007/BF00245394; AMRHEIN N, 1977, PLANT SCI LETT, V8, P313, DOI 10.1016/0304-4211(77)90148-1; BYNG G, 1981, PHYTOCHEMISTRY, V20, P289; CALLIES R, 1992, PLANT PHYSIOL, V100, P1584, DOI 10.1104/pp.100.3.1584; CONNELLY JA, 1986, Z NATURFORSCH C, V41, P69; DAVIN LB, 1992, RECENT ADV PHYTOCHEM, V26, P325; DEWICK PM, 1985, NAT PROD REP, V2, P495, DOI 10.1039/np9850200495; DOUGALL DK, 1980, BIOCH PLANTS, V2, P627; DOUGLAS CJ, 1992, RECENT ADV PHYTOCHEM, V26, P63; DURZAN DJ, 1983, PLANT PHYSL TREATISE, V8, P55; EBERHARDT TL, 1993, J BIOL CHEM, V268, P21088; FLOSS HG, 1985, RECENT ADV PHYTOCHEM, V20, P13; GAINES CG, 1982, PLANTA, V156, P233, DOI 10.1007/BF00393730; Gross G.G., 1985, BIOSYNTHESIS BIODEGR, P229; HAGEN SR, 1993, FOOD CHEM, V46, P319, DOI 10.1016/0308-8146(93)90127-2; Hanson K. R., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P577; JENSEN RA, 1985, RECENT ADV PHYTOCHEM, V20, P57; JUNG E, 1986, P NATL ACAD SCI USA, V83, P7231, DOI 10.1073/pnas.83.19.7231; KANAMORI K, 1988, J BIOL CHEM, V263, P2817; KOUKOL J, 1961, J BIOL CHEM, V236, P2692; KUESEL AC, 1989, ARCH MICROBIOL, V151, P434, DOI 10.1007/BF00416603; LEA PJ, 1974, NATURE, V251, P614, DOI 10.1038/251614a0; Lewis N.G., 1989, CHEM SIGNIFICANCE CO, P23, DOI [DOI 10.1007/978-1-4684-7511-1_2, 10.1007/978-1-4684-7511-1_2]; MARTIN F, 1986, NEW PHYTOL, V102, P85, DOI 10.1111/j.1469-8137.1986.tb00800.x; MARTIN F, 1985, FEBS LETT, V182, P350, DOI 10.1016/0014-5793(85)80331-8; MAXWELL CA, 1990, PLANT PHYSIOL, V93, P1552, DOI 10.1104/pp.93.4.1552; McLafferty F. W., 1993, INTERPRETATION MASS; MIFLIN BJ, 1975, BIOCHEM J, V149, P403, DOI 10.1042/bj1490403; MONSELISE EB, 1987, NEW PHYTOL, V107, P341, DOI 10.1111/j.1469-8137.1987.tb00186.x; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; OAKS A, 1985, ANNU REV PLANT PHYS, V36, P345; PANKHURST CE, 1979, J EXP BOT, V30, P1109, DOI 10.1093/jxb/30.6.1109; RAZAL RA, 1994, PHYTOCHEM ANALYSIS, V5, P98, DOI 10.1002/pca.2800050303; Razal RA, 1996, PHYTOCHEMISTRY, V41, P31, DOI 10.1016/0031-9422(95)00628-1; RHODES D, 1975, PLANTA, V125, P201, DOI 10.1007/BF00385596; RHODES D, 1989, PLANT PHYSIOL, V89, P1161, DOI 10.1104/pp.89.4.1161; RHODES D, 1976, PLANTA, V129, P203, DOI 10.1007/BF00398258; ROBINSON SA, 1991, PLANT PHYSIOL, V95, P509, DOI 10.1104/pp.95.2.509; RONZIO RA, 1969, BIOCHEMISTRY-US, V8, P1066, DOI 10.1021/bi00831a038; SIEHL DL, 1986, Z NATURFORSCH C, V41, P79; SIEHL DL, 1988, ARCH BIOCHEM BIOPHYS, V260, P822, DOI 10.1016/0003-9861(88)90513-9; THORPE TA, 1989, PLANT PHYSIOL, V91, P193, DOI 10.1104/pp.91.1.193; WIGHTMAN F, 1978, PHYTOCHEMISTRY, V17, P1455, DOI 10.1016/S0031-9422(00)94622-3	43	57	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12350	12355		10.1074/jbc.271.21.12350	http://dx.doi.org/10.1074/jbc.271.21.12350			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647837	hybrid			2022-12-27	WOS:A1996UL66000039
J	Ferby, IM; Waga, I; Hoshino, M; Kume, K; Shimizu, T				Ferby, IM; Waga, I; Hoshino, M; Kume, K; Shimizu, T			Wortmannin inhibits mitogen-activated protein kinase activation by platelet-activating factor through a mechanism independent of p85/p110-type phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LIGHT CHAIN KINASE; PHOSPHOLIPID TURNOVER; SIGNAL-TRANSDUCTION; MAP KINASES; PHOSPHORYLATION; NEUTROPHILS; GENERATION; RECEPTORS; MEMBRANE	We have shown previously that wortmannin partially inhibits mitogen-activated protein kinase (MAPK) activated by platelet-activating factor (PAF) in guinea pig neutrophils (Ferby, M. I., Waga, I., Sakanaka, C., Kume, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 30485-30488), To identify whether p85-dependent phosphatidylinositol 3-kinase is a target molecule of wortmannin in this inhibitory process, we established a murine macrophage cell line (P388D1), inducibly expressing a dominant-negative p85, Delta p85, Upon induction of Delta p85 by isopropyl-beta-D-thiogalactopyranoside, PAF still induced unaltered activation of MAPK, which was inhibited completely by wortmannin and 1,2-bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester in an additive manner. Thus, PAF activates MAPK in P388D1 cells via two distinct pathways, one calcium-dependent and another calcium-independent, but wortmannin-sensitive. The inhibition of calcium-independent activation of MAPK by wortmannin does not involve p85-dependent phosphatidylinositol 3-kinase.	UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Ferby, Ingvar/B-7895-2008	Kume, Kazuhiko/0000-0003-4232-1657; Ferby, Ingvar/0000-0002-3435-1728				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASMIS R, 1994, BIOCHEM J, V298, P543, DOI 10.1042/bj2980543; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DHAR A, 1991, J BIOL CHEM, V266, P18797; EAGER KB, 1986, METHOD ENZYMOL, V121, P59; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HAYASHI H, 1991, LIPIDS, V26, P1193, DOI 10.1007/BF02536530; HONDA Z, 1994, J BIOL CHEM, V269, P2307; INGRAHAM LM, 1982, BLOOD, V59, P1259; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAKISHIMA M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P245, DOI 10.1016/0167-4889(93)90051-P; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PINCKARD RN, 1992, J IMMUNOL, V148, P3528; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SCHULAM PG, 1991, J IMMUNOL, V146, P1642; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SHUTE JK, 1990, BIOCHEM PHARMACOL, V40, P2013, DOI 10.1016/0006-2952(90)90231-9; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VALONE FH, 1982, J IMMUNOL, V129, P1637; WAGA I, 1993, BIOCHEM BIOPH RES CO, V197, P465, DOI 10.1006/bbrc.1993.2502; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6	45	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11684	11688		10.1074/jbc.271.20.11684	http://dx.doi.org/10.1074/jbc.271.20.11684			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662643	hybrid			2022-12-27	WOS:A1996UL25000018
J	Greenfield, EM; Horowitz, MC; Lavish, SA				Greenfield, EM; Horowitz, MC; Lavish, SA			Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-KINASE-C; MESSENGER-RNA DEGRADATION; BONE-RESORPTION; CYCLIC-AMP; OSTEOSARCOMA CELLS; CYTOSOLIC CALCIUM; FACTOR INDUCTION; PHOSPHOLIPASE-C; STROMAL CELLS	Parathyroid hormone and other agents that stimulate bone resorption function, at least in part, by inducing osteoblasts to secrete cytokines that stimulate osteoclast differentiation and activity. We previously demonstrated that parathyroid hormone induces expression by osteoblasts of interleukin-6 and leukemia inhibitory factor without affecting the 16 other cytokines that were examined. We also showed that stimulation of osteoclast activity by parathyroid hormone is dependent on activation of the cAMP signal transduction pathway and secretion of interleukin-6 by osteoblasts. In the current study, we demonstrate that the rapid and transient stimulation of interleukin-6 and leukemia inhibitory factor is inhibited by actinomycin D and superinduced by protein synthesis inhibitors, the classical characteristics of an immediate-early gene response. Moreover, activation of cAMP signal transduction by parathyroid hormone and parathyroid hormone-related protein is necessary and sufficient to induce both interleukin-6 and leukemia inhibitory factor. In addition, cAMP analogues as well as vasoactive intestinal peptide and iso; proterenol, two neuropeptides that stimulate bone resorption by activating cAMP signal transduction in osteoblasts, also induce interleukin-6 and leukemia inhibitory factor in these cells. Taken together with our previous results, this study suggests that interleukin-6 is crucial for stimulation of bone resorption not only by parathyroid hormone, but also by parathyroid hormone-related protein, vasoactive intestinal peptide, and beta-adrenergic agonists, like isoproterenol.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, INST PATHOL, CLEVELAND, OH 44106 USA; YALE UNIV, SCH MED, DEPT ORTHOPAED & REHABIL, NEW HAVEN, CT 06520 USA	Case Western Reserve University; Case Western Reserve University; Yale University	Greenfield, EM (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPED, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NIAMS NIH HHS [AR40073, AR40507, AR41674] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041674, R01AR040507, R29AR041674, R01AR040073] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE E, 1988, J BONE MINER RES, V3, P635; ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALLAN EH, 1990, J CELL PHYSIOL, V145, P110, DOI 10.1002/jcp.1041450116; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BOS MP, 1992, BIOCHEM BIOPH RES CO, V184, P1317, DOI 10.1016/S0006-291X(05)80026-9; BOTELLA A, 1994, ENDOCRINOLOGY, V135, P2160, DOI 10.1210/en.135.5.2160; CHARD MD, 1991, ANN RHEUM DIS, V50, P727, DOI 10.1136/ard.50.10.727; DAVIDOVITCH Z, 1988, DENT CLIN N AM, V32, P411; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DERIGS HG, 1993, LEUKEMIA, V7, P630; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; EXTON JH, 1985, AM J PHYSIOL, V248, pE633, DOI 10.1152/ajpendo.1985.248.6.E633; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Foulkes, 1991, HORMONAL CONTROL REG, P257; FRANCHIMONT N, 1993, 4TH INT S OST, P249; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GREENFIELD EM, 1995, J CLIN INVEST, V96, P1238, DOI 10.1172/JCI118157; GREENFIELD EM, 1993, J BONE MINER RES, V8, P1163; GREENFIELD EM, 1996, IN PRESS BIOL MECH T; GREENFIELD EM, 1996, T ORTHOP RES SOC, V21, P337; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HERRMANNERLEE MPM, 1983, CALCIFIED TISSUE INT, V35, P70, DOI 10.1007/BF02405009; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOHMANN EL, 1983, ENDOCRINOLOGY, V112, P1233, DOI 10.1210/endo-112-4-1233; HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059; HOROWITZ M, 1990, PROG LEUC B, V10, P471; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; HUGHES FJ, 1993, BONE MINER, V21, P21, DOI 10.1016/S0169-6009(08)80117-1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIMI Y, 1992, J CELL PHYSIOL, V152, P71, DOI 10.1002/jcp.1041520110; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006-291X(92)91882-Q; KOJIMA I, 1985, AM J PHYSIOL, V248, pE36, DOI 10.1152/ajpendo.1985.248.1.E36; KUMAGAI H, 1989, CALCIFIED TISSUE INT, V45, P251, DOI 10.1007/BF02556045; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; LJUNGGREN O, 1993, BIOCHEM BIOPH RES CO, V193, P821, DOI 10.1006/bbrc.1993.1699; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; LUBBERT M, 1991, LEUKEMIA, V5, P361; MAGISTRETTI PJ, 1990, TRENDS PHARMACOL SCI, V11, P250, DOI 10.1016/0165-6147(90)90253-5; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAIMONE D, 1993, J NEUROIMMUNOL, V47, P73, DOI 10.1016/0165-5728(93)90286-8; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MALHOTRA RK, 1988, J BIOL CHEM, V263, P2123; MARTIN TJ, 1993, PHYSL PHARM BONE, P617; MARUSIC A, 1993, J BONE MINER RES, V8, P617; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MOORE RE, 1993, BONE MINER, V23, P301, DOI 10.1016/S0169-6009(08)80105-5; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; PANDOL SJ, 1986, AM J PHYSIOL, V250, pG553, DOI 10.1152/ajpgi.1986.250.4.G553; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PEARMAN AT, 1994, J BONE MINER RES  S1, V9, P416; POLLOCK JH, 1996, IN PRESS J BONE MINE, V11; REID IR, 1990, ENDOCRINOLOGY, V126, P1416, DOI 10.1210/endo-126-3-1416; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; SEHGAL PB, 1987, P NATL ACAD SCI USA, V84, P3663, DOI 10.1073/pnas.84.11.3663; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPANGELO BL, 1990, ENDOCRINOLOGY, V127, P403, DOI 10.1210/endo-127-1-403; STAHL J, 1990, J BIOL CHEM, V265, P8833; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUZUKI A, 1994, CELL SIGNAL, V6, P11, DOI 10.1016/0898-6568(94)90056-6; TANABE O, 1988, J IMMUNOL, V141, P3875; Vazquez D., 1979, INHIBITORS PROTEIN B; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; ZHANG YH, 1988, J BIOL CHEM, V263, P6177	80	111	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10984	10989		10.1074/jbc.271.18.10984	http://dx.doi.org/10.1074/jbc.271.18.10984			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631918	hybrid			2022-12-27	WOS:A1996UJ34200086
J	Higgs, HN; Glomset, JA				Higgs, HN; Glomset, JA			Purification and properties of a phosphatidic acid-preferring phospholipase A(1) from bovine testis - Examination of the molecular basis of its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BICINCHONINIC ACID; BRAIN; MEMBRANES; BINDING; LIPIDS; HEART	We recently identified a cytosolic phospholipase A(1) activity in bovine brain and testis that preferentially hydrolyzes phosphatidic acid substrates. We also showed that the enzyme displays sigmoidal kinetics toward phosphatidic acid substrates in a Triton X-100 mixed micelle assay system (Higgs, H. N., and Glomset, J. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9574-9578), In the present work we purified the bovine testis enzyme 14,000 fold and used a combination of size exclusion chromatography, labeling with the phospholipase A inhibitor, methyl arachidonyl fluorophosphonate, and SDS-polyacrylamide gel electrophoresis to provide evidence that it is a homotetramer of 110-kDa subunits. Studies of the molecular basis of the enzyme reaction in Triton micelles revealed that (a) a nonhydrolyzable sn-1-alkyl-2-oleoyl analogue of phosphatidic acid activated the enzyme 30-fold in a sigmoidal fashion (Hill coefficient 3.2, EC(50) 4 mol %) without substantially affecting its preference for specific diacyl phosphoglyceride substrates, (b) the activator promoted tight binding of the enzyme to micelles, and (c) the enzyme's activity toward unsaturated phosphatidic acid substrates was affected by the location and nature of the fatty acyl chain double bonds.	UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, REG PRIMATE RES CTR, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Higgs, Henry/0000-0002-2917-9644	NCRR NIH HHS [RR00166] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BADIANI K, 1992, BIOCHEM J, V288, P965, DOI 10.1042/bj2880965; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CARMAN GM, 1980, J FOOD BIOCHEM, V4, P53, DOI 10.1111/j.1745-4514.1980.tb00877.x; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; HOSTETLER KY, 1986, BIOCHEMISTRY-US, V25, P6456, DOI 10.1021/bi00369a017; HUTERER SJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P204, DOI 10.1016/0005-2760(93)90163-4; INOUE M, 1984, J BIOL CHEM, V259, P5083; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; KOYNOVA R, 1994, CHEM PHYS LIPIDS, V69, P1, DOI 10.1016/0009-3084(94)90024-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marsh D., 1990, CRC HDB LIPID BILAYE; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P139; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; NALBONE G, 1985, J LIPID RES, V26, P104; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PETE MJ, 1994, J BIOL CHEM, V269, P19494; PETE MJ, 1995, BBA-LIPID LIPID MET, V1256, P367, DOI 10.1016/0005-2760(95)00047-G; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATE MW, 1991, CHEM PHYS LIPIDS, V57, P147, DOI 10.1016/0009-3084(91)90073-K; UEDA H, 1993, J NEUROCHEM, V61, P1874, DOI 10.1111/j.1471-4159.1993.tb09829.x; UEDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1272, DOI 10.1006/bbrc.1993.2181; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Waite M, 1981, Methods Enzymol, V71 Pt C, P674	32	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10874	10883		10.1074/jbc.271.18.10874	http://dx.doi.org/10.1074/jbc.271.18.10874			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631903	hybrid			2022-12-27	WOS:A1996UJ34200071
J	Steinberger, P; Kraft, D; Valenta, R				Steinberger, P; Kraft, D; Valenta, R			Construction of a combinatorial IgE library from an allergic patient - Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNOGLOBULIN-E; EPSILON-CHAIN CDNA; MONOCLONAL-ANTIBODIES; PRATENSE POLLEN; PHAGE SURFACES; BINDING-SITE; CLONING; GENE; PROTEIN; LINKAGE	To characterize human IgE antibodies with specificity for a major allergen at the molecular level, we have constructed an IgE combinatorial library from a grass pollen allergic patient. cDNAs coding for IgE heavy chain fragments and for light chains were reverse-transcribed and polymerase chain reaction-amplified from RNA of peripheral blood lymphocytes and randomly combined in plasmid pComb3H to yield a combinatorial library of 5 x 10(7) primary clones. IgE Fabs with specificity for Phl p 5, a major timothy grass pollen allergen, were isolated by panning. Sequence analysis showed that the 4 of the Fabs used the same heavy chain fragments which had combined with different kappa light chains. Soluble recombinant IgE Fabs were purified by affinity chromatography to Phl p 5 and, like natural IgE antibodies, cross-reacted with group 5 allergens from different grass species. The described approach should facilitate studies on the molecular interaction between IgE antibodies and allergens and encourages the consideration of specific IgE Fabs that are capable of interfering with allergen-IgE binding as potential therapeutic tools.	UNIV VIENNA,INST GEN & EXPTL PATHOL,AKH,A-1090 VIENNA,AUSTRIA	University of Vienna				Steinberger, Peter/0000-0001-6848-4097; Valenta, Rudolf/0000-0001-5944-3365				BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BENNICH H, 1973, FEBS LETT, V33, P49, DOI 10.1016/0014-5793(73)80156-5; BENNICH HH, 1968, IMMUNOLOGY, V15, P323; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUFE A, 1994, J ALLERGY CLIN IMMUN, V94, P173, DOI 10.1016/0091-6749(94)90037-X; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; ISHIZAKA K, 1970, ANN ALLERGY, V28, P189; KABAT EA, 1987, SEQUENCES PROTEINS I, P674; KANG A S, 1991, Methods (Orlando), V2, P111, DOI 10.1016/S1046-2023(05)80211-7; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; KOCHWA S, 1971, ANN NY ACAD SCI, V190, P49, DOI 10.1111/j.1749-6632.1971.tb13523.x; KUROKAWA T, 1983, NUCLEIC ACIDS RES, V11, P3077, DOI 10.1093/nar/11.10.3077; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Leonard Davis G., 1986, BASIC METHODS MOL BI; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MATTHIESEN F, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P189; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; PRESTA L, 1994, J BIOL CHEM, V269, P26368; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENO M, 1983, NUCLEIC ACIDS RES, V11, P719, DOI 10.1093/nar/11.3.719; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; STEINBERGER P, 1995, J ALLERGY CLIN IMMUN, V96, P209, DOI 10.1016/S0091-6749(95)70010-2; TERRY WD, 1970, J IMMUNOL, V105, P783; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1994, ALLERGY CLIN IMMUNOL, V6, P165; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; VRTALA S, 1996, IN PRESS; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874	38	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10967	10972		10.1074/jbc.271.18.10967	http://dx.doi.org/10.1074/jbc.271.18.10967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631916	hybrid			2022-12-27	WOS:A1996UJ34200084
J	Li, CY; Gudas, LJ				Li, CY; Gudas, LJ			Murine laminin B1 gene regulation during the retinoic acid- and dibutyryl cyclic AMP-induced differentiation of embryonic F9 teratocarcinoma stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN MESSENGER-RNA; A-CHAIN; MULTIDOMAIN PROTEIN; MOUSE EMBRYOGENESIS; BASEMENT-MEMBRANES; RESPONSIVE ELEMENT; MOLECULAR-CLONING; ALBUMIN GENE; COLLAGEN-IV; B2 CHAIN	Retinoic acid (RA) and cyclic AMP analogs cause the differentiation of F9 embryonic teratocarcinoma stem cells into parietal endoderm, an epithelial cell of the early mouse embryo. Laminin B1 is induced in this differentiation process, but is not transcriptionally activated until 24-48 h after RA addition and is not maximally induced until approximately 72 h. Cyclic AMP analogs enhance this transcriptional activation. Although several DNase I hypersensitive sites (DHSS) were observed in the LAMB1 5'-flanking DNA, one of the sites, DHSS2, was detected only after 72 h of RA treatment. Transient transfections have demonstrated that the DHSS2 region functions as a 'late-acting RA-inducible enhancer,'' and motifs in this enhancer contain the homeobox protein-binding site TTATTAACA. Greater binding is observed at these sites by electrophoretic mobility shift assay when cells are cultured with RA and cyclic AMP analogs versus RA alone, and no binding is seen in extracts from RA-treated F9 RAR gamma(-/-) cells which lack RAR gamma mRNA and protein. Laminin B1 mRNA is not induced by RA in the RAR gamma(-/-) cells (Boylan, J. F., Lohnes, D., Taneja, R., Chambon, P., and Gudas, L. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9601-9605). Our data show that these DNA regulatory elements contribute to the transcriptional activation of the LAMBI gene during the later stages of the differentiation process.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Cornell University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024319] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD24319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; DECURTIS I, 1993, DEVELOPMENT, V118, P377; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAGO J, 1991, EXP CELL RES, V196, P246, DOI 10.1016/0014-4827(91)90258-V; DURKIN ME, 1986, DIFFERENTIATION, V32, P260, DOI 10.1111/j.1432-0436.1986.tb00582.x; DZIADEK M, 1985, DEV BIOL, V111, P372, DOI 10.1016/0012-1606(85)90491-9; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGEL J, 1991, BIOCHEM SOC T, V19, P8339; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FRENETTE GP, 1988, CANCER RES, V48, P5193; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; Gudas Lorraine J., 1994, P443; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P33, DOI 10.3109/15419069309095680; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KLEINMAN HK, 1993, VITAM HORM, V47, P161, DOI 10.1016/S0083-6729(08)60446-X; KROLL TG, 1994, J BIOL CHEM, V269, P9270; KURKINEN M, 1983, J BIOL CHEM, V258, P6543; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARINKOVICH P, 1993, J CELL BIOL, V119, P695; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SIMO P, 1991, DEVELOPMENT, V112, P477; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1988, J CELL PHYSIOL, V136, P305, DOI 10.1002/jcp.1041360213; WANG SY, 1989, J BIOL CHEM, V264, P15556; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572	70	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6810	6818		10.1074/jbc.271.12.6810	http://dx.doi.org/10.1074/jbc.271.12.6810			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636104	hybrid			2022-12-27	WOS:A1996UB15700039
J	Paz, K; Voliovitch, H; Hadari, YR; Roberts, CT; LeRoith, D; Zick, Y				Paz, K; Voliovitch, H; Hadari, YR; Roberts, CT; LeRoith, D; Zick, Y			Interaction between the insulin receptor and its downstream effectors - Use of individually expressed receptor domains for structure function analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE PHOSPHORYLATION; JUXTAMEMBRANE REGION; KINASE-ACTIVITY; INTACT-CELLS; BETA-SUBUNIT; PROTEINS; STIMULATE	A structural analysis has been carried out to determine which part of the intracellular domain of the insulin receptor (IR) beta subunit is involved in direct interaction with the receptor substrates IRS-1 and She. Toward this end, the juxtamembrane (JM) domain (amino acids 943-984) and the carboxyl-terminal (CT) region (amino acids 1245-1331) of IR were expressed in bacteria as (His)(6)-fusion peptides, and their interaction with IRS-1 and She was studied, We could demonstrate that the CT region of IR was sufficient to bind She, although significant, but much lower binding of She to the JM region could be detected as well. Furthermore, in vitro Tyr phosphorylation of the CT region potentiated its interactions with She 2-fold. In contrast, the JM region, but not the CT domain of the IR, was sufficient to mediate interactions between the IR and IRS-1. These interactions did not involve the pleckstrin homology (PH) region of IRS-1, since an IRS-I mutant, in which four ''blocks'' of the PH domain (pro(5)-pro(65)) were deleted, interacted with the JM region of IR with the same efficiency as native IRS-l, These results suggest that the IR interacts with its downstream effecters through distinct receptor regions, and that autophosphorylation of Tyr residues located at the CT domain of the IR can modulate these interactions.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; NIH, DIABET BRANCH, BETHESDA, MD 20982 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012; Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				BACKER JM, 1990, J BIOL CHEM, V265, P16450; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PANG L, 1994, J BIOL CHEM, V269, P10604; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, J BIOL CHEM, V270, P28325; SHEMER J, 1987, J BIOL CHEM, V262, P15476; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1989, J BIOL CHEM, V264, P12820; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZICK Y, 1983, J BIOL CHEM, V258, P75	49	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6998	7003		10.1074/jbc.271.12.6998	http://dx.doi.org/10.1074/jbc.271.12.6998			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636129	hybrid			2022-12-27	WOS:A1996UB15700064
J	Schalinske, KL; Eisenstein, RS				Schalinske, KL; Eisenstein, RS			Phosphorylation and activation of both iron regulatory proteins 1 and 2 in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; TRANSFERRIN RECEPTOR EXPRESSION; MESSENGER-RNA TRANSLATION; RESPONSIVE ELEMENT; 5-AMINOLEVULINATE SYNTHASE; DISULFIDE EXCHANGE; REDOX REGULATION; FERRITIN; DIFFERENTIATION; INVITRO	Iron regulatory proteins (IRPs) are RNA-binding proteins that post-transcriptionally regulate synthesis of iron uptake (transferrin receptor) and storage (ferritin) proteins. Our previous work demonstrating that IRP1 is phosphorylated by protein kinase C supported the hypothesis that factors in addition to iron modulate IRP function. We have investigated changes in activity and expression of both IRP1 and IRP2 during phorbol 12-myristate 13 acetate (PMA)-induced differentiation of HL-60 cells. In contrast to IRP1, IRP2 was highly phosphorylated in untreated cells. PMA stimulated phosphorylation of IRP1 and IRP2 by at least 2-3-fold without affecting incorporation of [S-35]methionine into the proteins. IRP1 and IRP2 isolated from PMA-treated cells displayed different phosphopeptides. Phosphorylation of IRPs was associated with a 2-fold increase in high affinity RNA binding activity without altering K-D, and this was accompanied by a 50% increase in transferrin receptor mRNA abundance. PMA acted on a latent pool of binding activity that is present in a nonaconitase oxidized form and is largely composed of a stable but inactive species of IRP2. Desferal and hemin modulated iron-responsive element binding activity in HL-60 cells without affecting the phosphorylation state of IRP1. Hemin appeared to reduce the abundance of phosphorylated IRP2. Thus, multiple factors affect the function of both IRPs and indicate that extracellular agents may program changes in cellular iron metabolism by altering the phosphorylation state of these regulatory RNA-binding proteins.	UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047219, R01DK047219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; ANDREESEN R, 1984, BLUT, V49, P195, DOI 10.1007/BF00319822; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHITAMBAR CR, 1983, J CLIN INVEST, V72, P1314, DOI 10.1172/JCI111087; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; CLERCH LB, 1995, ARCH BIOCHEM BIOPHYS, V317, P267, DOI 10.1006/abbi.1995.1162; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; FAZZONE H, 1993, J CLIN INVEST, V92, P1278, DOI 10.1172/JCI116700; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HO PTC, 1989, CANCER RES, V49, P1989; JABBAR SAB, 1994, LEUKEMIA RES, V18, P523, DOI 10.1016/0145-2126(94)90090-6; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; PANTOPOULOS K, 1995, RNA, V1, P155; RONDON IJ, 1995, FEBS LETT, V359, P267, DOI 10.1016/0014-5793(95)00066-I; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SANCHEZGARCIA I, 1993, J MOL BIOL, V231, P945, DOI 10.1006/jmbi.1993.1343; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; TANG CK, 1992, J BIOL CHEM, V267, P24466; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1989, J BIOL CHEM, V264, P13181; THEIL EC, 1994, BIOCHEM J, V304, P1; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	51	116	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7168	7176		10.1074/jbc.271.12.7168	http://dx.doi.org/10.1074/jbc.271.12.7168			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636154	hybrid			2022-12-27	WOS:A1996UB15700089
J	Sun, XY; Ollagnier, S; Schmidt, PP; Atta, M; Mulliez, E; Lepape, L; Eliasson, R; Graslund, A; Fontecave, M; Reichard, P; Sjoberg, BM				Sun, XY; Ollagnier, S; Schmidt, PP; Atta, M; Mulliez, E; Lepape, L; Eliasson, R; Graslund, A; Fontecave, M; Reichard, P; Sjoberg, BM			The free radical of the anaerobic ribonucleotide reductase from Escherichia coli is at glycine 681	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; S-ADENOSYLMETHIONINE; ACTIVATION; SULFUR; SYSTEM; GENE	The anaerobic ribonucleoside triphosphate reductase of Escherichia coli is an iron-sulfur protein carrying an oxygen-sensitive organic radical, which is essential for catalysis, The radical was tentatively proposed to be on glycine 681, based on a comparison with the glycyl radical-containing enzyme pyruvate formate-lyase. By EPR spectroscopy of selectively H-2- and C-13-labeled anaerobic ribonucleotide reductase, the radical was now unambiguously assigned to carbon-g of a glycine residue. The large H-1 hyperfine splitting (1.4 millitesla) was assigned to the alpha-proton, Site-directed mutagenesis was used to change glycine 681 into an alanine residue. In separate experiments, the two adjacent residues, cysteine 680 and tyrosine 682, were changed into serine and phenylalanine, respectively. All mutated proteins were retained on dATP-Sepharose, indicating that the mutant proteins had intact allosteric sites. They also contained amounts of iron comparable with the wild type reductase and showed the same iron-sulfur related spectrum, suggesting that the mutant proteins were properly folded. Of the three mutant proteins only the G681A protein completely lacked the detectable glycyl radical as well as enzyme activity. Our results identify glycine 681 as the stable free radical site in E. coli anaerobic ribonucleotide reductase.	UNIV STOCKHOLM,DEPT MOLEC BIOL,S-10691 STOCKHOLM,SWEDEN; UNIV GRENOBLE 1,LAB ETUD DYNAM & STRUCT & SELECT,URA CNRS 332,F-38041 GRENOBLE 9,FRANCE; KAROLINSKA INST,DEPT BIOCHEM 1,MED NOBEL INST,MBB,S-17177 STOCKHOLM,SWEDEN; UNIV STOCKHOLM,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN	Stockholm University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Karolinska Institutet; Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				BARONE V, 1995, J AM CHEM SOC, V117, P1083, DOI 10.1021/ja00108a026; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FREY M, 1994, J BIOL CHEM, V269, P12432; HARDER J, 1992, J BIOL CHEM, V267, P25548; Higuchi R., 1989, PCR TECHNOLOGY, P61; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SINCLAIR J, 1973, J CHEM PHYS, V59, P1569, DOI 10.1063/1.1680233; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; YOUNG P, 1994, J BIOL CHEM, V269, P20229	24	117	119	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6827	6831		10.1074/jbc.271.12.6827	http://dx.doi.org/10.1074/jbc.271.12.6827			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636106				2022-12-27	WOS:A1996UB15700041
J	Ursitti, JA; Kotula, L; DeSilva, TM; Curtis, PJ; Speicher, DW				Ursitti, JA; Kotula, L; DeSilva, TM; Curtis, PJ; Speicher, DW			Mapping the human erythrocyte beta-spectrin dimer initiation site using recombinant peptides and correlation of its phasing with the alpha-actinin dimer site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL SPECTRIN; TETRAMER BINDING-SITE; MEMBRANE SKELETON; HEREDITARY ELLIPTOCYTOSIS; PLASMA-MEMBRANE; IDENTIFICATION; EXPRESSION; MUTATIONS; DOMAIN; ULTRASTRUCTURE	Human erythroid spectrin dimer assembly is initiated by the association of a specific region near the N-terminal of beta-spectrin with a complementary region near the C-terminal of cr-spectrin (Speicher, D. W, Weglarz, L,, and DeSilva, T, M, (1992) J, Biol, Chem. 267, 14775-14782), Both spectrin subunits consist primarily of tandem, 106-residue long, homologous, triple-helical motifs, In this study, the minimal region of beta-spectrin required for association with rw-spectrin was determined using recombinant- peptides, The start site (phasing) for construction of dimerization competent beta-spectrin peptides was particularly critical. The beginning of the first homologous motif for both beta-spectrin and the related dimerization site of alpha-actinin is approximately 8 residues earlier than most spectrin motifs, A four-motif beta-spectrin peptide (beta 1-4(+)) with this earlier starting point bound to full-length alpha-spectrin with a K-d of about 10 nM, while deletion of these first 8 residues reduced binding nearly 10-fold, N- and C-terminal truncations of one or more motifs from beta 1-4(+) showed that the first motif was essential for dimerization since its deletion abolished binding, but beta 1(+) alone could not associate with alpha-monomers, The first two motifs (beta 1-2(+)) represented the minimum lateral dimer assembly site with a K-d of about 230 nM for interaction with full-length ar-spectrin or an cu-spectrin nucleation site recombinant peptide, alpha 18-21, Each additional motif increased the dimerization affinity by approximately 5-fold, In addition to this strong inter-subunit dimer association, interactions between the helices of a single triple-helical motif are frequently strong enough to maintain a noncovalent complex after internal protease cleavage similar to the interact-ions thought to be involved in tetramer formation, Analysis of hydrodynamic radii of recombinant peptides containing differing numbers of motifs showed that a single motif had a Stokes radius of 2.35 nm, while each additional motif added only 0.85 nm to the Stokes radius, This is the first direct demonstration that spectrin's flexibility arises from regions between each triple helical motif rather than from within the segment itself and suggests that current models of inter-motif connections may need to be revised.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute				Kotula, Leszek/0000-0002-7977-7124	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794, F32HL008840, R01HL033884] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33884, HL38794, HL08840] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1991, J CLIN INVEST, V87, P2169, DOI 10.1172/JCI115250; BARON MD, 1987, J BIOL CHEM, V262, P17623; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BLOCH R J, 1992, Trends in Cell Biology, V2, P186, DOI 10.1016/0962-8924(92)90231-B; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DIPAOLO BR, 1993, BLOOD, V82, P284, DOI 10.1182/blood.V82.1.284.bloodjournal821284; GARBARZ W, 1994, NATURE, V372, P620; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; PARQUET N, 1994, BLOOD, V84, P303; RANDON J, 1994, BRIT J HAEMATOL, V88, P534, DOI 10.1111/j.1365-2141.1994.tb05070.x; REIM DF, 1994, ANAL BIOCHEM, V216, P213, DOI 10.1006/abio.1994.1027; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEARS DE, 1986, BIOCHIM BIOPHYS ACTA, V870, P432, DOI 10.1016/0167-4838(86)90251-7; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WILMOTTE R, 1993, J CLIN INVEST, V91, P2091, DOI 10.1172/JCI116432; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YOSHINO H, 1991, J BIOCHEM, V110, P553, DOI 10.1093/oxfordjournals.jbchem.a123618; YOSHINO H, 1984, J BIOL CHEM, V259, P4496	42	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6636	6644		10.1074/jbc.271.12.6636	http://dx.doi.org/10.1074/jbc.271.12.6636			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636080	hybrid			2022-12-27	WOS:A1996UB15700015
J	Hu, ZX; Haghjoo, K; Jordan, F				Hu, ZX; Haghjoo, K; Jordan, F			Further evidence for the structure of the subtilisin propeptide and for its interactions with mature subtilisin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-AMYLOLIQUEFACIENS SUBTILISIN; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; PRO-SEQUENCE; DENATURED SUBTILISIN; SECONDARY-STRUCTURE; SECRETION; CHAPERONE; PROTEINS; BPN'	Evidence is presented for some secondary structure, very likely alpha-helical, of the propeptide of subtilisin E in aqueous salt solution, as well as for strong intermolecular interactions between the propeptide and the mature sequence both in the processed and unprocessed states (i.e. in prosubtilisin). Prosubtilisin is shown to exist as a dimer according to size exclusion high performance liquid chromatography under nondenaturing conditions; that dimer may be on the autoprocessing pathway. According to such a model, the prosequence of one prosubtilisin molecule is the template for the refolding of the mature sequence of the second, and, in turn, the hydrolytic process is intermolecular as well. Support for such an intermolecular folding model also includes potent slow binding inhibition of subtilisin by the propeptide, specific proteolysis of the propeptide by subtilisin, and evidence for intermolecular processing under a variety of conditions.	RUTGERS STATE UNIV,DEPT CHEM,NEWARK,NJ 07102	Rutgers State University Newark; Rutgers State University New Brunswick								Austin D J, 1994, Chem Biol, V1, P131, DOI 10.1016/1074-5521(94)90002-7; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BOTT R, 1988, J BIOL CHEM, V263, P7895; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; CASH P W, 1989, Peptide Research, V2, P292; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1989, PREDICTION PROTEIN S, P549; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; EGNELL P, 1992, MOL MICROBIOL, V6, P1115, DOI 10.1111/j.1365-2958.1992.tb01549.x; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAYASHI T, 1993, CHEM PHARM BULL, V41, P2063; HU Z, 1994, THESIS RUTGERS U NEW; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; IKAI A, 1976, BIOCHIM BIOPHYS ACTA, V445, P182, DOI 10.1016/0005-2744(76)90171-6; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JORDAN F, 1995, INTRAMOLECULAR CHAPE, P113; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; LLI Y, 1995, J BIOL CHEM, V270, P5127; MATSUBARA M, 1977, CHEM LETT TOKYO, P1783; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; OHTA Y, 1990, MOL MICROBIOL, V4, P275; Ottesen M., 1970, METHOD ENZYMOL, P199, DOI [10.1016/0076-6879(70)19014-8, DOI 10.1016/0076-6879(70)19014-8]; PARK SS, 1989, J BACTERIOL, V171, P2657, DOI 10.1128/jb.171.5.2657-2665.1989; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; Sambrook J, 1989, MOL CLONING LAB MANU, pE3; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; STAUFFER CE, 1971, BIOCHIM BIOPHYS ACTA, V251, P407, DOI 10.1016/0005-2795(71)90129-2; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; STRONGIN AY, 1978, J BACTERIOL, V133, P1401, DOI 10.1128/JB.133.3.1401-1411.1978; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WUTRICH K, 1986, NMR PROTEINS NUCLEIC, P17; ZHU X, 1990, THESIS RUTGERS U NEW; ZHU X, 1992, BIOCHEMISTRY-US, V11, P34; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	43	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3375	3384						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631936				2022-12-27	WOS:A1996TV72400010
J	Maeda, M; Aubry, L; Insall, R; Gaskins, C; Devreotes, PN; Firtel, RA				Maeda, M; Aubry, L; Insall, R; Gaskins, C; Devreotes, PN; Firtel, RA			Seven helix chemoattractant receptors transiently stimulate mitogen-activated protein kinase in Dictyostelium - Role of heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC-ANALYSIS; ADENYLYL CYCLASE; SUBUNIT	Mitogen-activated protein (MAP) kinases are involved in controlling a cell's responses to a variety of stimuli and can be activated by both protein tyrosine kinase and G protein-coupled receptors. It was shown previously that Dictyostelium MAP kinase ERK2 is required for normal activation of adenylyl cyclase and erk2 null cells are aggregation-deficient. In this manuscript, we show that the Dictyostelium MAP kinase ERK2 is rapidly and transiently activated in response to the chemoattractant cAMP. This response requires cAMP receptors, but is independent of the coupled G alpha 2 subunit and the only known G beta subunit. These data indicate that ligand-mediated receptor activation of adenylyl cyclase requires two receptor-dependent pathways, one of which requires heterotrimeric G proteins, including G alpha 2 and the only known G beta subunit, and the second of which requires ERK2. Our results suggest that ERK2 may be activated by a novel receptor-mediated pathway.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	University of California System; University of California San Diego; Johns Hopkins University			Insall, Robert/G-5611-2011	Insall, Robert/0000-0003-4898-040X; Aubry, Laurence/0000-0001-7640-1706	NIGMS NIH HHS [GM37830, GM28007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037830, R37GM028007, R01GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANHAASTERT PJM, 1992, ADENINE NUCLEOTIDES, P379; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUBITT AB, 1992, COLD SPRING HARB SYM, V57, P177, DOI 10.1101/SQB.1992.057.01.023; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; GASKINS C, 1994, MOL CELL BIOL, V14, P6996, DOI 10.1128/MCB.14.10.6996; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARLOW E, 1988, ANTIBODIES LABORATOR; HERELD D, 1992, INT REV CYTOL, V137B, P35; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MILNE JLS, 1995, J BIOL CHEM, V270, P5926, DOI 10.1074/jbc.270.11.5926; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; SCHNITZLER GR, 1995, CELL, V81, P737, DOI 10.1016/0092-8674(95)90535-9; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; SUN TJ, 1990, J CELL BIOL, V110, P1549, DOI 10.1083/jcb.110.5.1549; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	44	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3351	3354						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631932				2022-12-27	WOS:A1996TV72400006
J	Blanchoin, L; Didry, D; Carlier, MF; Pantaloni, D				Blanchoin, L; Didry, D; Carlier, MF; Pantaloni, D			Kinetics of association of myosin subfragment-1 to unlabeled and pyrenyl-labeled actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; TROPONIN-TROPOMYOSIN; HEAVY-MEROMYOSIN; BINDING; COMPLEX; ABSENCE; POLYMERIZATION; CONTRACTION; INTERACTS	The kinetics of reaction of myosin subfragment-1 (S-1) with F-actin have been monitored by the changes in light scattering and in pyrenyl-actin fluorescence at 20 degrees C, pH 7.5, and physiological ionic strength. The association rate constant of S-1 to F-actin decreases about 10-fold as the molar ratio of bound S-1 increases from 0 to 1. This decrease in k(+) is most likely due to the steric hindrance of available binding sites by initially bound S-1. The apparent rate constant for association of S-1 to bare filaments is 9 mu M(-1) s(-1), a value 1 order of magnitude higher than the one previously estimated from experiments in which S-1 was in excess over F-actin. The anticooperative binding kinetics of S-1 to F-actin are consistent with the negative cooperativity displayed in the equilibrium binding curves of S-1 to pyrenyl-F-actin. Fluorescence titration curves of partially labeled pyrenyl-F-actin by S-1 are sigmoidal, consistent with a 4-fold higher affinity of S-1 for unlabeled than for labeled actin. This conclusion is strengthened by kinetic data of S-1 binding to partially labeled F-actin, which exhibit a biphasic behavior due to the slower dissociation of S-1 from unlabeled than from labeled actin.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ANDREEV OA, 1992, J MUSCLE RES CELL M, V13, P523, DOI 10.1007/BF01737995; ANDREEV OA, 1993, BIOPHYS J, V65, P1027, DOI 10.1016/S0006-3495(93)81161-5; ANDREEV OA, 1993, BIOCHEMISTRY-US, V32, P12046, DOI 10.1021/bi00096a015; ARATA T, 1991, J BIOCHEM-TOKYO, V109, P335; BLANCHOIN L, 1995, J BIOL CHEM, V270, P7125, DOI 10.1074/jbc.270.13.7125; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P861; CARLIER MF, 1994, J BIOL CHEM, V269, P3829; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; FINLAYSON B, 1969, BIOCHEMISTRY-US, V8, P811, DOI 10.1021/bi00831a008; GEEVES MA, 1982, FEBS LETT, V140, P11, DOI 10.1016/0014-5793(82)80509-7; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GREENE LE, 1982, FEBS LETT, V139, P233, DOI 10.1016/0014-5793(82)80859-4; INOUE A, 1972, J BIOCHEM-TOKYO, V74, P923; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KNIGHT P, 1980, BIOCHEMISTRY-US, V19, P4682, DOI 10.1021/bi00561a022; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MIKI M, 1976, FEBS LETT, V66, P98, DOI 10.1016/0014-5793(76)80594-7; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MORNET D, 1981, BIOCHEMISTRY-US, V20, P2110, DOI 10.1021/bi00511a007; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAWADA K, 1969, BIOCHIM BIOPHYS ACTA, V172, P311, DOI 10.1016/0005-2728(69)90073-5; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TESI C, 1990, BIOCHEMISTRY-US, V29, P1846, DOI 10.1021/bi00459a026; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; VIBERT P, 1982, J MOL BIOL, V157, P299, DOI 10.1016/0022-2836(82)90236-4; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; YAMAMOTO K, 1990, BIOCHEMISTRY-US, V29, P844, DOI 10.1021/bi00455a035; YASUI M, 1984, J BIOCHEM-TOKYO, V96, P1673, DOI 10.1093/oxfordjournals.jbchem.a134999; YOUNG M, 1967, P NATL ACAD SCI USA, V58, P2393, DOI 10.1073/pnas.58.6.2393	39	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12380	12386		10.1074/jbc.271.21.12380	http://dx.doi.org/10.1074/jbc.271.21.12380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647841	hybrid			2022-12-27	WOS:A1996UL66000043
J	Banyai, L; Tordai, H; Patthy, L				Banyai, L; Tordai, H; Patthy, L			Structure and domain-domain interactions of the gelatin-binding site of human 72-kiiodalton type IV collagenase (gelatinase A, matrix metalloproteinase 2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE SEMINAL PLASMA; SECONDARY-STRUCTURE; GROWTH-FACTOR; PROTEIN; FIBRONECTIN; PDC-109; METASTASIS; ACTIVATION; INVASION	We have shown previously that all three fibronectin type II modules of gelatinase A contribute to its gelatin affinity. In the present investigation we have studied the structure and module-module interactions of this gelatin-binding domain by circular dichroism spectroscopy and differential scanning calorimetry. Comparison of the T-m values of the thermal transitions of isolated type II modules with those of bimodular or trimodular proteins has shown that the second type II module is significantly more stable in the trimodular protein coll 123 (T-m = 54 degrees C) than in the single-module protein coll 2 (T-m = 44 degrees C) or in the bimodular proteins coll 23 (T-m = 47 degrees C) and coll 12 (T-m = 48 degrees C). Analysis of the enthalpy changes associated with thermal unfolding of the second type II module suggests that it is stabilized by domain-domain interactions in coll 123. We propose that intimate contacts exist between the three tandem type II units and they form a single gelatin-binding site. Based on the three-dimensional structures of homologous metalloproteases and type II modules, a model is proposed in which the three type II units form an extension of the substrate binding cleft of gelatinase A.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST ENZYMOL,H-1518 BUDAPEST,HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences			Patthy, Laszlo/A-2353-2013; Patthy, Laszlo/Q-6058-2019	Tordai, Hedvig/0000-0002-0875-5569				ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BORKAKOTI N, 1994, STRUCT BIOL, V1, P106; CASTELLINO FJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P312, DOI 10.1016/0003-9861(86)90589-8; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOOLEY PR, 1994, STRUCT BIOL, V1, P111; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STAMS T, 1994, STRUCT BIOL, V1, P119; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STOCKER W, 1965, CURR OPIN STRUC BIOL, V5, P383; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026	45	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12003	12008		10.1074/jbc.271.20.12003	http://dx.doi.org/10.1074/jbc.271.20.12003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662603	hybrid			2022-12-27	WOS:A1996UL25000064
J	Doring, F; Degtiar, VE; Grabner, M; Striessnig, J; Hering, S; Glossmann, H				Doring, F; Degtiar, VE; Grabner, M; Striessnig, J; Hering, S; Glossmann, H			Transfer of L-type calcium channel IVS6 segment increases phenylalkylamine sensitivity of alpha(1A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; MESSENGER-RNAS; RECEPTOR; D600; MECHANISM; BLOCKERS; SUBUNIT; HEART; CELLS	Conditioned (''use-dependent'') inhibition by phenylalkylamines (PAAs) is a characteristic property of L-type calcium (Ca2+) channels. To determine the structural elements of the PAA binding domain we transferred sequence stretches of the pore-forming regions of repeat III and/or IV from the skeletal muscle alpha(1) subunit (alpha(1S)) to the class A alpha(1) subunit (alpha(1A)) and expressed these chimeras together with beta(1a) and alpha(2)/delta subunits in Xenopus oocytes. The corresponding barium currents (I-Ba) were tested for PAA sensitivity during trains of depolarizing test pulses (conditioned block). I-Ba of oocytes expressing the alpha(1A) subunit were only weakly inhibited by PAAs (less than 10% conditioned block of I-Ba during a 100-ms pulse train of 0.1 Hz). Transfer of the transmembrane segment IVS6 from alpha(1S) to alpha(1A) produced an enhancement of PAA sensitivity of the resulting alpha(1A)/alpha(1S) chimera comparable to L-type alpha(1) subunits (about 35% conditioned block of I-Ba during a 100-ms pulse train of 0.1 Hz). Our results demonstrate that substitution of 11 amino acids within the segment IVS6 of alpha(1A) with the corresponding residues of alpha(1S) is sufficient to transfer L-type PAA sensitivity into the low sensitive class A Ca2+ channel.	INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA				Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266; Doring, Frank/0000-0003-1017-1498				Bezprozvanny Ilya, 1995, Biophysical Journal, V68, pA260; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GOLL A, 1986, N-S ARCH PHARMACOL, V334, P303, DOI 10.1007/BF00508786; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HERING S, 1989, CIRC RES, V64, P928, DOI 10.1161/01.RES.64.5.928; HERING S, 1993, METHOD PHARMACOL, V7, P189; Hille B., 1992, IONIC CHANNELS EXCIT; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	34	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11745	11749		10.1074/jbc.271.20.11745	http://dx.doi.org/10.1074/jbc.271.20.11745			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662622	hybrid			2022-12-27	WOS:A1996UL25000027
J	Pillinger, MH; Feoktistov, AS; Capodici, C; Solitar, B; Levy, J; Oei, TT; Philips, MR				Pillinger, MH; Feoktistov, AS; Capodici, C; Solitar, B; Levy, J; Oei, TT; Philips, MR			Mitogen-activated protein kinase in neutrophils and enucleate neutrophil cytoplasts - Evidence for regulation of cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; MAP KINASE; POLYMORPHONUCLEAR LEUKOCYTES; TYROSINE PHOSPHORYLATION; RECEPTOR; GRB2; RAS; INSULIN; GRANULOCYTES; INHIBITION	We employed neutrophils and enucleate neutrophil cytoplasts to study the activation of the mitogen-activated protein kinases (MAPKs) p44(erk1) and p42(erk2) in neutrophils by inflammatory agonists that engage G protein-linked receptors. Formyl-methionyl-leucyl-phenylalanine (FMLP) rapidly and transiently activated MAPK in neutrophils and cytoplasts, consistent with a role in signaling for neutrophil functions. FMLP stimulated p21(ras) activation in neutrophils and Raf-1 translocation from cytosol to plasma membrane in cytoplasts, with kinetics consistent with events upstream of MAPK activation. Insulin, a protein tyrosine kinase receptor (PTKR) agonist, stimulated neutrophil MAPK activation, demonstrating an intact system of PTKR signaling in these post-mitotic cells. FMLP- and insulin-stimulated MAPK activation in cytoplasts were inhibited by Bt(2)cAMP, consistent with signaling through Raf-1 and suggesting a mechanism for cAMP inhibition of neutrophil function. However, Bt(2)cAMP had no effect on FMLP-stimulated MAPK activation in neutrophils. The extent of MAPK activation by various chemoattractants correlated with their capacity to stimulate neutrophil and cytoplast homotypic aggregation. Consistent with its effects on MAPK, Bt(2)cAMP inhibited FMLP-stimulated aggregation in cytoplasts but not neutrophils. Insulin had no independent effect but primed neutrophils for aggregation in response to FMLP. Our studies support a p21(ras)-, Raf-1-dependent pathway for MAPK activation in neutrophils and suggest that neutrophil adhesion may be regulated, in part, by MAPK.			Pillinger, MH (corresponding author), NYU,MED CTR,DIV RHEUMATOL NB16N1,SCH MED,DEPT MED,550 1ST AVE,NEW YORK,NY 10016, USA.			Mark, Philips/0000-0002-1179-8156; Pillinger, Michael/0000-0003-3168-1542	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011949, R37AR011949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19721-19] Funding Source: Medline; NIAID NIH HHS [AI36244] Funding Source: Medline; NIAMS NIH HHS [AR11949-28] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAVALOT F, 1992, HORM METAB RES, V24, P225, DOI 10.1055/s-2007-1003298; CAVALOT F, 1993, HORM METAB RES, V25, P321, DOI 10.1055/s-2007-1002109; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; ERVENS J, 1991, BIOCHEM SOC T, V19, P59, DOI 10.1042/bst0190059; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FUSSGANGER RD, 1976, J BIOL CHEM, V251, P2761; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719	44	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12049	12056		10.1074/jbc.271.20.12049	http://dx.doi.org/10.1074/jbc.271.20.12049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662646	hybrid			2022-12-27	WOS:A1996UL25000070
J	Whalen, SG; Gingras, AC; Amankwa, L; Mader, S; Branton, PE; Aebersold, R; Sonenberg, N				Whalen, SG; Gingras, AC; Amankwa, L; Mader, S; Branton, PE; Aebersold, R; Sonenberg, N			Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4F; PHASE SEQUENCE-ANALYSIS; CAP-BINDING-PROTEIN; PHORBOL ESTERS; GROWTH-FACTOR; FACTOR 4E; LEVEL; SITE; TRANSFORMATION; PICOMOLE	Translation initiation in eukaryotes is facilitated by the mRNA 5' cap structure (m(7)GpppX, where X is any nucleotide) that binds the multisubunit initiation factor eIF4F through one of its subunits, eIF4E. eIF4E is a phosphoprotein whose phosphorylation state positively correlates with cell growth. Protein kinase C phosphorylates eIF4E in vitro, and possibly in vivo. Using recombinant eIF4E incubated in vitro with purified protein kinase C and analyzed by solid-phase phosphopeptide sequencing in combination with high performance liquid chromatography coupled to mass spectrometry, we demonstrated that the third amino acid of the peptide SGSTTK (Ser(209)) is the major site of phosphorylation. This finding is consistent with the newly assigned in vivo phosphorylation site of eIF4E (Joshi, B., Cai, A L., Keiper, B. D., Minich, W. B., Mendez, R., Beach, C. M., Stepinski, J., Stolarski, R., Darzynkiewicz, E., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 14597-14603). A S209A mutation resulted in dramatically reduced phosphorylation, both in vitro and in vivo. Furthermore, the mutant protein was phosphorylated on threonine (most probably threonine 210) in vivo. Here we show that in the presence of the recently characterized translational repressors 4E-BP1 or 4E-BP2, phosphorylation of eIF4E by protein kinase C is strongly reduced. This suggests a two-step model for the phosphorylation (and activation) of eIF4E by growth factors and hormones: first, dissociation of eIF4E from 4E-BPs, followed by eIF4E phosphorylation.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, MONTREAL, PQ H3G 1Y6, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6R 1Z3, CANADA; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA	McGill University; McGill University; University of British Columbia; University of Washington; University of Washington Seattle			Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				AEBERSOLD R, 1991, ANAL BIOCHEM, V199, P51, DOI 10.1016/0003-2697(91)90268-X; AEBERSOLD R, 1990, ANAL BIOCHEM, V187, P56, DOI 10.1016/0003-2697(90)90417-8; AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BU X, 1993, J BIOL CHEM, V268, P4975; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Frederickson R M, 1992, Semin Cell Biol, V3, P107; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GINGRAS AC, 1996, IN PRESS P NATL ACAD; GRAFF JR, 1995, INT J CANCER, V60, P255; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1991, NEW BIOL, V3, P601; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; VONMONTEUFFEL S, 1996, IN PRESS P NATL ACAD; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186	45	81	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11831	11837		10.1074/jbc.271.20.11831	http://dx.doi.org/10.1074/jbc.271.20.11831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662663	hybrid			2022-12-27	WOS:A1996UL25000041
J	Xu, X; Zeng, WZ; Muallem, S				Xu, X; Zeng, WZ; Muallem, S			Regulation of the inositol 1,4,5-trisphosphate-activated Ca2+ channel by activation of G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PANCREATIC ACINAR-CELLS; CALCIUM RELEASE; ENDOPLASMIC-RETICULUM; ADENINE-NUCLEOTIDES; LUMINAL CA2+; RECEPTOR; STORES; TRISPHOSPHATE; KINASE	Streptolysin O-permeable pancreatic acini were used to study the regulation of the inositol 1,4,5-trisphosphate (IP3)-activated Ca2+ channel (IPACC) by agonists and antagonists, Measurements of the apparent affinity for IP3 (KappIP3) showed that the IPACC is dynamically controlled during cell stimulation and inhibition, i.e. agonists decreased and antagonists increased KappIP3. KappIP3 was also independently regulated by thimerosal, Ca2+ content of the stores, the incubation temperature, activation of protein kinases, and inhibition of protein phosphatases, but none of these mechanisms contributed to the regulation by agonists and antagonists, Incubating the cells with low concentration of GTP gamma S or AlF3 reproduced the effect of the agonist on KappIP3. Moreover, low [GTP gamma S] allowed activation of the IPACC by agonists at basal levels of IP3 and markedly impaired channel inactivation by antagonists, Channel sensitization by GTP gamma S also restored the ability of thimerosal to mobilize Ca2+ from internal stores with no change in cellular IP3 levels, The combination of low [GTP gamma S] and thimerosal locked the channel in an open, antagonist-insensitive state. All modulatory effects of GTP gamma S are independent of phospholipase C activation and IP3 production. We propose that the dynamic regulation of the IPACC by a G protein-dependent mechanism can play a major role in triggering and maintaining Ca2+ oscillations at low agonist concentrations when minimal or no changes in IP3 level take place.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38938, DK 46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABICH M, 1991, ENDOCRINOLOGY, V129, P1463, DOI 10.1210/endo-129-3-1463; BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1995, J BIOL CHEM, V270, P3588, DOI 10.1074/jbc.270.8.3588; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; LYNCH CJ, 1985, J BIOL CHEM, V260, P1593; MANGER JP, 1989, J BIOL CHEM, V264, P8821; Martell A. E., 1976, CRITICAL STABILITY C, V3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; NUNN DL, 1992, MOL PHARMACOL, V41, P115; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PARYS JB, 1993, J BIOL CHEM, V268, P25206; PINES M, 1995, IN PRESS J BONE MINE; PITTET D, 1989, J BIOL CHEM, V264, P18489; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; TARVER AP, 1987, J BIOL CHEM, V262, P17268; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHANG BX, 1994, J BIOL CHEM, V269, P17132; ZHAO H, 1990, J BIOL CHEM, V265, P14822	45	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11737	11744		10.1074/jbc.271.20.11737	http://dx.doi.org/10.1074/jbc.271.20.11737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662624	hybrid			2022-12-27	WOS:A1996UL25000026
J	Hess, JF; Casselman, JT; FitzGerald, PG				Hess, JF; Casselman, JT; FitzGerald, PG			Gene structure and cDNA sequence identify the beaded filament protein CP49 as a highly divergent type I intermediate filament protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS FIBER CELL; AMINO-ACID SEQUENCE; CHICK LENS; CYTOSKELETAL PROTEIN; PLASMA-MEMBRANE; ALPHA-CRYSTALLIN; SKIN DISEASES; BOVINE LENS; KERATIN; FILENSIN	The fiber cell of the vertebrate ocular lens assembles a cytoskeletal structure, the beaded filament, which contains two proteins unique to the fiber cell: CP49 (phakinin) and CP115/CP95 (filensin). We report here the complete primary sequence and gene structure for human CP49, These data show that CP49 is a member of the intermediate filament family, but highly unusual in several regards. 1) CP49 primary sequence does not permit unambiguous assignment to any existing class of intermediate filament protein, but exhibits a gene structure that is identical to the Type I cytokeratins. 2) CP49 essentially lacks one of the three major domains that characterize all intermediate filament proteins, the carboxyl terminal tail domain. 3) CP49 shows substitutions at 3 of 4 residues in the otherwise highly conserved intermediate filament protein motif LNDR. Notably, this divergence includes an Arg to Cys substitution that has only been observed in the mutant human cytokeratin K14, a mutation shown to cause the skin blistering seen in the genetic disorder Dowling-Meara epidermolysis bullosa simplex.	UNIV CALIF DAVIS,SCH MED,DEPT CELL BIOL & HUMAN ANAT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL EYE INSTITUTE [R01EY008747] Funding Source: NIH RePORTER; NEI NIH HHS [EY08747] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BLOEMENDAL H, 1984, CIBA F SYMP, V106, P177; BLOEMENDAL H, 1982, EXP EYE RES, V35, P61, DOI 10.1016/S0014-4835(82)80023-7; BRADLEY RH, 1979, EXP EYE RES, V28, P441, DOI 10.1016/0014-4835(79)90119-2; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; ELLIS M, 1984, EXP EYE RES, V38, P195, DOI 10.1016/0014-4835(84)90103-9; FITZGERALD PG, 1989, CURR EYE RES, V8, P801, DOI 10.3109/02713688909000870; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; FITZGERALD PG, 1988, CURR EYE RES, V7, P1243, DOI 10.3109/02713688809033228; FITZGERALD PG, 1990, CURR EYE RES, V9, P1083, DOI 10.3109/02713689008997582; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1983, CELL, V34, P332, DOI 10.1016/0092-8674(83)90367-7; FUCHS E, 1991, BIOCHEM SOC T, V19, P1112, DOI 10.1042/bst0191112; FUCHS E, 1994, J INVEST DERMATOL, V103, pS25, DOI 10.1111/1523-1747.ep12398924; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GOUMARI F, 1993, J CELL BIOL, V121, P847; HESS JF, 1993, CURR EYE RES, V12, P77, DOI 10.3109/02713689308999499; HESS JF, 1995, CURR EYE RES, V14, P11, DOI 10.3109/02713689508999909; IFEANYI F, 1990, CURR EYE RES, V9, P259, DOI 10.3109/02713689009044521; Ireland M, 1989, Lens Eye Toxic Res, V6, P623; IRELAND M, 1983, EXP EYE RES, V36, P531, DOI 10.1016/0014-4835(83)90046-5; IRELAND M, 1984, EXP EYE RES, V38, P637, DOI 10.1016/0014-4835(84)90182-9; KIBBELAAR MA, 1979, EUR J BIOCHEM, V95, P543, DOI 10.1111/j.1432-1033.1979.tb12995.x; KRIEG TM, 1985, J BIOL CHEM, V260, P5867; MAISEL H, 1984, CURR EYE RES, V3, P369, DOI 10.3109/02713688408997222; MAISEL H, 1977, EXPERIENTIA, V33, P525, DOI 10.1007/BF01922252; MAISEL H, 1972, EXP EYE RES, V14, P7, DOI 10.1016/0014-4835(72)90136-4; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MASAKI S, 1992, BIOCHEM BIOPH RES CO, V186, P190, DOI 10.1016/S0006-291X(05)80792-2; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MERDES A, 1993, J CELL BIOL, V123, P1507, DOI 10.1083/jcb.123.6.1507; ORII H, 1993, CURR EYE RES, V12, P583, DOI 10.3109/02713689309001836; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; RAFFERTY NS, 1974, J ULTRA MOL STRUCT R, V46, P239, DOI 10.1016/S0022-5320(74)80059-6; RAMAEKERS FCS, 1980, EXP CELL RES, V127, P309, DOI 10.1016/0014-4827(80)90437-1; REIGER M, 1988, J MOL BIOL, V204, P841; REMINGTON SG, 1993, J CELL SCI, V105, P1057; Sambrook J., 2002, MOL CLONING LAB MANU; SANDILANDS A, 1995, J CELL SCI, V108, P1397; SAUK JJ, 1984, J CELL BIOL, V99, P1590, DOI 10.1083/jcb.99.5.1590; SAWADA K, 1995, CURR EYE RES, V14, P545, DOI 10.3109/02713689508998401; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; Stewart M, 1990, CURR OPIN CELL BIOL, V2, P91, DOI 10.1016/S0955-0674(05)80037-7; WEBER K, 1991, BIOCHEM SOC T, V19, P1021, DOI 10.1042/bst0191021; WEBER K, 1985, ANN NY ACAD SCI, V455, P126, DOI 10.1111/j.1749-6632.1985.tb50408.x	54	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6729	6735		10.1074/jbc.271.12.6729	http://dx.doi.org/10.1074/jbc.271.12.6729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636093	hybrid			2022-12-27	WOS:A1996UB15700028
J	Iobst, ST; Drickamer, K				Iobst, ST; Drickamer, K			Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE N-ACETYLGALACTOSAMINE; MOLECULAR-CLONING; LECTIN; EXPRESSION; GLYCOSIDES; SEQUENCE; PROTEINS; SITE; DNA	Asialoglycoprotein receptors on the surfaces of both hepatocytes and peritoneal macrophages bind terminal galactose residues of desialylated glycoproteins and mediate endocytosis and eventual degradation of these ligands. The hepatic receptor binds oligosaccharides with terminal N-acetylgalactosamine residues more tightly than ligands with terminal galactose residues, but the macrophage receptor shows no such differential binding affinity. Carbohydrate recognition domains from the macrophage receptor and the major subunit of the hepatic receptor have been expressed in a bacterial system and have been shown to retain the distinct binding selectivities of the receptors from which they derive. Binding of a series of N-acyl derivatives of galactosamine suggests that the a-substituent of these sugars interacts with the surface of the hepatic receptor with highest affinity binding observed for the N-propionyl derivative. Chimeric sugar-binding domains have been used to identify three regions of the hepatic receptor that are essential for establishing selectivity for N-acetylgalactosamine over galactose, Based on these results and the orientation of N-acetylgalactosamine when bound to an homologous galactose-binding mutant of rat serum mannose-binding protein, a fourth region likely to interact with N-acetylgalactosamine has been identified and probed by site-directed mutagenesis. The results of these studies define a binding pocket for the 2-substituent of N-acetylgalactosamine in the hepatic asialoglycoprotein receptor.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HORTON D, 1966, BIOCH PREP, V11, P1; II M, 1990, J BIOL CHEM, V265, P11295; IMAI Y, 1994, J IMMUNOL METHODS, V171, P23, DOI 10.1016/0022-1759(94)90224-0; IOBST ST, 1994, J BIOL CHEM, V269, P15512; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1982, BIOCHEMISTRY-US, V21, P1045, DOI 10.1021/bi00534a034; Maniatis T., 1982, MOL CLONING; NEUBERGER A, 1971, CARBOHYD RES, V17, P89, DOI 10.1016/S0008-6215(00)81545-1; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR M, 1979, J BIOL CHEM, V254, P3170; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P10008; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEIS WI, 1991, J BIOL CHEM, V266, P20678	25	67	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6686	6693		10.1074/jbc.271.12.6686	http://dx.doi.org/10.1074/jbc.271.12.6686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636087	hybrid			2022-12-27	WOS:A1996UB15700022
J	Kitazume, S; Kitajima, K; Inoue, S; Haslam, SM; Morris, HR; Dell, A; Lennarz, WJ; Inoue, Y				Kitazume, S; Kitajima, K; Inoue, S; Haslam, SM; Morris, HR; Dell, A; Lennarz, WJ; Inoue, Y			The occurrence of novel 9-O-sulfated N-glycolylneuraminic acid-capped alpha 2->5-O-glycolyl-linked oligo/polyNeu5Gc chains in sea urchin egg cell surface glycoprotein - Identification of a new chain termination signal for polysialyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAINBOW-TROUT EGGS; ADHESION MOLECULE; POLYSIALIC ACID; CARBOHYDRATE UNITS; POLY(SIALIC ACID); MASS-SPECTROMETRY; PLASMA-MEMBRANE; SPERM; PURIFICATION; RECEPTOR	We report the isolation and structural characterization of an oligo/polysialic acid-containing glycopeptide fraction (designated ESP-Sia) prepared from the egg cell surface complex of the sea urchin, Hemicentrotus pulcherrimus, by exhaustive pronase treatment, The carbohydrate chains isolated from ESP-Sia were shown 60 consist of O-linked oligo/polysialic acid-containing glycan units and N-linked carbohydrate chains. The present studies have revealed that the O-linked oligo/polysialic acid-containing glycan chains derived from the ESP-Sia were similar to those present in egg jelly coat polysialylated glycoprotein in being composed of tandem repeats of N-glycolylneuraminic acid (Neu5Gc) glycosidically Linked in a novel fashion through the glycolyl group, (-->5-O(glycolyl)Neu5Gc alpha 2-->)(n). However, they differ from the egg jelly coat in two key respects. First, the average degree of polymerization of the oligo/polysialic acid chains of ESP-Sia is only 3; a value far lower than that found in the jelly coat glycoprotein (average degree of polymerization was about 20). Second, ESP-Sia is uniquely characterized by the presence of 9-O-sulfated N-glycolylneuraminic acid (Neu5Gc9HSO(3)) residues at the nonreducing termini of the (-->5-(Oglycolyl)Neu5Gc alpha 2-->)(n) chains. The terminal sialyl residues in the Neu5Gc9HSO(3) alpha 2-->(-->5-(Oglycolyl)Neu5Gc alpha 2-->)(n) chain s were totally resistant to exosialidases. The discovery of Neu5Gc9HSO(3), as the nonreducing terminal residue of oligo/poly(-->5-O(glycolyl)Neu5Gc alpha 2-->)(n) group is especially noteworthy in that Neu5Gc9HSO(3) appears to be of limited distribution among glycoconjugates. Following the earlier discovery of oligo/polysialic acid chains capped with KDN, i.e. KDN alpha 2-->(-->8Neu5Gc alpha 2-->)(n), found in rainbow trout egg polysialoglycoproteins, it now appears that the sulfated Neu5Gc can serve a similar capping function.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Tokyo; Showa University; Imperial College London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM33184, GM33185] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184, R37GM033185, R01GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; DETERING NK, 1977, J CELL BIOL, V75, P899, DOI 10.1083/jcb.75.3.899; DHUME ST, 1995, GLYCOBIOLOGY, V5, P11, DOI 10.1093/glycob/5.1.11; DUBOIS M, 1956, ANAL CHEM, V135, P243; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FOLTZ KR, 1990, J CELL BIOL, V111, P2951, DOI 10.1083/jcb.111.6.2951; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; GROGAN T, 1994, LAB INVEST, V70, pA110; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P4851; IJUIN T, 1996, IN PRESS GLYCOCONJUG, V13; INOUE S, 1986, J BIOL CHEM, V261, P5256; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; INOUE Y, 1993, POLYSIALIC ACID MICR, P171; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; JAQUES LW, 1980, CARBOHYD RES, V83, P21, DOI 10.1016/S0008-6215(00)85360-4; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; KINSEY WH, 1981, J CELL BIOL, V91, P325, DOI 10.1083/jcb.91.2.325; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KITAZUME S, 1994, BIOCHEM BIOPH RES CO, V205, P893, DOI 10.1006/bbrc.1994.2748; KOCHETKOV NK, 1976, BIOCHIM BIOPHYS ACTA, V424, P274, DOI 10.1016/0005-2760(76)90195-8; KUBO H, 1990, J BIOCHEM-TOKYO, V108, P185, DOI 10.1093/oxfordjournals.jbchem.a123179; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; RUIZBRAVO N, 1986, DEV BIOL, V118, P202, DOI 10.1016/0012-1606(86)90088-6; SATO C, 1993, J BIOL CHEM, V268, P23675; SCOTT AA, 1994, J ACAD PATHOL, V70, pA120; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SHIMAMURA M, 1983, BIOCHEMISTRY-US, V22, P959, DOI 10.1021/bi00273a039; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; SUZUKI S, 1960, J BIOL CHEM, V235, P2768; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; ZUBER C, 1992, J BIOL CHEM, V267, P9965	45	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6694	6701		10.1074/jbc.271.12.6694	http://dx.doi.org/10.1074/jbc.271.12.6694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636088	hybrid			2022-12-27	WOS:A1996UB15700023
J	Morein, S; Andersson, AS; Rilfors, L; Lindblom, G				Morein, S; Andersson, AS; Rilfors, L; Lindblom, G			Wild-type Escherichia coli cells regulate the membrane lipid composition in a ''window'' between gel and non-lamellar structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; POLYMORPHIC PHASE-BEHAVIOR; P-31 NMR; ACHOLEPLASMA-LAIDLAWII; ETHER LIPIDS; FATTY-ACIDS; CLOSTRIDIUM-BUTYRICUM; LIQUID-CRYSTALLINE; NONLAMELLAR PHASES; BILAYER STABILITY	Escherichia coli strain K12 was grown at 17, 27, and 37 degrees C. The acyl chain composition of the membrane lipids varied with the growth temperature; the fraction of cis-vaccenoyl chains decreased, and the fraction of palmitoyl chains increased, when the growth temperature was increased. However, the polar head group composition did not change significantly, The equilibria between lamellar and reversed non-lamellar phases of lipids extracted from the inner membrane (IM), and from both the membranes (IOM), were studied with NMR and x-ray diffraction, At temperatures above the growth temperature the lipid extracts formed a reversed hexagonal phase, or a bicontinuous cubic phase, depending on the degree of hydration of the lipids, It was observed that: 1) at equal elevations above the growth temperature, IM lipid extracts, as well as IOM lipid extracts, have a nearly equal ability to form non-lamellar phases; 2) IM extracts have a stronger tendency than IOM extracts to form non lamellar phases; 3) non-lamellar phases are formed under conditions that are relatively close to the physiological ones; the membrane lipid monolayers are thus ''frustrated''; and 4) as a consequence of the change of the acyl chain structures, the temperature for the lamellar gel to liquid crystalline phase transition is changed simultaneously, and in the same direction, as the temperature for the lamellar to non-lamellar phase transition. With a too large fraction of saturated acyl chains the membrane lipids enter a gel state, and with a too large fraction of unsaturated acyl chains the lipids transform to non-lamellar phases, It is thus concluded that the regulation of the acyl chain composition in wild-type cells of E. coli is necessary for the organism to be able to grow in a ''window'' between a lamellar gel phase and reversed non-lamellar phases.	UMEA UNIV, DEPT PHYS CHEM, S-90187 UMEA, SWEDEN	Umea University								AIBARA S, 1972, BIOCHIM BIOPHYS ACTA, V270, P301; [Anonymous], 1992, INTERMOLECULAR SURFA; Ansell G.V., 1973, FORM FUNCTION PHOSPH; BARTON PG, 1975, J BIOL CHEM, V250, P4470; BRENTEL I, 1987, BIOCHIM BIOPHYS ACTA, V904, P401, DOI 10.1016/0005-2736(87)90390-7; BURNELL E, 1980, BIOCHIM BIOPHYS ACTA, V597, P492, DOI 10.1016/0005-2736(80)90222-9; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CRONAN JE, 1994, J BACTERIOL, V176, P3069, DOI 10.1128/JB.176.10.3069-3071.1994; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P31; CULLIS PR, 1976, BIOCHIM BIOPHYS ACTA, V436, P523, DOI 10.1016/0005-2736(76)90438-7; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAVIS MTB, 1974, BIOCHIM BIOPHYS ACTA, V373, P224, DOI 10.1016/0005-2736(74)90147-3; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3; ERIKSSON PO, 1985, CHEM PHYS LIPIDS, V37, P357, DOI 10.1016/0009-3084(85)90089-1; FABRIE CHJP, 1994, CHEM PHYS LIPIDS, V70, P133, DOI 10.1016/0009-3084(94)90081-7; GOLDFINE H, 1987, BIOCHEMISTRY-US, V26, P2814, DOI 10.1021/bi00384a024; GOLDFINE H, 1982, CURR TOP MEMBR TRANS, V17, P1; GOLDFINE H, 1987, BIOCHIM BIOPHYS ACTA, V904, P283, DOI 10.1016/0005-2736(87)90377-4; GRUNER SM, 1988, BIOCHEMISTRY-US, V27, P2853, DOI 10.1021/bi00408a029; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; GULIK A, 1985, J MOL BIOL, V182, P131, DOI 10.1016/0022-2836(85)90032-4; HAUKSSON JB, 1994, BBA-LIPID LIPID MET, V1214, P124, DOI 10.1016/0005-2760(94)90035-3; HAUKSSON JB, 1995, BBA-LIPID LIPID MET, V1258, P1, DOI 10.1016/0005-2760(95)00074-M; HAUKSSON JB, 1994, BBA-LIPID LIPID MET, V1215, P341, DOI 10.1016/0005-2760(94)90063-9; HAZEL JR, 1990, PROG LIPID RES, V29, P167, DOI 10.1016/0163-7827(90)90002-3; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; IANZINI F, 1990, ARCH BIOCHEM BIOPHYS, V278, P1, DOI 10.1016/0003-9861(90)90223-L; ISHINAGA M, 1979, J BIOCHEM-TOKYO, V86, P161; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; JACKSON MB, 1978, BIOCHIM BIOPHYS ACTA, V512, P472, DOI 10.1016/0005-2736(78)90157-8; JOHNSTON NC, 1988, BIOCHIM BIOPHYS ACTA, V961, P1, DOI 10.1016/0005-2760(88)90124-5; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1105, P253, DOI 10.1016/0005-2736(92)90202-W; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; KOYNOVA R, 1994, CHEM PHYS LIPIDS, V69, P1, DOI 10.1016/0009-3084(94)90024-8; LEWIS RNAH, 1989, BIOCHEMISTRY-US, V28, P541, DOI 10.1021/bi00428a020; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LINDBLOM G, 1994, PROG NUCL MAG RES SP, V26, P483, DOI 10.1016/0079-6565(94)80014-6; LINDBLOM G, 1992, ADV COLLOID INTERFAC, V41, P101, DOI 10.1016/0001-8686(92)80009-M; LINDBLOM G, 1993, J BIOL CHEM, V268, P16198; LINDBLOM G, 1991, BIOCHEMISTRY-US, V30, P10938, DOI 10.1021/bi00109a019; LUGTENBERG EJJ, 1976, BIOCHIM BIOPHYS ACTA, V441, P38, DOI 10.1016/0005-2760(76)90279-4; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MARR AG, 1962, J BACTERIOL, V84, P1260, DOI 10.1128/JB.84.6.1260-1267.1962; McElhaney R.N., 1984, BIOMEMBRANE, V12, P249; MCLAUGHLIN AC, 1975, J MAGN RESON, V20, P146, DOI 10.1016/0022-2364(75)90162-6; MOREIN S, 1994, ANAL BIOCHEM, V216, P47, DOI 10.1006/abio.1994.1006; NAKAYAMA H, 1980, BIOCHIM BIOPHYS ACTA, V601, P1, DOI 10.1016/0005-2736(80)90508-8; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; Osborn M J, 1974, Methods Enzymol, V31, P642; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; PLUSCHKE G, 1981, J BIOL CHEM, V256, P3207; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCK JL, 1984, BIOCHEMISTRY-US, V23, P4955, DOI 10.1021/bi00316a020; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1994, J BIOL CHEM, V269, P28670; RILFORS L, 1985, BIOCHIM BIOPHYS ACTA, V813, P151, DOI 10.1016/0005-2736(85)90228-7; RILFORS L, 1982, FEBS LETT, V149, P293, DOI 10.1016/0014-5793(82)81120-4; RILFORS L, 1994, BIOCHEMISTRY-US, V33, P6110, DOI 10.1021/bi00186a010; Rilfors L., 1984, Biomembranes, V12, P205; Rilfors L, 1993, Subcell Biochem, V20, P109; Seddon J.M., 1993, PHOSPHOLIPIDS HDB, P403; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P5010, DOI 10.1021/bi00438a016; SILVIUS JR, 1982, LIPID PROTEIN INTERA, V2, P2339; SJOLUND M, 1989, BIOCHEMISTRY-US, V28, P1323; SMAAL EB, 1985, J LIPID RES, V26, P634; SUUTARI M, 1994, CRIT REV MICROBIOL, V20, P285, DOI 10.3109/10408419409113560; THURMOND RL, 1996, IN PRESS STRUCTURAL; WELLS MA, 1963, BIOCHEMISTRY-US, V2, P1259, DOI 10.1021/bi00906a015; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x; [No title captured]	78	300	303	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6801	6809		10.1074/jbc.271.12.6801	http://dx.doi.org/10.1074/jbc.271.12.6801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636103	hybrid			2022-12-27	WOS:A1996UB15700038
J	Panchenko, MV; StetlerStevenson, WG; Trubetskoy, OV; Gacheru, SN; Kagan, HM				Panchenko, MV; StetlerStevenson, WG; Trubetskoy, OV; Gacheru, SN; Kagan, HM			Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase - Potential role of procollagen C-proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMELYSIN CATALYTIC DOMAIN; PURIFIED LYSYL OXIDASE; AMINO-ACID-SEQUENCE; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; PARTIAL-PURIFICATION; VACCINIA VIRUS; SMOOTH-MUSCLE; MESSENGER-RNA	Lysyl oxidase is secreted from fibrogenic cells as a 50-kDa proenzyme that is proteolytically processed to the mature enzyme in the extracellular space. To characterize the secreted proteinase activity, a truncated, recombinant form of lysyl oxidase was prepared as a proteinase substrate containing the sequence of the propeptide cleavage region, The processing proteinase activity secreted by cultured fibrogenic cells resists inhibitors of serine or aspartyl proteinases as well as tissue inhibitor of matrix metalloproteinases-2 (MMP-2) but is completely inhibited by metal ion chelators. Known metalloproteinases were tested for their activity toward this substrate. Carboxyl-terminal procollagen proteinase (C-proteinase), MMP-2, and conditioned fibrogenic cell culture medium cleave the lysyl oxidase substrate to the size of the mature enzyme. The NH2-terminal sequence generated by arterial smooth muscle conditioned medium and the C-proteinase but not by MMP-2, i.e. Asp-Asp Pro-Tyr, was identical to that previously identified in mature lysyl oxidase isolated from connective tissue, The C-proteinase activity against the model substrate was inhibited by a synthetic oligopeptide mimic of the cleavage sequence (Ac-Met-Val-Gly-Asp-Asp-Pro-Tyr-Asn-amide), whereas this peptide also inhibited the generation of lysyl oxidase activity in the medium of fetal rat lung fibroblasts in culture. In toto, these results identify a secreted metalloproteinase activity participating in the activation of prolysyl oxidase, identify inhibitors of the processing activity, and implicate procollagen C-proteinase in this role.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; NCI,NIH,PATHOL LAB,BETHESDA,MD 20892; OSTEOARTHRITIS SCI INC,CAMBRIDGE,MA 02139	Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Panchenko, Maria/0000-0001-6247-6598	NHLBI NIH HHS [HL 13262, HL 46902] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902, P01HL013262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CONTENTE S, 1993, GENOMICS, V16, P401; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; DARLAK K, 1990, J BIOL CHEM, V265, P5199; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; EMONARD H, 1990, CELL MOL BIOL, V36, P131; EVANS CH, 1991, J SURG RES, V51, P399, DOI 10.1016/0022-4804(91)90140-H; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KAGAN HM, 1980, J BIOL CHEM, V255, P3656; KAGAN HM, 1995, J CELL BIOCHEM, V59, P329, DOI 10.1002/jcb.240590305; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; NAGAN N, 1994, J BIOL CHEM, V269, P22366; NJIEHA FK, 1982, BIOCHEMISTRY-US, V21, P757, DOI 10.1021/bi00533a028; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU Y, 1992, J BIOL CHEM, V267, P24199; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	42	164	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7113	7119		10.1074/jbc.271.12.7113	http://dx.doi.org/10.1074/jbc.271.12.7113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636146	hybrid			2022-12-27	WOS:A1996UB15700081
J	Czarnota, GJ; Ottensmeyer, FP				Czarnota, GJ; Ottensmeyer, FP			Structural states of the nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW IONIC-STRENGTH; CORE PARTICLE; HISTONE HYPERACETYLATION; PROJECTION DIRECTIONS; NEUTRON-SCATTERING; CHROMATIN; DNA; RECONSTRUCTION; RESOLUTION; HYDRATION	The nucleosome is the fundamental component of the eukaryotic chromosome, participating in the packaging of DNA and in the regulation of gene expression. Its numerous interactions imply a structural dynamism, Previous biophysical studies under limited sets of conditions have not been able to reconcile structural differences and transitions observed, We have determined a series of nucleosome conformations over a > 10,000-fold range in salt concentration using a combination of biochemical methods, spectroscopic electron microscopy, and three-dimensional reconstruction techniques for randomly oriented single particles, This study indicates several ionic strength-dependent nucleosome conformations and also reconciles the differences between currently existing divergent models for the nucleosome. At low ionic environments, the particle appears highly elongated, becoming more compact and prolate ellipsoidal as ionic strength is increased to 10 mM NaCl. At 30 mM NaCl, the particle exhibits a spheroidal conformation, As ionic strength is increased to 150 mM. NaCl, the nucleosome conformation changes and becomes oblate, Above 450 mM NaCl, the structure becomes highly elongated again, The result of this study is a unifying concept in which the three-dimensional structure of the nucleosome is inferred to be dynamic in response to ionic interactions and in accord with biochemical and genetic studies.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA	University of Toronto	Czarnota, GJ (corresponding author), ONTARIO CANC INST, DIV MOLEC & STRUCT BIOL, 610 UNIV AVE, TORONTO, ON M5G 2M9, CANADA.							ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAZETTJONES DP, 1996, IN PRESS NUCLEIC ACI; BENTLEY GA, 1984, J MOL BIOL, V176, P55, DOI 10.1016/0022-2836(84)90382-6; BERTRAND E, 1984, ARCH BIOCHEM BIOPHYS, V229, P395, DOI 10.1016/0003-9861(84)90167-X; BODE J, 1983, EUR J BIOCHEM, V130, P437, DOI 10.1111/j.1432-1033.1983.tb07170.x; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; BURCH JBE, 1980, NUCLEIC ACIDS RES, V8, P4969, DOI 10.1093/nar/8.21.4969; CHUNG DG, 1985, BIOCHEMISTRY-US, V24, P8028, DOI 10.1021/bi00348a029; CROWTHER RA, 1970, PROC R SOC LON SER-A, V317, P319, DOI 10.1098/rspa.1970.0119; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; CZARNOTA GJ, 1993, 51ST P ANN M MICR SO, P194; CZARNOTA GJ, 1994, P INT C ELECTRON MIC, P441; DIETERICH AE, 1981, BIOPOLYMERS, V20, P111, DOI 10.1002/bip.1981.360200108; DONG F, 1990, BIOCHEMISTRY-US, V29, P10710, DOI 10.1021/bi00499a020; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; FARROW NA, 1993, ULTRAMICROSCOPY, V52, P141, DOI 10.1016/0304-3991(93)90185-Z; GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879; Goncharov A. B., 1987, Soviet Physics - Crystallography, V32, P504; GORDON VC, 1978, P NATL ACAD SCI USA, V75, P660, DOI 10.1073/pnas.75.2.660; Grunstein M., 1992, TRANSCRIPTIONAL REGU, P1295; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HARAUZ G, 1984, SCIENCE, V226, P936, DOI 10.1126/science.6505674; HJELM RP, 1977, CELL, V10, P139, DOI 10.1016/0092-8674(77)90148-9; KORNBERG RD, 1981, SCI AM, V244, P48, DOI 10.1038/scientificamerican0281-52; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LIBERTINI LJ, 1982, BIOCHEMISTRY-US, V21, P3327, DOI 10.1021/bi00257a013; LOCKLEAR L, 1990, NUCLEIC ACIDS RES, V18, P7015, DOI 10.1093/nar/18.23.7015; MISELL DL, 1977, IMAGE ANAL ENHANCEME, P199; MOUDRIANAKIS EN, 1993, COLD SPRING HARB SYM, V58, P273, DOI 10.1101/SQB.1993.058.01.032; OLIVA R, 1987, J BIOL CHEM, V262, P17016; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; OOHARA I, 1987, J MOL BIOL, V196, P399, DOI 10.1016/0022-2836(87)90700-5; OOHARA I, 1987, J MOL BIOL, V196, P389, DOI 10.1016/0022-2836(87)90699-1; OTTENSMEYER FP, 1992, 50TH P ANN M EL MICR, P1058; PARDON JF, 1977, NUCLEIC ACIDS RES, V4, P3199, DOI 10.1093/nar/4.9.3199; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUPLEY JA, 1991, ADV PROTEIN CHEM, V41, P37; SCOPES RK, 1988, PROTEIN PURIFICATION, P199; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; SUAU P, 1977, NUCLEIC ACIDS RES, V4, P3769, DOI 10.1093/nar/4.11.3769; Svedberg T, 1940, THE ULTRACENTRIFUGE; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TURNER BM, 1991, J CELL SCI, V99, P13; UBERBACHER EC, 1989, J BIOMOL STRUCT DYN, V7, P1; UBERBACHER EC, 1983, BIOCHEMISTRY-US, V22, P4916, DOI 10.1021/bi00290a007; van Holde K.E., 1988, CHROMATIN; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; WILHELM ML, 1980, BIOCHEMISTRY-US, V19, P4327, DOI 10.1021/bi00559a028; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; YAGER TD, 1984, J BIOL CHEM, V259, P4212; ZABAL MMZ, 1993, J MICROSC-OXFORD, V172, P205, DOI 10.1111/j.1365-2818.1993.tb03414.x	55	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3677	3683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631980				2022-12-27	WOS:A1996TV72400054
J	Hansen, S; Hupp, TR; Lane, DP				Hansen, S; Hupp, TR; Lane, DP			Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; ACTIVATING MUTATIONS; ESCHERICHIA-COLI; GENE-PRODUCT; MUTANT FORMS; CELL-CYCLE; EXPRESSION; CONFORMATION	Conformational stability is a prerequisite for the physiological activity of the tumor suppressor protein p53. p53 protein can be allosterically activated for DNA binding by phosphorylation or through noncovalent interaction with proteins such as DnaK the Escherichia coli homologue of the heat shock protein Hsp70. We present in vitro evidence for a rapid temperature-dependent change in the conformation and tetrameric nature of wild-type p53 upon incubation at 37 degrees C, which correlates with a permanent loss in DNA binding activity. We show that p53 is allosterically regulated for stabilization of the wild-type conformation and DNA binding activity at 37 degrees C by binding of two classes of ligands to regulatory sites on the N and C terminus of the molecule through which an intrinsic instability of p53 is neutralized. Deletion of the domain conferring instability at the C terminus is sufficient to confer enhanced stability to the total protein. DnaK binding to the C terminus can profoundly protect p53 at 37 degrees C from a temperature-dependent loss of the DNA binding activity but does not renature or activate denatured p53. In contrast, another activator of the DNA binding activity of latent p53, the monoclonal antibody PAb421, which also interacts with the C terminus of the protein, is not able to protect p53 from thermal denaturation. Two monoclonal antibodies to the N terminus of p53, PAb1801 and DO-1, do not activate the latent DNA binding function of p53 but can protect the p53 wild-type conformation at 37 degrees C. Thus, activation of the DNA binding function of p53 is not synonymous with protection from thermal denaturation, and therefore, both of these pathways may be used in cells to control the physiological activity of p53. The protection of p53 conformation from heat denaturation by interacting proteins suggests a novel mechanism by which p53 function could be regulated in vivo.	UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, CRC CELL TRANSFORMAT GRP, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEGROS Y, 1994, ONCOGENE, V9, P2071; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	60	91	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3917	3924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632013				2022-12-27	WOS:A1996TV72400087
J	HitchcockDeGregori, SE; An, YM				HitchcockDeGregori, SE; An, YM			Integral repeats and a continuous coiled coil are required for binding of striated muscle tropomyosin to the regulated actin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ALPHA-TROPOMYOSIN; SKELETAL-MUSCLE; POLYMERIZABLE TROPOMYOSIN; AMINO TERMINUS; THIN FILAMENT; TROPONIN-T; SEQUENCE; PROTEINS; ISOFORM	Tropomyosin is a coiled-coil protein that binds along the length of filamentous actin and contains sequence repeats that correspond to actin monomers in the filament. Analysis of striated muscle alpha-tropomyosin mutants in which internal sequence has been deleted or replaced with non-tropomyosin sequence showed that the following parameters are important for high affinity, cooperative binding of tropomyosin-troponin to actin. 1) Tropomyosin must be a coiled coil along its entire length. 2) An integral number of repeats corresponding to the actin monomers along its length is more important than the total number. 3) In comparison, the actin affinity is relatively insensitive to changes in the sequence of the internal regions of tropomyosin. The re suits suggest that the internal sequence repeats function as weakly interacting spacers to allow proper alignment of the ends on the regulated actin filament.			HitchcockDeGregori, SE (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT NEUROSCI & CELL BIOL,675 HOES LN,PISCATAWAY,NJ 08854, USA.				NHLBI NIH HHS [HL35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DABROWSKA R, 1983, J MUSCLE RES CELL M, V4, P143, DOI 10.1007/BF00712027; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FUJIME S, 1971, J MOL BIOL, V62, P251, DOI 10.1016/0022-2836(71)90144-6; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; HAMMELL RL, 1996, IN PRESS J BIOL CHEM; HAMMELL RL, 1993, MOL BIOL CELL, V4, P259; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; OBRIEN EJ, 1971, PHILOS T ROY SOC B, V261, P201, DOI 10.1098/rstb.1971.0051; PARRY DAD, 1975, J MOL BIOL, V98, P519, DOI 10.1016/S0022-2836(75)80084-2; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PHILLIPS GN, 1986, J MOL BIOL, V192, P128, DOI 10.1016/0022-2836(86)90469-9; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WHITBY FG, 1992, J MOL BIOL, V227, P441, DOI 10.1016/0022-2836(92)90899-U; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	50	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3600	3603						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631967				2022-12-27	WOS:A1996TV72400041
J	Imanaka, T; Shiina, Y; Takano, T; Hashimoto, T; Osumi, T				Imanaka, T; Shiina, Y; Takano, T; Hashimoto, T; Osumi, T			Insertion of the 70-kDa peroxisomal membrane protein into peroxisomal membranes in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; ACYL-COA OXIDASE; TARGETING SIGNAL; ZELLWEGER SYNDROME; 3-KETOACYL-COA THIOLASE; ENDOPLASMIC-RETICULUM; FIREFLY LUCIFERASE; CARBOXY TERMINUS; IMPORT; BIOGENESIS	Biosynthesis and intracellular transport of 70-kDa peroxisomal membrane protein (PMP70) has been studied in rat hepatoma, H-4-II-E cells. Pulse-chase analysis showed that a newly synthesized S-35-PMP70 first appeared in the cytosolic fraction and was then transported into the peroxisomal fraction. The half-life of S-35-PMP70 in the cytosolic fraction was approximately 3 min. Integration of S-35-PMP70 into membranes occurred in the peroxisomal fraction and was completed within 30 min. No proteolytic processing of S-35-PMP70 was observed. An in vitro import system was reconstituted to characterize the insertion mechanism of PMP70 into peroxisomes. Peroxisomes isolated from rat liver were incubated at 26 degrees C with [S-35]methionine-labeled in vitro translation products of PMP70 mRNA in the presence of the cytosolic fraction. The peroxisomes were reisolated and insertion of S-35-PMP70 into the membrane was analyzed using a Na2CO3 procedure. The binding and insertion of S-35-PMP70 were dependent on temperature and incubation time and was specific for peroxisomes, Pretreatment of peroxisomes with trypsin and chymotrypsin almost abolished the binding and insertion of S-35-PMP70, The translation products contained several truncated S-35-PMP70s. The NH2 terminally truncated S-35-PMP70s, with a molecular mass greater than 50 kDa, bound to and inserted into peroxisomal membranes, whereas truncated S-35-PMP70s smaller than 45 kDa did not, These results suggest that PMP70 is post-translationally transported to peroxisomes without processing and inserted into peroxisomal membranes by a specific mechanism in which a proteinaceous receptor and a certain internal sequence of PMP70 are involved.	SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN; HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN	Shinshu University; University of Hyogo	Imanaka, T (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOLEC PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN.			Imanaka, Tsuneo/0000-0003-4677-1356				BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; De Duve C., 1955, BIOCHEM J, V60, P605; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1985, J BIOL CHEM, V260, P5603; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GARTNER J, 1991, PEDIATR RES, V29, P141; GOODMAN JM, 1984, J BIOL CHEM, V259, P8485; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HARTL FU, 1987, ARCH BIOCHEM BIOPHYS, V255, P109, DOI 10.1016/0003-9861(87)90300-6; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; IMANAKA T, 1992, BIOCHIM BIOPHYS ACTA, V1134, P197, DOI 10.1016/0167-4889(92)90176-C; JUST WW, 1967, PEROXISOMES BIOL MED, P402; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIURA S, 1994, EUR J BIOCHEM, V223, P141, DOI 10.1111/j.1432-1033.1994.tb18975.x; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SANTOS MJ, 1994, J BIOL CHEM, V269, P24890; SATO R, 1990, J BIOL CHEM, V265, P11880; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SOTO U, 1993, EXP CELL RES, V205, P66, DOI 10.1006/excr.1993.1059; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675	41	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3706	3713						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631984				2022-12-27	WOS:A1996TV72400058
J	Shen, F; Seabra, MC				Shen, F; Seabra, MC			Mechanism of digeranylgeranylation of rab proteins - Formation of a complex between monogeranylgeranyl-rab and rab escort protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; ALPHA-SUBUNIT; CDNA CLONING; COMPONENT-A; BINDING; CHOROIDEREMIA; PRENYLATION; TRANSPORT	Rab proteins are Ras-related small GTPases that are digeranylgeranylated at carboxyl-terminal cysteines, a modification essential for their action as molecular switches regulating intracellular vesicular transport, Geranylgeranylation of Rabs is a complex reaction that requires a catalytic Rab geranylgeranyl transferase (GGTase) and a Rab escort protein (REP), REP binds unprenylated Rab and presents it to Rab GGTase, After GG transfer, REP remains associated with diGG-Rab, which leads to insertion of the Rab into a specific membrane, We used recombinant Rab1a single cysteine mutants that accept only one GG group to study the mechanism of the digeranylgeranylation reaction. Using the prenylation assay, gel filtration chromatography, and density ultracentrifugation, we show that REP, but not Rab GGTase, forms a stable complex with unprenylated, monoGG- and diGG-Rab1a. The REP . monoGG-Rab1a complex is stable in the presence of detergents or phospholipids, whereas the REP . diGG-Rab1a complex partially dissociates under these conditions, The stoichiometry of the REP . Rab complex appears to be 1:1 before prenylation, Prenylation induces a change in complex stoichiometry, with the formation of a 2:2 or 2:1 REP . Rab complex, A possible mechanism by which Rab proteins are digeranylgeranylated is suggested by the current studies, We propose that each geranylgeranyl addition is an independent reaction that leads to the production of monoGG-Rab and diGG-Rab, respectively, The stability of the REP . monoGG-Rab complex prevents monoGG-Rab from dissociating from REP prior to the second geranylgeranylation reaction, ensuring efficient digeranylgeranylation of Rab substrates.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GIANNAKOUROS T, 1992, FEBS LETT, V297, P103, DOI 10.1016/0014-5793(92)80337-G; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712	29	85	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3692	3698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631982				2022-12-27	WOS:A1996TV72400056
J	WarnCramer, BJ; Lampe, PD; Kurata, WE; Kanemitsu, MY; Loo, LWM; Eckhart, W; Lau, AF				WarnCramer, BJ; Lampe, PD; Kurata, WE; Kanemitsu, MY; Loo, LWM; Eckhart, W; Lau, AF			Characterization of the mitogen-activated protein kinase phosphorylation sites on the connexin-43 gap junction protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; TYROSINE PHOSPHORYLATION; SUBSTRATE RECOGNITION; COMMUNICATION; INVITRO; DETERMINANTS; MUTAGENESIS; INHIBITION; PROMOTER; SEQUENCE	We have previously demonstrated that epidermal growth factor induced a rapid, transient decrease in gap junctional communication and increase in serine phosphorylation on the connexin-43 gap junction protein in T51B rat liver epithelial cells, The kinase(s) responsible for phosphorylation and specific serine targets in connexin-43 have not been identified. There are three consensus mitogen-activated protein (MAP) kinase serine phosphorylation sequences in the carboxyl-terminal tail of connexin-43 and purified MAP kinase phosphorylated connexin-43 in vitro on tryptic peptides that comigrated with a subset of peptides from connexin-43 phosphorylated in vivo in cells treated with epidermal growth factor. These data suggested that MAP kinase may phosphorylate connexin-43 directly in vivo, We have utilized a glutathione S-transferase fusion protein containing the cytoplasmic tail of connexin-43 to characterize MAP kinase phosphorylation. Site-directed mutagenesis, phosphotryptic peptide analysis, and peptide sequencing have confirmed that MAP kinase can phosphorylate connexin-43 at Ser(255), Ser(279), and Ser(282), which correspond to the consensus sites recognized earlier. Characterization of MAP kinase-mediated phosphorylation of connexin-43 has defined potential targets for phosphorylation in vivo following activation of the epidermal growth factor receptor and has provided the basis for studies of the effects of phosphorylation, at specific molecular sites, on the regulation of gap junctional communication.	UNIV HAWAII MANOA, SCH MED, DEPT MOLEC BIOL & GENET, HONOLULU, HI 96813 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98109 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	University of Hawaii System; University of Hawaii Manoa; Fred Hutchinson Cancer Center; Salk Institute	WarnCramer, BJ (corresponding author), CANC RES CTR HAWAII, DEPT MOLEC CARCINOGENESIS, 1236 LAUHALA ST, HONOLULU, HI 96813 USA.				NCI NIH HHS [CA 52098, CA 13884, CA 09370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098, R37CA013884, R01CA013884, T32CA009370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CASPAR DLD, 1977, J CELL BIOL, V74, P605, DOI 10.1083/jcb.74.2.605; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROW DS, 1992, ONCOGENE, V7, P999; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; FLAGGNEWTON JL, 1981, J MEMBRANE BIOL, V63, P105, DOI 10.1007/BF01969452; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERTZBERG EI, 1988, MODERN CELL BIOL GAP, V7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KURATA WE, 1994, ONCOGENE, V9, P329; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAGE E, 1986, HEART CARDIOVASCULAR; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHANNON JD, 1995, TECH PROT CHEM, V6, P117, DOI 10.1016/S1080-8914(06)80017-7; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKEDA A, 1989, J BIOCHEM-TOKYO, V106, P723, DOI 10.1093/oxfordjournals.jbchem.a122923; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772	49	244	250	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3779	3786						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631994				2022-12-27	WOS:A1996TV72400068
J	Wu, S; Moomaw, CR; Tomer, KB; Falck, JR; Zeldin, DC				Wu, S; Moomaw, CR; Tomer, KB; Falck, JR; Zeldin, DC			Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ENDOGENOUS EPOXYEICOSATRIENOIC ACIDS; RAT-KIDNEY; ENANTIOFACIAL SELECTIVITY; STENOTOMUS-CHRYSOPS; COS CELLS; METABOLISM; OXYGENASE; IDENTIFICATION; LOCALIZATION	A cDNA encoding a human cytochrome P450 arachidonic acid epoxygenase was isolated from a human liver cDNA library. Sequence analysis revealed that this 1,876-base pair cDNA contained an open reading frame and encoded a new 502-amino acid protein designated CYP2J2. Blot hybridization analysis of RNA prepared from human tissues revealed that CYP2J2 was highly expressed in the heart. Recombinant CYP2J2 protein was prepared using the baculovirus expression system and purified to near electrophoretic homogeneity. The enzyme metabolized arachidonic acid predominantly via olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids (catalytic turnover 65 pmol of product formed/nmol of cytochrome P450/min at 30 degrees C). Epoxidation of arachidonic acid by CYP2J2 at the 14,15-olefin was highly enantioselective for (14R,15S)-epoxyeicosatrienoic acid (76% optical purity). Immunoblotting of microsomal fractions prepared from human tissues using a polyclonal antibody raised against the recombinant hemoprotein confirmed primary expression of CYP2J2 protein in human heart. The in vivo significance of CYP2J2 was suggested by documenting the presence of epoxyeicosatrienoic acids in the human heart using gas chromatography/mass spectroscopy. importantly, the chirality of CYP2J2 products matched that of the epoxyeicosatrienoic acid enantiomers present, in vivo, in human heart. We propose that CYP2J2 is one of the enzymes responsible for epoxidation of endogenous arachidonic acid pools in human heart and that epoxyeicosatrienoic acids may, therefore, play important functional roles in cardiac physiology.	NIEHS, PULM PATHOBIOL LAB, NIH, RES TRIANGLE PK, NC 27709 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; NIEHS, MOLEC BIOPHYS LAB, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Falck, John/0000-0002-9219-7845	NIGMS NIH HHS [GM31278, GM37922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM NG, 1987, J MOL CELL CARDIOL, V19, P73, DOI 10.1016/S0022-2828(87)80546-1; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA J, 1984, FEBS LETT, V178, P319, DOI 10.1016/0014-5793(84)80625-0; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; Capdevila Jorge H., 1995, P443; CARROLL MA, 1987, EUR J PHARMACOL, V138, P281, DOI 10.1016/0014-2999(87)90445-6; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; COMPTE J, 1978, BIOCHIMIE PARIS, V60, P1289; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GED C, 1988, BIOCHEMISTRY-US, V27, P6929, DOI 10.1021/bi00418a039; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GONZALEZ FJ, 1991, METHOD ENZYMOL, V206, P93; GONZALEZ FJ, 1991, METHOD ENZYMOL, V206, P85; GUENGERICH FP, 1979, MOL PHARMACOL, V15, P154; GUENGERICH FP, 1992, LIFE SCI, V50, P1471; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HECKER M, 1994, J PHYSIOL-LONDON, V481, P407, DOI 10.1113/jphysiol.1994.sp020449; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; IMAOKA S, 1993, J PHARMACOL EXP THER, V267, P1012; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KARARA A, 1993, J BIOL CHEM, V268, P13565; KARMAZYN M, 1991, CAN J PHYSIOL PHARM, V69, P719, DOI 10.1139/y91-108; KARMAZYN M, 1984, J MOL CELL CARDIOL, V16, P1071, DOI 10.1016/S0022-2828(84)80019-X; KARMAZYN M, 1989, CAN J PHYSIOL PHARM, V67, P912, DOI 10.1139/y89-144; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; LU AYH, 1979, PHARMACOL REV, V31, P277; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MOFFAT MP, 1993, AM J PHYSIOL, V264, pH1154, DOI 10.1152/ajpheart.1993.264.4.H1154; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; PATEL L, 1989, PROSTAGLANDINS, V38, P615, DOI 10.1016/0090-6980(89)90044-0; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; PRITCHARD KA, 1990, BIOCHEM BIOPH RES CO, V167, P137, DOI 10.1016/0006-291X(90)91741-A; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; RIFKIND AB, 1994, J BIOL CHEM, V269, P3387; ROSOLOWSKY M, 1991, ADV PROSTAG THROMB L, V21, P213; SCHWARTZMAN ML, 1990, KIDNEY INT, V37, P94, DOI 10.1038/ki.1990.13; SERABJITSINGH CJ, 1979, J BIOL CHEM, V254, P9901; SHEPHARD EA, 1989, ANN HUM GENET, V53, P23, DOI 10.1111/j.1469-1809.1989.tb01119.x; SMOLOWITZ RM, 1991, DRUG METAB DISPOS, V19, P113; SRIVASTAVA PK, 1991, MOL PHARMACOL, V40, P69; STEGEMAN JJ, 1982, MOL PHARMACOL, V21, P517; UMBENHAUER DR, 1987, BIOCHEMISTRY-US, V26, P1094, DOI 10.1021/bi00378a016; Waterman M.R, 1991, METHOD ENZYMOL, V206, P100, DOI 10.1016/0076-6879(91)06081-d; WOLF CR, 1990, BIOCHEM SOC T, V18, P21, DOI 10.1042/bst0180021; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438	76	400	417	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3460	3468						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631948				2022-12-27	WOS:A1996TV72400022
J	Deng, G; Royle, G; Wang, S; Crain, K; Loskutoff, DJ				Deng, G; Royle, G; Wang, S; Crain, K; Loskutoff, DJ			Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; S-PROTEIN; THROMBIN; CLONING; LATENT; PLASMA; IDENTIFICATION; INACTIVATION; SPECIFICITY	Plasminogen activator inhibitor 1 (PAI-1) binds to the somatomedin B (SMB) domain of vitronectin (VN), a domain present in at least seven other proteins. In this study, we investigate the PAI-1 binding activity of these SMB homologs and attempt to more specifically localize the PAI-1 binding site within this domain. SMB(VN) and several of its homologs were expressed in Escherichia coli, purified, and tested for PAI-1 binding activity in a competitive ligand binding assay. Although recombinant SMB(VN) was fully active in this assay, none of the homologs bound to PAT-1 or competed with VN for PAI-1 binding. These inactive homologs are structurally related to SMB(VN), having 33-45% sequence identity and containing all 8 cysteines at conserved positions. Thus, homolog-scanning experiments were conducted by exchanging progressively larger portions of the NH2- or COOH-terminal regions of active SMB(VN) with the corresponding regions of the inactive homologs. These experiments revealed that the minimum PAI-1-binding sequence was present in the central region (residues 12-30) of SMB(VN). Alanine scanning mutagenesis further demonstrated that each of the 8 cysteines as well as Gly(12), Asp(22), Leu(24), Try(27), Tyr(28) and Asp(34) were critical for PAI-1 binding and were required to stabilize PAI-1 activity. These results indicate that the PAI-1 binding motif is localized to residues 12-30 of SMB(VN) and suggest that this motif is anchored in the active conformation by disulfide bonds.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL31950, HL07195-19, HL09400-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195, F32HL009400, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUGHMAN G, 1992, J IMMUNOL, V149, P1488; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KOOISTRA T, 1986, BIOCHEM J, V239, P497, DOI 10.1042/bj2390497; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LEVIN EG, 1987, BLOOD, V70, P1090; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; MERBERG DM, 1993, INT CONGR SER, V1042, P45; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MURATA J, 1994, J BIOL CHEM, V269, P30479; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SATO R, 1990, J BIOL CHEM, V265, P21232; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; TOMASINI BR, 1990, PROGR HEMOSTASIS THR, P269; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	44	97	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12716	12723		10.1074/jbc.271.22.12716	http://dx.doi.org/10.1074/jbc.271.22.12716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662688				2022-12-27	WOS:A1996UN47400007
J	Ye, S; Eriksson, P; Hamsten, A; Kurkinen, M; Humphries, SE; Henney, AM				Ye, S; Eriksson, P; Hamsten, A; Kurkinen, M; Humphries, SE; Henney, AM			Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1; PROTEIN; METALLOPROTEINASES; INHIBITORS; ACTIVATOR; BINDING; PLAQUES; CELLS	There is a common polymorphism in the promoter sequence of the human stromelysin-1 gene, with one allele having a run of six adenosines (6A) and the other five adenosines (5A), We have previously reported, in a 3-year follow-up study of patients with coronary atherosclerosis, that those patients who are homozygous for the 6A allele show a more rapid progression of the disease, In this study, we have investigated whether the 5A/6A promoter polymorphism plays a role in the regu- lation of stromelysin-1 gene expression, In transient transfection experiments, a stromelysin-1 promoter construct with 6A at the polymorphic site was found to express less of the chloramphenicol acetyltransferase reporter gene than a construct containing 5A. Electrophoretic mobility shift assay and DNase I footprinting revealed the interaction of one or more nuclear protein(s) with the DNA sequence at the 5A/6A polymorphic site. The binding of one of the nucleoprotein factors was more readily detectable with an oligonucleotide probe corresponding to the 6A allele as compared with a probe corresponding to the 5A allele. Replacing the core binding sequence with a random DNA sequence abolished the interaction between the nuclear protein(s) and the probe and also increased reporter gene expression in transiently transfected cells. Thus, the common 5A/6A polymorphism of the human stromelysin-1 promoter appears to play an important role in regulating stromelysin-1 gene expression and may be involved in the progression of coronary heart disease.	UNIV LONDON UNIV COLL, SCH MED, DEPT MED, DIV CARDIOVASC GENET, LONDON WC1E 6JJ, ENGLAND; KAROLINSKA HOSP, KING GUSTAF V RES INST, ATHEROSCLEROSIS RES UNIT, S-17176 STOCKHOLM, SWEDEN; WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, CTR MOLEC MED & GENET, DETROIT, MI 48202 USA	University of London; University College London; UCL Medical School; Karolinska Institutet; Karolinska University Hospital; Wayne State University; Wayne State University			Ye, Shu/C-4067-2009; Ye, Shu/R-6384-2017	Ye, Shu/0000-0002-4126-4278; Humphries, Stephen E/0000-0002-8221-6547; Eriksson, Per/0000-0002-5635-2692				ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; ANGOTTI E, 1994, J BIOL CHEM, V269, P17371; BOUGHARIOS G, 1994, CLIN CHIM ACTA, V231, P69, DOI 10.1016/0009-8981(94)90255-0; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; DAVIES MJ, 1990, CIRCULATION, V82, P38; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GIOVANNA B, 1991, NUCLEIC ACIDS RES, V19, P3723; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HUMPHRIES SE, 1995, ARTERIOSCL THROM VAS, V15, P96, DOI 10.1161/01.ATV.15.1.96; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1985, BIOESSAYS, V2, P55, DOI 10.1002/bies.950020204; MURPHY G, 1991, British Journal of Rheumatology, V30, P25; Murphy G, 1992, Matrix Suppl, V1, P224; Murphy Gillian, 1993, P287; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RICHARDSON PD, 1989, LANCET, V2, P941; SANZ L, 1994, J BIOL CHEM, V269, P10044; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; TYAGI SC, 1995, ATHEROSCLEROSIS, V116, P43, DOI 10.1016/0021-9150(95)05520-7; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANG M, U56422 GENB; YE S, 1995, THROMB HAEMOSTASIS, V74, P837; YE S, 1995, BRIT HEART J, V73, P209	44	416	441	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13055	13060		10.1074/jbc.271.22.13055	http://dx.doi.org/10.1074/jbc.271.22.13055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662692	hybrid			2022-12-27	WOS:A1996UN47400058
J	Baumann, C; Otridge, J; Gollnick, P				Baumann, C; Otridge, J; Gollnick, P			Kinetic and thermodynamic analysis of the interaction between TRAP (trp RNA-binding attenuation protein) of Bacillus subtilis and trp leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATOR INTERACTION; ESCHERICHIA-COLI; RIBOSOMAL-RNA; OPERON; EXPRESSION; EQUILIBRIUM; ACID	In Bacillus subtilis, expression of the tryptophan biosynthetic genes is regulated in response to tryptophan by an RNA-binding protein called TRAP (trp RNA-binding attenuation protein). TRAP has been shown to contain 11 identical subunits arranged in a symmetrical ring. Kinetic and thermodynamic parameters of the interaction between tryptophan-activated TRAP and trp leader RNA were studied. Results from glycerol gradients and mobility shift gels indicate that two TRAP 11-mers bind to each trp leader RNA. A filter binding assay was used to determine an apparent binding constant of 8.0 +/- 1.3 x 10(9) M(-1) (K-d = 0.12 +/- 0.02 nM) for TRAP and an RNA containing residues +36 to +92 of the trp leader RNA in 1 mM L-tryptophan at 37 degrees C. The temperature dependence of K-app was somewhat unexpected demonstrating that the Delta H of the interaction is highly unfavorable at +15.9 kcal mol(-1). Therefore, the interaction is completely driven by a Delta S of +97 cal mol(-1) K-1. The interaction between tryptophan-activated TRAP and trp leader RNA displayed broad salt and pH activity profiles. Finally, the rate of RNA dissociation from the RNA . TRAP . tryptophan ternary complex was found to be very slow in high concentrations of tryptophan (>40 mu M) but increased in lower tryptophan concentrations. This suggests that dissociation of tryptophan from the ternary complex is the rate-limiting step in RNA dissociation.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BEAUDETTE NV, 1980, CRC CR REV BIOCH MOL, V9, P145, DOI 10.3109/10409238009105433; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMMACK KA, 1970, BIOCHEM J, V117, P745, DOI 10.1042/bj1170745; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; HURLBURT BK, 1992, J BIOL CHEM, V267, P16783; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; MOUGEL M, 1986, BIOCHEMISTRY-US, V25, P2756, DOI 10.1021/bi00358a003; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SU SL, 1990, BIOCHEMISTRY-US, V29, P6033, DOI 10.1021/bi00477a022; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991	31	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12269	12274		10.1074/jbc.271.21.12269	http://dx.doi.org/10.1074/jbc.271.21.12269			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647825	hybrid			2022-12-27	WOS:A1996UL66000027
J	Chacko, S; Padlan, EA; Portolano, S; McLachlan, SM; Rapoport, B				Chacko, S; Padlan, EA; Portolano, S; McLachlan, SM; Rapoport, B			Structural studies of human autoantibodies - Crystal structure of a thyroid peroxidase autoantibody Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; 3-DIMENSIONAL STRUCTURE; HUMAN-IMMUNOGLOBULIN; RESOLUTION; FRAGMENT; CLONING; DISEASE; GENES; EXPRESSION; REPERTOIRE	The three-dimensional structure of the Fab of TR1.9, a high-affinity IgG1,kappa human autoantibody to thyroid peroxidase, was determined crystallographically to a resolution of 2.0 Angstrom. The combining site was found to be relatively flat, like other antibodies to large proteins, Sequence differences from the most closely related germline genes mainly occur at positions occupied by residues with outward-pointing side chains. An increased deformability of the second and third complementarity determining regions of the heavy chain may result from the replacement of two germline asparagines and the presence of several glycines, and may allow ''induced fit'' in the binding to antigen. Four exposed charged residues, resulting from the use of a particular D (diversity) and J (joining) segments in the assembly of the heavy chain, may contribute to the high affinity of antigen binding. The crystal structure of TR1.9 Fab is the first for a human IgG high-affinity autoantibody.	NIDDK, NIH, MOLEC BIOL LAB, BETHESDA, MD 20895 USA; UNIV CALIF SAN FRANCISCO, THYROID MOL BIOL UNIT 111T, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [DK 36182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUENGER AT, 1992, X PLOR SYSTEM CRYSTA; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P125; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; EIGENBROT C, 1994, PROTEINS, V18, P49, DOI 10.1002/prot.340180107; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; HARATA K, 1994, ACTA CRYSTALLOGR D, V50, P250, DOI 10.1107/S0907444993013290; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HUANG DB, 1994, BIOCHEMISTRY-US, V33, P14848, DOI 10.1021/bi00253a024; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JAUME JC, 1995, J CLIN ENDOCR METAB, V80, P1000, DOI 10.1210/jc.80.3.1000; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kabat E. A., 1991, SEQUENCES PROTEINS I; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLEIN R, 1993, EUR J IMMUNOL, V23, P3248, DOI 10.1002/eji.1830231231; KOSHLAND DE, 1973, SCI AM, V229, P52, DOI 10.1038/scientificamerican1073-52; LUZZATI V, 1953, ACTA CRYSTALLOGR, V6, P142, DOI 10.1107/S0365110X53000508; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V78, P944, DOI 10.1210/jc.78.4.944; PADLAN EA, 1995, FASEB J, V9, P133, DOI 10.1096/fasebj.9.1.7821752; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PADLAN EA, 1994, ANTIBODY ANTIGEN COM; PASCUAL V, 1992, J RHEUMATOL, V19, P50; PORTOLANO S, 1993, J IMMUNOL, V151, P2839; PORTOLANO S, 1992, J CLIN INVEST, V90, P720, DOI 10.1172/JCI115943; PORTOLANO S, 1991, BIOCHEM BIOPH RES CO, V179, P372, DOI 10.1016/0006-291X(91)91380-U; PORTOLANO S, 1993, J IMMUNOL, V150, P880; POSNER B, 1993, GENE, V128, P111, DOI 10.1016/0378-1119(93)90161-U; PRUMMEL MF, 1994, MOL CELL ENDOCRINOL, V102, P161, DOI 10.1016/0303-7207(94)90109-0; RAPOPORT B, 1995, IMMUNOL TODAY, V16, P43, DOI 10.1016/0167-5699(95)80070-0; RYPNIEWSKI WR, 1993, BIOCHEMISTRY-US, V32, P9851, DOI 10.1021/bi00088a041; Sasisekharan V., 1962, COLLAGEN, P39; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SHIN EK, 1991, EMBO J, V10, P3641, DOI 10.1002/j.1460-2075.1991.tb04930.x; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON KP, 1992, J BIOL CHEM, V267, P10842; [No title captured]	48	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12191	12198		10.1074/jbc.271.21.12191	http://dx.doi.org/10.1074/jbc.271.21.12191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647813	hybrid			2022-12-27	WOS:A1996UL66000015
J	Kobayashi, A; Sogawa, K; FujiiKuriyama, Y				Kobayashi, A; Sogawa, K; FujiiKuriyama, Y			Cooperative interaction between AhR center dot Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CYTOCHROME P-450C GENE; PLANAR AROMATIC-COMPOUNDS; DNA-BINDING ACTIVITY; DIOXIN RECEPTOR; REGULATORY ELEMENTS; TRANSCRIPTION; CLONING; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; IDENTIFICATION	Expression of CYP1A1 gene is regulated in a substrate-inducible manner through at least two kinds of regulatory DNA elements in addition to the TATA sequence, XRE (xenobiotic responsive element), and BTE (basic transcription element), a GC box sequence, The trans-acting factor on the XRE is a heterodimer consisting of arylhydrocarbon receptor (AhR) and AhR nuclear translocator (Arnt), while Sp1 acts as a regulatory factor on the BTE. We have investigated how these factors interact with one another to induce expression of the CYP1A1 gene. Both in vivo transfection assays using Drosophila Schneider line 2 (SL2) cells, which is devoid of endogenous Sp1, AhR, and Arnt, and in vitro transcription assays using baculovirus-expressed AhR, Amt, and Sp1 proteins revealed that these factors enhanced synergistically expression of the reporter genes driven by a model CYP1A1 promoter, consisting of four repeated XRE sequences and a BTE sequence, in agree ment with previous observation (Yanagida, A., Sogawa, K., Yasumoto, K., and Fujii-Kuriyama, Y. (1990) Mol. Cell. Biol. 10, 1470-1475). We have proved by coimmunoprecipitation assays and DNase I footprinting that both AhR and Arnt interact with the zinc finger domain of Sp1 via their basic HLH/PAS domains. When either the AhR Amt heterodimer or Sp1 was bound to its cognate DNA element, DNA binding of the second factor was facilitated Survey of DNA sequences in the promoter region shows that the XRE and GC box elements are commonly found in the genes whose expressions are induced by polycyclic aromatic hydrocarbons, suggesting that the two regulatory DNA elements and their cognate trans-acting factors constitute a common mechanism for induction of a group of drug-metabolizing enzymes.	TOHOKU UNIV, FAC SCI, DEPT CHEM, SENDAI, MIYAGI 98077, JAPAN	Tohoku University			Kobayashi, Akira/AAN-8003-2020	Kobayashi, Akira/0000-0001-9727-1218				ASMAN DC, 1993, J BIOL CHEM, V268, P12530; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAIN S, 1994, J BIOL CHEM, V269, P31518; KOBAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P91, DOI 10.1093/oxfordjournals.jbchem.a124727; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; NOCERA PPD, 1983, P NATL ACAD SCI USA, V80, P7095; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470; YASUMOTO K, 1993, THESIS TOHOKU U SEND	38	124	125	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12310	12316		10.1074/jbc.271.21.12310	http://dx.doi.org/10.1074/jbc.271.21.12310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647831	hybrid			2022-12-27	WOS:A1996UL66000033
J	Komissarov, AA; Calcutt, MJ; Marchbank, MT; Peletskaya, EN; Deutscher, SL				Komissarov, AA; Calcutt, MJ; Marchbank, MT; Peletskaya, EN; Deutscher, SL			Equilibrium binding studies of recombinant anti-single-stranded DNA Fab - Role of heavy chain complementarity-determining regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET CIRCULAR-DICHROISM; VARIABLE REGIONS; ANTIBODIES; PROTEIN; AUTOANTIBODY; MICE	We previously isolated nucleic acid-binding antibody fragments (Fab) from bacteriophage display libraries representing the immunoglobulin repertoire of autoimmune mice to expedite the analysis of antibody-DNA recognition, In the present study, the binding properties of one such anti-DNA Fab, high affinity single-stranded (ss) DNA-binding Fab (DNA-1), were defined using equilibrium gel filtration and fluorescence titration, Results demonstrated that DNA-1 had a marked preference for oligo(dT) (100 nM dissociation constant) and required oligo(dT) >5 nucleotides in length, A detailed analysis of the involvement of the individual heavy chain (H) complementarity determining regions (CDR) ensued using previously constructed HCDR transplantation mutants between DNA-1 and low affinity ssDNA-binding Fab (D5), a Fab that binds poorly to DNA (Calcutt, M. J. Komissarov, A. A., Marchbank, M. T., and Deutscher, S. L. (1996) Gene (Amst.) 168, 9-14), Circular dichroism studies indicated that the wild type and mutant Fab studied were of similar overall secondary structure and may contain similar combining site shapes. The conversion of D5 to a high affinity oligo(dT)-binding Fab occurred only in the presence of DNA-1 HCDR3. Results with site-specific mutants in HCDR1 further suggested a role of residue 33 in interaction with nucleic acid, The results of these studies are compared with previously published data on DNA-antibody recognition.	UNIV MISSOURI, SCH MED, DEPT BIOCHEM, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia					NIGMS NIH HHS [GM-47979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CALCUTT MJ, 1993, GENE, V137, P77, DOI 10.1016/0378-1119(93)90254-Z; Calcutt MJ, 1996, GENE, V168, P9, DOI 10.1016/0378-1119(95)00717-2; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CYGLER M, 1987, J BIOL CHEM, V262, P643; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P3299, DOI 10.1073/pnas.85.10.3299; GULLIVER GA, 1994, J BIOL CHEM, V269, P7934; GULLIVER GA, 1995, BIOCHEMISTRY-US, V34, P5158, DOI 10.1021/bi00015a029; GULLIVER GA, 1994, J BIOL CHEM, V269, P24040; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRISHNAN MR, 1993, J IMMUNOL, V150, P4948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; MARION TN, 1992, IMMUNOL REV, V128, P123, DOI 10.1111/j.1600-065X.1992.tb00835.x; POLYMENIS M, 1994, J IMMUNOL, V152, P5318; POWELL MD, 1993, BIOCHEMISTRY-US, V32, P12538, DOI 10.1021/bi00097a034; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SANG BC, 1989, J BIOMOL STRUCT DYN, V7, P693, DOI 10.1080/07391102.1989.10508514; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P321, DOI 10.1172/JCI111704; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; WOODY RW, 1978, BIOPOLYMERS, V17, P1451, DOI 10.1002/bip.1978.360170606	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12241	12246		10.1074/jbc.271.21.12241	http://dx.doi.org/10.1074/jbc.271.21.12241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647821	hybrid			2022-12-27	WOS:A1996UL66000023
J	Ward, DG; Cavieres, JD				Ward, DG; Cavieres, JD			Binding of 2'(3')-O-(2,4,6-trinitrophenyl)ADP to soluble alpha beta protomers of Na,K-ATPase modified with fluorescein isothiocyanate - Evidence for two distinct nucleotide sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; (NA+ + K+)-ATPASE; ACTIVE-SITE; SODIUM-PUMP; CONFORMATIONAL-CHANGES; POTASSIUM-TRANSPORT; MAMMALIAN KIDNEY; REACTIVE SITE; ATP SITE	The overall reaction of well defined solubilized protomers of Na,K-ATPase (one alpha plus one beta subunit) retains the dual ATP dependence observed with the membrane-bound enzyme, with distinctive ATP effects in the submicromolar and submillimolar ranges (Ward, D. G., and Cavieres, J. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5332-5336). We have now found that the K+-phosphatase activity of the alpha beta protomers is still inhibited by 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-diphosphate (TNP-ADP). What is most significant is that the TNP-ADP effect can be observed clearly with protomeric enzyme whose high affinity ATP site has been blocked covalently with fluorescein isothiocyanate. We conclude that nucleotides can bind at two discrete sites in each protomeric unit of Na,K-ATPase.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Leicester				Ward, Douglas/0000-0002-2328-1445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; AMLER E, 1992, BIOPHYS J, V61, P553, DOI 10.1016/S0006-3495(92)81859-3; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CAVIERES JD, 1987, FEBS LETT, V225, P145, DOI 10.1016/0014-5793(87)81147-X; CAVIERES JD, 1975, NATURE, V255, P338, DOI 10.1038/255338a0; CHETVERIN AB, 1986, FEBS LETT, V196, P121, DOI 10.1016/0014-5793(86)80225-3; Cleland W. W, 1970, ENZYMES, V2, P1; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V307, P386, DOI 10.1016/0005-2736(73)90104-1; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1988, J BIOL CHEM, V263, P7961; FORTES PAG, 1985, FED PROC, V44, P1443; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V26, P2889; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KANAZAWA T, 1967, J BIOCHEM-TOKYO, V61, P555, DOI 10.1093/oxfordjournals.jbchem.a128586; KAPLAN JH, 1982, ANN NY ACAD SCI, V402, P292, DOI 10.1111/j.1749-6632.1982.tb25750.x; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; KOEPSELL H, 1982, J BIOL CHEM, V257, P733; KUDOH F, 1979, J BIOCHEM, V86, P1023, DOI 10.1093/oxfordjournals.jbchem.a132595; LAZDUNSKI M, 1976, PROG BIOORG CHEM, V3, P82; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; NAGAI K, 1966, BIOCHIM BIOPHYS ACTA, V128, P410, DOI 10.1016/0926-6593(66)90193-7; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OTTOLENGHI P, 1983, BIOCHIM BIOPHYS ACTA, V727, P89, DOI 10.1016/0005-2736(83)90372-3; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; POST RL, 1972, J BIOL CHEM, V247, P6530; ROBINSON JD, 1969, BIOCHEMISTRY-US, V8, P3348, DOI 10.1021/bi00836a032; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1980, J BIOL CHEM, V255, P9852; TRAN CM, 1986, BIOCHIM BIOPHYS ACTA, V860, P9, DOI 10.1016/0005-2736(86)90492-X; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; WALTON TJH, 1994, J PHYSIOL-LONDON, V477P, pP26; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; WARD DG, 1994, J PHYSIOL-LONDON, V482, pP42; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	46	48	48	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12317	12321		10.1074/jbc.271.21.12317	http://dx.doi.org/10.1074/jbc.271.21.12317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647832	hybrid			2022-12-27	WOS:A1996UL66000034
J	Cole, AA; Chubinskaya, S; Schumacher, B; Huch, K; CsSzabo, G; Yao, J; Mikecz, K; Hasty, KA; Kuettner, KE				Cole, AA; Chubinskaya, S; Schumacher, B; Huch, K; CsSzabo, G; Yao, J; Mikecz, K; Hasty, KA; Kuettner, KE			Chondrocyte matrix metalloproteinase-8 - Human articular chondrocytes express neutrophil collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; SUBSTRATE-SPECIFICITY; AGGRECAN FRAGMENTS; CARTILAGE AGGRECAN; OSTEOARTHRITIS; DEGRADATION; POPULATIONS; PROTEINASE; RNA	This study confirms that normal human articular chondrocytes express neutrophil collagenase or matrix metalloproteinase-8 (MMP-8), a gene product previously thought to be expressed exclusively by neutrophil leukocytes. Both MMP-8 protein and mRNA were present in articular cartilages collected from normal human donors. Cartilage extracts were assayed by immunoblotting and by analysis of enzymatic activity on gelatin-substrate gels. Latent MMP-8 extracted from cartilage has a molecular mass of 55 kDa; active MMP-8 was identified at 46 and 42 kDa. In the absence of a reducing agent, MMP-8 migrated in a high molecular mass complex above 200 kDa. Northern blotting results demonstrated the expression of MMP-8 in chondrocytes, which could be up-regulated by stimulation with interleukin 1 beta. In addition, reverse transcription-polymerase chain reaction using nested primers and in situ hybridization revealed the presence of MMP-8 mRNA in chondrocytes. The presence of both MMP-8 protein and message in cartilage supports the concept that neutrophil collagenase could be the enzyme described as ''aggrecanase.''	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT ORTHOPED SURG, RUSH MED COLL, CHICAGO, IL 60612 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA; VET ADM MED CTR, MEMPHIS, TN 38104 USA	Rush University; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Cole, AA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, RUSH MED COLL, 1653 W CONGRESS PKWY, CHICAGO, IL 60612 USA.			Mikecz, Katalin/0000-0003-1506-4296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022603, R23AI022603, R29AI022603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22603] Funding Source: Medline; NIAMS NIH HHS [2-P50-AR-39239] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BURRIS TS, 1995, T ORTHOP RES SOC, V20, P335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUBINSKAYA S, 1995, T ORTHOP RES SOC, V20, P342; COLE AA, 1993, DEV BIOL, V159, P528, DOI 10.1006/dbio.1993.1261; Cole AA, 1995, ACTA ORTHOP SCAND, V66, P98, DOI 10.3109/17453679509157661; DEAN DD, 1989, MATRIX, V9, P366, DOI 10.1016/S0934-8832(89)80041-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FOSANG AJ, 1994, T ORTHOP RES SOC, V19, P48; FULOP C, 1993, J BIOL CHEM, V268, P17377; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1990, ARTHRITIS RHEUM, V33, P388, DOI 10.1002/art.1780330312; HASTY KA, 1987, ARTHRITIS RHEUM, V30, P695, DOI 10.1002/art.1780300613; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HORWITZ AL, 1977, P NATL ACAD SCI USA, V74, P897, DOI 10.1073/pnas.74.3.897; HUCH K, 1995, T ORTHOP RES SOC, V20, P338; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; MAINARDI CL, 1991, AM J MED SCI, V302, P171, DOI 10.1097/00000441-199109000-00010; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GN, 1994, ANN NY ACAD SCI, V732, P436, DOI 10.1111/j.1749-6632.1994.tb24778.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOLLEY DE, 1976, EUR J BIOCHEM, V69, P421, DOI 10.1111/j.1432-1033.1976.tb10926.x; YAO JL, 1992, CARDIOVASC RES, V26, P603, DOI 10.1093/cvr/26.6.603	32	163	165	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11023	11026		10.1074/jbc.271.18.11023	http://dx.doi.org/10.1074/jbc.271.18.11023			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631924	hybrid			2022-12-27	WOS:A1996UJ34200092
J	Mehta, DP; Ichikawa, M; Salimath, PV; Etchison, JR; Haak, R; Manzi, A; Freeze, HH				Mehta, DP; Ichikawa, M; Salimath, PV; Etchison, JR; Haak, R; Manzi, A; Freeze, HH			A lysosomal cysteine proteinase from Dictyostelium discoideum contains N-acetylglucosamine-1-phosphate bound to serine but not mannose-6-phosphate on N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; ALPHA-MANNOSIDASE; ENZYMES; IDENTIFICATION; CHROMATOGRAPHY; GLYCOPROTEINS; PURIFICATION	Previous studies showed that vegetative Dictyostelium discoideum cells make a lysosomal proteinase, proteinase-1, that contains multiple GlcNAc-alpha-1-P residues in phosphodiester linkage to serine, We extended these studies and, in contrast to earlier reports, found that proteinase-1 contains 7.5 mol of Fuc, 8 mol of Man, 2 mol of Xyl, and 30 mol of GlcNAc per calculated mol of protein but no Man-6-P residues, The protein binds to con canavalin A and wheat germ agglutinin lectin affinity columns, and PNGase-F digestion released most of the mannose and xylose but little of the GlcNAc, beta-Elimination under reducing conditions released only GlcNAc-alpha-1-P, There was no evidence for the release of disaccharides or of fucitol, A rabbit antiserum and monoclonal antibodies prepared against proteinase-1 recognize GlcNAc-alpha-1-P residues in immunoblots and are specifically competed by UDP-GlcNAc or GlcNAc-alpha-1-P, Use of other monoclonal antibodies showed the presence of mannose-6-sulfate on N-linked sugar chains, and alpha-fucose residues on the protein, Thus, proteinase-1 has at least two types of modifications: GlcNAc-alpha-1-P Ser, which we call phosphoglycosylation, and N-linked oligosaccharides. This is the first purified lysosomal enzyme in Dictyostelium that does not contain Man-6-P residues, The GlcNAc-alpha-1-P-specific antibodies also recognize a group of developmentally regulated proteins, especially enriched in vegetative cells, Some of them are also lysosomal cysteine proteinases, and all bind to the GlcNAc-alpha-1-P-specific monoclonal antibody but not to the mammalian CI-Man-6-P receptor, Conversely, lysosomal enzymes that have Man-6-P do not bind to the GlcNAc-alpha-1-P-specific antibody, An exception to this is beta-N-acetylglucosaminidase, where 15% of the activity binds to this antibody, Thus, there appear to be two sets of lysosomal enzymes with distinct post-translational modifications.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego				Freeze, Hudson/0000-0001-6316-0501	PHS HHS [32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENNETT VD, 1986, J BIOL CHEM, V261, P5355; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1993, ADV CELL MOL BIOL M, V1, P341; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Clamp J R, 1971, Methods Biochem Anal, V19, P229, DOI 10.1002/9780470110386.ch3; CLAUSEN H, 1988, MOL IMMUNOL, V25, P199, DOI 10.1016/0161-5890(88)90068-5; DIMOND RL, 1974, J BIOL CHEM, V249, P5628; EY PL, 1986, METHOD ENZYMOL, V121, P497; FINN DJ, 1987, BIOCHEM BIOPH RES CO, V148, P834, DOI 10.1016/0006-291X(87)90951-X; FREEZE HH, 1980, J BIOL CHEM, V255, P1081; FREEZE HH, 1985, J BIOL CHEM, V260, P8857; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; FREEZE HH, 1991, J BIOL CHEM, V267, P4431; FREEZE HH, 1991, DEV GENET, V11, P463; FREEZE HH, 1993, CELL SURFACE CARBOHY, P285; GABEL CA, 1984, J BIOL CHEM, V259, P3762; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; GUSTAFSON GL, 1980, BIOCHEM BIOPH RES CO, V94, P1439, DOI 10.1016/0006-291X(80)90580-X; GUSTAFSON GL, 1979, J BIOL CHEM, V254, P2471; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Harlow E., 1988, ANTIBODIES LAB MANUA; JUDELSON HS, 1988, DIFFERENTIATION, V37, P7, DOI 10.1111/j.1432-0436.1988.tb00790.x; JUDELSON HS, 1988, ARCH BIOCHEM BIOPHYS, V253, P305; LOOMIS WF, 1975, DICTYOSTELIUM DISCOI, P105; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MEHTA DP, 1995, ARCH BIOCHEM BIOPHYS, V321, P191, DOI 10.1006/abbi.1995.1385; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; NORTH MJ, 1985, BIOCHEM SOC T, V23, P288; PARK JT, 1949, J BIOL CHEM, V181, P149; ROUX L, 1988, J BIOL CHEM, V263, P8879; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SOUZA GM, 1995, J BIOL CHEM, V270, P28938, DOI 10.1074/jbc.270.48.28938; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P9; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; YOSHIMA H, 1979, ARCH BIOCHEM BIOPHYS, V194, P394, DOI 10.1016/0003-9861(79)90632-5	41	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10897	10903		10.1074/jbc.271.18.10897	http://dx.doi.org/10.1074/jbc.271.18.10897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631906	hybrid			2022-12-27	WOS:A1996UJ34200074
J	Caniggia, I; Liu, J; Kuliszewski, M; Tanswell, AK; Post, M				Caniggia, I; Liu, J; Kuliszewski, M; Tanswell, AK; Post, M			Fetal lung fibroblasts selectively down-regulate proteoglycan synthesis in response to elevated oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; GLYCOSAMINOGLYCAN SYNTHESIS; ARTICULAR-CARTILAGE; PULMONARY FIBROSIS; HYALURONIC-ACID; SMOOTH-MUSCLE; I BIGLYCAN; RAT LUNG; DECORIN	Cell proliferation is in part regulated by extracellular matrix, Therefore, it is possible that elevated O-2 may indirectly affect lung fibroblast growth via modulation of extracellular matrix, In the present study, we investigated the effect of elevated O-2 on the synthesis of glycosaminoglycans (GrAGs) and proteoglycans (PGs) by fetal lung fibroblasts. A 48-h exposure to greater than or equal to 50% O-2 reduced the incorporation of [H-3]glucosamine and (SO4)-S-35 into GAGs by fetal lung fibroblasts. The relative proportion of the individual GAG molecules was not altered by elevated O-2, Fibroblasts exposed to 50% O-2 secreted less [S-35]proteoglycans into the medium than controls. Specifically, the synthesis of the small soluble PG, biglycan, was decreased by exposure to 50% O-2. Fetal lung fibroblasts did not synthesize the small chondroitin/dermatan sulfate FG decorin, Elevated O-2 concentrations also reduced the synthesis of membrane- and matrix-associated PGs, Furthermore, exposure of fetal lung fibroblasts to greater than or equal to 50% O-2 resulted in a decreased mRNA expression for biglycan and versican core protein sequences, Ttl contrast, elevated O, increased the message for type I collagen and fibronectin without affecting that of p-actin. The inhibitory effect of elevated O-2 on biglycan mRNA and protein expression was overcome by incubating the cells in 3% O-2 after the 48-h exposure to 50% O-2. The latter treatment also reversed the increased mRNA expression of type I collagen associated with elevated O-2 but not that of fibronectin, These results demonstrate that fetal lung fibroblasts, in response to elevated oxygen concentrations, selectively down-regulate their GAG and PG synthesis and that this O-2 effect is reversible.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PAEDIAT,MRC,GRP LUNG DEV,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Caniggia, Isabella/G-6466-2013	Caniggia, Isabella/0000-0001-7340-2359				BASSET F, 1986, AM J PATHOL, V122, P443; BATES EJ, 1984, ANN RHEUM DIS, V43, P462, DOI 10.1136/ard.43.3.462; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BJERMER L, 1987, BRIT MED J, V295, P803, DOI 10.1136/bmj.295.6602.803; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; CANIGGIA I, 1992, EXP CELL RES, V202, P252, DOI 10.1016/0014-4827(92)90072-G; CANTOR JO, 1980, P SOC EXP BIOL MED, V164, P1; CANTOR JO, 1983, P SOC EXP BIOL MED, V173, P362; CASTOR CW, 1983, IN VITRO CELL DEV B, V19, P462; CHANDRAKASAN G, 1991, CELL MOL BIOL, V37, P751; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; DURR RA, 1987, EXP MOL PATHOL, V47, P219, DOI 10.1016/0014-4800(87)90077-3; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P168; FERRARA TB, 1992, AM J RESP CELL MOL, V6, P219, DOI 10.1165/ajrcmb/6.2.219; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; JUUL SE, 1991, LUNG SCI F, P413; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KASHIHARA N, 1992, P NATL ACAD SCI USA, V89, P6309, DOI 10.1073/pnas.89.14.6309; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LEE YJ, 1987, J CHROMATOGR-BIOMED, V419, P275, DOI 10.1016/0378-4347(87)80286-4; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391; MARTIN GR, 1989, PEPTIDE GROWTH FACTO, V2, P463; MAST BA, 1993, MATRIX, V13, P441, DOI 10.1016/S0934-8832(11)80110-1; MILLIGAN SA, 1995, EXP LUNG RES, V21, P559, DOI 10.3109/01902149509031759; MOORE AM, 1995, AM J PHYSIOL-LUNG C, V268, pL78, DOI 10.1152/ajplung.1995.268.1.L78; PANASYUK A, 1994, FREE RADICAL BIO MED, V16, P157, DOI 10.1016/0891-5849(94)90139-2; RILEY DJ, 1984, TOXICOL APPL PHARM, V75, P554, DOI 10.1016/0041-008X(84)90192-3; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SMITH CI, 1990, CELL DIFFER DEV, V32, P83, DOI 10.1016/0922-3371(90)90102-3; Snedecor GW, 1980, STAT METHODS, V7th; STEEL RGD, 1970, PRINCIPLES PROCEDURE; TANSWELL AK, 1990, BIOCHIM BIOPHYS ACTA, V1044, P269, DOI 10.1016/0005-2760(90)90313-M; THURLBECK WM, 1978, HUM PATHOL, V9, P492, DOI 10.1016/S0046-8177(78)80130-0; Toole B.P., 1981, CELL BIOL EXTRACELLU, P259, DOI DOI 10.1007/978-1-4613-0881-2_10; VENESSMEEHAN KA, 1994, AM J RESP CELL MOL, V11, P509, DOI 10.1165/ajrcmb.11.5.7946380; WESTERNGRENTHOR.G, 1993, J CLIN INVEST, V92, P623; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	49	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6625	6630		10.1074/jbc.271.12.6625	http://dx.doi.org/10.1074/jbc.271.12.6625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636078	hybrid			2022-12-27	WOS:A1996UB15700013
J	Howles, PN; Carter, CP; Hui, DY				Howles, PN; Carter, CP; Hui, DY			Dietary free and esterified cholesterol absorption in cholesterol esterase (bile salt-stimulated lipase) gene-targeted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; LEUKEMIA INHIBITORY FACTOR; EMBRYONIC STEM-CELLS; ACYL COENZYME-A; RAT-LIVER; INTESTINAL-CELLS; HYDROLASE; EXPRESSION; ACYLTRANSFERASE; TRANSPORT	The involvement of pancreatic cholesterol esterase (bile salt-stimulated lipase) in cholesterol absorption through the intestine has been controversial. We have addressed this issue by using homologous recombination in embryonic stem cells to produce mice lacking a functional cholesterol esterase gene. Cholesterol esterase knockout mice and their wild type counterparts were fed a bolus dose of [H-3]cholesterol and a trace amount of [beta-C-14]sitosterol by gavage. The ratio of the two radiolabels excreted in the feces over a 24-h period was found to be similar in the control and cholesterol esterase-null mice, Similar results were observed when the radiolabeled sterols were supplied in an emulsion with phospholipid and triolein or in lipid vesicles with phosphatidylcholine. Cholesterol absorption results were similar between the control and cholesterol esterase-null mice regardless of whether the animals were fed a low fat diet or a high fat/high cholesterol diet. The rate of [H-3]cholesterol appearance in the serum of the gene-targeted mice paralleled that observed in control animals. In contrast to these results, when experiments were performed with [H-3]cholesteryl oleate instead of [H-3]cholesterol, a higher amount of the H-3 radiolabel was found excreted in feces and dramatically less of the radiolabel was detected in the serum of the cholesterol esterase-null mice in comparison with that detected in control animals. Serum cholesterol levels were not significantly different between control and cholesterol esterase-null mice fed either control or an atherogenic diet. These results indicate that cholesterol esterase is responsible for mediating intestinal absorption of cholesteryl esters but does not play a primary role in free cholesterol absorption.	UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHAT SG, 1982, BIOCHEM BIOPH RES CO, V109, P486, DOI 10.1016/0006-291X(82)91747-8; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CHEN Q, 1989, BIOCHIM BIOPHYS ACTA, V1004, P372, DOI 10.1016/0005-2760(89)90086-6; CHEN Q, 1994, BBA-LIPID LIPID MET, V1210, P239, DOI 10.1016/0005-2760(94)90127-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK SB, 1984, J LIPID RES, V25, P148; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUELAND S, 1993, J LIPID RES, V34, P923; FERNANDEZ E, 1989, BIOCHIM BIOPHYS ACTA, V1001, P249, DOI 10.1016/0005-2760(89)90107-0; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; GALLO LL, 1984, J LIPID RES, V25, P604; GALLO LL, 1987, J LIPID RES, V28, P381; GALLO LL, 1977, P SOC EXP BIOL MED, V156, P277; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRUNDY SM, 1968, J LIPID RES, V9, P374; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; HERNELL O, 1994, J PEDIATR-US, V125, pS56, DOI 10.1016/S0022-3476(06)80737-7; HUANG Y, 1990, J LIPID RES, V31, P2029; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KIRK EA, 1995, J LIPID RES, V36, P1522; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KRAUSE BR, 1993, J LIPID RES, V34, P279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI QT, 1993, BIOCHIM BIOPHYS ACTA, V1166, P145, DOI 10.1016/0005-2760(93)90090-V; LIPKA G, 1995, J BIOL CHEM, V270, P5917, DOI 10.1074/jbc.270.11.5917; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; MCKEAN ML, 1992, FASEB J, V6, pA1388; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PHILLIPS GB, 1960, BIOCHIM BIOPHYS ACTA, V41, P361, DOI 10.1016/0006-3002(60)90026-3; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; RUDD EA, 1987, BIOCHIM BIOPHYS ACTA, V918, P106, DOI 10.1016/0005-2760(87)90184-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; SHAMIR R, 1995, BIOCHEMISTRY-US, V34, P6351, DOI 10.1021/bi00019a013; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; THOMSON ABR, 1993, CAN J PHYSIOL PHARM, V71, P531, DOI 10.1139/y93-078; THURNHOFER H, 1991, BIOCHIM BIOPHYS ACTA, V1064, P275, DOI 10.1016/0005-2736(91)90312-V; TRABER MG, 1990, GASTROENTEROLOGY, V98, P96, DOI 10.1016/0016-5085(90)91296-I; TREADWELL CR, 1968, HANDBOOK PHYSIOLOG 6, V3, P1407; WATT SM, 1981, J LIPID RES, V22, P157; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WILSON MD, 1994, J LIPID RES, V35, P943; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465; ZOLFAGHARI R, 1989, P NATL ACAD SCI USA, V86, P6913, DOI 10.1073/pnas.86.18.6913	52	159	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7196	7202		10.1074/jbc.271.12.7196	http://dx.doi.org/10.1074/jbc.271.12.7196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636157	hybrid			2022-12-27	WOS:A1996UB15700092
J	Hughes, PE; DiazGonzalez, F; Leong, L; Wu, CY; McDonald, JA; Shattil, SJ; Ginsberg, MH				Hughes, PE; DiazGonzalez, F; Leong, L; Wu, CY; McDonald, JA; Shattil, SJ; Ginsberg, MH			Breaking the integrin hinge - A defined structural constraint regulates integrin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; EXTRACELLULAR-MATRIX; PLATELET ACTIVATION; CYTOPLASMIC DOMAIN; FOCAL ADHESIONS; GPIIB-IIIA; RECEPTOR; MODULATION; AFFINITY; MUTATION	Integrins are heterodimeric (alpha, beta) cell adhesion receptors, We demonstrate that point mutations in the cytoplasmic domains of both the alpha and beta subunits promote constitutive signaling by the integrin alpha(IIIb)beta(3). BY generating charge reversal mutations, we show these ''activating'' mutations may act by disrupting a potential salt bridge between the membrane-proximal portions of the alpha and beta subunit cytoplasmic domains, Thus, the modulation of specific interactions between the alpha and beta subunit cytoplasmic domains may regulate transmembrane signaling through integrins, In addition, these activating mutations induce dominant alterations in cellular behavior, such as the assembly of the extracellular matrix, Consequently, somatic mutations in integrin cytoplasmic domains could have profound effects in vivo on integrin-dependent functions such as matrix assembly, cell migration, and anchorage-dependent cell growth and survival.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; MAYO CLIN SCOTTSDALE, SAMUEL C JOHNSON MED RES CTR, SCOTTSDALE, AZ 85259 USA	Scripps Research Institute; Mayo Clinic; Mayo Clinic Phoenix			Diaz-Gonzalez, Federico/R-2382-2019	Diaz-Gonzalez, Federico/0000-0002-4139-9295; Leong, Lilley/0000-0003-1041-0110				ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BRIESEWITZ R, 1995, MOL BIOL CELL, V6, P997, DOI 10.1091/mbc.6.8.997; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CROWE DT, 1994, J BIOL CHEM, V269, P14411; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAGHMAI R, 1992, P NATL ACAD SCI USA, V89, P7890, DOI 10.1073/pnas.89.17.7890	32	491	498	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6571	6574		10.1074/jbc.271.12.6571	http://dx.doi.org/10.1074/jbc.271.12.6571			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636068				2022-12-27	WOS:A1996UB15700003
J	Kolatkar, AR; Weis, WI				Kolatkar, AR; Weis, WI			Structural basis of galactose recognition by C-type animal lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; MOLECULAR-CLONING; N-ACETYLGALACTOSAMINE; CDNA	The asialoglycoprotein receptors and many other C-type (Ca2+-dependent) animal lectins specifically recognize galactose- or N-acetylgalactosamine-terminated oligosaccharides. Analogous binding specificity can be engineered into the homologous rat mannose-binding protein A by changing three amino acids and inserting a glycine-rich loop (Iobst, S. T,, and Drickamer, K. (1994) J. Biol, Chem. 269, 15512-15519), Crystal structures of this mutant complexed with beta-methyl galactoside and N-acetylgalactosamine (GalNAc) reveal that as with wild-type mannose-binding proteins, the 3- and 4-OH groups of the sugar directly coordinate Ca2+ and form hydrogen bonds with amino acids that also serve as Ca2+ ligands, The different stereochemistry of the 3- and 4-OH groups in mannose and galactose, combined with a fixed Ca2+ coordination geometry, leads to different pyranose ring locations in the two cases. The glycine-rich loop provides selectivity against mannose by holding a critical tryptophan in a position optimal for packing with the apolar face of galactose but incompatible with mannose binding, The 2-acetamido substituent of GalNAc is in the vicinity of amino acid positions identified by site-directed mutagenesis (Iobst, S. T,, and Drickamer, K. (1996) J, Biol, Chem. 271, 6686-6693) as being important for the formation of a GalNAc-selective binding site.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA	Stanford University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGYAL SJ, 1972, AUST J CHEM, V25, P1695, DOI 10.1071/CH9721695; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; II M, 1990, J BIOL CHEM, V265, P11295; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; IOBST ST, 1994, J BIOL CHEM, V269, P15505; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE RT, 1991, J BIOL CHEM, V266, P4810; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; VAVASSEUR F, 1990, INT J CANCER, V45, P744, DOI 10.1002/ijc.2910450429; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WEISS WI, 1996, IN PRESS ANN REV BIO, V65	26	171	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6679	6685		10.1074/jbc.271.12.6679	http://dx.doi.org/10.1074/jbc.271.12.6679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636086	hybrid			2022-12-27	WOS:A1996UB15700021
J	McCarter, JD; Withers, SG				McCarter, JD; Withers, SG			Unequivocal identification of Asp-214 as the catalytic nucleophile of Saccharomyces cerevisiae alpha-glucosidase using 5-fluoro glycosyl fluorides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM BETA-GLUCOSIDASE; ACID-SEQUENCE SIMILARITIES; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; HYDROLASES; CLASSIFICATION; INHIBITORS; MECHANISM; AMYLASE; PEPTIDE	Yeast alpha-glucosidase is a member of a sequence-related family of alpha-glycosidases (Family 13) that includes important digestive alpha-amylases and alpha-glucosidases. These enzymes catalyze the hydrolysis of alpha-linked oligosaccharides by a two-step mechanism involving a glycosyl-enzyme intermediate. This intermediate can be trapped by use of 5-fluoro-alpha-D-glucosyl fluoride or 5-fluoro-beta-L-idosyl fluoride, members of a new class of mechanism-based glycosidase inactivators. Both of these trapped 5-fluoro glycosyl enzyme intermediates are catalytically competent, turning over when freed of excess inactivator and releasing free enzyme. Two glycosylated peptides in proteolytic digests of these trapped glycosyl enzyme intermediates were identified by use of neutral loss scans on an electrospray ionization triple quadrupole mass spectrometer. Further tandem mass spectrometric analysis in daughter ion scan mode allowed identification of Asp-214 as the catalytic nucleophile in yeast alpha-glucosidase, and this identification was confirmed by aminolysis of the labeled peptide and high resolution mass spectrometry. This residue is one of three active site carboxylates that are completely conserved in this family, thus confirming the role of Asp-214 and the equivalent residues in other family members as the catalytic nucleophile. The other two conserved carboxylates are likely involved in acid/base catalysis.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA	University of British Columbia								BUSCH KL, 1983, TANDEM MASS SPECTROM; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KONSTANTINIDIS A, 1991, BIOCHEM J, V279, P587, DOI 10.1042/bj2790587; Leatherbarrow R.J, 1990, GRAFIT VERSION 3 0; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1996, J AM CHEM SOC, V118, P241, DOI 10.1021/ja952732a; MCCARTER JD, 1995, THESIS U BRIT COLUMB; MIAO SC, 1994, J BIOL CHEM, V269, P10975; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; MOOSER G, 1991, J BIOL CHEM, V266, P8916; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; QUARONI A, 1976, J BIOL CHEM, V251, P3250; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TAKASE K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P281, DOI 10.1016/0167-4838(92)90249-D; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1995, PROTEIN SCI, V4, P361; YUAN JM, 1994, BIOCHEM J, V299, P527, DOI 10.1042/bj2990527	28	120	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6889	6894		10.1074/jbc.271.12.6889	http://dx.doi.org/10.1074/jbc.271.12.6889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636115	hybrid			2022-12-27	WOS:A1996UB15700050
J	Emi, Y; Ikushiro, S; Iyanagi, T				Emi, Y; Ikushiro, S; Iyanagi, T			Xenobiotic responsive element-mediated transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR AROMATIC-COMPOUNDS; INDUCIBLE EXPRESSION; PROMOTER REGION; HUMAN BILIRUBIN; P-450C GENE; AH RECEPTOR; RAT; CLONING; IDENTIFICATION; CELLS	We have isolated genomic DNA clones containing rat UDP-glucuronosyltransferase family 1 (UGT1) sequences and have shown drug-responsive and tissue-specific alternative expression of multiple first exons (Emi, Y., Ikushiro, S., and Iyanagi, T. (1995) J. Biochem. (Tokyo) 117, 392-399). The UGT1 locus encodes at least nine UGT1 isoforms. UGT1A1 is a major 3-methylcholanthene (MC)-inducible form in rat liver, In this report, we have identified a cis-acting element necessary for transcriptional activation of UGT1A1 in hepatocytes. A promoter region was fused to a chloramphenicol acetyltransferase gene, and the resultant construct was transiently transfected into hepatocytes. A DNA fragment carrying 1,100 nucleotides derived from the 5'-flanking region of the UGT1A1 gene was enough for MC induction. Unidirectional deletion of this region revealed that there existed one xenobiotic responsive element (XRE), TGCGTG, between -134 and -129, When a single base substitution was introduced into the XRE, MC-induced expression of the UGT1A1 gene was completely abolished. In addition, an XRE deleted construct failed to respond to MC. Gel mobility shift assays showed MC-inducible binding of the nuclear aromatic hydrocarbon receptor-ligand complex to this motif, Gel shift coupled DNase I protection analyses revealed that the GCGTG-core sequence was a target site of the liganded aromatic hydrocarbon receptor. These results suggest that the XRE participates in induction of the rat UGT1A1 gene by MC.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HIMEJI,HYOGO 67812,JAPAN	University of Hyogo								ALMB JG, 1994, BIOCHEMISTRY-US, V33, P10513; [Anonymous], 1980, GLUCURONIDATION DRUG; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; CLARKE DJ, 1992, FEBS LETT, V299, P183, DOI 10.1016/0014-5793(92)80243-A; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; EMI Y, 1990, P NATL ACAD SCI USA, V87, P9746, DOI 10.1073/pnas.87.24.9746; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; IYANAGI T, 1991, J BIOL CHEM, V266, P24048; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; KASPER CB, 1980, ENZYMATIC BASIS DETO, V2, P3; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LI Y, 1992, J BIOL CHEM, V267, P15097; Maxam A M, 1980, Methods Enzymol, V65, P499; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OWENS IS, 1977, J BIOL CHEM, V252, P2827; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1990, BIOCHEM BIOPH RES CO, V169, P260, DOI 10.1016/0006-291X(90)91462-2; SHEN ES, 1989, J BIOL CHEM, V264, P17754; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	38	123	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3952	3958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632018	hybrid			2022-12-27	WOS:A1996TV72400092
J	Gorr, SU				Gorr, SU			Differential storage of prolactin, granins (chromogranin B and secretogranin II), and constitutive secretory markers in rat pituitary GH(4)C(1) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROTEIN-I; GH4C1 CELLS; REGULATED PATHWAY; AGGREGATION; CALCIUM; PROTEOGLYCAN; GRANULES; FORMS; LINE	The rat pituitary cell line GH(4)C(1) secretes granins (chromogranin B and secretogranin II) and prolactin by the regulated secretory pathway. The intracellular storage of prolactin is preferentially induced by hormone treatment with estradiol, insulin, and epidermal growth factor. The goal of this study was to determine the effect of hormone treatment on storage of granins and constitutive secretory markers. The granins were efficiently stored in both hormone-treated and -untreated cells (17% of total secreted in 4 h). Secreted alkaline phosphatase (SEAP), a truncated membrane protein that would not be expected to enter secretory granules, and glycosaminoglycan, a marker for the constitutive secretory pathway, exhibited 70-80% secretion under both conditions. In comparison, the relative prolactin secretion was 31 and 68% from hormone-treated and -untreated cells, respectively. Phorbol ester and KCl stimulated prolactin secretion 2.3-fold from untreated cells and 5.5-fold from hormone-treated cells. In contrast, SEAP secretion was stimulated 1.5-fold from both treated and untreated cells, consistent with secretion by the constitutive secretory pathway. Stimulated secretion of granins was detected from both hormone-treated and -untreated cells. These results suggest that granin and prolactin storage are differentially regulated and that the constitutive secretory pathway is not affected by hormone treatment.			Gorr, SU (corresponding author), UNIV LOUISVILLE,HLTH SCI CTR,DEPT BIOL & BIOPHYS SCI,ENDOCRINE CELL BIOL LAB,LOUISVILLE,KY 40292, USA.				NIDCR NIH HHS [DE11469] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011469] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARRANDALE JM, 1994, MOL ENDOCRINOL, V8, P1083, DOI 10.1210/me.8.8.1083; BURGESS TL, 1984, J CELL BIOL, V99, P2223, DOI 10.1083/jcb.99.6.2223; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1988, BONE MINER, V4, P17; GORR SU, 1992, J BIOL CHEM, V267, P21595; GORR SU, 1987, BONE MINER, V2, P251; GORR SU, 1991, J BIOL CHEM, V266, P5780; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GORR SU, 1990, J BIOL CHEM, V265, P3012; GORR SU, 1987, CALCIUM REGULATION B, V9, P49; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HINKLE PM, 1992, ENDOCRINOLOGY, V130, P3503, DOI 10.1210/en.130.6.3503; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; REAVES BJ, 1990, MOL ENDOCRINOL, V4, P1017, DOI 10.1210/mend-4-7-1017; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SCAMMELL JG, 1990, J HISTOCHEM CYTOCHEM, V38, P117, DOI 10.1177/38.1.2403576; SCAMMELL JG, 1990, J HISTOCHEM CYTOCHEM, V38, P949, DOI 10.1177/38.7.2192000; SCAMMELL JG, 1993, TRENDS ENDOCRIN MET, V4, P14, DOI 10.1016/1043-2760(93)90058-M; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; SCHMIDT WK, 1994, J BIOL CHEM, V269, P27115; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; THOMPSON ME, 1992, ENDOCRINOLOGY, V131, P318, DOI 10.1210/en.131.1.318	33	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3575	3580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631964				2022-12-27	WOS:A1996TV72400038
J	Kentrup, H; Becker, W; Heukelbach, J; Wilmes, A; Schurmann, A; Huppertz, C; Kainulainen, H; Joost, HG				Kentrup, H; Becker, W; Heukelbach, J; Wilmes, A; Schurmann, A; Huppertz, C; Kainulainen, H; Joost, HG			Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION SITES; CONSERVED FEATURES; IDENTIFICATION; ENCODES; FAMILY; AUTOPHOSPHORYLATION; CLASSIFICATION; SEQUENCES; INVITRO	The cDNA of a novel, ubiquitously expressed protein kinase (Dyrk) was cloned from a rat brain cDNA library, The deduced amino acid sequence (763 amino acids) contains a catalytic domain that is only distantly related to that of other mammalian protein kinases, Its closest relative is the protein kinase Mnb of Drosophila, which is presumably involved in postembryonic neurogenesis (85% identical amino acids within the catalytic domain). Outside the catalytic domain, the sequence comprises several striking structural features: a bipartite nuclear translocation signal, a tyrosine-rich hydrophilic motif flanking the nuclear localization signal, a PEST region, a repeat of 13 histidines, a repeat of 17 serine/threonine residues, and an alternatively spliced insertion of nine codons, A recombinant glutathione S-transferase-Dyrk fusion protein catalyzed autophosphorylation and histone phosphorylation on tyrosine and serine/threonine residues with an apparent K-m of approximately 3.4 mu M. Exchange of two tyrosine residues in the ''activation loop'' between subdomains VII and VIII for phenylalanine almost completely suppressed the activity and tyrosine autophosphorylation of Dyrk, Tyrosine autophosphorylation was also reduced by exchange of the tyrosine (Tyr-219) in a tyrosine phosphorylation consensus motif, The data suggest that Dyrk is a dual specificity protein kinase that is regulated by tyrosine phosphorylation in the activation loop and might be a component of a signaling pathway regulating nuclear functions.	RHEIN WESTFAL TH AACHEN, FAK MED, INST PHARMAKOL & TOXIKOL, D-52057 AACHEN, GERMANY	RWTH Aachen University			Joost, Hans-Georg/J-4462-2013; Becker, Walter/B-8889-2008	Joost, Hans-Georg/0000-0002-5860-606X; Becker, Walter/0000-0002-0347-4768; Kainulainen, Heikki/0000-0001-5102-4350; Schurmann, Annette/0000-0002-4113-4377				BECKER W, 1994, J BIOL CHEM, V269, P22586; BOWDISH KS, 1994, MOL CELL BIOL, V14, P7909, DOI 10.1128/MCB.14.12.7909; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3; WANG QM, 1994, J BIOL CHEM, V269, P14566; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YUAN CJ, 1993, J BIOL CHEM, V268, P17683; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	41	207	221	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3488	3495						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631952				2022-12-27	WOS:A1996TV72400026
J	Rozema, D; Gellman, SH				Rozema, D; Gellman, SH			Artificial chaperone-assisted refolding of carbonic anhydrase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLODEXTRIN INCLUSION COMPLEXES; CHLORIDE-DENATURED RHODANESE; MOLTEN-GLOBULE STATE; GUANIDINIUM CHLORIDE; LAURYL MALTOSIDE; PROTEIN; HEAT; INTERMEDIATE; AGGREGATION; DETERGENT	We recently reported a new approach to protein refolding that utilizes a pair of low molecular weight folding assistants, a detergent and a cyclodextrin (Rozema, D., and Gellman, S. H. (1995) J. Am. Chem. Soc. 117, 2373-2374). Here, we provide a detailed study of carbonic anhydrase B (CAB) refolding assisted by these ''artificial chaperones.'' When CAB is heated in the presence of a competent detergent, or when guanidinium-denatured CAB is diluted to nondenaturing guanidinium concentration in the presence of such a detergent, the detergent forms a complex with the nonnative protein, thereby preventing aggregation, CAB is unable to refold from the detergent-complexed state, but folding can be induced by introduction of a cyclodextrin, which strips the detergent away from the protein, Use of artificial chaperones provides excellent yields of reactivated CAB under conditions that lead to little or no reactivation in the absence of the refolding assistants. Our studies show that the detergent can capture the unfolded protein even at submicellar concentrations, but that not all CAB-detergent complexes lead efficiently to refolded enzyme upon introduction of the stripping agent, Effective refolding appears to require that detergent stripping occur as rapidly as possible; intrinsically slow methods of detergent removal (dialysis or use of macroscopic adsorbents) are less effective than cyclodextrin at inducing renaturation upon detergent removal, The detailed characterization of artificial chaperone-assisted CAB refolding reported here should guide the application of this strategy to other proteins.	UNIV WISCONSIN, DEPT CHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANATHAPADMANABH.KP, 1993, INTERACTIONS SURFACT, P319; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASSIM JY, 1969, BIOCHEMISTRY-US, V8, P1947, DOI 10.1021/bi00833a026; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1992, BIO-TECHNOL, V10, P1013, DOI 10.1038/nbt0992-1013; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; CLELAND JL, 1993, ACS S SERIES, V526; DHARMAWARDANA UR, 1993, LANGMUIR, V9, P2258, DOI 10.1021/la00033a003; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; EFTINK MR, 1989, J AM CHEM SOC, V111, P6765, DOI 10.1021/ja00199a041; EPSTEIN CJ, 1962, J BIOL CHEM, V237, P2175; GEORGIOU G, 1991, ACS S SERIES, V470; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guo J. H., 1992, SURFACTANT SCI TECHN, V327, P1008, DOI [10.1126/science.1182570, 10.1126/science.288.5464.301]; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; INOUE Y, 1983, CARBOHYD RES, V118, P37, DOI 10.1016/0008-6215(83)88033-1; KARUPPIAH N, 1995, BIOCHEM BIOPH RES CO, V211, P60, DOI 10.1006/bbrc.1995.1778; KUSZEWSKI J, 1994, PROTEIN SCI, V3, P1945, DOI 10.1002/pro.5560031106; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LIGHT A, 1985, Biotechniques, V3, P298; LIVERI VT, 1992, THERMOCHIM ACTA, V199, P125; MATSUI Y, 1985, TOP CURR CHEM, V128, P61; MCCOY LF, 1981, BIOCHEMISTRY-US, V20, P3062, DOI 10.1021/bi00514a012; Pace C N, 1986, Methods Enzymol, V131, P266; PALEPU R, 1988, CAN J CHEM, V66, P325, DOI 10.1139/v88-056; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; SCHOTT H, 1964, J PHYS CHEM-US, V68, P3612, DOI 10.1021/j100794a029; TAGUCHI H, 1993, J BIOL CHEM, V268, P5371; TAKAHASHI S, 1986, B CHEM SOC JPN, V59, P1129, DOI 10.1246/bcsj.59.1129; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; TANDON S, 1988, BIOCHIM BIOPHYS ACTA, V955, P19, DOI 10.1016/0167-4838(88)90175-6; WANG Z, 1992, PROTEIN SCI, V1, P522; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; WONG KP, 1973, J BIOL CHEM, V248, P8518; XIE Y, 1996, IN PRESS PROTEIN SCI; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811; ZARDENETA G, 1992, EUR J BIOCHEM, V210, P831, DOI 10.1111/j.1432-1033.1992.tb17486.x	45	189	205	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3478	3487						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631951				2022-12-27	WOS:A1996TV72400025
J	vanKesteren, RE; Tensen, CP; Smit, AB; vanMinnen, J; Kolakowski, LF; Meyerhof, W; Richter, D; vanHeerikhuizen, H; Vreugdenhil, E; Geraerts, WPM				vanKesteren, RE; Tensen, CP; Smit, AB; vanMinnen, J; Kolakowski, LF; Meyerhof, W; Richter, D; vanHeerikhuizen, H; Vreugdenhil, E; Geraerts, WPM			Co-evolution of ligand-receptor pairs in the vasopressin oxytocin superfamily of bioactive peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BETA-2-ADRENERGIC RECEPTOR; SEQUENCE ALIGNMENT; PROTEIN; NEUROPEPTIDES; CONOPRESSIN; EXPRESSION	In order to understand the molecular mechanisms that underlie the co-evolution of related yet functionally distinct peptide-receptor pairs, we study receptors for the vasopressin-related peptide Lys-conopressin in the mollusc Lymnaea stagnalis, In addition to a previously cloned Lys-conopressin receptor (LSCPR1), we have now identified a novel Lys-conopressin receptor subtype, named LSCPR2. The two receptors have a differential distribution in the reproductive organs and the brain, which suggests that they are involved in the control of distinct aspects of reproduction and mediate transmitter-like and/or modulatory effects of Lys-conopressin on different types of central neurons. In contrast to LSCPR1, LSCPR2 is maximally activated by both Lys-conopressin and Ile-conopressin, an oxytocin-like synthetic analog of Lys-conopressin. Together with a study of the phylogenetic relationships of Lys-conopressin receptors and their vertebrate counterparts, these data suggest that LSCPR2 represents an ancestral receptor to the vasopressin/oxytocin receptor family in the vertebrates, Based on our findings, we provide a theory of the molecular co-evolution of the functionally distinct ligand-receptor pairs of the vasopressin/oxytocin superfamily of bioactive peptides.	FREE UNIV AMSTERDAM,INST NEUROSCI,GRAD SCH NEUROSCI AMSTERDAM,DEPT BIOCHEM,1081 HV AMSTERDAM,NETHERLANDS; CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV HAMBURG,INST ZELLBIOCHEM & KLIN NEUROBIOL,D-20246 HAMBURG,GERMANY	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Vrije Universiteit Amsterdam; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Hamburg	vanKesteren, RE (corresponding author), FREE UNIV AMSTERDAM,FAC BIOL,INST NEUROSCI,GRAD SCH NEUROSCI AMSTERDAM,DEPT EXPTL ZOOL,1081 HV AMSTERDAM,NETHERLANDS.		van Kesteren, Ronald E/E-2505-2014; Smit, August B/E-8410-2011	Tensen, Cornelis/0000-0002-5325-1888; van Kesteren, Ronald/0000-0002-9592-3777				ACHER R, 1993, REGUL PEPTIDES, V45, P1, DOI 10.1016/0167-0115(93)90174-7; ACHER R, 1980, PROC R SOC SER B-BIO, V210, P21, DOI 10.1098/rspb.1980.0116; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; CHAUVET J, 1994, P NATL ACAD SCI USA, V91, P11266, DOI 10.1073/pnas.91.23.11266; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; CRUZ LJ, 1987, J BIOL CHEM, V262, P15821; CUNNINGHAM ET, 1991, TRENDS NEUROSCI, V14, P406, DOI 10.1016/0166-2236(91)90032-P; GERAERTS WPM, 1994, FLEXIBILITY CONSTRAI, P209; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; Hruby V. J., 1981, TOPICS MOL PHARM, V1, P99; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; IVELL R, 1992, MOL CELL ENDOCRINOL, V89, P59, DOI 10.1016/0303-7207(92)90211-N; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAHLMANN S, 1994, P NATL ACAD SCI USA, V91, P1342, DOI 10.1073/pnas.91.4.1342; MAYER EA, 1991, AM J PHYSIOL, V261, pG171, DOI 10.1152/ajpgi.1991.261.2.G171; MCMASTER D, 1992, PEPTIDES, V13, P413, DOI 10.1016/0196-9781(92)90069-F; MEYERHOF W, 1988, P NATL ACAD SCI USA, V85, P714, DOI 10.1073/pnas.85.3.714; MEYERHOF W, 1993, NEUROTRANSMITTER REC, P339; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NIELSEN DB, 1994, TOXICON, V32, P845, DOI 10.1016/0041-0101(94)90009-4; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SHARIF M, 1992, NATURE, V357, P279, DOI 10.1038/357279a0; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; Van Der Steen W. J., 1969, NETH J ZOOL, V19, P131, DOI DOI 10.1163/002829669X00170; VANKESTEREN RE, 1995, NEURON, V15, P897, DOI 10.1016/0896-6273(95)90180-9; VANKESTEREN RE, 1995, J NEUROSCI, V15, P5989	47	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3619	3626						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631971				2022-12-27	WOS:A1996TV72400045
J	Richards, JP; Bachinger, HP; Goodman, RH; Brennan, RG				Richards, JP; Bachinger, HP; Goodman, RH; Brennan, RG			Analysis of the structural properties of cAMP-responsive element-binding protein (CREB) and phosphorylated CREB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; CIRCULAR-DICHROISM SPECTRA; NUCLEAR FACTOR CREB; DNA-BINDING; SECONDARY STRUCTURE; TRANSACTIVATION DOMAIN; ACTIVATION DOMAINS; GENE-TRANSCRIPTION; GCN4; EXPRESSION	The transcription factor CREB (cAMP responsive element binding protein) is activated by protein kinase A (PKA) phosphorylation of a single serine residue. To investigate possible mechanisms of CREB regulation by phosphorylation, we initiated a structural and biophysical characterization of the full-length, wild-type CREB protein, an altered CREB protein (CREB/SER) in which the three cysteine residues in the DNA-binding domain were replaced with serine residues and a truncated protein (ACT265) which encompasses the entire activation domain of CREB. Circular dichroism (CD) reveals that CREB and CREB/SER have identical secondary structures and contain approximately 20% alpha-helix, 9% beta-strand, 34% beta-turn, and 37% random coil structures. PKA phosphorylation does not alter the CD spectra, and therefore the secondary structure, of CREB or of CREB bound to DNA. Protease cleavage patterns indicate that PKA phosphorylation does not induce a global conformational change in CREB. Furthermore, PKA phosphorylation does not change the DNA binding affinity of CREB for either canonical or non-canonical CRE sequences as measured by a fluorescence anisotropy DNA binding assay. Since PKA phosphorylation of CREB results in its specific binding to the transcriptional coactivators CREB-binding protein and p300, we suggest that the PKA activation of CREB occurs by the production of specific, complementary interactions with these proteins, rather than through the previously proposed mechanisms of a phosphorylation-dependent conformational change or increased DNA binding affinity.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SHRINERS HOSP CRIPPLED CHILDREN,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University				Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45423] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; CHRIVIA JC, 1993, NATURE, V365, P8575; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1994, ONCOGENE, V9, P463; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTIN SC, 1990, FEBS LETT, V272, P103, DOI 10.1016/0014-5793(90)80458-U; MERINO A, 1989, J BIOL CHEM, V264, P21266; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1990, METABOLISM, V39, P6, DOI 10.1016/0026-0495(90)90198-L; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PERCIPALLE P, 1995, EMBO J, V14, P3200, DOI 10.1002/j.1460-2075.1995.tb07322.x; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMWANI JJ, 1989, BIOCHEMISTRY-US, V28, P6538, DOI 10.1021/bi00442a002; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YEAGLE PL, 1990, BIOCHEMISTRY-US, V29, P1508, DOI 10.1021/bi00458a023; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG XY, 1992, ANAL BIOCHEM, V201, P366, DOI 10.1016/0003-2697(92)90353-9	65	110	113	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13716	13723		10.1074/jbc.271.23.13716	http://dx.doi.org/10.1074/jbc.271.23.13716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662719	hybrid			2022-12-27	WOS:A1996UP38500063
J	Ibeanu, GC; Ghanayem, BI; Linko, P; Li, LP; Pedersen, LG; Goldstein, JA				Ibeanu, GC; Ghanayem, BI; Linko, P; Li, LP; Pedersen, LG; Goldstein, JA			Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID; SUBSTRATE-SPECIFICITY; LAURATE (OMEGA-1)-HYDROXYLASE; SEQUENCE REQUIREMENTS; CATALYTIC ACTIVITY; MOLECULAR-MODEL; ENZYMES; BINDING; 15-ALPHA-HYDROXYLASE	Human P450 2C19 is selective for 4'-hydroxylation of S-mephenytoin and 5-hydroxylation of omeprazole, while the structurally homologous P450 2C9 has low activity toward these substrates. To identify the critical amino acids that determine the specificity of human P450 2C19, we constructed chimeras of P450 2C9 replacing various proposed substrate binding sites (SRS) with those of P450 2C19 and then replaced individual residues of P450 2C9 by site directed mutagenesis. The 339 NH2-terminal amino acid residues (SRS-1--SRS-4) and amino acids 160-383 (SRS-2--SRS-5) of P450 2C19 conferred omeprazole 5-hydroxylase activity to P450 2C9. In contrast, the COOH terminus of P450 2C19 (residues 340-490 including SRS-5 and SRS-6), residues 228-339 (SRS-3 and SRS-4) and residues 292-383 (part of SRS-4 and SRS-B) conferred only modest increases in activity. A single mutation Ile(99) --> His increased omeprazole 5-hydroxylase to similar to 51% of that of P450 2C19. A chimera spanning residues 160-227 of P450 2C19 also exhibited omeprazole 5-hydroxylase activity which was dramatically enhanced by the mutation Ile(99) --> His, A combination of two mutations, Ile(99) --> His and Ser(200) --> Pro, converted P450 2C9 to an enzyme with a turnover number for omeprazole 5-hydroxylation, which resembled that of P450 2C19. Mutation of Pro(221) --> Thr enhanced this activity. Residue 99 is within SRS-1, but amino acids 220 and 221 are in the F-G loop and outside any known SRS. Mutation of these three amino acids did not confer significant S-mephenytoin 5-hydroxylase activity to P450 2C9, although chimeras containing SRS-1--SRS-4 and SRS-2--SRS-5 of P450 2C19 exhibited activity toward this substrate. Our results thus indicate that amino acids 99, 220, and 221 are key residues that determine the specificity of P450 2C19 for omeprazole.	NIEHS, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Li, Leping/F-6497-2019; Pedersen, Lee G/E-3405-2013	Li, Leping/0000-0003-4208-0259; Pedersen, Lee G/0000-0003-1262-9861				AOYAMA T, 1989, J BIOL CHEM, V264, P21327; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FALETTO MB, 1992, J BIOL CHEM, V267, P2032; GHANAYEM BI, 1994, 6 N AM INT SOC STUD, P50; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; GOLDSTEIN JA, 1994, BIOCHEMISTRY-US, V33, P1743, DOI 10.1021/bi00173a017; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASLER JA, 1994, MOL PHARMACOL, V46, P338; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; IWASAKI M, 1993, J BIOL CHEM, V268, P759; IWASAKI M, 1995, BIOCHEMISTRY-US, V34, P5054, DOI 10.1021/bi00015a016; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LAUGHTON CA, 1993, J STEROID BIOCHEM, V44, P399, DOI 10.1016/0960-0760(93)90243-P; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LEWIS DFV, 1992, J COMPUT AID MOL DES, V6, P235, DOI 10.1007/BF00123379; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RICHARDSON TH, 1994, J BIOL CHEM, V269, P23937; ROSE MD, 1990, METHODS YEAST GENETI, P180; STRAUB P, 1993, J BIOL CHEM, V268, P21997; STRAUB P, 1993, ARCH BIOCHEM BIOPHYS, V306, P521, DOI 10.1006/abbi.1993.1547; SULLIVAN TH, 1996, IN PRESS PHARMACOGEN; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; UNO T, 1992, J BIOCHEM-TOKYO, V112, P155, DOI 10.1093/oxfordjournals.jbchem.a123856; UNO T, 1989, J BIOCHEM-TOKYO, V106, P569, DOI 10.1093/oxfordjournals.jbchem.a122897; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	46	82	83	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12496	12501		10.1074/jbc.271.21.12496	http://dx.doi.org/10.1074/jbc.271.21.12496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647857	hybrid			2022-12-27	WOS:A1996UL66000059
J	Simos, G; Maison, C; Georgatos, SD				Simos, G; Maison, C; Georgatos, SD			Characterization of p18, a component of the lamin B receptor complex and a new integral membrane protein of the avian erythrocyte nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BENZODIAZEPINE RECEPTOR; INTERMEDIATE FILAMENTS; MOLECULAR-CLONING; ATTACHMENT SITE; PLASMA-MEMBRANE; GENE ENCODES; BINDING; EXPRESSION; VIMENTIN	Employing avian erythrocytes, we have previously isolated a multimeric complex consisting of the lamin B receptor (LBR, or p58), the nuclear lamins, an LBR-specific kinase, a 34-kDa protein, and an 18-kDa polypeptide termed p18. As the LBR kinase and the 34-kDa component have been recently characterized, we now proceed in the characterization of p18. We show here that p18 is an integral membrane protein specific to the erythrocyte nuclear envelope which binds to LBR and B-type lamins. NH2-terminal sequencing indicates that p18 is distinct from other nuclear envelope components, but has similarity to the mitochondrial isoquinoline-binding protein. In situ analysis by immunoelectron microscopy and examination of digitonin-permeabilized cells by indirect immunofluorescence show that p18, unlike LBR and other lamin-binding proteins, is equally distributed between the inner and outer nuclear membrane. Furthermore, cycloheximide inhibition experiments reveal that the fraction of p18 that resides in the outer nuclear membrane does not represent nascent chains en route to the inner nuclear membrane, but rather material in equilibrium with the p18 that partitions with the inner nuclear membrane. The paradigm of p18 suggests that transmembrane complexes formed by the nuclear lamins and LBR provide potential docking sites for integral membrane proteins of the nuclear envelope that equilibrate between the rough endoplasmic reticulum and the inner nuclear membrane.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAM,D-69117 HEIDELBERG,GERMANY; UNIV CRETE,DEPT BASIC SCI,FAC MED,GR-71110 IRAKLION,CRETE,GREECE	European Molecular Biology Laboratory (EMBL); University of Crete			Simos, George/AAH-2596-2021	Georgatos, Spyros/0000-0002-2078-7467; Simos, George/0000-0001-5453-3185				BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; Galfre G, 1981, Methods Enzymol, V73, P3; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1989, J CELL BIOL, V108, P2069, DOI 10.1083/jcb.108.6.2069; GEORGATOS SD, 1994, J CELL BIOCHEM, V55, P69, DOI 10.1002/jcb.240550108; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HARRIS JR, 1971, J ULTRA MOL STRUCT R, V36, P8, DOI 10.1016/S0022-5320(71)80085-0; JAMIESON JD, 1968, J CELL BIOL, V39, P580, DOI 10.1083/jcb.39.3.580; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; PADAN R, 1990, J BIOL CHEM, V265, P7808; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; RANGES GE, 1982, J EXP MED, V156, P1057, DOI 10.1084/jem.156.4.1057; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; TORRISI MR, 1985, J CELL BIOL, V101, P1300, DOI 10.1083/jcb.101.4.1300; TORRISI MR, 1987, J CELL BIOL, V104, P733, DOI 10.1083/jcb.104.3.733; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YE Q, 1994, J BIOL CHEM, V269, P11306; ZENTGRAF H, 1971, J BIOL CHEM, V246, P2986	55	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12617	12625		10.1074/jbc.271.21.12617	http://dx.doi.org/10.1074/jbc.271.21.12617			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647873	hybrid			2022-12-27	WOS:A1996UL66000075
J	Costantini, P; Chernyak, BV; Petronilli, V; Bernardi, P				Costantini, P; Chernyak, BV; Petronilli, V; Bernardi, P			Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED MEMBRANE TRANSITION; RAT-LIVER MITOCHONDRIA; CYCLOSPORINE-A; HEART-MITOCHONDRIA; DIVALENT-CATIONS; INNER MEMBRANE; REDOX STATE; CALCIUM; INHIBITION; CHANNELS	After accumulation of a Ca2+ load, the addition of uncoupler to respiring rat liver mitochondria is followed by opening of the permeability transition pore (MTP), a voltage-dependent channel sensitive to cyclosporin A. The channel's voltage threshold is profoundly affected under conditions of oxidative stress, with a shift to more negative values that may cause MTP opening at physiological membrane potentials. in this paper we further clarify the mechanisms by which oxidative agents affect the apparent voltage dependence of the MTP. We show that two sites can be experimentally distinguished. (i) A first site is in apparent oxidation-reduction equilibrium with the pyridine nucleotide (PN) pool (NADH/NAD + NADPH/NADP); PN oxidation is matched by increased MTP open probability under conditions where the glutathione pool is kept in the fully reduced state; this site can be blocked by N-ethylmaleimide but not by monobromobimane, a thiol-selective reagent, (ii) A second site coincides with the oxidation-reduction-sensitive dithiol we have recently identified (Petronilli, V., Costantini, P., Scorrano, L., Colonna, R,. Passamonti, S., and Bernardi, P. (1994) J. Biol. Chem. 269, 16638-16642); dithiol cross-linking at this site by arsenite or phenylarsine oxide is matched by increased MTP open probability under conditions where the PN pool is kept in the fully reduced state; at variance from the first, this site can be blocked by both N-ethlymaleimide and monobromobimane and is probably in equilibrium with the glutathione pool. Based on these findings, we reassess the mechanisms by which many oxidative agents affect the MTP and resolve conflicting reports on the relative role of PN and glutathione oxidation in the permeability transition within the framework of MTP (dys)regulation at two separate sites.	UNIV PADUA,SCH MED,DEPT BIOMED SCI,CNR,RIC UNIT STUDY PHYSIOL MITOCHONDRIA,I-35121 PADUA,ITALY; UNIV PADUA,SCH MED,DEPT BIOMED SCI,LAB BIOPHYS & MEMBRANE BIOL,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua			Chernyak, Boris V/D-9917-2012; Petronilli, Valeria/C-3558-2015; Bernardi, Paolo/C-3656-2008	Chernyak, Boris V/0000-0003-1523-0864; Petronilli, Valeria/0000-0003-4026-6404; Bernardi, Paolo/0000-0001-9187-3736				BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1996, IN PRESS J BIOENERG; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CHERNYAK BV, 1995, FEBS LETT, V365, P75, DOI 10.1016/0014-5793(95)00411-2; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; ESPOSTI MD, 1994, BIOCHEM J, V301, P161, DOI 10.1042/bj3010161; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HOEK JB, 1988, BIOCHEM J, V254, P1; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LEE AC, 1994, J BIOL CHEM, V269, P30974; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; LENARTOWICZ E, 1992, BIOCHEM BIOPH RES CO, V184, P1088, DOI 10.1016/0006-291X(92)90703-N; LOTSCHER HR, 1979, P NATL ACAD SCI USA, V76, P4340, DOI 10.1073/pnas.76.9.4340; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; MEURY J, 1990, ARCH MICROBIOL, V154, P475, DOI 10.1007/BF00245231; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLLS DG, 1980, BIOCHEM J, V188, P113, DOI 10.1042/bj1880113; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHWEIZER M, 1994, BIOCHEM PHARMACOL, V48, P967, DOI 10.1016/0006-2952(94)90367-0; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; WOLKOWICZ PE, 1980, J BIOL CHEM, V255, P348; ZAHLER WL, 1968, J BIOL CHEM, V243, P716; ZAHREBELSKI G, 1995, HEPATOLOGY, V21, P1361, DOI 10.1002/hep.1840210521; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	55	377	386	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6746	6751		10.1074/jbc.271.12.6746	http://dx.doi.org/10.1074/jbc.271.12.6746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636095	hybrid			2022-12-27	WOS:A1996UB15700030
J	Philo, JS; Wen, J; Wypych, J; Schwartz, MG; Mendiaz, EA; Langley, KE				Philo, JS; Wen, J; Wypych, J; Schwartz, MG; Mendiaz, EA; Langley, KE			Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR DISULFIDE LINKAGES; TYROSINE KINASE RECEPTOR; HUMAN GROWTH-HORMONE; HAMSTER OVARY CELLS; ONCOGENE C-KIT; PROTO-ONCOGENE; W-LOCUS; GENE-PRODUCT; SI-LOCUS; LIGAND	Stem cell factor (SCF) is a cytokine that is active toward hematopoietic progenitor cells and other cell types, including germ cells, melanocytes, and mast cells, which express its receptor, the tyrosine kinase, Kit. SCF exists as noncovalently associated dimer at concentrations where it has been possible to study its quaternary structure; it stimulates dimerization and autophosphorylation of Kit at the cell surface, We have used recombinant versions of human SCF and human Kit extracellular domain (sKit) to study SCF-Kit interactions, By size exclusion chromatography, plus various physical chemical methods including light scattering, sedimentation equilibrium, and titration calorimetry, we demonstrate the formation of complexes containing a dimer of SCF (unglycosylated SCF1-165) plus two molecules of sKit, The concentrations of SCF and sKit in these studies were in the range of 0.35-16.2 mu M. The data are analyzed and discussed in the context of several possible models for complex formation, In particular, the sedimentation data are not consistent with a model involving cooperative binding. The K-d estimate for SCF-sKit interaction, obtained by sedimentation equilibrium, is about 17 nM at 25 degrees C, With glycosylated SCF1-165, the K-d is considerably higher.	AMGEN INC,THOUSAND OAKS,CA 91320	Amgen			Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRIZZI MF, 1994, ONCOGENE, V9, P1583; BROUDY VC, 1994, BLOOD, V83, P2145; BROUDY VC, 1992, BLOOD, V80, P60; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAS SK, 1982, J BIOL CHEM, V257, P13679; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUJIO K, 1994, LAB INVEST, V70, P511; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LANGLEY KE, 1993, BLOOD, V81, P656; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, V90; LAUFFENBURGER DA, 1993, RECEPTORS, P160; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, J BIOL CHEM, V267, P10866; LIU YC, 1993, BIOCHEM BIOPH RES CO, V197, P1094, DOI 10.1006/bbrc.1993.2590; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; LU HS, 1992, ARCH BIOCHEM BIOPHYS, V298, P150, DOI 10.1016/0003-9861(92)90106-7; MAEDA H, 1992, DEVELOPMENT, V116, P369; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PHILO J, 1994, J BIOL CHEM, V269, P27840; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; TURNER AM, 1995, BLOOD, V85, P2052, DOI 10.1182/blood.V85.8.2052.bloodjournal8582052; TURNER AM, 1992, BLOOD, V80, P374; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WYPYCH J, 1995, BLOOD, V85, P66, DOI 10.1182/blood.V85.1.66.bloodjournal85166; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	52	53	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6895	6902		10.1074/jbc.271.12.6895	http://dx.doi.org/10.1074/jbc.271.12.6895			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636116	hybrid			2022-12-27	WOS:A1996UB15700051
J	Austin, SJ; Fujimoto, W; Marvin, KW; Vollberg, TM; Lorand, L; Jetten, AM				Austin, SJ; Fujimoto, W; Marvin, KW; Vollberg, TM; Lorand, L; Jetten, AM			Clotting and regulation of cornifin beta, a new member of the cornifin/spr family - Suppression by retinoic acid receptor-selective retinoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEAL EPITHELIAL-CELLS; CROSS-LINKED ENVELOPE; HUMAN EPIDERMAL-CELLS; SQUAMOUS DIFFERENTIATION; KERATINOCYTE; EXPRESSION; GENE; TRANSGLUTAMINASE; INVOLUCRIN; PROTEINS	In this study, we describe the isolation and characterization of a cDNA clone C12 that encodes a new member of the cornifin/small proline-rich protein (spr) family, which we have named cornifin beta, C12 encodes a 1.1-kilobase pair mRNA and a 24,3-kDa cytosolic protein with a high proline content (19%). Its total amino acid sequence exhibits a 37-66% identity while the first 30 amino acids at the amino terminus are 87% identical to that of members of the cornifin family, At its carboxyl terminus, cornifin beta contains 21 tandem repeats of an octapeptide, Cornifin beta expression is restricted to several squamous epithelia, It is highly expressed in esophagus, tongue, and oral mucosa but, in contrast to cornifin alpha, is not detectable in the epidermis. Both retinoic acid and a retinoid selective for the nuclear retinoic acid receptors were very potent suppressors of cornifin beta expression while an analog selective for the nuclear retinoid X receptors was much less effective, suggesting that a specific retinoid signaling pathway is involved in this suppression, Cornifin beta can function through some of its Gln residues as an amine acceptor in transglutaminase-catalyzed cross-linking reactions, These results indicate that cornifin beta functions as a cross-linked envelope precursor.	NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445				ABERNETHY JL, 1977, J BIOL CHEM, V252, P1837; AN G, 1993, J BIOL CHEM, V268, P10977; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1992, CELL GROWTH DIFFER, V3, P549; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MARVIN KW, 1992, P NATL ACAD SCI USA, V87, P9333; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MURTHY SNP, 1994, J BIOL CHEM, V269, P22907; NOJI S, 1990, ACTA HISTOCHEM CYTOC, V23, P353, DOI 10.1267/ahc.23.353; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; REARICK JI, 1987, J BIOL CHEM, V262, P13069; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SMITS HL, 1987, MOL CELL BIOL, V7, P4017, DOI 10.1128/MCB.7.11.4017; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4	32	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3737	3742						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631988	hybrid			2022-12-27	WOS:A1996TV72400062
J	Brizzi, MF; Aronica, MG; Rosso, A; Bagnara, GP; Yarden, Y; Pegoraro, L				Brizzi, MF; Aronica, MG; Rosso, A; Bagnara, GP; Yarden, Y; Pegoraro, L			Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93(fes), STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; DNA-BINDING PROTEINS; HUMAN-NEUTROPHILS; INTERFERON-GAMMA; RESPIRATORY BURST; GROWTH-FACTOR; GM-CSF; TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; MULTIPLE CYTOKINES	Granulocyte-macrophage colony-stimulating factor (GM-CSF), supports proliferation, differentiation, and functional activation of hemopoietic cells by its interaction with a heterodimeric receptor. Although GM-CSF receptor is devoid of tyrosine kinase enzymatic activity, GM-CSF-induced peripheral blood polymorphonuclear leukocytes (PMN) functional activation is mediated by the phosphorylation of a large number of intracellular signaling molecules. We have previously shown that JAK2 becomes tyrosine-phosphorylated in response to GM-CSF in PMN. In the present study we demonstrate that also the signal transducers and activators of transcription (STAT) family members STAT1 p91 and STAT3 p92 and the product of the c-fps/fes protooncogene become tyrosine-phosphorylated upon GM-CSF stimulation and physically associated with both GM-CSF receptor beta common subunit and JAK2. Moreover GM-CSF was able to induce JAK2 and p93(fes) catalytic activity. We also demonstrate that the association of the GM-CSF receptor beta common subunit with JAK2 is ligand-dependent. Finally we demonstrate that GM-CSF induces a DNA-binding complex that contains both p91 and p92, These results identify a new signal transduction pathway activated by GM-CSF and provide a mechanism for rapid activation of gene expression in GM-CSF-stimulated PMN.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; UNIV BOLOGNA,IST ISTOL & EMBRIOL,CTR INTERDIPARTIMENTALE RIC GIORGIO PRODI,I-40126 BOLOGNA,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; University of Bologna; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016					ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BERKOW RL, 1990, BLOOD, V75, P2445; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUI Y, 1994, J IMMUNOL, V152, P5420; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; FLEISCHMANN J, 1986, BLOOD, V68, P708; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUBES P, 1990, AM J PHYSIOL, V259, pG859, DOI 10.1152/ajpgi.1990.259.5.G859; LAMB P, 1994, BLOOD, V83, P2063; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MCCOLL SR, 1991, BLOOD, V78, P1842; MCCOLL SR, 1991, J IMMUNOL, V146, P1204; MIURA O, 1994, BLOOD, V84, P1501; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NACCACHE PH, 1994, BLOOD, V84, P616, DOI 10.1182/blood.V84.2.616.bloodjournal842616; NACCACHE PH, 1988, J IMMUNOL, V140, P3541; NACCACHE PH, 1990, BLOOD, V76, P2098; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; OKUDA K, 1991, BLOOD, V78, P1928; OKUDA K, 1992, BLOOD, V79, P2880; PALES E, 1991, EMBO J, V10, P2077; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROLLET E, 1994, J IMMUNOL, V153, P353; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOCINSKI MA, 1988, BLOOD, V72, P691; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TIAN SS, 1994, BLOOD, V84, P1760; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WIRTHMUELLER U, 1989, J IMMUNOL, V142, P3213; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	123	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3562	3567						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631962				2022-12-27	WOS:A1996TV72400036
J	Costello, CA; Kelleher, NL; Abe, M; McLafferty, FW; Begley, TP				Costello, CA; Kelleher, NL; Abe, M; McLafferty, FW; Begley, TP			Mechanistic studies on thiaminase I - Overexpression and identification of the active site nucleophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BONDS; PROTEINS; CLEAVAGE; SEQUENCE; PEPTIDES; ANALOGS	Thiaminase I (EC 2.5.1.2) catalyzes the replacement of the thiazole moiety of thiamin with a wide variety of nucleophiles. Here we report the sequencing of a thiaminase I clone from Bacillus thiaminolyticus, the overexpression of the cloned gene in Escherichia coli, and the purification and characterization of the enzyme. Recombinant thiaminase I functions as a monomer with a K-m for thiamin of 3.7 +/- 0.6 mu M and a k(cat) of 34 s(-1). Electrospray ionization Fourier-transform mass spectrometry identified a single sequencing error and demonstrated heterogeneity, finding molecular weights of 42, 127, 42, 198, and 42,255 due to added Ala and Gly-Ala at the amino terminus. Similar analysis of the 4-amino-2-methyl-6-chloropyrimidine (8) inactivated enzyme indicated that the active site nucleophile involved in catalysis of the substitution reaction is located between Pro(79) and Thr(177). Subsequent cysteine-specific labeling and site-directed mutagenesis identified Cys(113) as the active site nucleophile.	CORNELL UNIV,BAKER LAB 120,DEPT CHEM,ITHACA,NY 14853; YAMAGUCHI UNIV,SCH MED,DEPT MICROBIOL,UBE,YAMAGUCHI 755,JAPAN	Cornell University; Yamaguchi University			Begley, Tadhg/B-5801-2015		NIDDK NIH HHS [DK44083] Funding Source: Medline; NIGMS NIH HHS [GM16609, T32 GM08384] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044083, R56DK044083, R01DK044083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016609, T32GM008384, R37GM016609] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1987, BIOCHIM BIOPHYS ACTA, V909, P213, DOI 10.1016/0167-4781(87)90080-7; BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN M, 1994, J BACTERIOL, V176, P5796, DOI 10.1128/JB.176.18.5796-5801.1994; DOUTHIT HA, 1966, ARCH BIOCHEM BIOPHYS, V113, P331, DOI 10.1016/0003-9861(66)90194-9; DUFFY P, 1981, AM J CLIN NUTR, V34, P1584, DOI 10.1093/ajcn/34.8.1584; EARL JW, 1994, NATURE, V368, P683, DOI 10.1038/368683a0; Evans W C, 1975, Vitam Horm, V33, P467; FUJITA A, 1972, J VITAMINOL, V18, P67, DOI 10.5925/jnsv1954.18.67; FUJITA A, 1954, ADV ENZYMOL REL S BI, V15, P389; HAYASHI R, 1957, NUTR REV, V15, P65, DOI 10.1111/j.1753-4887.1957.tb00468.x; HITZEMAN RA, 1983, SCIENCE, V219, P620, DOI 10.1126/science.6186023; HUTTER JA, 1987, BIOCHEMISTRY-US, V26, P1969, DOI 10.1021/bi00381a028; KELLEHER NL, 1995, J AM SOC MASS SPECTR, V6, P981, DOI 10.1016/1044-0305(95)00584-Z; KIMURA Y, 1987, EXPERIENTIA, V43, P888, DOI 10.1007/BF01951652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEADER IG, 1970, METHODS ENZYMOL A, V18, P207; LIENHARD GE, 1970, BIOCHEMISTRY-US, V9, P3011, DOI 10.1021/bi00817a012; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LITTLE DP, 1994, ANAL CHEM, V66, P2809, DOI 10.1021/ac00090a004; MURATA K, 1982, ANN NY ACAD SCI, V378, P146, DOI 10.1111/j.1749-6632.1982.tb31193.x; NICEWONGER R, 1995, IN PRESS BIOORG CHEM; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PUZACH SS, 1984, BIOCHEMISTRY-MOSCOW+, V49, P1010; SENKO MW, 1994, ANAL CHEM, V66, P2801, DOI 10.1021/ac00090a003; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THANNHAUSER TW, 1987, METHOD ENZYMOL, V143, P115; URAY G, 1993, BIOORG CHEM, V21, P294, DOI 10.1006/bioo.1993.1025; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WITTLIFF J, 1970, METHOD ENZYMOL, V8, P229; WITTLIFF JL, 1968, BIOCHEMISTRY-US, V7, P736, DOI 10.1021/bi00842a032	35	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3445	3452						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631946	hybrid			2022-12-27	WOS:A1996TV72400020
J	Hawes, BE; Luttrell, LM; vanBiesen, T; Lefkowitz, RJ				Hawes, BE; Luttrell, LM; vanBiesen, T; Lefkowitz, RJ			Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID DERIVED CELLS; RECEPTOR; NEUTROPHILS; FIBROBLASTS; ASSOCIATION; EXPRESSION; P21(RAS)	The beta gamma-subunit of G(i) mediates mitogen-activated protein (MAP) kinase activation through a signaling pathway involving Shc tyrosine phosphorylation, subsequent formation of a multiprotein complex including Shc, Grb2, and Sos, and sequential activation of Ras, Raf, and MEK. The mechanism by which G beta gamma mediates tyrosine phosphorylation of Shc, however, is unclear. This study assesses the role of phosphatidylinositol 3-kinase (PI-3K) in G beta gamma-mediated MAP kinase activation, We show that G(i)-coupled receptor- and G beta gamma-stimulated MAP kinase activation is attenuated by the PI-3K inhibitors wortmannin and LY294002 or by overexpression of a dominant negative mutant of the p85 subunit of PI-3K, Wortmannin and LY294002 also inhibit G(i)-coupled receptor-stimulated Ras activation. The PI-3K inhibitors do not affect MAP kinase activation stimulated by overexpression of Sos, a constitutively active mutant of Ras, or a constitutively active mutant of MEK. These results demonstrate that PI-3K activity is required in the G beta gamma-mediated MAP kinase signaling pathway at a point upstream of Sos and Ras activation.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VICIANA PR, 1994, NATURE, V370, P527; WINITZ S, 1994, J BIOL CHEM, V269, P1889; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	49	317	322	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12133	12136		10.1074/jbc.271.21.12133	http://dx.doi.org/10.1074/jbc.271.21.12133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647803	hybrid			2022-12-27	WOS:A1996UL66000005
J	Shyadehi, AZ; Lamb, DC; Kelly, SL; Kelly, DE; Schunck, WH; Wright, JN; Corina, D; Akhtar, M				Shyadehi, AZ; Lamb, DC; Kelly, SL; Kelly, DE; Schunck, WH; Wright, JN; Corina, D; Akhtar, M			The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: Lanosterol 14 alpha-demethylase, P-450(14DM), and CYP51)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL AROMATASE; CHOLESTEROL-BIOSYNTHESIS; CYTOCHROME-P-450; PURIFICATION; DEMETHYLASE; ENZYMES; EXPRESSION; YEAST	The Candida albicans sterol 14 alpha-demethylase gene (P-450(14DM), CYP51) was transferred to the yeast plasmid YEp51 placing it under the control of the GAL10 promoter. The resulting construct (YEp51:CYP51) when transformed into the yeast strain GRF18 gave a clone producing 1.5 mu mol of P-450/liter of culture, the microsomal fraction of which contained up to 2.5 nmol of P-450/mg of protein. Two oxygenated precursors for the 14 alpha-demethylase, 3 beta-hydroxylanost-7-en-32-al and 3 beta-hydroxylanost-7-en-32-ol, variously labeled with H-2 and O-18 at C-32 were synthesized. In this study the conversion of [32-H-2,32-O-16]- and [32-H-2,32-O-18]3 beta-hydroxylanost-7-en-32-al with the recombinant 14 alpha-demethylase was performed under O-16(2) or O-18(2) and the released formic acid analyzed by mass spectrometry. The results showed that in the acyl-carbon bond cleavage step (i.e. the deformylation process) the original carbonyl oxygen at C-32 of the precursor is retained in formic acid and the second oxygen of formate is derived from molecular oxygen; precisely the same scenario that has previously been observed for the acyl-carbon cleavage steps catalyzed by aromatase (P-450(arom)) and 17 alpha-hydroxylase-17,20-lyase (P-450(17 alpha),CYP17). In the light of these results the mechanism of the acyl-carbon bond cleavage step catalyzed by the 14 alpha-demethylase is considered.	UNIV SOUTHAMPTON, DEPT BIOCHEM, SOUTHAMPTON SO16 7PX, HANTS, ENGLAND; UNIV SHEFFIELD, DEPT BIOCHEM & MOLEC BIOL, SHEFFIELD S10 2UH, S YORKSHIRE, ENGLAND; MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY	University of Southampton; University of Sheffield; Helmholtz Association; Max Delbruck Center for Molecular Medicine								AKHTAR M, 1993, J STEROID BIOCHEM, V44, P375, DOI 10.1016/0960-0760(93)90241-N; AKHTAR M, 1994, PURE APPL CHEM, V66, P2387, DOI 10.1351/pac199466102387; AKHTAR M, 1994, BIOCHEMISTRY-US, V33, P4410, DOI 10.1021/bi00180a039; AKHTAR M, 1994, J CHEM SOC PERK T 1, P263, DOI 10.1039/p19940000263; AKHTAR M, 1978, BIOCHEM J, V169, P449, DOI 10.1042/bj1690449b; AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; AKHTAR M, 1991, NAT PROD REP, V8, P527, DOI 10.1039/np9910800527; AOYAMA Y, 1987, J BIOL CHEM, V262, P1239; BARTON DHR, 1970, J CHEM SOC C, P1033, DOI 10.1039/j39700001033; BATTEN PL, 1972, J CHEM SOC PERK T 1, P739, DOI 10.1039/p19720000739; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; CORINA DL, 1973, ANAL BIOCHEM, V53, P571, DOI 10.1016/0003-2697(73)90108-5; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; GUENGERICH FP, 1991, METHOD ENZYMOL, V206, P130; HITCHCOCK CA, 1989, BIOCHEM J, V263, P573, DOI 10.1042/bj2630573; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; KELLY SL, 1993, BIOCHEM SOC T, V21, P1034, DOI 10.1042/bst0211034; KELLY SL, 1995, BIOCHEM BIOPH RES CO, V207, P910, DOI 10.1006/bbrc.1995.1272; LAI MH, 1989, NUCLEIC ACIDS RES, V17, P804, DOI 10.1093/nar/17.2.804; LEEROBICHAUD P, 1995, BIOCHEMISTRY-US, V34, P14104, DOI 10.1021/bi00043a015; OH SS, 1993, J STEROID BIOCHEM, V44, P389, DOI 10.1016/0960-0760(93)90242-O; OMURA T, 1964, J BIOL CHEM, V239, P2370; SANTOS MAS, 1993, EMBO J, V12, P607, DOI 10.1002/j.1460-2075.1993.tb05693.x; SCHELLER U, 1994, J BIOL CHEM, V269, P12779; SKINNER SJM, 1969, BIOCHEM J, V114, P75, DOI 10.1042/bj1140075; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; SONODA Y, 1993, BIOCHIM BIOPHYS ACTA, V1170, P92; STEVENSON DE, 1988, J CHEM SOC PERK T 1, P2043, DOI 10.1039/p19880002043; SWINNEY DC, 1994, BIOCHEMISTRY-US, V33, P2185, DOI 10.1021/bi00174a027; TAN L, 1986, EUR J BIOCHEM, V156, P243, DOI 10.1111/j.1432-1033.1986.tb09574.x; TRZASKOS J, 1986, J BIOL CHEM, V261, P4651; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066	32	114	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12445	12450		10.1074/jbc.271.21.12445	http://dx.doi.org/10.1074/jbc.271.21.12445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647850	hybrid			2022-12-27	WOS:A1996UL66000052
J	Bogenhagen, DF				Bogenhagen, DF			Interaction of mtTFB and mtRNA polymerase at core promoters for transcription of Xenopus laevis mtDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; YEAST MITOCHONDRIA; SPECIFICITY FACTOR; DNA; PROTEINS; NUCLEAR; SUBUNIT; GENE	Transcription of Xenopus laevis mitochondrial DNA requires mtRNA polymerase and a dissociable factor, xl-mtTFB, that is distinct from the HMG-box factor known as mtTFA. This paper presents the purification of mtTFB and characterizes its DNA binding properties. xl-mtTFB activity copurifies with a 40-kDa polypeptide on silver-stained protein gels. Activity can be recovered following elution of this 40-kDa polypeptide from an SDS-polyacrylamide gel. xl-mtTFB is capable of binding to DNA, but this binding is relatively nonspecific and is easily competed by heterologous DNA.			Bogenhagen, DF (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.				NIGMS NIH HHS [GM29681] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOSHECHKIN I, 1995, MOL CELL BIOL, V15, P7032; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; BISWAS TK, 1992, J MOL BIOL, V226, P335, DOI 10.1016/0022-2836(92)90951-F; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2910, DOI 10.1128/MCB.8.7.2910; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2917, DOI 10.1128/MCB.8.7.2917; CAIRNS SS, 1986, J BIOL CHEM, V261, P8481; DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; KELLY JL, 1986, J BIOL CHEM, V261, P348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; RIEMEN G, 1993, MOL GEN GENET, V237, P49, DOI 10.1007/BF00282783; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053	27	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12036	12041						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662670				2022-12-27	WOS:A1996UL25000068
J	Myette, JR; Niles, EG				Myette, JR; Niles, EG			Characterization of the vaccinia virus RNA 5'-triphosphatase and nucleoside triphosphate phosphohydrolase activities - Demonstration that both activities are carried out at the same active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CAPPING ENZYME; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; GUANYLYLTRANSFERASE; VIRIONS; TRANSCRIPTION; PURIFICATION; ASSOCIATION; MECHANISM; SUBUNITS	D1R(1-545), an active subdomain of the large subunit of vaccinia virus mRNA capping enzyme possessing ATPase, RNA 5'-triphosphatase, and guanylyltransferase activities, was expressed in Escherichia coli and shown to be functionally equivalent to the heterodimeric enzyme (Myette, J. R., and Niles, E. G. (1996) J. Biol. Chem. 271, 11936-11944). A detailed characterization of the phosphohydrolytic activities of D1R(1-545) demonstrates that, in addition to ATPase and RNA 5'-triphosphatase activities, the capping enzyme also possesses a general nucleoside triphosphate phosphohydrolase activity that lacks a preference for the nucleoside base or sugar. Nucleoside triphosphate and mRNA saturation kinetics are markedly different, with RNA exhibiting a K-m and turnover number 100- and 10-fold less, respectively, than those values measured for any NTP. The linear competitive inhibition of RNA 5'-triphosphatase activity by ATP, and the relative manner by which both ATPase and RNA 5'-triphosphatase activities are inhibited by specific oligonucleotides, kinetically demonstrate that each activity is carried out at a common active site. Direct UV photo-cross-linking of either P-32-radiolabeled ATP or 23-mer triphosphorylated RNA, followed by cyanogen bromide cleavage of the photo-linked enzyme, localizes the major binding site for both ATP and RNA to a region between amino acids 1 and 221. The inability of ATP to competitively inhibit either E similar to GMP formation or the transfer of GMP to RNA kinetically differentiates the phosphohydrolase active site from the guanylyltransferase active site.	SUNY BUFFALO,SCH MED & BIOMED SCI,CTR ADV MOL BIOL IMMUNOL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Myette, JR (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214, USA.				NIAID NIH HHS [AI28824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYLISS CD, 1995, J BIOL CHEM, V270, P1550, DOI 10.1074/jbc.270.4.1550; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; MAO XD, 1994, J BIOL CHEM, V269, P24472; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1994, BIOCHEMISTRY-US, V33, P9898, DOI 10.1021/bi00199a011; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587	27	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11945	11952		10.1074/jbc.271.20.11945	http://dx.doi.org/10.1074/jbc.271.20.11945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662636	hybrid			2022-12-27	WOS:A1996UL25000057
J	Gu, Y; Sarnecki, C; Fleming, MA; Lippke, JA; Bleackley, RC; Su, MSS				Gu, Y; Sarnecki, C; Fleming, MA; Lippke, JA; Bleackley, RC; Su, MSS			Processing and activation of CMH-1 by granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFICIENT	Granzyme B plays an essential role in cytotoxic T lymphocyte (CTL)-mediated cell killing, Recent studies suggest that granzyme B may exert its effect by cleaving and activating CPP32, a member of the interleukin-1 beta-converting enzyme/Ced-3 family of cysteine proteases, We have examined the processing and activation of CMH-1, a close homologue of CPP32, by granzyme B in vitro, We have found that granzyme B specifically cleaves CMH-1 at Asp(198)-Ser(199) between the p20 and p12 and activates the cysteine protease, Cleavage between p20 and the prosequence of CMH-1 at Asp(23)-Ala(24) is autocatalytic and is not required for CMH-1 activity in vitro. The cleavage and activation of CMH-1 by granzyme B in vitro suggest that, in addition to CPP32, CMH-1 may also play a role in CTL-mediated cell killing.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	Vertex Pharmaceuticals; University of Alberta								BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P394; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10816	10820		10.1074/jbc.271.18.10816	http://dx.doi.org/10.1074/jbc.271.18.10816			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631895	hybrid			2022-12-27	WOS:A1996UJ34200063
J	Law, DA; NannizziAlaimo, L; Phillips, DR				Law, DA; NannizziAlaimo, L; Phillips, DR			Outside-in integrin signal transduction - alpha(IIb)beta(3)-(GP IIb-IIIa) tyrosine phosphorylation induced by platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GLANZMANN THROMBASTHENIA; RECEPTOR; PROTEIN; ACTIVATION; FIBRINOGEN; ASSOCIATION; ADHESION; SUBUNIT; PEPTIDE	alpha(IIb)beta(3)-(GPIIb-IIIa) is the most abundant integrin expressed on platelets and plays a critical role in platelet aggregation and normal hemostasis. In response to platelet stimulation by agonists such as thrombin, alpha(IIb)beta(3) becomes a receptor for the adhesive proteins fibrinogen, von Willebrand factor, vitronectin, and fibronectin. Binding of extracellular matrix ligands allows the integrin to transmit a signal to the inside of the cell, but the exact mechanisms whereby integrins transduce these signals remain unclear. In this paper we demonstrate that the beta(3) subunit of alpha(IIb)beta(3) was phosphorylated on tyrosine residues in response to thrombin induced platelet aggregation. However, tyrosine phosphorylation was not observed when platelets were stimulated by thrombin in the presence of an inhibitor of aggregation. Phosphotyrosine was only detected when platelets were solubilized under protein-denaturing conditions, A peptide corresponding to residues 740-762 of the beta(3) cytoplasmic domain was capable of binding the signaling proteins SHC and GRB2, GRB2 binding occurred only when both tyrosine residues (Tyr-747 and Tyr-759) were phosphorylated. SHC binding also occurred to a peptide monophosphorylated at Tyr-759, The data suggest that tyrosine phosphorylation of an integrin beta subunit may be important in initiating outside in signaling cascades by inducing association of signaling components directly with the integrin.	COR THERAPEUT INC,S SAN FRANCISCO,CA 94080									CAEN JP, 1966, AM J MED, V41, P4, DOI 10.1016/0002-9343(66)90003-9; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1991, BLOOD, V77, P75; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1990, BLOOD, V75, P2363; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shock David D., 1995, Blood, V86, p451A; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMIGUCHI A, 1990, BIOCHIM BIOPHYS ACTA, V1054, P8; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	48	207	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10811	10815		10.1074/jbc.271.18.10811	http://dx.doi.org/10.1074/jbc.271.18.10811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631894	hybrid			2022-12-27	WOS:A1996UJ34200062
J	Rolin, S; HanocqQuertier, J; PaturiauxHanocq, F; Nolan, D; Salmon, D; Webb, H; Carrington, M; Voorheis, P; Pays, E				Rolin, S; HanocqQuertier, J; PaturiauxHanocq, F; Nolan, D; Salmon, D; Webb, H; Carrington, M; Voorheis, P; Pays, E			Simultaneous but independent activation of adenylate cyclase and glycosylphosphatidylinositol-phospholipase C under stress condition in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM; CYCLIC-AMP; GUANYLATE-CYCLASE; EXPRESSION SITE; PROCYCLIC FORMS; DIFFERENTIATION; MEMBRANE; DISTINCT	Previous observations suggested a concomitant relationship between the release of the variant surface glycoprotein (VSG) and the activation of adenylate cyclase in the bloodstream form of the parasitic protozoan Trypanosoma brucei, In order to evaluate this hypothesis, adenylate cyclase activity was measured in live trypanosomes subjected to different treatments known to induce the shedding of the VSG coat, namely low pH and trypsin digestion, In both cases adenylate cyclase activation occurred in parallel with the release of the VSG, The latter was found to be mediated by the glycosylphosphatidylinositol-specific phospholipase C that cleaves the glycosylphosphatidylinositol anchor of the protein (VSG lipase). Furthermore, both adenylate cyclase and VSG release were activated by the incubation of trypanosomes with specific inhibitors of protein kinase C, suggesting a repressive role for protein kinase C on both VSG lipase and adenylate cyclase activities. Significantly, in mutant trypanosomes lacking VSG lipase, adenylate cyclase was activated under conditions where VSG release did not occur. Moreover, VSG release was also found to occur in the absence of activation of the cyclase, as observed in the presence of low concentration of the thiol modifying reagent p-chloromercuriphenylsulfonic acid. These observations provide the first demonstration that release of the VSG in response to cellular stress is mediated by the VSG lipase and that while both release of the VSG and activation of adenylate cyclase occur in response to the same stimuli they are not obligatorily coupled.	UNIV BRUSSELS, DEPT MOLEC BIOL, B-1640 RHODE ST GENESE, BELGIUM; UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	University of Cambridge; Trinity College Dublin			Salmon, Didier/M-5670-2013	Carrington, Mark/0000-0002-6435-7266; Nolan, Derek/0000-0002-3742-4304				ABOAGYEKWARTENG T, 1991, BIOCHEM J, V275, P7, DOI 10.1042/bj2750007; ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BALTZ T, 1976, ANN INST PASTEUR IMM, VC127, P761; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V2, P762; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRUN R, 1979, ACTA TROP, V36, P289; CARRINGTON M, 1991, CELL BIOL INT REP, V15, P1101, DOI 10.1016/0309-1651(91)90058-Q; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FROMMEL TO, 1988, EXP PARASITOL, V66, P213, DOI 10.1016/0014-4894(88)90093-8; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GONZALESPERDOMO M, 1988, EXP PARASITOL, V66, P205, DOI 10.1016/0014-4894(88)90092-6; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P109; HERELD D, 1986, J BIOL CHEM, V261, P3813; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KEITH K, 1990, MOL BIOCHEM PARASIT, V43, P107, DOI 10.1016/0166-6851(90)90135-9; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MacManus J P, 1978, Adv Cyclic Nucleotide Res, V9, P485; MANCINI PE, 1981, MOL BIOCHEM PARASIT, V3, P19, DOI 10.1016/0166-6851(81)90074-8; MARTIN BR, 1978, BIOCHEM J, V175, P207, DOI 10.1042/bj1750207; MORI T, 1980, J BIOL CHEM, V255, P8378; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PARSONS M, 1991, MOL BIOCHEM PARASIT, V45, P241, DOI 10.1016/0166-6851(91)90091-J; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RANGELALDAO R, 1987, MOL BIOCHEM PARASIT, V22, P39, DOI 10.1016/0166-6851(87)90067-3; REED SL, 1985, INFECT IMMUN, V49, P844, DOI 10.1128/IAI.49.3.844-847.1985; REINWALD E, 1985, EUR J BIOCHEM, V151, P385, DOI 10.1111/j.1432-1033.1985.tb09113.x; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; RUBEN L, 1991, J BIOL CHEM, V266, P24351; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANCHEZ MA, 1995, J BIOL CHEM, V270, P17551, DOI 10.1074/jbc.270.29.17551; STRICKLER JE, 1975, SCIENCE, V190, P1110, DOI 10.1126/science.171773; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VICKERMAN K, 1969, J PROTOZOOL, V16, P54, DOI 10.1111/j.1550-7408.1969.tb02233.x; VOORHEIS HP, 1980, EUR J BIOCHEM, V113, P223, DOI 10.1111/j.1432-1033.1980.tb06160.x; VOORHEIS HP, 1982, EUR J BIOCHEM, V123, P371, DOI 10.1111/j.1432-1033.1982.tb19778.x; VOORHEIS HP, 1981, EUR J BIOCHEM, V116, P471, DOI 10.1111/j.1432-1033.1981.tb05360.x; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; WADMAN IA, 1991, BIOCHEM J, V276, P621, DOI 10.1042/bj2760621; WALTER RD, 1978, TROPENMED PARASITOL, V29, P439; WALTER RD, 1982, MOL BIOCHEM PARASIT, V6, P287, DOI 10.1016/0166-6851(82)90061-5; WARD J, 1987, MOL BIOCHEM PARASIT, V23, P1, DOI 10.1016/0166-6851(87)90180-0; WHEELERALM E, 1992, J PROTOZOOL, V39, P413, DOI 10.1111/j.1550-7408.1992.tb01473.x; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZHANG YH, 1991, J BIOL CHEM, V266, P22954; ZHANG YH, 1993, J BIOL CHEM, V268, P1786; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028; ZIEGELBAUER K, 1990, EUR J BIOCHEM, V192, P373, DOI 10.1111/j.1432-1033.1990.tb19237.x	65	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10844	10852		10.1074/jbc.271.18.10844	http://dx.doi.org/10.1074/jbc.271.18.10844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631899	hybrid			2022-12-27	WOS:A1996UJ34200067
J	Sung, P; Guzder, SN; Prakash, L; Prakash, S				Sung, P; Guzder, SN; Prakash, L; Prakash, S			Reconstitution of TFIIH and requirement of its DNA helicase subunits, Rad3 and Rad25, in the incision step of nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; INITIATION; MUTATION; PROTEIN; ATPASE; YEAST; GENE	Yeast TFIIH is composed of six subunits: Rad3, Rad25, TFB1, SSL1, p55, and p38. In addition to TFIIH, we have purified a subassembly of the factor that lacks Rad3 and Rad25 and which we refer to as TFIIHi. In the in vitro nucleotide excision repair (NER) system that consists entirely of purified proteins, we show that neither TFIIHi nor a mixture of purified Rad3 and Rad25 proteins is active in NER but that the combination of TFIIHi with Rad3 and Rad25 promotes the incision of UV-damaged DNA. These results provide the first evidence for a direct requirement of Rad3, Rad25, and of one or more of the TFIIHi subunits in the incision step of NER. The NER efficacy of TFIIH is greatly diminished or abolished upon substitution of Rad3 with the rad3 Arg-48 mutant protein or Rad25 with the rad25 Arg-392 mutant protein, respectively, thus indicating a role of the Rad3 and Rad25 DNA helicase functions in the incision of damaged DNA. Our results further indicate that the carboxyl-terminal domain kinase (CTD) TFIIK is dispensable for the incision of damaged DNA in vitro. These studies reveal the differential requirement of Rad3 DNA helicase and CTD kinase activities in damage specific incision versus RNA polymerase II transcription.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035035, R01CA035035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	20	58	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10821	10826		10.1074/jbc.271.18.10821	http://dx.doi.org/10.1074/jbc.271.18.10821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631896	hybrid			2022-12-27	WOS:A1996UJ34200064
J	Witcher, LL; Collins, R; Puttagunta, S; Mechanic, SE; Munson, M; Gumbiner, B; Cowin, P				Witcher, LL; Collins, R; Puttagunta, S; Mechanic, SE; Munson, M; Gumbiner, B; Cowin, P			Desmosomal cadherin binding domains of plakoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; CELL-ADHESION MOLECULE; JUNCTIONAL PLAQUE PROTEIN; BETA-CATENIN; DROSOPHILA HOMOLOG; EPITHELIAL-CELLS; ARMADILLO; ASSOCIATION; UVOMORULIN; EXPRESSION	Plakoglobin is a major component of both desmosomes and adherens junctions. At these sites it binds to the cytoplasmic domains of cadherin cell-cell adhesion proteins and regulates their adhesive and cytoskeletal binding functions. Plakoglobin also forms distinct cytosolic protein complexes that function in pathways of tumor suppression and cell fate determination. Recent studies in Xenopus suggest that cadherins inhibit the signaling functions of plakoglobin presumably by sequestering this protein at the membrane and depleting its cytosolic pool. To understand the reciprocal regulation between desmosomal cadherins (desmoglein and desmocollin) and plakoglobin, we have sought to identify the binding domains involved in the formation of these protein complexes. Plakoglobin comprises 13 central repeats flanked by amino-terminal and carboxyl-terminal domains. Our results show that repeats 1-4 are involved in binding desmoglein-1. In contrast, the interaction of plakoglobin with desmocollin-1a is sensitive to deletion of either end of the central repeat domain. The binding sites for two adherens junction components, alpha-catenin and classical cadherins, overlap these sites. Competition among these proteins for binding sites on plakoglobin may therefore account for the distinct composition of adherens junctions and desmosomes.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,RONALD O PERELMAN DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	New York University; New York University; New York University; Memorial Sloan Kettering Cancer Center				Cowin, Pamela/0000-0002-1827-1154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429, R37GM037432, R01GM037432] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47429, GM37432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; HATZFELD M, 1994, J CELL SCI, V107, P2259; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; PUTTAGUNTA S, 1994, J BIOL CHEM, V269, P1949; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; Sherman F., 1986, METHODS YEAST GENETI; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SORKIN BC, 1991, P NATL ACAD SCI USA, V88, P11545, DOI 10.1073/pnas.88.24.11545; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790	51	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10904	10909		10.1074/jbc.271.18.10904	http://dx.doi.org/10.1074/jbc.271.18.10904			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631907				2022-12-27	WOS:A1996UJ34200075
J	Yan, SZ; Hahn, D; Huang, ZH; Tang, WJ				Yan, SZ; Hahn, D; Huang, ZH; Tang, WJ			Two cytoplasmic domains of mammalian adenylyl cyclase form a G(s alpha)- and forskolin-activated enzyme in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; PURIFICATION	Mammalian adenylyl cyclases have two homologous cytoplasmic domains (C-1 and C-2). The first cytoplasmic domain of type I enzyme (IC1) and the second cytoplasmic domain of type II enzyme (IIC2-Delta 3, a construct in which 36 N-terminal amino acids of the C-2 region are deleted) were expressed and purified to homogeneity. Alone, each had no adenylyl cyclase activity; however, mixing of the two domains in vitro resulted in G(s alpha)- and forskolin activated enzyme activity. The turnover number for G(s alpha)- and forskolin-stimulated enzyme activity of the complex between IC1 and IIC2-Delta 3 was 8.2 s(-1). The concentration of IIC2-Delta 3 to achieve half-maximal activation of IC1 was 0.8 and 1.3 mu M when stimulated by forskolin and G(s alpha), respectively. The concentration of IIC2-Delta 3 needed to complex with IC1 was reduced 10-fold (0.08 mu M) when the enzyme was activated by both forskolin and G(s alpha), suggesting that G(s alpha) and forskolin increased the affinity of the two cytoplasmic domains for each other.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Chicago				Tang, Wei-Jen/0000-0002-8267-8995				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1994, J BIOL CHEM, V269, P12190; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; Harlow E., 1988, ANTIBODIES LAB MANUA; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1994, METHOD ENZYMOL, V237, P146; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; WATSON PA, 1994, J BIOL CHEM, V269, P28893; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	26	90	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10941	10945		10.1074/jbc.271.18.10941	http://dx.doi.org/10.1074/jbc.271.18.10941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631912	hybrid			2022-12-27	WOS:A1996UJ34200080
J	Anderson, JT; Rogers, RP; Jarrett, HW				Anderson, JT; Rogers, RP; Jarrett, HW			Ca2+-calmodulin binds to the carboxyl-terminal domain of dystrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEX; PROTEIN-KINASE; CROSS-LINKING; ACTIN-BINDING; CALMODULIN; SEQUENCE; SITE; PHOSPHODIESTERASE; PURIFICATION; FLUORESCENT	The unique COOH-terminal domain of dystrophin (mouse dystrophin protein sequences 3266-3678) was expressed as a chimeric fusion protein (with the maltose-binding protein), and its binding to calmodulin was assessed, This fusion protein, called DysS9, bound to calmodulin-Sepharose, bound biotinylated calmodulin, caused characteristic changes in the fluorescence emission spectrum of dansyl-calmodulin, and had an apparent affinity for dansyl-calmodulin of 54 nM. Binding in each case was Ca2+-dependent. The maltose-binding protein does not bind calmodulin, and thus binding resides in the dystrophin-derived sequences. Deletion mutation experiments further localize the high affinity calmodulin binding to mouse dystrophin protein sequences 3293-3349, and this domain contains regions with chemical characteristics found in the calmodulin-binding sequences in other proteins. The COOH-terminal domain provides sites of attachment of dystrophin to membrane proteins, and calmodulin binding may modulate these interactions.	UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; ANDERSON JP, 1987, J BIOL CHEM, V262, P6365; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BONETKERRACHE A, 1994, FEBS LETT, V355, P49, DOI 10.1016/0014-5793(94)01162-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Jarrett H W, 1980, Ann N Y Acad Sci, V356, P119, DOI 10.1111/j.1749-6632.1980.tb29605.x; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; JARRETT HW, 1986, J BIOL CHEM, V261, P4967; JARRETT HW, 1991, J BIOL CHEM, V266, P362; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KAKIUCHI S, 1981, FEBS LETT, V132, P144, DOI 10.1016/0014-5793(81)80449-8; KAKIUCHI S, 1985, CALCIUM BIOL SYSTEMS, P275; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUISE M, 1993, BIOCHEM J, V293, P243, DOI 10.1042/bj2930243; MADHAVAN R, 1995, BIOCHEMISTRY-US, V34, P12204, DOI 10.1021/bi00038a014; MADHAVAN R, 1994, BIOCHEMISTRY-US, V33, P5797, DOI 10.1021/bi00185a018; MADHAVAN R, 1992, BIOCHEM BIOPH RES CO, V185, P753, DOI 10.1016/0006-291X(92)91690-R; MADHAVAN R, 1995, FASEB J, V9, pA1409; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MILNER RE, 1993, J BIOL CHEM, V268, P21901; Sambrook J., 2002, MOL CLONING LAB MANU; SENTER L, 1993, BIOCHEM BIOPH RES CO, V192, P899, DOI 10.1006/bbrc.1993.1500; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WAGNER KR, 1994, J NEUROCHEM, V62, P1947; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; WLASH MP, 1995, BIOCHEMISTRY-US, V34, P5561; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	47	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6605	6610		10.1074/jbc.271.12.6605	http://dx.doi.org/10.1074/jbc.271.12.6605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636075	hybrid			2022-12-27	WOS:A1996UB15700010
J	Kelly, SE; Bachurski, CJ; Burhans, MS; Glasser, SW				Kelly, SE; Bachurski, CJ; Burhans, MS; Glasser, SW			Transcription of the lung-specific surfactant protein C gene is mediated by thyroid transcription factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; INSITU HYBRIDIZATION; SP-A; EXPRESSION; ELEMENTS; TISSUE; LOCALIZATION; SEQUENCE; PROMOTER; REGIONS	Surfactant protein C (SP-C) is expressed in alveolar Type II epithelial cells of the lung, In order to determine the mechanism(s) that regulate gene transcription, we have analyzed the activation of the murine SP-C promoter in mouse lung epithelial cells (RILE cells) and in HeLa cells after co-transfection with a vector expressing rat thyroid transcription factor-1 (TTF-1). TTF-1 transactivated SP-C-chloramphenicol acetyltransferase constructs containing -13 kilobase pairs to -320 base pairs (bp) of the 5' flanking region of the SP-C gene. Essential cis-acting elements were functionally localized to between -320 and -180 bp from the start of transcription by transfection analysis. Five DNase-protected regions, indicating multiple protein-DNA interactions within the -320 bp TTF-l-responsive region of the SP-C gene, were identified by I)Nase footprint analysis. A 40-bp segment of SP-C DNA from -197 to -158 linked to a heterologous promoter chloramphenicol acetyltransferase construct activated expression after co-transfection with CMV-TTF-1 in HeLa and RILE cells, The -197 to -158 segment contained two consensus TTF-1 sites, which were specifically identified as TTF-1 binding sites by gel retardation and antibody supershift with MLE cell nuclear extracts and purified TTF-1 homeodomain protein, Site-specific mutagenesis of either of the TTF-1 binding sites completely blocked activation by TTF-1, indicating both sites are required for TTF stimulation of SP-C transcription.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center				Bachurski, Cindy/0000-0002-3118-0636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752, R01HL050046, R29HL050046] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50046, HL07752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DAMANTE G, 1991, P NATL ACAD SCI USA, V88, P5388, DOI 10.1073/pnas.88.12.5388; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GLASSER SW, 1988, J BIOL CHEM, V263, P10326; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WHITSETT JA, 1992, PULMONARY SURFACTANT, P55; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; WOPHLFORDLENANE CL, 1992, AM J RESPIR CELL MOL, V6, P225; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	32	200	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6881	6888		10.1074/jbc.271.12.6881	http://dx.doi.org/10.1074/jbc.271.12.6881			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636114	hybrid			2022-12-27	WOS:A1996UB15700049
J	Li, QT; Karam, SM; Gordon, JI				Li, QT; Karam, SM; Gordon, JI			Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE STOMACH; EPITHELIAL-CELLS; BETA-SUBUNIT; CORPUS; DYNAMICS; GENE; EXPRESSION; MIGRATION; LINEAGE	The self-renewing epithelial populations present in the gastric units of the mouse stomach are descended from a multipotent stem cell and undergo an orderly migration-associated differentiation followed by apoptosis, The steady state census of the three principal cell types (acid-producing parietal cells, mucus-producing pit cells, and pepsinogen and intrinsic factor-producing zymogenic cells) is accurately controlled, despite marked differences in the rates of migration of each lineage, A transgenic mouse model has been created to define functional interrelationships between the proliferation, differentiation, and death programs of these Lineages, Nucleotides -1035 to +24 of the noncatalytic beta subunit gene of mouse H+/K+-ATPase were used to direct expression of an attenuated diphtheria toxin A subunit in the parietal cell lineage, These transcriptional regulatory elements are not active in members of the pit and zymogenic lineages, Stomachs, prepared from postnatal day 28-80 transgenic mice and their normal littermates, were subjected to single- and multilabel immunohistochemical studies as well as qualitative and quantitative light and electron microscopic morphologic analyses, The toxin produced complete ablation of differentiated parietal cells, Loss of parietal cells was accompanied by a 5-fold increase in the number of undifferentiated granule-free cells located in the proliferative compartment of gastric units, This amplified population of granule-free cells included the multipotent stem cell as well as committed precursors of the pit and zymogenic lineages, Loss of mature parietal cells was also associated with (i) a block in the differentiation program of the zymogenic lineage with an accumulation of pre-neck cells and a depletion of their neck and mature zymogenic cell descendants, and (ii) an similar to 2-fold amplification of pit cells, These findings are consistent with the notion that epithelial homeostasis within gastric units is maintained by instructive interactions between their different cell lineages, Unlike pit and zymogenic cells, parietal cells complete their differentiation in the gastric unit's proliferative compartment before undergoing a bipolar migration along the unit, Thus, the mature parietal cell is in a strategic position to influence decision-making among gastric epithelial cell precursors and to modulate the migration-associated terminal differentiation programs of the pit and zymogenic lineages.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; KUWAIT UNIV,FAC MED,DEPT ANAT,SAFAT 13110,KUWAIT	Washington University (WUSTL); Kuwait University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33487] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CANFIELD VA, 1991, P NATL ACAD SCI USA, V88, P8247, DOI 10.1073/pnas.88.18.8247; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FALK P, 1995, AM J PHYSIOL-GASTR L, V268, pG553, DOI 10.1152/ajpgi.1995.268.4.G553; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HOGAN B, 1986, MANIPULATING MOUSE E; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MORLEY GP, 1992, J BIOL CHEM, V267, P1165	20	170	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3671	3676						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631979	hybrid			2022-12-27	WOS:A1996TV72400053
J	Patstone, G; Maher, P				Patstone, G; Maher, P			Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL SPECIFICITY; FGF RECEPTORS; FAMILY; PROTEINS; HEPARIN; UVOMORULIN; DIVERSITY; MECHANISM; CLONING; KINASE	High affinity fibroblast growth factor (FGF) receptors contain a cluster of acidic amino acids in their extracellular domains that is reminiscent of the calcium binding domains of some cell adhesion molecules. Based on this observation, we used a calcium blotting technique to show that FGFR-1 binds calcium and that calcium binding is not observed in a mutagenized form of the receptor that lacks the acidic box region. The acidic box also binds other divalent cations, including copper. This latter interaction appears unique since the binding of copper to FGFR-1 mediates the binding of the receptor to immobilized heparin. While this observation may help explain the angiogenic properties of copper, divalent cation binding to FGF receptors may also mediate the interaction between FGF receptors, cell adhesion molecules and other proteoglycan components of the extracellular matrix.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18811] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; CHAUDHURI MM, 1993, J CELL PHYSIOL, V157, P209, DOI 10.1002/jcp.1041570202; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FUCHS F, 1972, INT J PEPT PROT RES, V4, P147; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GULLINO PM, 1986, ANTICANCER RES, V6, P153; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOU JZ, 1992, J BIOL CHEM, V267, P17804; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCAUSLAN BR, 1980, EXP CELL RES, V130, P147, DOI 10.1016/0014-4827(80)90051-8; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAJU KS, 1984, CANCER RES, V44, P1579; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TERRELL GE, 1991, MATRIX, V11, P108, DOI 10.1016/S0934-8832(11)80214-3; UENO H, 1992, J BIOL CHEM, V267, P1470; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	34	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3343	3346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631930				2022-12-27	WOS:A1996TV72400004
J	SteinerMordoch, S; Shirvan, A; Schuldiner, S				SteinerMordoch, S; Shirvan, A; Schuldiner, S			Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULE MEMBRANE; BETA-ADRENERGIC-RECEPTOR; AMINE TRANSPORTER; RESERPINE BINDING; VESICLES	Vesicular monoamine transporters (VMAT) catalyze transport of serotonin, dopamine, epinephrine, and norepinephrine into subcellular storage organelles in a variety of cells. Accumulation of the neurotransmitter depends on the proton electrochemical gradient (Delta<(mu)over tilde>(H+)) across the organelle membrane and involves VMAT-mediated exchange of two lumenal protons with one cytoplasmic amine. Mutagenic analysis of the role of two conserved Asp residues located in transmembrane segments X and XI of rat VMAT type I reveals an important role of these two residues in catalysis. Replacement of Asp 431 with either Glu or Ser inhibits VMAT-mediated [H-3]serotonin transport. The mutated proteins are unimpaired in ligand recognition as measured with the high affinity ligand [H-3]reserpine or coupling to the proton electrochemical gradient as judged by its ability to accelerate [H-3]reserpine binding. Therefore, the Asp residue is needed as such in this position and even a conservative replacement with Glu generates a protein that can catalyze only partial reactions but cannot complete the transport cycle. Replacement of Asp 404 with either Ser or Cys inhibits all VMAT-mediated reactions measured. However, replacement with Glu generated a protein that catalyzed [H-3]serotonin transport with modified properties. Whereas the mutated protein binds [H-3]reserpine to normal levels and the pH optimum of this reaction is only slightly affected, the optimum pH for transport activity shifted to the acid side and became very sharp; in addition the sensitivity to the inhibitor tetrabenazine increased significantly in this mutated protein. The results point to the need of a carboxyl moiety in position 404. A slight change in its relative location or in the environment around it has a significant effect on the pK of group(s) involved in steps after ligand recognition and coupling to the first H+.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GASNIER B, 1985, BIOCHEMISTRY-US, V24, P1239, DOI 10.1021/bi00326a028; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; ISAMBERT MF, 1981, FEBS LETT, V136, P13, DOI 10.1016/0014-5793(81)81205-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LANYI JK, 1992, BIOCHIM BIOPHYS ACTA, V1099, P102, DOI 10.1016/0167-4838(92)90458-P; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; NIRENBERG M, 1995, IN PRESS P NATL ACAD; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, IN PRESS J NEUROSCI; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1989, J BIOL CHEM, V264, P14865; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHERMAN D, 1981, EUR J BIOCHEM, V116, P535, DOI 10.1111/j.1432-1033.1981.tb05369.x; SCHULDINER S, 1978, P NATL ACAD SCI USA, V75, P3713, DOI 10.1073/pnas.75.8.3713; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUCHI R, 1992, BIOCHEMISTRY-US, V31, P12500, DOI 10.1021/bi00164a029; SUCHI R, 1991, BIOCHEMISTRY-US, V30, P6490, DOI 10.1021/bi00240a020; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	36	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13048	13054		10.1074/jbc.271.22.13048	http://dx.doi.org/10.1074/jbc.271.22.13048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662678	hybrid			2022-12-27	WOS:A1996UN47400057
J	Wright, LS; Bertics, PJ; Siegel, FL				Wright, LS; Bertics, PJ; Siegel, FL			Calmodulin N-methyltransferase - Kinetics, mechanism, and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; DEPENDENT ENZYMES; CELL-GROWTH; NAD KINASE; RAT-BRAIN; PROTEIN; BINDING; PHOSPHODIESTERASE; METHYLATION; DNA	The present study was undertaken to determine kinetic and inhibition parameters and the mechanism of S-adenosyl-L-methionine:calmodulin-L-lysine N-6-methyl-transferase (EC 2.1.1.60, CLNMT), an enzyme for which calmodulin is a substrate. Partially purified CLNMT isolated from rat testes had a V-max of 540 pmol/min/mg and K-m values for mushroom demethylcalmodulin and S-adenosyl-L-methionine of 230 nM and 2.0 mu M, respectively. Kinetic analysis indicated a complex Bi Bi sequential kinetic mechanism for CLNMT where S-adenosyl-L-methionine binds initially and is followed by demethylcalmodulin binding. When the effects of 20 different compounds that are either inhibitors of calmodulin-specific or methylation-specific functions were examined, CLNMT displayed a pattern of inhibition which differs from that seen with calmodulin-activated enzymes. The product of calmodulin methylation, fully trimethylated calmodulin, and nonmethylatable VU-3 calmodulin acted as competitive inhibitors of CLNMT, with K-i values of 310 and 400 nM, respectively. Of the 13 compounds tested, which are inhibitors of calmodulin-dependent cyclic nucleotide phosphodiesterase, only the calmodulin-binding domain from Ca2+/calmodulin-dependent kinase II, melittin, and calmidazolium were effective inhibitors of CLNMT and each exhibited a complex pattern of inhibition with K-is values of 21, 50, and 65 nM, respectively. The only potent methylation-specific inhibitor was S-adenosyl-L-homocysteine, which also displayed a complex pattern of inhibition.	UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53705; UNIV WISCONSIN,SCH MED,DEPT BIOMOL CHEM,MADISON,WI 53705; UNIV WISCONSIN,SCH MED,WAISMAN CTR,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NICHD NIH HHS [HD03352] Funding Source: Medline; NINDS NIH HHS [NS24669] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024669] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BARBES C, 1990, FEMS MICROBIOL LETT, V69, P239; BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BARNETTE MS, 1983, BIOCHEM PHARMACOL, V32, P2929, DOI 10.1016/0006-2952(83)90398-2; BERGER SJ, 1987, EXP CELL RES, V169, P149, DOI 10.1016/0014-4827(87)90233-3; BORCHARDT RT, 1979, TRANSMETHYLATION, P197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; COX R, 1985, BIOCHEM INT, V10, P63; DELORENZO RJ, 1982, FED PROC, V41, P2265; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; GALLIEN CL, 1984, EXP CELL RES, V155, P397, DOI 10.1016/0014-4827(84)90200-3; GIETZEN K, 1983, BIOCHIM BIOPHYS ACTA, V736, P109, DOI 10.1016/0005-2736(83)90175-X; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; GIETZEN K, 1980, BIOCHEM BIOPH RES CO, V94, P674, DOI 10.1016/0006-291X(80)91285-1; GRECO WR, 1982, COMPUT BIOMED RES, V15, P39, DOI 10.1016/0010-4809(82)90051-9; GREGORI L, 1985, J BIOL CHEM, V260, P5232; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HAN CH, 1993, BIOCHEMISTRY-US, V32, P13974, DOI 10.1021/bi00213a030; HEGEMANN L, 1991, EUR J PHARM-MOLEC PH, V207, P17, DOI 10.1016/S0922-4106(05)80032-X; HIDAKA H, 1985, CALMODULIN ANTAGONIS, P13; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOYAL JL, 1994, J BIOL CHEM, V269, P30039; KATOH N, 1982, BIOCHEM J, V202, P217, DOI 10.1042/bj2020217; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; LEUNG PC, 1984, J BIOL CHEM, V259, P2742; LEVIN RM, 1976, MOL PHARMACOL, V12, P581; LUTHRA MG, 1982, BIOCHIM BIOPHYS ACTA, V692, P271, DOI 10.1016/0005-2736(82)90531-4; MAVRI J, 1994, PROTEINS, V18, P381, DOI 10.1002/prot.340180408; MAZZEI GJ, 1984, BIOCHEM PHARMACOL, V33, P125, DOI 10.1016/0006-2952(84)90379-4; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; MURTAUGH TJ, 1986, J NEUROCHEM, V47, P164; NEIL SMA, 1993, BRIT J DERMATOL, V128, P143; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OH SH, 1990, PLANT PHYSIOL, V93, P880, DOI 10.1104/pp.93.3.880; OH SH, 1992, ARCH BIOCHEM BIOPHYS, V297, P28, DOI 10.1016/0003-9861(92)90636-B; OH SH, 1992, THESIS U TENNESSEE K; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PECH LL, 1994, BBA-GEN SUBJECTS, V1199, P183, DOI 10.1016/0304-4165(94)90114-7; PFEIFER GP, 1983, BIOCHIM BIOPHYS ACTA, V740, P323, DOI 10.1016/0167-4781(83)90141-0; PROZIALECK WC, 1983, ANNU REP MED CHEM, V18, P203; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RASMUSSEN C, 1993, J BIOL CHEM, V268, P23788; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REID DG, 1990, J BIOL CHEM, V265, P9744; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROBERTS DM, 1993, P NATL ACAD SCI USA, V89, P8394; ROUFOGALIS BD, 1983, CAN J BIOCHEM CELL B, V61, P927, DOI 10.1139/o83-118; ROWE PM, 1986, J BIOL CHEM, V261, P7060; ROWE PM, 1983, ANAL BIOCHEM, V133, P394, DOI 10.1016/0003-2697(83)90100-8; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; SANO H, 1983, EUR J BIOCHEM, V135, P181, DOI 10.1111/j.1432-1033.1983.tb07635.x; SANO H, 1980, EUR J BIOCHEM, V105, P471, DOI 10.1111/j.1432-1033.1980.tb04522.x; SAVILLE MK, 1994, BIOCHEM J, V299, P863, DOI 10.1042/bj2990863; SCHAEFFER P, 1987, BIOCHEM PHARMACOL, V36, P1989, DOI 10.1016/0006-2952(87)90498-9; Segel I.H., 1975, ENZYME KINETICS; SHI YQ, 1992, J BIOL CHEM, V267, P9547; Siegel F. L., 1990, PROTEIN METHYLATION, P33; SIMMS SA, 1991, J BIOL CHEM, V266, P12741; SONG QS, 1994, MOL CELL ENDOCRINOL, V99, P1; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WEISS B, 1980, CALMODULIN CELL FUNC, P319; WRIGHT LS, 1993, PROTEIN EXPRES PURIF, V4, P417, DOI 10.1006/prep.1993.1055; WRIGHT LS, 1991, BIOCHIM BIOPHYS ACTA, V1079, P174, DOI 10.1016/0167-4838(91)90123-H; YEE WC, 1989, BIOCHEM BIOPH RES CO, V162, P483, DOI 10.1016/0006-291X(89)92023-8; ZHANG MJ, 1994, J BIOL CHEM, V269, P5099; ZIMMER M, 1987, EUR J BIOCHEM, V164, P411, DOI 10.1111/j.1432-1033.1987.tb11073.x	73	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12737	12743		10.1074/jbc.271.22.12737	http://dx.doi.org/10.1074/jbc.271.22.12737			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662690	hybrid			2022-12-27	WOS:A1996UN47400009
J	Bai, RL; Pei, XF; Boye, O; Getahun, Z; Grover, S; Bekisz, J; Nguyen, NY; Brossi, A; Hamel, E				Bai, RL; Pei, XF; Boye, O; Getahun, Z; Grover, S; Bekisz, J; Nguyen, NY; Brossi, A; Hamel, E			Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2,4-DICHLOROBENZYL THIOCYANATE; ANTIMITOTIC AGENT; TAXOL; PROTEIN; CHROMATOGRAPHY; CONFORMATIONS; SEPARATION; MUTANTS; NMR	The colchicine analog 3-chloroacetyl-3-demethylthiocolchicine (3CTC) is a competitive inhibitor of colchicine binding to tubulin, binds to tubulin at 37 degrees C, but not at 0 degrees C, and covalently reacts with beta-tubulin at 37 degrees C, but not at 0 degrees C, in a reaction inhibited by colchicine site drugs. The approximate intramolecular distance be tween the oxygen at position C-3 in 3CTC and the chlorine atom of the 3-chloroacetyl group is 3 Angstrom. Using decylagarose chromatography, we purified beta-tubulin that had reacted with 3-(chloromethyl-[C-14]carbonyl)-3-demethylthiocolchicine ([C-14]3CTC). This beta-tubulin was digested with formic acid, cyanogen bromide, endoproteinase Glu-C, or endoproteinase Lys C, and the radiolabeled peptide(s) were isolated. The sequences of these peptides indicated that as much as 90% of the covalent reaction between the [C-14]3CTC and beta-tubulin occurred at cysteine 354. This finding indicates that the C-3 oxygen atom of colchicinoids is within 3 Angstrom of the sulfur atom of the Cys-354 residue, suggests that the colchicine A ring lies between Cys-354 and Cys-239, based on the known 9 Angstrom distance between these residues, and may indicate that the tropolone C ring lies between the peptide region containing Cys-239 and the amino-terminal beta-tubulin sequence, based on the labeling pattern observed following direct photoactivation of tubulin-bound colchicine.	NCI,MOLEC PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892; NIDDK,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; GEORGETOWN UNIV,DEPT CHEM,WASHINGTON,DC 20057; US FDA,CTR BIOL EVALUAT & RES,FACIL BIOTECHNOL RESOURCES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University; US Food & Drug Administration (FDA)								ABRAHAM I, 1986, P NATL ACAD SCI USA, V83, P6839, DOI 10.1073/pnas.83.18.6839; BAI RL, 1989, BIOCHIM BIOPHYS ACTA, V994, P12, DOI 10.1016/0167-4838(89)90056-3; BAI RL, 1989, BIOCHEMISTRY-US, V28, P5606, DOI 10.1021/bi00439a040; BIELLMANN JF, 1976, EUR J BIOCHEM, V63, P477, DOI 10.1111/j.1432-1033.1976.tb10250.x; BOYE O, 1991, MED CHEM RES, V1, P142; BOYE O, 1992, J LABELLED COMPOUNDS, V33, P293; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; DUBOIS J, 1993, TETRAHEDRON, V49, P6533, DOI 10.1016/S0040-4020(01)81822-6; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; GROVER S, 1992, BIOCHEM BIOPH RES CO, V187, P1350, DOI 10.1016/0006-291X(92)90451-P; GUERITTEVOEGELEIN F, 1990, ACTA CRYSTALLOGR C, V46, P781, DOI 10.1107/S0108270189009376; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KEATES RAB, 1981, P NATL ACAD SCI-BIOL, V78, P5638, DOI 10.1073/pnas.78.9.5638; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Landon, 1977, Methods Enzymol, V47, P145; LESSINGER L, 1978, ACTA CRYSTALLOGR B, V34, P578, DOI 10.1107/S0567740878003568; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MCCARTHY AD, 1982, FEBS LETT, V147, P256, DOI 10.1016/0014-5793(82)81054-5; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SCHMITT H, 1976, J MOL BIOL, V102, P743, DOI 10.1016/0022-2836(76)90289-8; SCHMITT H, 1978, EXP CELL RES, V115, P408, DOI 10.1016/0014-4827(78)90295-1; SHEIRNEISS G, 1978, CELL, V15, P639, DOI 10.1016/0092-8674(78)90032-6; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VANDERVELDE DG, 1993, J AM CHEM SOC, V115, P11650, DOI 10.1021/ja00077a095; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; WILLIAMS HJ, 1993, TETRAHEDRON, V49, P6545, DOI 10.1016/S0040-4020(01)81823-8; WILLIAMS RF, 1985, J BIOL CHEM, V260, P1379; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820; ZIMMERMAN CL, 1977, ANAL BIOCHEM, V77, P569, DOI 10.1016/0003-2697(77)90276-7	37	90	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12639	12645		10.1074/jbc.271.21.12639	http://dx.doi.org/10.1074/jbc.271.21.12639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647876	hybrid			2022-12-27	WOS:A1996UL66000078
J	Li, SW; Resnicoff, M; Baserga, R				Li, SW; Resnicoff, M; Baserga, R			Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL-TRANSDUCTION; IGF-1 RECEPTOR; EXPRESSION; ACTIVATION; CELLS; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OVEREXPRESSION; FIBROBLASTS	The insulin-like growth factor I receptor (IGF-IR) controls the extent of cell proliferation in a variety of cell types by at least 3 different ways: it is mitogenic, it causes transformation, and it protects cells from apoptosis. Previous reports indicated that certain domains in the C terminus of the IGF-IR transmitted a transforming signal that is additional to and separate from the mitogenic signal. We have now mutated the four serine residues at 1280-1283 of the IGF-IR, and transfected the mutant receptor into R(-) cells. Cells expressing the mutant receptor are fully responsive to IGF-I-mediated mitogenesis, but are not transformed (no colony formation in soft agar). Several downstream signal transducers are not affected by the mutation, again suggesting a separate pathway for transformation. The mutant receptor can act as a dominant negative for growth, but cannot induce apoptosis in cells with endogenous wild-type receptors.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIA NIH HHS [AG00378] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BASERGA R, 1995, CANCER RES, V55, P249; Burgaud JL, 1996, EXP CELL RES, V223, P412, DOI 10.1006/excr.1996.0096; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DANGELIS T, 1995, J CELL PHYSL, V164, P214; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; FALCO JP, 1988, ONCOGENE, V2, P573; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Hongo A, 1996, ONCOGENE, V12, P1231; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LONG L, 1995, CANCER RES, V55, P1006; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAOUIS M, 1994, J BIOL CHEM, V269, P27762; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P503; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	70	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12254	12260		10.1074/jbc.271.21.12254	http://dx.doi.org/10.1074/jbc.271.21.12254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647823	hybrid			2022-12-27	WOS:A1996UL66000025
J	Shin, EK; Tevosian, SG; Yee, AS				Shin, EK; Tevosian, SG; Yee, AS			The N-terminal region of E2F-1 is required for transcriptional activation of a new class of target promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; THYMIDINE KINASE GENE; HERPES-SIMPLEX VIRUS; BINDING PROTEIN; ADENOVIRUS; EXPRESSION; RB; TRANSACTIVATION; COMPLEX; P107	Because of its expression in numerous cells, the herpes simplex virus thymidine kinase promoter (HSV-TK) is one of the best characterized promoters. Using the HSV-TK promoter as a model system, we have defined a new mode of E2F-1 transcriptional activation which utilizes the N-terminal region of E2F-1, We demonstrate that E2F-1 strongly activated HSV-TK, but in the absence of consensus E2F DNA elements, Nonetheless, E2F-1 could bind to GC-rich elements, which were conclusively identified in classic studies of HSV-TK as SP-1 sites. Second, the transcriptional activation of HSV-TK required the entire E2F-1 protein, including the N-terminal 89 amino acids, In contrast, the N-terminal 89 amino acids of E2F-1 were dispensable for transcriptional activation through consensus E2F sites, Third, we demonstrated that S phase entry is not sufficient for activation of HSV-TK by E2F-1, while the activation through consensus E2F sites is strictly linked to the cell cycle. Taken together, the activation of HSV-TK by E2F-1 proceeds by a different mechanism directed in part through the N-terminal region of E2F-1 and may be uncoupled from the known cell cycle regulatory role.	TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044634] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK-34928] Funding Source: Medline; NIGMS NIH HHS [GM44634] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COOK WJ, 1995, MOL CELL BIOL, V15, P4998; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FELDMAN LT, 1982, P NATL ACAD SCI-BIOL, V79, P4952, DOI 10.1073/pnas.79.16.4952; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; IMBALZANO AN, 1991, J VIROL, V65, P565, DOI 10.1128/JVI.65.2.565-574.1991; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; NEVINS JR, 1992, SCIENCE, V258, P424; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY J, 1995, CURR TOP MICROBIOL, V208, P1; SUNG NS, 1994, MOL CELL BIOL, V14, P7144, DOI 10.1128/MCB.14.11.7144; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	49	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12261	12268		10.1074/jbc.271.21.12261	http://dx.doi.org/10.1074/jbc.271.21.12261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647824	hybrid			2022-12-27	WOS:A1996UL66000026
J	Slominski, A; Baker, J; Rosano, TG; Guisti, LW; Ermak, G; Grande, M; Gaudet, SJ				Slominski, A; Baker, J; Rosano, TG; Guisti, LW; Ermak, G; Grande, M; Gaudet, SJ			Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYINDOLE-O-METHYLTRANSFERASE; XENOPUS-LAEVIS; ACETYLTRANSFERASE; DEACETYLATION; MELANOGENESIS; TRACT; CELLS	Biotransformation of [H-3]serotonin by cultured hamster skin to H-3-metabolites corresponding to N-acetylserotonin (NAS), melatonin, and 5-methoxytryptamine (5-MT) was demonstrated. This process was time-dependent, with the highest production of radioactive NAS and melatonin metabolites after 3 and 5 h of incubation followed by a decrease in the rate of metabolite release into the media. Conversely, the formation of radioactive metabolite corresponding to 5-MT increased gradually during skin culture, reaching the highest level after 24 h of incubation. The production of H-3-metabolites, corresponding to NAS, melatonin, and 5-MT, was stimulated by forskolin with a maximum effect of forskolin at 10 mu M concentration. The gas chromatographic/mass spectroscopy analysis of the fraction eluting at the retention time of NAS standard material showed that it contained NAS, further confirming production and release of NAS into the media by hamster skin. Therefore, we conclude that mammalian skin can acetylate serotonin to NAS and postulate that the NAS is further metabolized by the skin to form melatonin which is subsequently transformed to 5-MT.	ALBANY MED COLL, DEPT PATHOL & LAB MED, ALBANY, NY 12208 USA; MERRIMACK COLL, DEPT BIOL, BOSTON, MA 01845 USA	Albany Medical College; Merrimack College				Slominski, Andrzej/0000-0001-8963-3995				BINKLEY S, 1975, ENDOCRINOLOGY, V96, P848, DOI 10.1210/endo-96-4-848; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; Bos JD, 1990, SKIN IMMUNE SYSTEM S; BRAMMER GL, 1994, LIFE SCI, V55, P775, DOI 10.1016/0024-3205(94)00561-3; CAHILL GM, 1989, P NATL ACAD SCI USA, V86, P1098, DOI 10.1073/pnas.86.3.1098; CHAMPION RH, 1990, TXB DERMATOLOGY; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; Gilbert Scott F., 1988, DEV BIOL; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; GRACE MS, 1993, J NEUROCHEM, V60, P990, DOI 10.1111/j.1471-4159.1993.tb03246.x; Hadley M.E., 1988, ENDOCRINOLOGY; HUETHER G, 1992, LIFE SCI, V51, P945, DOI 10.1016/0024-3205(92)90402-B; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; KOPIN IJ, 1961, J BIOL CHEM, V236, P3072; KVEDER S, 1961, J BIOL CHEM, V236, P3214; LOGAN A, 1980, J INVEST DERMATOL, V74, P47, DOI 10.1111/1523-1747.ep12514608; MILSTONE LM, 1988, ANN NY ACAD SCI, V548, P1, DOI 10.1111/j.1749-6632.1988.tb18787.x; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; ROGAWSKI MA, 1979, J NEUROCHEM, V32, P1219, DOI 10.1111/j.1471-4159.1979.tb11049.x; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; SLOMINSKI A, 1988, J CELL SCI, V89, P287; SUGDEN D, 1987, METHOD ENZYMOL, V142, P590; Yu H. L., 2020, ARXIV PREPRINT ARXIV	30	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12281	12286		10.1074/jbc.271.21.12281	http://dx.doi.org/10.1074/jbc.271.21.12281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647827	hybrid			2022-12-27	WOS:A1996UL66000029
J	Communi, D; Lecocq, R; Erneux, C				Communi, D; Lecocq, R; Erneux, C			Arginine 343 and 350 are two active site residues involved in substrate binding by human type I D-myo-inositol 1,4,5-trisphosphate 5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; HUMAN-PLATELETS; PROTEIN-KINASE; POLYPHOSPHATE-5-PHOSPHATASE; TRISPHOSPHATE; METABOLISM; LIVER; 5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE; IDENTIFICATION; PHOSPHATES	The crucial role of two reactive arginyl residues within the substrate binding domain of human Type I D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) 5-phosphatase has been investigated by chemical modification and site-directed mutagenesis. Chemical modification of the enzyme by phenylglyoxal is accompanied by irreversible inhibition of enzymic activity. Our studies demonstrate that phenylglyoxal forms an enzyme inhibitor complex and that the modification reaction is prevented in the presence of either Ins(1,4,5)P-3, D-myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) or 2,3-bisphosphoglycerate (2,3-BPG). Direct [H-3]Ins(1,4,5)P-3 binding to the covalently modified enzyme is dramatically reduced. The stoichiometry of labeling with C-14-labeled phenylglyoxal is shown to be 2.1 mol of phenylglyoxal incorporated per mol of enzyme. A single [C-14]phenylglyoxal-modified peptide is isolated following a-chymotrypsin proteolysis of the radiolabeled Ins(1,4,5)P-3 5-phosphatase and reverse-phase high performance liquid chromatography (HPLC). The peptide sequence (i.e. M-N-T-R-C-P-A-W-C-D-R-I-L) corresponds to amino acids 340-352 of Ins(1,4,5)P-3 5-phosphatase. An estimate of the radioactivity of the different phenylthiohydantoin amino acid derivatives shows the modified amino acids to be Arg-343 and Arg-350. Furthermore, two mutant enzymes were obtained by site directed mutagenesis of the two arginyl residues to alanine, and both mutant enzymes have identical UV circular dichroism (CD) spectra. The two mutants (i.e. R343A and R350A) show increased K-m values for Ins(1,4,5)P-3 (10- and 15-fold, respectively) resulting in a dramatic loss in enzymic activity. In conclusion, we have directly identified two reactive arginyl residues as part of the active site of Ins(1,4,5)P-3 5-phosphatase. These results point out the crucial role for substrate recognition of a 10 amino acids-long sequence segment which is conserved among the primary structure of inositol and phosphatidylinositol polyphosphate 5-phosphatases.			Communi, D (corresponding author), UNIV BRUSSELS,INST INTERDISCIPLINARY RES,CAMPUS ERASME,BLDG C,RT LENNIK 808,B-1070 BRUSSELS,BELGIUM.							ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; COMMUNI D, 1995, BIOCHEM J, V310, P109, DOI 10.1042/bj3100109; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V143, P351; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; FOSTER WB, 1981, J BIOL CHEM, V256, P882; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HANSEN CA, 1986, J BIOL CHEM, V261, P8100; HIXSON CS, 1979, J BIOL CHEM, V254, P7509; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KINCAID RL, 1988, METHOD ENZYMOL, V159, P627; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LIN K, 1992, J BIOL CHEM, V267, P19163; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; PAVELAVRANCIC M, 1994, J BIOL CHEM, V269, P14962; PETTERSON G, 1977, ANAL BIOCHEM, V83, P346; RIDER MH, 1992, EUR J BIOCHEM, V207, P967, DOI 10.1111/j.1432-1033.1992.tb17131.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; STEPHENS L, 1995, BIOCHEM SOC T, V23, P207, DOI 10.1042/bst0230207; STOREY DJ, 1984, NATURE, V312, P374, DOI 10.1038/312374a0; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; WELLS TNC, 1994, BIOCHEMISTRY-US, V33, P5777, DOI 10.1021/bi00185a015; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YU FX, 1992, J BIOL CHEM, V267, P14616; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHANG YP, 1993, BIOCHEM BIOPH RES CO, V190, P1080, DOI 10.1006/bbrc.1993.1159	42	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11676	11683		10.1074/jbc.271.20.11676	http://dx.doi.org/10.1074/jbc.271.20.11676			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662625	hybrid			2022-12-27	WOS:A1996UL25000017
J	Jackson, JD; Petrykowska, H; Philipsen, S; Miller, W; Hardison, R				Jackson, JD; Petrykowska, H; Philipsen, S; Miller, W; Hardison, R			Role of DNA sequences outside the cores of DNase hypersensitive sites (HSs) in functions of the beta-globin locus control region - Domain opening and synergism between HS2 and HS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; HIGH-LEVEL EXPRESSION; HUMAN ERYTHROID-CELLS; TRANSGENIC MICE; MINIMAL REQUIREMENTS; CHROMATIN STRUCTURE; GENE-CLUSTER; ENHANCER; ORGANIZATION; CONSERVATION	The roles of each DNase hypersensitive site (HS), and the DNA sequences between them, in the activity of the locus control region of the mammalian beta-globin gene domain were examined by placing human and rabbit restriction fragments containing the cores of HS2, HS3, HS4, and HS5, along with varying amounts of flanking DNA, upstream of a hybrid epsilon-globin-luciferase reporter gene and testing for effects on expression both prior to and after integration into the chromosomes of K562 cells, a human erythroid cell line. Prior to integration, fragments containing HS2 enhanced expression to the greatest extent, and the modest enhancement by some fragments containing HS3 correlated with the presence of a well-conserved binding site for AP1/NFE2. The stronger effects of larger locus control region DNA fragments in clones of stably transfected cells indicates a role for sequences outside the HS cores after integration into the genome. The strong effect of a 1.9-kilobase Hin-dIII fragment containing HS3 after, but not prior to, integration argues for the presence of a chromatin domain opening activity. Use of a rabbit DNA fragment containing both HS2 and HS3 demonstrated a synergistic interaction between the two HSs when their natural context and spacing are preserved.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT COMP SCI & ENGN,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,MGC,3000 DR ROTTERDAM,NETHERLANDS	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Erasmus University Rotterdam			Hardison, Ross C/G-1142-2010	Hardison, Ross C/0000-0003-4084-7516	NIDDK NIH HHS [DK27635] Funding Source: Medline; NLM NIH HHS [LM05573, LM05110] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027635] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [N01LM005573, R01LM005110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, PHILOS T ROY SOC B, V339, P183, DOI 10.1098/rstb.1993.0015; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARDISON R, 1994, GENOMICS, V21, P344, DOI 10.1006/geno.1994.1275; HARDISON R, 1993, DNA SEQUENCE, V4, P163, DOI 10.3109/10425179309015629; HARDISON R, 1995, MOL BIOL HEMOGLOBIN, P405; HUG BA, 1992, NUCLEIC ACIDS RES, V21, P5771; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; JIMENEZ G, 1992, NUCLEIC ACIDS RES, V20, P5797, DOI 10.1093/nar/20.21.5797; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LI QL, 1990, P NATL ACAD SCI USA, V87, P8207, DOI 10.1073/pnas.87.21.8207; LI QL, 1994, BLOOD, V84, P1399; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Miller J. H, 1972, EXPT MOL GENETICS; MOON AM, 1991, BLOOD, V77, P2272; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1994, BBA-GENE STRUCT EXPR, V1219, P351, DOI 10.1016/0167-4781(94)90059-0; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TREPICCHIO WL, 1993, MOL CELL BIOL, V13, P7457, DOI 10.1128/MCB.13.12.7457; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YU Z, 1994, GENE, V139, P139	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11871	11878		10.1074/jbc.271.20.11871	http://dx.doi.org/10.1074/jbc.271.20.11871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662652	hybrid, Green Submitted, Green Published			2022-12-27	WOS:A1996UL25000047
J	Muller, S; Straub, A; Schroder, S; Bauer, PH; Lohse, MJ				Muller, S; Straub, A; Schroder, S; Bauer, PH; Lohse, MJ			Interactions of phosducin with defined G protein beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; LIGHT-DEPENDENT PHOSPHORYLATION; BACULOVIRUS EXPRESSION SYSTEM; HETEROTRIMERIC G-PROTEINS; FUNCTIONAL-CHARACTERIZATION; GUANINE-NUCLEOTIDES; BINDING; PURIFICATION; RHODOPSIN; CELLS	Phosducin has recently been identified as a cytosolic protein that interacts with the beta gamma-subunits of G proteins and thereby may regulate transmembrane signaling. It is expressed predominantly in the retina but also in many other tissues, which raises the question of its potential specificity for retinal versus nonretinal beta gamma-subunits. We have therefore expressed and purified different combinations of beta- and gamma-subunits from Sf9 cells and have also purified transducin-beta gamma from bovine retina and a mixture of beta gamma complexes from bovine brain. Their interactions with phosducin were determined in a variety of assays for beta gamma function: support of ADP-ribosylation of alpha(0) by pertussis toxin, enhancement of the GTPase activity of alpha(0), and enhancement of rhodopsin phosphorylation by the beta-adrenergic receptor kinase 1 (beta ARK1). There were only moderate differences in the effects of the various beta gamma complexes alone on alpha(0), but there were marked differences in their ability to support beta ARK1 catalyzed rhodopsin phosphorylation. Phosducin inhibited all beta gamma-mediated effects and showed little specificity toward specific defined beta gamma complexes with the exception of transducin-beta gamma (beta(1) gamma(1)), which was inhibited more efficiently than the other beta gamma combinations. In a direct binding assay, there was no apparent selectivity of phosducin for any beta gamma combination tested. Thus, in contrast to beta ARK1, phosducin does not appear to discriminate strongly between different G protein beta- and gamma-subunits.	UNIV WURZBURG,INST PHARMACOL,D-97078 WURZBURG,GERMANY; UNIV MUNICH,MOLEC BIOL LAB,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Munich			Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				ASANO T, 1993, J BIOL CHEM, V268, P20512; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1986, NATURE, V322, P869; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEITHIER H, 1992, EUR J BIOCHEM, V204, P1169, DOI 10.1111/j.1432-1033.1992.tb16744.x; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MULLER S, 1995, BIOCHEM SOC T, V23, P141; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	44	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11781	11786		10.1074/jbc.271.20.11781	http://dx.doi.org/10.1074/jbc.271.20.11781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662655	hybrid			2022-12-27	WOS:A1996UL25000033
J	Nakagawa, T; Goto, K; Kondo, H				Nakagawa, T; Goto, K; Kondo, H			Cloning, expression, and localization of 230-kDa phosphatidylinositol 4-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL KINASE; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; 2ND MESSENGERS; RAT-LIVER; PROTEIN; IDENTIFICATION; PURIFICATION; 4-PHOSPHATE; VESICLES	A phosphatidylinositol (PI) 4-kinase cDNA was cloned from a rat brain cDNA library. This cDNA encoded a protein of 2041 amino acids with a calculated molecular weight of 231,317. The deduced amino acid sequence shared the identity of 52.3 and 34.4% in the presumed catalytic domain with two yeast PI 4-kinases, STT4 and PIK1, respectively, and showed 31.7% identity to p110 alpha subunit of rat PI 3-kinase in the same domain. In addition, a 3' half coding region of the present cDNA was 89.6% identical to and its deduced amino acid sequence was 98.2% identical to the sequence for PI4K alpha, a recently reported human PI 4-kinase of type II, suggesting that PI4K alpha is an alternative form of the present PI 4-kinase molecule. The present cDNA contained sequences encoding the ankyrin repeat domain, lipid kinase unique domain, pleckstrin homology domain, presumed lipid kinase/protein kinase homology domain, proline-rich region, and SH3 domain. By examining PI kinase activity in transfected COS-7 cells using the epitope tag immunoprecipitation as well as the conventional way, the product phosphatidylinositol phosphate was identified as phosphatidylinositol 4-phosphate but not phosphatidylinositol 3-phosphate. This PI 4-kinase activity was markedly enhanced in the presence of Triton X-100 but relatively insensitive to inhibition by adenosine. By epitope tag immunohistochemistry, the immunoreactivity for this PI 4-kinase molecule was largely localized in close association with the membranes of the Golgi vesicles and vacuoles. By in situ hybridization analysis, the expression of mRNA for this PI 4-kinase was evident throughout the gray matter of entire brain with higher expression intensity in fetal brain. These data imply that this novel PI 4-kinase is involved in some processes essential to neuronal differentiation and maturation in eluding the synaptogenesis and synaptic plasticity.	TOHOKU UNIV,SCH MED,DEPT ANAT,SENDAI,MIYAGI 980,JAPAN	Tohoku University								BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CAMPBELL CR, 1985, J BIOL CHEM, V260, P948; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; COLLINS CA, 1983, J BIOL CHEM, V258, P2130; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; EDMANN G, 1987, BIOCHEMISTRY-US, V26, P6845; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; KATO H, 1989, J BIOL CHEM, V264, P3116; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P2; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PORTER FD, 1988, J BIOL CHEM, V263, P8989; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOOKE NE, 1984, BIOCHEM J, V219, P471, DOI 10.1042/bj2190471; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	37	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12088	12094		10.1074/jbc.271.20.12088	http://dx.doi.org/10.1074/jbc.271.20.12088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662589	hybrid			2022-12-27	WOS:A1996UL25000076
J	Feehan, C; Darlak, K; Kahn, J; Walcheck, B; Spatola, AF; Kishimoto, TK				Feehan, C; Darlak, K; Kahn, J; Walcheck, B; Spatola, AF; Kishimoto, TK			Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor - Identification with an L-selectin-alkaline phosphatase reporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS RELEASE; NODE HOMING RECEPTOR; SURFACE EXPRESSION; CELL ACTIVATION; FACTOR-ALPHA; PRECURSOR; PROTEINS; CLEAVAGE; CD43; MODULATION	Expression of the L-selectin adhesion molecule can be rapidly down-modulated by regulated proteolysis at a membrane-proximal site, The L-selectin secretase has remained undefined, and the secretase activity is resistant to a broad panel of common protease inhibitors, We have developed an L-selectin-alkaline phosphatase reporter, consisting of the ectodomain of human placental alkaline phosphatase fused to the membrane-proximal cleavage, transmembrane, and cytoplasmic domains of L-selectin, to aid in the screening for L-selectin secretase inhibitors, A hydroxamic acid-based metalloprotease inhibitor, KD-IX-73-4, inhibited release of the L-selectin-alkaline phosphatase reporter in a dose-dependent manner, The hydroxamic acid-based peptide was also found to inhibit wild type L-selectin down-regulation from the surfaces of phorbol myristate acetate-activated peripheral blood lymphocytes and phytohemagglutinin-stimulated lymphoblasts. Analysis of the proteolytic cleavage fragments of L-selectin confirmed that KD-IX-73-4 inhibited L-selectin proteolysis. Lymphocyte L-selectin was not down-regulated when co-cultured with formylmethionylleucylphenylalanine-stimulated neutrophils, suggesting that the putative secretase acts in cis with the membrane-bound L-selectin. These results suggest that the L-selectin secretase activity may involve a cell surface, zinc-dependent metalloprotease, although L-selectin shedding is not affected by EDTA and may be related to the recently described activity involved in processing of membrane-bound TNF-alpha.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL DIS,RIDGEFIELD,CT 06877; UNIV LOUISVILLE,DEPT CHEM & BIOCHEM,LOUISVILLE,KY 40292	Boehringer Ingelheim; University of Louisville								ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BAZIL V, 1992, J IMMUNOL, V149, P747; BAZIL V, 1991, J IMMUNOL, V147, P1567; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BAZIL V, 1994, J IMMUNOL, V152, P1314; BERG M, 1990, BLOOD, V76, P2381; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DELPOZO MA, 1994, EUR J IMMUNOL, V24, P2586, DOI 10.1002/eji.1830241104; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1995, AGENT ACTION SUPPL, V47, P121; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SHIPP MA, 1991, BLOOD, V78, P1834; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SPATOLA AF, 1992, PEPTIDES CHEM BIOL, P820; SPERTINI O, 1991, LEUKEMIA, V5, P300	35	129	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7019	7024		10.1074/jbc.271.12.7019	http://dx.doi.org/10.1074/jbc.271.12.7019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636132	hybrid			2022-12-27	WOS:A1996UB15700067
J	Tamechika, I; Itakura, M; Saruta, Y; Furukawa, M; Kato, A; Tachibana, S; Hirose, S				Tamechika, I; Itakura, M; Saruta, Y; Furukawa, M; Kato, A; Tachibana, S; Hirose, S			Accelerated evolution in inhibitor domains of porcine elafin family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABLE PROTEINASE-INHIBITOR; ELASTASE-SPECIFIC INHIBITOR; REACTIVE CENTER REGIONS; AMINO-ACID-SEQUENCE; REPETITIVE SEQUENCES; PROTEASE INHIBITORS; HUMAN KERATINOCYTES; MOLECULAR-CLONING; CROSS-LINKING; PURIFICATION	Through the analysis of the porcine gene encoding the elastase inhibitor elafin, we demonstrated that there are at least three closely related members of the elafin family, and their genes have arisen by accelerated evolution. A porcine genomic DNA Library was screened with a previously cloned human elafin cDNA probe, and several positive clones were obtained that can be distinguished by a combination of restriction enzymes, Sequence analysis of these clones revealed the presence of three homologous members whose genes, all consisting of three exons and two introns, are almost identical except the exon 2 sequences encoding the inhibitor domain called ''WAP motif''; the intron sequences are related to each other with sequence similarities of 93-98%, whereas the exon 2 sequences exhibited only 60-77% similarities among the three members. The extreme divergence in the exon 2 sequences compared to the highly conserved intron sequences may be generated by accelerated mutations confined in a short stretch of the genes following recent duplication events of a single ancestral gene, An RNase protection assay indicated that the messages of the elafin family members are abundantly expressed in the trachea and intestine, suggesting that the most likely selective forces for the accelerated evolution are extrinsic proteinases produced by invasive microorganisms.	TOKYO INST TECHNOL, DEPT BIOL SCI, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; EISAI & CO LTD, TSUKUBA RES LABS, TSUKUBA, IBARAKI 30026, JAPAN	Tokyo Institute of Technology; Eisai Co Ltd			Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CASTAGNARO A, 1992, J MOL BIOL, V224, P1003, DOI 10.1016/0022-2836(92)90465-V; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOODMAN M, 1981, PROG BIOPHYS MOL BIO, V38, P105, DOI 10.1016/0079-6107(81)90012-2; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ITO O, 1990, PEPTIDE CHEMISTRY 1989, P353; JENSEN LS, 1989, J BIOL CHEM, V264, P15781; JIN L, 1990, MOL BIOL EVOL, V7, P82; KIMURA M, 1981, J MOL EVOL, V17, P110, DOI 10.1007/BF01732682; Kimura M., 1983, NEUTRAL THEORY MOL E; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOLHUIZEN HOF, 1995, BIOL CHEM H-S, V376, P1; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; NAKASHIMA KI, 1995, P NATL ACAD SCI USA, V92, P5605, DOI 10.1073/pnas.92.12.5605; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NEI M, 1986, MOL BIOL EVOL, V3, P418; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAY BK, 1994, J BIOL CHEM, V269, P22080; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SINGER DS, 1987, NUCLEIC ACIDS RES, V15, P2780, DOI 10.1093/nar/15.6.2780; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; SUZUKI Y, 1990, J BIOCHEM, V107, P173, DOI 10.1093/oxfordjournals.jbchem.a123021; TAKAHASHI H, 1992, ANIM GENET, V23, P443, DOI 10.1111/j.1365-2052.1992.tb02164.x; TSUNEMI M, 1992, BIOCHEM BIOPH RES CO, V185, P967, DOI 10.1016/0006-291X(92)91721-2; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	45	42	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7012	7018		10.1074/jbc.271.12.7012	http://dx.doi.org/10.1074/jbc.271.12.7012			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636131	hybrid			2022-12-27	WOS:A1996UB15700066
J	vandeLocht, A; Stubbs, MT; Bauer, M; Bode, W				vandeLocht, A; Stubbs, MT; Bauer, M; Bode, W			Crystallographic evidence that the F2 kringle catalytic domain linker of prothrombin does not cover the fibrinogen recognition exosite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; PRO-ARG CHLOROMETHYLKETONE; HUMAN ALPHA-THROMBIN; PROTEIN; ACTIVATION; RESOLUTION; BINDING; REFINEMENT; FRAGMENT-1; INHIBITORS	The 2.6-Angstrom x-ray crystal structure of bovine alpha-thrombin in complex with rhodniin, a protein inhibitor isolated from the bug Rhodnius prolixus, has been solved and refined. The structure has enabled us to trace the N-terminal part of the 49-residue A-chain of bovine alpha-thrombin for the first time, which is fixed in a U-shaped loop on the molecular surface opposite the active site canyon. Model building shows that the 25 amino acid residues that link the A-chain and F2 kringle cannot run through the fibrinogen recognition exosite. This demonstrates that this fibrinogen recognition exosite is available in prothrombin and meizothrombin.			vandeLocht, A (corresponding author), MAX PLANCK INST BIOCHEM, DEPT STRUCT RES, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.			Stubbs, Milton/0000-0003-1278-9013				ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; ARNI RK, 1994, CHEM PHYS LIPIDS, V67-8, P59, DOI 10.1016/0009-3084(94)90124-4; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LIU LW, 1991, J BIOL CHEM, V266, P23632; NI F, 1993, J BIOL CHEM, V268, P16899; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TURK D, 1992, THESIS TU MUNCHEN; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1994, J BIOL CHEM, V269, P27441; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; [No title captured]	31	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3413	3416						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631941				2022-12-27	WOS:A1996TV72400015
J	Couvineau, A; RouyerFessard, C; Maoret, JJ; Gaudin, P; Nicole, P; Laburthe, M				Couvineau, A; RouyerFessard, C; Maoret, JJ; Gaudin, P; Nicole, P; Laburthe, M			Vasoactive intestinal peptide (VIP)(1) receptor - Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; VIP RECEPTORS; TISSUE DISTRIBUTION; RAT; PHI; POLYPEPTIDE; SECRETIN; LIVER; GRF	Vasoactive intestinal peptide (VIP)(1) receptors in rats and humans recognize peptide histidine isoleucineamide (PHI) with high and low affinity, respectively. We took advantage of this phenotypic difference to identify the domain responsible for the selective recognition of PHI by rat and human receptors which display >80% sequence identity. After transfection of human and rat receptors in COS cells, the ratio of IC50 for PHI/IC50 for VIP (referred to as P/V) in inhibiting I-125-VIP binding was shown to be >1,000 and <40, respectively. Construction of eight rat/human receptor chimerae by overlap polymerase chain reaction and determination of their P/V ratios demonstrated that the critical domain for PHI recognition is present within a sequence comprising part of the first extracellular loop and third transmembrane domain. This domain contains three different amino acids numbered according to human and rat sequences, respectively, e.g. Gln(207) (human) versus His(208) (rat), Gly(211) versus Ala(212) and Met(219) versus Val(220). Site-directed mutagenesis introducing individual, double, or triple mutations in a chimeric construct revealed that all three amino acids were involved in the recognition of PHI. Triple mutations were then introduced in the wild type receptors i.e. Q207H, G211A, M219V human VIP1 receptor and H208Q, A212G, V220M rat VIP1 receptor, resulting in a complete change in their phenotype from human to rat and from rat to human, respectively. The results demonstrate that three nonadjacent amino acids are responsible for the selective recognition of PHI by human and rat VIP1 receptors.			Couvineau, A (corresponding author), UNIV PARIS 07, FAC MED XAVIER BICHAT, INSERM, U410, UNIT RECH NEUROENDOCRINOL & BIOL CELLUL DIGEST, F-75870 PARIS 18, FRANCE.		couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				BATAILLE D, 1980, FEBS LETT, V114, P240, DOI 10.1016/0014-5793(80)81124-0; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1986, J BIOL CHEM, V261, P4482; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; FAHRENKRUG J, 1989, HDB PHYSL GASTROINTE, V2, P611; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; LABURTHE M, 1983, FEBS LETT, V159, P89, DOI 10.1016/0014-5793(83)80422-0; LABURTHE M, 1985, LIFE SCI, V36, P991, DOI 10.1016/0024-3205(85)90396-0; LABURTHE M, 1986, MOL PHARMACOL, V29, P23; LABURTHE M, 1988, ANN NY ACAD SCI, V527, P296; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SVOBODA M, 1994, BIOCHEM BIOPH RES CO, V205, P1617, DOI 10.1006/bbrc.1994.2852; SVOBODA M, 1995, INT SOC NEUR SAT S V; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Voisin T, 1996, J BIOL CHEM, V271, P574, DOI 10.1074/jbc.271.1.574	28	66	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12795	12800		10.1074/jbc.271.22.12795	http://dx.doi.org/10.1074/jbc.271.22.12795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662697	hybrid			2022-12-27	WOS:A1996UN47400018
J	Pansegrau, W; Lanka, E				Pansegrau, W; Lanka, E			Mechanisms of initiation and termination reactions in conjugative DNA processing - Independence of tight substrate binding and catalytic activity of relaxase (TraI) of IncP alpha plasmid RP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER ORIGIN; BACTERIAL CONJUGATION; SEQUENCE MOTIFS; STRAND TRANSFER; NICK REGIONS; PROTEIN; SITE; MOBILIZATION; REPLICATION; CLEAVAGE	The relaxase (TraI) of plasmid RP4 (IncP alpha) plays a key role in initiation and termination of transfer DNA replication during conjugative transmission of the plasmid. TraI functions as a DNA strand transferase that cleaves a unique phosphodiester bond at nic of the transfer origin. The cleavage reaction consists in a reversible transesterification that leads to transfer of the 5' phosphoryl at nic to the hydroxyl group of TraI Tyr-22. Hence, cleavage results in the covalent attachment of TraI to the 5' terminus of the plasmid strand destined for transfer. To investigate the protein's ability to function in a ''second cleavage'' reaction proposed to terminate rolling circle mode transfer DNA replication, single-stranded oligonucleotides containing the nic region were immobilized at their 3' ends on magnetic beads and cleaved by TraI. The resulting covalent TraI-oligonucleotide adducts were active in the joining reaction but unable to cleave oligonucleotides containing an intact nic region, indicating that second cleavage probably requires a TraI dimer, since a monomer is insufficient. The covalently attached oligonucleotide determines the affinity of the relaxase for the 3' terminus of the T-strand. To further the biochemical characterization of TraI-catalyzed reactions, me used specific TraI mutants, showing that amino acid residues in each relaxase motif are involved in substrate binding. To uncouple substrate binding and cleaving-joining we applied partially biotinylated TraI mutant proteins that were immobilized to magnetic beads. Using this approach we could demonstrate that tight DNA substrate binding and cleaving-joining are independent processes. Enhanced topoisomerase activity of some TraI mutants was correlated with low specific substrate binding affinity in conjunction with high cleaving-joining activity.	MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	Max Planck Society								BALZER D, 1994, J BACTERIOL, V176, P4285, DOI 10.1128/jb.176.14.4285-4295.1994; BHATTACHARJEE M, 1992, J BACTERIOL, V174, P6659, DOI 10.1128/JB.174.20.6659-6665.1992; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ERICKSON MJ, 1993, MOL MICROBIOL, V7, P289, DOI 10.1111/j.1365-2958.1993.tb01120.x; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; GAO Q, 1994, MOL MICROBIOL, V11, P449, DOI 10.1111/j.1365-2958.1994.tb00326.x; HANAI R, 1993, J BIOL CHEM, V268, P23830; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KORNBERG A, 1992, DNA REPLICATION, P553; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LESSL M, 1993, J BACTERIOL, V175, P6415, DOI 10.1128/jb.175.20.6415-6425.1993; MEYER R, 1989, J BACTERIOL, V171, P799, DOI 10.1128/jb.171.2.799-806.1989; PANSEGRAU W, 1994, J BIOL CHEM, V269, P2782; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PANSEGRAU W, 1991, THESIS FREIE U BERLI; RAO XM, 1994, J BACTERIOL, V176, P5958, DOI 10.1128/jb.176.19.5958-5961.1994; RASOOLY A, 1994, EMBO J, V13, P5245, DOI 10.1002/j.1460-2075.1994.tb06856.x; RASOOLY A, 1994, J BACTERIOL, V176, P2450, DOI 10.1128/JB.176.8.2450-2453.1994; Sambrook, 1989, MOL CLONING LAB MANU, P68; SCHERZINGER E, 1993, EUR J BIOCHEM, V217, P929, DOI 10.1111/j.1432-1033.1993.tb18323.x; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229; WATERS VL, 1992, J BACTERIOL, V174, P6666, DOI 10.1128/JB.174.20.6666-6673.1992; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; ZIEGELIN G, 1992, J BIOL CHEM, V267, P17279	33	54	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13068	13076		10.1074/jbc.271.22.13068	http://dx.doi.org/10.1074/jbc.271.22.13068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662726				2022-12-27	WOS:A1996UN47400060
J	Agarwal, C; Chandraratna, RAS; Johnson, AT; Rorke, EA; Eckert, RL				Agarwal, C; Chandraratna, RAS; Johnson, AT; Rorke, EA; Eckert, RL			AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPEUTIC ANTICANCER AGENTS; KERATIN GENE-EXPRESSION; ACID RECEPTOR; VITAMIN-A; IDENTIFICATION; CARCINOMA; IMMORTALIZATION; DIFFERENTIATION; CLONING; FAMILY	Retinoids are important physiological agents that regulate epithelial cell differentiation and proliferation. The importance of these agents in regulating growth, development, and differentiation has led to a search for new retinoid agonists and antagonists. In the present manuscript we show that AGN193109, a retinoid analog, is an efficient antagonist of retinoid action in human cervical epithelial cells. Treatment of ECE16-1 cells with natural or synthetic retinoids reduces cytokeratin K5, K6, K14, K16, and K17 levels, increases cytokeratin K7, K8, and K19 levels, increases retinoic acid receptor-beta (RAR beta) mRNA levels, suppresses proliferation, and alters cell morphology. Co-treatment with AGN193109 prevents these responses. Half-maximal and maximal antagonism is observed at a molar ratio of AGN193109: retinoid agonist of 1:1 and 10:1, respectively. When administered alone AGN193109 has no agonist activity. Thus, AGN193109, which binds to RAR alpha, RAR beta, and RAR gamma with K-d values = 2, 2, and 3 nM, respectively, but is unable to bind to the retinoid X receptors, is a highly active antagonist of retinoid action in ECE16-1 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ENVIRONM HLTH SCI,CLEVELAND,OH 44106; ALLERGAN PHARMACEUT INC,DEPT CHEM,RETINOID RES,IRVINE,CA 92713; ALLERGAN PHARMACEUT INC,DEPT BIOL,IRVINE,CA 92713	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; AbbVie; Allergan; AbbVie; Allergan					NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGARWAL C, 1994, CANCER RES, V54, P2108; Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521; AGARWAL C, 1991, CANCER RES, V51, P3982; AGARWAL C, 1993, DIFFERENTIATION, V52, P185, DOI 10.1111/j.1432-0436.1993.tb00629.x; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BEARD RL, 1995, J MED CHEM, V38, P2820, DOI 10.1021/jm00015a004; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOEDTKER H, 1971, BIOCHIM BIOPHYS ACTA, V240, P448, DOI 10.1016/0005-2787(71)90539-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHANDRARATNA RAS, 1995, BIOORG MED CHEM LETT, V5, P523, DOI 10.1016/0960-894X(95)00065-2; CHOO CK, 1995, CARCINOGENESIS, V16, P375, DOI 10.1093/carcin/16.2.375; ECKERT RL, 1984, P NATL ACAD SCI-BIOL, V81, P4321, DOI 10.1073/pnas.81.14.4321; EYROLLES L, 1994, J MED CHEM, V37, P1508, DOI 10.1021/jm00036a017; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1990, METHOD ENZYMOL, V189, P223; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; GORODESKI GI, 1990, ENDOCRINOLOGY, V126, P399, DOI 10.1210/endo-126-1-399; GORODESKI GI, 1989, DIFFERENTIATION, V42, P75, DOI 10.1111/j.1432-0436.1989.tb00609.x; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HEMBREE JR, 1994, CANCER RES, V54, P3160; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; KANEKO S, 1991, MED CHEM RES, V1, P220; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LIPPMAN SM, 1993, J NATL CANCER I, V85, P499, DOI 10.1093/jnci/85.6.499; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RIBOT TE, 1994, J AM ACAD DERMATOL, V30, P581; SIZEMORE N, 1993, CANCER RES, V53, P4511; SIZEMORE N, 1993, DIFFERENTIATION, V54, P219, DOI 10.1111/j.1432-0436.1993.tb01603.x; STRICKLAND S, 1983, CANCER RES, V43, P5268; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANLEYEN SA, 1994, J CELL PHYSL, V160, P265; WEINSTEIN GD, 1993, J INVEST DERMATOL, V100, P544; YOSHIMURA H, 1995, J MED CHEM, V38, P3163, DOI 10.1021/jm00016a020; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	43	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12209	12212		10.1074/jbc.271.21.12209	http://dx.doi.org/10.1074/jbc.271.21.12209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647816	hybrid			2022-12-27	WOS:A1996UL66000018
J	Traxler, B; Murphy, C				Traxler, B; Murphy, C			Insertion of the polytopic membrane protein MalF is dependent on the bacterial secretion machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; MUTANTS; EXPORT; TRANSLOCATION; COMPONENT	We examined the dependence of protein export and membrane protein insertion on SecE and SecA, two components of the secretion (Sec) apparatus of Escherichia coli. The magnitude of the secretion defect observed for signal sequence-containing proteins in cells depleted of SecE is larger and more general than that in many temperature- or cold-sensitive Sec mutants. In addition, we show that the proper insertion of the polytopic MalF protein (synthesized without a signal sequence) into the cytoplasmic membrane is also SecE-dependent. In contrast to an earlier study (McGovern, K., and Beckwith, J. (1991) J. Biol. Chem. 266, 20870-20876), the membrane insertion of MalF also is inhibited by treatment of cells with sodium azide, a potent inhibitor of SecA. Therefore, our data strongly suggest that the cytoplasmic membrane insertion of MalF is dependent on the same cellular machinery as is involved in the export of signal sequence-containing proteins. We propose that the mechanism of export from the cytoplasm is related for both signal sequence-containing and cytoplasmic membrane proteins, but hydrophobic membrane proteins such as MalF may have a higher affinity for the Sec apparatus.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	Traxler, B (corresponding author), UNIV WASHINGTON,DEPT MICROBIOL,BOX 35742,SEATTLE,WA 98195, USA.							AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; JANDER G, 1996, IN PRESS J BACT, V178; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SELIGMAN L, 1994, J BIOL CHEM, V269, P19888; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; VONHEIJNE G, 1994, FEBS LETT, V346, P69, DOI 10.1016/0014-5793(94)00296-7; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	23	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12394	12400		10.1074/jbc.271.21.12394	http://dx.doi.org/10.1074/jbc.271.21.12394			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647843	hybrid			2022-12-27	WOS:A1996UL66000045
J	Udagawa, T; McIntyre, BW				Udagawa, T; McIntyre, BW			ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; EXTRACELLULAR-MATRIX; ADHESION; FIBRONECTIN; EXPRESSION; GENE; CARCINOMA; CYCLE; LINE	Using a gastric derived tumor line, we investigated the involvement of beta 1 integrin and Rho in cell growth regulation in response to collagen. The addition of C3 exoenzyme from Clostridium botulinum to specifically ribosylate and inhibit the function of the rho gene products inhibited cellular proliferation in a dose-dependent fashion. C3 exoenzyme exhibited broad cytostatic activity toward a number of tumor lines and induced G(0)/G(1), accumulation, cyclin A inhibition, and pronounced alterations in cell morphology. Integrin-mediated adhesion to collagen led to the expression of the cyclin A gene whose expression could be blocked using anti-beta 1 integrin monoclonal antibodies. Phospholipid levels were induced upon beta 1 integrin-mediated adhesion to collagen, and the phospholipid induction was inhibited by either antibodies to beta 1 integrin or pretreatment of cells with C3 exoenzyme. Significant reduction in phospholipid levels correlated with proliferation for a panel of tumor lines deprived of adhesion to substrate. These results implicate a novel role for integrins and Rho in the regulation of tumor growth in response to matrix.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					PHS HHS [62596] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BEDNARCZYK JL, 1993, J CELL BIOCHEM, V51, P465, DOI 10.1002/jcb.2400510412; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUN JS, 1993, MOL BIOL CELL, V4, P271; DAVIS LS, 1990, J IMMUNOL, V145, P785; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLDMANN WH, 1992, BIOCHEMISTRY-US, V31, P7665, DOI 10.1021/bi00148a030; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HART MJ, 1994, J BIOL CHEM, V269, P62; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HELSETH E, 1990, APMIS, V98, P996, DOI 10.1111/j.1699-0463.1990.tb05026.x; HUANG MN, 1990, BIOTECHNIQUES, V9, P710; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JUST I, 1992, J BIOL CHEM, V267, P10274; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; Karpatkin S, 1988, Prog Clin Biol Res, V283, P585; KLEINMAN HK, 1981, J CELL BIOL, V88, P473, DOI 10.1083/jcb.88.3.473; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MANIATIS T, 1982, MOL CLONING LABORATO, pA3; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PIGNATELLI M, 1988, P NATL ACAD SCI USA, V85, P5561, DOI 10.1073/pnas.85.15.5561; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POTTEN CS, 1994, GROWTH FACTORS, V10, P53, DOI 10.3109/08977199409019603; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUGGIERO M, 1989, ONCOGENE, V4, P767; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAUTER G, 1994, INT J CANCER, V57, P508, DOI 10.1002/ijc.2910570412; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; UDAGAWA T, 1995, CLIN EXP METASTAS, V13, P427, DOI 10.1007/BF00118182; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	54	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12542	12548		10.1074/jbc.271.21.12542	http://dx.doi.org/10.1074/jbc.271.21.12542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647863	hybrid			2022-12-27	WOS:A1996UL66000065
J	Watanabe, S; Itoh, T; Arai, K				Watanabe, S; Itoh, T; Arai, K			JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; INTERLEUKIN-3; PHOSPHORYLATION; PATHWAY; FAMILY; LINES	Interleukin-3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) is known to activate JAK2 in various cells, but the role of JAK2 in IL-3 or GM-CSF receptor signal transduction is largely unknown. We have now examined the role of JAK2 in GM-CSF-induced signaling events in BA/F3 cells. In BA/F3 cells expressing hGMR, activation of JAK2 by hGM-CSF requires the box1 region of hGMR beta. Dominant negative JAK2 (Delta JAK2), which lacked the kinase domain suppressed mIL-3- or hGM-CSF-induced c-fos promoter activation as well as c-myc promoter activation/cell proliferation, thereby suggesting that JAK2 is involved in the signaling of both pathways. Further analyses of the role of JAK2 in c-fos gene activation in BA/F3 cells expressing hGMR revealed that Delta JAK2 inhibited hGM-CSF-induced phosphorylation of Shc and protein tyrosine phosphatase 1D. Within hGMR beta, the several tyrosine residues which exist are related to activation of Shc or protein tyrosine phosphatase 1D, and are phosphorylated in response to hGM-CSF stimulation. In addition, we observed that Delta JAK2 inhibited hGM-CSF-induced phosphorylation of hGMR beta. Taken together, our results suggest that JAK2 activated by the box1 region of hGMR mediates hGM-CSF-induced c-fos promoter activation through phosphorylation of hGMR.	UNIV TOKYO,INST MED SCI,DEPT MED & DEV BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Itoh, Tohru/GYQ-8698-2022	Itoh, Tohru/0000-0002-6579-1638				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KANAKURA Y, 1990, BLOOD, V76, P706; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Maniatis T., 1982, MOL CLONING; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TORIGOE T, 1992, BLOOD, V80, P617; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE S, 1995, J BIOL CHEM, V270, P9615, DOI 10.1074/jbc.270.16.9615; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	50	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12681	12686		10.1074/jbc.271.21.12681	http://dx.doi.org/10.1074/jbc.271.21.12681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647882	hybrid			2022-12-27	WOS:A1996UL66000084
J	Karim, S; Habib, A; LevyToledano, S; Maclouf, J				Karim, S; Habib, A; LevyToledano, S; Maclouf, J			Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDES; HUMAN-PLATELETS; INDUCIBLE CYCLOOXYGENASE; MESSENGER-RNA; SYNTHASE; EXPRESSION; INHIBITION; ASPIRIN; PROTEINS	The presence of prostaglandin (PG) H-2 in the supernatant of human umbilical vein endothelial cells (HUVEC) stimulated by thrombin restores the capacity of aspirin-treated platelets to generate thromboxane (TX) B-2. Induction of cyclooxygenase-2 (Cox-2) by interleukin (IL)-1 alpha or a phorbol ester increases this formation. HUVEC treated with aspirin lost their capacity to generate PGs but recovery occurred after 3 or 6-h induction of Cox-2 with phorbol ester or IL-1 alpha. Enzyme activity of the newly synthesized Cox-2 in aspirin-treated cells, evaluated after immunoprecipitation, was similar to untreated cells but after 18 h of cell stimulation only 50-60% recovery of Cox-1 was observed. The use of SC58125, a selective Cox-2 inhibitor, confirmed these findings in intact cells. Cyclooxygenase activity was related to the amount of Cox proteins present in the cells, but after induction of Cox-25, contribution of the latter to PG production was 6-8-fold that of Cox-1 . Aspirin-treated or untreated cells were incubated in the absence or presence of SC58125 and stimulated by thrombin, the ionophore A23187, or exogenous arachidonic acid. The production of endogenous (6-keto-PGF(1 alpha), PGE(2), PGF(2 alpha)) versus transcellular (TXB(2)) metabolites was independent of the inducer, the source of arachidonic acid and the Cox isozyme. However, in acetylsalicylic acid-treated cells, after 6-h stimulation with IL 1 alpha, newly synthesized Cox-2 produced less TXB(2) than 6-keto-PGF-(1 alpha) compared to untreated cells. At later times (>18 h), there was no metabolic difference between the cells. These studies suggest that in HUVEC, Cox compartmentalization occurring after short-term activation may selectively affect transcellular metabolism, but not constitutive production, of PGs.	HOP LARIBOISIERE,INSERM,U348,INST FEDERAT RECH BIOL CIRCULAT LARIBOISIERE,F-75475 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Habib, Aida/H-8647-2019	Habib, Aida/0000-0001-6027-0043				BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; FITZPATRICK FA, 1978, NATURE, V273, P302, DOI 10.1038/273302a0; GORMAN RR, 1983, PROSTAGLANDINS, V26, P325, DOI 10.1016/0090-6980(83)90099-0; HABIB A, 1992, ARCH BIOCHEM BIOPHYS, V298, P544, DOI 10.1016/0003-9861(92)90448-6; HABIB A, 1993, J BIOL CHEM, V268, P23448; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAWATA R, 1995, J IMMUNOL, V155, P818; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; MACLOUF J, 1980, EUR J BIOCHEM, V109, P561, DOI 10.1111/j.1432-1033.1980.tb04828.x; MARCUS AJ, 1993, J LIPID RES, V34, P2017; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; PATSCHEKE H, 1981, HAEMOSTASIS, V10, P14; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; SCHAFER AI, 1984, J CLIN INVEST, V73, P1105, DOI 10.1172/JCI111296; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; ZYGLEWSKA T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P78, DOI 10.1016/0167-4781(92)90101-5	35	117	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12042	12048		10.1074/jbc.271.20.12042	http://dx.doi.org/10.1074/jbc.271.20.12042			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662657	hybrid			2022-12-27	WOS:A1996UL25000069
J	Rohde, LH; Julian, J; Babaknia, A; Carson, DD				Rohde, LH; Julian, J; Babaknia, A; Carson, DD			Cell surface expression of HIP, a novel heparin/heparan sulfate-binding protein, of human uterine epithelial cells and cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN HEPARAN-SULFATE; MOUSE EMBRYOS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; ELECTROPHORESIS; ATTACHMENT; RESOLUTION; CLEAVAGE; ADHESION; RL95	Previous studies established that uterine epithelial cells and cell lines express cell surface heparin/heparan sulfate (HP/HS)-binding proteins (Wilson, O., Jacobs, A. L., Stewart, S., and Carson, D. D. (1990) J. Cell. Physiol. 143, 60-67; Raboudi, N., Julian, J., Rohde, L. H., and Carson, D. D. (1992) J. Biol. Chem. 267, 11930-11939). The accompanying paper (Liu, S., Smith, S. E., Julian, J., Rohde, L. H., Karin, N. J., and Carson, D. D. (1996) J. Biol. Chem. 271, 11817-11823) describes the cloning of a full-length cDNA corresponding to a candidate cell surface HP/HS interacting protein, HIP, expressed by a variety of human epithelia. A synthetic peptide was synthesized corresponding to an amino acid sequence predicted from the cDNA sequence and used to prepare a rabbit polyclonal antibody. This antibody reacted with a protein with an apparent M(r) of 24,000 by SDS-polyacrylamide gel electrophoresis that was highly enriched in the 100,000 x g particulate fraction of RL95 cells. This molecular weight is similar to that of the protein expressed by 3T3 cells transfected with HIP cDNA. HIP was solubilized from this particulate fraction with NaCl concentrations greater than or equal to 0.8 M demonstrating a peripheral association consistent with the lack of a membrane spanning domain in the predicted cDNA sequence. HIP was not released by heparinase digestion suggesting that the association is not via membrane-bound HS proteoglycans. NaCl solubilized HIP bound to heparin-agarose in physiological saline and eluted with NaCl concentrations of 0.75 M and above. Furthermore, incubation of I-125-HP With transblots of the NaCl solubilized HIP preparations separated by two-dimensional gel electrophoresis demonstrated direct binding of HP to HIP. Indirect immunofluorescence studies demonstrated that HIP is expressed on the surfaces of intact RL95 cells. Binding of HIP antibodies to RL95 cell surfaces at 4 degrees C was saturable and blocked by preincubation with the peptide antigen. Single cell suspensions of RL95 cells formed large aggregates when incubated with antibodies directed against HIP but not irrelevant antibodies. Finally, indirect immunofluorescence studies demonstrate that HIP is expressed in both lumenal and glandular epithelium of normal human endometrium throughout the menstrual cycle. In addition, HIP expression increases in the predecidual cells of post ovulatory day 13-15 stroma. Collectively, these data indicate that HIP is a membrane-associated HP-binding protein expressed on the surface of normal human uterine epithelia and uterine epithelial cell lines.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; WOMENS HLTH INST CALIF,COSTA MESA,CA 92626	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BISWAS C, 1988, J CELL PHYSIOL, V136, P147, DOI 10.1002/jcp.1041360119; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; DAS SK, 1994, DEVELOPMENT, V120, P1071; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; JALKANEN M, 1987, MED BIOL, V65, P41; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KISALUS LL, 1987, ANAT RECORD, V218, P402, DOI 10.1002/ar.1092180408; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KURAMOTO H, 1972, Acta Obstetrica et Gynaecologica Japonica (English Edition), V19, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; POOLE AR, 1986, BIOCHEM J, V236, P1; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; REDINI F, 1989, BIOCHIM BIOPHYS ACTA, V991, P359, DOI 10.1016/0304-4165(89)90129-3; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; WATT SM, 1993, BLOOD, V82, P2649; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	35	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11824	11830		10.1074/jbc.271.20.11824	http://dx.doi.org/10.1074/jbc.271.20.11824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662617	hybrid			2022-12-27	WOS:A1996UL25000040
J	Simmons, WW; Closs, EI; Cunningham, JM; Smith, TW; Kelly, RA				Simmons, WW; Closs, EI; Cunningham, JM; Smith, TW; Kelly, RA			Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes Regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR SMOOTH-MUSCLE; NECROSIS-FACTOR-ALPHA; ECOTROPIC RETROVIRUS RECEPTOR; HUMAN ENDOTHELIAL-CELLS; CULTURED ANIMAL-CELLS; MESSENGER-RNA; MOLECULAR-CLONING; RELAXING FACTOR; RAT-LIVER	Cytokine-dependent production of nitric oxide (NO) by rat cardiac myocytes is a consequence of increased expression of the inducible isoform of nitric oxide synthase (iNOS or NOS2) and, in the presence of insulin, depresses the contractile function of these cells in vivo and in vitro. Experiments reported here show that L-lysine, a competitive antagonist of L-arginine uptake, suppressed NO production (detected as nitrite accumulation) by interleukin (IL)-1 beta and interferon (IFN) gamma-pretreated cardiac myocytes by 70%, demonstrating that NO production is dependent on L-arginine uptake, Cardiac myocytes constitutively exhibit a high affinity L-arginine transport system (K-m = 125 mu M; V-max = 44 pmol/2 x 10(5) cells/min), Following a 24-h exposure to IL-1 beta and IFN gamma, arginine uptake increases (V-max = 167 pmol/2 x 10(5) cells/min) and a second low affinity L-arginine transporter activity appears (K-m = 1.2 mM). To examine the molecular basis for these cytokine-induced changes in arginine transport, we examined expression of three related arginine transporters previously identified in other cell types, mRNA for the high affinity cationic amino acid transporter-1 (CAT-1) is expressed in resting myocytes and steady-state levels increase by 10-fold following exposure to IL-1 beta and IFN gamma. Only cytokine-pretreated myocytes expressed a second high-affinity L-arginine transporter, CAT-2B, as well as a low-affinity L-arginine transporter, CAT-2A. In addition, insulin, which potentiated cytokine-dependent NO production independent of any change in NOS activity, increased myocyte L-arginine uptake by 2-fold and steady-state levels of CAT-1, but not CAT-2A or CAT-2B mRNA Thus, NO production by cardiac myocytes exposed to IL-1 beta plus IFN gamma appears to be dependent on the coinduction of CAT-1, CAT-2A, and CAT-2B, while insulin independently augments L-arginine transport through CAT-1.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289	NATIONAL CANCER INSTITUTE [R01CA061246] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141] Funding Source: NIH RePORTER; NCI NIH HHS [CA61246] Funding Source: Medline; NHLBI NIH HHS [R37-HL36141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALTMAN P, 1967, BLOOD OTHER BODY FLU, P75; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BRADY AJB, 1993, AM J PHYSIOL, V265, pH176, DOI 10.1152/ajpheart.1993.265.1.H176; BRADY AJB, 1992, AM J PHYSIOL, V263, pH1963, DOI 10.1152/ajpheart.1992.263.6.H1963; BUNE AJ, 1995, FEBS LETT, V366, P127, DOI 10.1016/0014-5793(95)00495-U; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DIETRICK J, 1988, Current Surgery, V45, P189; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; GROCOTTMASON R, 1994, AM J PHYSIOL, V266, pH1699, DOI 10.1152/ajpheart.1994.266.5.H1699; GROCOTTMASON R, 1994, AM J PHYSIOL-HEART C, V267, pH1804, DOI 10.1152/ajpheart.1994.267.5.H1804; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HUSSON A, 1986, ENDOCRINOLOGY, V119, P1171, DOI 10.1210/endo-119-3-1171; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KAWAMOTO S, 1986, BIOCHEM BIOPH RES CO, V136, P955, DOI 10.1016/0006-291X(86)90425-0; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LING PR, 1994, METABOLISM, V43, P279, DOI 10.1016/0026-0495(94)90093-0; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; LUSCHER TF, 1993, CIRCULATION, V87, P1746, DOI 10.1161/01.CIR.87.5.1746; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; PLUMB JA, 1989, CANCER RES, V49, P4435; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHOTT CA, 1993, BRIT J PHARMACOL, V108, P38, DOI 10.1111/j.1476-5381.1993.tb13436.x; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOUNG LH, 1992, CIRC RES, V71, P393, DOI 10.1161/01.RES.71.2.393; ZENNI GC, 1992, CIRC SHOCK, V37, P198	87	148	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11694	11702		10.1074/jbc.271.20.11694	http://dx.doi.org/10.1074/jbc.271.20.11694			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662674	hybrid			2022-12-27	WOS:A1996UL25000020
J	Westphal, V; Marcusson, EG; Winther, JR; Emr, SD; vandenHazel, H				Westphal, V; Marcusson, EG; Winther, JR; Emr, SD; vandenHazel, H			Multiple pathways for vacuolar sorting of yeast proteinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-Y; PROPEPTIDE; MUTANT; GENE; SACCHAROMYCES; HYDROLASES	The sorting of the yeast proteases proteinase A and carboxypeptidase Y to the vacuole is a saturable, receptor-mediated process. Information sufficient for vacuolar sorting of the normally secreted protein invertase has in fusion constructs previously been found to reside in the propeptide of proteinase A. We found that sorting of such a hybrid protein is dependent on the vacuolar protein sorting receptor Vps10p. This was unexpected, as strains disrupted for VPS10 sort more than 85% of the proteinase A to the vacuole. Consistent with a role for Vps10p in sorting of proteinase A, we found that 1) overproduction of Vps10p suppressed the missorting phenotype associated with overproduction of proteinase A, 2) overproduction of proteinase A induced missorting of carboxypeptidase Y, 3) vacuolar sorting of proteinase A in a Delta vps10 strain was readily saturated by modest overproduction of proteinase A, and 4) Vps10p and proteinase A interact directly and specifically as shown by chemical cross-linking. Interestingly, overexpression of two telomere-linked VPS10 homologues, VTH1 and VTH2 suppressed the missorting phenotypes of a Delta vps10 strain. However, disruption of the VTH1 and VTH2 genes did not affect the sorting of proteinase A. We conclude that proteinase A utilizes at least two mechanisms for sorting, a Vps10p-dependent path and a Vth1p/Vth2p/Vps10p-independent path.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK; UNIV CALIF SAN DIEGO, SCH MED, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Marcusson, Eric/0000-0002-0504-8674	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; CARLSON M, 1985, MOL CELL BIOL, V5, P2894, DOI 10.1128/MCB.5.11.2894; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VANDENHAZEL HB, 1995, J BIOL CHEM, V270, P8602, DOI 10.1074/jbc.270.15.8602; vanVoorst F, 1996, J BIOL CHEM, V271, P841, DOI 10.1074/jbc.271.2.841; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; WINSTON F, 1983, METHOD ENZYMOL, V101, P211; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x	23	52	56	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11865	11870		10.1074/jbc.271.20.11865	http://dx.doi.org/10.1074/jbc.271.20.11865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662642	hybrid			2022-12-27	WOS:A1996UL25000046
J	Parks, GD				Parks, GD			Differential effects of changes in the length of a signal anchor domain on membrane insertion, subunit assembly, and intracellular transport of a type II integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS NEURAMINIDASE; HEMAGGLUTININ-NEURAMINIDASE; ENDOPLASMIC-RETICULUM; SIMIAN VIRUS-5; TRANSMEMBRANE PROTEINS; GOLGI RETENTION; CELL-SURFACE; SEQUENCE; GLYCOPROTEIN; RECEPTOR	The length requirement for a functional uncleaved signal/anchor (S/A) domain of the paramyxovirus hemagglutinin-neuraminidase (HN) type II glycoprotein was analyzed. HN mutants with progressive NH2-terminal S/A deletions or insertions were expressed in HeLa cells, and the membrane targeting, folding, tetramer assembly, and intracellular transport of the proteins were examined. Changing the length of the S/A by two residues resulted in HN mutants that displayed aberrant endoplasmic reticulum (ER) membrane targeting or translocation. This phenotype did not simply reflect upper or lower limitations on the size of a functional S/A, because normal signaling was restored by further alterations involving three or four residues. Likewise, ER-to-Golgi transport of mutants containing deletions of one or two S/A residues was delayed (similar to 30% of WT) or blocked, but transport was restored for a mutant with a total of three deleted residues. HN mutants with S/A insertions of three or four Leu residues differed from wild-type HN by having heterogeneous Golgi-specific carbohydrate modifications. Differences in ER-to-Golgi transport of the mutants did not strictly correlate with defects in either native folding of the ectodomain or the assembly of two dimers into a tetramer. Together, these data suggest that efficient entry into and exit from the ER are sensitive to changes in the HN S/A that may reflect alterations to a structural requirement along one side of an alpha-helix.			Parks, GD (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MICROBIOL & IMMUNOL, MED CTR, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034329] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34329] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN DJ, 1988, J VIROL, V62, P3824, DOI 10.1128/JVI.62.10.3824-3831.1988; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V54, P1; HOGUE BG, 1994, J GEN VIROL, V75, P1015, DOI 10.1099/0022-1317-75-5-1015; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEWIS BA, 1983, J MOL BIOL, V166, P203, DOI 10.1016/S0022-2836(83)80006-0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MCGINNES L, 1993, VIROLOGY, V196, P101, DOI 10.1006/viro.1993.1458; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NAYAK DP, 1989, ANNU REV MICROBIOL, V43, P465, DOI 10.1146/annurev.mi.43.100189.002341; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1990, VIROLOGY, V178, P498, DOI 10.1016/0042-6822(90)90347-T; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PARKS GD, 1995, VIROLOGY, V213, P263, DOI 10.1006/viro.1995.1569; PARKS GD, 1994, J VIROL, V68, P4862, DOI 10.1128/JVI.68.8.4862-4872.1994; PATERSON RG, 1990, J CELL BIOL, V110, P999, DOI 10.1083/jcb.110.4.999; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RANDALL RE, 1987, J GEN VIROL, V68, P2769, DOI 10.1099/0022-1317-68-11-2769; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; SAKAGUCHI T, 1989, VIROLOGY, V169, P260, DOI 10.1016/0042-6822(89)90151-7; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILLIAMS MA, 1988, MOL CELL BIOL, V8, P1186, DOI 10.1128/MCB.8.3.1186; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	52	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7187	7195		10.1074/jbc.271.12.7187	http://dx.doi.org/10.1074/jbc.271.12.7187			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636156	hybrid			2022-12-27	WOS:A1996UB15700091
J	Reddy, ASN; Safadi, F; Narasimhulu, SB; Golovkin, M; Hu, X				Reddy, ASN; Safadi, F; Narasimhulu, SB; Golovkin, M; Hu, X			A novel plant calmodulin-binding protein with a kinesin heavy chain motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; ARABIDOPSIS; EXPRESSION; SEQUENCES; IDENTIFICATION; DROSOPHILA; CALCIUM; FAMILY; CELLS; BRAIN	Calmodulin, a ubiquitous calcium-binding protein, regulates many diverse cellular functions by modulating the activity of the proteins that interact with it. Here, we report isolation of a cDNA encoding a novel kinesin-like calmodulin-binding protein (KCBP) from Arabidopsis using biotinylated calmodulin as a probe, Calcium-dependent binding of the cDNA encoded protein to calmodulin is confirmed by S-35-labeled calmodulin. Sequence analysis of a full-length cDNA indicates that it codes for a protein of 1261 amino acids, The predicted amino acid sequence of the KCBP has a domain of about 340 amino acids in the COOH terminus that shows significant sequence similarity with the motor domain of kinesin heavy chains and kinesin-like proteins and contains ATP and microtubule binding sites typical of these proteins. Outside the motor domain, the KCBP has no sequence similarity with any of the known kinesins, but contains a globular domain in the NH2 terminus and a putative coiled-coil region in the middle. By analyzing the calmodulin binding activity of truncated proteins expressed in Escherichia coli, the calmodulin binding region is mapped to a stretch of about 50 amino acid residues in the COOH terminus region of the protein. Using a synthetic peptide, the calmodulin binding domain is further narrowed down to a 23-amino acid stretch. The synthetic peptide binds to calmodulin with high affinity in a calcium-dependent manner as judged by electrophoretic mobility shift assay of calmodulin-peptide complex. The KCBP is coded by a single gene and is highly expressed in developing flowers and suspension cultured cells. Although many kinesin heavy chains and kinesin-like proteins have been extensively characterized at the biochemical and molecular level in evolutionarily distant organisms, none of them is known to bind calmodulin. The plant kinesin-like protein with a calmodulin binding domain and a unique amino-terminal region is a new member of the kinesin superfamily. The presence of a calmodulin-binding motif in a kinesin heavy chain-like protein suggests a role for calcium and calmodulin in kinesin-driven motor function(s) in plants.	COLORADO STATE UNIV,CELL & MOLEC BIOL PROGRAM,FT COLLINS,CO 80523	Colorado State University	Reddy, ASN (corresponding author), COLORADO STATE UNIV,DEPT BIOL,FT COLLINS,CO 80523, USA.		Safadi, Fayez/AAU-8699-2021	Reddy, Anireddy/0000-0002-4038-4091				ALLAN E, 1985, PLANTA, V165, P493, DOI 10.1007/BF00398094; BAUM G, 1993, J BIOL CHEM, V268, P19610; BETHKE PC, 1994, PLANT CELL, V6, P277, DOI 10.2307/3869645; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; CYR RJ, 1991, J CELL SCI, V100, P311; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAUWALDER M, 1986, PLANTA, V168, P461, DOI 10.1007/BF00392265; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURSO NA, 1994, PLANT CELL, V6, P893, DOI 10.1105/tpc.6.6.893; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FORDHAMSKELTON AP, 1994, PLANT MOL BIOL REP, V12, P355; GILROY S, 1994, BIOESSAYS, V16, P677, DOI 10.1002/bies.950160914; GODDARD RH, 1994, PLANT PHYSIOL, V104, P1; GOODSON HV, 1994, J CELL SCI, V107, P1875; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOBAYASHI H, 1994, PLANTA, V194, P388, DOI 10.1007/BF00197540; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING V, 1992, PLANT PHYSIOL, V100, P970, DOI 10.1104/pp.100.2.970; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; LLOYD CW, 1991, CYTOSKELETAL BASIS P; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; LUKAS TJ, 1987, CALCIUM BINDING PROT, P533; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITSUI H, 1994, PLANT MOL BIOL, V25, P865, DOI 10.1007/BF00028881; MITSUI H, 1993, MOL GEN GENET, V238, P362, DOI 10.1007/BF00291995; MUTO S, 1984, Z PFLANZENPHYSIOL, V114, P421, DOI 10.1016/S0044-328X(84)80062-8; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OH SH, 1992, ARCH BIOCHEM BIOPHYS, V297, P28, DOI 10.1016/0003-9861(92)90636-B; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; Pereira Andrea, 1994, Modern Cell Biology, V13, P269; PERERA IY, 1992, PLANT MOL BIOL, V19, P649, DOI 10.1007/BF00026791; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY ASN, 1994, BIOCHEM BIOPH RES CO, V199, P1089, DOI 10.1006/bbrc.1994.1342; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; REDDY ASN, 1995, P 6 INT C AR RES, P407; ROBERTS DM, 1986, CRIT REV PLANT SCI, V4, P311, DOI 10.1080/07352688609382230; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 2002, MOL CLONING LAB MANU; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEAGULL RW, 1989, CRIT REV PLANT SCI, V8, P131, DOI 10.1080/07352688909382273; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; STINEMETZ CL, 1987, PLANT PHYSIOL, V84, P1337, DOI 10.1104/pp.84.4.1337; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STIRLING DA, 1992, MOL MICROBIOL, V6, P703, DOI 10.1111/j.1365-2958.1992.tb01519.x; TIEZZI A, 1992, CELL MOTIL CYTOSKEL, V21, P132, DOI 10.1002/cm.970210206; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANN REV BIOCH, V59, P906; VANTARD M, 1985, J CELL BIOL, V101, P488, DOI 10.1083/jcb.101.2.488; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RG, 1993, P NATL ACAD SCI USA, V90, P2807, DOI 10.1073/pnas.90.7.2807; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; WICK SM, 1985, PROTOPLASMA, V126, P198, DOI 10.1007/BF01281795; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	81	142	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7052	7060		10.1074/jbc.271.12.7052	http://dx.doi.org/10.1074/jbc.271.12.7052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636137	hybrid			2022-12-27	WOS:A1996UB15700072
J	Mizushima, T; Ishikawa, Y; Obana, E; Hase, M; Kubota, T; Katayama, T; Kunitake, T; Watanabe, E; Sekimizu, K				Mizushima, T; Ishikawa, Y; Obana, E; Hase, M; Kubota, T; Katayama, T; Kunitake, T; Watanabe, E; Sekimizu, K			Influence of cluster formation of acidic phospholipids on decrease in the affinity for ATP of DnaA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; SYNTHETIC BILAYER-MEMBRANES; SELF-ORGANIZATION; ENZYMATIC REPLICATION; INITIATION PROTEIN; ORIGIN; AMPHIPHILES; ASSOCIATION; ACTIVATION; PRIMASE	DnaA protein is the initiator of chromosomal DNA replication in Escherichia coli. We examined the influence of artificial mixed membrane composed of synthetic acidic (phosphate) lipid and basic (ammonium) lipid on the affinity of DnaA protein for ATP. Two sets of acidic and basic lipids with distinguishable numbers of hydrophobic alkyl chains were devised. Synthetic membranes made of the sole acidic Lipid but not the basic bilayers inhibited the ATP binding to DnaA protein and stimulated the release of ATP from the ATP-DnaA complex. The basic bilayer-forming compounds served as the matrix for the guest acidic lipids. Acidic lipids dispersed in the basic matrix membrane had little effect on ATP binding and on ATP release. Conversely, acidic lipids forming cluster structures in the mixed artificial membranes inhibited the ATP binding and stimulated the release of ATP. These observations suggest that in mixed lipid bilayers, a cluster structure of acidic lipids seems to be an important parameter to decrease the affinity of DnaA protein for ATP.	OITA UNIV,DEPT APPL CHEM,FAC ENGN,OITA 87011,JAPAN; KYUSHU UNIV,FAC PHARMACEUT SCI,HIGASHI KU,FUKUOKA 81282,JAPAN; KYUSHU UNIV,FAC ENGN,FUKUI 81282,JAPAN	Oita University; Kyushu University; Kyushu University				Katayama, Tsutomu/0000-0001-9994-1684				ATLUNG T, 1984, MOL GEN GENET, V197, P125, DOI 10.1007/BF00327932; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; EVANS DF, 1988, LANGMUIR, V4, P3, DOI 10.1021/la00079a002; FLETCHER PDI, 1989, J CHEM SOC FARAD T 1, V85, P147, DOI 10.1039/f19898500147; FUJITA A, 1994, CHEM LETT, P1219, DOI 10.1246/cl.1994.1219; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GAYAMA S, 1990, EMBO J, V9, P3761, DOI 10.1002/j.1460-2075.1990.tb07589.x; HAMACHI I, 1994, J AM CHEM SOC, V116, P8811, DOI 10.1021/ja00098a052; HAMACHI I, 1991, J AM CHEM SOC, V113, P9625, DOI 10.1021/ja00025a031; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; ISHIKAWA Y, 1994, J AM CHEM SOC, V116, P5579, DOI 10.1021/ja00092a008; ISHIKAWA Y, 1991, J AM CHEM SOC, V113, P621, DOI 10.1021/ja00002a034; JONSTROMER M, 1990, J PHYS CHEM-US, V94, P7549, DOI 10.1021/j100382a045; KANEMASA Y, 1967, BIOCHIM BIOPHYS ACTA, V144, P382; KANFER J, 1963, J BIOL CHEM, V238, P2919; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; KIM JM, 1989, MEM FAC ENG KYUSHU U, V49, P93; KIMIZUKA N, 1993, J AM CHEM SOC, V115, P4387, DOI 10.1021/ja00063a077; KORNBERG A, 1992, DNA REPLICATOIN; KUNITAKE T, 1986, J CHEM SOC CHEM COMM, P655, DOI 10.1039/c39860000655; KUNITAKE T, 1981, J AM CHEM SOC, V103, P5401, DOI 10.1021/ja00408a021; Kunitake T., 1986, Memoirs of the Faculty of Engineering, Kyushu University, V46, P221; KUNITAKE T, 1983, J AM CHEM SOC, V105, P6070, DOI 10.1021/ja00357a018; KUNITAKE T, 1992, ANGEW CHEM INT EDIT, V31, P709, DOI 10.1002/anie.199207091; KUNITAKE T, 1984, J AM CHEM SOC, V106, P1978, DOI 10.1021/ja00319a014; KUNITAKE T, 1991, J CHEM SOC P2, V6, P885; LOUARN J, 1984, MOL GEN GENET, V195, P125; NAKASHIMA N, 1984, B CHEM SOC JPN, V57, P3252; NICOLAIDIS AA, 1978, J BACTERIOL, V135, P178, DOI 10.1128/JB.135.1.178-189.1978; NISHIMI T, 1994, RECL TRAV CHIM PAY B, V113, P201; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OHKI M, 1972, J MOL BIOL, V68, P249, DOI 10.1016/0022-2836(72)90212-4; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHIMOMURA M, 1983, BER BUNSEN PHYS CHEM, V87, P1134, DOI 10.1002/bbpc.19830871211; SHIMOMURA M, 1982, J AM CHEM SOC, V104, P1757, DOI 10.1021/ja00370a061; SJOBERG M, 1993, LANGMUIR, V9, P937; SUEOKA N, 1968, COLD SPRING HARB SYM, V33, P695, DOI 10.1101/SQB.1968.033.01.078; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WOLFWATZ H, 1979, J BACTERIOL, V140, P43, DOI 10.1128/JB.140.1.43-49.1979; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YAMAGUCHI K, 1975, J BACTERIOL, V124, P1030, DOI 10.1128/JB.124.2.1030-1033.1975; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	46	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3633	3638						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631973				2022-12-27	WOS:A1996TV72400047
J	Nakayama, J; Fukuda, MN; Hirabayashi, Y; Kanamori, A; Sasaki, K; Nishi, T; Fukuda, M				Nakayama, J; Fukuda, MN; Hirabayashi, Y; Kanamori, A; Sasaki, K; Nishi, T; Fukuda, M			Expression cloning of a human G(T3) - Synthase G(D3) and G(T3) are synthesized by a single enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CELL-ADHESION; GANGLIOSIDE GD3; HUMAN-MELANOMA; RECEPTOR; ANTIGENS; GENE; GLYCOPROTEINS; GLYCOLIPIDS; PROTEINS	Gangliosides of the C series such as G(T3) are polysialylated glycosphingolipids whose synthesis is developmentally regulated. Here we report the expression cDNA cloning and characterization of G(T3) synthase that adds the second alpha-2,8-sialic acid to G(D3), NeuNAc alpha 2-->8NeuNAc alpha 2-->3Gal beta 1-->4Glc-Cer, thus forming G(T3), NeuNAc alpha 2-->8NeuNAc alpha 2-->8NeuNAc alpha 2-->3Gal beta 1-->4Glc-->Cer. Unexpectedly, the cloned cDNA was found to be identical to the cDNA that encodes G(D3) synthase. The newly identified enzyme was therefore named G(D3)/G(T3) synthase (G(D3)/G(T3)ST). G(D3)/G(T3)ST synthesized G(T3) most efficiently when G(M3), NeuNAc alpha 2-->3Gal beta 1-->4Glc-->Cer, was incubated as an acceptor, indicating that G(D3)/G(T3)ST is a polysialyltransferase that can transfer more than one sialic acid residue via alpha-2,8 linkage to gangliosides. Moreover, a longer period of incubation of G(D3) with G(D3)/G(T3)ST produced a significant amount of G(T3) and higher polysialogangliosides. Among various cell lines expressing G(D3)/G(T3)ST, higher polysialogangliosides including G(T3) were detected only in cell lines where the amount of G(D3)/G(T3) mRNA is sufficiently high. The expression of G(D3)/G(T3)ST mRNA among human tissues is highly restricted to fetal and adult brains. The G(D3)/G(T3)ST gene was found to be located at chromosome 12, region p12. Taken together, these results indicate that C series polysialogangliosides are synthesized by a ganglioside-specific polysialyltransferase, G(D3)/G(T3)ST, that is specifically expressed in neural tissues.	LA JOLLA CANC RES FDN, CANC RES CTR, GLYCOBIOL PROGRAM, LA JOLLA, CA 92037 USA; INST PHYS & CHEM RES, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN; KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, MACHIDA, TOKYO 194, JAPAN	Sanford Burnham Prebys Medical Discovery Institute; RIKEN; Kyowa Kirin Ltd				Hirabayashi, Yoshio/0000-0002-5774-7354	NCI NIH HHS [R01 CA33895] Funding Source: Medline; NIDDK NIH HHS [DK 37016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO S, 1979, J BIOL CHEM, V254, P2224; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BOUQUIER S, 1995, J BIOL CHEM, V270, P4632; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CHRISTMANSON L, 1990, FEBS LETT, V267, P160, DOI 10.1016/0014-5793(90)80314-9; DUBOIS C, 1986, J BIOL CHEM, V261, P3826; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; Fukuda M., 1992, CELL SURFACE CARBOHY; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HARAYOKOYAMA M, 1995, J BIOL CHEM, V270, P8115, DOI 10.1074/jbc.270.14.8115; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; HIRABAYASHI Y, 1988, J BIOCHEM, V104, P973, DOI 10.1093/oxfordjournals.jbchem.a122593; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MULERIS M, 1993, CANCER GENET CYTOGEN, V69, P161, DOI 10.1016/0165-4608(93)90097-6; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NAKAYAMA J, 1993, J HISTOCHEM CYTOCHEM, V41, P1563, DOI 10.1177/41.10.8245415; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OHTA S, 1993, CANCER IMMUNOL IMMUN, V36, P260, DOI 10.1007/BF01740908; ONDA M, 1995, GENE, V159, P225, DOI 10.1016/0378-1119(95)00075-H; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; ROSNER H, 1985, DEV BRAIN RES, V18, P85, DOI 10.1016/0165-3806(85)90252-4; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SPIEGEL S, 1987, P NATL ACAD SCI USA, V84, P141, DOI 10.1073/pnas.84.1.141; SUZUKI Y, 1986, J BIOL CHEM, V261, P7057; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YATES AJ, 1988, NEUROCHEM PATHOL, V8, P157	50	83	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3684	3691						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631981				2022-12-27	WOS:A1996TV72400055
J	Takeuchi, Y; Nakayama, K; Matsumoto, T				Takeuchi, Y; Nakayama, K; Matsumoto, T			Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MC3T3-E1 CELLS; EXTRACELLULAR-MATRIX; MODULATION; 1,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; PROLIFERATION; PROTEOGLYCANS; STIMULATION; PHENOTYPE	Although transforming growth factor (TGF)-beta enhances bone formation, it inhibits the differentiation of osteoblasts. To clarify the regulatory mechanism of osteoblastic differentiation and TGF-beta actions, the relationship among differentiation, TCF-beta actions, and matrix protein synthesis was examined using murine osteoblast like MC3T3-E1 cells. Alkaline phosphatase (ALP) activity continued to increase during long-term cultures, and the increase was closely associated with a reduction in cell surface TGF-beta receptors competent to bind TGF-beta. Both the stimulation of proteoglycan synthesis and the inhibition of ALP activity by TGF-beta were also suppressed, Collagen synthesis inhibitors and an anti-alpha 2 beta 1 integrin blocking antibody blocked the changes in ALP activity and TGF-beta receptors, and a DGEA peptide that interferes binding of collagen to alpha 2 beta 1 integrin also blocked the increase in ALP activity. Furthermore, when MC3T3-E1 cells were cultured on extracellular matrix layers obtained from these cells, all the differentiation-associated changes could be observed without collagen production, and the extracellular matrix-induced differentiation was also blocked by an anti-alpha 2 beta 1 integrin antibody. These results demonstrate that the interaction of cell surface alpha 2 beta 1 integrin with matrix collagen synthesized by osteoblasts themselves is involved in the osteoblastic differentiation and the reduction in cell surface receptors and actions of TGF-beta. It is suggested that matrix collagen synthesized under the stimulation by TGF-beta plays an important role in the regulation of osteoblastic differentiation and TGF-beta actions by differentiation-associated down-regulation of TGF-beta receptors.			Takeuchi, Y (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.							BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; HARADA S, 1991, J BONE MINER RES, V6, P903; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HOCK JM, 1990, ENDOCRINOLOGY, V126, P421, DOI 10.1210/endo-126-1-421; HU JS, 1990, J BIOL CHEM, V265, P7914; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBARAKI K, 1992, J BONE MINER RES, V7, P743; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO T, 1991, BONE, V12, P27, DOI 10.1016/8756-3282(91)90051-J; MERCIER T, 1995, BBA-MOL CELL RES, V1266, P64, DOI 10.1016/0167-4889(94)00240-F; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OUE Y, 1994, BONE, V15, P361, DOI 10.1016/8756-3282(94)90301-8; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUVA LJ, 1993, J BONE MINER RES, V8, P379; TAKEUCHI Y, 1989, J BIOL CHEM, V264, P18407; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TAKEUCHI Y, 1990, BIOCHEM J, V266, P15, DOI 10.1042/bj2660015; TAKEUCHI Y, 1993, J BONE MINER RES, V8, P821; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915	43	156	162	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3938	3944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632016				2022-12-27	WOS:A1996TV72400090
J	Elgawish, A; Glomb, M; Friedlander, M; Monnier, VM				Elgawish, A; Glomb, M; Friedlander, M; Monnier, VM			Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-EPSILON-CARBOXYMETHYLLYSINE; ALDOSE REDUCTASE INHIBITION; DIABETIC RATS; LIPID-PEROXIDATION; PROTEIN GLYCATION; OXIDATIVE STRESS; OXIDASE ACTIVITY; FREE-RADICALS; TAIL TENDONS; VITAMIN-E	The Maillard reaction has been implicated in crosslinking and fluorescence formation of collagen exposed to high glucose in vitro. However, several pharmacologic agents, whose action seems unrelated to pathways of nonenzymatic glycation, have been demonstrated to prevent cross-linking in diabetes. To clarify this discrepancy, kinetic changes in glycation, glycoxidation (carboxymethyllysine, CML), and cross-linking (measured as tendon breaking time, TBT) were evaluated in rat tail tendons incubated in 5 and 30 mM glucose in vitro, and in tendons implanted in vivo into diabetic rat peritoneal cavity. In vitro, rates were found to be both O-2- and glucose-dependent. Tendon preglycation and presence of added 2 mM glycosylamine and Amadori compounds (Amadori product of glucose and propylamine) catalyzed these changes in a primarily O-2-dependent manner. In the presence of Amadori compounds, kinetic changes were dramatically increased and were preventable by addition of catalase to the medium. Tendons implanted into diabetic rat peritoneum became more rapidly glycoxidized and cross-linked when implanted at day 30 from diabetes onset (high tissue glycation) compared to day 3 (low tissue glycation) in spite of similar glycation kinetics, suggesting a mechanistic dissociation between glycation, glycoxidation, and crosslinking in diabetes. Indeed, intraperitoneal injection of catalase and other antioxidants dramatically suppressed cross-linking, fluorescence formation, and, to some extent, glycoxidation, without affecting glycation, This study confirms the role of oxidative stress in protein cross-linking by the Maillard reaction in vitro and provides the first evidence for a role of H2O2 in crosslinking in diabetes. Whereas Amadori products are a potent source of H2O2 formation in vitro, their precise contribution to H2O2 generation and the actual role of Maillard reaction products in collagen cross-linking in diabetes requires further investigation.	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; AOKI Y, 1992, DIABETOLOGIA, V35, P913, DOI 10.1007/BF00401418; BAKER JR, 1994, CLIN CHEM, V40, P1950; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BRENNAN M, 1989, J BIOL CHEM, V264, P20953; BROWNLEE M, 1983, J EXP MED, V158, P1739, DOI 10.1084/jem.158.5.1739; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; CHACE KV, 1991, ARCH BIOCHEM BIOPHYS, V288, P473, DOI 10.1016/0003-9861(91)90223-6; CHANG K, 1980, DIABETES, V29, P778, DOI 10.2337/diabetes.29.10.778; COHEN MP, 1991, GEN PHARMACOL, V22, P603, DOI 10.1016/0306-3623(91)90063-C; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HUNT JV, 1993, BIOCHEM J, V291, P529, DOI 10.1042/bj2910529; ILLING EKB, 1951, BIOCHEM J, V48, P637, DOI 10.1042/bj0480637; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; JOHNSON RN, 1983, CLIN CHIM ACTA, V127, P87, DOI 10.1016/0009-8981(83)90078-5; KARPEN CW, 1984, DIABETES, V33, P239, DOI 10.2337/diabetes.33.3.239; KAWAKISHI S, 1994, MAILLARD REACTIONS C; KOWLURU R, 1995, DIABETES, V44, pA117; KUCHINSKAS EJ, 1962, ARCH BIOCHEM BIOPHYS, V97, P370, DOI 10.1016/0003-9861(62)90090-5; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MADIA AM, 1979, BIOCHIM BIOPHYS ACTA, V585, P481, DOI 10.1016/0304-4165(79)90181-8; MARTINMATEO MC, 1978, BIOMED EXPRESS, V29, P56; MICHEEL F, 1959, CHEM BER-RECL, V92, P2836, DOI 10.1002/cber.19590921127; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAGARAJ RH, 1993, DIABETES, V42, pA240; NAMIKI M, 1975, J AGR FOOD CHEM, V23, P487, DOI 10.1021/jf60199a024; NIMNI ME, 1968, J BIOL CHEM, V243, P1457; NIMNI NE, 1966, SCIENCE, V150, P905; ODETTI P, 1994, LAB INVEST, V70, P61; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; PARCHMENT RE, 1990, P NATL ACAD SCI USA, V87, P4340, DOI 10.1073/pnas.87.11.4340; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Resmini P., 1990, ITAL J FOOD SCI, V3, P173; RICHARD S, 1991, DIABETES, V40, P1049, DOI 10.2337/diabetes.40.8.1049; SAKURAI T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P27, DOI 10.1016/0005-2760(90)90106-8; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SELL DR, 1995, HDB PHYSL, P253; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SUAREZ G, 1988, J CLIN INVEST, V82, P624, DOI 10.1172/JCI113641; WATKINS NG, 1987, J BIOL CHEM, V262, P7207; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WENINGER M, 1992, NEPHRON, V62, P80, DOI 10.1159/000187000; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; Wolff SP, 1987, DIABETIC COMPLICATIO, P167; YU PH, 1993, DIABETES, V42, P594, DOI 10.2337/diabetes.42.4.594; YUE DK, 1984, DIABETES, V33, P745, DOI 10.2337/diabetes.33.8.745; YUE DK, 1985, DIABETES, V34, P74, DOI 10.2337/diabetes.34.1.74; ZYZAK DV, 1995, ARCH BIOCHEM BIOPHYS, V316, P547, DOI 10.1006/abbi.1995.1073	58	163	170	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12964	12971		10.1074/jbc.271.22.12964	http://dx.doi.org/10.1074/jbc.271.22.12964			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662699	hybrid			2022-12-27	WOS:A1996UN47400045
J	Hirano, M; Osada, S; Aoki, T; Hirai, S; Hosaka, M; Inoue, J; Ohno, S				Hirano, M; Osada, S; Aoki, T; Hirai, S; Hosaka, M; Inoue, J; Ohno, S			MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappa B activation and degradation of I kappa B-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-SUBSPECIES BLOCKS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PHOSPHORYLATION; INHIBITOR; ENCODES; ELEMENT; VIRUS; CELLS	Signal-dependent activation of the transcription factor NF-kappa B is dominantly regulated by degradation of I kappa B-alpha protein. However, the signaling pathways that lead to the degradation are not clear. Here we report that mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) kinase, an activator of stress-activated protein kinases/jun kinase-1 (SAPKs/JNK1), is involved in such signaling pathways. The transient overexpression of MEK kinase in NIH3T3 fibroblasts activates kappa B-CAT reporter expression in a synergistic: manner with TNF alpha stimulation. In contrast, overexpression of kinase-negative MEK kinase suppresses TNF alpha-induced reporter expression. The overexpression of MEK kinase suppresses the inhibitory activity of co-transfected I kappa B-alpha on the kappa B-CAT or human immunodeficiency virus-long terminal repeat-luciferase reporter expression and causes the simultaneous disappearance of the overexpressed I kappa B-alpha. The disappearance of exogenous I kappa B-alpha by the overexpression of MER kinase is prevented by calpain inhibitor-I, an inhibitor of I kappa B-alpha degradation. These results suggest that MEK kinase is a signal mediator involved in TNF alpha-induced NF-kappa B activation and that the activation of NF-kappa B by MER kinase is regulated through the degradation of I kappa B-alpha.	YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOLEC,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT UROL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	Yokohama City University; Yokohama City University; University of Tokyo			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN Z, 1955, GENE DEV, V9, P1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirai S, 1996, ONCOGENE, V12, P641; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V206, P429, DOI 10.1006/bbrc.1995.1059; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROSENTHAL N, 1983, SCIENCE, V222, P749, DOI 10.1126/science.6314501; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067	38	155	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13234	13238		10.1074/jbc.271.22.13234	http://dx.doi.org/10.1074/jbc.271.22.13234			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662753	hybrid			2022-12-27	WOS:A1996UN47400084
J	Kurita, K; Honda, K; Suzuma, S; Takamatsu, H; Nakamura, K; Yamane, K				Kurita, K; Honda, K; Suzuma, S; Takamatsu, H; Nakamura, K; Yamane, K			Identification of a region of Bacillus subtilis Ffh, a homologue of mammalian SRP54 protein, that is essential for binding to small cytoplasmic RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; METHIONINE-RICH DOMAIN; COLI 4.5S RNA; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; NASCENT PREPROLACTIN; SACCHAROMYCES-CEREVISIAE; SEQUENCE RECOGNITION; PHENOTYPIC SELECTION	Bacillus subtilis Ffh and scRNA are homologues of mammalian SRP54 and SR9 RNA, respectively, which are components of the eukaryotic signal recognition particle (SR9). Ffh (446 amino acids) interacts with scRNA to form a stable complex in vivo. Here, we identified an RNA-binding domain of Ffh. The results obtained using a series of deletion mutants show that amino acid positions 364 to 432 in the C-terminal region of Ffh correlates with its ability to bind RNA. The amino acid sequence of this region is well conserved among members of the SRP54 protein family. This sequence contains two hydrophobic regions (h2, 364 to 391, and h3, 416 to 435), separated by the positively charged amino acid motif, (398)RRKRIAKGSG(407). Among the basic amino acid residues in this region, Arg-401 was essential for binding to scRNA, but Arg-399 and Lys-400 were not. The co-existence of Arg-398 and Lye-404 was necessary for the same affinity as wild type Ffh. The two glycine residues of the (405)GSG(407) were also essential. MH23 peptide (91 amino acids) encompassing from 356 to 446, consisting of h2-RRKRIAKGSG-h3, bound scRNA with the same affinity as wild type Ffh, whereas a 24-amino acid synthetic peptide (392)DIINASRRKRIAKGSGTSVQEVNR(415) did not. The region containing two hydrophobic segments separated by the positively charged motif is the minimal requirement of Ffh for RNA binding.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; HONDA K, 1993, J BACTERIOL, V175, P4885, DOI 10.1128/JB.175.15.4885-4894.1993; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Johnston D.S.T., 1992, P NATL ACAD SCI USA, V89, P10979; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KROLKIEWICZ S, 1994, MOL GEN GENET, V245, P565, DOI 10.1007/BF00282219; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LINDSTROM JT, 1993, PLANT MOL BIOL, V23, P1265, DOI 10.1007/BF00042359; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NAKAMURA K, 1992, J BACTERIOL, V174, P2185, DOI 10.1128/JB.174.7.2185-2192.1992; NAKAMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1394, DOI 10.1006/bbrc.1994.1385; NISHIGUCHI M, 1994, J BACTERIOL, V176, P157, DOI 10.1128/JB.176.1.157-165.1994; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SAMUELSSON T, 1993, NUCLEIC ACIDS RES, V21, P847, DOI 10.1093/nar/21.4.847; SAMUELSSON T, 1992, NUCLEIC ACIDS RES, V20, P5763, DOI 10.1093/nar/20.21.5763; SELINGER D, 1994, NUCLEIC ACIDS RES, V22, P2557, DOI 10.1093/nar/22.13.2557; SELINGER D, 1993, MOL CELL BIOL, V13, P1353, DOI 10.1128/MCB.13.3.1353; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WOOD H, 1992, NUCLEIC ACIDS RES, V20, P5919, DOI 10.1093/nar/20.22.5919; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	47	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13140	13146		10.1074/jbc.271.22.13140	http://dx.doi.org/10.1074/jbc.271.22.13140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662730	hybrid			2022-12-27	WOS:A1996UN47400070
J	Nielsen, KL; Holtet, TL; Etzerodt, M; Moestrup, SK; Gliemann, J; SottrupJensen, L; Thogersen, HC				Nielsen, KL; Holtet, TL; Etzerodt, M; Moestrup, SK; Gliemann, J; SottrupJensen, L; Thogersen, HC			Identification of residues in alpha-macroglobulins important for binding to the alpha(2)-macroglobulin receptor low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; MESSENGER-RNA; LIMITED PROTEOLYSIS; MOLECULAR-CLONING; DOMAIN-STRUCTURE; HIGH-AFFINITY; HALF-CYSTINE; SEQUENCE; INHIBITOR; COMPLEXES	Variants of the receptor binding domain of both human alpha(2)-macroglobulin and the corresponding domain of hen egg white ovomacroglobulin have been expressed in Escherichia coli and refolded in vitro, Competition experiments with methylamine treated alpha(2)-macroglobulin for binding to the multifunctional alpha(2)-macroglobulin receptor identify two Lys residues (residues 1370 and 1374 in human alpha(2)-macroglobulin) spaced by three amino acid residues as crucial for receptor binding, From this result and mutational evidence from other ligands for the alpha(2)-macroglobulin receptor, a tentative sequence motif for receptor binding is proposed.	AARHUS UNIV,DEPT CHEM,GENE EXPRESS LAB,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT BIOCHEM MED,DK-8000 AARHUS C,DENMARK	Aarhus University; Aarhus University; Aarhus University			Nielsen, Kåre Lehmann L/A-1181-2013; Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Nielsen, Kåre Lehmann L/0000-0002-5598-4401; Moestrup, Søren Kragh/0000-0003-3862-2107; 				BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; EGGERTSEN G, 1991, MOL BIOL MED, V8, P287; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; FELDMAN SR, 1984, ARCH BIOCHEM BIOPHYS, V235, P267, DOI 10.1016/0003-9861(84)90275-3; GEHRING MR, 1987, J BIOL CHEM, V262, P446; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLTET TL, 1994, FEBS LETT, V344, P242, DOI 10.1016/0014-5793(94)00349-1; HUBER R, 1970, NATURWISSENSCHAFTEN, V57, P389, DOI 10.1007/BF00599976; JONES DH, 1990, NATURE, V344, P793, DOI 10.1038/344793a0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NIELSEN KL, 1994, DNA SEQUENCE, V5, P111, DOI 10.3109/10425179409039712; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; THOMSEN NK, 1993, ARCH BIOCHEM BIOPHYS, V300, P327, DOI 10.1006/abbi.1993.1045; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	45	81	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12909	12912		10.1074/jbc.271.22.12909	http://dx.doi.org/10.1074/jbc.271.22.12909			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662686	hybrid			2022-12-27	WOS:A1996UN47400036
J	Beard, WA; Osheroff, WP; Prasad, R; Sawaya, MR; Jaju, M; Wood, TG; Kraut, J; Kunkel, TA; Wilson, SH				Beard, WA; Osheroff, WP; Prasad, R; Sawaya, MR; Jaju, M; Wood, TG; Kraut, J; Kunkel, TA; Wilson, SH			Enzyme-DNA interactions required for efficient nucleotide incorporation and discrimination in human DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; MUTAGENESIS	In the crystal structure of a substrate complex, the side chains of residues Asn(279), Tyr(271), and Arg(283) of DNA polymerase beta are within hydrogen bonding distance to the bases of the incoming deoxynucleoside 5'-triphosphate (dNTP), the terminal primer nucleotide, and the templating nucleotide, respectively (Pelletier, H., Sawaya, M., R., Kumar, A., Wilson, S. H., and Kraut, J. (1994) Science 264, 1891-1903), We have altered these side chains through individual site-directed mutagenesis, Each mutant protein was expressed in Escherichia coli and was soluble, The mutant enzymes were purified and characterized to probe their role in nucleotide discrimination and catalysis, A reversion assay was developed on a short (5 nucleotide) gapped DNA substrate containing an opal codon to assess the effect of the amino acid substitutions on fidelity, Substitution of the tyrosine at position 271 with phenylalanine or histidine did not influence catalytic efficiency (k(cat)/K-m) or fidelity, The hydrogen bonding potential between the side chain of Asn(279) and the incoming nucleotide was removed by replacing this residue with alanine or leucine, Although catalytic efficiency was reduced as much as 17-fold for these mutants, fidelity was not, In contrast, both catalytic efficiency and fidelity decreased dramatically for all mutants of Arg(283) (Ala > Leu > Lys), The fidelity and catalytic efficiency of the alanine mutant of Arg(283) decreased 160- and 5000-fold, respectively, relative to wild-type enzyme, Sequence analyses of the mutant DNA resulting from short gap filling synthesis indicated that the types of base substitution errors produced by the wild-type and R283A mutant were similar and indicated misincorporations resulting in frequent T . dGTP and A . dGTP mispairing. With R283A, a dGMP was incorporated opposite a template thymidine as often as the correct nucleotide. The x-ray crystallographic structure of the alanine mutant of Arg(283) verified the loss of the mutated side chain, Our results indicate that specific interactions between DNA polymerase beta and the template base, but not hydrogen bonding to the incoming dNTP or terminal primer nucleotide, are required for both high catalytic efficiency and nucleotide discrimination.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; NIEHS, MOLEC GENET LAB, RES TRIANGLE PK, NC 27709 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Diego			Kunkel, Thomas A./D-5088-2019; Wood, Thomas/B-6172-2012; Wilson, Samuel H/E-6644-2019; Wood, Thomas/GWZ-2481-2022	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293; Wood, Thomas/0000-0001-8962-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839, P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06839, ES06676] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FEIG DI, 1993, BIOCHEMISTRY-US, V32, P4466, DOI 10.1021/bi00067a040; FEIG DI, 1994, J MOL BIOL, V235, P33, DOI 10.1016/S0022-2836(05)80009-9; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; Kennard O, 1988, STRUCTURE EXPRESSION, V2, P1; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PELLETIER H, 1996, IN PRESS BIOCHEMISTR; PRASAD R, 1994, J BIOL CHEM, V269, P18096; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842	29	191	192	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12141	12144		10.1074/jbc.271.21.12141	http://dx.doi.org/10.1074/jbc.271.21.12141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647805	hybrid			2022-12-27	WOS:A1996UL66000007
J	Chobert, MN; Grondin, G; Brouillet, A; Laperche, Y; Beaudoin, AR				Chobert, MN; Grondin, G; Brouillet, A; Laperche, Y; Beaudoin, AR			Control of gamma-glutamyl transpeptidase expression by glucocorticoids in the rat pancreas - Correlation with granule formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ACINAR AR42J CELLS; SINGLE COPY GENE; EXOCRINE PANCREAS; TRANSFERASE TRANSPEPTIDASE; ZYMOGEN GRANULES; MEMBRANE-PROTEIN; MESSENGER-RNAS; AMYLASE GENE; SECRETION	Glucocorticoids are known to promote the formation of zymogen granules in acinar cells of the exocrine pancreas in vivo as well as in vitro. To gain insight into the mechanism of this regulation, we studied the effects of glucocorticoids on the synthesis of two components of the secretory granule membrane, the glycoprotein 2 (GP-2) and the gamma-glutamyl transpeptidase (GGT). It was demonstrated that following adrenalectomy, degranulation of pancreatic acinar cells is accompanied by a sharp decrease in GGT and GP-2 synthesis as measured by mRNA and protein accumulation. The decline of GGT synthesis was prevented by glucocorticoid replacement therapy, whereas GP-2 synthesis could be maintained with either glucocorticoid or estradiol treatment. These in vivo observations were corroborated and extended in an in vitro study using AR42J pancreatic cells. With this cell line, it was demonstrated that dexamethasone induces the formation of zymogen granules and the accumulation of a specific GGT transcript (mRNA III) by decreasing its degradation rate. At the same time, the GP-2 mRNA level was not modified by the hormonal treatment. These data demonstrate that glucocorticoids exert a positive control on the GGT expression in pancreatic cells at a post-transcriptional level. GGT, an enzyme of the glutathione metabolism, could play a significant role in protein packaging in secretory cells.	UNIV SHERBROOKE,FAC SCI,DEPT BIOL,SHERBROOKE,PQ J1K 2R1,CANADA	University of Sherbrooke	Chobert, MN (corresponding author), HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE.		Brouillet, Arthur/S-4499-2018					ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTISTINI B, 1990, LIFE SCI, V47, P2435, DOI 10.1016/0024-3205(90)90488-D; BEAUDOIN AR, 1986, ENDOCRINOLOGY, V119, P2106, DOI 10.1210/endo-119-5-2106; BEAUDOIN AR, 1993, J HISTOCHEM CYTOCHEM, V41, P225, DOI 10.1177/41.2.7678269; BEAUDOIN AR, 1992, INT REV CYTOL, V132, P177, DOI 10.1016/S0074-7696(08)62456-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUILLET A, 1994, J BIOL CHEM, V269, P14878; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CHIN RJ, 1992, J PEDIATR GASTROENTE, V12, P243; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; DITTIE A, 1992, EUR J CELL BIOL, V58, P243; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; GITHENS S, 1991, INT J PANCREATOL, V8, P97; GRIFFITH OW, 1980, J BIOL CHEM, V255, P5011; GRONDIN G, 1992, EUR J CELL BIOL, V57, P155; GROSSMAN A, 1969, ENDOCRINOLOGY, V85, P956, DOI 10.1210/endo-85-5-956; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFOREST L, 1992, BIOCHEM BIOPH RES CO, V184, P888, DOI 10.1016/0006-291X(92)90674-A; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEE PC, 1990, BIOCHIM BIOPHYS ACTA, V1049, P244, DOI 10.1016/0167-4781(90)90093-H; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; LOGSDON CD, 1986, J BIOL CHEM, V261, P2096; LOGSDON CD, 1987, J BIOL CHEM, V262, P15765; LU RB, 1987, J STEROID BIOCHEM, V26, P213; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MACDONALD RJ, 1980, NATURE, V287, P117, DOI 10.1038/287117a0; OKAMOTO T, 1994, BIOCHEMISTRY-US, V33, P11536, DOI 10.1021/bi00204a016; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PAEK I, 1987, MOL CELL BIOL, V87, P12496; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; SIEGRIST S, 1990, BIOCHEM J, V267, P621, DOI 10.1042/bj2670621; WITHIAMLEITCH M, 1993, BIOCHEM BIOPH RES CO, V194, P1167, DOI 10.1006/bbrc.1993.1945	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12431	12437		10.1074/jbc.271.21.12431	http://dx.doi.org/10.1074/jbc.271.21.12431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647848	hybrid			2022-12-27	WOS:A1996UL66000050
J	Inagaki, H; Matsushima, Y; Nakamura, K; Ohshima, M; Kadowaki, T; Kitagawa, Y				Inagaki, H; Matsushima, Y; Nakamura, K; Ohshima, M; Kadowaki, T; Kitagawa, Y			A large DNA-binding nuclear protein with RNA recognition motif and serine/arginine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; MOLECULAR-CLONING; DROSOPHILA-MELANOGASTER; ATTACHMENT SITES; MATRIX PROTEINS; HELA-CELLS; SEQUENCE; CDNA; GENE; ORGANIZATION	cDNA species encoding a large DNA-binding protein (NP220) of 1978 amino acids was isolated from human cDNA libraries. Human NP220 binds to double-stranded DNA fragments by recognizing clusters of cytidines. Immunofluorescent microscopy with antiserum directed against NP220 revealed a punctate or ''speckled'' pattern and coiled body-like structures in the nucleoplasm of various human cell lines. These structures diffused in the cytoplasm during mitosis. Western blot analysis showed that NP220 is enriched in the lithium 3,5-diiodosalicylate insoluble fraction of nuclei. The domain essential for DNA binding is localized in C-terminal half of NP220. Human NP220 shares three types of domains (MH1, MH2, and MH3) with the acidic nuclear protein, matrin 3 (Belgrader, P., Dey, R., and Berezney, R. (1991) J. Biol. Chem. 266, 9893-9899). MH1 is a 48-amino acid sequence near the N terminus of both human NP220 and rat matrin 3. MH2 is a 75-amino acid sequence homologous to the RNA recognition motifs of heterogeneous nuclear RNP I and L. It is repeated three times in NP220 and twice in matrin 3. MH3 is a 60-amino acid sequence at the C terminus of both NP220 and matrin 3. NP220 has an arginine/serine rich domain commonly found in pre-mRNA splicing factors. Close to the domain essential for DNA binding, there are nine repeats of the sequence LVTVDEVIEEEDL. Thus, NP220 is a novel type of nucleoplasmic protein with multiple domains.	NAGOYA UNIV, BIOSCI CTR, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; NAGOYA UNIV, SCH AGR SCI, GRAD PROGRAM BIOCHEM REGULAT, NAGOYA, AICHI 46401, JAPAN	Nagoya University; Nagoya University			Inagaki, Hidetoshi/J-9071-2018	Inagaki, Hidetoshi/0000-0001-7820-3420				AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALL EE, 1991, NUCLEIC ACIDS RES, V19, P397, DOI 10.1093/nar/19.2.397; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREY MR, 1995, P NATL ACAD SCI USA, V92, P5915, DOI 10.1073/pnas.92.13.5915; Frohman Michael A., 1994, P14; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GASSER SM, 1989, INT REV CYTOL, V119, P57; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; JACKSON DA, 1990, NUCLEIC ACIDS RES, V18, P4385, DOI 10.1093/nar/18.15.4385; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VERHEIJEN R, 1988, J CELL SCI, V90, P11; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	65	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12525	12531		10.1074/jbc.271.21.12525	http://dx.doi.org/10.1074/jbc.271.21.12525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647861	hybrid			2022-12-27	WOS:A1996UL66000063
J	Yurchak, LK; Hardwick, JS; Amrein, K; Pierno, K; Sefton, BM				Yurchak, LK; Hardwick, JS; Amrein, K; Pierno, K; Sefton, BM			Stimulation of phosphorylation of Tyr(394) by hydrogen peroxide reactivates biologically inactive, non-membrane-bound forms of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; T-CELL ACTIVATION; LYMPHOCYTES-T; P56LCK; P56(LCK); GENE; CD4; SRC; AUTOPHOSPHORYLATION; EXPRESSION	Lck, a lymphocyte-specific tyrosine protein kinase, is bound to cellular membranes as the result of myristoylation and palmitoylation of its amino terminus. Its activity is inhibited by phosphorylation of tyrosine 505 and stimulated by phosphorylation of tyrosine 394. The Tyr-505 --> Phe mutant of Lck (F505Lck) exhibits elevated biological activity and constitutive phosphorylation of Tyr-394 in vivo. Mutations at sites of fatty acyla tion that prevent F505Lck from associating with cellular membranes abolish the biological activity of the molecule in vivo, compromise its activity as a protein kinase in vivo and in vitro, and eliminate the phosphorylation of Tyr-394. Here, we show that exposure of cells expressing cytoplasmic or nuclear forms of F505Lck to H2O2, a general inhibitor of tyrosine protein phosphatases, restores the catalytic activity of these mutant proteins through stimulation of phosphorylation of Tyr-394. H2O2 treatment induced the phosphorylation of Tyr-394 on catalytically inactive forms of Lck regardless of cellular localization. Phosphorylation of Tyr-394 therefore need not occur by autophosphorylation. Thus, there appear to be two mechanisms through which the phosphorylation of Lck at Tyr-394 can occur. One is restricted to the plasma membrane and does not require the presence of oxidants. The other is operational in the nucleus as well as the cytosol and is responsive to oxidants.	SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92037; UNIV CALIF SAN DIEGO,PROGRAM MOL PATHOL,SAN DIEGO,CA 92037	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [CA 42350, CA 17289, CA 14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195, R01CA017289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULET I, 1987, BIOCHEM BIOPH RES CO, V149, P56, DOI 10.1016/0006-291X(87)91604-4; BUSS JE, 1986, J VIROL, V4, P2696; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1988, ONCOGENE, V2, P305; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKAMURA K, 1993, ONCOGENE, V8, P3133; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	43	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12549	12554		10.1074/jbc.271.21.12549	http://dx.doi.org/10.1074/jbc.271.21.12549			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647864	hybrid			2022-12-27	WOS:A1996UL66000066
J	Fang, SM; Burton, ZF				Fang, SM; Burton, ZF			RNA polymerase II-associated protein (RAP) 74 binds transcription factor (TF) IIB and blocks TFIIB-RAP30 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TFIIB; INITIATION-FACTOR; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; SUBUNIT; PURIFICATION; SELECTION; SEQUENCE; RAP30/74; CDNA	A set of deletion mutants of human RNA polymerase II-associated protein (RAP) 30, the small subunit of transcription factor IIF (TFIIF; RAP30/74), was constructed to map functional domains. Mutants were tested for accurate transcriptional activity, RAP74 binding, and TFIIB binding. Transcription assays indicate the importance of both N- and C-terminal sequences for RAP30 function. RAP74 binds to the N-terminal region of RAP30 between amino acids 1 and 98. TFIIB binds to an overlapping region of RAP30, localized to amino acids 1-176 (amino acids 27-152 comprise a minimal binding region), The C-terminal region of RAP74 (amino acids 358-517) binds directly and independently to TFIIB, Interestingly, RAP74 blocks TFIIB-RAP30 binding, both by binding TFIIB and by binding RAP30. When the TFIIF complex is intact, therefore, TFIIB TFIIF contact is maintained through RAP74. If the TFIIB-RAP30 interaction is physiologically important, the TFIIF complex must dissociate within some transcription complexes.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University								ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; DAHMUS ME, 1994, TRANSCRIPTION MECHAN, P243; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HA L, 1991, NATURE, V352, P689; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LUTHY R, 1990, SEQUENCE ANAL PRIMER, P61; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUN Z, 1994, P NATL ACAD SCI USA, V92, P3127; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	48	45	45	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11703	11709		10.1074/jbc.271.20.11703	http://dx.doi.org/10.1074/jbc.271.20.11703			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662660	hybrid			2022-12-27	WOS:A1996UL25000021
J	Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A				Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A			The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; RESIDUES; SUBSTRATE; ENZYME; CHOLINESTERASE; MUTAGENESIS; CONSTANTS; BUTYRYLCHOLINESTERASE; IDENTIFICATION; DETERMINANTS	The role of the functional architecture of human acetylcholinesterase (HuAChE) active center in facilitating reactions with organophosphorus inhibitors was examined by a combination of site-directed mutagenesis and kinetic studies of phosphorylation with organophosphates differing in size of their alkoxy substituents and in the nature of the leaving group. Replacements of residues Phe-295 and Phe-297, constituting the HuAChE acyl pocket, increase up to 80-fold the reactivity of the enzymes toward diisopropyl phosphorofluoridate, diethyl phosphorofluoridate, and p-nitrophenyl diethyl phosphate (paraoxon), indicating the role of this subsite in accommodating the phosphate alkoxy substituent. On the other hand, a decrease of up to 160-fold in reactivity was observed for enzymes carrying replacements of residues Tyr-133, Glu-202, and Glu-450, which are constituents of the hydrogen bond network in the HuAChE active center, which maintains its unique functional architecture. Replacement of residues Trp-86, Tyr-337, and Phe-338 in the alkoxy pocket affected reactivity toward diisopropyl phosphorofluoridate and paraoxon, but to a lesser extent that toward diethyl phosphorofluoridate, indicating that both the alkoxy substituent and the p-nitrophenoxy leaving group interact with this subsite. In all cases the effects on reactivity toward organophosphates, demonstrated in up to 10,000-fold differences in the values of bimolecular rate constants, were mainly a result of altered affinity of the HuAChE mutants, while the apparent first order rate constants of phosphorylation varied within a narrow range. This finding indicates that the main role of the functional architecture of HuAChE active center in phosphorylation is to facilitate the formation of enzyme-inhibitor Michaelis complexes and that this affinity, rather than the nucleophilic activity of the enzyme catalytic machinery, is a major determinant of HuAChE reactivity toward organophosphates.	ISRAEL INST BIOL RES,DEPT BIOCHEM,IL-70450 NESS ZIONA,ISRAEL; ISRAEL INST BIOL RES,DEPT ORGAN CHEM,IL-70450 NESS ZIONA,ISRAEL									Aldridge W. N., 1972, ENZYME INHIBITORS SU; ANDERSEN RA, 1977, GEN PHARMACOL, V8, P331, DOI 10.1016/0306-3623(77)90009-X; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARAK D, 1994, J BIOL CHEM, V269, P6296; BENSCHOP HP, 1988, ACCOUNTS CHEM RES, V21, P368, DOI 10.1021/ar00154a003; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FORSBERG A, 1984, EUR J BIOCHEM, V140, P153, DOI 10.1111/j.1432-1033.1984.tb08079.x; FOURNIER D, 1992, J BIOL CHEM, V267, P14270; FRIBOULET A, 1990, BIOCHEMISTRY-US, V29, P914, DOI 10.1021/bi00456a010; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GNATT A, 1994, J NEUROCHEM, V62, P749; GOZES A, 1992, J BIOL CHEM, V267, P17640; GRAY PJ, 1989, BIOCHEM J, V257, P419, DOI 10.1042/bj2570419; GRAY PJ, 1987, TOXICOL APPL PHARM, V91, P140, DOI 10.1016/0041-008X(87)90201-8; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HART GJ, 1973, BIOCHEMISTRY-US, V12, P2940, DOI 10.1021/bi00739a026; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; KEMP JR, 1990, TOXICOL APPL PHARM, V104, P264; Kovach I M, 1991, J Enzyme Inhib, V4, P201, DOI 10.3109/14756369109035844; KRONMAN C, 1994, J BIOL CHEM, V269, P27819; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LIU W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185, DOI 10.1016/0167-4838(86)90220-7; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MAIN AR, 1976, BIOL CHOLINERGIC FUN, P269; MAIN AR, 1966, BIOCHEM J, V100, P265; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; ORDENTLICH A, 1993, FEBS LETT, V334, P215, DOI 10.1016/0014-5793(93)81714-B; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Rogers D.F., 1990, MATH ELEMENTS COMPUT, P247; RYU SM, 1991, CHEM RES TOXICOL, V4, P517, DOI 10.1021/tx00023a004; SAUNDERS BC, 1948, J CHEM SOC, P695, DOI 10.1039/jr9480000695; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SHAFFERMAN A, 1993, MED DEFENSE BIOSCI R, V3, P1111; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WANG C, 1982, TOXICOL APPL PHARM, V66, P409, DOI 10.1016/0041-008X(82)90307-6	48	100	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11953	11962		10.1074/jbc.271.20.11953	http://dx.doi.org/10.1074/jbc.271.20.11953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662593	hybrid			2022-12-27	WOS:A1996UL25000058
J	Mauviel, A; Chung, KY; Agarwal, A; Tamai, K; Uitto, J				Mauviel, A; Chung, KY; Agarwal, A; Tamai, K; Uitto, J			Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; TISSUE INHIBITOR; IV COLLAGENASE; FOS; METALLOPROTEINASES; DEXAMETHASONE; FACTOR-BETA-1; PROTEIN	Transforming growth factor-beta (TGF-beta) plays a major role in regulating connective tissue deposition by controlling both extracellular matrix production and degradation. In this study, we show that TGF-beta transcriptionally represses both basal and tumor necrosis factor-alpha-induced collagenase (matrix metalloprotease-1) gene expression in dermal fibroblasts in culture, whereas it activates its expression in epidermal keratinocytes. We demonstrate that this differential effect of TGF-beta on collagenase gene expression is due to a cell type-specific induction of distinct oncogenes of the Jun family, which participate in the formation of AP-1 complexes with different trans-activating properties. Specifically, our data indicate that the inhibitory effect of TGF-beta in fibroblasts is likely to be mediated by jun-B, based on the following observations: (a) TGF-beta induces high levels of jun-B expression and (b) over-expression of jun-B mimics TGF-beta effect in inhibiting basal collagenase promoter activity and preventing tumor necrosis factor-alpha-induced trans-activation of the collagenase promoter. In contrast, TGF-beta induction of collagenase gene expression in keratinocytes is preceded by transient elevation of c-jun proto-oncogene expression. Over-expression of c-jun leads to trans-activation of the collagenase promoter in both cell types, suggesting that c-jun is a ubiquitous inducer of collagenase gene expression. Transfection of keratinocytes with an antisense c-jun construct together with a collagenase promoter/reporter gene construct inhibits basal and TGF-beta induced up-regulation of the collagenase promoter activity, implying that c-jun mediates TGF-beta effect in this cell type. Collectively, our data suggest differential signaling pathways for TGF-beta in dermal fibroblasts and epidermal keratinocytes, leading to cell type-specific induction of two AP-1 components with opposite transcriptional activities.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University	Mauviel, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,233 S 10TH ST,RM 430,PHILADELPHIA,PA 19107, USA.		MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [T32-AR07561, R01-AR41439] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, R01AR041439] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MELLSTROM B, 1991, ONCOGENE, V6, P1959; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETERSON MJ, 1990, J INVEST DERMATOL, V97, P341; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RYSECK RP, 1991, ONCOGENE, V6, P533; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SALO T, 1991, J BIOL CHEM, V266, P11436; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	35	137	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10917	10923		10.1074/jbc.271.18.10917	http://dx.doi.org/10.1074/jbc.271.18.10917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631909	hybrid			2022-12-27	WOS:A1996UJ34200077
J	Usobiaga, P; Medrano, FJ; Gasset, M; Garcia, JL; Saiz, JL; Rivas, G; Laynez, J; Menendez, M				Usobiaga, P; Medrano, FJ; Gasset, M; Garcia, JL; Saiz, JL; Rivas, G; Laynez, J; Menendez, M			Structural organization of the major autolysin from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL LYTIC ENZYMES; PNEUMOCOCCAL AMIDASE; ESCHERICHIA-COLI; CHOLINE; PROTEIN; BACTERIOPHAGES; PURIFICATION; EXPRESSION; EVOLUTION; DYNAMICS	LytA amidase is the best known bacterial autolysin, It breaks down the N-acetylmuramoyl-L-alanine bonds in the peptidoglycan backbone of Streptococcus pneumoniae and requires the presence of choline residues in the cell-wall teichoic acids for activity. Genetic experiments have supported the hypothesis that its 36-kDa chain has evolved by the fusion of two independent modules: the NH2-terminal module, responsible for the catalytic activity, and the COOH-terminal module, involved in the attachment to the cell wall. The structural organization of LytA amidase and of its isolated COOH-aerminal module (C-LytA) and the variations induced by choline binding have been examined by differential scanning calorimetry and analytical ultracentrifugation. Deconvolution of calorimetric curves have revealed a folding of the polypeptide chain in several independent or quasi-independent cooperative domains, Elementary transitions in C-LytA are close but not identical to those assigned to the COOH-terminal module in the complete amidase, particularly in the absence of choline, These results indicate that the NH2-terminal region of the protein is important for attaining the native tertiary fold of the COOH terminus, Analytical ultracentrifugation studies have shown that LytA exhibits a monomer <----> dimer association equilibrium, through the COOH-terminal part of the molecule. Dimerization is regulated by choline interaction and involves the preferential binding of two molecules of choline per dimer, Sedimentation velocity experiments give frictional ratios of 1.1 for C-LytA monomer and 1.4 for C-LytA and LytA dimers; values that deviated from that of globular rigid particles, When considered together, present results give evidence that LytA amidase might be described as an elongated molecule consisting of at least four domains per subunit (two per module) designated here in as N1, N2, C1, and C2. Intersubunit cooperative interactions through the C2 domain in LytA dimer occur under all experimental conditions, while C-LytA requires the saturation of low affinity choline binding sites, The relevance of the structural features deduced here for LytA amidase is examined in connection with its biological function.	CSIC,INST QUIM FIS ROCASOLANO,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Rivas, German/AFL-7528-2022; Gasset, Maria/I-2050-2014; Rivas, German/AAG-7458-2022; Gasset, Maria/K-4339-2012; Medrano, Francisco Javier/ABF-9860-2020; Menendez, Margarita/M-1795-2014; Garcia Lopez, Jose Luis/G-9139-2015	Rivas, German/0000-0003-3450-7478; Gasset, Maria/0000-0001-6436-4055; Rivas, German/0000-0003-3450-7478; Gasset, Maria/0000-0001-6436-4055; Menendez, Margarita/0000-0002-3267-4443; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Medrano, Francisco/0000-0002-8185-9751				BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BRIESE T, 1985, EUR J BIOCHEM, V146, P417, DOI 10.1111/j.1432-1033.1985.tb08668.x; DIAZ E, 1991, J BIOL CHEM, V266, P5464; DIAZ E, 1990, P NATL ACAD SCI USA, V87, P8125, DOI 10.1073/pnas.87.20.8125; DIAZ E, 1989, J BIOL CHEM, V264, P1236; FISHER N, 1993, EUR J BIOCHEM, V215, P851; FORMANEK H, 1983, TARGET PENICILLIN, P55; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; GARCIA P, 1986, GENE, V43, P265, DOI 10.1016/0378-1119(86)90215-5; GARCIA P, 1990, GENE, V86, P81, DOI 10.1016/0378-1119(90)90116-9; HU CQ, 1987, BIOCHEMISTRY-US, V26, P178, DOI 10.1021/bi00375a025; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LOPEZ R, 1992, FEMS MICROBIOL LETT, V100, P439, DOI 10.1016/0378-1097(92)90243-H; MARKIEWICZ Z, 1990, J BACTERIOL, V172, P2241, DOI 10.1128/jb.172.5.2241-2244.1990; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; PESSEN H, 1985, METHOD ENZYMOL, V117, P219; Rogers H., 1980, MICROBIAL CELL WALLS, P437; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANCHEZPUELLES JM, GENE, V61, P13; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, J BIOL CHEM, V268, P6125; SHAN F, 1990, LANCET, V335, P38; TANFORD C, 1961, PHYSICAL CHEMISTRY M, P254; TOMASZ A, 1971, P NATL ACAD SCI USA, V68, P1848, DOI 10.1073/pnas.68.8.1848; Tomasz A., 1984, MICROBIAL CELL WALL, P3; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WYMAN J, 1990, BINDING LINKAGE, P46	35	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6832	6838		10.1074/jbc.271.12.6832	http://dx.doi.org/10.1074/jbc.271.12.6832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636107	hybrid, Green Published			2022-12-27	WOS:A1996UB15700042
J	Baglia, FA; Walsh, PN				Baglia, FA; Walsh, PN			A binding site for thrombin in the apple 1 domain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; BLOOD-COAGULATION FACTOR; ACTIVATED FACTOR-XII; HEAVY-CHAIN; FACTOR-IX; HAGEMAN-FACTOR; FUNCTIONAL-CHARACTERIZATION; PLASMA; PREKALLIKREIN; IDENTIFICATION	Previously we defined a binding site for high molecular weight kininogen (HK) in the Al domain of factor XI (FM). Since thrombin can activate FXI and HK inhibits the activation of FM by thrombin, we have identified a thrombin binding site in FXI. Both the recombinant Al domain (Glu(1)-Ser(90)) and a synthetic peptide (Phe(56)-Ser(86)) containing the HK binding site inhibited FM activation by thrombin. Both a monoclonal antibody, 5F7, recognizing the A1 domain, and the rA1 domain were shown to be competitive inhibitors of thrombin-catalyzed FXI activation. The peptides Ala(45)-Arg(54) and Va1(59)-Arg(70) acted synergistically to inhibit FXI activation by thrombin. Mutant rA1 domain constructs (Val(64) --> Ala and Ile(77) --> Ala), which do not inhibit FXI binding to HK, retain full capacity to inhibit FXI activation by thrombin. The peptide Ala(45)-Arg(54) inhibited thrombin-catalyzed FXI activation, whereas it had no effect on FXI binding to HK. In contrast, the peptide Asn(72)-Leu(83) (which inhibited FXI binding to HK) did not inhibit FXI activation by thrombin. Thus, a thrombin binding site exists in the Al domain of FXI spanning residues Ala(45)-Arg(70) that is contiguous with but separate and distinct from the HK binding site. These sites may regulate which ligand is bound to FXI and through which pathway FXI is activated.	TEMPLE UNIV, SCH MED, SOL SHERRY THROMBOSIS RES CTR, PHILADELPHIA, PA 19104 USA; TEMPLE UNIV, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NHLBI NIH HHS [HL25661, HL45486, HL46213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486, R01HL046213, R01HL025661] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BAGLIA FA, 1989, BLOOD, V74, P244; BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BRUNNEE T, 1993, BLOOD, V81, P580; BUDZYNSKI AZ, 1979, BIOCHIM BIOPHYS ACTA, V584, P284, DOI 10.1016/0304-4165(79)90273-3; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERWALD H, 1993, J BIOL CHEM, V268, P14527; KENT SBH, 1985, SYNTHETIC PEPTIDES B; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; NAITO K, 1991, J BIOL CHEM, V266, P7353; OHKUBO I, 1982, FED PROC, V41, P656; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAGNI MV, 1985, BLOOD, V65, P719; REVAK SD, 1977, J CLIN INVEST, V59, P1167, DOI 10.1172/JCI108741; SCHMAIER AH, 1987, HEMOSTASIS THROMBOSI, P188; SCOTT CF, 1984, BLOOD, V63, P42; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715; SEGAL IH, 1974, ENZYME KINETICS; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WALSH PN, 1993, METHOD ENZYMOL, V222, P65; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343	40	65	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3652	3658						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631976				2022-12-27	WOS:A1996TV72400050
J	Tamm, A; Kister, A; Nolte, KU; Gessner, JE; Schmidt, RE				Tamm, A; Kister, A; Nolte, KU; Gessner, JE; Schmidt, RE			The IgG binding site of human Fc gamma RIIIB receptor involves CC' and FG loops of the membrane-proximal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; SINGLE AMINO-ACID; MONOCLONAL-ANTIBODIES; HUMAN-NEUTROPHILS; ALPHA-SUBUNIT; HIGH-AFFINITY; HUMAN IMMUNOGLOBULIN; EPSILON-RI; POLYMORPHISM; EXPRESSION	Fc gamma receptors for the Fc part of IgG are the mediators for antibody effector functions. Fc gamma RIII and Fc gamma RII are low affinity receptors that, through the interaction with immune complexes, initiate a variety of immunological responses, such as phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators. me set out to define the IgG binding site on human Fc gamma RIII. We assumed that potential beta-turns in Ig-like domains are the most probable determinants for ligand binding, and chimeric Fc gamma RIIIB/Fc epsilon RI receptors as well as single residue mutants were constructed in these regions of Fc gamma RIIIB. Substitution of four amino acids in the membrane-proximal domain (Gln(126), Arg(156), Lys(162), Val(164)) resulted in decreased binding of human IgG1. Lys(162) and Val(164) were found also to be crucial for the interaction with the IgG-binding inhibitory monoclonal antibody 3G8. In a putative three-dimensional model constructed in this study, these residues map on the CC' loop (Gln(126)), on F beta-sheet (Arg(156)), and on the FG loop (Lys(162), Val(164)). Our data are consistent with the study about human Fc gamma RII (Hulett, M. D., Witort, E., Brinkworth, R. I., McKenzie, I. F. C., and Hogarth, P. M. (1994) J. Biol. Chem. 269, 15287-15293), suggesting that common structural determinants, i.e. FG loop or the GFC surface of the membrane-proximal domain, can be involved in interactions with IgG by both low affinity receptor classes Fc gamma RII and Fc gamma RIII.	HANNOVER MED SCH,DEPT CLIN IMMUNOL,D-30625 HANNOVER,GERMANY; DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA 02115	Hannover Medical School; Harvard University; Dana-Farber Cancer Institute								ANDERSON CL, 1990, J IMMUNOL, V145, P196; BACON DJ, 1988, J MOL GRAPHICS, V6, P261; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BREDIUS RGM, 1994, IMMUNOLOGY, V83, P624; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Carayannopoulos Leon, 1993, P283; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; CLARK MR, 1991, EUR J IMMUNOL, V21, P1911, DOI 10.1002/eji.1830210820; DEHAAS M, 1995, LEUKOCYTE TYPING 5, V1, P811; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GERGELY J, 1990, FASEB J, V4, P3275, DOI 10.1096/fasebj.4.15.2253843; GESSNER JE, 1995, IMMUNOBIOLOGY, V193, P341, DOI 10.1016/S0171-2985(11)80564-4; GESSNER JE, 1995, J BIOL CHEM, V270, P1350, DOI 10.1074/jbc.270.3.1350; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HIBBS ML, 1985, IMMUNOGENETICS, V22, P335, DOI 10.1007/BF00430917; HIBBS ML, 1994, J IMMUNOL, V152, P4466; Hindley Siobhan A., 1993, Biochemical Society Transactions, V21, p337S; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HUIZINGA TWJ, 1990, BLOOD, V75, P1211; HUIZINGA TWJ, 1988, LEUKOCYTE TYPING, V4, P582; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; IERINO FL, 1993, J IMMUNOL, V150, P1794; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4605, DOI 10.1021/bi00389a002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LAH M, 1990, IMMUNOGENETICS, V31, P202, DOI 10.1007/BF00211557; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LUND J, 1991, J IMMUNOL, V147, P2657; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; OLSSON L, 1980, P NATL ACAD SCI-BIOL, V77, P5429, DOI 10.1073/pnas.77.9.5429; ORY PA, 1989, J CLIN INVEST, V83, P1676, DOI 10.1172/JCI114067; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; SARMAY G, 1985, EUR J IMMUNOL, V15, P1037, DOI 10.1002/eji.1830151015; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SAUL FA, 1978, J BIOL CHEM, V253, P585; SCHMIDT RE, 1995, LEUKOCYTE TYPING, V1, P805; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; UCIECHOWSKI P, 1992, EUR J IMMUNOL, V22, P1635, DOI 10.1002/eji.1830220643; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANCE BA, 1993, J IMMUNOL, V151, P6429; VANCE BA, 1992, FASEB J, V6, pA1620; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WERFEL T, 1989, J IMMUNOL, V142, P1102; WERNER G, 1986, LEUKOCYTE TYPING, V2, P109; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	59	46	83	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3659	3666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631977				2022-12-27	WOS:A1996TV72400051
J	Dzeja, PP; Zeleznikar, RJ; Goldberg, ND				Dzeja, PP; Zeleznikar, RJ; Goldberg, ND			Suppression of creatine kinase-catalyzed Phosphotransfer results in increased phosphoryl transfer by adenylate kinase in intact skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSPORT; ADENOSINE-TRIPHOSPHATE; COMPARTMENTATION; METABOLISM; PHOSPHATE; ATP; KINETICS; HEART; SHUTTLE; CELLS	The kinetics of creatine kinase (CK) and adenylate kinase (AK) activities were monitored in intact diaphragm muscle by O-18 phosphoryl oxygen exchange to assess whether these two phosphotransferases provide an interrelated function integral to high energy phosphoryl metabolism. This possibility was examined by quantitating the net rates of CK- and AK-catalyzed phosphoryl transfer in comparison to the total cellular ATP metabolic rate when CK activity in the intact diaphragm muscle was progressively inhibited by 2,4-dinitrofluorobenzene. In noncontracting muscle from untreated rats, net rates of CK- and AK-catalyzed phosphotransfer were equivalent to 88 and 7%, respectively, of the total ATP metabolic rate. These results were compared with reported (31)p NMR analyses of total creatine phosphate flux to estimate that each creatine phosphate molecule produced undergoes about 50 unidirectional CK-catalyzed phosphotransfers in transit to an ATP consumption site in the intact muscles. Graded inhibition by 2,4-dinitrofluorobenzene of intracellular CK activity by up to 98% resulted in a progressive shift in phosphotransferase catalysis from the CK to the AK system; the sum of the net rates of phosphoryl transfer by combining the increasing AK and decreasing CK activities continued to approximate the total cellular ATP metabolic rate. These results indicate that in diaphragm muscle CK and AK operate as interrelated cellular high energy phosphoryl transfer systems through which the majority of newly generated ATP is processed prior to its utilization.	UNIV MINNESOTA, SCH MED,DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V8, P361; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; CHANCE B, 1957, NATURE, V179, P1235, DOI 10.1038/1791235a0; DAWIS SM, 1989, BIOPHYS J, V55, P79, DOI 10.1016/S0006-3495(89)82782-1; DZEJA P, 1985, BIOCHEM INT, V10, P259; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GOLDBETER A, 1976, PROG THEOR BIOL, V4, P65; HOCHACHAKA PW, 1994, MUSCLES MOL METABOLI; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; KINGSLEYHICKMAN PB, 1987, BIOCHEMISTRY-US, V26, P7501, DOI 10.1021/bi00397a045; KRAUSE SM, 1992, J BIOL CHEM, V267, P2480; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P146; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P98, DOI 10.1139/y82-016; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MITCHELL P, 1991, BIOSCIENCE REP, V11, P297, DOI 10.1007/BF01130212; MOERLAND TS, 1994, AM J PHYSIOL, V267, pC127, DOI 10.1152/ajpcell.1994.267.1.C127; NAGLE S, 1970, KLIN WOCHENSCHR, V48, P332, DOI 10.1007/BF01484859; REICH JG, 1981, ENERGY METABOLISM CE, P95; SAKS VA, 1974, CIRC RES, V35, P138; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; SHOUBRIDGE EA, 1985, BIOCHIM BIOPHYS ACTA, V847, P25, DOI 10.1016/0167-4889(85)90148-X; STUCKI JW, 1980, EUR J BIOCHEM, V109, P257, DOI 10.1111/j.1432-1033.1980.tb04791.x; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; ZAHLER R, 1987, BIOPHYS J, V51, P883, DOI 10.1016/S0006-3495(87)83416-1; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	34	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12847	12851		10.1074/jbc.271.22.12847	http://dx.doi.org/10.1074/jbc.271.22.12847			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662747	hybrid			2022-12-27	WOS:A1996UN47400026
J	Ahn, T; Kim, HM				Ahn, T; Kim, HM			Differential effect of precursor ribose binding protein of Escherichia coli and its signal peptide on the SecA penetration of lipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANES; APOCYTOCHROME-C; MODEL MEMBRANES; PHOSPHOLIPIDS; TRANSLOCATION; EXPORT; ATP; DOMAINS; PHOSPHATIDYLGLYCEROL; INTERACTS	Digestion of vesicle-bound SecA by trypsin entrapped within the vesicles showed that refolding precursor ribose-binding protein (pRBP) of Escherichia coli retards the lipid bilayer penetration by SecA while the signal peptide enhances it. This discrepancy was found to be due to reduced SecA binding to the vesicles in the presence of the pRBP while the signal peptide induced a tight binding. Studies on the binding of 1-anilino-8-naphthalene sulfonate (ANS) to SecA indicated that SecA assumes more closed conformation upon interaction with pRBP and signal peptide induces more open structure of SecA. Kinetic studies of ANS binding to SecA upon dilution of unfolded pRBP with SecA solution showed an initial fast ANS binding, which was followed by a slow release of ANS. This suggests that first the signal peptide portion of the pRBP binds with the SecA making its structure more open and then the subsequent binding of the mature domain makes the SecA structure more compact. The pRBP enhanced the digestion of SecA added to the E. coli inverted vesicles, suggesting an inhibition of SecA penetration while the signal peptide had an opposite effect, agreeing with the results from the model systems above. When the pRBP and ATP were present together, however, the penetration of SecA increased dramatically underlining the importance of the SecY/E complex for the membrane insertion of SecA.	KOREA ADV INST SCI & TECHNOL, DEPT BIOL SCI, TAEJON 305701, SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)								AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18148; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; Chi SW, 1995, BIOPHYS J, V69, P2703, DOI 10.1016/S0006-3495(95)80141-4; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM JH, 1992, J BACTERIOL, V174, P5219, DOI 10.1128/JB.174.16.5219-5227.1992; KIM YJ, 1994, CELL, V78, P845; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; RANDALL LL, 1985, EMBO J, V4, P1875; RIETVELD A, 1986, J BIOL CHEM, V261, P3846; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TESCHKE CM, 1991, J BIOL CHEM, V266, P11789; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4; YI GS, 1994, BIOPHYS J, V66, P1604, DOI 10.1016/S0006-3495(94)80952-X	39	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12372	12379		10.1074/jbc.271.21.12372	http://dx.doi.org/10.1074/jbc.271.21.12372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647840	hybrid			2022-12-27	WOS:A1996UL66000042
J	Siegers, K; Heinzmann, S; Entian, KD				Siegers, K; Heinzmann, S; Entian, KD			Biosynthesis of lantibiotic nisin - Posttranslational modification of its prepeptide occurs at a multimeric membrane-associated lanthionine synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL GENE ISOLATION; LACTOCOCCUS-LACTIS; PROTEIN; EXPRESSION; EPIDERMIN; SUBTILIN; PRECURSOR; SEQUENCE; CLONING; SYSTEM	The lantibiotic nisin of Lactococcus lactis is matured from a ribosomally synthesized prepeptide by posttranslational modification. Genetic and biochemical evidence suggests that genes nisB and nisC of the nisin gene cluster encode proteins necessary for prenisin modification. Inactivation of both genes resulted in complete loss of nisin production. The preparation of membrane vesicles revealed that NisB and NisC are attached to the cellular membrane, and co-immunoprecipitation experiments showed that they are associated with each other. By using the yeast two-hybrid system, which is a highly sensitive method to unravel protein-protein interactions, we could show that the nisin prepeptide physically interacts with the NisC protein, suggesting that NisC contains a binding site for prenisin. This was also confirmed by co-immunoprecipitation of the NisC protein and the NisA prepeptide by antibodies directed against the leader sequence of the nisin prepeptide. The two-hybrid analysis also confirmed the interaction between NisB and NisC as well as the interaction between NisC and the NisT ABC transporter. A minor interaction was also indicated between prenisin and the NisB protein. Furthermore, the two-hybrid investigations also revealed that at least two molecules of NisC and two molecules of NisT are part of the modification and transport complex. Our results suggest that lantibiotic maturation and secretion occur at a membrane associated multimeric lanthionine synthetase complex consisting of proteins NisB, NisC, and the ABC transporter molecules NisT.	UNIV FRANKFURT, INST MICROBIOL, D-60439 FRANKFURT, GERMANY	Goethe University Frankfurt			Entian, Karl-Dieter/D-3080-2011					ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x; BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BENZ R, 1991, NISIN NOVEL LANTIBIO; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; Chevalier RJ, 1957, ANN TECHNOL AGR, V2, P117; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DEVOS WM, 1995, MOL MICROBIOL, V17, P427, DOI 10.1111/j.1365-2958.1995.mmi_17030427.x; DODD HM, 1990, J GEN MICROBIOL, V136, P555, DOI 10.1099/00221287-136-3-555; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; ENGELKE G, 1994, APPL ENVIRON MICROB, V60, P816; Entian KD, 1996, ANTON LEEUW INT J G, V69, P109, DOI 10.1007/BF00399416; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GASSON MJ, 1983, J BACTERIOL, V154, P1; GILMORE MS, 1994, J BACTERIOL, V176, P7335, DOI 10.1128/JB.176.23.7335-7344.1994; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; HORINOUCHI S, 1980, P NATL ACAD SCI-BIOL, V77, P7079, DOI 10.1073/pnas.77.12.7079; HURST A, 1981, ADV APPL MICROBIOL, V27, P263; INGRAM LC, 1969, BIOCHIM BIOPHYS ACTA, V184, P216, DOI 10.1016/0304-4165(69)90121-4; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KALETTA C, 1989, ARCH MICROBIOL, V152, P16, DOI 10.1007/BF00447005; KALETTA C, 1991, NISIN NOVEL LANTIBIO; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KLEIN C, 1992, APPL ENVIRON MICROB, V58, P132, DOI 10.1128/AEM.58.1.132-142.1992; KLEIN C, 1993, APPL ENVIRON MICROB, V59, P296, DOI 10.1128/AEM.59.1.296-303.1993; KLEIN C, 1994, APPL ENVIRON MICROB, V60, P2793, DOI 10.1128/AEM.60.8.2793-2801.1994; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; MEYER C, 1995, EUR J BIOCHEM, V232, P478, DOI 10.1111/j.1432-1033.1995.tb20834.x; NIEDERACHER D, 1987, MOL GEN GENET, V206, P505, DOI 10.1007/BF00428892; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; RINCE A, 1994, APPL ENVIRON MICROB, V60, P1652, DOI 10.1128/AEM.60.5.1652-1657.1994; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; SAHL HG, 1985, J BACTERIOL, V162, P833, DOI 10.1128/JB.162.2.833-836.1985; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHNELL N, 1992, EUR J BIOCHEM, V204, P57, DOI 10.1111/j.1432-1033.1992.tb16605.x; SCHNELL N, 1989, FEMS MICROBIOL LETT, V58, P263, DOI 10.1016/0378-1097(89)90050-5; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SCHNELL N, 1991, NISIN NOVEL LANTIBIO; SCHULLER F, 1989, EUR J BIOCHEM, V182, P181, DOI 10.1111/j.1432-1033.1989.tb14815.x; SIEGERS K, 1995, APPL ENVIRON MICROB, V61, P1082, DOI 10.1128/AEM.61.3.1082-1089.1995; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAUTZ D, 1983, ANAL BIOCHEM, V132, P503; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	51	109	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12294	12301		10.1074/jbc.271.21.12294	http://dx.doi.org/10.1074/jbc.271.21.12294			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647829	hybrid			2022-12-27	WOS:A1996UL66000031
J	vanderSpek, JC; Sutherland, JA; Ratnarathorn, M; Howland, K; Ciardelli, TL; Murphy, JR				vanderSpek, JC; Sutherland, JA; Ratnarathorn, M; Howland, K; Ciardelli, TL; Murphy, JR			DAB(389) interleukin-2 receptor binding domain mutations - Cytotoxic probes for studies of ligand-receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FUSION PROTEIN; TARGET-CELLS; EFFICIENT DELIVERY; FRAGMENT-A; TOXIN; CYTOSOL; CHAIN; PHOSPHORYLATION; PROLIFERATION	Site-directed mutagenesis was used to generate point mutations in the diphtheria toxin-related fusion protein, DAB(389) interleukin-2 (IL-2). Thr-439, in the IL-2 receptor binding domain of the fusion toxin, was changed to a Pro residue. The resultant fusion toxin, DAB(389) IL-2(T439P), was 300-fold less cytotoxic than wild type DAB(389) IL-2, partially as the result of a 100-fold decrease in binding affinity for the high affinity form of the IL-2 receptor. However, DAB(389) IL-2(T439P) stimulated DNA synthesis to a greater extent than expected. Studies of intoxication kinetics indicated that the increased stimulation might result from an increased contact time between the mutated IL-2 receptor binding domain and the receptor, perhaps due to a decreased internalization rate. Another mutant, DAB(389) IL-2(Q514D), in which a Gln residue at position 514 was changed to an Asp, was 2000-fold less cytotoxic than wild type DAB(389) IL-2. This mutant had a 50-fold decrease in binding affinity, did not stimulate DNA synthesis and also had a reduced rate of intoxication. Gln-514 appears to play a role in receptor binding and activation, whereas Thr-439 appears to be involved with receptor binding and signaling internalization of the fusion toxin-receptor complex.	BOSTON UNIV,MED CTR,DEPT MED,BOSTON,MA 02118; DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; VET ADM MED CTR,WHITE RIVER JCT,VT 05001	Boston University; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)	vanderSpek, JC (corresponding author), BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118, USA.				NCI NIH HHS [CA-60934] Funding Source: Medline; NIGMS NIH HHS [R01 GM 52858-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1991, CURRENT PROTOCOL S15, V1; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BECKNER SK, 1987, BIOCHEM BIOPH RES CO, V145, P176, DOI 10.1016/0006-291X(87)91303-9; BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; BERNDT WG, 1992, INTERLEUKIN, V2, P12; BUCHLI P, 1993, ARCH BIOCHEM BIOPHYS, V207, P411; CHANG DZ, 1995, MOL PHARMACOL, V47, P206; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; ISHII T, 1988, J IMMUNOL, V141, P174; LANDGRAF BE, 1992, J BIOL CHEM, V267, P18511; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MILLS GB, 1985, J BIOL CHEM, V260, P2500; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUAVE K, 1991, P NATL ACAD SCI USA, V88, P4636; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	25	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12145	12149		10.1074/jbc.271.21.12145	http://dx.doi.org/10.1074/jbc.271.21.12145			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647806	hybrid			2022-12-27	WOS:A1996UL66000008
J	Vihinen, T; Maatta, A; Jaakkola, P; Auvinen, P; Jalkanen, M				Vihinen, T; Maatta, A; Jaakkola, P; Auvinen, P; Jalkanen, M			Functional characterization of mouse syndecan-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEOGLYCANS; FIBROBLAST GROWTH-FACTOR; CELL-SURFACE PROTEOGLYCAN; REDUCTASE GENE PROMOTER; BOX-BINDING-PROTEINS; HEPARAN-SULFATE; PEPTIDE CORE; TRANSIENT EXPRESSION; EPITHELIAL-CELLS; LESS PROMOTER	The members of the syndecan family are temporally and spatially expressed heparan sulfate proteoglycans of various tissues, where they mediate extracellular influences on cell morphology and behavior. Functional characterization of the mouse syndecan-1 promoter was carried out in order to elucidate the mechanisms involved in the maintenance of the high transcription levels of syndecan-1 gene in various epithelia. For that 9.5 kilobase pairs of the upstream region of mouse syndecan-1 gene were cloned, sequenced, and used to prepare chimaeric constructs with a reporter gene followed by transient or stable transfections into NMuMG epithelial and 3T3 fibroblastic cells. In NMuMG cells, cultured either in the presence or absence of serum, the 2.5-kilobase pair promoter region resulted in the constitutive transcription activity, whereas in 3T3 cells the serum depletion decreased the promoter activity significantly. Deletion of the upstream sequences to -437 base pairs relative to the translation initiation site had little effect on this promoter activity. Further deletion to -365 base pairs removed three GT boxes and slightly increased the promoter activity, whereas the deletion of the next two GC boxes (to -326 base pair) reduced the promoter activity dramatically. All of the GC or GT box sequences bound the same set of Sp1-like nuclear proteins in gel shift assays. Nuclear protein binding was also demonstrated around both of the most intense transcription initiation sites. Mutation of these regions separately resulted in total loss of transcription initiation from the deleted site and decreased the promoter activity in relation to the intensity of the abolished start site. This indicates that the transcription initiation of the syndecan-1 gene is directed through initiator-like elements directly overlapping the start sites, as shown for several TATA-less housekeeping and growth regulated genes. We assume that the constitutive high level gene expression in epithelial cells is achieved by the proximal promoter, which is controlled by members of Sp1 transcription factor family.	TURKU CTR BIOTECHNOL,FIN-20521 TURKU,FINLAND; TURKU UNIV,DEPT BIOCHEM MED,FIN-20520 TURKU,FINLAND	University of Turku			Auvinen, Petri/D-5044-2009; Jaakkola, Panu M/B-4355-2012; Auvinen, Petri/AAP-8117-2021	Auvinen, Petri/0000-0002-3947-4778; Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BACIU PC, 1994, J BIOL CHEM, V269, P696; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN XR, 1992, ONCOGENE, V7, P1805; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HINKES MT, 1993, J BIOL CHEM, V268, P11440; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MALI M, 1993, J BIOL CHEM, V268, P24215; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Maxam A M, 1980, Methods Enzymol, V65, P499; MIETTINEN HM, 1994, MOL BIOL CELL, V5, P1325, DOI 10.1091/mbc.5.12.1325; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NASO MF, 1994, J BIOL CHEM, V269, P32999; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIDLEY RC, 1993, BLOOD, V81, P767; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTRA M, 1994, J BIOL CHEM, V269, P579; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WU RL, 1994, J BIOL CHEM, V269, P28450; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	70	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12532	12541		10.1074/jbc.271.21.12532	http://dx.doi.org/10.1074/jbc.271.21.12532			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647862	hybrid			2022-12-27	WOS:A1996UL66000064
J	Lecain, E; Chenivesse, X; Spagnoli, R; Pompon, D				Lecain, E; Chenivesse, X; Spagnoli, R; Pompon, D			Cloning by metabolic interference in yeast and enzymatic characterization of Arabidopsis thaliana sterol Delta 7-reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B RECEPTOR; SACCHAROMYCES-CEREVISIAE; CHOLESTEROL-BIOSYNTHESIS; MICROSOMAL-ENZYMES; GENE ENCODES; MEMBRANE; MUTANTS; PROTEIN; IDENTIFICATION; PURIFICATION	Reduction of the Delta 7 double bond of sterols, a key biosynthetic step in higher eukaryotes, is lacking in lower eukaryotes like the yeast Saccharomyces cerevisiae, leading to terminal sterols with a Delta 5,7-conjugated diene structure, Genes encoding two sterol reductases involved, respectively, in the reduction of sterol Delta 14 and Delta 24(28) double bonds have been cloned to date, but no sequence information was available on the enzyme responsible for Delta 7-bond reduction, This study presents the cloning of the NADPH-sterol Delta 7-reductase (Delta 7-red) from Arabidopsis thaliana, based on a metabolic interference approach in yeast, The principle is the functional expression of a plant cDNA library in the yeast strain FY1679-28C tolerant to sterol modifications and the selection of clones resistant to the polyene fungicide nystatin, The toxicity of this compound is dependent on the presence of Delta 5,7-unsaturated sterols in the yeast plasma membrane, One clone out of 10(5) transformants exhibits a cDNA-dependent alteration of cell sterol composition, The 1290-base pair cDNA open reading frame was isolated and sequenced, The corresponding protein presents a significant sequence similarity with yeast Delta 14- and Delta 24(28)-reductases and with human lamin B receptor. The coding sequence was extracted by polymerase chain reaction and inserted into a galactose-inducible yeast expression vector to optimize expression, Analysis using transformed wild type yeast or sterol altered mutants, indicated that Delta 5,7-ergosta- and cholesta-sterols are efficiently reduced in vivo, regardless of the structural variations on the side chain, No reductase activity was observed toward the Delta 14 or the Delta 5 positions of sterols, In vivo extensive Delta 7-reduction of the free and esterified pools of sterols was observed upon induction of the enzyme, Ergosterol present before induction was reduced into ergosta-5,22-dieneol, whereas ergosta-5-eneol is the new end product of sterol neosynthesis, indicating that the yeast Delta 22 desaturase may be no longer active on C-7-saturated sterols, In vitro tests indicated that Delta 7-reductase activity is preferentially associated with the endoplasmic reticulum membrane and confirmed the previous finding that NADPH is the reducing agent.	UNIV PARIS 06, CNRS, CTR MOLEC GENET, F-91198 GIF SUR YVETTE, FRANCE; ROUSSEL UCLAF, DEPT BIOTECHNOL, UNITE RECH BIOTECHNOL, F-93235 ROMAINVILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay								AOYAMA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1320, DOI 10.1006/bbrc.1994.1848; AUFENANGER J, 1986, BIOCHEM PHARMACOL, V35, P911, DOI 10.1016/0006-2952(86)90076-6; BARD M, 1977, LIPIDS, V12, P645, DOI 10.1007/BF02533759; BOTTEMA CDK, 1985, BIOCHIM BIOPHYS ACTA, V813, P313, DOI 10.1016/0005-2736(85)90247-0; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; CLEJAN S, 1985, J BIOL CHEM, V260, P2884; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DEMPSEY ME, 1969, METHOD ENZYMOL, V15, P501; FRYBERG M, 1973, J AM CHEM SOC, V95, P5745; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARTMANN MA, 1987, METHOD ENZYMOL, V148, P632; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KAWATA S, 1986, J BIOL CHEM, V261, P3790; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; LAI MH, 1994, GENE, V140, P41; LEES N D, 1989, Steroids, V53, P567, DOI 10.1016/0039-128X(89)90032-9; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LORENZ RT, 1989, J BACTERIOL, V171, P6169, DOI 10.1128/jb.171.11.6169-6173.1989; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; MINET M, 1992, PLANT J, V2, P417; MOLZAHN SW, 1972, J GEN MICROBIOL, V72, P339, DOI 10.1099/00221287-72-2-339; OSUMI T, 1978, J BIOCHEM-TOKYO, V83, P681, DOI 10.1093/oxfordjournals.jbchem.a131961; PAIK YK, 1986, J BIOL CHEM, V261, P6470; PARKS LW, 1978, CRC CR REV MICROBIOL, V6, P301, DOI 10.3109/10408417809090625; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; POPJAK G, 1989, J BIOL CHEM, V264, P6230; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROCKMILL B, 1991, METHOD ENZYMOL, V194, P1456; RODRIGUEZ RJ, 1983, ARCH BIOCHEM BIOPHYS, V225, P861, DOI 10.1016/0003-9861(83)90099-1; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; STEINBERG D, 1969, METHOD ENZYMOL, V15, P514; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TATON M, 1991, BIOCHEM BIOPH RES CO, V181, P465, DOI 10.1016/S0006-291X(05)81442-1; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	47	54	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10866	10873		10.1074/jbc.271.18.10866	http://dx.doi.org/10.1074/jbc.271.18.10866			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631902	hybrid			2022-12-27	WOS:A1996UJ34200070
J	Hammer, JA; Jung, G				Hammer, JA; Jung, G			The sequence of the Dictyostelium myo J heavy chain gene predicts a novel, dimeric, unconventional myosin with a heavy chain molecular mass of 258 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA MYOSIN; LOCALIZATION; DISCOIDEUM; CALMODULIN; PROTEIN; ISOFORM; MUSCLE; DISRUPTION; ALIGNMENT; MOTILITY	The complete sequence of the Dictyostelium myo J heavy chain gene has been determined hom overlapping genomic clones. The gene spans similar to 7400 base pairs, is split by two small introns, and encodes a 2241-residue, 258-kDa heavy chain polypeptide that that is composed of an N-terminal 944-residue myosin head domain, a central 863-residue domain that is predicted to form an cu helical coiled-coil containing six hinges, and a C-terminal 434-residue globular domain. The head domain is notable in that it contains a similar to 30 residue insert near the nucleotide binding pocket, and five potential calmodulin/myosin light chain binding sites at the head/tail junction. The existence within the Myo J tail domain of both an extensive coiled-coil structure and a large globular domain suggests that this myosin is dimeric and incapable of self-assembly into filaments. While these properties, as well as the overall predicted structure of the Myo J protein, are reminiscent of class V myosins, the sequence of the 434-residue globular tail piece of Myo J shows no similarity to that of either yeast or vertebrate myosins V. Consistent with this, phylogenetic analyses based on myosin head sequence comparisons do not classify Myo J as a type V myosin. These and other sequence comparisons indicate that Myo J and two as-yet-unclassified unconventional myosins from Arabidopsis represent members of the newest class within the myosin superfamily (class XI). Northern blots analyses suggest that Myo J may function predominantly in vegetative Dictyostelium cells. Finally, Southern blot analyses suggest that Dictyostelium possesses another myosin that is very closely related to Myo J.			Hammer, JA (corresponding author), NHLBI,CELL BIOL LAB,NIH,SECT MOLEC CELL BIOL,BLDG 3,RM B1-22,BETHESDA,MD 20892, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FOK AK, 1993, J CELL SCI, V106, P1103; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P569; HAARER BK, 1994, J CELL SCI, V107, P1055; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HAMMER JA, 1994, J CELL BIOL, V127, P1779, DOI 10.1083/jcb.127.6.1779; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JUNG G, 1993, J BIOL CHEM, V268, P14981; JUNG G, 1996, IN PRESS J CELL BIOL; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; Kimura M., 1983, NEUTRAL THEORY MOL E; KINEKEMA M, 1994, PLANT MOL BIOL, V26, P2239; KINEKEMA M, 1994, J MOL BIOL, V239, P591; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOOSEKER MS, IN PRESS ANN REV CEL; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON MD, 1995, J CELL SCI, V108, P1093; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; SPUDICH JA, 1989, CELL REGUL, V1, P1; Spudich JA, 1987, METHODS CELL BIOL, V28; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1994, P NATL ACAD SCI USA, V91, P9446, DOI 10.1073/pnas.91.20.9446; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; URRUTIA RA, 1993, BIOCHIM BIOPHYS ACTA, V1173, P225, DOI 10.1016/0167-4781(93)90185-G; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	55	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7120	7127		10.1074/jbc.271.12.7120	http://dx.doi.org/10.1074/jbc.271.12.7120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636147	hybrid			2022-12-27	WOS:A1996UB15700082
J	Watanabe, S; Okuno, S; Kitani, T; Fujisawa, H				Watanabe, S; Okuno, S; Kitani, T; Fujisawa, H			Inactivation of calmodulin-dependent protein kinase IV by autophosphorylation of serine 332 within the putative calmodulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CEREBELLAR GRANULE CELLS; PHENOTYPIC SELECTION; BRAIN CALMODULIN; EXPRESSION; GENE; GR; PEPTIDES; SEQUENCE; PHOSPHOSERINE	When brain calmodulin-dependent protein kinase IV is incubated with calmodulin-dependent protein kinase IV kinase under the phosphorylation conditions in the presence of Ca2+/calmodulin, rapid initial incorporation of 1 mol of phosphate into 1 mol of the enzyme by the action of the kinase kinase occurs, resulting in marked activation of the enzyme, and the subsequent incorporation of more than 3 mol of phosphate by autophosphorylation occurs, resulting in no significant change in the activity (Okuno, S., Kitani, T., and Fujisawa, H. (1994) J. Biochem, (Tokyo) 116, 923-930; Okuno, S., Kitani, T., and Fujisawa, H. (1995) J. Biochem, (Tokyo) 117, 686-690), After the maximal phosphorylation, the continued incubation in the presence of excess EGTA resulted in additional autophosphorylation of the enzyme, leading to a complete loss of the Ca2+/calmodulin-dependent activity, while causing no significant change in the Ca2+/calmodulin-independent activity. The amino acid sequence analysis revealed that the autophosphorylation after removal of Ca2+ occurred on Ser(332), Ser(333), Ser(337), and Ser(341), Analysis by site-directed mutagenesis clearly showed that the autophosphorylation site responsible for the inactivation is Ser(332). Thus, calmodulin-dependent protein kinase IV activated by the kinase kinase may lose its Ca2+/calmodulin-dependent activity by autophosphorylation on Ser(332) located within the putative calmodulin-binding domain in the absence of Ca2+.			Watanabe, S (corresponding author), ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN.							BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Corbin J D, 1974, Methods Enzymol, V38, P287; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; IKEDA A, 1991, J BIOL CHEM, V266, P11582; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KATOH T, 1991, J BIOL CHEM, V266, P3039; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KITANI T, 1995, J BIOCHEM-TOKYO, V117, P1070, DOI 10.1093/oxfordjournals.jbchem.a124808; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGELS LA, 1992, J BIOL CHEM, V267, P5847; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4; VANTHOFF JH, 1884, ETUDES DYNAMIQUE CHI, P87	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6903	6910		10.1074/jbc.271.12.6903	http://dx.doi.org/10.1074/jbc.271.12.6903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636117	hybrid			2022-12-27	WOS:A1996UB15700052
J	Yao, XB; Cheng, L; Forte, JG				Yao, XB; Cheng, L; Forte, JG			Biochemical characterization of ezrin-actin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC PARIETAL-CELLS; BETA-ACTIN; 80-KDA PHOSPHOPROTEIN; APICAL MICROVILLI; MEMBRANE; PURIFICATION; PROFILIN; PROTEINS; POLYMERIZATION; LOCALIZATION	The highly related actin isoforms are thought to have different functions. We recently demonstrated a polarized distribution of actin isoforms in gastric parietal cells and association of gastric ezrin with the cytoplasmic beta-actin isoform (Yao, X., Chaponnier, C., Gabbiani, G., and Forte, J. G. (1995) Mol. Biol. Cell. 6, 541-557). Here we used ultrastructural immunocytochemistry to verify that beta-actin is located within canalicular microvilli and the apical cortex of parietal cells, similar to the localization reported for ezrin. Furthermore, we tested whether ezrin binds preferentially to cytoplasmic beta-actin compared with the skeletal muscle alpha-actin isoform. Purified cytoplasmic beta-actin (from erythrocytes) and skeletal alpha-actin were assembled with gastric ezrin. Co-sedimentation experiments showed that gastric ezrin selectively co-pelleted with the beta-actin isoform and only very poorly with alpha-actin. Binding of erythrocytic beta-actin to ezrin is saturable with a molar ratio of similar to 1:10 (ezrin: actin) and a dissociation constant similar to 4.6 x 10(-8) M. In addition, ezrin promoted pyrene-labeled actin assembly, with predominant effects on filament elongation and a distinct preference for beta-actin compared with alpha-actin. Given these isoform-selective associations, we speculate that actin isoforms might segregate into different functional domains and exert specificity by interacting with isoform-orientated binding proteins.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Yao, Xuebiao/P-5771-2014					ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HANZEL DK, 1989, AM J PHYSIOL, V256, pG1082, DOI 10.1152/ajpgi.1989.256.6.G1082; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KOUYAMA T, 1980, EUR J BIOCHEM, V105, P279, DOI 10.1111/j.1432-1033.1980.tb04499.x; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; NORTH AJ, 1994, J CELL SCI, V107, P445; OGIHARA S, 1995, MOL BIOL CELL, V6, P2155; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; PUSZKIN S, 1978, BIOCHIM BIOPHYS ACTA, V513, P205, DOI 10.1016/0005-2736(78)90174-8; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; ROZYCKI MD, 1994, CURR OPIN CELL BIOL, V6, P87, DOI 10.1016/0955-0674(94)90121-X; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	36	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7224	7229		10.1074/jbc.271.12.7224	http://dx.doi.org/10.1074/jbc.271.12.7224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636161	hybrid			2022-12-27	WOS:A1996UB15700096
J	Hugunin, M; Quintal, LJ; Mankovich, JA; Ghayur, T				Hugunin, M; Quintal, LJ; Mankovich, JA; Ghayur, T			Protease activity of in vitro transcribed and translated Caenorhabditis elegans cell death gene (ced-3) product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA; EXPRESSION; ACTIVATION; SEQUENCE; ENCODES; CLONING; ENZYME; CDNA	The Caenorhabditis elegans cell death gene, ced-3, encodes one of the two proteins required for apoptosis in this organism. The primary sequence similarities between Ced-3 and the mammalian interleukin-1 beta converting enzyme (ICE) suggest that these two proteins may have functionally similar active sites and that Ced-3 may function as a cysteine protease, Here we report that in vitro transcribed and translated Ced-S protein (p56) underwent rapid processing to smaller fragments. Replacement of the predicted active site cysteine of Ced-3 with serine (C364S) prevented the generation of smaller proteolytic fragments, suggesting that the processing might be an autocatalytic process. Peptide aldehydes with aspartic acid at the P1 position blocked Ced-3 autocatalysis. Furthermore, the protease inhibition profile of Ced-3 was similar to the profile reported for ICE. These functional data demonstrate that Ced-3 is an Asp-dependent cysteine protease with substrate specificity similar to that of ICE. Aurintricarboxylic acid, an inhibitor of apoptosis in mammalian cells, blocked Ced-3 autocatalytic activity, suggesting that an aurintricarboxylic acid-sensitive Ced-3/ICE-related protease might be involved in the apoptosis pathway(s) in mammalian cells.	BASF BIORES CORP,WORCESTER,MA 01605	BASF								AYALA JM, 1994, J IMMUNOL, V153, P2592; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1991, Patent No. 15577; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; COHEN JJ, 1984, J IMMUNOL, V132, P38; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008; GRAY PW, 1986, J IMMUNOL, V137, P3644; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ROLANDO AM, 1993, J CELL BIOCHEM, V18, P147; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAMIN TT, 1994, FASEB J, V8, P644; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	38	42	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3517	3522						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631956	hybrid			2022-12-27	WOS:A1996TV72400030
J	Kalies, KU; Hartmann, E				Kalies, KU; Hartmann, E			Membrane topology of the 12- and the 25-kDa subunits of the mammalian signal peptidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; SEQUENCE RECEPTOR; SPANNING PROTEINS; SECRETORY PROTEIN; ESCHERICHIA-COLI; PURIFICATION; COMPONENTS; RIBOSOMES	The cleavage of signal sequences of secretory and membrane proteins by the signal peptidase complex occurs in the lumen of the endoplasmic reticulum. Mammalian signal peptidase consists of five subunits. Four have been cloned, SPC18, SPC21, SPC22/23, and SPC25, of which all but SPC25 have been demonstrated to be single-spanning membrane proteins exposed to the lumen of the endoplasmic reticulum. We have determined the cDNA sequence of the remaining 12-kDa subunit (SPC12) as well as the membrane topologies of SPC12 and SPC25 in rough microsomes. Both polypeptides span the membrane twice with their N and C termini facing the cytosol and contain only very small, if any, lumenal domains. Therefore, SPC12 and SPC25 are likely to be involved in processes other than the enzymatic cleavage of the signal sequence.	MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Hartmann, Enno/C-5687-2013					BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; FUJIMOTO Y, 1984, J BIOCHEM-TOKYO, V96, P1125, DOI 10.1093/oxfordjournals.jbchem.a134930; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VOGEL F, 1990, EUR J CELL BIOL, V53, P197; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WHITLEY P, 1993, BIOCHEMISTRY-US, V32, P8534, DOI 10.1021/bi00084a020; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	32	40	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3925	3929						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632014				2022-12-27	WOS:A1996TV72400088
J	Marhamati, DJ; Sonenshein, GE				Marhamati, DJ; Sonenshein, GE			B-Myb expression in vascular smooth muscle cells occurs in a cell cycle-dependent fashion and down-regulates promoter activity of type I collagen genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; MESSENGER-RNA; HEMATOPOIETIC-CELLS; FUNCTIONAL-ANALYSIS; PROTO-ONCOGENE; LYSYL OXIDASE; GROWTH-FACTOR; V-MYB; A-MYB; DNA	The members of the Myb family of transcription factors are defined by homology in the DNA-binding domain; all bind the Myb-binding site (MBS) sequence (YG(A/G)C(A/C/G)GTT(G/A)). Here we report that cultured bovine vascular smooth muscle cells (SMCs) express B-myb. Levels of B-myb RNA found in exponential growth were reduced dramatically in serum-deprived quiescent SMCs; B-myb mRNA levels increased in the cell cycle during the late G(1) to S phase transition following restimulation with serum, epidermal growth factor, or phorbol ester plus insulin-like growth factor-1. Changes in the rate of B-myb gene transcription could account for part of the observed increase following serum addition. Treatment of SMC cultures with actinomycin D indicated a >4-h half-life for B-myb mRNA during the S phase of the cell cycle. Cotransfection of either a bovine or human B-myb expression vector down-regulated the activity of a multimerized MBS element-driven reporter construct in SMCs. Putative MBS elements were detected upstream of the promoters of the two chains of type I collagen, which we have found to be expressed inversely with growth state of the SMC (Kindy, M. S., Chang, C.-J., and Sonenshein, G. E. (1988) J. Biol. Chem. 263, 11426-11430). In cotransfection experiments, B-myb expression down-regulated the promoter activity of alpha 1(I) and alpha 2(I) collagen constructs an average of 92 and 82%, respectively. Thus, B-myb represents a potential link in the observed inverse relationship between collagen gene expression and growth of vascular SMCs.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007429, P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13262, HL07429] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; ANG AH, 1990, BIOCHEM J, V265, P461, DOI 10.1042/bj2650461; ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BEDALOV A, 1994, J BIOL CHEM, V269, P4903; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BOAST S, 1990, J BIOL CHEM, V265, P13351; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BROWN KE, 1991, J BIOL CHEM, V266, P23268; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHANG CJ, 1991, MATRIX, V11, P242, DOI 10.1016/S0934-8832(11)80231-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HUGHES AFW, 1942, J ANAT, V77, P266; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KINDY MS, 1988, J BIOL CHEM, V263, P11426; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LEHRACH H, 1979, BIOCHEMISTRY-US, V18, P3146, DOI 10.1021/bi00581a036; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIAU G, 1989, J BIOL CHEM, V264, P10315; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MISKULIN M, 1986, BIOCHEMISTRY-US, V25, P1408, DOI 10.1021/bi00354a033; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; POOLE JCF, 1971, AM J PATHOL, V62, P391; REILLY CF, 1989, J BIOL CHEM, V264, P6990; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1985, ANN NY ACAD SCI, V454, P292, DOI 10.1111/j.1749-6632.1985.tb11869.x; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; STEPP MA, 1986, J BIOL CHEM, V261, P6542; STRAUSS BH, 1994, CIRC RES, V75, P650, DOI 10.1161/01.RES.75.4.650; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TASHIRO S, 1995, ONCOGENE, V10, P1699; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WU Y, 1992, J BIOL CHEM, V267, P24199	61	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3359	3365						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631934				2022-12-27	WOS:A1996TV72400008
J	Taylor, JM; JacobMosier, GG; Lawton, RG; VanDort, M; Neubig, RR				Taylor, JM; JacobMosier, GG; Lawton, RG; VanDort, M; Neubig, RR			Receptor and membrane interaction sites on G beta - A receptor-derived peptide binds to the carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; GAMMA-SUBUNIT; SYNTHETIC PEPTIDES; BOVINE BRAIN; ALPHA-SUBUNITS; HIGH-AFFINITY; RHODOPSIN; IDENTIFICATION; TRANSDUCIN; DOMAIN	The functional organization of G beta gamma is poorly understood, Regions of bovine brain G beta gamma that interact with a photoaffinity derivative of an alpha(2)-adrenergic receptor-derived peptide from the third intracellular loop (diazo-pyruvoyl-modified peptide Q (DAP-Q)) and a hydrophobic membrane probe (3-trifluoromethyl-3-(m-iodophenyl)diazirine (TID)) were examined. We previously showed that DAP-Q cross-links to specific, competable sites on both the alpha and beta subunits of G(o)/G(i) but not on the gamma subunit and that beta gamma subunit was required for stimulation of G(o)/G(i) GTPase activity (Taylor, J. M., Jacob Mosier, G. G., Lawton, R. G., Remmers, A. E., and Neubig, R. R. (1994) J. Biol. Chem. 269, 27618-27624). Similarly, we show here that the membrane-associated photoprobe [I-125]TID labels alpha and beta but not gamma. We have now mapped the sites of incorporation of DAP-Q and TID into the beta subunit, TID labels both the 14-kDa amino-terminal and the 23-kDa carboxyl-terminal fragments from a partial tryptic digest of beta while DAP-Q labels only the carboxyl-terminal fragment, Further mapping with endopeptidase Lys C reveals substantial labeling of multiple fragments by TID while DAP-Q labels predominantly a similar to 6-kDa fragment within the carboxyl-terminal 60 amino acids of beta(1). Thus, regions within the 7th (or possibly 6th) WD-40 repeat of the beta subunit of G protein interact with the receptor-derived peptide while membrane interaction involves multiple sites throughout the beta subunit.	UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT NUCL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Taylor, Joan/0000-0002-8794-5167; Neubig, Richard/0000-0003-0501-0008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLGM46417] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIGMS NIH HHS [GM39561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FRIELLE T, 1983, BIOCHEMISTRY-US, V22, P5709, DOI 10.1021/bi00294a005; GARCIAHIGUERA I, 1995, J BIOL CHEM, V271, P528; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HETHIER H, 1992, EUR J BIOCHEM, V204, P1169; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MOSIER GGJ, 1995, J ORG CHEM, V60, P6953, DOI 10.1021/jo00126a055; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; Roth J, 1975, Methods Enzymol, V37, P223; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENKER A, 1991, J BIOL CHEM, V266, P802; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SPIEGEL AM, 1994, G PROTEINS, P77; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TAYLOR JM, 1994, PEPTIDES, V15, P829, DOI 10.1016/0196-9781(94)90038-8; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; WADE SM, 1994, MOL PHARMACOL, V45, P1191; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; YI F, 1991, J BIOL CHEM, V266, P3900	49	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3336	3339						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631928				2022-12-27	WOS:A1996TV72400002
J	Tsai, HL; Kou, GH; Chen, SC; Wu, CW; Lin, YS				Tsai, HL; Kou, GH; Chen, SC; Wu, CW; Lin, YS			Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; DNA-BINDING PROTEIN; GENE AMPLIFICATION; CAP SITE; EXPRESSION; SEQUENCE; PROMOTER; PRODUCT; TRANSFORMATION	The IE2 gene of human cytomegalovirus has been implicated in the development of coronary restenosis, and the gene product appears to inhibit p53-dependent transactivation. Here we describe an analysis of the IE2 p53 interaction. Repression of p53 function by IE2 requires two separable domains of IE2. The N terminus of IE2 interacts with p53. IE2 has little effect on the ability of p53 to bind specific DNA sequences. Reduction of the transactivation activity of p53 is caused by a transcriptional repression function contributed by the C-terminal domain of IE2, These findings suggest that IE2 may function as a transcriptional repressor, which is recruited to p53's target genes by interacting with p53.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, DEPT ZOOL, TAIPEI 10764, TAIWAN	Academia Sinica - Taiwan; National Taiwan University								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALBRECHT T, 1993, MOL ASPECTS HUMAN CY; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BECKER Y, 1993, MOL ASPECTS HUMAN CY; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANG D, 1993, J VIROL, V67, P323, DOI 10.1128/JVI.67.1.323-331.1993; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUKAC DM, 1994, J VIROL, V68, P5184, DOI 10.1128/JVI.68.8.5184-5193.1994; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; PIZZORNO MC, 1991, J VIROL, V65, P3839, DOI 10.1128/JVI.65.7.3839-3852.1991; PIZZORNO MC, 1990, J VIROL, V64, P6154, DOI 10.1128/JVI.64.12.6154-6165.1990; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Stenberg R.M., 1993, MOL ASPECTS HUMAN CY, VVolume 2, P330; STJEOR SC, 1977, J GEN VIROL, V37, P65, DOI 10.1099/0022-1317-37-1-65; STJEOR SC, 1974, J VIROL, V13, P353, DOI 10.1128/JVI.13.2.353-362.1974; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATHEN MW, 1982, J VIROL, V41, P462, DOI 10.1128/JVI.41.2.462-477.1982; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	57	100	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3534	3540						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631958				2022-12-27	WOS:A1996TV72400032
J	Damaj, BB; McColl, SR; Mahana, W; Crouch, MF; Naccache, PH				Damaj, BB; McColl, SR; Mahana, W; Crouch, MF; Naccache, PH			Physical association of G(i2)alpha with interleukin-8 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; G-PROTEIN; CHEMOTACTIC CYTOKINES; GENE-EXPRESSION; HIGH-AFFINITY; GRO-ALPHA; FIBROBLASTS; BINDING; CELLS; LEUKOCYTES	Interleukin-8 (IL-8), one of the major mediators of the inflammatory response, belongs to a family of chemokines that includes NAP-2 (neutrophil-activating peptide-2) and Gro-alpha and whose biological activities are directed to a great extent toward neutrophils. Two distinct receptors have been described with overlapping, but not identical, binding affinities for IL-8, NAP-2, and Gro-alpha. This study was designed to examine the intracellular pathways activated upon the occupation of each of the IL-8 receptors (IL-8R). The formation of a physical coupling between IL-8 receptors and the alpha-subunit of heterotrimeric G proteins was tested in neutrophils by examining the presence of the former in anti-G alpha immune precipitates. The addition of IL-8 to a suspension of human neutrophils led to a time-dependent detection of IL-8 in anti-G(i2)alpha (raised against amino acids 159-168 (LERIAQSDYI) of G(i2)alpha) and anti-G(t) alpha (raised against the COOH-terminal 10 amino acids (KENLKDCGLF) of G(t) alpha), but not anti-G(q), immunoprecipitates. Similar results were obtained in human 293 cells stably transfected with IL-8RA or IL-8RB. The peptide derived from the COOH-terminal sequence of G(t) inhibited the co-immunoprecipitation of IL-8R and G(i) observed in response to the anti-G(t) alpha and anti-G(i2)alpha antibodies. On the other hand, the G(i2)alpha peptide only inhibited the immunoprecipitation induced by the anti-G(i2)alpha antibody. Peptides derived from G(i1)alpha or G(i3)alpha had no effect in this assay. The introduction of the anti-G(i2)alpha or anti-(t) alpha antibodies or their neutralizing peptides, but not the G(i1)alpha or G(i3)alpha peptides, into 293 IL-8RA or 293 IL-8RB cells completely blocked the calcium responses obtained upon stimulation with IL-8. These results demonstrate that the occupation of either type of IL-8 receptor leads to a physical coupling to the alpha-subunit of G(i2). In addition, the use of the subunit-specific peptides identified two functionally important but distinct regions of G(i) alpha, one involved in receptor/G(i) alpha interaction (KENLKDCGLF) and the other mediating downstream signal transmission (LERIAQSDYI). Finally, the results of this study also validate the use of the transfected 293 cell line as a model for the study of the signal transduction pathway(s) initiated by IL-8.	CHU LAVAL,CTR RECH RHUMATOL & IMMUNOL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA; NIAID,IMMUNOGENET LAB,NIH,ROCKVILLE,MD 20852; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV NEUROSCI,CANBERRA,ACT 2601,AUSTRALIA	Laval University; Laval University; University of Adelaide; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Australian National University; John Curtin School of Medical Research								BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1993, CLIN INVESTIGATOR, V71, P812; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BIGNOLD LP, 1992, INT ARCH ALLERGY IMM, V97, P350, DOI 10.1159/000236144; CASSATELLA MA, 1993, BIOCHEM BIOPH RES CO, V190, P660, DOI 10.1006/bbrc.1993.1099; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CROUCH MF, 1993, CELL SIGNAL, V5, P41, DOI 10.1016/0898-6568(93)90006-8; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; DJEU JY, 1990, J IMMUNOL, V144, P2205; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; GEISER T, 1993, J BIOL CHEM, V268, P15419; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1993, CANCER INVEST, V11, P743, DOI 10.3109/07357909309046949; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; JESAITIS AJ, 1993, EUR J HAEMATOL, V51, P288; KASLOW HR, 1992, FASEB J, V6, P2684, DOI 10.1096/fasebj.6.9.1612292; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEE J, 1992, J BIOL CHEM, V267, P16283; LHEUREUX G, 1994, BLOOD, V85, P522; LIU JH, 1992, J INFECT DIS, V166, P1089; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MCCOLL SR, 1993, J IMMUNOL, V150, P4550; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; ODAKE H, 1993, EXP MOL PATHOL, V58, P14, DOI 10.1006/exmp.1993.1002; PETERSEN F, 1994, J IMMUNOL, V152, P2467; RATHANASWAMI P, 1993, ARTHRITIS RHEUM, V36, P1295, DOI 10.1002/art.1780360914; ROLLET E, 1994, J IMMUNOL, V153, P353; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; STICHERLING M, 1993, J INVEST DERMATOL, V101, P573, DOI 10.1111/1523-1747.ep12366023; STRIETER RM, 1994, J LAB CLIN MED, V123, P183; STRIETER RM, 1992, AM J PATHOL, V141, P397; TORTI M, 1992, BIOCHEM BIOPH RES CO, V186, P440, DOI 10.1016/S0006-291X(05)80827-7; TSIEN RY, 1982, J CELL BIOL, V94, P3325; UI M, 1984, TRENDS PHARMACOL SCI, V4, P272; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; YE RD, 1993, J IMMUNOL, V150, P1383	43	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12783	12789		10.1074/jbc.271.22.12783	http://dx.doi.org/10.1074/jbc.271.22.12783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662698	hybrid			2022-12-27	WOS:A1996UN47400016
J	Fixman, ED; Fournier, TM; Kamikura, DM; Naujokas, MA; Park, M				Fixman, ED; Fournier, TM; Kamikura, DM; Naujokas, MA; Park, M			Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr-Met oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; PAPILLARY THYROID CARCINOMAS; SCATTER FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; ACTIVATION; ONCOGENE; GENE	The Tpr-Met oncoprotein, which is a member of a family of tyrosine kinase oncoproteins generated following genomic rearrangement, consists of the catalytic kinase domain of the hepatocyte growth factor/scatter factor receptor tyrosine kinase (Met) fused downstream from sequences encoded by the tpr gene. We have previously demonstrated that a single tyrosine residue in the carboxyl terminus, Tyr(489), is highly phosphorylated and is essential for efficient transformation of Fr3T3 fibroblasts by Tpr-Met and for the association of Tpr-Met with the Grb2 adaptor protein and phosphatidylinositol 3'-kinase. We show here that Tyr(489) is also required for association of Tpr-Met with phospholipase C gamma and the tyrosine phosphatase, SHPTP2/Syp. To distinguish which of these substrates are required for cell transformation by the Tpr-Met oncoprotein, we generated a novel Tpr-Met mutant that selectively fails to associate with the Grb2 adaptor protein. Utilizing this mutant, together with additional Tpr-Met mutants containing Tyr to Phe substitutions, we have demonstrated that transformation of Fr3T3 fibroblasts by the Tpr-Met oncoprotein is dependent upon pathways downstream of Shc and Grb2 and that pathways downstream of phosphatidylinositol 3'-kinase, phospholipase G gamma, and SHPTP2/Syp are insufficient for transformation.	MCGILL UNIV, MOLEC ONCOL GRP, ROYAL VICTORIA HOSP, DEPT MED, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MOLEC ONCOL GRP, ROYAL VICTORIA HOSP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MOLEC ONCOL GRP, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FIXMAN ED, 1995, ONCOGENE, V10, P237; FLETTO DL, 1993, HEPATOCYTE GROWTH FA, P108; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HALABAN R, 1992, ONCOGENE, V7, P2195; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	109	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13116	13122		10.1074/jbc.271.22.13116	http://dx.doi.org/10.1074/jbc.271.22.13116			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662733	hybrid			2022-12-27	WOS:A1996UN47400066
J	Logan, HM; Cathala, N; Grignon, C; Davidian, JC				Logan, HM; Cathala, N; Grignon, C; Davidian, JC			Cloning of a cDNA encoded by a member of the Arabidopsis thaliana ATP sulfurylase multigene family - Expression studies in yeast and in relation to plant sulfur nutrition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSIMILATORY SULFATE REDUCTION; SACCHAROMYCES-CEREVISIAE; PISUM-SATIVUM; ACTIVATION; METABOLISM; PROTEIN; GENE; TRANSFORMATION; PURIFICATION; LOCALIZATION	An Arabidopsis thaliana ATP sulfurylase cDNA (ASA1), encoding a putative chloroplastic isoform, has been cloned by functional complementation of a Saccharomyces cerevisiae (met3) ATP sulfurylase mutant which also has a poor sulfate transport capacity. Homologous complementation of the yeast mutant with the ATP sulfurylase gene restores both ATP sulfurylase function and sulfate transport. Heterologous complementation restores only ATP sulfurylase function as demonstrated by low [S-35]sulfate influx measurements and selenate resistance. A structural relationship between ATP sulfurylase and sulfate membrane transporters in yeast is proposed. The sequence of ASA1 is homologous to deduced plant and animal ATP sulfurylase sequences. Analyses indicate a potential tyrosine phosphorylation site which is unique to higher eukaryote sequences, ASA1 is specified by a single copy gene that is part of a multigene family in A. thaliana. At least two ASA1 copies are found in Brassica napus plants. ASA1 transcripts were found in all organs examined, with the highest transcript abundance and ATP sulfurylase activity in leaves or cotyledons. Absence of sulfate from culture media transiently increased B. napus transcript abundance, indicating that initially, the response to sulfate deprivation is transcriptionally regulated.	ECOLE NATL SUPER AGRON MONTIPELLIER,LAB BIOCHIM & PHYSIOL VEGETALES,INST NATL RECH AGRON,CNRS,F-34060 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE; Institut Agro; Montpellier SupAgro			North, Helen/AAD-4964-2020	North, Helen/0000-0002-5749-2603				ALI N, 1994, J BIOL CHEM, V269, P31626; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BELL CI, 1995, J EXP BOT, V46, P73, DOI 10.1093/jxb/46.1.73; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRETON A, 1977, J BACTERIOL, V132, P224, DOI 10.1128/JB.132.1.224-232.1977; BRUNOLD C, 1989, PLANTA, V179, P228, DOI 10.1007/BF00393693; BRUNOLD C, 1987, PHYSIOL PLANTARUM, V70, P168, DOI 10.1111/j.1399-3054.1987.tb06127.x; CHEREST H, 1985, GENE, V34, P269; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHEREST H, 1992, GENETICS, V130, P51; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABEEL M, 1981, P NATL ACAD SCI-BIOL, V78, P5026, DOI 10.1073/pnas.78.8.5026; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVITO PC, 1964, J BACTERIOL, V88, P1341, DOI 10.1128/JB.88.5.1341-1348.1964; DOMONEY C, 1987, PLANTA, V170, P562, DOI 10.1007/BF00402992; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HAWKESFORD MJ, 1993, PLANTA, V190, P297, DOI 10.1007/BF00196957; HERSCHBACH C, 1994, J EXP BOT, V45, P1069, DOI 10.1093/jxb/45.8.1069; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLONUS D, 1994, PLANT J, V6, P105, DOI 10.1046/j.1365-313X.1994.6010105.x; KLONUS D, 1995, PLANT PHYSIOL, V107, P653, DOI 10.1104/pp.107.2.653; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAUE BE, 1994, J BACTERIOL, V176, P3723, DOI 10.1128/JB.176.12.3723-3729.1994; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; MINET M, 1992, PLANT J, V2, P417; MURILLO M, 1995, ARCH BIOCHEM BIOPHYS, V323, P195, DOI 10.1006/abbi.1995.0026; Nagahara U, 1935, JPN J BOT, V7, P389; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; OSSLUND T, 1982, PLANT PHYSIOL, V70, P39, DOI 10.1104/pp.70.1.39; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RASBAND WS, 1995, MICROBEAM ANAL, V4, P137; RENNENBERG H, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P53; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1993, ARCH BIOCHEM BIOPHYS, V307, P272, DOI 10.1006/abbi.1993.1590; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; VONARB C, 1986, PHYSIOL PLANTARUM, V67, P81, DOI 10.1111/j.1399-3054.1986.tb01266.x; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9	58	75	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12227	12233		10.1074/jbc.271.21.12227	http://dx.doi.org/10.1074/jbc.271.21.12227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647819	hybrid, Green Published			2022-12-27	WOS:A1996UL66000021
J	Vallett, SM; Sanchez, HB; Rosenfeld, JM; Osborne, TF				Vallett, SM; Sanchez, HB; Rosenfeld, JM; Osborne, TF			A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR PROMOTER; A REDUCTASE; SEQUENCE; IDENTIFICATION; REPRESSION; REGION	In earlier studies the DNA site required for sterol regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase was shown to be distinct from the classic sterol regulatory element (SRE-1) of the low density lipoprotein receptor gene (Osborne, T. F. (1991) J. Biol. Chem. 266, 13947-13951), However, oxysterol-resistant cells that continuously overproduce one of the sterol regulatory element binding proteins in the nucleus result in high unregulated expression of both genes (Yang, J., Brown, M. S., Ho, Y. K., and Goldstein, J. L. (1995) J. Biol, Chem. 270, 12152-12161) suggesting a direct role for the SREBPs in the activation of the reductase gene, In the present studies we demonstrate that SREBP-1 binds to two adjacent sites within the previously identified sterol regulatory element of the reductase gene even though there is only limited homology with the SRE-1 of the receptor. We also show that SREBP-1 specifically activates the reductase promoter in transient DNA transfection studies in HepG2 cells and that mutations which eliminate sterol regulation and SREBP-1 binding also abolish transient activation by SREBP-1, Although specific, the magnitude of the activation observed is considerably lower than for the low density lipoprotein (LDL) receptor analyzed in parallel, suggesting there is an additional protein required for activation of the reductase promoter that is limiting in the transient assay, SREBP also binds to two additional sites in the reductase promoter which probably play an auxiliary role in expression. When the DNA sequence within the sites are aligned with each other and with the LDL receptor SRE-1, a consensus half-site is revealed 5'-PyCAPy-3'. The LDL receptor element contains two half-sites oriented as a direct repeat spaced by one nucleotide. The SREBP proteins are special members of the basic-helix-loop-helix-zipper (bHLHZip) family of DNA binding proteins since they bind the classic palindromic E-box site as well as the direct repeat SRE-1 element. The SREBP binding sites in both the reductase and those recently identified in other sterol regulated promoters appear to contain a half-site with considerable divergence in the flanking residues, Here we also show that a 22-amino acid domain located immediately adjacent to the basic domain of the bHLHZip region is required for SREBP to efficiently recognize divergent sites in the reductase and 3-hydroxy-3-methylglutaryl-CoA synthase promoters but, interestingly, this domain is not required for efficient binding to the LDL direct repeat SRE-1 or to a palindromic high-affinity E-box element.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRENOWITZ M, 1993, FOOTPRINTING TECHNIQ, P1; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; Maxam A M, 1980, Methods Enzymol, V65, P499; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Sambrook J, 1989, MOL CLONING LABORATO, P545; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SMITH JR, 1990, THESIS U TEXAS DALLA; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yokoyama C., 1993, CELL, V75, P185	30	195	202	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12247	12253		10.1074/jbc.271.21.12247	http://dx.doi.org/10.1074/jbc.271.21.12247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647822	hybrid			2022-12-27	WOS:A1996UL66000024
J	Boisrame, A; Beckerich, JM; Gaillardin, C				Boisrame, A; Beckerich, JM; Gaillardin, C			Sls1p, an endoplasmic reticulum component, is involved in the protein translocation process in the yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ALKALINE EXTRACELLULAR PROTEASE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; ESCHERICHIA-COLI; GENE; SECRETION; POLYPEPTIDES; HOMOLOG; RNA	Signal recognition particle-dependent targeting of secretory proteins to the endoplasmic reticulum membrane is predominant in the yeast Yarrowia lipolytica. A conditional lethal mutant of the SCR2-encoded 7S RNA provided the first in vivo evidence for involvement of this particle in cotranslational translocation (He, F., Beckerich, J. M., and Gaillardin, C. M. (1992) J. Biol. Chem. 267, 1932-1937), In order to identify partners of 7S RNA or signal recognition particle in their function, we selected synthetic lethal mutations with the 7S RNA mutation (sls), The SLS1 gene, cloned by complementation of the sls1 mutant growth defect, encodes a 426-amino acid polypeptide containing a NH2-terminal signal peptide and a COOH-terminal endoplasmic reticulum (ER) retention motif, The SLS1 gene product behaves as a lumenal protein of the ER. Sls1p was sedimented with membrane-rich organelles and was resistant to protease degradation without prior membrane solubilization. Immunofluorescence microscopy showed a typical endoplasmic reticulum perinuclear staining. Co-immunoprecipitation revealed that Sls1p resides close to the major translocation apparatus component, Sec61p. Deletion of the SLS1 gene led to a temperature-sensitive growth phenotype. Synthesis of several secretory proteins was shown to be specifically reduced in Delta sls1 cells, We propose that Sls1p acts in the preprotein translocation process, interacting directly with translocating polypeptides to facilitate their transfer and/or help their folding in the ER.			Boisrame, A (corresponding author), INRA,LAB GENET MOL & CELLULAIRE,INST NATL AGRONOM,CTR GRIGNON,CNRS,F-78850 THIVERVAL GRIGNON,FRANCE.							BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FABRE E, 1992, J BIOL CHEM, V267, P15049; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE F, 1992, J BIOL CHEM, V267, P1932; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; YAVER DS, 1992, J CELL BIOL, V116, P605, DOI 10.1083/jcb.116.3.605	30	37	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11668	11675		10.1074/jbc.271.20.11668	http://dx.doi.org/10.1074/jbc.271.20.11668			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662639	Green Published, hybrid			2022-12-27	WOS:A1996UL25000016
J	Cheng, M; Zhen, E; Robinson, MJ; Ebert, D; Goldsmith, E; Cobb, MH				Cheng, M; Zhen, E; Robinson, MJ; Ebert, D; Goldsmith, E; Cobb, MH			Characterization of a protein kinase that phosphorylates serine 189 of the mitogen-activated protein kinase homolog ERK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTOR; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; IDENTIFICATION; INSULIN; PATHWAY; INVITRO; CELLS	A novel protein kinase activity present in nuclear and cytosolic extracts has been identified and partially purified as a consequence of its tight binding to and phosphorylation of the extracellular signal-regulated protein kinase (ERK) 3. This novel protein kinase is inactivated by treatment with phosphoprotein phosphatase 2A. The ERK3 protein kinase was immunologically distinct from mitogen-activated protein (MAP) kinase/ERK kinases (MEK) 1 and 2 which phosphorylate the ERK3-related MAP kinases ERK1 and ERK2. This ERK3 kinase phosphorylated a single site on ERK3, Ser(189), comparable to Thr(183), one of the two activating phospho rylation sites of ERK2. To test the specificity of the ERK3 kinase, mutants of ERK3 and ERK2 were made in which the phosphorylated residues were exchanged. The double mutant S189T,G191Y ERK3, in which the phosphorylated residues from ERK2 replaced the comparable residues in ERK3, was phosphorylated by the ERK3 kinase but only on threonine. The ERK3 kinase did not phosphorylate ERK2 or ERK2 mutants. These findings indicate that although the ERK3 kinase is highly specific for ERK3, it does not recognize tyrosine, a feature that distinguishes it from MEKs that phosphorylate other ERK/MAP kinase family members.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVIN DE, 1993, J NIH RES, V5, P49; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; SEGER R, 1992, J BIOL CHEM, V267, P14373; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	34	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12057	12062		10.1074/jbc.271.20.12057	http://dx.doi.org/10.1074/jbc.271.20.12057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662649	hybrid			2022-12-27	WOS:A1996UL25000071
J	Fisher, MD; Frost, SC				Fisher, MD; Frost, SC			Translocation of GLUT1 does not account for elevated glucose transport in glucose-deprived 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MURINE FIBROBLASTS; INSULIN; PROTEIN; EXPRESSION; CELLS; DEPRIVATION; STARVATION; HEPG2	Glucose deprivation increases the rate of glucose transport in 3T3-L1 adipocytes in a protein synthesis-dependent fashion. To determine if translocation of either GLUT1 or GLUT4 is responsible for this phenomenon, we adapted existing fractionation procedures toward isolating 3T3-L1 adipocyte membranes. By Western blot analysis of equal protein, GLUT1 was distributed between plasma membranes, high density ''microsomal'' membranes, and low density ''microsomal'' membranes isolated from control cells. GLUT4 comigrated with high density and low density membranes. Glucose deprivation for 12 h did not alter the distribution of either GLUT1 or GLUT4, despite an 8-10-fold increase in glucose transport activity in intact cells, Importantly, increased transport activity was retained in plasma membrane vesicles isolated from glucose-deprived cells. These data show for the first time that the increase in transport activity associated with glucose deprivation does not result from the translocation of either of the glucose transporters known to exist in 3T3-L1 adipocytes. As GLUT4 is excluded from the plasma membrane, these data provide evidence for activation of GLUT1.	UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIDDK NIH HHS [DK 45035] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; JAMES DE, 1993, J CELL SCI, V104, P607; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAYOR P, 1992, DIABETES, V41, P274, DOI 10.2337/diabetes.41.3.274; ORTIZ PA, 1992, BIOCHEMISTRY-US, V31, P5386, DOI 10.1021/bi00138a021; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; YAMADA K, 1983, J BIOL CHEM, V258, P9786; YANG J, 1992, J BIOL CHEM, V267, P10393	19	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11806	11809		10.1074/jbc.271.20.11806	http://dx.doi.org/10.1074/jbc.271.20.11806			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662621	hybrid			2022-12-27	WOS:A1996UL25000037
J	Li, CH; Ramjeesingh, M; Bear, CE				Li, CH; Ramjeesingh, M; Bear, CE			Purified cystic fibrosis transmembrane conductance regulator (CFTR) does not function as an ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; CELL-LINE; RECONSTITUTION; PROTEINS; CAMP	The gene mutated in cystic fibrosis codes for the cystic fibrosis transmembrane conductance regulator (CFTR). Previously, we provided definitive evidence that CFTR functions as a phosphorylation-regulated chloride channel in our planar lipid bilayer studies of the purified, reconstituted protein. Recent patch-clamp studies have lead to the suggestion that CFTR may also be capable of conducting ATP or inducing this function in neighboring channels. In the present study, we assessed the ATP channel activity of purified CFTR and found that the purified protein does not function as an ATP channel in planar bilayer studies of single channel activity nor in ATP flux measurements in proteoliposomes. Hence, CFTR does not possess intrinsic ATP channel activity and its putative role in cellular ATP transport may be indirect.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GARTY H, 1983, J BIOL CHEM, V258, P3094; GOLDBERG AFX, 1991, J MEMBRANE BIOL, V124, P199, DOI 10.1007/BF01994354; Grygorczyk R., 1996, Biophysical Journal, V70, pA71; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2	20	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11623	11626		10.1074/jbc.271.20.11623	http://dx.doi.org/10.1074/jbc.271.20.11623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662751	hybrid			2022-12-27	WOS:A1996UL25000008
J	Loh, C; Shaw, KTY; Carew, J; Viola, JPB; Luo, C; Perrino, BA; Rao, A				Loh, C; Shaw, KTY; Carew, J; Viola, JPB; Luo, C; Perrino, BA; Rao, A			Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; LYMPHOCYTES-T; PHOSPHATASE-ACTIVITY; MESSENGER-RNA; ACTIVATION; PROTEIN; FK506; TARGET; FK-506; COMPLEXES	NFAT1 (previously termed NFATp) is a cytoplasmic transcription factor involved in the induction of cytokine genes. We have previously shown that the dephosphorylation of NFAT1, accompanied by its nuclear translocation and increased DNA binding activity, is regulated by calcium- and calcineurin-dependent mechanisms, as each of these hallmarks of NFAT1 activation is elicited by ionomycin and blocked by the immunosuppressive drugs cyclosporin A and FK506 (Shaw, K. T.-Y., Ho, A. M., Raghavan, A., Kim, J., Jain, J., Park, J., Sharma, S., Rao, A., and Hogan, P. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11205-11209). Here we show that the activation state of NFAT1 in T cells is remarkably sensitive to the level of calcineurin activity. Addition of cyclosporin A, even in the presence of ongoing ionomycin stimulation, results in rephosphorylation of NFAT1, its reappearance in the cytoplasm, and a return of its DNA binding activity to low levels. Similar effects are observed upon removal of ionomycin or addition of EGTA. We also demonstrate a direct interaction between calcineurin and NFAT1 that is consistent with a direct enzyme-substrate relation between these two proteins and that may underlie the sensitivity of NFAT1 activation to the level of calcineurin activity. The NFAT1-calcineurin interaction, which involves an N-terminal region of NFAT1 conserved in other NFAT family proteins, may provide a target for the design of novel immunosuppressive drugs.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOL & CELLULAR BIOL,BOSTON,MA 02115; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oregon Health & Science University			Viola, Joao P.B./AAP-4125-2020	Viola, Joao P.B./0000-0002-0698-3146	NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042471, R37CA042471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P111; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LOH C, 1994, J BIOL CHEM, V269, P8817; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; TOCCI MJ, 1989, J IMMUNOL, V143, P718; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Zhou Songyang, 1995, Nature (London), V373, P536	54	259	268	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10884	10891		10.1074/jbc.271.18.10884	http://dx.doi.org/10.1074/jbc.271.18.10884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631904	hybrid			2022-12-27	WOS:A1996UJ34200072
J	Reilly, TJ; Baron, GS; Nano, FE; Kuhlenschmidt, MS				Reilly, TJ; Baron, GS; Nano, FE; Kuhlenschmidt, MS			Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from Francisella tularensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC PHOSPHOLIPASE-C; PSEUDOMONAS-AERUGINOSA; LEISHMANIA-DONOVANI; HUMAN-NEUTROPHILS; PROTEINS; IDENTIFICATION; HYDROLYSIS; BACTERIA; KINETICS; ENZYME	Acid phosphatases (Acp) of intracellular pathogens have recently been implicated as virulence factors that enhance intracellular survival through suppression of the respiratory burst. We describe here the identification, purification, characterization, and sequencing of a novel burst-inhibiting acid phosphatase from the facultative intracellular bacterium, Francisella tularensis. Similar to other the burst-inhibiting Acps, F. tularensis Acp (AcpA) is tartrate-resistant and has broad substrate specificity. The AcpA enzyme is unique, however, in that it is easily released from the bacterial cell in soluble form, is a basic enzyme, suppresses the respiratory burst of not only fMet-Leu-Phe but also phorbol 12-myristate 13-acetate-stimulated neutrophils and does not fit into any of the three currently recognized classes of acid phosphatase. We also report the complete nucleotide sequence of the gene acpA, encoding AcpA, and the deduced primary structure of its encoded polypeptide. Comparative sequence analyses of AcpA is discussed. To our knowledge, this is the first report describing the cloning and sequencing of a burst-inhibiting acid phosphatase.	UNIV ILLINOIS, COLL VET MED, DEPT PATHOBIOL, URBANA, IL 61801 USA; UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA, BC V8W 3P6, CANADA	University of Illinois System; University of Illinois Urbana-Champaign; University of Victoria				Kuhlenschmidt, Mark/0000-0003-1196-0763				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTHONY LSD, 1991, INFECT IMMUN, V59, P3291, DOI 10.1128/IAI.59.9.3291-3296.1991; BACA OG, 1993, INFECT IMMUN, V61, P4232, DOI 10.1128/IAI.61.10.4232-4239.1993; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLIGAN JE, 1995, CURRENT PROTOCOLS IM, V2; CONLAN JW, 1992, INFECT IMMUN, V60, P5164, DOI 10.1128/IAI.60.12.5164-5171.1992; DAS S, 1986, MOL BIOCHEM PARASIT, V20, P143, DOI 10.1016/0166-6851(86)90026-5; DIPIETRO DL, 1967, J BIOL CHEM, V242, P3391; DOCAMPO R, 1976, EXPERIENTIA, V32, P972, DOI 10.1007/BF01933918; DOWLING JN, 1992, MICROBIOL REV, V56, P32, DOI 10.1128/MMBR.56.1.32-60.1992; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FORSMAN M, 1994, INT J SYST BACTERIOL, V44, P38, DOI 10.1099/00207713-44-1-38; GLEW RH, 1982, COMP BIOCHEM PHYS B, V72, P581, DOI 10.1016/0305-0491(82)90510-7; HOLLIS DG, 1989, J CLIN MICROBIOL, V27, P1601, DOI 10.1128/JCM.27.7.1601-1608.1989; KURIOKA S, 1976, ANAL BIOCHEM, V75, P281, DOI 10.1016/0003-2697(76)90078-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAWRENCE GL, 1981, ARCH BIOCHEM BIOPHYS, V206, P122, DOI 10.1016/0003-9861(81)90073-4; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MDLULI KE, 1994, MICROBIOL-SGM, V140, P3309, DOI 10.1099/13500872-140-12-3309; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NANO FE, 1988, MICROB PATHOGENESIS, V5, P109, DOI 10.1016/0882-4010(88)90013-7; NEWBURGER PE, 1980, BLOOD, V55, P85; OSTROFF RM, 1990, J BACTERIOL, V172, P5915, DOI 10.1128/jb.172.10.5915-5923.1990; OSTROFF RM, 1987, J BACTERIOL, V169, P4597, DOI 10.1128/jb.169.10.4597-4601.1987; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REMALEY AT, 1985, J BIOL CHEM, V260, P880; SAHA AK, 1985, J CLIN MICROBIOL, V22, P329, DOI 10.1128/JCM.22.3.329-332.1985; SAHA AK, 1985, ARCH BIOCHEM BIOPHYS, V243, P150, DOI 10.1016/0003-9861(85)90783-0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHAPIRO SZ, 1992, INFECT IMMUN, V60, P3921, DOI 10.1128/IAI.60.9.3921-3924.1992; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; SUZUKI Y, 1980, J CLIN INVEST, V66, P1409, DOI 10.1172/JCI109994; TAINER J, 1994, NATURE, V370, P506, DOI 10.1038/370506a0; TIAN ZP, 1993, INT J PEPT PROT RES, V42, P155; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6	42	123	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10973	10983		10.1074/jbc.271.18.10973	http://dx.doi.org/10.1074/jbc.271.18.10973			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631917	hybrid			2022-12-27	WOS:A1996UJ34200085
J	Herrmann, C; Horn, G; Spaargaren, M; Wittinghofer, A				Herrmann, C; Horn, G; Spaargaren, M; Wittinghofer, A			Differential interaction of the Ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; RAS-P21 GTPASE; P21(RAS); DOMAIN; ASSOCIATION; INHIBITION; MECHANISM; GENE; P21	The interactions of H-Ras, R-Ras, and Rap1A with the Ras-binding domains (RED) of the c-Raf kinase and of the Ral guanine nucleotide exchange factor (RGF) was studied biochemically in solution, From deletion cloning the RGF-RBD was defined as a 97-amino acid-long fragment from the C-terminal end of the human RGF, which is an independent folding domain with high stability. Interestingly, whereas H-Ras binds with high affinity (K-D = 20 nM) to Raf-RBD and with low affinity (K-D = 1 mu M) to RGF-RBD, Rap1A shows the opposite behavior, The binding of both RBDs to R-Ras is weak and shows no specificity. The interaction between Rap1A and RGF-RBD shows similar characteristics to the Ras-Raf interaction because it is blocked by mutations in the effector region (D38A) and it inhibits the dissociation of guanine nucleotide, which is the basis for the quantitative measurements in this work, Furthermore, the binding of RGF-RBD inhibits the interaction between Rap1A and Rap-GAP. As long as the cellular localizations of the different proteins and their biological functions are not clarified, these biochemical data seem to indicate that Ral-guanine nucleotide exchange factors is an effector molecule of Rap1A rather than of H-Ras.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS	Utrecht University	Herrmann, C (corresponding author), MAX PLANCK INST MOLEK PHYSIOL, RHEINLANDDAMM 201, D-44139 DORTMUND, GERMANY.		Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COX AD, 1994, ONCOGENE, V9, P3281; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HATA Y, 1990, J BIOL CHEM, V265, P7104; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1988, J BIOL CHEM, V263, P11792; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PIZON V, 1994, J CELL SCI, V107, P1661; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RENSLAND H, 1992, POSSIBILITIES LIMITA; REY I, 1994, ONCOGENE, V9, P685; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	57	302	306	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6794	6800		10.1074/jbc.271.12.6794	http://dx.doi.org/10.1074/jbc.271.12.6794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636102				2022-12-27	WOS:A1996UB15700037
J	Lanza, A; Tornaletti, S; Rodolfo, C; Scanavini, MC; Pedrini, AM				Lanza, A; Tornaletti, S; Rodolfo, C; Scanavini, MC; Pedrini, AM			Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID EXCHANGE; XERODERMA PIGMENTOSUM; MICROCOCCUS-LUTEUS; PYRIMIDINE DIMERS; HUMAN FIBROBLASTS; SIMIAN VIRUS-40; REPAIR; CAMPTOTHECIN; BREAKAGE; MECHANISM	DNA topoisomerases have been proposed as the proteins involved in the formation of the DNA-protein cross-links detected after ultraviolet light (UV) irradiation of cellular DNA. This possibility has been investigated by studying the effects of UV-induced DNA damage on human DNA topoisomerase I action, UV lesions impaired the enzyme's ability to relax negatively supercoiled DNA. Decreased relaxation activity correlated with the stimulation of cleavable complexes, Accumulation of cleavable complexes resulted from blockage of the rejoining step of the cleavage-religation reaction, Mapping of cleavage sites on the pAT153 genome indicated UV-induced cleavage at discrete positions corresponding to sites stimulated also by the topoisomerase I inhibitor camptothecin, except for one, Subsequent analysis at nucleotide level within the sequence encompassing the UV-specific cleavage site revealed the precise positions of sites stimulated by camptothecin with respect to those specific for UV irradiation, Interestingly, one of the UV-stimulated cleavage sites was formed within a sequence that did not contain dimerized pyrimidines, suggesting transmission of the distortion, caused by photodamage to DNA, into the neighboring sequences, These results support the proposal that DNA structural alterations induced by UV lesions can be sufficient stimulus to induce cross-linking of topoisomerase I to cellular DNA.	CNR,IST GENET BIOCHIM & EVOLUZIONIST,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR)			Rodolfo, Carlo/H-8953-2019; Lanza, Annalisa/AAJ-3298-2020	Rodolfo, Carlo/0000-0001-7087-545X; Lanza, Annalisa/0000-0003-1422-6994	Telethon [E.0197] Funding Source: Medline	Telethon(Fondazione Telethon)		Andersen A H, 1994, Adv Pharmacol, V29A, P83; ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BRASH DE, 1988, DNA REPAIR LABORATOR, P327; CAMILLONI G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P73, DOI 10.1016/0167-4781(91)90214-7; CAMILLONI G, 1989, P NATL ACAD SCI USA, V86, P3080, DOI 10.1073/pnas.86.9.3080; CASERTA M, 1994, J CELL BIOCHEM, V55, P93, DOI 10.1002/jcb.240550111; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P3800, DOI 10.1073/pnas.74.9.3800; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; CLEAVER JE, 1981, EXP CELL RES, V136, P27, DOI 10.1016/0014-4827(81)90034-3; CLEAVER JE, 1983, J MOL BIOL, V170, P305, DOI 10.1016/S0022-2836(83)80150-8; CODERONI S, 1993, MOL BIOL REP, V17, P129, DOI 10.1007/BF00996220; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; DEGRASSI F, 1989, MUTAT RES, V211, P125, DOI 10.1016/0027-5107(89)90112-7; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DOWNES CS, 1988, BIOESSAYS, V8, P179, DOI 10.1002/bies.950080602; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FORNACE AJ, 1976, BIOCHIM BIOPHYS ACTA, V435, P95, DOI 10.1016/0005-2787(76)90196-9; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HOLDEN HE, 1989, ENVIRON MOL MUTAGEN, V13, P238, DOI 10.1002/em.2850130308; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ikeda H, 1994, Adv Pharmacol, V29A, P147; ISHII K, 1983, J BIOL CHEM, V258, P2728; KAUFMANN WK, 1989, CARCINOGENESIS, V10, P1, DOI 10.1093/carcin/10.1.1; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; PEDRINI AM, 1983, P NATL ACAD SCI-BIOL, V80, P1787, DOI 10.1073/pnas.80.7.1787; PEDRINI AM, 1984, PROTEINS INVOLVED DN, P449; PEDRINI AM, 1986, MECHANISMS DNA DAMAG, P295; PERINI R, 1993, J MOL BIOL, V231, P634, DOI 10.1006/jmbi.1993.1315; Pommier Y, 1994, Adv Pharmacol, V29B, P73; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RODOLFO C, 1994, NUCLEIC ACIDS RES, V22, P314, DOI 10.1093/nar/22.3.314; ROSENSTEIN BS, 1991, PHOTOBIOLOGY, P27; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; YEH YC, 1994, J BIOL CHEM, V269, P15498	50	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6978	6986		10.1074/jbc.271.12.6978	http://dx.doi.org/10.1074/jbc.271.12.6978			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636127	hybrid			2022-12-27	WOS:A1996UB15700062
J	Moggs, JG; Yarema, KJ; Essigmann, JM; Wood, RD				Moggs, JG; Yarema, KJ; Essigmann, JM; Wood, RD			Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; NUCLEASE; BINDING; CIS-DIAMMINEDICHLOROPLATINUM(II)	Nucleotide excision repair by mammalian enzymes removes DNA damage as part of similar to 30-mer oligonucleotides by incising phosphodiester bonds on either side of a lesion, We analyzed this dual incision reaction at a single 1,3-intrastrand d(GpTpG)-cisplatin cross-link in a closed circular duplex DNA substrate. Incisions were formed in the DNA with human cell extracts in which DNA repair synthesis was inhibited. The nicks were mapped by restriction fragment end labeling and primer extension analysis. Principal sites of cleavage were identified at the 9th phosphodiester bond 3' to the lesion and at the 16th phosphodiester bond 5' to the lesion. The predominant product was found to be a 26-mer platinated oligonucleotide by hybridization to a P-32-labeled complementary DNA probe. Oligonucleotides were formed at the same rate as the 3' cleavage, suggesting that both incisions are made in a near-synchronous manner. There was, however, a low frequency of 5' incisions in the absence of 3' cleavage. The dual incision reaction was reconstituted using the purified mammalian proteins XPA, RPA, XPC, TFIIH, XPG, and a fraction containing ERCC1-XPF and IF7. All of these components were required in order to observe any cleavage.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	Massachusetts Institute of Technology (MIT)			Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892	NCI NIH HHS [CA52127] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA052127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARONE F, 1995, PHOTOCHEM PHOTOBIOL, V61, P61, DOI 10.1111/j.1751-1097.1995.tb09243.x; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; CALSOU P, 1994, NUCLEIC ACIDS RES, V22, P4937, DOI 10.1093/nar/22.23.4937; CALVERT H, 1993, PHARMACOKINETICS CAN, V17, P189; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Oliver Timothy, 1993, Current Opinion in Oncology, V5, P559, DOI 10.1097/00001622-199305000-00018; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; Patel D. J., 1992, CURR OPIN STRUC BIOL, V2, P345; RAMPINO NJ, 1994, P NATL ACAD SCI USA, V91, P10977, DOI 10.1073/pnas.91.23.10977; SAMBROOK J, 1989, MOL CLONING LABORATO, P421; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; ZOU Y, 1994, BIOCHEMISTRY-US, V33, P5404, DOI 10.1021/bi00184a007	47	175	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7177	7186		10.1074/jbc.271.12.7177	http://dx.doi.org/10.1074/jbc.271.12.7177			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636155	hybrid			2022-12-27	WOS:A1996UB15700090
J	Powell, W; Reines, D				Powell, W; Reines, D			Mutations in the second largest subunit of RNA polymerase II cause 6-azauracil sensitivity in yeast and increased transcriptional arrest in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; TERMINATION SITES; SACCHAROMYCES-CEREVISIAE; INVITRO TRANSCRIPTION; CALF THYMUS; COMPLEXES; DNA; PURIFICATION; INITIATION; INHIBITION	Yeast RNA polymerase II enzymes containing single amino acid substitutions in the second largest subunit were analyzed in vitro for elongation-related defects. Mutants were chosen for analysis based on their ability to render yeast cells sensitive to growth on medium containing 6-azauracil. RNA polymerase II purified from three different 6-azauracil-sensitive yeast strains displayed increased arrest at well characterized arrest sites in vitro. The extent of this defect did not correlate with sensitivity to growth in the presence of 6-azauracil. The most severe effect resulted from mutation rpb2-10 (P1018S), which occurs in region H, a domain highly conserved between prokaryotic and eukaryotic RNA polymerases that is associated with nucleotide binding. The average elongation rate of this mutant enzyme is also slower than wild type. We suggest that the slowed elongation rate and an increase in dwell time of elongating pol II leads to rpbB-10's arrest-prone phenotype. This mutant enzyme can respond to SII for transcriptional read-through and carry out SII-activated nascent RNA cleavage.	EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Powell, Wade H./0000-0002-3727-2822	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1996, IN PRESS METHODS ENZ; COULTER DE, 1985, J BIOL CHEM, V260, P3190; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FLORES O, 1989, J BIOL CHEM, V264, P8913; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; IWABE N, 1991, J MOL EVOL, V32, P700; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JIN DJ, 1991, J BIOL CHEM, V266, P14478; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NUDLER E, 1995, JCELL, V81, P351; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; RUET A, 1978, EUR J BIOCHEM, V90, P325, DOI 10.1111/j.1432-1033.1978.tb12608.x; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCAFE C, 1990, MOL CELL BIOL, V10, P1271; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889; SHAABAN SA, 1995, MOL CELL BIOL, V15, P1467; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782	55	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6866	6873		10.1074/jbc.271.12.6866	http://dx.doi.org/10.1074/jbc.271.12.6866			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636112	Green Accepted, hybrid			2022-12-27	WOS:A1996UB15700047
J	Yan, K; Kalyanaraman, V; Gautam, N				Yan, K; Kalyanaraman, V; Gautam, N			Differential ability to form the G protein beta gamma complex among members of the beta and gamma subunit families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; 3RD FORM; CDNA; IDENTIFICATION; TRANSDUCIN; DIVERSITY; SEQUENCE; BINDING; HOMOLOGY	We have determined the relative abilities of several members of the G protein beta and gamma subunit families to associate with each other using the yeast two-hybrid system. We show first that the mammalian beta 1 and gamma 3 fusion proteins form a complex in yeast and that formation of the complex activates the reporter gene for beta-galactosidase. Second, the magnitude of reporter activity stimulated by various combinations of beta and gamma subunit types varies widely. Third, the reporter activity evoked by a particular combination of beta and gamma subunit types is not correlated with the expression levels of these sub-unit types in the yeast cells. Finally, the reporter activity shows a direct relationship with the amount of hybrid py complex formed in the cell as determined by immunoprecipitation, These results suggest that different beta and gamma subunit types interact with each other with widely varying abilities, and this in combination with the level of expression of a subunit type in a mammalian cell determines which G protein will be active in that cell. The strong preference of all gamma subunit types for the beta 1 subunit type explains the preponderence of this subunit type in most G proteins.	WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)								BECKER DM, 1991, METHOD ENZYMOL, V194, P182; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CLARK KL, 1993, MOL CELL BIOL, V13, P1; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARPER JW, 1993, CELL, V75, P805; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PRINTEN JA, 1994, GENETICS, V138, P609; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	44	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7141	7146		10.1074/jbc.271.12.7141	http://dx.doi.org/10.1074/jbc.271.12.7141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636150				2022-12-27	WOS:A1996UB15700085
J	Choi, JY; Stukey, J; Hwang, SY; Martin, CE				Choi, JY; Stukey, J; Hwang, SY; Martin, CE			Regulatory elements that control transcription activation and unsaturated fatty acid-mediated repression of the Saccharomyces cerevisiae OLE1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; YEAST; DISRUPTION; TRANSFORMATION; DESATURASE; EXPRESSION; DEFICIENT; CLONING; CELLS; RNA	In Saccharomyces cerevisiae, unsaturated fatty acids are formed from saturated acyl-CoA precursors by Ole1p, a Delta-9 fatty acid desaturase, OLE1 mRNA levels are differentially regulated by the addition of saturated or unsaturated fatty acids to the growth medium, One component of this regulation system involves the control of OLE1 transcription, Saturated fatty acids induce a 1.6-fold increase in transcription activity, whereas a large family of unsaturated fatty acids repress OLE1 transcription as much as 60-fold, A deletion analysis of OLE1 promoter::lacZ fusion reporter genes identified a 111-base pair (bp) fatty acid-regulated (FAR) region approximately 580 bp upstream of the start codon that is essential for transcription activation and unsaturated fatty acid repression, Deletion of an 88-bp sequence within that region resulted in a complete loss in transcription activation and unsaturated fatty acid regulation, The 111-bp FAR element strongly activates transcription and confers unsaturated fatty acid regulation on a heterologous CYC1 promoter test plasmid, Essential elements required for unsaturated fatty acid repression of OLE1 were found in the 5' and 3' region of the 111-bp sequence, The FAR element-mediated activation and fatty acid repression of transcription was found to be closely tied to fatty acyl-CoA metabolism, Two fatty acid activation genes, FAA1 and FAA4, were found to be essential for unsaturated fatty acid repression of OLE1 through the FAR sequences, Disruption of either gene results in reduced levels of unsaturated fatty acid repression; disruption of both genes completely blocks the regulatory response, Acyl-CoA binding protein (ACBP) plays a role in determining the level of FAR element activated transcription, Disruption of the ACBP gene causes a >5-fold activation of OLE1 transcription and a similar increase in OLE1 mRNA levels. Unsaturated fatty acid repression of OLE1 transcription, however, is not affected by the disrupted ACBP gene. These studies show that promoter elements responsible for unsaturated fatty acid-mediated transcription repression are tightly linked to OLE1 activation sequences and that OLE1 transcription levels are closely tied to acyl-CoA metabolism.	RUTGERS STATE UNIV, DEPT BIOL SCI, BUR BIOL RES, NELSON BIOL LAB, PISCATAWAY, NJ 08855 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHINGTON BA, 1991, GENE, V102, P39, DOI 10.1016/0378-1119(91)90535-J; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Guarante L., 1992, MOL CELLULAR BIOL YE, P49; Hablacher M, 1993, J BIOL CHEM, V268, P10946; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1976, P NATL ACAD SCI USA, V73, P386, DOI 10.1073/pnas.73.2.386; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Maniatis T, 1989, MOL CLONING; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Miller J. H, 1972, EXPT MOL GENETICS; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Numa S, 1984, FATTY ACID METABOLIS, P1; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SCHULLER HJ, 1994, EUR J BIOCHEM, V225, P213, DOI 10.1111/j.1432-1033.1994.00213.x; SMITH SJ, 1993, YEAST, V9, P1177, DOI 10.1002/yea.320091104; STRUHL K, 1986, BIOTECHNOLOGY, V9, P35; TURI TG, 1992, J BIOL CHEM, V267, P2046	30	123	133	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3581	3589						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631965				2022-12-27	WOS:A1996TV72400039
J	Cotto, JJ; Kline, M; Morimoto, RI				Cotto, JJ; Kline, M; Morimoto, RI			Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation - Evidence for a multistep pathway of regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; MOLECULAR-CLONING; COILED-COIL; HELA-CELLS; YEAST; OLIGOMERIZATION; EXPRESSION; PROMOTER; PROTEIN	Exposure of mammalian cells in culture to the antiinflammatory drugs sodium salicylate or indomethacin results in activation of heat shock factor 1 (HSF1) DNA binding activity. We have previously shown that the drug-induced HSF1 becomes associated with the heat shock elements of the hsp70 promoter, yet transcription of the hsp70 gene is not induced (Jurivich, D. A., Sistonen, L., Kroes, R. A., and Morimoto, R. I. (1992) Science 255, 1243-1245). In this study, we have examined the basis for uncoupling the heat shock transcriptional response. Comparison of heat shock and drug-induced forms of HSF1 has revealed that the transcriptionally inert drug-induced HSF1 is constitutively but not inducibly serine-phosphorylated, whereas heat shock-induced HSF1 is both constitutively and inducibly serine-phosphorylated. The transcriptionally inert intermediate represented by drug-induced HSF1 can be converted to the transcriptionally active state by a subsequent exposure to heat shock. The only detectable change in HSF1 is the acquisition of inducible serine phosphorylation. These data reveal that acquisition of the trimeric DNA binding state of HSF1 is independent of and precedes inducible phosphorylation and furthermore that inducible phosphorylation correlates with transcriptional activation.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038109, R01GM038109] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38109] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; AMICI C, 1995, CANCER RES, V55, P4452; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GIARDINA C, 1995, J BIOL CHEM, V270, P10369, DOI 10.1074/jbc.270.18.10369; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; GREEN M, 1995, MOL CELL BIOL, V15, P3354; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HOJ A, 1994, EMBO J, V13, P2617; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KROPP E, 1994, SCIENCE, V265, P956; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORIMOTO R I, 1990, P1; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	49	245	251	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3355	3358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631933				2022-12-27	WOS:A1996TV72400007
J	Toma, L; Pinhal, MAS; Dietrich, CP; Nader, HB; Hirschberg, CB				Toma, L; Pinhal, MAS; Dietrich, CP; Nader, HB; Hirschberg, CB			Transport of UDP-galactose into the Golgi lumen regulates the biosynthesis of proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MUTANT DEFICIENT; HEPARAN-SULFATE; CHONDROITIN SULFATE; ENDOPLASMIC-RETICULUM; BASEMENT-MEMBRANE; KERATAN SULFATES; PURIFICATION; APPARATUS; OLIGOSACCHARIDES; RECONSTITUTION	The lumen of the Golgi apparatus is the subcellular site where galactose is transferred, from UDP-galactose, to the oligosaccharide chains of glycoproteins, glycolipids, and proteoglycans. The nucleotide sugar, which is synthesized in the cytosol, must first be transported into the Golgi lumen by a specific UDP-galactose transporter, Previously, a mutant polarized epithelial cell (MDCKII-RCA(r)) with a 2% residual rate of transport of UDP-galactose into the lumen of Golgi vesicles was described (Brandli, A. W., Hansson, G. C., Rodriquez-Boulan, E., and Simons, K. (1988) J. Biol. Chem. 263, 16283-16290). The mutant has an enrichment in glucosyl ceramide and cell surface glycoconjugates bearing terminal N-acetylglucosamine, as well as a 75% reduction in sialylation of cell surface glycoproteins and glycosphingolipids. We have now studied the biosynthesis of galactose containing proteoglycans in this mutant and the corresponding parental cell line. Wild-type Madin-Darby canine kidney cells synthesize significant amounts of chondroitin sulfate, heparan sulfate, and keratan sulfate, while the above mutant synthesizes chondroitin sulfate and heparan sulfate but not keratan sulfate, the only proteoglycan containing galactose in its glycosaminoglycan polymer, The mutant also synthesizes chondroitin 6-sulfate rather than only chondroitin 4-sulfate as wild-type cells. Together, the above results demonstrate that the Golgi membrane UDP-galactose transporter is rate-limiting in the supply of UDP-galactose into the Golgi lumen; this in turn results in selective galactosylation of macromolecules. Apparently, the K-m for galactosyltransferases involved in the synthesis of Linkage regions of heparan sulfate and chondroitin sulfate are significantly lower than those participating in the synthesis of keratan sulfate polymer, glycoproteins, and glycolipids. The results also suggest that the 6-O-sulfotransferases, in the absence of their natural substrates (keratan sulfate) may catalyze the sulfation of chondroitin 4-sulfate as alternative substrate.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655; UNIFESP,ESCOLA PAULISTA MED,SAO PAULO,BRAZIL	University of Massachusetts System; University of Massachusetts Worcester; Universidade Federal de Sao Paulo (UNIFESP)			Nader, Helena Bonciani/D-9253-2012; Pinhal, Maria Aparecida Silva/J-1797-2012	Pinhal, Maria Aparecida Silva/0000-0003-4001-1663; NADER, HELENA/0000-0002-7569-2166; Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 34396] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BRILES EB, 1981, BIOCHEM BIOPH RES CO, V103, P38, DOI 10.1016/0006-291X(81)91657-0; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DIETRICH CP, 1977, BIOCHEM BIOPH RES CO, V75, P329, DOI 10.1016/0006-291X(77)91046-4; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; GOWDA DC, 1986, J BIOL CHEM, V261, P4926; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HORTON DSPQ, 1986, EUR J BIOCHEM, V161, P139, DOI 10.1111/j.1432-1033.1986.tb10134.x; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KLEINMAN HK, 1983, BIOCHEMISTRY-US, V22, P4969, DOI 10.1021/bi00290a014; KRAMER PM, 1971, BIOCHEMISTRY-US, V10, P1437; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MCGARRITY GJ, 1982, EXP CELL RES, V139, P199, DOI 10.1016/0014-4827(82)90333-0; MEYER K, 1970, CHEM MOL BIOL INTERC, V1, P15; MICHELACCI YM, 1986, INT J BIOL MACROMOL, V8, P108, DOI 10.1016/0141-8130(86)90008-5; MILLA ME, 1992, J BIOL CHEM, V267, P103; NADER HB, 1984, J BIOL CHEM, V259, P1431; NADER HB, 1990, J BIOL CHEM, V265, P16807; NADER HB, 1989, J CELL PHYSIOL, V140, P305, DOI 10.1002/jcp.1041400216; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OBRINK B, 1975, CONNECT TISSUE RES, V3, P187, DOI 10.3109/03008207509152178; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; SENO N, 1965, J BIOL CHEM, V240, P1005; STNALEY P, 1980, ACS SYM SER, V28, P214; TAI GH, 1993, BIOCHEM J, V291, P889, DOI 10.1042/bj2910889; TODA N, 1970, BIOCHIM BIOPHYS ACTA, V208, P227, DOI 10.1016/0304-4165(70)90241-2	31	80	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3897	3901						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632010				2022-12-27	WOS:A1996TV72400084
J	Feng, GS; Ouyang, YB; Hu, DP; Shi, ZQ; Gentz, R; Ni, JA				Feng, GS; Ouyang, YB; Hu, DP; Shi, ZQ; Gentz, R; Ni, JA			Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; SIGNALING GENE SEM-5; SH3 DOMAINS; GRB2; SOS; TRANSDUCTION; ACTIVATION; RECEPTOR; ASSOCIATION	A human cytoplasmic signaling protein has been cloned that possesses the same structural arrangement of SH3-SH2-SH3 domains as Grb2, This protein is designated Grap for Grb2-related adaptor protein, The single 2.3-kilobase (kb) grap transcript was expressed predominantly in thymus and spleen, while the ubiquitously expressed grb2 gene produced two mRNA species of 3.8 and 1.5 kb, Grap and Grb2 consist of 217 amino acids and share 59% amino acid sequence identity, with highest homology in the N-terminal SH3 domain. The GrapSH2 domain interacts with ligand-activated receptors for stem cell factor (c-kit) and erythropoietin (EpoR). Grap also forms a stable complex with the Bcr-Abl oncoprotein via its SH2 domain in K562 cells, Furthermore, Grap is associated with a Ras guanine nucleotide exchange factor mSos1, primarily through its N-terminal SH3 domain, These results show that a family of Grb2-like proteins exist and couple signals from receptor and cytoplasmic tyrosine kinases to the Ras signaling pathway.	HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Feng, GS (corresponding author), INDIANA UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOL, WALTHER ONCOL CTR,975 W WALNUT ST, RM 501, INDIANAPOLIS, IN 46202 USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	108	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12129	12132		10.1074/jbc.271.21.12129	http://dx.doi.org/10.1074/jbc.271.21.12129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647802	hybrid			2022-12-27	WOS:A1996UL66000004
J	Kozasa, T; Gilman, AG				Kozasa, T; Gilman, AG			Protein kinase C phosphorylates G(12 alpha) and inhibits its interaction with G(beta gamma)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY COMPONENT; ADENYLATE-CYCLASE; BINDING; G-ALPHA-12; ALPHA; SITE; SPECIFICITY; SUBUNITS; CELLS; GI2	Of nine G protein alpha subunits examined, only alpha(12) and alpha(z) served as substrates for phosphorylation by various iso forms of protein kinase C in vitro. A close homolog of alpha(12), alpha(13), was not phosphorylated. Exposure of NIH 3T3 cells that stably express alpha(12) to phorbol 12-myristate 13-acetate also resulted in phosphorylation of the protein. Phosphorylation in vitro occurred near the amino terminus (probably Ser(38)), and approximately 1 mol of phosphate was incorporated per mol of alpha(12). Although G protein heterotrimers containing either alpha(12) or alpha(z) were poor substrates for phosphorylation, the isolated a subunits were phosphorylated equally well in their GDP- or GTP gamma S bound forms. The guanine nucleotide binding properties of purified alpha(12) and alpha(z) were unaltered by phosphorylation, as was the capacity of alpha(z) to inhibit type V adenylyl cyclase. However, phosphorylation of either protein greatly reduced its affinity for G protein beta gamma subunits, consistent with the newly determined crystal structure of a G protein heterotrimer. We suggest that protein kinase C regulates alpha(12)- and alpha(z)-mediated signaling pathways by preventing their association with beta gamma.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FUJISE A, 1994, J BIOL CHEM, V269, P31642; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	34	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12562	12567		10.1074/jbc.271.21.12562	http://dx.doi.org/10.1074/jbc.271.21.12562			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647866	hybrid			2022-12-27	WOS:A1996UL66000068
J	Missiaen, L; DeSmedt, H; Parys, JB; Sienaert, I; Vanlingen, S; Casteels, R				Missiaen, L; DeSmedt, H; Parys, JB; Sienaert, I; Vanlingen, S; Casteels, R			Threshold for inositol 1,4,5-trisphosphate action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LUMINAL CA2+ INCREASES; CALCIUM RELEASE; CYTOSOLIC CA2+; RECEPTOR; HEPATOCYTES; TRISPHOSPHATE; AFFINITY; STORES; SENSITIVITY	We developed a unidirectional Ca-45(2+) efflux technique in which 60 cumulative doses of inositol 1,4,5-trisphosphate (InsP(3)), each lasting 6 s, were subsequently added to permeabilized A7r5 cells. This technique allowed an accurate determination of the threshold for InsP(3) action, which was around 32 nM InsP(3) under control conditions. The InsP(3)-induced Ca2+ release was characterized by an initial rapid phase, after which the normalized rate progressively decreased. The slowing of the release was associated with a shift of the threshold to higher InsP(3) concentrations. Stimulatory concentrations of thimerosal (10 mu M) shifted the threshold to 4.5 nM InsP(3) and increased both the cooperativity and the max imal normalized rate of Ca2+ release. This low threshold was maintained when the thimerosal concentration was increased to inhibitory levels (100 mu M) but then the effects on the cooperativity and on the normalized rate of Ca2+ release disappeared. Oxidized glutathione (5 mM) was much less effective in stimulating the release and did not have an effect on the threshold or on the cooperativity. ATP (5 mM) stimulated the release despite a shift in threshold toward higher InsP(3) concentrations. Luminal Ca2+ did not affect the threshold for InsP(3) action but stimulated the normalized release at each InsP(3) concentration. The inhibitory effect of 10 mu M free cytosolic Ca2+ was associated with a shift in threshold to higher InsP(3) concentrations and a decreased cooperativity of the release process. We conclude that this novel technique of accurately measuring the threshold for InsP(3) action under various experimental conditions has allowed us to refine the analysis of the kinetic parameters involved in the regulation of the InsP(3) receptor.			Missiaen, L (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GAMBERUCCI A, 1995, CELL CALCIUM, V17, P431, DOI 10.1016/0143-4160(95)90089-6; GUILLEMETTE G, 1987, P NATL ACAD SCI USA, V84, P8195, DOI 10.1073/pnas.84.23.8195; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HILLY M, 1993, J BIOL CHEM, V268, P16488; HIROSE K, 1994, NATURE, V372, P791; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1995, J BIOL CHEM, V270, P3588, DOI 10.1074/jbc.270.8.3588; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; LIPINSKY D, 1993, PFLUG ARCH EUR J PHY, V425, P140, DOI 10.1007/BF00374514; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEZNA M, 1995, NATURE, V376, P300, DOI 10.1038/376300a0; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1994, BIOCHEM J, V300, P81, DOI 10.1042/bj3000081; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARYS JB, 1995, BIOCHEM BIOPH RES CO, V209, P451, DOI 10.1006/bbrc.1995.1523; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PARYS JB, 1993, J BIOL CHEM, V268, P25206; Patel S, 1995, BIOCHEM J, V312, P789, DOI 10.1042/bj3120789; POITRAS M, 1993, J BIOL CHEM, V268, P24078; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; Schrenzel J, 1995, BIOPHYS J, V69, P2378, DOI 10.1016/S0006-3495(95)80107-4; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC813, DOI 10.1152/ajpcell.1995.269.3.C813; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149	48	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12287	12293		10.1074/jbc.271.21.12287	http://dx.doi.org/10.1074/jbc.271.21.12287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647828	hybrid			2022-12-27	WOS:A1996UL66000030
J	Huber, A; Sander, P; Paulsen, R				Huber, A; Sander, P; Paulsen, R			Phosphorylation of the InaD gene product, a photoreceptor membrane protein required for recovery of visual excitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; DROSOPHILA PHOTORECEPTORS; EXTRACELLULAR CALCIUM; LIGHT ADAPTATION; GATED CHANNEL; PHOTOTRANSDUCTION; RHODOPSIN; ARRESTIN; OPSIN; MELANOGASTER	In an approach directed to isolate and characterize key proteins of the transduction cascade in photoreceptors using the phosphoinositide signaling pathway, we have isolated the Calliphora homolog of the Drosophila InaD gene product, which in Drosophila InaD mutants causes slow deactivation of the light response. By screening a retinal cDNA library with antibodies directed against photoreceptor membrane proteins, we have isolated a cDNA coding for an amino acid sequence of 665 residues (M(r) = 73,349). The sequence displays 65.3% identity (77.3% similarity) with the Drosophila InaD gene product. Probing Western blots with monospecific antibodies directed against peptides comprising amino acids 272-542 (anti-InaD-(272-542)) or amino acids 643-655 (anti-InaD-(643-655)) of the InaD gene product revealed that the Calliphora InaD protein is specifically associated with the signal-transducing rhabdomeral photoreceptor membrane from which it can be extracted by high salt buffer containing 1.5 M NaCl. As five out of eight consensus sequences for protein kinase C phosphorylation reside within stretches of 10-16 amino acids that are identical in the Drosophila and Calliphora InaD protein, the InaD gene product is likely to be a target of protein kinase C, Phosphorylation studies with isolated rhabdomeral photoreceptor membranes followed by InaD immunoprecipitation revealed that the InaD protein is a phosphoprotein. In vitro phosphorylation is, at least to some extent, Ca2+-dependent and activated by phorbol 12-myristate 13-acetate, The inaC-encoded eye-specific form of a protein kinase C (eye-PKC) is co-precipitated by antibodies specific for the InaD protein from detergent extracts of rhabdomeral photoreceptor membranes, suggesting that the InaD protein and eye-PKC are interacting in these membranes. Co-precipitating with the InaD protein and eye-PKC are two other key components of the transduction pathway, namely the trp protein, which is proposed to form a Ca2+ channel, and the norpA-encoded phospholipase C, the primary target enzyme of the transduction pathway, It is proposed that the rise of the intracellular Ca2+ concentration upon visual excitation initiates the phosphorylation of the InaD protein by eye-PKC and thereby modulates its function in the control of the light response.			Huber, A (corresponding author), UNIV KARLSRUHE, INST ZOOL 1, KAISERSTR 12, POSTFACH 6980, D-76128 KARLSRUHE, GERMANY.		Huber, Armin/GYU-6322-2022	Huber, Armin/0000-0003-3977-089X				BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harlow E., 1988, ANTIBODIES LAB MANUA; HUBER A, 1990, J BIOL CHEM, V265, P17906; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KOMORI N, 1994, INSECT BIOCHEM MOLEC, V24, P607, DOI 10.1016/0965-1748(94)90097-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MATSUMOTO H, 1982, SCIENCE, V217, P839, DOI 10.1126/science.7100927; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; MATSUMOTO H, 1984, SCIENCE, V223, P184, DOI 10.1126/science.6419348; MCKAY RR, 1994, J NEUROGENET, V9, P177, DOI 10.3109/01677069409167278; MOJET MH, 1993, J COMP PHYSIOL A, V173, P335, DOI 10.1007/BF00212698; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; PAULSEN R, 1984, J COMP PHYSIOL, V155, P39, DOI 10.1007/BF00610929; PERETZ A, 1994, J GEN PHYSIOL, V104, P1057, DOI 10.1085/jgp.104.6.1057; PICHER J, 1992, BIOCHEMISTRY-US, V31, P3193; PLANGGER A, 1994, J BIOL CHEM, V269, P26969; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; Sambrook J., 1989, MOL COLONING LAB MAN, V2nd; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDLER C, 1991, J COMP PHYSIOL A, V169, P299; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	47	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11710	11717		10.1074/jbc.271.20.11710	http://dx.doi.org/10.1074/jbc.271.20.11710			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662634	hybrid			2022-12-27	WOS:A1996UL25000022
J	Tremethick, DJ; Hyman, L				Tremethick, DJ; Hyman, L			High mobility group proteins 14 and 17 can prevent the close packing of nucleosomes by increasing the strength of protein contacts in the linker DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; CHROMATIN STRUCTURE; CORE PARTICLE; INVITRO; BINDING; TRANSCRIPTION; DOMAIN	High mobility group (HMG) proteins 14 and 17 are abundant chromatin-associated proteins found in all higher eukaryotic nuclei. This observation demonstrates that HMGs 14 and 17 must have an important and universal function with regard to the structure and function of chromatin. What this function is, including how they interact with a nucleosomal array in vivo, is not known. Recently, we have demonstrated that HMGs 14 and 17 can organize nucleosomes into a regular array and increase the repeat length from 145 to about 160-165 base pairs in vitro. In addition, they can increase the apparent repeat length of chromatin deficient in histones H2A/H2B from 125 to approximately 145 base pairs. Importantly, this template was transcriptionally active. In this study, we report five new observations that begin to address the mechanism by which HMGs 14 and 17 space nucleosomal particles. First, we demonstrate that both human placenta HMG 14 and HMG 17 can space nucleosomes to produce a chromatin template with a repeat length around 160 base pairs. This result further highlights the similarity between these proteins in terms of protein structure and perhaps function. Second, we show that digestion of HMG containing chromatin with micrococcal nuclease produces DNA fragments that were approximately 10 and 20 base pairs longer than nucleosome core-particle DNA. This suggests that HMG 14 or HMG 17 can protect, directly or indirectly, at least an additional 10 base pairs of linker DNA from micrococcal digestion. However, this HMG-containing particle does not produce a strong kinetic block, and further digestion results in the eventual accumulation of DNA fragments 145 base pairs in length. Third, by comparing the full-length protein with different domains, we demonstrate that the acidic carboxyl-terminal domain is absolutely required for nucleosome spacing; neither the nucleosome binding domain of HMG 14 or HMG 17 nor the amino-terminal domain plus the nucleosome binding domain of HMG 14 could space nucleosomes. Fourth, we demonstrate that extensive micrococcal nuclease digestion of chromatin deficient in histones H2A/H2B led to the accumulation of DNA fragments about 110 base pairs in length, which is presumably the length of DNA associated with a nucleosomal particle deficient in one H2A/H2B dimer. Incorporation of either HMG 14 or HMG 17 into this chromatin results in the disappearance of this band and increase in the accumulation of fragments around 140-150 base pairs in length. Finally, in contrast to spacing of complete nucleosomes, we find that the nucleosome binding domain of HMG 17 (but not the nucleosome binding of HMG 14) is the only domain required for spacing of H2A/H2B-deficient chromatin.			Tremethick, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BRAWLEY JV, 1992, BIOCHEMISTRY-US, V31, P364, DOI 10.1021/bi00117a008; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COOK GR, 1989, J BIOL CHEM, V264, P1799; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; DREW HR, 1993, J MOL BIOL, V230, P824, DOI 10.1006/jmbi.1993.1204; EINICK L, 1985, EXP CELL RES, V156, P295; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GONZALEZ PJ, 1990, J BIOL CHEM, V265, P8225; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; LU Q, 1994, J CELL BIOCHEM, V55, P83, DOI 10.1002/jcb.240550110; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; SASI R, 1982, J BIOL CHEM, V257, P1448; SCHWARZ PM, 1994, J BIOL CHEM, V269, P15041; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; TREMETHICK DJ, 1994, J BIOL CHEM, V269, P28436; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; van Holde KE., 1989, SPRINGER SERIES MOL; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WEISCHET WO, 1979, NUCLEIC ACIDS RES, V6, P1843, DOI 10.1093/nar/6.5.1843; WOLFFE A P, 1990, New Biologist, V2, P211; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	35	27	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12009	12016		10.1074/jbc.271.20.12009	http://dx.doi.org/10.1074/jbc.271.20.12009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662614	hybrid			2022-12-27	WOS:A1996UL25000065
J	Kimura, K; Saijo, M; Tanaka, M; Enomoto, T				Kimura, K; Saijo, M; Tanaka, M; Enomoto, T			Phosphorylation-independent stimulation of DNA topoisomerase II alpha activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CYCLE-DEPENDENT PHOSPHORYLATION; FISSION YEAST; ATP HYDROLYSIS; PHORBOL ESTER; CELLS; ENZYME; CONDENSATION; SEPARATION; INVITRO	It has been suggested that casein kinase II phosphorylates DNA topoisomerase II alpha (topo II alpha) in mouse FM3A cells, by comparison of phosphopeptide maps of topo II alpha labeled in intact cells and of topo II alpha phosphorylated by various kinases in vitro. The phosphorylation of purified topo II alpha by casein kinase II, which attached a maximum of two phosphate groups per topo II alpha molecule, had no effect on the activity of topo II alpha. Dephosphorylation of purified topo II alpha by potato acid phosphatase, which almost completely dephosphorylated the topo II alpha, did not reduce the activity of topo II alpha. The incubation itself, regardless of phosphorylation or dephosphorylation status, stimulated the enzyme activity in both reactions. Topo II alpha activity was stimulated by incubation in a medium containing low concentrations of glycerol but not in that containing high concentrations of glycerol, such as the 50% in which purified topo II alpha is stored. The stimulation of topo II alpha activity by incubation was dependent on the concentration of topo II alpha, requiring a relatively high concentration of topo II alpha.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	University of Tokyo								ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERNARDI R, 1995, INT J ONCOL, V6, P203; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; FRERE V, 1995, J BIOL CHEM, V270, P17502, DOI 10.1074/jbc.270.29.17502; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; KIMURA K, 1994, J BIOL CHEM, V269, P24523; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LAMHASNI S, 1995, BIOCHEMISTRY-US, V34, P3632, DOI 10.1021/bi00011a018; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAKENO H, 1991, CANCER RES, V51, P3951; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10990	10995		10.1074/jbc.271.18.10990	http://dx.doi.org/10.1074/jbc.271.18.10990			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631919	hybrid			2022-12-27	WOS:A1996UJ34200087
J	Chang, ZY; Primm, TP; Jakana, J; Lee, IH; Serysheva, I; Chiu, W; Gilbert, HF; Quiocho, FA				Chang, ZY; Primm, TP; Jakana, J; Lee, IH; Serysheva, I; Chiu, W; Gilbert, HF; Quiocho, FA			Mycobacterium tuberculosis 16-kDa antigen (Hsp16.3) functions as an oligomeric structure in vitro to suppress thermal aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CRYO-ELECTRON MICROSCOPY; ALPHA-CRYSTALLIN; MOLECULAR-WEIGHT; MONOCLONAL-ANTIBODIES; FAMILY; EXPRESSION; IDENTIFICATION; CHAPERONES; LEPRAE	Tuberculosis continues to be a major disease threatening millions of lives worldwide. Several antigens of Mycobacferium tuberculosis, identified by monoclonal antibodies, have been cloned and are being exploited in the development of improved vaccines and diagnostic reagents. We have expressed and purified the 18-kDa antigen, an immunodominant antigen with serodiagnostic value, which has been previously cloned and shown to share low sequence homology with the alpha-crystallin-related small heat shock protein family. Sedimentation equilibrium analytical ultracentrifugation and dynamic light scattering demonstrate the formation of a specific oligomer, 149 +/- 8 kDa, consisting of approximately nine monomers. In 4 M urea, a smaller oligomer of 47 +/- 6 kDa (or trimer) is produced. Analysis by electron cryomicroscopy reveals a triangular shaped oligomeric structure arising from the presence of three subparticles or globules. Taken together, the data suggest an antigen complex structure of a trimer of trimers. This antigen, independent of ATP addition, effectively suppresses the thermal aggregation of citrate synthase at 40 degrees C, indicating that it can function as a molecular chaperone in vitro. A complex between the antigen and heat-denatured citrate synthase can be detected and isolated using high performance Liquid chromatography. We propose to rename the 16-kDa antigen Hsp16.3 to be consistent with other members of the small heat shock protein family.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02250] Funding Source: Medline; NIGMS NIH HHS [GM 40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUZEID C, 1988, J GEN MICROBIOL, V134, P531; ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Ausubel FM, 1992, CURRENT PROTOCOLS MO; AVILASAKAR AJ, 1994, J MOL BIOL, V239, P689, DOI 10.1006/jmbi.1994.1406; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ZY, 1994, J BIOL CHEM, V269, P1956; COATES ARM, 1981, LANCET, V2, P167; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ENGERS HD, 1986, INFECT IMMUN, V51, P718; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HOCKERTZ MK, 1991, FEBS LETT, V280, P375, DOI 10.1016/0014-5793(91)80335-Z; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IVANYI J, 1988, BRIT MED BULL, V44, P635, DOI 10.1093/oxfordjournals.bmb.a072273; JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313, DOI 10.1128/JCM.26.11.2313-2318.1988; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KATO K, 1994, J BIOL CHEM, V269, P11274; KINGSTON AE, 1987, INFECT IMMUN, V55, P3149, DOI 10.1128/IAI.55.12.3149-3154.1987; KONG TH, 1993, P NATL ACAD SCI USA, V90, P2608, DOI 10.1073/pnas.90.7.2608; LAMB FI, 1990, J IMMUNOL, V144, P1922; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LEE BY, 1992, INFECT IMMUN, V60, P2066, DOI 10.1128/IAI.60.5.2066-2074.1992; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NERLAND AH, 1988, J BACTERIOL, V170, P5919, DOI 10.1128/jb.170.12.5919-5921.1988; NOWAK R, 1995, SCIENCE, V267, P1763, DOI 10.1126/science.7892595; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHONINGH R, 1990, J CLIN MICROBIOL, V28, P708; SINGH M, 1970, J BIOL CHEM, V245, P4636; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VERBON A, 1990, J GEN MICROBIOL, V136, P955, DOI 10.1099/00221287-136-5-955; VERBON A, 1992, J BACTERIOL, V174, P1352, DOI 10.1128/jb.174.4.1352-1359.1992; VERSTIJNEN CPHJ, 1989, RES MICROBIOL, V140, P653, DOI 10.1016/0923-2508(89)90197-6; YOUNG D, 1990, MOL BIOL MYCOBACTERI, P1; YOUNG DB, 1991, INFECT IMMUN, V59, P3086, DOI 10.1128/IAI.59.9.3086-3093.1991	47	200	212	8	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7218	7223		10.1074/jbc.271.12.7218	http://dx.doi.org/10.1074/jbc.271.12.7218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636160	hybrid			2022-12-27	WOS:A1996UB15700095
J	Halvorson, LM; Kaiser, UB; Chin, WW				Halvorson, LM; Kaiser, UB; Chin, WW			Stimulation of luteinizing hormone beta gene promoter activity by the orphan nuclear receptor, steroidogenic factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; FACTOR-I; TRANSGENIC MICE; MAMMALIAN-CELLS; KEY REGULATOR; EXPRESSION; PITUITARY; GONADOTROPIN; EVOLUTION; ELEMENTS	The orphan nuclear receptor, steroidogenic factor-1 (SF-1), is expressed in the pituitary and in the gonadotrope precursor cell line, alpha T3-1, where it is believed to enhance expression of the common gonadotropin alpha-subunit gene through transactivation of the gonadotrope-specific element (GSE), Sequence analysis of the rat luteinizing hormone beta-subunit (LH beta) gene promoter revealed the presence of a consensus GSE at -127 to -119 (TGACCTTGT). We have demonstrated the ability of SF-l to bind specifically to this putative GSE sequence by electrophoretic mobility shift assay, utilizing both alpha T3-1 nuclear extracts and in vitro translated SF-l. In addition, mutation of the putative LH beta-GSE (TGAAATTGT) eliminated specific DNA binding, To examine the ability of SF-l to enhance LHP promoter activity, CV-1 cells, which lack endogenous SF-l, were cotransfected with an SF-l-containing expression vector and an LH beta-luciferase reporter construct, When cotransfected with -209/+5 of the LH beta promoter, SF-1 increased luciferase activity by 56-fold, SF-1 responsiveness was markedly diminished with loss of the putative GSE region in deletion constructs and in the presence of a two base pair mutation, analogous to the mutation which eliminated DNA binding, Finally, the LH beta-GSE was able to confer SF-1 responsiveness on a heterologous minimal growth hormone promoter, GH50 (57-fold), We conclude that SF-l both binds to and transactivates the rat LHP promoter, These data suggest that SF-1 may participate in the expression of the LH beta gene by the gonadotrope.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02111	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Tufts University	Halvorson, LM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,GW THORN RES BLDG,RM 913,20 SHATTUCK ST,BOSTON,MA 02115, USA.				NICHD NIH HHS [HD00849, HD19938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849, R01HD019938, R37HD019938] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HONDA S, 1993, J BIOL CHEM, V268, P7494; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KAY TWH, 1992, MOL ENDOCRINOL, V6, P1767, DOI 10.1210/me.6.11.1767; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MORRIS AE, 1990, GENE, V94, P289, DOI 10.1016/0378-1119(90)90400-L; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; Sambrook J., 2002, MOL CLONING LAB MANU; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SUEN CS, 1994, J BIOL CHEM, V269, P1314; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	32	154	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6645	6650		10.1074/jbc.271.12.6645	http://dx.doi.org/10.1074/jbc.271.12.6645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636081	hybrid			2022-12-27	WOS:A1996UB15700016
J	Hawdon, JM; Jones, BF; Hoffman, DR; Hotez, PJ				Hawdon, JM; Jones, BF; Hoffman, DR; Hotez, PJ			Cloning and characterization of Ancylostoma-secreted protein - A novel protein associated with the transition to parasitism by infective hookworm larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; HYMENOPTERA VENOM; TRICHOSTRONGYLUS-COLUBRIFORMIS; TRICHINELLA-SPIRALIS; MOLECULAR-CLONING; 3RD-STAGE LARVAE; CROSS-REACTIVITY; ALLERGENS; PRODUCTS; PURIFICATION	The developmentally arrested third stage infective larva of hookworms resumes development upon entry into the definitive host. This transition to parasitism can be modeled in vitro by stimulating infective larvae with a low molecular weight ultrafiltrate of host serum together with methylated glutathione analogues. When stimulated to resume development in vitro, activated larvae of the hookworm Ancylostoma caninum released a 42-kDa protein, termed Ancylostoma-secreted protein (ASP). ASP was the major protein released by activated hookworm larvae, Degenerate oligonucleotide primers, based on a partial internal amino acid sequence of the protein, were used together with flanking vector sequence primers to amplify a fragment hom a third stage larval cDNA library by polymerase chain reaction. The fragment was used as a probe to isolate a longer done from the larval cDNA library. The full-length ASP cDNA was found to encode a 424-amino acid protein with homology to the antigen 5/antigen 3 family of proteins from hymenopteran venoms and a family of cysteine-rich secretory proteins. ASP was expressed in bacterial cells, and a polyclonal antiserum against purified recombinant ASP was produced. The antiserum, which was demonstrated to be specific for ASP, was used as a probe to measure the kinetics of ASP release by hookworm larvae. ASP is released within 30 min of stimulation, with the majority released by 4 h. Low levels of ASP were released continuously following activation, but only if the stimuli were present in the incubation medium. The compound 4,7-phenanthroline, previously shown to inhibit larval activation, also inhibited release of ASP. The specific, rapid release of ASP by activated infective larvae suggests that this molecule occupies a critical and central role in the transition from the external environment to parasitism.	E CAROLINA UNIV, DEPT PATHOL & LAB MED, GREENVILLE, NC 27858 USA	University of North Carolina; East Carolina University	Hawdon, JM (corresponding author), YALE UNIV, SCH MED,DEPT PEDIAT,MED HELMINTHOL LAB,501 LEPH, 60 COLL ST, NEW HAVEN, CT 06520 USA.		Hawdon, John/I-1201-2019	Hawdon, John/0000-0002-6164-1413; Hotez, Peter/0000-0001-8770-1042	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032726, F32AI008561] Funding Source: NIH RePORTER; NIAID NIH HHS [F32AI08561, R29AI32726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1982, BIOCHEMISTRY-US, V21, P1693, DOI 10.1021/bi00536a034; ARNHEIM N, 1992, ANNU REV BIOCHEM, V61, P131, DOI 10.1146/annurev.bi.61.070192.001023; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BROOKS DE, 1986, EUR J BIOCHEM, V161, P13, DOI 10.1111/j.1432-1033.1986.tb10118.x; CHAREST NJ, 1988, MOL ENDOCRINOL, V2, P999, DOI 10.1210/mend-2-10-999; CORNELISSEN BJC, 1987, NUCLEIC ACIDS RES, V15, P6799, DOI 10.1093/nar/15.17.6799; DOPHEIDE TAA, 1991, MOL BIOCHEM PARASIT, V45, P101, DOI 10.1016/0166-6851(91)90031-Z; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FRENKEL MJ, 1992, MOL BIOCHEM PARASIT, V50, P27, DOI 10.1016/0166-6851(92)90241-B; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAMBLE HR, 1986, AM J VET RES, V47, P2396; GASBARRE LC, 1985, INFECT IMMUN, V48, P540, DOI 10.1128/IAI.48.2.540-545.1985; HAENDLER B, 1993, ENDOCRINOLOGY, V133, P192, DOI 10.1210/en.133.1.192; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Hawdon J.M., 1991, P274; HAWDON JM, 1990, J PARASITOL, V76, P394, DOI 10.2307/3282673; HAWDON JM, 1991, J HELMINTHOL SOC W, V58, P140; HAWDON JM, 1995, MOL BIOCHEM PARASIT, V69, P127, DOI 10.1016/0166-6851(94)00203-Y; HAWDON JM, 1992, EXP PARASITOL, V75, P40, DOI 10.1016/0014-4894(92)90120-Y; HAWDON JM, 1995, EXP PARASITOL, V80, P205, DOI 10.1006/expr.1995.1025; HAWDON JM, 1993, EXP PARASITOL, V77, P489, DOI 10.1006/expr.1993.1110; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; JAIN R, 1992, BIOTECHNIQUES, V12, P58; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTOWLERS MW, 1988, PARASITOLOGY, V96, pS123, DOI 10.1017/S0031182000086017; Miller T. A., 1971, Adv Parasitology, V9, P153, DOI 10.1016/S0065-308X(08)60161-X; MIZUKI N, 1992, MOL CELL ENDOCRINOL, V89, P25, DOI 10.1016/0303-7207(92)90207-M; MONROY FG, 1989, INT J PARASITOL, V19, P125, DOI 10.1016/0020-7519(89)90030-1; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; MOYLE M, 1994, J BIOL CHEM, V269, P10008; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; ODONNELL IJ, 1989, INT J PARASITOL, V19, P793, DOI 10.1016/0020-7519(89)90068-4; RAYBOURNE R, 1986, EXP PARASITOL, V62, P92, DOI 10.1016/0014-4894(86)90012-3; RHOADS ML, 1983, EXP PARASITOL, V56, P41, DOI 10.1016/0014-4894(83)90095-4; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Rogers W. P., 1968, Advances in Parasitology, V6, P327; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVIN KW, 1990, MOL BIOCHEM PARASIT, V41, P167, DOI 10.1016/0166-6851(90)90179-P; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; SOMMERVILLE RI, 1987, ADV PARASIT, V26, P239, DOI 10.1016/S0065-308X(08)60298-5; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; TEMPLETON NS, 1993, BIOTECHNIQUES, V15, P52; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7	53	223	232	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6672	6678		10.1074/jbc.271.12.6672	http://dx.doi.org/10.1074/jbc.271.12.6672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636085	hybrid, Green Published			2022-12-27	WOS:A1996UB15700020
J	Howitt, SM; Rodgers, AJW; Jeffrey, PD; Cox, GB				Howitt, SM; Rodgers, AJW; Jeffrey, PD; Cox, GB			A mutation in which alanine 128 is replaced by aspartic acid abolishes dimerization of the b-subunit of the F0F1-ATPase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; UNC OPERON; C-SUBUNIT; SYNTHASE; PERMEABILITY; ORGANIZATION; PORTION; GENES	Site-directed mutagenesis was used to investigate the roles of a short, series of hydrophobic amino acids in the b-subunit of the Escherichia coli F0F1-ATPase. A mutation affecting one of these, G131D, had been previously characterized and was found to interrupt assembly of the F0F1-ATPase (Jans, D. A., Hatch, L., Fimmel, A. L., Gibson, D., and Cox, G. B. (1985) J. Bacteriol. 162, 420-426). To extend this work, aspartic acid was substituted for each one of the residues from positions 124 to 132. The properties of mutants in this series are consistent with the region hom Val(124) to Gly(131) forming an alpha-helix. Two of the mutations, V124D and A128D, resulted in a similar phenotype to the G131D mutation. This suggested that Val(124), Ala(128), and Gly(131) form a helical face which may have a role in inter- or intrasubunit interactions, This was tested by overexpressing and purifying the cytoplasmic domains of the wild type and A128D mutant b-subunits. Sedimentation equilibrium centrifugation indicated that the wild type domain formed a dimer whereas the mutant was present as a monomer.			Howitt, SM (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.		Howitt, Susan M/C-9308-2009; Rodgers, Andrew/AAT-8756-2021; Rodgers, Andrew/H-3527-2013	Howitt, Susan M/0000-0002-2192-2317; Rodgers, Andrew/0000-0003-2063-4521; Rodgers, Andrew/0000-0002-8897-6221				BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; COX GB, 1970, BIOCHEM J, V177, P551; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DUNN SD, 1992, J BIOL CHEM, V267, P7630; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; JANS DA, 1984, BIOCHEM J, V221, P43, DOI 10.1042/bj2210043; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; JANS DA, 1984, J BACTERIOL, V160, P764, DOI 10.1128/JB.160.2.764-770.1984; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PILLER SC, 1995, P NATL ACAD SCI USA, V93, P111; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5	29	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7038	7042		10.1074/jbc.271.12.7038	http://dx.doi.org/10.1074/jbc.271.12.7038			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636135	hybrid			2022-12-27	WOS:A1996UB15700070
J	Zhao, X; Siu, CH				Zhao, X; Siu, CH			Differential effects of two hydrocephalus/MASA syndrome-related mutations on the homophilic binding and neuritogenic activities of the cell adhesion molecule L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; HOMOPHILIC BINDING; NEURITE OUTGROWTH; IG SUPERFAMILY; NG-CAM; DOMAINS; EXPRESSION; NEURONS; MEMBER	The cell adhesion molecule L1 plays an important role in neural development, We have previously demonstrated that the second immunoglobulin-like domain (Ig2) of L1 contains both hemophilic binding and neuritogenic activities (Zhao, X, and Siu, C,-H. (1995) J, Biol, Chem. 270, 29413-29421), Recently, two mutations (R184Q and H210Q) within the Ig2 region of the human L1 gene have been shown to be responsible for X-linked hydrocephalus and the related MASA (mental retardation, aphasia, shuffling gait, and adducted thumbs) syndrome, Glutathione S-transferase-Ig2 fusion proteins containing these mutations were used to evaluate their effects on L1, The homophilic binding activity of fusion proteins and their ability to promote neurite outgrowth from retinal cells were examined. The R184Q mutation led to a complete loss of both homophilic binding and neuritogenic activities, while the H210Q mutation resulted only in a partial loss, These results provide, for the first time, direct demonstration of the deleterious effects of hydrocephalus/MASA mutations on two intrinsic properties of L1.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto								APPEL F, 1993, J NEUROSCI, V13, P4764; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BRUMMENDORF T, 1993, NEURON, V10, P711; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DJABALI M, 1990, GENOMICS, V7, P587, DOI 10.1016/0888-7543(90)90203-7; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HIRSCH E, 1994, DEV DYNAM, V201, P108, DOI 10.1002/aja.1002010203; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; JOUET M, 1995, AM J HUM GENET, V56, P1304; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MIURA M, 1992, J BIOL CHEM, V267, P10752; MONTGOMERY AMP, 1996, IN PRESS J CELL BIOL; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; SANDIG M, 1994, J BIOL CHEM, V269, P14841; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; ZHAO XO, 1995, J BIOL CHEM, V270, P29413, DOI 10.1074/jbc.270.49.29413; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	31	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6563	6566		10.1074/jbc.271.12.6563	http://dx.doi.org/10.1074/jbc.271.12.6563			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636066	hybrid			2022-12-27	WOS:A1996UB15700001
J	Usachenko, SI; Gavin, IM; Bavykin, SG				Usachenko, SI; Gavin, IM; Bavykin, SG			Alterations in nucleosome core structure in linker histone-depleted chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; PRIMARY ORGANIZATION; YEAST CHROMATIN; DNASE-I; TRANSCRIPTION; ACETYLATION; PLANT; GENE; PROTEIN	We have previously shown that the sequential arrangement of histone-DNA contacts is essentially the same in the nucleosomal core of sea urchin sperm nuclei, where chromatin is highly condensed and repressed, and in nuclei hom lily bud sepals or yeast, where chromatin is highly active in transcription and replication and is significantly or completely depleted of histone H1, However, the difference in the strength of some histone-DNA contacts has not been understood or discussed, In this work, we demonstrate that some of these differences are due to a conformational change in the nucleosomal core. We show that the nucleosomal core in linker histone-depleted chromatin is in a different conformational state compared with the nucleosomal core in folded chromatin or in isolated core nucleosomes, This conformational state is characterized by altered strengths in the histone H4 and H2A/H2B contacts with the regions of sharply bent nucleosomal DNA around sites +/-1 and +/-4 and site +/-5, respectively, We demonstrate that this conformation, which we call the ''stretched nucleosome,'' is a general feature of unfolded linker histone-depleted chromatin and may occur during chromatin activation, Our results suggest that this nucleosome structural alteration does not depend on chromatin sources and histone variants studied in this work, In addition, we show that this alteration is reversible and is caused by the stretching of Linker DNA during chromatin unfolding.	RUSSIAN ACAD SCI, VA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, RUSSIA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS								ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALLAN J, 1980, P NATL ACAD SCI-BIOL, V77, P885, DOI 10.1073/pnas.77.2.885; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BAVYKIN S, 1993, P NATL ACAD SCI USA, V90, P3918, DOI 10.1073/pnas.90.9.3918; BAVYKIN SG, 1985, NUCLEIC ACIDS RES, V13, P3439, DOI 10.1093/nar/13.10.3439; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BAVYKIN SG, 1988, FEBS LETT, V228, P149, DOI 10.1016/0014-5793(88)80605-7; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BELYAVSKY AV, 1980, J MOL BIOL, V139, P519, DOI 10.1016/0022-2836(80)90144-8; BOLUND LA, 1973, EUR J BIOCHEM, V35, P546, DOI 10.1111/j.1432-1033.1973.tb02871.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CERTA U, 1984, NUCLEIC ACIDS RES, V12, P7975, DOI 10.1093/nar/12.21.7975; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GREYLING HJ, 1983, EUR J BIOCHEM, V137, P221, DOI 10.1111/j.1432-1033.1983.tb07818.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LOHR D, 1979, P NATL ACAD SCI USA, V76, P4285, DOI 10.1073/pnas.76.9.4285; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; PRUNELL A, 1979, SCIENCE, V204, P855, DOI 10.1126/science.441739; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Sambrook J, 1989, MOL CLONING LAB MANU, pE3; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SPIKER S, 1976, ARCH BIOCHEM BIOPHYS, V176, P510, DOI 10.1016/0003-9861(76)90194-6; SPIKER S, 1985, ANNU REV PLANT PHYS, V36, P235; STEINMETZ M, 1978, EUR J BIOCHEM, V83, P615, DOI 10.1111/j.1432-1033.1978.tb12131.x; STRICKLAND M, 1978, EUR J BIOCHEM, V89, P443, DOI 10.1111/j.1432-1033.1978.tb12547.x; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMA F, 1988, ARCHITECTURE EUKARYO, P163; TURNER BM, 1991, J CELL SCI, V99, P13; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WINTERSBERGER U, 1973, EUR J BIOCHEM, V33, P123, DOI 10.1111/j.1432-1033.1973.tb02663.x; WORCEL A, 1977, CELL, V12, P83, DOI 10.1016/0092-8674(77)90187-8; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; ZLATANOVA J, 1992, J CELL SCI, V103, P889	57	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3831	3836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632001				2022-12-27	WOS:A1996TV72400075
J	Kaberdin, VR; Chao, YH; Sue, LC				Kaberdin, VR; Chao, YH; Sue, LC			RNase E cleaves at multiple sites in bubble regions of RNA I stem loops yielding products that dissociate differentially from the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ANTISENSE RNAI; COPY NUMBER; GENE; DEGRADATION; REPLICATION; PLASMIDS; PCNB; INVIVO	Earlier work has shown that RNase E cleaves RNAI, the antisense repressor of replication of ColE1-type plasmids, producing pRNAI(-5), whose further decay is mediated by the poly(A)-dependent activity of polynucleotide phosphorylase and other 3' to 5' exonucleases. Using a poly(A) polymerase-deficient strain to impede exonucleolytic decay, we show that RNAI is additionally cleaved by RNase E at multiple sites, generating a series of decay intermediates that are differentially retained by the RNA binding domain (RBD) of RNase E. Primer extension analysis of RNAI decay intermediates and RNase T-1 mapping of the cleavage products of RNAI generated in vitro by affinity-purified RNase E showed that RNase E can cleave internucleotide bonds in the bubble regions of duplex RNA segments and in single-stranded regions. Chemical in situ probing of a complex formed between RNAI and the RBD indicates that binding to the RBD destabilizes RNAI secondary structure. Our results suggest a model in which a series of sequential RNase E-mediated cleavages occurring at multiple sites of RNAI, some of which may be made more accessible to RNase E by the destabilizing effects of its RBD, generate RNA fragments that are further degraded by poly(A)-dependent 3' to 5' exonucleases.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan			Kaberdin, Vladimir/C-3870-2017; Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022	Kaberdin, Vladimir/0000-0002-7166-5136; Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304				ALIFANO P, 1994, GENE DEV, V8, P3021, DOI 10.1101/gad.8.24.3021; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HAJNSDORF E, 1994, J MOL BIOL, V239, P439, DOI 10.1006/jmbi.1994.1387; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MICZAK A, 1991, MOL MICROBIOL, V5, P1801, DOI 10.1111/j.1365-2958.1991.tb01929.x; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PAPAVASSILIOU AG, 1993, ANAL BIOCHEM, V214, P331, DOI 10.1006/abio.1993.1498; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Sambrook J, 1989, MOL CLONNING LAB MAN; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13103	13109		10.1074/jbc.271.22.13103	http://dx.doi.org/10.1074/jbc.271.22.13103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662734	hybrid			2022-12-27	WOS:A1996UN47400064
J	Qian, WJ; Zhu, SH; Sobolev, AY; Wek, RC				Qian, WJ; Zhu, SH; Sobolev, AY; Wek, RC			Expression of vaccinia virus K3L protein in yeast inhibits eukaryotic initiation factor-2 kinase GCN2 and the general amino acid control pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; FACTOR-II; TRANSLATION INITIATION; EIF-2-ALPHA KINASE; PHOSPHORYLATION; IDENTIFICATION; INTERFERON; ACTIVATION	Phosphorylation of the alpha subunit of eukaryotic initiation factor-2 (eIF-2) is a well characterized mechanism regulating protein synthesis. Viral and cellular proteins have been identified that regulate the activity of the eIF-2 alpha kinases. The regulatory protein, K3L, from vaccinia virus is homologous to the amino terminus of eIF-2 alpha and is thought to inhibit the activity of the double-stranded RNA-dependent kinase suppressing the antiviral mechanism mediated by this kinase. We investigated whether K3L can inhibit the activity of the yeast eIF-2 alpha kinase GCN2. Expression of K3L protein in yeast reduced the level of eIF-2 alpha phosphorylation by GCN2 and blocked the stimulation of the general amino acid control pathway in response to starvation conditions. Accompanying in vitro studies showed that recombinant K3L protein reduced GCN2 autophosphorylation and phosphorylation elF-2 alpha. In agreement with the hypothesis that K3L inhibits eIF-2 alpha kinases by functioning as a pseudosubstrate, we observed that K3L directly interacted with the kinase catalytic domain of GCN2. Together, these results indicate that K3L is a specific inhibitor of eIF-2 alpha kinases from mammals and yeast and suggest that the kinases contain common structural features important for recognition of their substrate eIF-2 alpha.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NIGMS NIH HHS [GM49164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164, R29GM049164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CARROLL K, 1993, J BIOL CHEM, V268, P12837; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLEMENS MJ, 1994, BIOCHIMIE, V76, P770, DOI 10.1016/0300-9084(94)90081-7; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DEALDANA CRV, 1993, P NATL ACAD SCI USA, V90, P7215; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ERNST H, 1987, J BIOL CHEM, V262, P1206; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HANNIG EM, 1990, GENETICS, V126, P546; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1993, TRANSLATIONAL REGULA, V2, P87; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Moore DD, 1995, GLOB MOB SURV; PROUD CG, 1991, EUR J BIOCHEM, V195, P771, DOI 10.1111/j.1432-1033.1991.tb15765.x; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P217; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	41	16	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13202	13207		10.1074/jbc.271.22.13202	http://dx.doi.org/10.1074/jbc.271.22.13202			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662715				2022-12-27	WOS:A1996UN47400079
J	Aumais, JP; Lee, HS; DeGannes, C; Horsford, J; White, JH				Aumais, JP; Lee, HS; DeGannes, C; Horsford, J; White, JH			Function of directly repeated half-sites as response elements for steroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; HUMAN ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTORS; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; NUCLEAR RECEPTORS; AMINO-ACIDS; GENE-EXPRESSION; FAR UPSTREAM; X-RECEPTOR	The mouse mammary tumor virus promoter has been shown to be inducible by glucocorticoids and progesterone. Although steroid hormone receptors bind with high affinity to palindromic response elements, the hormone-responsive region of the mouse mammary tumor virus promoter contains a pair of directly repeated half-sites that are important for hormone inducibility. Recent experiments have also indicated that direct repeats can function as estrogen response elements. Here, we have investigated DNA binding by steroid receptors to direct repeats and provide evidence using gel retardation assays, methylation interference, and gene transfer experiments that direct repeats of TGTTCT or RGGTCA motifs function as response elements for glucocorticoid (GR) or estrogen receptors (ER), respectively, by binding receptor homodimers. Specific GR- or ER-DNA complexes were observed on direct repeats with different spacings between half-sites, indicating that binding of steroid receptors to direct repeats is more flexible than binding to palindromic elements. This flexibility was further emphasized by the observation that the GR could also bind to everted repeats of TGTTCT motifs separated by 9 base pairs. The isolated DNA binding domains of the GR and ER bound cooperatively to palindromes, but no evidence was observed for cooperative binding to direct repeats. Under similar conditions the DNA binding domains of retinoid receptors retinoid X receptor and retinoic acid receptor bound to direct repeats cooperatively as heterodimers. Similarly, ER derivative HE15, which lacks a functional ligand binding domain, bound palindromic response elements but failed to bind direct repeats. These results indicate that the dimerization domain in the ligand binding domain is essential for binding of steroid receptors to direct re peats and that the dimerization domain in the D-box of the DNA binding domain is not functional under these conditions. Moreover, the results suggest that steroid receptor DNA binding domains may lack dimerization domains outside the D-box, which would function in binding to direct repeats, in contrast to receptors for retinoids and thyroid hormone. A comparison of the mechanisms of binding of steroid receptors and retinoid and thyroid hormone receptors to direct repeats is presented.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN B M, 1990, New Biologist, V2, P587; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MADER S, 1993, J BIOL CHEM, V268, P591; Nawaz Zafar, 1992, Gene Expression, V2, P39; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RICHARD S, 1990, J BIOL CHEM, V265, P6098; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1986; TURKASPA R, 1988, VIROLOGY, V167, P630, DOI 10.1016/0042-6822(88)90127-4; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	68	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12568	12577		10.1074/jbc.271.21.12568	http://dx.doi.org/10.1074/jbc.271.21.12568			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647867	hybrid			2022-12-27	WOS:A1996UL66000069
J	Bossard, MJ; Tomaszek, TA; Thompson, SK; Amegadzie, BY; Hanning, CR; Jones, C; Kurdyla, JT; McNulty, DE; Drake, FH; Gowen, M; Levy, MA				Bossard, MJ; Tomaszek, TA; Thompson, SK; Amegadzie, BY; Hanning, CR; Jones, C; Kurdyla, JT; McNulty, DE; Drake, FH; Gowen, M; Levy, MA			Proteolytic activity of human osteoclast cathepsin K - Expression, purification, activation, and substrate identification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-PROTEINASES; BONE-RESORPTION; ESCHERICHIA-COLI; PAPAIN PRECURSOR; INSECT CELLS; INHIBITORS; SECRETION; SEQUENCE; PEPTIDE; ENZYME	Human cathepsin K is a recently identified protein with high primary sequence homology to members of the papain cysteine protease superfamily including cathepsins S, L, and B and is selectively expressed in osteoclasts (Drake, F. H., Dodds, R., James, I., Conner, J., Debouck, C., Richardson, S., Lee, E., Rieman, D., Barth low, R., Hastings, G., and Gowen, M. (1996) J. Biol. Chem. 271, 12511-12516). To characterize its catalytic properties, cathepsin K has been expressed in baculovirus-infected SF21 cells and the soluble recombinant protein isolated from growth media was purified. Purified protein includes an inhibitory pro-leader sequence common to this family of protease. Conditions for enzyme activation upon removal of the pro sequence have been identified. Fluorogenic peptides have been identified as substrates for mature cathepsin K, In addition, two protein components of bone matrix, collagen and osteonectin, have been shown to be substrates of the activated protease. Cathepsin K is inhibited by E-64 and leupeptin, but not by pepstatin, EDTA, phenylmethylsulfonyl fluoride, or phenanthroline, consistent with its classification within the cysteine protease class. Leupeptin has been characterized as a slow binding inhibitor of cathepsin K (k(obs)/[I] = 273,000 M(-1) s(-1)). Cathepsin K may represent the elusive protease implicated in degradation of protein matrix during bone resorption and represents a novel molecular target in treatment of disease states associated with excessive bone loss such as osteoporosis.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AMEGADZIE BY, 1995, CELL BIOL INT, V19, P477, DOI 10.1006/cbir.1995.1091; AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; Baron Roland, 1993, P3; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; BROMME D, 1993, J BIOL CHEM, V268, P4832; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BROMME D, 1989, BIOCHEM J, V264, P475; BROMMED, 1996, J BIOL CHEM, V271, P2126; CLELAND WW, 1979, ADV ENZYMOL, V29, P1; COHEN LW, 1990, GENE, V88, P263, DOI 10.1016/0378-1119(90)90041-O; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; LERNER UH, 1992, J BONE MINER RES, V7, P433; Li Y. P., 1994, Molecular Biology of the Cell, V5, p335A; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; RAWLINGS ND, 1992, BIOL CHEM H-S, V373, P1211, DOI 10.1515/bchm3.1992.373.2.1211; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Termine John D., 1993, P21; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1990, J BIOL CHEM, V265, P16661; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708	33	429	447	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12517	12524		10.1074/jbc.271.21.12517	http://dx.doi.org/10.1074/jbc.271.21.12517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647860	hybrid			2022-12-27	WOS:A1996UL66000062
J	Grab, B; Miles, AJ; Furcht, LT; Fields, GB				Grab, B; Miles, AJ; Furcht, LT; Fields, GB			Promotion of fibroblast adhesion by triple-helical peptide models of type I collagen-derived sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-REACTIVE SITES; MELANOMA CELL-ADHESION; BINDING-SITE; IDENTIFICATION; ATTACHMENT; RECOGNITION; FIBRONECTIN; INTEGRINS; RECEPTOR; CHAIN	The dissection of the activities mediated by type I collagen requires an approach by which the influence of triple-helical conformation can be evaluated. The alpha(1) beta(1) and alpha(2) beta(1) integrin binding sites within type I collagen are dependent upon triple-helical conformation and contained within residues 124-822 from alpha 1(I). Seven alpha 1(I)-derived triple-helical peptides (THPs) were synthesized based on charge clustering (alpha 1(I)256-270, alpha 1(I)385-396, alpha 1(I)406-417, alpha 1(I)415-423, alpha 1(I)448-456, alpha 1(I)496-507, and alpha 1(I)526-537). Three additional THPs were synthesized (alpha 1(I)85-96, alpha 1(I)433-441, and alpha 1(I)772-786) based on previously described or proposed activities (Kleinman, H. K., McGoodwin, E. B., Martin, G. R., Klebe, R. J., Fietzek, P. P., and Wooley, D. E. (1978) J. Biol. Chem. 253, 5642-5646; Staatz, W. D., Fok, K. F., Zutter, M. M., Adams, S. P., Rodriguez, B. A., and Santoro, S. A. (1991) J. Biol. Chem. 266, 7363-7367; San Antonio, J. D., Lander, A. D., Karnovsky, M. J., and Slayter, H. S. (1994) J. Cell Biol. 125, 1179-1188). Of the ten THPs, alpha 1(I)772-786 THP had the greatest activity, with half-maximal normal dermal fibroblast adhesion occurring at a peptide concentration of 1.6 mu M. Triple-helicity was essential for activity of this sequence, as the non-triple-helical peptide analog (alpha 1(I)772-786 SSP) exhibited considerably lower levels of cell adhesion promotion even at peptide concentrations as high as 100 mu M. Within the sequence itself, residues 784-786 (Gly-Leu-Hyp) were important for cellular recognition, as the alpha 1(I)772-783 THP had greatly reduced cell adhesion activity compared with alpha 1(I)772-786 THP. Preliminary studies indicate that the beta(1) integrin subunit mediates fibroblast adhesion to alpha 1(I)772-786 THP. The identification of fibroblast integrin binding sites within type I collagen may have important implications for understanding collagen metabolism.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA 63671] Funding Source: Medline; NIAMS NIH HHS [AR 01929] Funding Source: Medline; PHS HHS [KD 44494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; BHATNAGAR RS, 1992, FASEB J, V6, pA288; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; COLLER BS, 1989, BLOOD, V74, P182; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; DOLZ R, 1986, BIOPOLYMERS, V25, P1069, DOI 10.1002/bip.360250607; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FIELDS C G, 1991, Peptide Research, V4, P95; Fields C G, 1994, Methods Mol Biol, V35, P29; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1995, ANAL BIOCHEM, V231, P57, DOI 10.1006/abio.1995.1503; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FIELDS CG, 1992, ANAL BIOCHEM, V203, P245, DOI 10.1016/0003-2697(92)90309-U; Fields G. B., 1992, SYNTHETIC PEPTIDES U, P77; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; FITZSIMMONS CM, 1986, THROMB HAEMOSTASIS, V56, P95; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GRAB B, 1996, PEPTIDES CHEM STRUCT, P603; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HAWIGER J, 1987, HUM PATHOL, V18, P111, DOI 10.1016/S0046-8177(87)80330-1; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KLEINMAN HK, 1978, J BIOL CHEM, V253, P5642; KNOWLES GC, 1991, J CELL SCI, V98, P551; KOSEKI N, 1994, CELL ADHES COMMUN, V1, P355, DOI 10.3109/15419069409097266; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LABHARD ME, 1990, MATRIX, V10, P124, DOI 10.1016/S0934-8832(11)80178-2; LI SW, 1995, MATRIX BIOL, V14, P593, DOI 10.1016/S0945-053X(05)80009-5; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NORRIS WD, 1990, J CELL SCI, V95, P255; PERRIS R, 1993, J CELL SCI, V106, P1357; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; QIAN JJ, 1992, FASEB J, V7, pA1306; RAO GHR, 1994, J BIOL CHEM, V269, P13899; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; RUGGIERO F, 1994, EXP CELL RES, V206, P167; SAELMAN EUM, 1993, BLOOD, V82, P3029; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHARFFETTERKOCHANEK K, 1992, J INVEST DERMATOL, V98, P3, DOI 10.1111/1523-1747.ep12493266; SODEK J, 1988, BIOL MECH TOOTH ERUP, V2, P303; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; TUCKWELL DS, 1994, J CELL SCI, V107, P993; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VANDERZEE E, 1995, J CELL SCI, V108, P3307; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1974, J EXP MED, V140, P1482, DOI 10.1084/jem.140.6.1482; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883; WINKLER J R, 1991, Journal of Cell Biology, V115, p442A; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	67	80	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12234	12240		10.1074/jbc.271.21.12234	http://dx.doi.org/10.1074/jbc.271.21.12234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647820	hybrid			2022-12-27	WOS:A1996UL66000022
J	Muhlebach, SM; Wirz, T; Brandle, U; Perriard, JC				Muhlebach, SM; Wirz, T; Brandle, U; Perriard, JC			Evolution of the creatine kinases - The chicken acidic type mitochondrial creatine kinase gene as the first nonmammalian gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; STRUCTURAL CHARACTERIZATION; MOLECULAR-CLONING; MUSCLE; BRAIN; ISOENZYMES; PROTEIN; TISSUE; CDNA	In both mammals and birds, the creatine kinase (CK) family consists of four types of genes: cytosolic brain type (B-CK); cytosolic muscle type (M-CK); mitochondrial ubiquitous, acidic type (Mi(a)-CK); and mitochondrial sarcomeric, basic type (Mi(b)-CK). We report here the cloning of the chicken Mi(a)-CK cDNA and its gene. Amino acid sequences of the mature chicken Mi-CK proteins show about 90% identity to the homologous mammalian isoforms. The leader peptides, however, which are isoenzyme-specifically conserved among the mammalian Mi-CKs, are quite different in the chicken with amino acid identity values compared with the mammalian leader peptides of 38.5-51.3%. The chicken Mi(a)-CK gene spans about 7.6 kilobases and contains 9 exons. The region around exon 1 shows a peculiar base composition, with more than 80% GC, and has the characteristics of a CpG island. The upstream sequences lack TATA or CCAAT boxes and display further properties of housekeeping genes. Several transcription factor binding sites known from mammalian Mi-CK genes are absent from the chicken gene. Although the promoter structure suggests a ubiquitous range of expression, analysis of Mi(a)-CK transcripts in chicken tissues shows a restricted pattern and therefore does not fulfill all criteria of a housekeeping enzyme.	SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	ETH Zurich								BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; CHENG JM, 1994, CIRCULATION, V90, P634; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P251; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DAOUK GH, 1988, J BIOL CHEM, V263, P2442; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVEREUX JP, 1991, GCG SOFTWARE PACKAGE; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELLINGTON WR, 1989, J EXP BIOL, V143, P177; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAAS RC, 1989, J BIOL CHEM, V264, P2890; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEMMER W, 1993, FEBS LETT, V327, P35, DOI 10.1016/0014-5793(93)81034-W; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; HOSSLE JP, 1988, BIOCHEM BIOPH RES CO, V151, P408, DOI 10.1016/0006-291X(88)90608-0; ISHIDA Y, 1991, FEBS LETT, V283, P37, DOI 10.1016/0014-5793(91)80548-H; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; KWIATKOWSKI RW, 1985, DEV BIOL, V112, P84, DOI 10.1016/0012-1606(85)90121-6; KWIATKOWSKI RW, 1984, NUCLEIC ACIDS RES, V12, P6925, DOI 10.1093/nar/12.18.6925; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MARIMAN E C M, 1987, Genomics, V1, P126, DOI 10.1016/0888-7543(87)90004-8; MARIMAN ECM, 1989, NUCLEIC ACIDS RES, V17, P6385, DOI 10.1093/nar/17.15.6385; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; ORDAHL CP, 1984, J BIOL CHEM, V259, P5224; PAYNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P352, DOI 10.1016/0167-4781(91)90176-M; PERRIARD JC, 1989, CELLULAR MOL BIOL MU, P545; QUEST AFG, 1990, FEBS LETT, V262, P299, DOI 10.1016/0014-5793(90)80214-4; QUEST AFG, 1990, FEBS LETT, V269, P457, DOI 10.1016/0014-5793(90)81215-A; RATTO A, 1989, EUR J BIOCHEM, V186, P195, DOI 10.1111/j.1432-1033.1989.tb15195.x; ROSENBERG UB, 1981, EUR J BIOCHEM, V116, P87, DOI 10.1111/j.1432-1033.1981.tb05304.x; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16963; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; STEEGHS K, 1995, DNA CELL BIOL, V14, P539, DOI 10.1089/dna.1995.14.539; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; SUZUKI JC, 1994, ISOZYMES, V237, P358; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1985, Cell Muscle Motil, V6, P239; WATTS DC, 1971, BIOCH EVOLUTION ORIG, P150; WIRZ T, 1990, J BIOL CHEM, V265, P11656; WYSS M, 1990, J BIOL CHEM, V265, P15900; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; XU Y, 1994, COMPUT APPL BIOSCI, V10, P613	63	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11920	11929		10.1074/jbc.271.20.11920	http://dx.doi.org/10.1074/jbc.271.20.11920			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662608	hybrid			2022-12-27	WOS:A1996UL25000054
J	Rowland, O; Segall, J				Rowland, O; Segall, J			Interaction of wild-type and truncated forms of transcription factor IIIA from Saccharomyces cerevisiae with the 5 S RNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; INDIVIDUAL ZINC FINGERS; DNA-BINDING DOMAIN; RIBOSOMAL-RNA; FACTOR-TFIIIA; CRYSTAL-STRUCTURE; FUNCTIONAL DOMAINS; FACTOR COMPLEXES; XENOPUS TFIIIA; 5S-RNA GENE	Transcription factor (TF) IIIA, which contains nine zinc finger motifs, binds to the internal control region of the 5 S RNA gene as the first step in the assembly of a multifactor complex that promotes accurate initiation of transcription by RNA polymerase III. We have monitored the interaction of wild-type and truncated forms of yeast TFIIIA with the 5 S RNA gene. The DNase I footprints obtained with full-length TFIIIA and a polypeptide containing the amino-terminal five zinc fingers (TF5) were indistinguishable, extending from nucleotides +64 to +99 of the 5 S RNA gene. This suggests that fingers 6 through 9 of yeast TFIIIA are not in tight association with DNA. The DNase I footprint obtained with a polypeptide containing the amino-terminal four zinc fingers (TF4) was 14 base pairs shorter than that of TF5, extending from nucleotides +78 to +99 on the nontranscribed strand and from nucleotides +79 to +98 on the transcribed strand of the 5 S RNA gene. Protection provided by a polypeptide containing the first three zinc fingers (TF3) was similar to that provided by TF4, with the exception that protection on the nontranscribed strand ended at nucleotide +80, rather than nucleotide +78. Methylation protection analysis indicated that finger 5 makes major groove contacts with guanines +73 and +74. The amino-terminal four zinc fingers make contacts that span the internal control region, which extends from nucleotides +81 to +94 of the 5 S RNA gene, with finger 4 appearing to contact guanine +82. Measurements of the apparent K-d values of the TFIIIA DNA complexes indicated that the amino-terminal three zinc fingers of TFIIIA have a binding energy that is similar to that of the full-length protein.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Rowland, Owen/ABH-2744-2021	Rowland, Owen/0000-0002-2752-2584				ARAKAWA H, 1995, CYTOGENET CELL GENET, V70, P235, DOI 10.1159/000134041; ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIEKER JJ, 1984, J BIOL CHEM, V259, P6158; BOGENHAGEN DF, 1993, MOL CELL BIOL, V13, P5149, DOI 10.1128/MCB.13.9.5149; BOGENHAGEN DF, 1985, J BIOL CHEM, V260, P6466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; DREW PD, 1995, GENE, V159, P215, DOI 10.1016/0378-1119(95)00145-V; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HANAS JS, 1983, P NATL ACAD SCI-BIOL, V80, P2142, DOI 10.1073/pnas.80.8.2142; HANSEN PK, 1993, J MOL BIOL, V233, P191, DOI 10.1006/jmbi.1993.1499; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEE Y, 1995, NUCLEIC ACIDS RES, V23, P634, DOI 10.1093/nar/23.4.634; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILNE CA, 1993, J BIOL CHEM, V268, P11364; MOOREFIELD B, 1994, J BIOL CHEM, V269, P20857; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFART KH, 1989, J BIOL CHEM, V264, P1702; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VELDHOEN N, 1994, BIOCHEMISTRY-US, V33, P7568, DOI 10.1021/bi00190a009; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1994, RNA POLYMERASE 3 TRA; WOYCHIK NA, 1992, P NATL ACAD SCI USA, V89, P3999, DOI 10.1073/pnas.89.9.3999; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028; ZANG WQ, 1995, BIOCHEMISTRY-US, V34, P15545, DOI 10.1021/bi00047a021	68	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12103	12110		10.1074/jbc.271.20.12103	http://dx.doi.org/10.1074/jbc.271.20.12103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662611	hybrid			2022-12-27	WOS:A1996UL25000078
J	Tetsuka, T; Baier, LD; Morrison, AR				Tetsuka, T; Baier, LD; Morrison, AR			Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells - Evidence for post-transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR KAPPA-B; OXIDATION-REDUCTION; PHORBOL ESTER; ACTIVATION; GENE; PHOSPHORYLATION; PROMOTER; RNA	Glomerular mesangial cells produce reactive oxygen intermediates when stimulated by interleukin-1 (IL-1) or turner necrosis factor. Recent observations suggest that reactive oxygen intermediates may play a role in IL-1 and tumor necrosis factor signaling and may upregulate gene expression. We therefore evaluated the effects of antioxidants on IL-1 beta-induced cyclooxygenase-2 (Cox-2) and inducible nitric-oxide synthase (iNOS) expression in rat mesangial cells, The oxidant scavenger, pyrrolidine dithiocarbamate (PDTC), inhibited iNOS expression at the transcriptional level, since PDTC abolished iNOS mRNA accumulation. In contrast, PDTC inhibited Cox-a expression at the post-transcriptional level, since PDTC did not affect IL-1 beta-induced Cox-2 mRNA levels but inhibited Cox-2 protein expression and prostaglandin E(2) production. Another antioxidant, rotenone, which inhibits reactive oxygen intermediate production by inhibiting the mitochondrial electron transport system, did not inhibit IL-1 beta-induced iNOS and Cox-2 mRNA expression but inhibited iNOS and Cox-2 protein expression, suggesting a post-transcriptional target for the inhibition of iNOS and Cox-2 expression induced by IL-1 beta. These results suggest that not only transcriptional regulation but also post-transcriptional mechanisms are involved in redox-sensitive inhibition of cytokine induced Cox-2 and iNOS expression. These results suggest a novel approach for intervention in cytokine-mediated inflammatory processes.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK 38111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; JAGUS R, 1981, J BIOL CHEM, V256, P1324; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MALTER JS, 1991, J BIOL CHEM, V266, P3167; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; ROVIN BH, 1995, KIDNEY INT, V48, P1263, DOI 10.1038/ki.1995.410; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; TETSUKA T, 1994, P NATL ACAD SCI USA, V91, P12168, DOI 10.1073/pnas.91.25.12168; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	19	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11689	11693		10.1074/jbc.271.20.11689	http://dx.doi.org/10.1074/jbc.271.20.11689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662662	hybrid			2022-12-27	WOS:A1996UL25000019
J	Abe, K; Ruan, ZS; Maloney, PC				Abe, K; Ruan, ZS; Maloney, PC			Cloning, sequencing, and expression in Escherichia coli of OxlT, the oxalate:formate exchange protein of Oxalobacter formigenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; RECONSTITUTION; DECARBOXYLASE; PURIFICATION; ANTIPORT; GENE	OxlT is the oxalate/formate exchange protein that represents the vectorial component of a proton-motive metabolic cycle in Oxalobacter formigenes. Here we report the cloning and sequencing of OxlT and describe its expression in Escherichia coli. The OxlT amino acid sequence specifies a polytopic hydrophobic protein of 418 residues with a mass of 44,128 daltons. Analysis of hydropathy and consideration of the distribution of charged residues suggests an OxlT secondary structure having 12 transmembrane segments, oriented so that the N and C termini face the cytoplasm. Expression of OxlT in E. coli coincides with appearance of a capacity to carry out the self-exchange of oxalate and the heterologous, electrogenic exchange of oxalate with formate. The unusually high velocity of OxlT-mediated transport is also preserved in E. coli. We conclude that the essential features of OxlT are retained on its expression in E. coli.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, R01GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; KUHNER CH, 1987, ANN M AM SOC MICR WA; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNG HY, 1991, AM J KIDNEY DIS, V17, P381, DOI 10.1016/S0272-6386(12)80627-5; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; ROST B, 1995, PROTEIN SCI, V4, P521; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARERO JP, 1995, J BACTERIOL, V177, P297; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	29	54	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6789	6793		10.1074/jbc.271.12.6789	http://dx.doi.org/10.1074/jbc.271.12.6789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636101	hybrid			2022-12-27	WOS:A1996UB15700036
J	Malek, SN; Yang, CH; Earnshaw, WC; Kozak, CA; Desiderio, S				Malek, SN; Yang, CH; Earnshaw, WC; Kozak, CA; Desiderio, S			p150(TSP), conserved nuclear phosphoprotein that contains multiple tetratricopeptide repeats and binds specifically to SH2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; AFFINITY PHOSPHOTYROSYL PEPTIDE; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; RECEPTOR; GRB2; SOS; TRANSFORMATION; RECOGNITION; ACTIVATOR	Src homology 2 (SH2) domains are structural modules that function in the assembly of multicomponent signaling complexes by binding to specific phosphopeptides. The tetratricopeptide repeat (TPR) is a distinct structural motif that has been suggested to mediate protein-protein interactions, Among SH2-binding phosphoproteins purified from the mouse B cell lymphoma A20, a 150-kDa species was identified and the corresponding complementary DNA (cDNA) was molecularly cloned, This protein encoded by this cDNA, which we have termed p150(TSP) (for TPR-containing, SH2-binding phosphoprotein), is located predominantly in the nucleus and is highly conserved in evolution, The gene encoding p150(TSP) (Tsp) was mapped to chromosome 7 of the mouse with gene order: centromere-Tyr-Wnt11-Tsp-Zp2. The amino-terminal two-thirds of p150(TSP) consist almost entirely of tandemly arranged TPR units, which mediate specific, homotypic protein interactions in transfected cells. The carboxyl-terminal third of p150(TSP) which is serine- and glutamic acid-rich, is essential for SH2 binding; this interaction is dependent on serine/threonine phosphorylation but independent of tyrosine phosphorylation, The sequence and binding properties of p150(TSP) suggest that it may mediate interactions between TPR-containing and SH2-containing proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; NIAID, NIH, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CACERES A, 1984, J NEUROSCI, V4, P394; CASAMAYOR A, 1995, YEAST, V11, P1281, DOI 10.1002/yea.320111308; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6952	6962		10.1074/jbc.271.12.6952	http://dx.doi.org/10.1074/jbc.271.12.6952			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636124	hybrid			2022-12-27	WOS:A1996UB15700059
J	MarzalCasacuberta, A; BlancoVaca, F; Ishida, BY; JulveGil, J; Shen, JH; CalvetMarquez, S; GonzalezSastre, F; Chan, L				MarzalCasacuberta, A; BlancoVaca, F; Ishida, BY; JulveGil, J; Shen, JH; CalvetMarquez, S; GonzalezSastre, F; Chan, L			Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; FISH EYE SYNDROME; HEPATIC LIPASE; ESTERIFICATION RATE; SERUM-LIPOPROTEINS; TANGIER DISEASE; GENE; HDL; EXPRESSION; TRANSPORT	The concentration of high density lipoproteins (HDL) is inversely related to the risk of atherosclerosis, The two major protein components of HDL are apolipoprotein (apo) A-I and apoA-II. To study the role of apoA-II in lipoprotein metabolism and atherosclerosis, we have developed three lines of C57BL/6 transgenic mice expressing human apoA-II (lines 25.3, 21.5, and 11.1). Northern blot experiments showed that human apoA-II mRNA was present only in the liver of transgenic mice, SDS-polyacrylamide gel electrophoresis and Western blot analysis demonstrated a 17.4-kDa human apoA-II in the HDL fraction of the plasma of transgenic mice, After 3 months on a regular chow, the plasma concentrations of human apoA-II were 21 +/- 4 mg/dl in the 25.3 line, 51 +/- 6 mg/dl in the 21.5 line, and 74 +/- 4 mg/dl in the 11.1 line. The concentration of cholesterol in plasma was significantly lower in transgenic mice than in control mice because of a decrease in HDL cholesterol that was greatest in the Line that expressed the most apoA-II (23 mg/dl in the 11.1 line versus 63 mg/dl in control mice). There was also a reduction in the plasma concentration of mouse apoA-I (32 +/- 2, 56 +/- 9, 91 +/- 7, and 111 +/- 2 mg/dl for lines 11.1, 21.5, 25.3, and control mice, respectively) that was inversely correlated with the amount of human apoA-II expressed, Additional changes in plasma lipid/lipoprotein profile noted in line 11.1 that expressed the highest level of human apoA-II include elevated triglyceride, increased proportion of total plasma, and RDL free cholesterol and a marked (>10-fold) reduction in mouse apoA-II. Total endogenous plasma lecithin:cholesterol acyltransferase (LCAT) activity was reduced to a level directly correlated with the degree of increased plasma human apoA-II in the transgenic lines, LCAT activity toward erogenous substrate was, however, only slightly decreased, The biochemical changes in the 11.1 line, which is markedly deficient in plasma apoA-I, an activator for LCAT, are reminiscent of those in patients with partial LCAT deficiency, Feeding the transgenic mice a high fat, high cholesterol diet maintained the mouse apoA-I concentration at a normal level (69 +/- 14 mg/dl in line 11.1 compared with 71 +/- 6 mg/dl in non-transgenic controls) and prevented the appearance of HDL deficiency, All this happened in the presence of a persistently high plasma human apoA-II (96 +/- 14 mg/dl), Paradoxical HDL elevation by high fat diets has been observed in humans and is reproduced in human apoA-II overexpressing transgenic mice but not in control mice. Finally, HDL size and morphology varied substantially in the three transgenic lines, indicating the importance of apoA-II concentration in the modulation of HDL formation, The LCAT and HDL deficiencies observed in this study indicate that apoA-II plays a dynamic role in the regulation of plasma HDL metabolism.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOLEC, E-08025 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, INST RECERA, E-08025 BARCELONA, SPAIN; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV RES MED & RADIAT BIOPHYS, BERKELEY, CA 94720 USA; UNIV AUTONOMA BARCELONA, UNITAT ANAT & EMBRIOL, E-08193 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, SERV BIOQUIM, E-08025 BARCELONA, SPAIN	Baylor College of Medicine; Baylor College of Medicine; Autonomous University of Barcelona; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Autonomous University of Barcelona			Julve, Josep/I-1003-2017; Blanco-Vaca, Francisco/AAC-2600-2022	Julve, Josep/0000-0002-6531-2246; Blanco-Vaca, Francisco/0000-0001-7380-5385	NHLBI NIH HHS [HL47443, HL16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047443, R01HL016512, R37HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHORIK PS, 1982, CLIN CHEM, V28, P1375; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BLANCOVACA F, 1992, J LIPID RES, V33, P1785; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; BROWN WV, 1969, J BIOL CHEM, V244, P5687; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CARSON SD, 1987, J BIOL CHEM, V262, P718; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHENG ML, 1988, BIOCHEM GENET, V26, P657, DOI 10.1007/BF00553867; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1993, J CLIN INVEST, V91, P522, DOI 10.1172/JCI116231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAY MA, 1991, ARTERIOSCLER THROMB, V11, P415, DOI 10.1161/01.ATV.11.2.415; CZARNECKA H, 1995, BIOCHEMISTRY-US, V34, P4385, DOI 10.1021/bi00013a030; DEEB SS, 1990, AM J HUM GENET, V46, P822; DOBIASOVA M, 1992, J LIPID RES, V33, P1411; DOBIASOVA M, 1986, PHYSIOL BOHEMOSLOV, V35, P319; FONTANALSFERRER N, 1988, CLIN CHEM, V34, P1753; FORTE TM, 1984, ARTERIOSCLEROSIS, V4, P130, DOI 10.1161/01.ATV.4.2.130; FORTE TM, 1995, J LIPID RES, V36, P148; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; FRUCHART JC, 1993, CIRCULATION, V87, P22; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GLASS CK, 1983, J BIOL CHEM, V258, P7161; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; HUSSAIN MM, 1990, BIOCHEMISTRY-US, V29, P209, DOI 10.1021/bi00453a029; IKEWAKI K, 1995, ARTERIOSCL THROM VAS, V15, P306, DOI 10.1161/01.ATV.15.3.306; ISHIDA BY, 1992, J LIPID RES, V33, P1073; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; KLEIN HG, 1992, J CLIN INVEST, V89, P499, DOI 10.1172/JCI115612; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; KNOTT TJ, 1985, NUCLEIC ACIDS RES, V13, P6387, DOI 10.1093/nar/13.17.6387; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; MILLER CG, 1987, J LIPID RES, V28, P311; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MOWRI HO, 1992, J LIPID RES, V33, P1269; OHTA T, 1994, ARTERIOSCLER THROMB, V14, P1137, DOI 10.1161/01.ATV.14.7.1137; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; PARKS JS, 1995, J LIPID RES, V36, P349; PONSIN G, 1993, J BIOL CHEM, V268, P3114; QU SJ, 1993, BIOCHEMISTRY-US, V32, P3089, DOI 10.1021/bi00063a021; ROSSENEU M, 1981, EUR J BIOCHEM, V117, P347, DOI 10.1111/j.1432-1033.1981.tb06344.x; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Scanu A M, 1980, Ann N Y Acad Sci, V348, P160, DOI 10.1111/j.1749-6632.1980.tb21298.x; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SERRATSERRAT J, 1993, ATHEROSCLEROSIS, V101, P43, DOI 10.1016/0021-9150(93)90100-9; STOLTZFUS LJ, 1994, CIRCULATION, V90, P81; TAILLEUX A, 1994, CIRCULATION, V90, P81; THUREN T, 1991, J BIOL CHEM, V266, P4853; VADIVELOO PK, 1993, BIOCHEMISTRY-US, V32, P9480, DOI 10.1021/bi00087a028; WANG CS, 1987, BIOCHIM BIOPHYS ACTA, V920, P9, DOI 10.1016/0005-2760(87)90305-5; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WARDEN CH, 1993, P NATL ACAD SCI USA, V90, P10886, DOI 10.1073/pnas.90.22.10886; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	70	67	67	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6720	6728		10.1074/jbc.271.12.6720	http://dx.doi.org/10.1074/jbc.271.12.6720			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636092	hybrid			2022-12-27	WOS:A1996UB15700027
J	Salzet, M; Bulet, P; Weber, WM; Clauss, W; VergerBocquet, M; Malecha, J				Salzet, M; Bulet, P; Weber, WM; Clauss, W; VergerBocquet, M; Malecha, J			Structural characterization of a novel neuropeptide from the central nervous system of the leech Erpobdella octoculata - The leech osmoregulator factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THEROMYZON-TESSULATUM OFM; SEX SEGMENTAL GANGLIA; SUPRAESOPHAGEAL GANGLION; YOLK PROTEIN; OXYTOCIN; NEURONS; IDENTIFICATION; VITELLOGENIN; SUBSTANCE; PEPTIDE	Purification of a material immunoreactive to an antiserum against the C-terminal part of the oxytocin (Pro-Leu-Gly-amide) and present in the central nervous system of the Pharyngobdellid leech Erpobdella octoculata was performed by reversed-phase high performance liquid chromatography combined with both enzyme-linked immunosorbent and dot immunobinding assays for oxytocin. The amino acid sequence of the purified peptide (Ile-Pro-Glu-Pro-Tyr-Val-Trp-Asp) was established by Edman degradation and confirmed be electrospray mass spectrometry measurement. When injected in leeches, purified or synthetic peptides exert an antidiuretic effect, the most effective ranged between 10 pmol and 1 nmol. They provoked an uptake of water 1-2 h post-injection. Furthermore, electrophysiological experiments conducted in the leech Hirudo medicinalis revealed an inhibition of the potency of Na+ conductances of leech skin by this peptide. Immunocytochemical studies with an antiserum against synthetic oxytocin-like molecule provided the cytological basis for existence of a neuropeptide, since large amounts of immunoreactive neurons were detected ih the central nervous systems of E. octoculata. The purified molecule is both different to peptides of the oxytocin/vasopressin family and is a novel neuropeptide in the animal kingdom, It was named the leech osmoregulator factor (LORF). An identification of the proteins immunoreactive to an antiserum against oxytocin performed at the level of both central nervous systems extracts and in vitro central nervous system-translated RNA products indicated that in the two cases, a single protein was detected. These proteins with a molecular masses of, respectively, similar to 34 kDa (homodimer of 17 kDa) for the central nervous systems extracts and similar to 19 kDa for in vitro central nervous system-translated RNA products were not recognized by the antiserum against MSEL- and VLDV-neurophysin (proteins associated to oxytocin and vasopressin), confirming that LORF did not belong to the oxytocin/vasopressin family.	INST BIOL MOLEC & CELLULAIRE, UPR 9022 CNRS, F-67084 STRASBOURG, FRANCE; UNIV GIESSEN, INST TIERPHYSIOL, D-35392 GIESSEN, GERMANY	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Justus Liebig University Giessen	Salzet, M (corresponding author), UNIV SCI & TECH LILLE FLANDRES ARTOIS, GRP NEUROENDOCRINOL, LAB PHYLOGENIE MOLEC ANNELIDES, F-59655 VILLENEUVE DASCQ, FRANCE.		BULET, Philippe/C-8557-2014; Salzet, Michel/A-7675-2011	BULET, Philippe/0000-0001-9016-265X; Salzet, Michel/0000-0003-4318-0817				Acher R., 1985, P1147; BAERT JL, 1991, EUR J BIOCHEM, V201, P191, DOI 10.1111/j.1432-1033.1991.tb16273.x; BAERT JL, 1992, EUR J BIOCHEM, V209, P563, DOI 10.1111/j.1432-1033.1992.tb17321.x; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P251; CZECHOWICZ K, 1968, Zoologica Poloniae, V18, P81; DEWITH ND, 1992, NEUROREPORT, V3, P612, DOI 10.1097/00001756-199207000-00017; HAGADORN IRVINE REY, 1958, J MORPH, V102, P55, DOI 10.1002/jmor.1051020104; KLIPPENSTEIN GL, 1976, BIOCHEMISTRY-US, V15, P1128, DOI 10.1021/bi00650a027; KULKARNI GK, 1978, HYDROBIOLOGIA, V59, P197, DOI 10.1007/BF00036498; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALECHA J, 1989, CAN J ZOOL, V67, P636, DOI 10.1139/z89-091; MALECHA J, 1983, GEN COMP ENDOCR, V49, P344, DOI 10.1016/0016-6480(83)90198-3; MALECHA J, 1989, CR ACAD SCI III-VIE, V309, P127; Muller K. J., 1981, NEUROBIOLOGY LEECH, P320; ORCHARD I, 1980, J NEUROBIOL, V11, P229, DOI 10.1002/neu.480110302; ROSCA D. I., 1958, STUD CERCETARI BIOL [CLUJ], V9, P113; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SALZET M, 1994, EUR J BIOCHEM, V221, P269, DOI 10.1111/j.1432-1033.1994.tb18738.x; SALZET M, 1993, COMP BIOCHEM PHYS A, V104, P75, DOI 10.1016/0300-9629(93)90011-R; SALZET M, 1993, BRAIN RES, V601, P173, DOI 10.1016/0006-8993(93)91708-Z; SALZET M, 1992, COMP BIOCHEM PHYS C, V102, P483, DOI 10.1016/0742-8413(92)90147-Y; SALZET M, 1995, J BIOL CHEM, V270, P1575, DOI 10.1074/jbc.270.4.1575; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawyer R. T, 1986, LEECH BIOL BEHAV, V1; TRAMU G, 1983, NEUROENDOCRINOLOGY, V37, P467, DOI 10.1159/000123595; VERGERBOCQUET M, 1992, CAN J ZOOL, V70, P856, DOI 10.1139/z92-122; WEBER WM, 1995, AM J PHYSIOL-REG I, V268, pR605, DOI 10.1152/ajpregu.1995.268.3.R605; WEBER WM, 1993, J COMP PHYSIOL B, V163, P153	28	16	16	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7237	7243		10.1074/jbc.271.12.7237	http://dx.doi.org/10.1074/jbc.271.12.7237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636163	hybrid			2022-12-27	WOS:A1996UB15700098
J	Schuur, ER; Henderson, GA; Kmetec, LA; Miller, JD; Lamparski, HG; Henderson, DR				Schuur, ER; Henderson, GA; Kmetec, LA; Miller, JD; Lamparski, HG; Henderson, DR			Prostate-specific antigen expression is regulated by an upstream enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RESPONSE ELEMENT; ADENOCARCINOMA CELL-LINE; GENE-EXPRESSION; CARCINOMA; LNCAP; KALLIKREIN; CANCER; RNA; DNA	Prostate cancer can be detected using assays for blood-borne prostate-specific antigen (PSA), which is the clinically most useful diagnostic marker of malignant disease, This paper characterizes the 5'-flanking prostate-specific enhancer which controls expression of the human PSA gene This enhancer, located between -5824 and -3738, is androgen-responsive and requires a promoter for activity, Inductions of 12-100-fold activity occur at 1 nM concentrations of the testosterone analog R1881. The enhancer demonstrated tissue specificity as judged by transfections of several human cell lines. Electrophoretic mobility shift assays comparing nuclear extracts from breast cancer cells MCF-7, and prostate cancer cells LNCaP, showed three regions of prostate-specific binding, These three regions are -4168 to -4797 (region I), -4710 to 4479 (region II), and -4168 to -3801 (region III), Region III contained a putative androgen response element at -4136 that markedly affected activity if mutated, These data suggest that prostate-specific gene expression may involve interaction of prostate-specific proteins or protein complexes with the enhancer in addition to binding of the androgen receptor to androgen response elements.	CALYDON INC, MENLO PK, CA 94025 USA; STANFORD UNIV, SCH MED, DEPT SURG, STANFORD, CA 94305 USA	Stanford University								ABMAYR SM, 1994, CURRENT PROTOCOLS MO, V2; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ANDRIOLE GL, 1991, ANNU REV MED, V42, P9, DOI 10.1146/annurev.med.42.1.9; ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; AUMULLER G, 1990, PROSTATE, V17, P31, DOI 10.1002/pros.2990170105; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; DIGBY M, 1989, NUCLEIC ACIDS RES, V17, P2137, DOI 10.1093/nar/17.5.2137; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRE S, 1994, J BIOL CHEM, V269, P5857; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; GAFFNEY EV, 1979, JNCI-J NATL CANCER I, V63, P913; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HSIEH JT, 1993, CANCER RES, V53, P2852; KINGSTON RE, 1994, CURRENT PROTOCOLS MO, V2; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MICKEY DD, 1977, CANCER RES, V37, P4049; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAPMAN J, 1992, PROSTATE, P159; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	35	258	288	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7043	7051		10.1074/jbc.271.12.7043	http://dx.doi.org/10.1074/jbc.271.12.7043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636136	hybrid			2022-12-27	WOS:A1996UB15700071
J	Vasilescu, S; Ptushkina, M; Linz, B; Muller, PP; McCarthy, JEG				Vasilescu, S; Ptushkina, M; Linz, B; Muller, PP; McCarthy, JEG			Mutants of eukaryotic initiation factor eIF-4E with altered mRNA cap binding specificity reprogram mRNA selection by ribosomes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RNA 5' CAP; MESSENGER-RNA; PROTEIN-SYNTHESIS; SECONDARY STRUCTURE; ESCHERICHIA-COLI; TRANSLATION; YEAST; EXPRESSION; PURIFICATION	Recognition of the 5'-end of eukaryotic mRNA by the ribosomal 43 S preinitiation complex involves the eukaryotic translation initiation factor elF-4E (eIF-4 alpha). Deletion mutants of the eIF-4E gene of Saccharomyces cerevisiae (CDC33) encoded proteins with reduced affinity for the 5'-cap. One of these mutant proteins lacked any detectable binding to a cap analogue binding column, yet was still able to support cell growth. More than 17% of the total eIF-4E amino acid sequence could be removed without fully inactivating this factor, At least 30 of the N-terminal amino acids are not essential for function, The minimal functional eIF-4E protein segment therefore comprises at most 176 amino acids. The translation and growth defects of the deletion mutants could be at least partially compensated by increases in eIF-4E synthesis, possibly due to a mass-action effect on mRNA binding. Electroporation of yeast spheroplasts with in vitro synthesized mRNA allowed us to characterize the ability of elF-4E mutant strains to distinguish between capped and uncapped mRNAs in vivo. Our data show that the cap specificity of eIF-4E determines to what extent the translational apparatus differentiates between capped and uncapped mRNAs and indicate the minimum relative mRNA (cap) binding activity of eIF-4E required for yeast cell viability.	GESELL BIOTECHNOL FORSCH MBH, NATL BIOTECHNOL RES CTR, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH			Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DOBSON MJ, 1983, NUCLEIC ACIDS RES, V11, P2287, DOI 10.1093/nar/11.8.2287; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; EVERETT JG, 1992, YEAST, V8, P1007, DOI 10.1002/yea.320081203; GASIOR E, 1979, J BIOL CHEM, V254, P3965; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Guthrie C., 1991, METHOD ENZYMOL, V194, P21; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; ISHIDA T, 1983, BIOCHEM BIOPH RES CO, V115, P849, DOI 10.1016/S0006-291X(83)80012-6; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG V, 1994, J BIOL CHEM, V269, P6117; LANKER S, 1992, J BIOL CHEM, V267, P21167; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	41	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7030	7037		10.1074/jbc.271.12.7030	http://dx.doi.org/10.1074/jbc.271.12.7030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636134	hybrid			2022-12-27	WOS:A1996UB15700069
J	Berthelsen, J; Vandekerkhove, J; Blasi, F				Berthelsen, J; Vandekerkhove, J; Blasi, F			Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP-1 controlled promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; TRANSCRIPTION FACTOR; RNA-POLYMERASE; BINDING-SITES; PHORBOL-ESTER; ELEMENT; EXPRESSION; INDUCTION; ENHANCER; MOUSE	Basal as well as induced transcription from the human urokinase type plasminogen activator gene requires an enhancer containing two elements, a combined PEA3/AP-1 and a consensus AP-1 site. The integrity of each of these binding sites as well as their cooperation is required for activating transcription. The two elements are separated by a 74-base pair cooperation mediating (COM) region required for the cooperation between the transactivating sites. The COM region contains binding sites for four different unidentified urokinase-type plasminogen activator enhancer factors (UEF 1 to 4), all four required for correct COM activity. We have purified UEF3 from HeLa nuclear extracts by several chromatographic steps including DNA affinity purification. Purification and UV cross-linking data showed that UEF3 is a complex of three polypeptides (p40, p50, and p64). Amino acid sequence from one peptide of p64 was obtained, which showed no homology to other known proteins. Both crude and purified UEF3 specifically bound to the sequence TGACAG as shown by electrophoretic mobility shifts and methylation interference studies. DNA-binding specificity of purified UEF3 was identical to that of NIP, a non-characterized factor binding and regulating multiple AP-1-regulated promoters like stromelysin and interleukin-3. Thus UEF3 appears to be a general DNA-binding factor involved in modulating the transcriptional response of AP-1 containing promoters.	UNIV MILAN,DEPT GENET & BIOL MICROORGANISMS,I-20135 MILAN,ITALY; IST SCI SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN,DENMARK; STATE UNIV GHENT,GENET LAB,B-9000 GHENT,BELGIUM	University of Milan; Vita-Salute San Raffaele University; University of Copenhagen; Ghent University				Blasi, Francesco/0000-0001-9406-1784				BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; Blasi F, 1990, Semin Cancer Biol, V1, P117; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P588; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MATSUDAIRA P, 1978, ANAL BIOCHEM, V87, P1386; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; RITTER LM, 1995, MOL CELL BIOL, V15, P3110; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J, 1989, MOL CLONING LABORATO; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699	23	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3822	3830						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632000				2022-12-27	WOS:A1996TV72400074
J	Coquil, JF; Mauger, JP; Claret, M				Coquil, JF; Mauger, JP; Claret, M			Inositol 1,4,5-trisphosphate slowly converts its receptor to a state of higher affinity in sheep cerebellum membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM RELEASE; TRISPHOSPHATE RECEPTOR; INSP3 RECEPTOR; PURKINJE-CELLS; FUNCTIONAL-CHARACTERIZATION; ENDOPLASMIC-RETICULUM; CA2+ STORES; BINDING	Incubation of cerebellar microsomes with D-myo-inositol 1,4,5-trisphosphate (InsP(3)) (0.01-1 mu M), at 4 or 20 degrees C in a cytosolic-like medium devoid of Ca2+ and Mg2+, followed by InsP(3) removal, induced an increase in InsP(3) binding determined with 1 nM [H-3]InsP(3). At 20 degrees C, and pH 7.1, maximal stimulation (1.5-2.5-fold) was obtained with 1 mu M InsP(3), and the EC(50) was 60 +/- 5 mu M. Several lines of evidence suggested that the activating site is identical with the InsP(3) binding site: (i) activation and binding exhibited the same inositol phosphate specificity; (ii) addition of decavanadate, a competitive inhibitor of [H-3]InsP(3) binding, to the preincubation mixture, prevented the activating effect of InsP(3); (iii) the concentration of InsP(3) giving half-maximal activation was close to that giving half-maximal InsP(3) binding. The time course of activation was found to be much slower than that of binding. While a t(1/2) less than 0.4 s has been measured recently at neutral pH and 20 degrees C for binding of 0.5 nM [H-3]InsP(3) (Hannaert-Merah, Z., Coquil, J.-F., Combettes, L., Claret, M., Mauger, J.-P., and Champeil, P. (1994) J. Biol. Chem. 269, 29642-29649), a 20-s preincubation with 1 mu M InsP(3) was required to half-maximally stimulate binding. Under the present conditions, the InsP(3)-induced binding increase was only partially reversible. However, this effect was not blocked by antiproteases suggesting that it did not involve proteolysis. Taking advantage of the marked difference in the kinetics of InsP(3) binding and InsP(3)-dependent activation, we performed binding experiments on a short period (3 s) to determine the effect of InsP(3) pretreatment on the binding parameters. The data showed that this treatment increased the affinity of the receptor without changing the number of binding sites (control: K-D = 107 nM, B-max = 28 pmol/mg of protein; after preincubation with 1 mu M InsP(3): K-D = 53 nM, B-max = 32 pmol/mg of protein). The two states of the receptor bound InsP(3) with a Hill coefficient close to 1 on a 3-s scale. In agreement with the effect of InsP(3) pretreatment, equilibrium binding experiments performed on 10-min incubations revealed an apparent positive cooperative behavior (apparent Hill coefficient = 1.6; apparent K-D = 66 nM). These results report a new regulatory process of the InsP(3) receptor in cerebellum occurring independently of Ca2+ and on a relatively long time scale.			Coquil, JF (corresponding author), UNIV PARIS 11, INSERM, U274, UNITE RECH, F-91405 ORSAY, FRANCE.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DANIEL H, 1992, EXP BRAIN RES, V90, P327; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOHR KJ, 1989, BIOCHEM J, V262, P83; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PARKER I, 1989, J NEUROSCI, V9, P4068; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; TAKEI K, 1992, J NEUROSCI, V12, P489; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WATRAS J, 1994, BIOCHEMISTRY-US, V33, P14359, DOI 10.1021/bi00251a050; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	59	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3568	3574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631963				2022-12-27	WOS:A1996TV72400037
J	Li, SW; Seitz, R; Lisanti, MP				Li, SW; Seitz, R; Lisanti, MP			Phosphorylation of caveolin by Src tyrosine kinases - The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PROTEIN; CELLS; MEMBRANE; EXPRESSION	Caveolae are flask-shaped plasma membrane specializations that are thought to exist in most cell types. A 22-kDa protein, caveolin, is an integral membrane component of caveolae membranes in vivo. Previous studies have demonstrated that caveolin is phosphorylated on tyrosine by oncogenic viral Src (v-Src) and that caveolin is physically associated as a hetero-oligomeric complex with normal cellular Src (c-Src) and other Src family tyrosine kinases. Caveolin contains eight conserved tyrosine residues that may serve as potential substrates for Src, Here, we have begun to study the phosphorylation of caveolin by Src family tyrosine kinases both in vitro and in vivo. Using purified recombinant components, we first reconstituted the phosphorylation of caveolin by Src kinase in vitro, Microsequencing of Src-phosphorylated caveolin revealed that phosphorylation occurs within the extreme N-terminal region of full-length caveolin between residues 6 and 26, This region contains three tyrosine residues at positions 6, 14, and 25. Deletion mutagenesis demonstrates that caveolin residues 1-21 are sufficient to support this phosphorylation event, implicating tyrosine 6 and/or 14, In vitro phosphorylation of caveolin-derived synthetic peptides and site-directed mutagenesis directly show that tyrosine 14 is the principal substrate for Src kinase, In support of these observations, tyrosine 14 is the only tyrosine residue within caveolin that bears any resemblance to the known recognition motifs for Src family tyrosine kinases. In order to confirm or refute the relevance of these in vitro studies, we next analyzed the tyrosine phosphorylation of endogenous caveolin in v-Src transformed NIH 3T3 cells. In vivo, two isoforms of caveolin are known to exist: alpha-caveolin contains residues 1-178 and beta-caveolin contains residues 32-178. Only alpha-caveolin underwent tyrosine phosphorylation in v-Src transformed NIH 3T3 cells, although beta-caveolin is well expressed in these cells. As beta-caveolin lacks residues 1-31 (and therefore tyrosine 14), these in vivo studies directly demonstrate the validity of our in vitro studies, Because alpha- and beta-caveolin are known to assume a distinct but overlapping subcellular distribution within a single cell, v-Src phosphorylation of alpha-caveolin may only affect a subpopulation of caveolae that contain alpha-caveolin.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; RES GENET INC,HUNTSVILLE,AL 35801	Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Li, PhD,EIC,FRSM,FRSB, Shengwen Calvin/0000-0002-9699-9204	NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6	34	299	311	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3863	3868						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632005				2022-12-27	WOS:A1996TV72400079
J	Tilbrook, PA; Bittorf, T; Busfield, SJ; Chappell, D; Klinken, SP				Tilbrook, PA; Bittorf, T; Busfield, SJ; Chappell, D; Klinken, SP			Disrupted signaling in a mutant J2E cell line that shows enhanced viability, but does not proliferate or differentiate, with erythropoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELLS; RESPONSIVE CELLS; ERYTHROID-CELLS; KINASE-ACTIVITY; RECEPTOR; ASSOCIATION; ACTIVATION; DEATH; STIMULATION	The immature erythroid J2E cell line proliferates and terminally differentiates following erythropoietin stimulation, In contrast, the mutant J2E-NR clone does not respond to erythropoietin by either proliferating or differentiating. Here we show that erythropoietin can act as a viability factor for both the J2E and J2E-NR lines, indicating that erythropoietin-initiated maturation is separable from the prevention of cell death. The inability of J2E-NR cells to mature in response to erythropoietin was not due to a defect in the erythropoietin receptor sequence, although surface receptor numbers were reduced, Both the receptor and Janus kinase 2 were phosphorylated after erythropoietin stimulation of J2E-NR cells, However, protein interactions with the erythropoietin receptor and Grb2 were restricted in the mutant cells. Subsequent investigation of several other signaling molecules exposed numerous alterations in J2E-NR cells; phosphorylation changes to phosphatidylinositol 3-kinase, phospholipase C gamma, p120 GAP, and mitogen-activated protein kinases (p42 and p44) observed in erythropoietin-stimulated J2E cells were not seen in the J2E-NR line. These data indicate that some pathways activated during erythropoietin-induced differentiation may not be essential for the prevention of apoptosis.	ROYAL PERTH HOSP, DEPT BIOCHEM, PERTH, WA 6001, AUSTRALIA; UNIV WESTERN AUSTRALIA, DEPT BIOCHEM, PERTH, WA 6001, AUSTRALIA; UNIV ROSTOCK, DEPT MED BIOCHEM, D-18057 ROSTOCK, GERMANY	Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Rostock								BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BITTORF T, 1994, CELL SIGNAL, V6, P305, DOI 10.1016/0898-6568(94)90035-3; BITTORF T, 1996, IN PRESS INT J BIOCH; BUSFIELD SJ, 1992, BLOOD, V80, P412; BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; BUSFIELD SJ, 1995, CELL GROWTH DIFFER, V6, P429; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P87; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P317, DOI 10.3109/08977199308991592; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P307, DOI 10.3109/08977199308991591; CALLUS B, 1995, EXP CELL RES, V219, P39, DOI 10.1006/excr.1995.1202; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; HANAZONO Y, 1993, BLOOD, V81, P3193; HE TC, 1994, J BIOL CHEM, V269, P18291; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIBOI E, 1992, BLOOD, V80, P1183; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SPIVAK JL, 1991, BLOOD, V77, P1228; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAXMAN DJ, 1995, J BIOL CHEM, V270, P6619, DOI 10.1074/jbc.270.12.6619; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V203, P1912, DOI 10.1006/bbrc.1994.2411; TORTI M, 1992, J BIOL CHEM, V267, P8293; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	59	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3453	3459						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631947				2022-12-27	WOS:A1996TV72400021
J	Guy, HI; Evans, DR				Guy, HI; Evans, DR			Function of the major synthetase subdomains of carbamyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; ATP-BINDING-SITES; CARBONIC-PHOSPHORIC ANHYDRIDE; COOH-TERMINAL DOMAIN; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; LARGE SUBUNIT; NUCLEOTIDE-SEQUENCE	The amidotransferase domain (GLNase) of mammalian carbamyl-phosphate synthetase II hydrolyzes glutamine and transfers ammonia to the synthetase domain where carbamyl phosphate is formed in a three-step reaction sequence. The synthetase domain consists of two homologous subdomains, CPS.A and CPS.B. Recent studies suggest that CPS.A catalyzes the initial ATP dependent-activation of bicarbonate, whereas CPS.B uses a second ATP to form carbamyl phosphate. To establish the function of these substructural elements, we have cloned and expressed the mammalian protein and its subdomains in Escherichia coli. Recombinant CPSase (GLNase-CPS.A-CPS.B) was found to br fully functional. Two other proteins were made; the first consisted of only GLNase and CPS.A, whereas the second lacked CPS.A and had the GLNase domain fused directly to CPS.B. Remarkably, both proteins catalyzed the entire series of reactions involved in glutamine-dependent carbamyl phosphate synthesis. The stoichiometry, like that of the native enzyme, was 2 mol of ATP utilized per mol of carbamyl phosphate formed. GLN-CPS.B is allosterically regulated, whereas GLN-CPS.A was insensitive to effectors, a result consistent with evidence showing that allosteric effectors bind to CPS.B. These properties are not peculiar to the mammalian protein, because the separately cloned CPS.A subdomain of the E. coli enzyme was also found to catalyze carbamyl phosphate synthesis. Gel filtration chromatography and chemical cross-linking studies showed that these molecules are dimers, a structural organization that may be a prerequisite for the overall reaction. Thus, the homologous CPS.A and CPS.B subdomains are functionally equivalent, although in the native enzyme they may have different functions resulting from their juxtaposition relative to the other components in the complex.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P5576, DOI 10.1021/bi00367a035; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BEIN K, 1991, J BIOL CHEM, V266, P3791; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; CERVERA J, 1993, J BIOL CHEM, V268, P12504; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FOLEY R, 1971, BIOCHEMISTRY-US, V10, P4562, DOI 10.1021/bi00800a034; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1994, J BIOL CHEM, V269, P23808; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; KANAZAWA H, 1982, BIOCHEM BIOPH RES CO, V105, P1257, DOI 10.1016/0006-291X(82)90922-6; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LIM F, 1988, J BIOL CHEM, V263, P11493; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MARSHALL M, 1961, J BIOL CHEM, V236, P2229; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; MEEK TD, 1987, BIOCHEMISTRY-US, V26, P2584, DOI 10.1021/bi00383a026; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1957, J BIOL CHEM, V229, P1019; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; POLAKIS SE, 1972, J BIOL CHEM, V247, P1335; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERS SG, 1983, J BIOL CHEM, V258, P7545; POWERS SG, 1980, J BIOL CHEM, V255, P1554; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RAUSHEL FM, 1992, BIOORG MED CHEM LETT, V2, P319, DOI 10.1016/S0960-894X(01)80209-2; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	73	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13762	13769		10.1074/jbc.271.23.13762	http://dx.doi.org/10.1074/jbc.271.23.13762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662713	hybrid			2022-12-27	WOS:A1996UP38500069
J	Demetriou, M; Binkert, C; Sukhu, B; Tenenbaum, HC; Dennis, JW				Demetriou, M; Binkert, C; Sukhu, B; Tenenbaum, HC; Dennis, JW			Fetuin/alpha 2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2 HS-GLYCOPROTEIN; TGF-BETA; HUMAN ALPHA-2-HS-GLYCOPROTEIN; SERUM CONCENTRATION; NEGATIVE REGULATION; BONE-FORMATION; BOVINE FETUIN; EXPRESSION; PROTEIN; KINASE	The serum glycoprotein fetuin is expressed during embryogenesis in multiple tissues including limb buds and has been shown to promote bone remodeling and stimulate cell proliferation in vitro. In this report, we demonstrate that fetuin antagonizes the antiproliferative action of transforming growth factor-beta 1 (TGF-beta 1) in cell cultures. Surface plasmon resonance measurements show that fetuin binds directly to TGF beta 1 and TGF-beta 2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6). In a competitive enzyme-linked immunosorbent assay, fetuin blocked binding of TGF-beta 1 to the extracellular domain of TGF-beta receptor type II (T beta RII), one of the primary TGF-beta-binding receptors. A comparison of fetuin and T beta RII shows homology in an 18-19-amino acid sequence, which we have designated TGF-beta receptor II homology 1 domain (TRH1). Since the TRH1 sequence is known to form a disulfide loop in fetuin, cyclized TRH1 peptides from both fetuin and T beta RII were chemically synthesized and tested for cytokine binding activity. Cyclized TRH1 peptide from T beta RII bound to TGF-beta 1 with greater affinity than to BMP-2, while the cyclized TRH1 peptide from fetuin bound preferentially to BMP-2. Finally, fetuin or neutralizing anti-TGF-beta antibodies blocked osteogenesis and deposition of calcium-containing matrix in cultures of dexamethasone-treated rat bone marrow cells. In summary, these experiments define the TRH1 peptide loop as a cytokine-binding domain in both T beta RII and fetuin and suggest that fetuin is a natural antagonist of TGF-beta and BMP activities.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,FAC DENT,MRC,PERIODONTAL PHYSIOL GRP,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Dennis, James/E-7268-2013					AKHOUNDI C, 1994, J BIOL CHEM, V269, P15925; ASHTON BA, 1980, CLIN SCI, V58, P435, DOI 10.1042/cs0580435; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLCLASURE GC, 1988, J CLIN ENDOCR METAB, V66, P187, DOI 10.1210/jcem-66-1-187; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; DICKSON IR, 1983, CALCIFIED TISSUE INT, V35, P16, DOI 10.1007/BF02405000; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; JONES CM, 1991, DEVELOPMENT, V111, P531; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; LEVINE JH, 1993, AM J PATHOL, V143, P368; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NIE ZT, 1992, AM J PHYSIOL, V263, pC551, DOI 10.1152/ajpcell.1992.263.3.C551; OCONNORMCCORT MD, 1994, ANN NY ACAD SCI, V766, P300; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; OURSLER MJ, 1993, ENDOCRINOLOGY, V133, P2187, DOI 10.1210/en.133.5.2187; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; PUCK TT, 1968, P NATL ACAD SCI USA, V59, P192, DOI 10.1073/pnas.59.1.192; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; WAKEFIELD LM, 1995, CLIN CANCER RES, V1, P129; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YANG F, 1991, BONE, V12, P7, DOI 10.1016/8756-3282(91)90048-N; YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167-4781(92)90522-2	61	226	253	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12755	12761		10.1074/jbc.271.22.12755	http://dx.doi.org/10.1074/jbc.271.22.12755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662721	hybrid			2022-12-27	WOS:A1996UN47400012
J	Shibata, T; Fujii, Y; Nakamura, Y; Nakamura, K; Yamane, K				Shibata, T; Fujii, Y; Nakamura, Y; Nakamura, K; Yamane, K			Identification of protein synthesis elongation factor G as a 4.5 S RNA-binding protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; SMALL CYTOPLASMIC RNA; SECONDARY STRUCTURE; 23S RNA; NASCENT PREPROLACTIN; SEQUENCE RECOGNITION; BACILLUS-SUBTILIS; GENETIC SELECTION; SRP-RNA	Escherichia coli 4.5 S RNA is metabolically stable and abundant. It consists of 114 nucleotides, and it is structurally homologous to domain TV of mammalian signal recognition particle (SRP) RNA. In this study, we found two 4.5 S RNA-binding proteins in cell extracts by means of a gel mobility shift assay. One protein was identified as Ffh, which has been characterized as 4.5 S RNA-binding protein. The other protein was separated from Ffh by two consecutive column chromatographic elutions and by monitoring the 4.5 S RNA binding activity. After the second chromatography, a dominant protein with an approximate molecular weight of 78,000 was associated with 4.5 S RNA binding activity. A sequence of the NH2-terminal 19 residues of the 78-kDa protein was completely identical to that of the protein elongation factor G (EF-G) of E. coli, and further it cross-reacted with antiserum against E. coli EF-G. The results obtained using a synthetic oligo RNA corresponding to the 23 S rRNA defining the EF-G binding site indicated that 4.5 S RNA and 23 S rRNA are competitive in 4.5 S RNA binding and that a decanucleotide sequence conserved between them serves as a binding site for EF-G. Conservation of the SRP RNA binding activity of EF-G from Bacillus sabtilis suggests that the binding of EF-G to SRP RNA is essential for its function.	UNIV TSUKUBA,INST BIOL SCI,IBARAKI,OSAKA 305,JAPAN	University of Tsukuba								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; BOURGAIZE DB, 1987, NATURE, V325, P281, DOI 10.1038/325281a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1991, NEW BIOL, V3, P430; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1989, J BACTERIOL, V171, P6517, DOI 10.1128/jb.171.12.6517-6520.1989; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1969, COLD SPRING HARB SYM, V34, P385, DOI 10.1101/SQB.1969.034.01.045; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LILJAS A, 1990, RIBOSOME, P309; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLAN MJ, 1975, EUR J BIOCHEM, V57, P431; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NAKAMURA K, 1992, J BACTERIOL, V174, P2185, DOI 10.1128/JB.174.7.2185-2192.1992; NAKAMURA K, 1992, NUCLEIC ACIDS RES, V20, P5227, DOI 10.1093/nar/20.19.5227; NAKAMURA K, 1995, MICROBIOL-SGM, V141, P2965, DOI 10.1099/13500872-141-11-2965; NIERHAUS KH, 1992, BIOCHIMIE, V74, P403, DOI 10.1016/0300-9084(92)90118-X; NISHIGUCHI M, 1994, J BACTERIOL, V176, P157, DOI 10.1128/JB.176.1.157-165.1994; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SAMUELSSON T, 1993, NUCLEIC ACIDS RES, V21, P847, DOI 10.1093/nar/21.4.847; SIMONEAU P, 1992, J BACTERIOL, V174, P627, DOI 10.1128/jb.174.2.627-629.1992; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; STRUCK JCR, 1990, EUR J BIOCHEM, V192, P17, DOI 10.1111/j.1432-1033.1990.tb19189.x; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; STRUCK JCR, 1990, J BACTERIOL, V172, P1284, DOI 10.1128/jb.172.3.1284-1288.1990; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2719, DOI 10.1093/nar/16.6.2719; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13162	13168		10.1074/jbc.271.22.13162	http://dx.doi.org/10.1074/jbc.271.22.13162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662727	hybrid			2022-12-27	WOS:A1996UN47400073
J	Wainwright, G; Webster, SG; Wilkinson, MC; Chung, JS; Rees, HH				Wainwright, G; Webster, SG; Wilkinson, MC; Chung, JS; Rees, HH			Structure and significance of mandibular organ-inhibiting hormone in the crab, Cancer pagurus - Involvement in multihormonal regulation of growth and reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; METHYL FARNESOATE; HOMARUS-AMERICANUS; CARCINUS-MAENAS; CRUSTACEAN REPRODUCTION; PROCAMBARUS-CLARKII; JUVENILE-HORMONE; LOBSTER; INVITRO; HEMOLYMPH	Current evidence indicates that methyl farnesoate is the crustacean equivalent of the juvenile hormones of insects. This putative hormone is produced by the mandibular organs and is negatively regulated by a neuropeptide produced and secreted by the X-organ-sinus gland complex of the eyestalk. To identify this neuropeptide, a bioassay was developed which measures the inhibition of methyl farnesoate synthesis by mandibular organs exposed to fractionated sinus gland extracts from the crab, Cancer pagurus. Two neuropeptides, named mandibular organ-inhibiting hormones (MOIH-1 and -2) repressed methyl farnesoate synthesis. MOIH-1 was fully sequenced by automated Edman degradation of endoproteinase-derived fragments and further characterized by mass spectrometry. This peptide consisted of 78 residues (M(r) 9235.6), with unblocked termini and three intrachain disulfide bridges. MOIH-2 appeared to be almost identical to MOIH-1 with the exception of a Gin for Lys substitution at position 33. Comparison with previously sequenced crustacean neuropeptides shows that these MOIHs are members of the ever expanding crustacean hyperglycemic hormone family, with significant sequence similarity to molt inhibiting hormones (MIHs). It is possible that these two structurally similar peptides (MIH, MOIH) may control mutually exclusive physiological phenomena (somatic and gonadal growth), suggesting a complex hormonal integration of these processes in crustaceans.	UNIV WALES,SCH BIOL SCI,BANGOR LL57 2UW,GWYNEDD,WALES; UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Bangor University; University of Liverpool			Chung, J.Sook/D-3832-2012	Chung, J.Sook/0000-0002-9318-304X				BAZIN F, 1976, CR ACAD SCI D NAT, V282, P739; BORST DW, 1987, INSECT BIOCHEM, V17, P1123, DOI 10.1016/0020-1790(87)90133-8; BORST DW, 1994, BIOL BULL, V186, P9, DOI 10.2307/1542032; BORST DW, 1974, STEROIDS, V24, P637, DOI 10.1016/0039-128X(74)90017-8; BORST DW, 1990, RECENT ADV COMP ARTH, P35; BRODY MD, 1989, INVERTEBR REPROD DEV, V16, P141, DOI 10.1080/07924259.1989.9672070; CHANG ES, 1990, BIOCHEM BIOPH RES CO, V171, P818, DOI 10.1016/0006-291X(90)91219-I; Chung JS, 1996, NEUROPEPTIDES, V30, P95, DOI 10.1016/S0143-4179(96)90061-X; DEKLEIJN DPV, 1994, FEBS LETT, V353, P255, DOI 10.1016/0014-5793(94)01055-2; DING Q, 1991, INSECT BIOCHEM, V21, P285, DOI 10.1016/0020-1790(91)90018-A; HINSCH GW, 1981, INT J INVER REP DEV, V3, P237; HINSCH GW, 1980, T AM MICROSC SOC, V99, P317, DOI 10.2307/3226007; HORN DHS, 1976, J INSECT PHYSIOL, V22, P901, DOI 10.1016/0022-1910(76)90263-8; KING LE, 1995, INSECT BIOCHEM MOLEC, V25, P495, DOI 10.1016/0965-1748(94)00089-H; Koeppe J.K., 1985, P165; LANDAU M, 1989, INVERTEBR REPROD DEV, V16, P165, DOI 10.1080/07924259.1989.9672073; LAUFER H, 1994, INSECT NEUROCHEMISTRY AND NEUROPHYSIOLOGY 1993, P203; Laufer H., 1988, Invertebrate Endocrinology, V2, P305; LAUFER H, 1993, AM ZOOL, V33, P365; LAUFER H, 1987, SCIENCE, V235, P202, DOI 10.1126/science.235.4785.202; LAUFER H, 1987, INSECT BIOCHEM, V17, P1129, DOI 10.1016/0020-1790(87)90134-X; Laufes H., 1986, Advances in Invertebrate Reproduction, V4, P135; LEE KJ, 1995, BIOCHEM BIOPH RES CO, V209, P1126, DOI 10.1006/bbrc.1995.1614; LI H, 1991, GEN COMP ENDOCR, V81, P335, DOI 10.1016/0016-6480(91)90159-4; MEUSY JJ, 1988, ZOOL SCI, V5, P217; PRESTWICH GD, 1990, GEN COMP ENDOCR, V80, P232, DOI 10.1016/0016-6480(90)90168-L; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; SAGI A, 1991, COMP BIOCHEM PHYS B, V99, P879, DOI 10.1016/0305-0491(91)90157-9; SEVALA VL, 1989, EXPERIENTIA, V45, P355, DOI 10.1007/BF01957476; SOYEZ D, 1987, J EXP ZOOL, V244, P479, DOI 10.1002/jez.1402440314; SOYEZ D, 1991, NEUROPEPTIDES, V20, P25, DOI 10.1016/0143-4179(91)90036-I; STAY B, 1994, ADV INSECT PHYSL, V25, P268; Sun Piera S., 1994, Molecular Marine Biology and Biotechnology, V3, P1; TAKETOMI Y, 1989, CELL BIOL INT REP, V9, P1069; TAMONE SL, 1993, GEN COMP ENDOCR, V89, P425, DOI 10.1006/gcen.1993.1050; TOBE SS, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P12; TSUKIMURA B, 1992, GEN COMP ENDOCR, V86, P297, DOI 10.1016/0016-6480(92)90114-Y; WAINWRIGHT G, 1995, THESIS U LIVERPOOL; WEBSTER SG, 1986, GEN COMP ENDOCR, V61, P237, DOI 10.1016/0016-6480(86)90201-7; WEBSTER SG, 1991, P ROY SOC B-BIOL SCI, V244, P247, DOI 10.1098/rspb.1991.0078; WEBSTER SG, 1986, J COMP PHYSIOL B, V156, P617, DOI 10.1007/BF00692738; WEBSTER SG, 1996, MARINE BIOL PORT ERI; WYATT GR, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P202; YUDIN AI, 1980, BIOL BULL, V159, P760, DOI 10.2307/1540840	44	136	144	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12749	12754		10.1074/jbc.271.22.12749	http://dx.doi.org/10.1074/jbc.271.22.12749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662685	hybrid			2022-12-27	WOS:A1996UN47400011
J	Zera, EM; Molloy, DP; Angleson, JK; Lamture, JB; Wensel, TG; Malinski, JA				Zera, EM; Molloy, DP; Angleson, JK; Lamture, JB; Wensel, TG; Malinski, JA			Low affinity interactions of GDP beta S and ribose- or phosphoryl-substituted GTP analogues with the heterotrimeric G protein, transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT MEMBRANES; H-RAS P21; CGMP PHOSPHODIESTERASE ACTIVATION; ELONGATION-FACTOR-TU; GUANINE-NUCLEOTIDES; GUANOSINE 5'-O-(2-THIODIPHOSPHATE); BOVINE TRANSDUCIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GAMMA-SUBUNITS	We have examined the effects of three commonly used classes of guanine nucleotide analogues on the retinal G protein, transducin (G(t)), and found them to be quite different from those that might be expected from results with other GTP-binding proteins, The most surprising results were with guanosine 5'-O-(2-thiodiphosphate) (GDP beta S); rather than inhibiting activation of G(t), GDP beta S addition activated G(t) as a result of a trace contaminant, Even when the contaminant levels were reduced 5-fold by chromatography, its effects dominated those of GDP beta S, which binds G(t) at least 1500-fold more weakly than guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). The affinity of G(t) for GDP was found to be at least 300-fold weaker than for GTP gamma S, while the affinities of GTP and GTP gamma S were similar. Ribose-modified GTP analogues, including 2'(3')-O-(N-methylanthraniloyl) GTP (mant-GTP), 2'(3')-O-[(2-aminoethyl)carbamyl] GTP (edGTP), and adducts of fluorescein 5-isothiocyanate and rhodamine B-isothiocyanate with edGTP, interacted extremely weakly, if at all, with the GTP binding site of the alpha subunit of G(t). They were neither effective activators of G(t) nor effective inhibitors of activation by GTP or GTP gamma S. A gamma-phosphoryl-modified analogue, an adduct of GTP gamma S and (5-(2(iodoacetyl)aminoethyl)amino)naphthalene-1-sulfonic acid (dnsGTP), also activated G(t) weakly, if at all, and did not inhibit its activation, The exclusion of these analogues points to the highly restrictive and specific nature of the GTP binding site of G(t), in contrast to those of numerous other GTP-binding proteins which are potently activated or inhibited by these analogues.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981, EY07001] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FIELDS TA, 1994, BIOCHEMISTRY-US, V33, P6877, DOI 10.1021/bi00188a017; HAZLETT TL, 1993, BIOCHEMISTRY-US, V32, P13575, DOI 10.1021/bi00212a025; HINGORANI VN, 1989, BIOCHEMISTRY-US, V28, P7424, DOI 10.1021/bi00444a041; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KALBITZER HR, 1990, EUR J BIOCHEM, V188, P355, DOI 10.1111/j.1432-1033.1990.tb15411.x; KELLEHER DJ, 1986, MOL PHARMACOL, V30, P603; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMB TD, 1988, J PHYSIOL-LONDON, V407, P463, DOI 10.1113/jphysiol.1988.sp017426; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOGSDON N, 1992, ANAL BIOCHEM, V205, P36, DOI 10.1016/0003-2697(92)90575-R; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; Means GE, 1971, CHEM MODIFICATION PR, P217; MILLS J S, 1991, Biophysical Journal, V59, p348A; MILLS JS, 1993, BIOPHYS J, V64, pA383; MOLLOY DP, 1990, THESIS NATL I MED RE; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANICO J, 1990, J BIOL CHEM, V265, P18922; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PARIS S, 1990, J BIOL CHEM, V265, P11567; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SATHER WA, 1987, P NATL ACAD SCI USA, V84, P9290, DOI 10.1073/pnas.84.24.9290; WATSON BS, 1995, BIOCHEMISTRY-US, V34, P7904, DOI 10.1021/bi00024a015; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; WIELAND T, 1990, J BIOL CHEM, V265, P20791; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12925	12931		10.1074/jbc.271.22.12925	http://dx.doi.org/10.1074/jbc.271.22.12925			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662741	hybrid			2022-12-27	WOS:A1996UN47400039
J	Hahn, H; Christiansen, J; Wicking, C; Zaphiropoulos, PG; Chidambaram, A; Gerrard, B; Vorechovsky, I; Bale, AE; Toftgard, R; Dean, M; Wainwright, B				Hahn, H; Christiansen, J; Wicking, C; Zaphiropoulos, PG; Chidambaram, A; Gerrard, B; Vorechovsky, I; Bale, AE; Toftgard, R; Dean, M; Wainwright, B			A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOOR PLATE; PROTEIN; GENE; NOTOCHORD	Drosophila patched is a segment polarity gene required for the correct patterning of larval segments and imaginal discs during fly development and has a close functional relationship with hedgehog. We have isolated a complete human PATCHED cDNA sequence, which encodes a putative protein of 1296 amino acids, and displays 39% identity and 60% similarity to the Drosophila PATCHED protein, Hydropathy analysis suggests that human PATCHED is an integral membrane protein with a pattern of hydrophobic and hydrophilic stretches nearly identical to that of Drosophila patched, In the developing mouse embryo, patched is initially detected within the ventral neural tube and later in the somites and limb buds, Expression in the limb buds is restricted to the posterior ectoderm surrounding the zone of polarizing activity, The results show that patched is expressed in target tissues of sonic hedgehog, a murine homolog of Drosophila hedgehog suggesting that patched/hedgehog interactions have been conserved during evolution. Human PATCHED maps to human chromosome 9q22.3, the candidate region for the nevoid basal cell carcinoma syndrome. Patched expression is compatible with the congenital defects observed in the nevoid basal cell carcinoma syndrome.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,HUMAN GENET SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES SUPPORT PROGRAM,SCI APPLICAT INT CORP,FREDERICK,MD 21702; UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,BRISBANE,QLD 4072,AUSTRALIA; CTR NUTR & TOXICOL,KAROLINSKA INST,DEPT BIOSCI,S-17157 HUDDINGE,SWEDEN; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Queensland; Karolinska Institutet; Yale University			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Wicking, Carol/J-1814-2014	Dean, Michael C/0000-0003-2234-0631; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092; Zaphiropoulos, Peter/0000-0003-4298-3861; Christiansen, Jeff/0000-0002-8146-1225				BALE AE, 1994, J INVEST DERMATOL, V103, pS126, DOI 10.1111/1523-1747.ep12399438; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P347, DOI 10.1111/j.1469-1809.1995.tb00756.x; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	25	175	189	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12125	12128		10.1074/jbc.271.21.12125	http://dx.doi.org/10.1074/jbc.271.21.12125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647801	hybrid			2022-12-27	WOS:A1996UL66000003
J	Esser, V; Brown, NF; Cowan, AT; Foster, DW; McGarry, JD				Esser, V; Brown, NF; Cowan, AT; Foster, DW; McGarry, JD			Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT I) - M-CPT I is the predominant CPT I isoform expressed in both white (epididymal) and brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; ENZYME-SYSTEM; LIVER; CLONING; ACID; DNA; OCTANOYLTRANSFERASE; SENSITIVITY; INHIBITORS; DEFICIENCY	We set out to determine if the cDNA encoding a carnitine palmitoyltransferase (CPT)-like protein recently isolated from rat brown adipose tissue (BAT) by Yamazaki ct al, (Yamazaki, N., Shinohara, Y., Shima, A., and Terada, H. (1995) FEES Lett. 363, 41-45) actually encodes the muscle isoform of mitochondrial CPT I (M-CPT I), To this end, a cDNA essentially identical to the original EAT clone was isolated from a rat heart library. When expressed in COS cells, the novel cDNA and our previously described cDNA for rat liver CPT I (L-CPT I) gave rise to products with the same kinetic characteristics (sensitivity to malonyl-CoA and K-m for carnitine) as CPT I in skeletal muscle and liver mitochondria, respectively. When labeled with [H-3]etomoxir, recombinant L-CPT I and putative M-CPT I, although having approximately the same predicated masses (88.2 kDa), migrated differently on SDS gels, as did CPT I from liver and muscle mitochondria The same was true for the products of in vitro transcription and translation of the L-CPT I and putative M-CPT I cDNAs. We conclude that the BAT cDNA does in fact encode M-CPT I. Northern blots using L- and M-CPT I cDNA probes revealed the presence of L-CPT I mRNA in liver and heart and its absence from skeletal muscle and BAT. M-CPT I mRNA, which was absent from liver, was readily detected in skeletal muscle and was particularly strong in heart and BAT. Whereas the signal for L-CPT I was more abundant than that for M-CPT I in RNA isolated from whole epididymal fat pad, this was reversed in purified adipocytes from this source, These findings, coupled with the kinetic properties and migration profiles on SDS gels of CPT I in brown and white adipocytes, indicate that the muscle form of the enzyme is the dominant, if not exclusive, species in both cell types.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,GIFFORD LABS,CTR DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,GIFFORD LABS,CTR DIABET RES,DALLAS,TX 75235	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018573, R01DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERGMAN AJIW, 1994, PEDIATR RES, V36, P582, DOI 10.1203/00006450-199411000-00007; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; BROWN NF, 1991, J BIOL CHEM, V266, P15446; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P19157; BROWN NF, 1993, BIOCHEM J, V294, P79, DOI 10.1042/bj2940079; BROWN NF, 1994, J BIOL CHEM, V269, P26438; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORR PB, 1995, HERZ, V20, P156; CORTI O, 1994, GENOMICS, V23, P94, DOI 10.1006/geno.1994.1463; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; ESSER V, 1993, J BIOL CHEM, V268, P5817; FALIKBORENSTEIN ZC, 1992, NEW ENGL J MED, V327, P24, DOI 10.1056/NEJM199207023270105; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GHADIMINEJAD I, 1991, BIOCHEM J, V277, P611, DOI 10.1042/bj2770611; JOHNSON TM, 1995, BIOCHEM J, V305, P439, DOI 10.1042/bj3050439; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1973, J CLIN INVEST, V52, P877, DOI 10.1172/JCI107252; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1995, BIOCHEM SOC T, V23, P321, DOI 10.1042/bst0230321; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MURTHY MSR, 1994, BIOCHEM J, V304, P31, DOI 10.1042/bj3040031; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; SAGGERSON ED, 1982, BIOCHEM J, V208, P673, DOI 10.1042/bj2080673; SAGGERSON ED, 1982, BIOCHEM J, V204, P373, DOI 10.1042/bj2040373; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G	41	132	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6972	6977		10.1074/jbc.271.12.6972	http://dx.doi.org/10.1074/jbc.271.12.6972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636126	hybrid			2022-12-27	WOS:A1996UB15700061
J	Gibson, S; August, A; Branch, D; Dupont, B; Mills, GB				Gibson, S; August, A; Branch, D; Dupont, B; Mills, GB			Functional LCK is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; CD28 RECEPTOR; PROTEIN-KINASE; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; LYMPHOCYTES; ANTIGEN; CLONING	Activation of CD28 on T lymphocytes initiates a cascade of intracellular events, which in concert with activation of the T cell receptor, culminates in production of cytokines and a functional immune response. One of the earliest biochemical changes observed following stimulation of CD28 is tyrosine phosphorylation. We have demonstrated that both the LCK and the EMT/ITK/TSK (EMT) intracellular tyrosine kinases are activated following cross-linking of CD28. Utilizing somatic cell mutants lacking LCK, we demonstrate that functional LCK is required for CD28-induced activation of EMT as evidenced by increased tyrosine phosphorylation and kinase activity. In support of a role for LCK in EMT activation, reconstitution of a LCK-negative Jurkat T cell line by transfection with normal LCK recreates CD28-mediated EMT activation. Furthermore, co-transfection of LCK and EMT into COS-7 cells showed that EMT becomes phosphorylated in the presence of LCK. In addition, increases in EMT association with CD28 were eliminated in a LCK-negative Jurkat cell line, but were restored following transfection of wild type LCK. The data are most compatible with a model in which LCK, either directly or indirectly, initiates EMT activation and association with CD28 following ligation of CD28.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV MED,HOUSTON,TX 77030; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 2C4,CANADA; TORONTO HOSP,TORONTO,ON M5G 2C4,CANADA; MEM SLOAN KETTERING INST CANC RES,PROGRAM IMMUNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; CANADIAN RES CROSS,TORONTO,ON M5G 2C4,CANADA	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Memorial Sloan Kettering Cancer Center; Rockefeller University				Gibson, Spencer/0000-0003-0119-732X	NCI NIH HHS [CA08748, CA22507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022507, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BRANCH DR, 1995, J IMMUNOL, V154, P3678; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GIBSON S, 1993, BLOOD, V82, P1561; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LU YL, 1992, J IMMUNOL, V149, P24; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMANDT R, 1994, J IMMUNOL, V152, P96; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHI YF, 1995, J IMMUNOL, V155, P1829; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	44	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7079	7083		10.1074/jbc.271.12.7079	http://dx.doi.org/10.1074/jbc.271.12.7079			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636141	hybrid			2022-12-27	WOS:A1996UB15700076
J	Cabado, AG; Yu, FH; Kapus, A; Lukacs, G; Grinstein, S; Orlowski, J				Cabado, AG; Yu, FH; Kapus, A; Lukacs, G; Grinstein, S; Orlowski, J			Distinct structural domains confer cAMP sensitivity and ATP dependence to the Na+/H+ exchanger NHE3 isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; CELL-VOLUME REGULATION; H+ EXCHANGER; INTRACELLULAR PH; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; ANTIPORTER; PHOSPHORYLATION; ACTIVATION; INHIBITION	Agents known to increase cAMP levels in renal and intestinal epithelia decrease sodium absorption by inhibiting NHE3, an isoform of the Na+/H+ exchanger ex pressed at high levels in apical membranes of these cells. In contrast, the ubiquitous, housekeeping isoform of the exchanger (NHE1) is stimulated by cAMP in some cell types. Optimal activity of NHE3 as well as NHE1 requires the presence of ATP, To gain insight into the molecular mechanisms of ATP dependence and cAMP regulation of NHE3, a series of mutations were constructed by progressively truncating segments of the C-terminal cytoplasmic domain of the transporter at amino acid positions 684, 638, and 579 (named NHE3 Delta 684, NHE3 Delta 638, and NHE3 Delta 579). In addition, chimeric antiporters were constructed with the N-terminal transmembrane domain of NHE3 linked to the entire cytoplasmic region of NHE1 (chimera NHE3/1) or vice versa (chimera NHE1/3). These constructs were heterologously expressed in antiport-deficient Chinese hamster ovary cells, and their activities were assessed by fluorimetric measurements of intracellular pH and by radioisotope determinations of Na+ influx. Forskolin, which directly stimulates adenylate cyclase, inhibited NHE3 as well as NHE1/3, but not NHE3/1, suggesting that the cytoplasmic domain of NHE3 was sufficient to confer sensitivity to inhibition by cAMP. Forskolin also inhibited the truncated mutant NHE3 Delta 684 to an extent similar to that for wild type NHE3. However, the inhibitory effect was greatly reduced in NHE3 Delta 638 and more profound truncations (NHE3 Delta 579) obliterated the effect of forskolin. These findings suggest that a region found between amino acids 579 and 684 is essential for the cAMP response of NHE3. In contrast, comparable ATP dependence was observed in all exchanger constructs examined, These observations indicate that ATP dependence is conferred by a region of the molecule in or adjacent to the transmembrane domain, which is most conserved between isoforms. It is concluded that different sites, and therefore different mechanisms, underlie inhibition of NHE3 by cAMP and by depletion of ATP.	HOSP SICK CHILDREN,DIV CELL BIOL,RES INST,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Toronto				Lukacs, Gergely/0000-0003-0900-0675; Yu, Frank/0000-0001-9306-1731; Orlowski, John/0000-0001-7371-175X				ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BIEMERSDERFER D, 1993, AM J PHYSIOL, V265, pF833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; OSS GG, 1994, J BIOL CHEM, V269, P8741; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1993, J BIOL CHEM, V268, P11917; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656	48	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3590	3599						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631966				2022-12-27	WOS:A1996TV72400040
J	Moriyama, Y; Tsujimura, T; Hashimoto, K; Morimoto, M; Kitayama, H; Matsuzawa, Y; Kitamura, Y; Kanakura, Y				Moriyama, Y; Tsujimura, T; Hashimoto, K; Morimoto, M; Kitayama, H; Matsuzawa, Y; Kitamura, Y; Kanakura, Y			Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ONCOGENIC ACTIVATION; POINT MUTATION; LIGAND; PROTEIN; DOMAIN; INTERNALIZATION; IDENTIFICATION; DELETION; DNA	The c-kit receptor tyrosine kinase (KIT) is constitutively activated in three different types of neoplastic mast cell lines by naturally occurring mutations that result in substitutions of Val or Tyr for Asp(814) in the phosphotransferase domain. In an effort to characterize the role of the Asp(814) residue, we have investigated the properties of mutant KITs in which the Asp(814) residue was deleted or mutated to a series of other amino acids. With the exception of rare instances, mutant KITs with substitutions of Asp(814) were found to be constitutively phosphorylated on tyrosine and activated in the absence of the ligand, stem cell factor (SCF), whereas a deletion mutant lacking Asp(814) (KITDel-Asp-814) did not exhibit tyrosine phosphorylation and activation even after treatment with SCF. In addition to constitutive activation, furthermore, both highly activated substitution mutants (KITVal-814 and KITTyr-814) and modestly activated substitution mutants (KITGly-814 and KITHis-814) were continuously degraded in the absence of SCF, whereas wild-type KIT (KITWild) required SCF stimulation to undergo degradation. These results suggested that the Asp(814) residue may play a crucial role in regulating enzymatic activity and expression of KIT and that various types of mutations at the Asp(814) residue may generate oncogenic protein with constitutive activation and degradation.	OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								ALASTAIR DR, 1991, GENES PHENOTYPES, V3, P105; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CARLHENRIK H, 1995, CELL, V80, P213; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HASHIMOTO K, 1996, IN PRESS AM J PATHOL; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KANAKURA Y, 1990, BLOOD, V76, P706; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEVEN K, 1988, SCIENCE, V241, P42; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	24	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3347	3350						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631931				2022-12-27	WOS:A1996TV72400005
J	Desaubry, L; Shoshani, N; Johnson, RA				Desaubry, L; Shoshani, N; Johnson, RA			Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3'-polyphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; BETA-GAMMA-SUBUNITS; CYCLIC-AMP; GUANOSINE TETRAPHOSPHATE; ESCHERICHIA-COLI; ADENOSINE; BRAIN; ACID; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS	The synthesis of a number of adenine nucleoside 3'-polyphosphates has been devised via a phosphotriester approach that combines the method of alkoxide activation with the use of 2,2,2-tribromoethyl phosphoromorpholinochloridate as a phosphorylating agent, The family of compounds included 3'ADP, 3'ATP, 2'-deoxy-3'ADP, 2'-deoxy-3'ATP, 2',5'-dideoxy-3'ADP, and 2',5'-dideoxy-3'ATP. Potency as inhibitors of adenylyl cyclases followed the order: 3'-mono- < 3'-di- < 3'-triphosphate and adenosine (Ado) < 2'-d-Ado < 2',5'-dd-Ado derivatives, with 2',5'-dideoxy-3'ATP exhibiting an IC50 of similar to 40 nM. This order was maintained with purified and recombinant forms of the type I enzyme, The nucleoside 3'-phosphates caused noncompetitive inhibition of the type I adenylyl cyclase from bovine brain, consistent with inhibition via the P-site, Inhibition was not due to hydrolytic products because this was minimal and inhibition kinetics by inorganic polyphosphates were inconsistent with those caused by the nucleoside 3'-polyphosphates. Only 3'ATP underwent cation-catalyzed, nonenzymatic hydrolysis, with the primary product being 2':3'-cAMP. Because 3'-ADP and 3'-ATP are naturally occurring, this class of compounds may physiologically regulate adenylyl cyclases and possibly other enzymes, mediating responses that include a reduction in 3':5'-cAMP levels and consequent reductions in protein kinase A-activated pathways.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970	NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BENNETT GN, 1976, BIOCHEMISTRY-US, V15, P4623, DOI 10.1021/bi00666a012; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1996, ESCHERICHIA COLI S T; CHARUBALA R, 1981, HETEROCYCLES, V15, P761; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; CLAUS TH, 1982, MOL CELL ENDOCRINOL, V26, P269, DOI 10.1016/0303-7207(82)90116-2; COOK PN, 1995, BIOCHEM PHARMACOL, V49, P1043, DOI 10.1016/0006-2952(95)98499-Y; DENHARTOG JAJ, 1981, RECL TRAV CHIM PAY B, V100, P317; DESAUBRY L, 1995, NUCLEOS NUCLEOT, V14, P1453, DOI 10.1080/15257779508010705; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; DESOUZA NJ, 1993, J ETHNOPHARMACOL, V38, P177, DOI 10.1016/0378-8741(93)90014-V; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; FAIN JN, 1972, J BIOL CHEM, V247, P6866; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GARTNER R, 1985, MOL CELL ENDOCRINOL, V42, P145, DOI 10.1016/0303-7207(85)90102-9; GREGA DS, 1987, J NEUROSCI, V7, P700; HAMEL E, 1975, BIOCHEMISTRY-US, V14, P5055, DOI 10.1021/bi00694a004; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HASLAM RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P1143, DOI 10.1016/0024-3205(72)90269-X; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; JOHNSON RA, 1977, ARCH BIOCHEM BIOPHYS, V183, P216, DOI 10.1016/0003-9861(77)90435-0; JOHNSON RA, 1980, J BIOL CHEM, V255, P8252; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; JOHNSON RA, 1977, RECEPTORS HORMONE AC, V1, P549; JOHNSON RA, 1994, CAN J PHYSL PHARM S1, V72, P511; JOHNSON RW, 1990, BEHAVIORAL ASPECTS A, P43; JOSSE J, 1965, BIOCHEMISTRY-US, V4, P2825, DOI 10.1021/bi00888a037; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOZARICH JW, 1975, BIOCHEMISTRY-US, V14, P981, DOI 10.1021/bi00676a017; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCKENZIE SG, 1973, CAN J PHYSIOL PHARM, V51, P190, DOI 10.1139/y73-027; MITCHEL REJ, 1967, CAN J BIOCHEM CELL B, V45, P89, DOI 10.1139/o67-010; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; REID IR, 1990, AM J PHYSIOL, V258, pE708, DOI 10.1152/ajpendo.1990.258.4.E708; RHAESE HJ, 1976, EUR J BIOCHEM, V64, P205, DOI 10.1111/j.1432-1033.1976.tb10289.x; RHAESE HJ, 1975, FEBS LETT, V53, P113, DOI 10.1016/0014-5793(75)80696-X; RHAESE HJ, 1974, FEBS LETT, V44, P87, DOI 10.1016/0014-5793(74)80312-1; SCHATTENKERK C, 1985, NUCLEIC ACIDS RES, V13, P3635, DOI 10.1093/nar/13.10.3635; SCHATTENKERK C, 1983, NUCLEIC ACIDS RES, V11, P7545, DOI 10.1093/nar/11.21.7545; SEGAL IH, 1975, ENZYME KINETICS, P125; SIMONCSITS A, 1974, BIOCHIM BIOPHYS ACTA, V340, P509, DOI 10.1016/0005-2787(74)90071-9; STUBNER D, 1989, FEBS LETT, V248, P155, DOI 10.1016/0014-5793(89)80452-1; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; SY J, 1973, P NATL ACAD SCI USA, V70, P2145, DOI 10.1073/pnas.70.7.2145; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TI GS, 1982, J AM CHEM SOC, V104, P1316, DOI 10.1021/ja00369a029; UCHIYAMA M, 1993, J ORG CHEM, V58, P373, DOI 10.1021/jo00054a020; VANBOOM JH, 1977, NUCLEIC ACIDS RES, V4, P1047, DOI 10.1093/nar/4.4.1047; VANBOOM JH, 1975, TETRAHEDRON LETT, P2779; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745	64	48	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14028	14034		10.1074/jbc.271.24.14028	http://dx.doi.org/10.1074/jbc.271.24.14028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662735	hybrid			2022-12-27	WOS:A1996UQ66000017
J	Kukimoto, M; Nishiyama, M; Tanokura, M; Adman, ET; Horinouchi, S				Kukimoto, M; Nishiyama, M; Tanokura, M; Adman, ET; Horinouchi, S			Studies on protein-protein interaction between copper-containing nitrite reductase and pseudoazurin from Alcaligenes faecalis S-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ACHROMOBACTER-CYCLOCLASTES; PSEUDOMONAS-AUREOFACIENS; ESCHERICHIA-COLI; STRAIN S-6; SITE; PURIFICATION; MUTAGENESIS; RESOLUTION; CENTERS	Site-directed mutagenesis of a copper-containing nitrite reductase (NIR) from Alcaligenes faecalis S-6 was carried out to identify the amino acid residues involved in interaction with its redox partner, pseudoazurin, in which four positively charged residues were previously shown to be important in the interaction, Ten negatively charged residues located on the surface of NIR were replaced independently by alanine or serine, All the altered NIRs showed CHI spectra and optical spectra identical to those of wild-type NIR, suggesting that all the replacements caused no gross change in the overall structure or in the environment of type 1 copper site, Kinetic analysis of electron transfer between pseudoazurin and altered NIRs revealed that the replacement of Glu-118, Glu-197, Asp-201, Glu-204, or Asp-205 by Ala caused. a significant increase in the K-m value for pseudoazurin compared with that of wild-type NIR. Furthermore, the simultaneous replacement of three of these residues (Glu-118, Glu-197, and Asp-201) caused a further increase in the K-m value. These results suggested that time negatively charged residues are involved in electrostatic interaction with pseudoazurin, Kinetic analyses of the altered NIRs (E118A, E197A, or D201A) with altered pseudoazurins (K10A, K57A, or K77A) implicate specific pairs of the charged residues that are involved in electrostatic interaction between NIR and pseudoazurin.	UNIV TOKYO,BIOTECHNOL RES CTR,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195	University of Tokyo; University of Tokyo; University of Washington; University of Washington Seattle			Kukimoto-Niino, Mutsuko/C-6704-2017	Kukimoto-Niino, Mutsuko/0000-0002-4178-1611; Nishiyama, Makoto/0000-0001-8143-8052; Tanokura, Masaru/0000-0001-5072-2480	NIGMS NIH HHS [GM31770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; ADMAN ET, 1989, J BIOL CHEM, V264, P87; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; DEREGE PJF, 1995, SCIENCE, V269, P1409, DOI 10.1126/science.7660123; DODD FE, 1995, BIOCHEMISTRY-US, V34, P10180, DOI 10.1021/bi00032a011; FENDERSON FF, 1991, BIOCHEMISTRY-US, V30, P7180, DOI 10.1021/bi00243a020; GLOCKNER AB, 1993, ARCH MICROBIOL, V160, P18; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HORMEL S, 1986, FEBS LETT, V197, P301, DOI 10.1016/0014-5793(86)80346-5; IWASAKI H, 1972, J BIOCHEM, V71, P645; IWASAKI Y, 1992, ELECTROANAL, V4, P771, DOI 10.1002/elan.1140040806; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KAKUTANI T, 1981, AGR BIOL CHEM TOKYO, V45, P23, DOI 10.1080/00021369.1981.10864492; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY E, 1992, BIOCHEM BIOPH RES CO, V187, P1529, DOI 10.1016/0006-291X(92)90476-2; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NISHIYAMA M, 1993, J GEN MICROBIOL, V139, P725, DOI 10.1099/00221287-139-4-725; NISHIYAMA M, 1992, PROTEIN ENG, V5, P177, DOI 10.1093/protein/5.2.177; NORGARD MV, 1978, GENE AMST, V3, P379; PETRATOS K, 1987, FEBS LETT, V218, P209, DOI 10.1016/0014-5793(87)81048-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; YAMAMOTO K, 1987, J BACTERIOL, V169, P5648, DOI 10.1128/jb.169.12.5648-5652.1987; ZUMFT WG, 1987, EUR J BIOCHEM, V168, P301, DOI 10.1111/j.1432-1033.1987.tb13421.x	32	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13680	13683		10.1074/jbc.271.23.13680	http://dx.doi.org/10.1074/jbc.271.23.13680			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662745	hybrid			2022-12-27	WOS:A1996UP38500058
J	MacDonald, RJ; SouthardSmith, EM; Kroon, E				MacDonald, RJ; SouthardSmith, EM; Kroon, E			Disparate tissue-specific expression of members of the tissue kallikrein multigene family of the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GENE FAMILY; MESSENGER-RNA; SUBMAXILLARY-GLAND; MOLECULAR-BIOLOGY; SUBMANDIBULAR-GLAND; NUCLEOTIDE-SEQUENCE; SERINE PROTEASE; CHAIN-REACTION; KININ SYSTEM	To understand the regulatory diversity of the rat Family of linked kallikrein genes, we have assayed the expression of family members in 20 major organs. Reverse transcription-polymerase chain reaction analysis using primers and hybridization probes specific for each of the 10 expressed kallikrein genes showed that no two family members share the same organ-specific pattern of expression. The only common site of expression for all 10 known active genes is the submandibular gland. The presence of the mRNA for at least one family member is detected in 19 of these 20 organs (liver excepted), from as few as three organs to as many as 18 for individual family members. For individual genes there can be more than a 10(5)-fold variation in mRNA levels among organs, from a limit of detection of slightly less than 1 mRNA molecule/10 cells to more than 10,000 mRNA molecules/cell. Despite high sequence conservation and close linkage, the members of this family are expressed in very different and complex patterns. A gradient of diversity of expression corresponds to the order of the genes within the kallikrein family locus.			MacDonald, RJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,MOL IMMUNOL CTR,6000 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Southard-Smith, Michelle/C-3488-2012; Kroon, Erna/V-5444-2019; MacDonald, Ray/AAA-1290-2022	KROON, EVERT/0000-0002-4069-3644; Southard-Smith, E Michelle/0000-0003-4718-5869	NIGMS NIH HHS [GM08203, GM31689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4512, DOI 10.1021/bi00338a005; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BERG T, 1992, J HISTOCHEM CYTOCHEM, V40, P83, DOI 10.1177/40.1.1309555; BERG T, 1992, RECENT PROGR KININS, V1, P19; BRADY JM, 1990, ARCH BIOCHEM BIOPHYS, V278, P342, DOI 10.1016/0003-9861(90)90269-5; BRADY JM, 1989, BIOCHEMISTRY-US, V28, P5203, DOI 10.1021/bi00438a043; CARRETERO OA, 1993, J HYPERTENS, V11, P693, DOI 10.1097/00004872-199307000-00002; CHAO J, 1983, J BIOL CHEM, V258, P5173; CHAPDELAINE P, 1984, J ANDROL, V5, P206; CHEN YP, 1988, BIOCHEMISTRY-US, V27, P7189, DOI 10.1021/bi00419a005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENTS JA, 1988, J BIOL CHEM, V263, P16132; CLEMENTS JA, 1989, J NEUROENDOCRINOL, V1, P199; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; CLEMENTS JA, 1990, J BIOL CHEM, V265, P1077; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; DOVER GA, 1986, PHILOS T R SOC B, V312, P275, DOI 10.1098/rstb.1986.0007; DOVER GA, 1982, NATURE, V289, P111; DUNBAR JC, 1987, BIOCHEMISTRY-US, V26, P3471, DOI 10.1021/bi00386a034; ELMOUJAHED A, 1990, FEBS LETT, V265, P137, DOI 10.1016/0014-5793(90)80903-V; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FIEDLER F, 1979, HDB EXPT PHARMACOLOG, V25, P103; FULLER PJ, 1988, MOL CELL ENDOCRINOL, V60, P225, DOI 10.1016/0303-7207(88)90182-7; FULLER PJ, 1989, BIOCHEM J, V264, P133, DOI 10.1042/bj2640133; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; GRISE C, 1981, CAN J BIOCHEM CELL B, V59, P250, DOI 10.1139/o81-034; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUTMAN N, 1991, EUR J BIOCHEM, V197, P425, DOI 10.1111/j.1432-1033.1991.tb15928.x; HIBNER BL, 1988, DEV BIOL, V125, P423, DOI 10.1016/0012-1606(88)90223-0; INOUE H, 1989, J BIOCHEM-TOKYO, V105, P834, DOI 10.1093/oxfordjournals.jbchem.a122754; KAFATOS FC, 1987, ADV GENET, V24, P223, DOI 10.1016/S0065-2660(08)60009-7; KEDES LH, 1979, ANNU REV BIOCHEM, V48, P837, DOI 10.1146/annurev.bi.48.070179.004201; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MA J, 1992, BIOCHEMISTRY-US, V31, P10922, DOI 10.1021/bi00159a036; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NOLLY H, 1993, HYPERTENSION, V21, P911, DOI 10.1161/01.HYP.21.6.911; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PRITCHETT DB, 1987, P NATL ACAD SCI USA, V84, P5545, DOI 10.1073/pnas.84.16.5545; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; SAED GM, 1990, CIRC RES, V67, P510, DOI 10.1161/01.RES.67.2.510; SAED GM, 1992, HYPERTENSION, V19, P262; SCICLI AG, 1993, J HYPERTENS, V11, P775, DOI 10.1097/00004872-199308000-00002; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; SOUTHARDSMITH M, 1992, DNA CELL BIOL, V11, P345; SPOEREL NA, 1989, J MOL BIOL, V209, P1, DOI 10.1016/0022-2836(89)90166-6; SWIFT GH, 1982, P NATL ACAD SCI-BIOL, V79, P7263, DOI 10.1073/pnas.79.23.7263; VANLEEUWEN BH, 1986, J BIOL CHEM, V261, P5529; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; WINES DR, 1989, THESIS U TEXAS SW ME; YAMAGUCHI T, 1991, J BIOL CHEM, V266, P5011	57	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13684	13690		10.1074/jbc.271.23.13684	http://dx.doi.org/10.1074/jbc.271.23.13684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662704	hybrid			2022-12-27	WOS:A1996UP38500059
J	Chen, L; Qi, H; Korenberg, J; Garrow, TA; Choi, YJ; Shane, B				Chen, L; Qi, H; Korenberg, J; Garrow, TA; Choi, YJ; Shane, B			Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; HAMSTER OVARY CELLS; MAMMALIAN-CELLS; FOLYLPOLY(GAMMA-GLUTAMATE) SYNTHETASE; BIOCHEMICAL-CHARACTERIZATION; CHROMOSOMAL LOCALIZATION; SUBSTRATE-SPECIFICITY; INSITU HYBRIDIZATION; INVITRO METABOLISM; FOLATE METABOLISM	Human cytosolic folylpolyglutamate synthetase (FPGS) was expressed in Escherichia coli and purified to homo geneity. Tetrahydrofolate and dihydrofolate were the most effective substrates, while 5-substituted folates were poor substrates. Most pteroyldiglutamates were better substrates than monoglutamates. The human FPGS gene spans 12 kilobases and contains 15 exons and 14 introns. A single FPGS gene was located to chromosome region 9q34.1. Four exon 1 variants were identified, each of which was spliced to exon 2. The exon 1 variant corresponding to the isolated cDNA contains two ATG codons and multiple transcription start sites in this region generates mitochondrial and cytosolic FPGS (Freemantle, S. J., Taylor, S. M., Krystal, G., and Moran, R. G. (1995) J. Biol. Chem. 270, 9579-9584). Exons 1B and 1C, generated by alternate splicing in intron 1, and exon 1A, which is 5' to exon 1 and may encode an additional mitochondrial isoform, are preceded by a number of potential promoter sites. Chinese hamster ovary cell transfectants expressing FPGS activity in the mitochondria contained normal mitochondrial and low cytosolic folylpolyglutamate pools. Mitochondrial FPGS activity is required for mitochondrial folate accumulation, while cytosolic FPGS activity is needed for establishment of normal cytosolic folate pools. The reconstructed FPGS gene restored normal cytosolic and mitochondrial folate metabolism in hamster cells.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, DEPT PEDIAT, MED BIRTH DEFECTS CTR, LOS ANGELES, CA 90048 USA	University of California System; University of California Berkeley; Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NCI NIH HHS [CA-41991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APTE AN, 1993, BIOTECHNIQUES, V15, P890; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P92; BOGNAR AL, 1983, J BIOL CHEM, V258, P2574; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOLANOWSKA WE, 1990, ARCH BIOCHEM BIOPHYS, V281, P198, DOI 10.1016/0003-9861(90)90432-X; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; CLARKE L, 1987, ARCH BIOCHEM BIOPHYS, V256, P585, DOI 10.1016/0003-9861(87)90616-3; COLL RJ, 1991, BIOCHEM PHARMACOL, V42, P833, DOI 10.1016/0006-2952(91)90043-5; COOK JD, 1987, BIOCHEMISTRY-US, V26, P530, DOI 10.1021/bi00376a027; DEBOERHA, 1986, MAXIMIZING GENE EXPR, P225; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; FOO SK, 1982, J BIOL CHEM, V257, P13587; FORT DW, 1993, BRIT J HAEMATOL, V84, P595, DOI 10.1111/j.1365-2141.1993.tb03133.x; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GEORGE S, 1987, BIOCHEMISTRY-US, V26, P522, DOI 10.1021/bi00376a026; HAGAN RL, 1991, BIOCHEM PHARMACOL, V41, P781, DOI 10.1016/0006-2952(91)90081-F; HANLON MH, 1990, CANCER RES, V50, P3207; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KELLEY JL, 1990, J MED CHEM, V33, P561, DOI 10.1021/jm00164a014; KIM JS, 1994, J BIOL CHEM, V269, P9714; KIM JS, 1993, J BIOL CHEM, V268, P21680; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ HJ, 1994, ONCOL RES, V6, P329; LI WW, 1992, CANCER RES, V52, P3908; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; LOWE KE, 1993, J BIOL CHEM, V268, P21665; MAGENIS RE, 1985, HUM GENET, V69, P300, DOI 10.1007/BF00291645; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MCGUIRE JJ, 1991, J CELL PHARM, V2, P317; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1989, CANCER RES, V49, P5275; PRISTUPA ZB, 1984, CAN J BIOCHEM CELL B, V62, P495, DOI 10.1139/o84-067; RUMBERGER BG, 1990, CANCER RES, V50, P4639; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHANE B, 1980, J BIOL CHEM, V255, P5655; SHANE B, 1989, VITAM HORM, V45, P263; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; STOVER P, 1993, ADV EXP MED BIOL, V338, P723; SUSSMAN DJ, 1986, SOMAT CELL MOLEC GEN, V12, P531, DOI 10.1007/BF01671939; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG FS, 1993, CANCER RES, V53, P3677; WHITEHEAD VM, 1990, BLOOD, V76, P44; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZHANG ZG, 1991, CANCER RES, V51, P3476	65	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13077	13087		10.1074/jbc.271.22.13077	http://dx.doi.org/10.1074/jbc.271.22.13077			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662720	hybrid			2022-12-27	WOS:A1996UN47400061
J	Ward, PP; Zhou, X; Conneely, OM				Ward, PP; Zhou, X; Conneely, OM			Cooperative interactions between the amino- and carboxyl-terminal lobes contribute to the unique iron-binding stability of lactoferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM TRANSFERRIN; MESSENGER-RNA; LACTOTRANSFERRIN; SEQUENCE; RELEASE; INVIVO; MILK; IDENTIFICATION; MEMBRANE; FRAGMENT	Lactoferrin is a member of the transferrin family of iron-binding proteins. Several functions have been ascribed to lactoferrin, including regulation of iron homeostasis, antibacterial properties, and regulation of myelopoiesis. However, the structural features of lactoferrin that are required for most of these functions are unknown. Previously, we reported the development of an efficient fungal expression system to produce recombinant human lactoferrin. The availability of this production system demonstrated the feasibility of producing mutant lactoferrins to address the structure/function relationship of the protein. In the present study, we used a site-directed mutagenesis approach to address the contribution of the bilobal structure of lactoferrin to its unique iron-binding stability. Like transferrin, lactoferrin consists of two repeated iron-binding lobes that bind one iron atom each. However, unlike transferrin, lactoferrin retains iron over a broad pH range, a key property that contributes to the unique iron-binding functions of the protein. Using mutants that selectively ablate the iron-binding function in either lobe, we demonstrate differential iron-binding stability of the amino- and carboxyl-terminal iron-binding lobes of lactoferrin. Further, we show that the unique iron-binding stability of the protein is imparted primarily by the carboxyl-terminal domain which functions cooperatively to stabilize iron-binding to the amino-terminal domain of lactoferrin.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine								AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; COX TM, 1979, BIOCHIM BIOPHYS ACTA, V558, P129; CROUCH SPM, 1992, BLOOD, V80, P235; DAY CL, 1992, J BIOL CHEM, V267, P13857; ELLISON RT, 1988, INFECT IMMUN, V56, P2774, DOI 10.1128/IAI.56.11.2774-2781.1988; FRANSSON GB, 1980, J PEDIATR-US, V96, P380, DOI 10.1016/S0022-3476(80)80676-7; GATIGNOL A, 1987, MOL GEN GENET, V207, P342, DOI 10.1007/BF00331599; GISLASON J, 1995, J PEDIATR GASTR NUTR, V21, P37, DOI 10.1097/00005176-199507000-00006; HASHIZUME S, 1983, BIOCHIM BIOPHYS ACTA, V763, P377, DOI 10.1016/0167-4889(83)90099-X; HENNART PF, 1991, AM J CLIN NUTR, V53, P32, DOI 10.1093/ajcn/53.1.32; HU WL, 1988, BIOCHEM J, V249, P435, DOI 10.1042/bj2490435; IYER S, 1993, EUR J CLIN NUTR, V47, P232; JELTSCH JM, 1982, EUR J BIOCHEM, V122, P291, DOI 10.1111/j.1432-1033.1982.tb05879.x; LINDLEY PF, 1988, BIOCHEMISTRY-US, V27, P5804; LINEBACKZINS J, 1980, J BIOL CHEM, V255, P708; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MACHNICKI M, 1993, INT J EXP PATHOL, V74, P433; MASSON PL, 1968, EUR J BIOCHEM, V6, P579, DOI 10.1111/j.1432-1033.1968.tb00484.x; MASSON PL, 1971, COMP BIOCHEM PHYSIOL, V39, P119, DOI 10.1016/0305-0491(71)90258-6; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MIKOGAMI T, 1994, AM J PHYSIOL, V267, pG1; NICHOLS BL, 1987, PEDIATR RES, V21, P563, DOI 10.1203/00006450-198706000-00011; ORAM JD, 1968, BIOCHIM BIOPHYS ACTA, V170, P351, DOI 10.1016/0304-4165(68)90015-9; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; REJMAN JJ, 1994, INT J BIOCHEM, V26, P201, DOI 10.1016/0020-711X(94)90146-5; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; SAWATZKI G, 1989, BLOOD CELLS, V15, P371; SHIMAZAKI K, 1993, J DAIRY SCI, V76, P946, DOI 10.3168/jds.S0022-0302(93)77421-4; VILJA P, 1985, J IMMUNOL METHODS, V76, P73, DOI 10.1016/0022-1759(85)90482-X; WARD PP, 1995, BIO-TECHNOL, V13, P498, DOI 10.1038/nbt0595-498; WILLIAMS J, 1982, TRENDS BIOCHEM SCI, V7, P394, DOI 10.1016/0968-0004(82)90183-9; YAMAUCHI K, 1993, INFECT IMMUN, V61, P719, DOI 10.1128/IAI.61.2.719-728.1993; YU LC, 1993, BIOCHEM J, V296, P107, DOI 10.1042/bj2960107; ZACALI JR, 1979, BLOOD, V54, P951; ZAGULSKI T, 1989, BRIT J EXP PATHOL, V70, P697	43	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12790	12794		10.1074/jbc.271.22.12790	http://dx.doi.org/10.1074/jbc.271.22.12790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662718	hybrid			2022-12-27	WOS:A1996UN47400017
J	Stover, DR; Furet, P; Lydon, NB				Stover, DR; Furet, P; Lydon, NB			Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; C-SRC; PDGF RECEPTOR; PP60C-SRC; FAMILY; AUTOPHOSPHORYLATION; ASSOCIATION; PP60(C-SRC); PROTEINS; PRODUCT	The Src family of kinases are held in an inactive state by interaction of their SH2 domain with a C-terminal phosphotyrosine. Dephosphorylation of this site can reactivate Src; however, recent evidence suggests that activation can also occur without dephosphorylation. In this study, platelet-derived growth factor receptor phosphorylation of Src on Tyr-213 specifically blocked binding of its SH2 domain to a phosphopeptide corresponding to the C-terminal regulatory sequence, while binding to other sequences, such as the platelet-derived growth factor receptor or a peptide from the epidermal growth factor receptor, was unaffected. Consequently, Src was activated over 50-fold. This is the first demonstration of regulation of a SH2 domain specificity by post-translational modification and is likely to be a general mechanism for regulation of all Src-like kinases.			Stover, DR (corresponding author), CIBA GEIGY LTD, DIV PHARMACEUT RES, K125308, CH-4002 BASEL, SWITZERLAND.							BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHANG JH, 1993, ONCOGENE, V8, P959; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1995, 5 INT C HORM CANC QU, P25; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1988, ONCOGENE, V3, P491; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SOULA M, 1993, J BIOL CHEM, V268, P27420; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; STOVER DR, 1994, J BIOL CHEM, V269, P26885; STOVER DR, 1993, TECHNIQUES PROTEIN C, V4, P193; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALKER F, 1993, J BIOL CHEM, V268, P19552; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12481	12487		10.1074/jbc.271.21.12481	http://dx.doi.org/10.1074/jbc.271.21.12481			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647855	hybrid			2022-12-27	WOS:A1996UL66000057
J	Benmerah, A; Begue, B; DautryVarsat, A; CerfBensussan, N				Benmerah, A; Begue, B; DautryVarsat, A; CerfBensussan, N			The ear of alpha-adaptin interacts with the COOH-terminal domain of the Eps15 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; PLASMA-MEMBRANE; CLONING; AP-2; COMPONENTS; COMPLEXES; SUBUNIT; BINDING; CHAINS; GOLGI	The role of Eps15 in clathrin-mediated endocytosis is supported by two observations. First, it interacts specifically and constitutively with the plasma membrane adaptor AP-2. Second, its NH2 terminus shows significant homology to the NH2 terminus of yeast End3p, necessary for endocytosis of Lu-factor. To gain further insight into the role of Eps15-AP-2 association, we have now delineated their sites of interactions. AP-2 binds to a domain of 72 amino acids (767-739) present in the COOH terminus of Fps15. This domain contains 4 of the 15 DPF repeats characteristic of the COOH-terminal domain of Eps15 and shares no homology with known proteins, including the related Fps15r protein. Precipitation of proteolytic fragments of AP-2 with Eps15-derived fusion proteins containing the binding site for AP-2 showed that Eps15 binds specifically to a 40-kDa fragment corresponding to the ear of alpha-adaptin, a result confirmed by precipitation of Eps15 by alpha-adaptin-derived fusion proteins. Our data indicate that this specific part of AP-2 binds to a cellular component and provide the tools for investigating the function(s) of the association between AP-2 and Eps15.	HOP NECKER ENFANTS MALAD,INSERM,U429,F-75743 PARIS 15,FRANCE; INST PASTEUR,CNRS,URA 1960,UNITE BIOL INTERACT CELLULAIRES,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Begue, Bernadette/I-2744-2017; benmerah, alexandre/H-3742-2017; Cerf-Bensussan, nadine/H-9505-2017	Begue, Bernadette/0000-0002-1228-9978; benmerah, alexandre/0000-0003-0188-8016; Cerf-Bensussan, nadine/0000-0003-0665-1245				AHLE S, 1989, J BIOL CHEM, V264, P20089; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LINDNER R, 1992, J BIOL CHEM, V267, P16567; NATKE IS, 1992, CELL, V68, P899; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; WONG WT, 1994, ONCOGENE, V9, P1591; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	29	166	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12111	12116		10.1074/jbc.271.20.12111	http://dx.doi.org/10.1074/jbc.271.20.12111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662627	hybrid			2022-12-27	WOS:A1996UL25000079
J	Jin, DJ				Jin, DJ			A mutant RNA polymerase reveals a kinetic mechanism for the switch between nonproductive stuttering synthesis and productive initiation during promoter clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-TEMPLATED TRANSCRIPTION; ESCHERICHIA-COLI; RIFAMPICIN-RESISTANT; TRANSCRIBING COMPLEX; PYRBI OPERON; BETA-SUBUNIT; INHIBITION; MUTATIONS; INVITRO; ELONGATION	During transcription initiation from galP2, one of the two promoters of the Escherichia coli galactose operon with an initially transcribed sequence of pppAUUUC, RNA polymerase (RNAP) is known to engage nonproductive stuttering synthesis, which is sensitive to the concentration of UTP. This study examines the effect of this nonproductive synthesis on promoter clearance and determines other parameters that might affect stuttering synthesis by analyzing a mutant RNAP, RpoB3449, that has altered its function at this process at galP2, RpoB3449 has dramatically diminished stuttering synthesis, and consequently, it has increased the rate of productive initiation due to its enhanced rate of promoter clearance of galP2 compared with wild-type RNAP. Thus, a direct linkage between promoter clearance and productive transcription is demonstrated. The mechanism by which the mutant RNAP has altered the switch between nonproductive stuttering synthesis and productive initiation during promoter clearance is studied. Apparently, RpoB3449 has increased its efficiency in incorporating CTP at the +5 position of the galP2 transcript leading to its reduced stuttering synthesis, indicating that the rate of an RNAP incorporating the CTP after a stretch of uridine residues is important for promoter clearance at galP2. Because RpoB3449 demonstrates ''wild-type'' stuttering synthesis at the mutant galP2 promoter, which contains the 6 residue at the +5 position, it indicates that the mutant RNAP has altered in binding CTP at this context, Further experiments indicate that it is the +5 position per se of the galP2 sequence rather than a particular nucleotide at that position that is critical in determining the switch between the two alternate pathways during transcription initiation, A checkpoint model for the switch between nonproductive and productive initiations during promoter clearance is discussed.			Jin, DJ (corresponding author), NCI,MOLEC BIOL LAB,NIH,BLDG 37,RM 2E14,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BUJARD H, 1986, RNA POLYMERASE REGUL, P95; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1994, HARVEY LECTURES 88, P1; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; GULLAND U, 1992, GENE, V114, P97, DOI 10.1016/0378-1119(92)90713-Y; GUO HC, 1990, BIOCHEMISTRY-US, V29, P10702, DOI 10.1021/bi00499a019; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HARLEY CB, 1988, NUCLEIC ACIDS RES, V16, P7269, DOI 10.1093/nar/16.15.7269; Hawley D. K., 1982, PROMOTERS STRUCTURE, P54; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JIN DJ, 1994, J BIOL CHEM, V269, P17221; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LIU CG, 1989, J BACTERIOL, V171, P3337, DOI 10.1128/jb.171.6.3337-3342.1989; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2259; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; MUSSO RE, 1977, CELL, V12, P847, DOI 10.1016/0092-8674(77)90283-5; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; XIONG XF, 1993, J MOL BIOL, V231, P569, DOI 10.1006/jmbi.1993.1310; ZHOU YN, 1995, J MOL BIOL, V253, P414, DOI 10.1006/jmbi.1995.0563	39	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11659	11667						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662641				2022-12-27	WOS:A1996UL25000015
J	Li, X; Galanakis, D; Gabriel, DA				Li, X; Galanakis, D; Gabriel, DA			Transient intermediates in the thrombin activation of fibrinogen - Evidence for only the desAA species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-BETA CHAIN; POLYMERIZATION SITES; LIGHT-SCATTERING; CALCIUM-BINDING; LOCALIZATION; CONVERSION; OLIGOMERS; KINETICS; SEGMENTS; CLEAVAGE	The structure of a fibrin gel depends on the nature of the fibrinogen activation products produced by thrombin and the physical condition under which assembly occurs. Two different structures of the intermediate fibrin protofibril have been proposed, the production of which requires different extents of fibrinopeptide A (FpA) cleavage from fibrinogen. The fibrin activation intermediates must be stable since time is required for the intermediates to diffuse to growing protofibrils. The classic Hall-Slayter model requires cleavage of both FpAs to form a desAA intermediate. The Hunziker model requires cleavage of only one FpA to form an AdesA intermediate. Electrophoretic quasi elastic light scattering has been used to show the time dependent production of the relevant fibrinogen activation intermediates that includes desAA but not AdesA.	UNIV N CAROLINA, SCH MED, DIV HEMATOL ONCOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ALKJAERSIG N, 1983, BIOCHEM J, V213, P75, DOI 10.1042/bj2130075; BAILEY K, 1951, NATURE, V167, P233, DOI 10.1038/167233a0; BALE MD, 1982, BIOPOLYMERS, V21, P2265, DOI 10.1002/bip.360211113; BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BUDZYNSKI AZ, 1983, ANN NY ACAD SCI, V408, P301, DOI 10.1111/j.1749-6632.1983.tb23253.x; CARR ME, 1989, BIOCHEMISTRY-US, V28, P1384, DOI 10.1021/bi00429a066; CARR ME, 1986, BIOCHEM J, V239, P513, DOI 10.1042/bj2390513; DIETLER G, 1986, BIOPOLYMERS, V25, P905, DOI 10.1002/bip.360250511; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; ENDRES GF, 1966, BIOCHEMISTRY-US, V5, P1561, DOI 10.1021/bi00869a016; ENDRES GF, 1972, ARCH BIOCHEM BIOPHYS, V153, P266, DOI 10.1016/0003-9861(72)90445-6; FERRY JD, 1952, P NATL ACAD SCI USA, V38, P566, DOI 10.1073/pnas.38.7.566; FERRY JD, 1947, J AM CHEM SOC, V69, P388, DOI 10.1021/ja01194a066; GALANAKIS DK, 1987, BIOCHEMISTRY-US, V26, P2389, DOI 10.1021/bi00382a046; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HENSCHEN A, 1990, ADV EXP MED BIOL, V281, P49; HERMANS J, 1979, P NATL ACAD SCI USA, V76, P1189, DOI 10.1073/pnas.76.3.1189; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HUNZIKER EB, 1990, J BIOL CHEM, V265, P7455; JANMEY PA, 1983, BIOCHEMISTRY-US, V22, P4336, DOI 10.1021/bi00287a026; JANMEY PA, 1982, BIOPOLYMERS, V21, P2253, DOI 10.1002/bip.360211112; JANMEY PA, 1983, BIOPOLYMERS, P2017; JOHNSON CS, 1981, SPECTROSCOPY BIOCH, V2, P177; Johnson Jr C. S., 1995, LASER LIGHT SCATTERI; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LAURENT TC, 1958, ACTA CHEM SCAND, V12, P1875, DOI 10.3891/acta.chem.scand.12-1875; NIEUWENHUIZEN W, 1982, BIOCHIM BIOPHYS ACTA, V707, P190, DOI 10.1016/0167-4838(82)90349-1; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; OLEXA SA, 1981, J BIOL CHEM, V256, P3544; PANDYA BV, 1985, J BIOL CHEM, V260, P2994; SCHERAGA HA, 1957, ADV PROTEIN CHEM, V12, P1, DOI 10.1016/S0065-3233(08)60115-1; SHAINOFF JR, 1970, THROMB DIATH HAEMO, V39, P203; SHIMIZU A, 1986, P NATL ACAD SCI USA, V83, P591, DOI 10.1073/pnas.83.3.591; SMITH GF, 1980, BIOCHEM J, V185, P1; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; Ware B. R., 1974, Advances in Colloid and Interface Science, V4, P1, DOI 10.1016/0001-8686(74)80001-1; WARE BR, 1971, CHEM PHYS LETT, V12, P81, DOI 10.1016/0009-2614(71)80621-8; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WILF J, 1986, BIOCHEMISTRY-US, V25, P3124, DOI 10.1021/bi00359a009	42	9	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11767	11771		10.1074/jbc.271.20.11767	http://dx.doi.org/10.1074/jbc.271.20.11767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662661	hybrid			2022-12-27	WOS:A1996UL25000031
J	DeNichilo, MO; Yamada, KM				DeNichilo, MO; Yamada, KM			Integrin alpha(v)beta(5)-dependent serine phosphorylation of paxillin in cultured human macrophages adherent to vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; FOCAL ADHESIONS; FIBRONECTIN; EXPRESSION; FIBROBLASTS; MODULATION; PP125(FAK)	The macrophage colony-stimulating factor (M-CSF) is able tct induce the expression of the alpha(v) beta(5) integrin receptor on the surface of cultured human macrophages (De Nichilo, M. O., and Burns, G. F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2517-2521). In the present study, we establish that the adhesion of M-CSF-treated macrophages to vitronectin is mediated by the integrin alpha(v) beta(5), and show by indirect immunofluorescence analysis that alpha(v) beta(5) and the cytoskeletal protein paxillin localize to focal contacts upon adhesion to vitronectin. Immunoprecipitation and Western blot analysis revealed that M-CSF-treated macrophages do not express focal adhesion kinase (FAK), thereby providing direct evidence for integrin dependent localization of paxillin to focal contacts in the absence of FAK expression. Investigation of paxillin phosphorylation by two dimensional phosphoamino acid analysis indicates that paxillin is 99% phosphorylated on serine residue(s) in response to vitronectin adhesion, and only 1% phosphorylated on tyrosine. Stimulation of protein kinase C (PKC) activity with the phorbol ester phorbol 12-myristate 13-acetate enhances paxillin phosphorylation, while two selective inhibitors of PKC, GF109203X and chelerythrine chloride, effectively block the phosphorylation of paxillin induced in response to vitronectin adhesion. Taken together, these data demonstrate that in M-CSF-treated macrophages adherent to vitronectin, paxillin localizes to focal contacts in the absence of FAK expression and is predominantly phosphorylated on serine residue(s) in a PKC-dependent manner.			DeNichilo, MO (corresponding author), NIDR, DEV BIOL LAB,NIH,BLDG 30,RM 404, 30 CONVENT DR MSC 4370, BETHESDA, MD 20892 USA.			Yamada, Kenneth/0000-0003-1512-6805				BARRY ST, 1994, J CELL SCI, V107, P2033; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRISSANSEN GW, 1990, INT IMMUNOL, V2, P267, DOI 10.1093/intimm/2.3.267; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SIEGEL JN, 1991, CURRENT PROTOCOLS IM; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VUORI K, 1993, J BIOL CHEM, V268, P21459; WAHL LM, 1991, CURRENT PROTOCOLS IM; WAHL SM, 1987, J IMMUNOL, V139, P1342; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1992, J CELL SCI, V101, P277; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	47	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11016	11022		10.1074/jbc.271.18.11016	http://dx.doi.org/10.1074/jbc.271.18.11016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631923	hybrid			2022-12-27	WOS:A1996UJ34200091
J	Ahn, J; Mundigl, O; Muth, TR; Rudnick, G; Caplan, MJ				Ahn, J; Mundigl, O; Muth, TR; Rudnick, G; Caplan, MJ			Polarized expression of GABA transporters in Madin-Darby canine kidney cells and cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MICROTUBULE-ASSOCIATED PROTEIN-2; RAT-BRAIN; DOPAMINE TRANSPORTER; GLYCINE TRANSPORTER; IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; MOUSE-BRAIN; COLOCALIZATION	At least three high affinity Na+- and Cl--dependent gamma-aminobutyric acid (GASA) transporters are known to exist in the rat and mouse brain, These transporters share 50-65% amino acid sequence identity with the kidney betaine transporter which also transports GABA but with lower affinity. The betaine transporter (BGT) is expressed on the basolateral surface of polarized Madin-Darby canine kidney (MDCK) cells. Recent evidence suggests that the signals and mechanisms involved in membrane protein sorting share many functional characteristics in polarized neurons and epithelial cells, It was previously shown that the rat GABA transporter GAT-1 is located in the presynaptic membrane of axons where it plays a role in terminating GABAergic neurotransmission, When expressed in MDCK cells by transfection, GAT-1 was sorted to the apical membrane, In this report, we have localized the other two GABA transporters, GAT-2 and GAT-3, in transfected MDCK cells by GABA uptake, immunofluorescence, and cell surface biotinylation. GAT-3, like GAT-1, localized to the apical membrane of MDCK cells while GAT-2, like BGT, localized to the basolateral membrane, We have also expressed BGT in low density cultures of hippocampal neurons by microinjection and immunolocalized it to the dendrites, The distribution of GAT-3 in these neurons after transfection was axonal as well as somatodendritic. These results indicate that highly homologous subtypes of GABA transporters are sorted differently when expressed in epithelial cells or neurons and suggest that these two cell types share the capacity to distinguish among these isoforms and target them to distinct destinations.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Caplan, Michael/0000-0001-5768-4405; Muth, Theodore/0000-0002-6882-1193	NIGMS NIH HHS [GM-42136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BORDEN LA, 1995, J NEUROCHEM, V64, P977; BORDEN LA, 1995, IN PRESS RECEPTORS C; CACERES A, 1986, J NEUROSCI, V6, P714; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GOSLIN K, 1990, CULTURING NERVE CELL, P251; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HOFFMAN BJ, 1991, SCIENCE, V254, P79; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; OLKKONEN VM, 1993, J NEUROSCI RES, V35, P445, DOI 10.1002/jnr.490350412; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RADIAN R, 1990, J NEUROSCI, V10, P1319; ROBERTS E, 1974, BIOCHEM PHARMACOL, V23, P2637, DOI 10.1016/0006-2952(74)90033-1; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, MOL PHARMACOL, V42, P563; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WECLEWICZ K, 1993, J NEUROSCI RES, V36, P173, DOI 10.1002/jnr.490360207; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197	50	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6917	6924		10.1074/jbc.271.12.6917	http://dx.doi.org/10.1074/jbc.271.12.6917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636119	hybrid			2022-12-27	WOS:A1996UB15700054
J	Aslund, F; Nordstrand, K; Berndt, KD; Nikkola, M; Bergman, T; Ponstingl, H; Jornvall, H; Otting, G; Holmgren, A				Aslund, F; Nordstrand, K; Berndt, KD; Nikkola, M; Bergman, T; Ponstingl, H; Jornvall, H; Otting, G; Holmgren, A			Glutaredoxin-3 from Escherichia coli - Amino acid sequence, H-1 and N-15 NMR assignments, and structural analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE DETERMINATION; GLUTATHIONE-DEPENDENT SYNTHESIS; PROTON PROTON DISTANCES; 3-DIMENSIONAL STRUCTURE; HUMAN THIOREDOXIN; MIXED DISULFIDE; PROTEINS; SPECTROSCOPY; DEOXYRIBONUCLEOTIDES; PURIFICATION	The primary and secondary structure of glutaredoxin-3 (Grx3), a glutathione-disulfide oxidoreductase from Escherichia coli, has been determined. The amino acid sequence of Grx3 consists of 82 residues and contains a redox-active motif, Cys-Pro-Tyr-Cys, typical of the glutaredoxin family. Sequence comparison reveals a homology (33% identity) to that of glutaredoxin-1 (Grx1) from E. coli as well as to other members of the thioredoxin superfamily. in addition to the active site cysteine residues, Grx3 contains one additional cysteine (Cys(65)) corresponding to one of the two non-active site (or structural) cysteine residues present in mammalian glutaredoxins. The sequence-specific H-1 and N-15 nuclear magnetic resonance assignments of reduced Grx3 have been obtained. From a combined analysis of chemical shifts, (3)J(HN alpha) coupling constants, sequential and medium range NOEs, and amide proton exchange rates, the secondary structure of reduced Grx3 was determined and found to be very similar to that inferred from amino acid sequence comparison to homologous proteins. The consequences of the proposed structural similarity to Grx1 are that Grx3, while possessing a largely intact GSH binding cleft, would have a very different spatial distribution of charged residues, most notably surrounding the active site cysteine residues and occurring in the proposed hydrophobic protein-protein interaction area. These differences may contribute to the observed very low K-cat of Grx3 as a reductant of insulin disulfides or as a hydrogen donor for ribonucleotide reductase. Thus, despite an identical active site disulfide motif and a similar secondary structure and tertiary fold, Grx3 and Grxl display large functional differences in in vitro protein disulfide oxide-reduction reactions.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	Karolinska Institutet; Swedish University of Agricultural Sciences			Otting, Gottfried/H-8413-2014; Berndt, Kurt/J-8574-2015	Otting, Gottfried/0000-0002-0563-0146; Berndt, Kurt/0000-0002-3049-967X				ABERG A, 1989, J BIOL CHEM, V264, P12249; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRIAND J, 1991, CHEM PHYS LETT, V185, P276, DOI 10.1016/S0009-2614(91)85060-A; BROWN NC, 1969, EUR J BIOCHEM, V9, P561, DOI 10.1111/j.1432-1033.1969.tb00646.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Creighton T E, 1986, Methods Enzymol, V131, P83; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FORMANKAY JD, 1989, BIOCHEMISTRY-US, V28, P7088, DOI 10.1021/bi00443a045; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOLLENBERG CP, 1992, EMBO GENBANK DDBJ DA; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; NORDSTRAND K, IN PRESS EUR J BIOPH; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; OSAPAY K, 1994, J MOL BIOL, V244, P183, DOI 10.1006/jmbi.1994.1718; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; SODANO P, 1991, J MOL BIOL, V221, P1311; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; SZILAGYI L, 1995, PROG NUCL MAG RES SP, V27, P325, DOI 10.1016/0079-6565(95)01011-2; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; Thelander L, 1978, Methods Enzymol, V51, P227; WILLIAMSON MP, 1993, J MAGN RESON SER B, V101, P63, DOI 10.1006/jmrb.1993.1008; WILLIAMSON MP, 1995, J MOL BIOL, V247, P541, DOI 10.1006/jmbi.1995.0160; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIA TH, 1992, PROTEIN SCI, V1, P310; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	62	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6736	6745		10.1074/jbc.271.12.6736	http://dx.doi.org/10.1074/jbc.271.12.6736			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636094	hybrid			2022-12-27	WOS:A1996UB15700029
J	Bergeron, A; Champetier, S; LaRue, H; Fradet, Y				Bergeron, A; Champetier, S; LaRue, H; Fradet, Y			MAUB is a new mucin antigen associated with bladder cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-ASSOCIATED GLYCOPROTEIN; POLYMORPHIC EPITHELIAL MUCIN; MONOCLONAL-ANTIBODY B72.3; MOLECULAR-CLONING; INTESTINAL MUCIN; GENE-EXPRESSION; DIFFERENTIATION ANTIGENS; IMMUNOLOGICAL PROPERTIES; CARBOHYDRATE ANTIGENS; MEMBRANE ANTIGEN	The M344 tumor-associated antigen, expressed in 70% of superficial bladder tumors, is a sialylated carbohydrate present on a high molecular mass thiol-reducible secreted mucin, which we named MAUB for mucin antigen of the urinary bladder, Herein we studied the relationship between MAUB and other known mucins in the MGH-U3 bladder cancer line where MAUB expression is modulated by culture conditions, Northern blots, immunoradiometric assays, and Western blots showed that only MUC1 and MUC2 are expressed in this MAUB-positive cell line, MUC1 differs from MAUB by its molecular mass and its non-oligomeric nature, while MUC2 has similar molecular mass and response to culture conditions. However, in double determinant immunoradiometric assays, MAUB and MUC2 did not cross react. Moreover, confocal microscopy showed different subcellular localization of the two antigens, Treatment of MGH-U3 cells with MUC2 antisense oligodeoxynucleotides resulted in decreased expression of MUGS and increased expression of MAUB, ruling out the possibility that monoclonal antibody M344 recognizes a different glycosylated form of MUC2, In addition, we identified a tumor specimen expressing MAUB but no MUC2 antigen or mRNA. Together, these results suggest that there is expression of at least three mucins in MGH-U3 cells and that MAUB is a cancer-associated mucin distinct from those identified so far.	HOP HOTEL DIEU, CTR RECH, LAB UROONCOL EXPT, QUEBEC CITY, PQ G1R 2J6, CANADA					Fradet, Yves/0000-0002-7581-2500; Bergeron, Alain/0000-0002-2875-0773				ABE M, 1989, CANCER RES, V49, P2834; Allard P, 1995, CLIN CANCER RES, V1, P1195; ANAGNOSTAKI E, 1990, BRIT J CANCER, V62, P52; APOSTOLOPOULOS V, 1994, CRIT REV IMMUNOL, V14, P293, DOI 10.1615/CritRevImmunol.v14.i3-4.40; ARKLIE J, 1981, INT J CANCER, V28, P23, DOI 10.1002/ijc.2910280105; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BECKETT ML, 1991, CANCER RES, V51, P1326; BLANK M, 1994, INT J CANCER, V59, P301, DOI 10.1002/ijc.2910590302; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BONNER RB, 1993, CANCER, V72, P2461, DOI 10.1002/1097-0142(19931015)72:8<2461::AID-CNCR2820720826>3.0.CO;2-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL J, 1987, CANCER RES, V47, P5476; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRD JC, 1991, CANCER RES, V51, P1026; CARBIN BE, 1987, UROL RES, V15, P191; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONN IG, 1988, J CLIN PATHOL, V41, P1191, DOI 10.1136/jcp.41.11.1191; CORDONCARDO C, 1992, AM J PATHOL, V140, P375; CREPIN M, 1990, BIORHEOLOGY, V27, P471; DAVIS HM, 1986, CANCER RES, V46, P6143; DEVINE P L, 1990, Journal of Tumor Marker Oncology, V5, P11; DEVINE PL, 1993, BRIT J CANCER, V67, P1182, DOI 10.1038/bjc.1993.223; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DURRANT LG, 1994, EUR J CANCER, V30A, P355, DOI 10.1016/0959-8049(94)90256-9; FEIZI T, 1987, BIOCHEM J, V245, P1; Fradet Y, 1993, Semin Urol, V11, P145; FRADET Y, 1987, P NATL ACAD SCI USA, V84, P7227, DOI 10.1073/pnas.84.20.7227; FRADET Y, 1990, INT J CANCER, V46, P990, DOI 10.1002/ijc.2910460607; Fradet Y, 1992, Semin Urol, V10, P28; FRADET Y, 1995, CURR OPIN UROL, V5, P267; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GAMBUS G, 1993, GASTROENTEROLOGY, V104, P93; GAMBUS G, 1995, INT J CANCER, V60, P146, DOI 10.1002/ijc.2910600122; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GOLD DV, 1988, TUMOR BIOL, V9, P137, DOI 10.1159/000217554; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAND PH, 1985, CANCER RES, V45, P833; HANSKI C, 1993, CANCER RES, V53, P4082; HERR HW, 1995, J CLIN ONCOL, V13, P1404, DOI 10.1200/JCO.1995.13.6.1404; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HO SB, 1993, CANCER RES, V53, P641; HO SB, 1995, CANCER RES, V55, P2681; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; ITOKU KA, 1992, HEMATOL ONCOL CLIN N, V6, P99, DOI 10.1016/S0889-8588(18)30365-4; ITZKOWITZ S, 1992, APMIS, V100, P173; JACOBS EL, 1991, CURR PROBL CANCER, V15, P300; JEROME KR, 1992, CANCER RES, V52, P5985; JOHNSON VG, 1986, CANCER RES, V46, P850; KIM YS, 1992, J CELL BIOCHEM, P91; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamerz Rolf, 1993, In Vivo (Athens), V7, P607; LAN MS, 1985, CANCER RES, V45, P305; LAN MS, 1990, CANCER RES, V50, P2997; LEONI F, 1988, HYBRIDOMA, V7, P129, DOI 10.1089/hyb.1988.7.129; LIN CW, 1985, CANCER RES, V45, P5070; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MIOTTI S, 1985, CANCER RES, V45, P826; OGATA S, 1992, CANCER RES, V52, P5971; PEREY L, 1992, CANCER RES, V52, P2563; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PRAT M, 1989, INT J CANCER, V44, P67, DOI 10.1002/ijc.2910440113; PRAT M, 1989, CANCER RES, V49, P1415; RAO JY, 1993, P NATL ACAD SCI USA, V90, P8287, DOI 10.1073/pnas.90.17.8287; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUEL J, 1990, CANCER RES, V50, P4801; SINGHAL A, 1990, BIOESSAYS, V12, P223, DOI 10.1002/bies.950120506; SOLOWAY MS, 1992, J CELL BIOCHEM, P120; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TAKASHI M, 1987, UROL INT, V42, P170, DOI 10.1159/000281888; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; WALSH MD, 1994, BRIT J UROL, V73, P256, DOI 10.1111/j.1464-410X.1994.tb07514.x; WURZNER R, 1990, J IMMUNOL METHODS, V126, P231, DOI 10.1016/0022-1759(90)90155-O; XING PX, 1992, J NATL CANCER I, V84, P699, DOI 10.1093/jnci/84.9.699; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599	86	17	22	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6933	6940		10.1074/jbc.271.12.6933	http://dx.doi.org/10.1074/jbc.271.12.6933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636121	hybrid			2022-12-27	WOS:A1996UB15700056
J	Saklatvala, J; Rawlinson, L; Waller, RJ; Sarsfield, S; Lee, JC; Morton, LF; Barnes, MJ; Farndale, RW				Saklatvala, J; Rawlinson, L; Waller, RJ; Sarsfield, S; Lee, JC; Morton, LF; Barnes, MJ; Farndale, RW			Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								p38 mitogen-activated protein kinase (MAPK) was identified in platelets on the basis of (a) its reactivity with antibodies to C-terminal and N-terminal peptides, and (b) its ability to activate MAPK-activated protein kinase-2, which phosphorylates the small heat shock protein, hsp27. p38 MAPK was activated in platelets by collagen fibers, a collagen-related cross-linked peptide, thrombin, or the thromboxane analogue U46619. A highly specific inhibitor of p38 MAPK, a pyridinyl imidazole known as SB203580, inhibited the platelet enzyme in vitro (IC50 similar to 0.5 mu M). At similar concentrations it also inhibited agonist-stimulated phosphorylation of hsp27 in platelets, and platelet aggregation and secretion induced by minimal aggregatory concentrations of collagen or U46619, but not thrombin. Inhibition of aggregation was overcome by increasing agonist dose. SB203580 might act by inhibiting thromboxane generation, but this was only inhibited by 10-20% at low agonist concentrations. p38 MAPK provides a crucial signal, which is necessary for aggregation caused by minimal concentrations of collagen fibers or U46619. Thrombin or high doses of these agonists generate signals that bypass the enzyme, or render the enzyme no longer rate-limiting.	SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	GlaxoSmithKline; University of Cambridge	Saklatvala, J (corresponding author), BABRAHAM INST,DEPT DEV & SIGNALLING,CYTOKINE LAB,CAMBRIDGE CB2 4AT,ENGLAND.							BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1995, J BIOL CHEM, V270, P27895; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	24	257	261	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6586	6589		10.1074/jbc.271.12.6586	http://dx.doi.org/10.1074/jbc.271.12.6586			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636072	hybrid			2022-12-27	WOS:A1996UB15700007
J	Tozser, J; Bagossi, P; Weber, IT; Copeland, TD; Oroszlan, S				Tozser, J; Bagossi, P; Weber, IT; Copeland, TD; Oroszlan, S			Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 PROTEINASE; RETROVIRAL PROTEASE; CLEAVAGE SITES; MOLECULAR-DYNAMICS; FORCE-FIELD; AMINO-ACID; REQUIREMENTS; SIMULATIONS	The retroviral proteinase (PR) seems to play crucial roles in the viral life cycle, therefore it is an attractive target for chemotherapy. Previously we studied the specificity of human immunodeficiency virus (HIV) type 1 and type 2 as well as equine infectious anemia virus PRs using oligopeptide substrates. Here a similar approach is used to characterize the specificity of avian myeloblastosis virus (AMV) PR and to compare it with those of the previously characterized lentiviral PRs. All peptides representing naturally occurring Gag and Gag-Pol cleavage sites were substrates of the AMV PR. Only half of these peptides were substrates of HIV-1 PR. The K-m values for AMV PR were in a micromolar range previously found for the lentiviral PRs; however, the K-cat values were in a 10-30-fold lower range. A series of peptides containing single amino acid substitutions in a sequence representing a naturally occurring HIV cleavage site was used to characterize the seven substrate binding subsites of the AMV PR. The largest differences were found at the P4 and P2 positions of the substrate. Detailed analysis of the results by molecular modeling and comparison with previously reported data revealed the common characteristics of the specificity of the retroviral PRs as well as its strong dependence on the sequence context of the substrate.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; NCI, FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB,NIH, FREDERICK, MD 21702 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tozser, J (corresponding author), DEBRECEN UNIV MED, SCH MED, DEPT BIOCHEM, POB 6, H-4012 DEBRECEN, HUNGARY.		Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Tozser, Jozsef/0000-0001-5076-8729	NATIONAL CANCER INSTITUTE [R01CA058166] Funding Source: NIH RePORTER; NCI NIH HHS [CA58166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9; BLAHA I, 1992, FEBS LETT, V309, P389, DOI 10.1016/0014-5793(92)80813-V; BLAHA I, 1991, INT J PEPT PROT RES, V38, P453; CAMERON CE, 1994, J BIOL CHEM, V269, P11170; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; CHENG YSE, 1990, GENE, V87, P243, DOI 10.1016/0378-1119(90)90308-E; GRANDGENETT D, 1985, J BIOL CHEM, V260, P8243; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GRINDE B, 1992, J BIOL CHEM, V267, P9481; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; HARRISON RW, 1994, PROTEIN ENG, V7, P1353, DOI 10.1093/protein/7.11.1353; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; Harrison RW, 1995, PROTEINS, V23, P463, DOI 10.1002/prot.340230402; HORTON R, 1991, J VIROL, V65, P1141, DOI 10.1128/JVI.65.3.1141-1148.1991; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KONVALINKA J, 1992, EMBO J, V11, P1141, DOI 10.1002/j.1460-2075.1992.tb05154.x; KONVALINKA J, 1991, FEBS LETT, V282, P73, DOI 10.1016/0014-5793(91)80447-B; KOTLER M, 1989, J BIOL CHEM, V264, P3428; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; MENENDEZARIAS L, 1994, J BIOL CHEM, V269, P16795; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PETTIT SC, 1991, J BIOL CHEM, V266, P14539; PHYLIP LH, 1990, BIOCHEM BIOPH RES CO, V171, P439, DOI 10.1016/0006-291X(90)91412-L; RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; ROBERTS MM, 1991, PROTEIN ENG, V4, P695, DOI 10.1093/protein/4.6.695; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; Swanstrom Ronald, 1994, Current Opinion in Biotechnology, V5, P409, DOI 10.1016/0958-1669(94)90050-7; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; WEBER IT, 1993, BIOCHEMISTRY-US, V32, P3354, DOI 10.1021/bi00064a019; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Winslow D L, 1995, AIDS, V9 Suppl A, pS183; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y	43	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6781	6788						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636100				2022-12-27	WOS:A1996UB15700035
J	Brandes, HK; Larimer, FW; Hartman, FC				Brandes, HK; Larimer, FW; Hartman, FC			The molecular pathway for the regulation of phosphoribulokinase by thioredoxin f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBULOSE-5-PHOSPHATE KINASE; SPINACH PHOSPHORIBULOKINASE; CYSTEINYL RESIDUE; ACTIVE-CENTER; REDUCED FORM; SITE; IDENTIFICATION; PHOTOSYNTHESIS; SULFHYDRYL	Phosphoribulokinase (PRK) is one of several plant enzymes that is regulated by thiol-disulfide exchange as mediated by thioredoxin, which contains spatially vicinal, redox-active cysteinyl residues, In an earlier study (Brandes, H. K., Larimer, F. W., Geck, M. K., Stringer, C. D., Schurmann, P., and Hartman, F. C. (1993) J. Biol. Chem, 268, 18411-18414), our laboratory identified Cys-46 of thioredoxin f (Trx), as opposed to the other candidate Cys-49, as the primary nucleophile that attacks the disulfide of target proteins. The goal of the present study was to identify which of the two redox-active cysteinyl residues of PRK (Cys-16 or Cys-55) is paired with Cys-46 of Trx in the interprotein disulfide intermediate of the overall oxidation-reduction pathway. Incubation of a mixture of the C16S mutant of PRK and the C49S mutant of Trx with Cu2+ results in covalent complex formation as detected by SDS-polyacrylamide gel electrophoresis. Complexation is fully reversible by dithiothreitol and is retarded by ligands for PRK. Under the same conditions, Cu2+ induces very little complex formation between the following pairs of mutants: C16S PRK/C46S Trx, C55S PRK/C49S Trx, and C55S PRK/C46S Trx. When either 5-thio-2-nitrobenzoate-derivatized C16S or C55S PRK, as mimics of the oxidized (disulfide) form of the enzyme, is mixed with C49S Trx, stable covalent complex formation occurs only with the C16S PRK. Thus, two independent approaches identify Cys-55 of PRK in the intermolecular disulfide pairing with Trx.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831; UNIV TENNESSEE,GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville								BRANDES HK, 1993, J BIOL CHEM, V268, P18411; BRANDES HK, 1996, IN PRESS J BIOL CHEM, V271; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1984, BIOSCIENCE, V34, P378, DOI 10.2307/1309730; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KRIEGER TJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P362, DOI 10.1016/0003-9861(87)90457-7; KRIEGER TJ, 1987, BIOCHIM BIOPHYS ACTA, V915, P112, DOI 10.1016/0167-4838(87)90130-0; LI HM, 1993, BIOCHEMISTRY-US, V32, P5800, DOI 10.1021/bi00073a012; MILANEZ S, 1988, GENE, V66, P55, DOI 10.1016/0378-1119(88)90224-7; PONTREMOLI S, 1962, J BIOL CHEM, V237, P643; PORTER MA, 1988, J BIOL CHEM, V263, P14846; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PORTER MA, 1988, J BIOL CHEM, V263, P123; PORTER MA, 1986, BIOCHEMISTRY-US, V25, P7314, DOI 10.1021/bi00371a011; PORTER MA, 1990, ARCH BIOCHEM BIOPHYS, V281, P330, DOI 10.1016/0003-9861(90)90452-5; PORTER MA, 1990, J PROTEIN CHEM, V9, P445, DOI 10.1007/BF01024620; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; RACKER E., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P300, DOI 10.1016/0003-9861(57)90496-4; REUTIMANN H, 1981, J BIOL CHEM, V256, P6796; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; YANG YF, 1991, J BIOL CHEM, V266, P12759	28	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3333	3335						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631927				2022-12-27	WOS:A1996TV72400001
J	Koshy, KM; Boggs, JM				Koshy, KM; Boggs, JM			Investigation of the calcium-mediated association between the carbohydrate head groups of galactosylceramide and galactosylceramide I-3 sulfate by electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CEREBROSIDE SULFATE; MELANOMA-CELLS; RECOGNITION; DIGALACTOSYLDIACYLGLYCEROL; MECHANISMS; CATIONS; BINDING	Calcium has been shown previously to cause aggregation of phosphatidylcholine/cholesterol liposomes containing galactosylceramide (GalCer) with similar liposomes containing cerebroside sulfate (galactosylceramide I-3 sulfate) (CBS), suggesting that it mediates a carbohydrate-carbohydrate association between these two glycolipids. In order to determine if such an association occurs, the noncovalent complexes formed on addition of calcium chloride to GalCer and CBS in methanol were examined by positive and negative ion spray mass spectrometry, Monomeric Ca2+ complexes of both lipids were observed. In addition, Ca2+ also caused oligomerization of GalCer. Oligomerization of CBS anion was not seen, but dimers would not have been observed, as they would be neutral. However, Ca2+ caused heterotypic complexation of GalCer and CBS, Although these heterotypic complexes were of low abundance in methanol compared with the other monomeric and homotypic oligomeric positive ions formed at low declustering potentials, the heterotypic dimer [GalCer . CBS . Ca2+-H](+) had the greatest stability of all oligomers formed and was the only one to survive at high declustering potentials. Na+ did not cause oligomerization of GalCer in methanol indicating that the complexes of GalCer with Ca2+ are not caused by van der Waals interactions between the lipid moieties. GalCer and CBS are present in high concentrations in myelin, This Ca2+-mediated carbohydrate-carbohydrate interaction, which can bridge apposing bilayers, may be involved in adhesion of the extracellular surfaces of the myelin sheath.	HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ANGYAL SJ, 1971, J CHEM SOC CHEM COMM, P500, DOI 10.1039/c29710000500; ANGYAL SJ, 1972, AUST J CHEM, V25, P1957, DOI 10.1071/CH9721957; [Anonymous], 1966, ADV CARBOHYD CHEM, V21, P209; BREWER GJ, 1992, BIOCHEMISTRY-US, V31, P1816, DOI 10.1021/bi00121a033; CAMILLERI P, 1993, RAPID COMMUN MASS SP, V7, P949, DOI 10.1002/rcm.1290071017; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; COOK WJ, 1977, METAL LIGAND INTER 2, P231; COOK WJ, 1972, J AM CHEM SOC, V95, P6442; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DOMOVS KB, 1960, J DAIRY SCI, V43, P1216, DOI 10.3168/jds.S0022-0302(60)90307-6; EGGENS I, 1989, J BIOL CHEM, V264, P9476; GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P2503, DOI 10.1021/bi00175a020; HAKOMORI S, 1991, PURE APPL CHEM, V63, P473, DOI 10.1351/pac199163040473; HUANG RTC, 1978, NATURE, V276, P624, DOI 10.1038/276624a0; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOPACZYK KC, 1965, J LIPID RES, V6, P140; KOSHY KM, 1983, CHEM PHYS LIPIDS, V34, P41, DOI 10.1016/0009-3084(83)90058-0; MENIKH A, 1993, EUR BIOPHYS J BIOPHY, V22, P249, DOI 10.1007/BF00180259; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; Norton W.T., 1977, MYELIN, P161; SIUZDAK G, 1993, J AM CHEM SOC, V115, P2877, DOI 10.1021/ja00060a040; SIUZDAK G, 1994, BIOORG MED CHEM LETT, V4, P2863, DOI 10.1016/S0960-894X(01)80829-5; SMITH RD, 1992, ORG MASS SPECTROM, V27, P811, DOI 10.1002/oms.1210270709; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; STEWART RJ, 1993, BIOCHEMISTRY-US, V32, P10666, DOI 10.1021/bi00091a017; VALENT BS, 1974, PLANT PHYSIOL, V54, P105, DOI 10.1104/pp.54.1.105; WEBB MS, 1988, BIOCHIM BIOPHYS ACTA, V938, P323, DOI 10.1016/0005-2736(88)90130-7; WHITFIELD DM, 1993, COORDIN CHEM REV, V122, P171, DOI 10.1016/0010-8545(93)80045-7; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7	32	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3496	3499						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631953				2022-12-27	WOS:A1996TV72400027
J	Murakami, Y; Ichiba, T; Matsufuji, S; Hayashi, S				Murakami, Y; Ichiba, T; Matsufuji, S; Hayashi, S			Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DEGRADATION; GENE; POLYAMINES	The degradation of ornithine decarboxylase (ODC) catalyzed by the 26 S proteasome is accelerated by antizyme, an ODC inhibitory protein induced by polyamines, Previously, we have found another possible regulatory protein of ODC degradation, antizyme inhibitor, Antizyme inhibitor binds to the antizyme with a higher affinity than that of ODC, releasing ODC from ODC-antizyme complex. We report here the cDNA sequence of rat heart antizyme inhibitor, The deduced sequence of the protein is highly similar to, but distinct from, sequences of ODCs from various species, Antizyme inhibitor contains amino acid residues required for formation of active sites of ODC, but it completely lacks ODC activity. Antizyme inhibitor has no homology with pep tide sequence in the mammalian ODC carboxyl terminus, which is needed for rapid turnover of ODC. It inhibits antizyme-dependent ODC degradation, but, unlike ODC, its degradation is not accelerated by antizyme.			Murakami, Y (corresponding author), JIKEI UNIV,SCH MED,DEPT BIOCHEM 2,MINATO KU,TOKYO 105,JAPAN.							AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FUJITA K, 1982, BIOCHEM J, V204, P647, DOI 10.1042/bj2040647; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; KITANI T, 1989, BIOCHIM BIOPHYS ACTA, V991, P44, DOI 10.1016/0304-4165(89)90026-3; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1989, BIOCHEM J, V259, P839, DOI 10.1042/bj2590839; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROM E, 1993, DNA CELL BIOL, V12, P499, DOI 10.1089/dna.1993.12.499; SHANTZ LM, 1994, CANCER RES, V54, P2313; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TOBIAS KE, 1993, EUR J BIOCHEM, V218, P245, DOI 10.1111/j.1432-1033.1993.tb18371.x; WEN L, 1989, J BIOL CHEM, V264, P9016	27	117	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3340	3342						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631929	hybrid			2022-12-27	WOS:A1996TV72400003
J	Tobin, AB; Keys, B; Nahorski, SR				Tobin, AB; Keys, B; Nahorski, SR			Identification of a novel receptor kinase that phosphorylates a phospholipase C-linked muscarinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLECYSTOKININ RECEPTOR; INOSITOL POLYPHOSPHATE METABOLISM; CHOLINERGIC RECEPTORS; PHOSPHOINOSITIDASE-C; PROTEIN-KINASE; DESENSITIZATION; INHIBITION; CELLS; DOMAIN	Phosphorylation of G-protein-linked receptors is thought to play a central role in receptor regulation and desensitization. Unlike the case of the extensively studied beta-adrenergic receptor/adenylate cyclase pathway, in which receptor-specific phosphorylation is known to be mediated by beta-adrenergic receptor kinase (beta-ARK), the kinases responsible for phosphorylation of phospholipase C-linked receptors have yet to be identified, although a role for beta-ARK has been implicated. This study describes the purification of a novel 40-kDa receptor kinase from porcine cerebellum that is able to phosphorylate the phospholipase C-linked m3-muscarinic receptor in an agonist-dependent manner. The assay for kinase activity was based on the ability of the kinase to phosphorylate a bacterial fusion protein, Ex-m3, containing amino acids Ser(345)-Leu(463) of the third intracellular loop of the m3-muscarinic receptor. Purification of the muscarinic receptor kinase from a high speed supernatant fraction of porcine cerebellum was achieved using the following steps: (i) 30-60% ammonium sulfate cut and successive chromatography on (ii) butyl-Sepharose (iii) Resource Q, (iv) Resource S, and (v) heparin-Sepharose. The purified protein kinase represented an similar to 18,600-fold purification and was a single polypeptide with a molecular weight of similar to 40 kDa. Based on the chromatographic mobility, molecular weight, and kinase inhibitor studies, the kinase, designated MRK, was shown to be distinct from previously characterized second messenger regulated protein kinases, beta-ARK, and other members of the G-protein-linked receptor kinase family. It therefore represents a new class of receptor kinase.			Tobin, AB (corresponding author), UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,POB 138,MED SCI BLDG,UNIV RD,LEICESTER LE1 9HN,LEICS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; ALBAS J, 1995, J BIOL CHEM, V270, P8944; ALI H, 1994, J BIOL CHEM, V269, P24557; BALLA T, 1988, J BIOL CHEM, V263, P4083; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HOFFMANN EK, 1984, J MEMBRANE BIOL, V78, P211, DOI 10.1007/BF01925969; INGLESE J, 1993, J BIOL CHEM, V268, P23737; ISHII K, 1994, J BIOL CHEM, V269, P1125; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KUMAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KWATRA MM, 1993, J BIOL CHEM, V268, P91961; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; MORO O, 1993, J BIOL CHEM, V268, P6862; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; TOBIN AB, 1995, BRIT J PHARMACOL, V116, P1723, DOI 10.1111/j.1476-5381.1995.tb16654.x; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; WAUGH MG, 1995, BRIT J PHARMACOL, V114, pP143; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	40	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3907	3916						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632012				2022-12-27	WOS:A1996TV72400086
J	Norbeck, J; Pahlman, AK; Akhtar, N; Blomberg, A; Adler, L				Norbeck, J; Pahlman, AK; Akhtar, N; Blomberg, A; Adler, L			Purification and characterization of two isoenzymes of DL-glycerol-3-phosphatase from Saccharomyces cerevisiae - Identification of the corresponding GPP1 and GPP2 genes and evidence for osmotic regulation of Gpp2p expression by the osmosensing mitogen-activated protein kinase signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE NAD+; YEAST; PHOSPHATASE; OSMOTOLERANCE; GLYCEROL; OSMOREGULATION; STRESS	The existence of specific DL-glycerol-3 phosphatase (EC 3.1.3.21) activity in extracts of Saccharomyces cerevisiae was confirmed by examining strains lacking nonspecific acid and alkaline phosphatase activities, During purification of the glycerol-3-phosphatase, two isozymes having very similar molecular weights were isolated by gel filtration and anion exchange chromotography, By microsequencing of trypsin-generated peptides the corresponding genes were identified as previously sequenced open reading frames of unknown function, The two genes, GPP1 (YIL053W) and GPP2 (YER062C) encode proteins that show 95% amino acid identity and have molecular masses of 30.4 and 27.8 kDa, respectively, The intracellular concentration of Gpp2p increases in cells subjected to osmotic stress, while the production of Gpp1p is unaffected by changes of external osmolarity, Both isoforms have a high specificity for DL-glycerol-3-phosphate, pH optima at 6.5, and K-m(G3P) in the range of 3-4 mM, The osmotic induction of Gpp2p is blocked in cells that are defective in the HOG-mitogen-activated protein kinase pathway, indicating that GPP2 is a target gene for this osmosensing signal transduction pathway, Together with DOG1 and DOG2, encoding two highly homologous enzymes that dephosphorylate 2-deoxyglucose-6-phosphate, GPP1 and GPP2 constitute a new family of genes for low molecular weight phosphatases.	GOTHENBURG UNIV,DEPT GEN & MARINE MICROBIOL,LUNDBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg				Norbeck, Joakim/0000-0001-6017-2689				ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDRE L, 1988, J GEN MICROBIOL, V134, P669; ANDRE L, 1991, FEBS LETT, V286, P13, DOI 10.1016/0014-5793(91)80930-2; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BATAILLE N, 1988, ELECTROPHORESIS, V9, P774, DOI 10.1002/elps.1150091113; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BLOMBERG A, 1995, ELECTROPHORESIS, V16, P1935, DOI 10.1002/elps.11501601320; BLOMBERG A, 1992, ADV MICROB PHYSIOL, V33, P145, DOI 10.1016/S0065-2911(08)60217-9; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brown A D, 1978, Adv Microb Physiol, V17, P181, DOI 10.1016/S0065-2911(08)60058-2; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; KANEKO Y, 1989, MOL GEN GENET, V220, P133, DOI 10.1007/BF00260867; KRAMER RA, 1980, P NATL ACAD SCI-BIOL, V77, P6541, DOI 10.1073/pnas.77.11.6541; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARTIN M, 1977, FEBS LETT, V83, P245, DOI 10.1016/0014-5793(77)81014-4; NORBECK J, 1995, ELECTROPHORESIS, V16, P149, DOI 10.1002/elps.1150160124; NORDSTROM K, 1968, J I BREWING, V74, P429, DOI 10.1002/j.2050-0416.1968.tb03154.x; NOSAKA K, 1990, BIOCHIM BIOPHYS ACTA, V1037, P147, DOI 10.1016/0167-4838(90)90160-H; OLZ R, 1993, J BACTERIOL, V175, P2205, DOI 10.1128/JB.175.8.2205-2213.1993; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PLANKERT U, 1991, EUR J BIOCHEM, V196, P191, DOI 10.1111/j.1432-1033.1991.tb15803.x; RANDEZGIL F, 1995, YEAST, V11, P1233, DOI 10.1002/yea.320111303; SANZ P, 1994, YEAST, V10, P1195, DOI 10.1002/yea.320100907; SHERMAN F, 1979, METHODS YEAST GENETI, P61; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSSMAN I, 1981, BIOCHIM BIOPHYS ACTA, V661, P199, DOI 10.1016/0005-2744(81)90004-8; TONINO GJM, 1963, BIOCHIM BIOPHYS ACTA, V67, P453; TSUBOI KK, 1956, ARCH BIOCHEM BIOPHYS, V61, P197, DOI 10.1016/0003-9861(56)90332-0; TSUBOI KK, 1957, J BIOL CHEM, V224, P621; VENTER U, 1989, NUCLEIC ACIDS RES, V17, P1353, DOI 10.1093/nar/17.4.1353; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499	38	168	180	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13875	13881		10.1074/jbc.271.23.13875	http://dx.doi.org/10.1074/jbc.271.23.13875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662716	hybrid			2022-12-27	WOS:A1996UP38500085
J	Gardella, TJ; Luck, MD; Fan, MH; Lee, CW				Gardella, TJ; Luck, MD; Fan, MH; Lee, CW			Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; EXPRESSION CLONING; MOLECULAR-CLONING; IDENTIFICATION; POLYPEPTIDE; CAMP	Polar residues within the transmembrane domains (TMs) of G protein-coupled receptors have been implicated to be important determinants of receptor function. We have identified mutations at two polar sites in the TM regions of the rat parathyroid hormone (PTH)/PTH-related peptide receptor, Arg-233 in TM 2 and Gln-451 in TM 7, that caused 17-200-fold reductions in the binding affinity of the agonist peptide PTH-(1-34) without affecting the binding affinity of the antagonist/partial agonist PTH-(3-34). When mutations at the TM 2 and TM 7 sites were combined, binding affinity for PTH-(1-34) was restored to nearly that of the wild type receptor. The double mutant receptors, however, were completely defective in signaling cAMP or inositol phosphate production in response to PTH-(1-34) agonist ligand. The results demonstrate that Arg-233 and Gln-451 have important roles in determining agonist binding affinity and transmembrane signaling. Furthermore, the finding that residues in TM 2 and TM 7 are functionally linked suggests that the TM domain topology of the PTH/PTH-related peptide receptor may resemble that of receptors in the rhodopsin/beta-adrenergic receptor family, for which structural and mutagenesis data suggest interactions between TMs 2 and 7.	HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MED, ENDOCRINE UNIT, BOSTON, MA 02114 USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DELEAN A, 1980, J BIOL CHEM, V255, P7108; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JI IH, 1991, J BIOL CHEM, V266, P14953; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; REAGAN JD, 1994, J BIOL CHEM, V269, P9; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; ROST B, 1995, PROTEIN SCI, V4, P521; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHERTLER G, 1995, NATURE, V362, P770; SEALFON S, 1995, MOL PHARMACOL, V270, P16683; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STROOP S, 1994, BIOCHEMISTRY-US, V34, P1050; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; ZHOU W, 1994, MOL PHARMACOL, V45, P165	44	72	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12820	12825		10.1074/jbc.271.22.12820	http://dx.doi.org/10.1074/jbc.271.22.12820			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662729	hybrid			2022-12-27	WOS:A1996UN47400022
J	Malinski, JA; Zera, EM; Angleson, JK; Wensel, TG				Malinski, JA; Zera, EM; Angleson, JK; Wensel, TG			High affinity interactions of GTP gamma S with the heterotrimeric G protein, transducin - Evidence at high and low protein concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT MEMBRANES; CGMP PHOSPHODIESTERASE ACTIVATION; BINDING REGULATORY PROTEINS; BOVINE CEREBRAL-CORTEX; VISUAL EXCITATION; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; RETINAL RODS; NUCLEOTIDE; RHODOPSIN	A well known difference in nucleotide binding characteristics between heterotrimeric G proteins and small GTP binding proteins of the Ras superfamily is that the former bind GTP or guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) with a much lower affinity (K-d similar to 10(-8)-10(-7) M) than the latter (K-d similar to 10(-11)-10(-10) M). We report here that the alpha subunit of the heterotrimeric G protein transducin (G(t)) binds GTP gamma S with an affinity comparable to that of Ras. High affinity binding was suggested by GTP gamma S titrations of rod outer segment samples with G(t) concentrations in the range of 7 nM to 300 nM; the results were more consistent with a dissociation constant for GTP gamma S in the subnanomolar range, than with one in the 10(-8)-10(-7) M range typically reported for heterotrimeric G proteins. Equilibrium binding experiments with G protein concentrations in the subnanomolar to nanomolar range confirmed this conclusion and revealed a dissociation constant of 50 pM, Thus, transducin's affinity for GTP gamma S, and by inference, for GTP, appears to be approximately three orders of magnitude higher than previously reported. These results raise the possibility that some results obtained with high concentrations of nucleotide analogues may be due to minute traces of contaminants such as GTP, GTP gamma S, or GTP alpha S, that have high affinities for G(t alpha).	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07001, EY07981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P237; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HUFF RM, 1985, J BIOL CHEM, V260, P864; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; KELLEHER DJ, 1986, MOL PHARMACOL, V30, P603; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MALINSKI JA, 1993, CELL MOTIL CYTOSKEL, V24, P304; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; ROBINSON WE, 1979, NATURE, V280, P398, DOI 10.1038/280398a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zera EM, 1996, J BIOL CHEM, V271, P12925, DOI 10.1074/jbc.271.22.12925	39	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12919	12924		10.1074/jbc.271.22.12919	http://dx.doi.org/10.1074/jbc.271.22.12919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662740	hybrid			2022-12-27	WOS:A1996UN47400038
J	Schwarz, D; Kisselev, P; Wessel, R; Jueptner, O; Schmid, RD				Schwarz, D; Kisselev, P; Wessel, R; Jueptner, O; Schmid, RD			alpha-Branched 1,2-diacyl phosphatidylcholines as effectors of activity of cytochrome P450SCC (CYP11A1) - Modeling the structure of the fatty acyl chain region of cardiolipln	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED CYTOCHROME-P-450SCC; PHOSPHOLIPID-VESICLES; CHOLESTEROL; P-450SCC; MEMBRANE; CLEAVAGE; MITOCHONDRIA; ACTIVATION; BEHAVIOR; BINDING	Cardiolipin has been shown to be the most effective activator of cholesterol side chain cleavage activity of cytochrome P450SCC, and evidence has been provided for a lipid effector site on the enzyme. Results suggested the headgroup of cardiolipin as major determinant of lipid interaction with P450SCC (Lambeth, J. D. (1981) J. Biol. Chem. 258, 4757-4762). The role of unsaturation is contradictory and open to question (Igarashi, Y. and Kimura, T. (1986) Biochemistry 25, 6461-6466). We synthesized phosphatidylcholines with fully saturated branched fatty acyl chains substituted in the 2-positions of the main chains and studied the influence of these lipids on the activity and other properties of P450SCC in vesicle-reconstituted systems. These saturated branched lipids, with regard to the fatty acyl moiety in molecular shape similar to cardiolipin but with the headgroup of phosphatidylcholines retained, showed a stimulatory efficiency higher than any other phospholipid and at least comparable to cardiolipin. Activation is sensitive to the acyl chain structure and composition. Results suggest that the shape of the molecule at least partially plays an important role in the process of stimulation of the activity of P450SCC. Because binding of cholesterol was increased by the branched lipids monitored optically by the fraction of P450SCC in the high spin form, it was concluded that these lipids, like cardiolipin and other lipids, exert their effects by regulating the binding of cholesterol to P450SCC. These data suggest that polymorphic lipids such as branched phosphatidylcholines and cardiolipin might influence P450SCC function by maintenance of the membrane curvature at a value optimal for activity.	BYELARUSSIAN ACAD SCI, INST BIOORGAN CHEM, MINSK 220141, BELARUS; UNIV STUTTGART, INST TECH BIOCHEM, D-70569 STUTTGART, GERMANY	National Academy of Sciences of Belarus (NASB); Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus; University of Stuttgart	Schwarz, D (corresponding author), MAX DELBRUCK CTR MOLEC MED, ROBERT ROESSLE STR 10, D-13125 BERLIN, GERMANY.							AMES BN, 1960, J BIOL CHEM, V235, P769; BREZESINSKI G, 1987, CHEM PHYS LIPIDS, V43, P257, DOI 10.1016/0009-3084(87)90022-3; CHASHCHIN VL, 1984, BIOCHIM BIOPHYS ACTA, V787, P27, DOI 10.1016/0167-4838(84)90104-3; CHENG B, 1983, LIPIDS, V18, P577, DOI 10.1007/BF02534665; Cullis P, 1983, CONCEPTS MEMBRANE ST, P39; DHARIWAL MS, 1989, BIOCHEMISTRY-US, V28, P8397, DOI 10.1021/bi00447a019; EPAND RM, 1991, CHEM PHYS LIPIDS, V57, P75, DOI 10.1016/0009-3084(91)90051-C; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4329, DOI 10.1016/S0021-9258(19)69437-8; HERMETTER A, 1981, CHEM PHYS LIPIDS, V28, P111, DOI 10.1016/0009-3084(81)90039-6; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; IGARASHI Y, 1986, BIOCHEMISTRY-US, V25, P6461, DOI 10.1021/bi00369a018; KOWLURU RA, 1983, J BIOL CHEM, V258, P8053; LAMBETH JD, 1981, J BIOL CHEM, V256, P4757; LAMBETH JD, 1980, J BIOL CHEM, V255, P8282; LAMBETH JD, 1982, J BIOL CHEM, V257, P1876; LAMBETH JD, 1990, FRONTIERS BIOTRANSFO, V3, P58; LEWIS RNAH, 1994, BIOPHYS J, V66, P1088, DOI 10.1016/S0006-3495(94)80890-2; OMURA T, 1964, J BIOL CHEM, V239, P2370; PEMBER SO, 1983, J BIOL CHEM, V258, P3198; RUCKPAUL K, 1993, HDB EXPT PHARM CYTOC, V105, P581; RUCKPAUL K, 1984, CYTOCHROME P450 STRU; RURUP J, 1994, CHEM PHYS LIPIDS, V72, P175, DOI 10.1016/0009-3084(94)90100-7; SCHMIDT W, 1983, J MEMBRANE BIOL, V76, P73, DOI 10.1007/BF01871454; SCHWARZ D, 1993, BIOCHEM BIOPH RES CO, V195, P889, DOI 10.1006/bbrc.1993.2128; SCHWARZ D, 1994, J STRUCT BIOL, V113, P207, DOI 10.1006/jsbi.1994.1055; SEYBERT DW, 1990, ARCH BIOCHEM BIOPHYS, V279, P188, DOI 10.1016/0003-9861(90)90480-M; SEYBERT DW, 1979, J BIOL CHEM, V254, P2088; USANOV S A, 1987, Biokhimiya, V52, P110; WARNER TG, 1977, J LIPID RES, V18, P548; YAMAKURA F, 1981, BIOCHIM BIOPHYS ACTA, V649, P343, DOI 10.1016/0005-2736(81)90424-7	33	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12840	12846		10.1074/jbc.271.22.12840	http://dx.doi.org/10.1074/jbc.271.22.12840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662703	hybrid			2022-12-27	WOS:A1996UN47400025
J	Kang, YJ; Chen, Y; Epstein, PN				Kang, YJ; Chen, Y; Epstein, PN			Suppression of cardiotoxicity by overexpression of catalase in the heart of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ANTHRACYCLINE CARDIOTOXICITY; DOXORUBICIN ADRIAMYCIN; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; N-ACETYLCYSTEINE; FREE-RADICALS; RAT-HEART; TOXICITY	Weak antioxidant capacity, particularly low catalase activity in the heart, may be a factor responsible for the high sensitivity of this organ to doxorubicin-induced oxidative damage. To test this hypothesis, a heart-specific promoter was used to drive the expression of murine catalase cDNA in transgenic mice. Fifteen healthy transgenic mouse lines were produced. Cardiac catalase activity was constitutively overexpressed in both atrium and ventricle, ranging from 2- to 630-fold higher than normal. This enzyme activity was not altered in liver, kidneys, lungs, and skeletal muscles. Other antioxidant components, including glutathione, glutathione peroxidase, glutathione reductase, metallothionein, and superoxide dismutase, were not altered in the catalase-overexpressing heart. Mice (7 weeks old) from several transgenic lines and from nontransgenic controls were treated intraperitoneally with doxorubicin at a single dose of 20 mg/kg and sacrificed on the 4th day after treatment. As compared to normal controls, transgenic lines expressing catalase activity 60- or 100-fold higher than normal exhibited a significant resistance to doxorubicin induced cardiac lipid peroxidation, elevation of serum creatine phosphokinase, and functional changes in the isolated atrium. Interestingly, 200-fold or greater elevation of catalase activity did not provide protection. The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses.			Kang, YJ (corresponding author), UNIV N DAKOTA, SCH MED, DEPT PHARMACOL & TOXICOL, POB 9037, GRAND FORKS, ND 58202 USA.			Epstein, Paul/0000-0002-7006-8954	NATIONAL CANCER INSTITUTE [R15CA063752, R29CA068125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044519] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; BACHUR NR, 1978, CANCER RES, V38, P1745; BOCHERENSGADIENT SA, 1992, J CARDIOVASC PHARM, V19, P770; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHEN Y, 1994, FREE RADICAL BIO MED, V17, P529, DOI 10.1016/0891-5849(94)90092-2; DEJONG J, 1990, RES COMMUN CHEM PATH, V68, P275; DEMANT EJF, 1984, EUR J BIOCHEM, V142, P571, DOI 10.1111/j.1432-1033.1984.tb08324.x; DOROSHOW JH, 1980, J CLIN INVEST, V65, P128, DOI 10.1172/JCI109642; EATON DL, 1991, METHOD ENZYMOL, V205, P83; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FERRANS VJ, 1978, CANCER TREAT REP, V62, P955; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FURUTA S, 1990, J BIOCHEM, V107, P708, DOI 10.1093/oxfordjournals.jbchem.a123113; GIANNI L, 1992, CANC TREATMENT HEART, P9; GULICK J, 1991, J BIOL CHEM, V266, P9180; HERMANSEN K, 1990, PHARMACOL TOXICOL, V66, P299, DOI 10.1111/j.1600-0773.1990.tb00751.x; HIDA H, 1995, BIOL TRACE ELEM RES, V47, P111, DOI 10.1007/BF02790107; HOGAN B, 1986, MANIPULATING MOUSE E; Ishikawa T., 1986, TARGET ORGAN TOXICIT, P129; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; JONES DP, 1978, J BIOL CHEM, V253, P6031; JULICHER RHM, 1985, RES COMMUN CHEM PATH, V47, P35; KALYANARAMAN B, 1984, BIOCHIM BIOPHYS ACTA, V799, P270, DOI 10.1016/0304-4165(84)90270-8; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; KIRSHENBAUM LA, 1993, AM J PHYSIOL, V265, pH484, DOI 10.1152/ajpheart.1993.265.2.H484; KOJIMA S, 1993, J PHARMACOL EXP THER, V266, P1699; LEE V, 1991, AM J PHYSIOL, V261, pH989, DOI 10.1152/ajpheart.1991.261.4.H989; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; MAO GD, 1993, J BIOL CHEM, V268, P416; MYERS C, 1983, SEMIN ONCOL, V10, P53; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NEBOT C, 1993, ANAL BIOCHEM, V214, P442, DOI 10.1006/abio.1993.1521; ODOM AL, 1992, BIOCHEM PHARMACOL, V43, P831, DOI 10.1016/0006-2952(92)90250-M; OLIVER LT, 1963, J LAB CLIN MED, V62, P159; OLSON RD, 1981, LIFE SCI, V29, P1393, DOI 10.1016/0024-3205(81)90001-1; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; POWELL SR, 1988, TOXICOL APPL PHARM, V96, P175, DOI 10.1016/0041-008X(88)90078-6; PRITSOS CR, 1992, BIOCHEM PHARMACOL, V44, P839, DOI 10.1016/0006-2952(92)90427-K; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPERANZA MJ, 1993, J BIOL CHEM, V268, P19039; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; THAYER WS, 1986, FEBS LETT, V202, P137, DOI 10.1016/0014-5793(86)80664-0; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UNVERFERTH DV, 1985, AM J CARDIOL, V56, P157, DOI 10.1016/0002-9149(85)90585-5; VANACKER SABE, 1993, CANCER RES, V53, P4603; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WILLIS EH, 1990, BIOTECHNIQUES, V9, P92	49	256	260	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12610	12616		10.1074/jbc.271.21.12610	http://dx.doi.org/10.1074/jbc.271.21.12610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647872	hybrid			2022-12-27	WOS:A1996UL66000074
J	Sheikh, H; Isacke, CM				Sheikh, H; Isacke, CM			A di-hydrophobic Leu-Val motif regulates the basolateral localization of CD44 in polarized Madin-Darby canine kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; HOMING RECEPTOR; SORTING SIGNAL; PHOSPHORYLATION; GLYCOPROTEIN; REQUIRES; DISTINCT	Both in vivo and in vitro the distribution of the resident plasma membrane adhesion protein, CD44, is restricted to the basolateral domain of polarized epithelial cells, suggesting a role in interepithelial interactions. To determine how this localization might be regulated, a range of CD44 cytoplasmic domain mutations were generated and a minimal 5 amino acid sequence, His(330)-Leu-Val-Asn-Lys(334), was identified which when deleted results in expression of CD44 on the apical microvillal membrane, Further mutagenesis throughout this regions pinpointed a critical di-hydrophobic motif, Leu(331)/Val(332), The ability of wild type but not mutant CD44 cytoplasmic domains to redirect an apically targeted protein, placental alkaline phosphatase, to the basolateral plasma membrane demonstrates that this sequence can function as a dominant localization signal. This His(330)-Lys(334) sequence is spatially separate from other CD44 regulatory elements and as discussed here, a comparison with known basolateral sorting sequences identified in other transmembrane proteins suggests that a distinct mechanism operates to retain resident plasma membrane proteins in their correct plasma membrane subdomains.			Sheikh, H (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,PRINCE CONSORT RD,LONDON SW7 2BB,ENGLAND.			Isacke, Clare/0000-0002-9222-3345				ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BERGER J, 1988, J BIOL CHEM, V263, P10016; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; HAGGERTY JG, 1992, J INVEST DERMATOL, V99, P374, DOI 10.1111/1523-1747.ep12616087; HUDSON DL, 1995, J CELL SCI, V108, P1959; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; ISACKE CM, 1994, J CELL SCI, V107, P2353; ISHIHARA A, 1988, J CELL BIOL, V106, P329, DOI 10.1083/jcb.106.2.329; JACOBSON K, 1984, J CELL BIOL, V99, P1624, DOI 10.1083/jcb.99.5.1624; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1993, J IMMUNOL, V151, P6490; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MILDE KF, 1994, IMMUNOGENETICS, V40, P437; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MILSTONE LM, 1994, J CELL SCI, V107, P3183; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; NEAME SJ, 1995, J CELL SCI, V108, P3127; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PERSCHL A, 1995, J CELL SCI, V108, P1033; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; UFF CR, 1995, EUR J IMMUNOL, V25, P1883, DOI 10.1002/eji.1830250714; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WANG C, 1992, HISTOCHEMISTRY, V98, P105, DOI 10.1007/BF00717001	53	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12185	12190		10.1074/jbc.271.21.12185	http://dx.doi.org/10.1074/jbc.271.21.12185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647812	hybrid			2022-12-27	WOS:A1996UL66000014
J	VanderMolen, MA; Rubin, CT; McLeod, KJ; McCauley, LK; Donahue, HJ				VanderMolen, MA; Rubin, CT; McLeod, KJ; McCauley, LK; Donahue, HJ			Gap junctional intercellular communication contributes to hormonal responsiveness in osteoblastic networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; PARATHYROID-HORMONE; BONE-CELLS; ALKALINE-PHOSPHATASE; PROTEIN CONNEXIN-43; COMMON RECEPTOR; OSTEO-SARCOMA; ROS 17/2.8; EXPRESSION; DENSITY	To evaluate whether intercellular coupling via connexin43 gap junction channels modulates hormonal responsiveness of cells in contact, we have created osteoblastic cell lines deficient in connexin43. Osteoblastic ROS 17/2.8 cells were transfected with a plasmid containing an antisense cDNA construct to rat connexin43. Control transfection did not alter cell-to-cell coupling nor connexin43 mRNA or protein expression relative to nontransfected ROS 17/2.8 cells. In contrast, stable transfection with an antisense connexin43 cDNA resulted in two clones, RCx4 and RCx16, which displayed significant decreases in connexin43 mRNA and protein expression and were dramatically deficient in cell-to-cell coupling. Phenotypically, all transfectants retained osteoblastic characteristics. However,cells rendered connexin43-deficient through antisense transfection displayed a dramatic attenuation in the cAMP response to parathyroid hormone, Alterations in hormonal responses were not due to changes in parathyroid hormone receptor number or binding kinetics nor to alterations in adenylyl cyclase activity. These results indicate that gap junctions may be required for mediating hormonal signals. Furthermore, these experiments support a regulatory role for connexin43-mediated intercellular communication in the modulation of hormonal responses within elaborately networked bone cells.	PENN STATE UNIV,COLL MED,MUSCULOSKELETAL RES LAB,DEPT ORTHOPAED & REHABIL,HERSHEY,PA 17033; SUNY STONY BROOK,MUSCULOSKELETAL RES LAB,DEPT ORTHOPED,STONY BROOK,NY 11794; UNIV MICHIGAN,SCH DENT,ANN ARBOR,MI 48109; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIA NIH HHS [AG10199, AG13087] Funding Source: Medline; NIEHS NIH HHS [ES06287] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG010199, R01AG013087] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BASTIAANSE EML, 1993, J MEMBRANE BIOL, V136, P135, DOI 10.1007/BF02505758; BOS MP, 1991, J CELL PHYSIOL, V147, P87, DOI 10.1002/jcp.1041470112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MEA, 1993, BONE, V14, P473, DOI 10.1016/8756-3282(93)90182-A; CHIBA H, 1994, CELL STRUCT FUNCT, V19, P173, DOI 10.1247/csf.19.173; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST GJ, 1993, J PHARMACOL EXP THER, V266, P1054; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; CIVITELLI R, 1992, ENDOCRINOLOGY, V130, P2392, DOI 10.1210/en.130.4.2392; COELHO CND, 1991, DEV BIOL, V144, P47, DOI 10.1016/0012-1606(91)90477-K; DEALY CN, 1994, DEV DYNAM, V199, P156, DOI 10.1002/aja.1001990208; DEMAY M, 1985, AM J PHYSIOL, V249, pE437, DOI 10.1152/ajpendo.1985.249.5.E437; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DONAHUE HJ, 1988, J BIOL CHEM, V263, P13522; DONAHUE HJ, 1995, J BONE MINER RES, V10, P881; DONAHUE HJ, 1992, BONE MINER S1, V17, P123; EGAN JJ, 1991, J CELL BIOCHEM, V45, P93, DOI 10.1002/jcb.240450116; EGRISE D, 1992, BONE, V13, P355, DOI 10.1016/8756-3282(92)90451-2; Fedotov V P, 1993, Biull Eksp Biol Med, V116, P619; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GREEN CR, 1994, DEV BIOL, V161, P12, DOI 10.1006/dbio.1994.1002; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JEANSONNE BG, 1979, J DENT RES, V58, P1415, DOI 10.1177/00220345790580042101; JONES SJ, 1993, ANAT EMBRYOL, V187, P343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1978, P NATL ACAD SCI USA, V75, P5417, DOI 10.1073/pnas.75.11.5417; MAJESKA RJ, 1985, ENDOCRINOLOGY, V116, P170, DOI 10.1210/endo-116-1-170; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Martinez Arias Alfonso, 1994, Trends in Genetics, V10, P219; MCCAULEY LK, 1994, MOL CELL ENDOCRINOL, V101, P331, DOI 10.1016/0303-7207(94)90250-X; MCLEOD KJ, 1993, J BONE MINER RES, V8, P977, DOI 10.1002/jbmr.5650080811; MODROWSKI D, 1993, CELL TISSUE RES, V271, P499, DOI 10.1007/BF02913733; MUNARISILEM Y, 1995, J CLIN INVEST, V95, P1429, DOI 10.1172/JCI117813; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; PECK WA, 1981, CALCIFIED TISSUE INT, V33, P409, DOI 10.1007/BF02409464; RODAN GA, 1984, ADV BONE MINERAL RES, V2, P240; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAEZ JC, 1990, IN VITRO TOXICOL, V3, P69; SCHILLER PC, 1992, MOL ENDOCRINOL, V6, P1433, DOI 10.1210/me.6.9.1433; SCHIRRMACHER K, 1992, CALCIFIED TISSUE INT, V51, P285, DOI 10.1007/BF00334489; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; VANDERPLAS A, 1988, BONE, V9, P107, DOI 10.1016/8756-3282(88)90111-1; WEINREB M, 1990, J BONE MINER RES, V5, P831; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; WONG GL, 1992, J BONE MINER RES, V7, P701; XIA SL, 1992, BIOCHEM BIOPH RES CO, V186, P1212, DOI 10.1016/S0006-291X(05)81535-9; YAMAGUCHI DT, 1994, J BONE MINER RES, V9, P791; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YANCEY SB, 1992, DEVELOPMENT, V114, P203; ZIMMERMANN B, 1984, J ANAT, V138, P351	55	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12165	12171		10.1074/jbc.271.21.12165	http://dx.doi.org/10.1074/jbc.271.21.12165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647809	hybrid			2022-12-27	WOS:A1996UL66000011
J	vanNocker, S; Walker, JM; Vierstra, RD				vanNocker, S; Walker, JM; Vierstra, RD			The Arabidopsis thaliana UBC7/13/14 genes encode a family of multiubiquitin chain-forming E2 enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; ESCHERICHIA-COLI; EXPRESSION; YEAST; PROTEINS; INVIVO; LOCALIZATION; DEGRADATION	Covalent modification of proteins by attachment of multiubiquitin chains serves as an essential signal for selective protein degradation in eukaryotes. The specificity of ubiquitin-protein conjugation is controlled in part by a diverse group of ubiquitin-conjugating enzymes (E2s or UBCs), We have previously reported that the product of the wheat TaUBC7 gene recognizes ubiquitin as a substrate for ubiquitination in vitro, catalyzing the condensation of free ubiquitin into multiubiquitin chains linked via lysine 48 (van Nocker, S., and Vierstra, R. D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10297-10301), Based on this activity, this E2 may play a central role in the ubiquitin proteolytic pathway by assembling chains in vivo. Here, we describe the cloning and characterization of a three-member gene family from Arabidopsis thaliana (designated AtUBC7/13/14) encoding structural homologs of TaUBC7. Like TaUBC7, recombinant AtUBC7/13/14 proteins formed multiubiquitin chains in vitro. AtUBC7/13/14 mRNAs were found in all tissues examined, and unlike related UBCs from yeast, the levels of mRNA were not elevated by heat stress or cadmium exposure, Transgenic Arabidopsis were engineered to express increased levels of active AtUBC7, for the first time altering the level of an E2 in a higher eukaryote, Plants expressing high levels of AtUBC7 exhibited no phenotypic abnormalities and were not noticeably enriched in multiubiquitinated conjugates. These findings indicate that the in vivo synthesis of multiubiquitin chains is not rate-limited by the abundance of AtUBC7 and/or involves other, yet undefined components.	UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BARTLING D, 1993, PLANT MOL BIOL, V23, P387, DOI 10.1007/BF00029013; BEERS EP, 1992, J BIOL CHEM, V267, P15432; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENSCHIK P, 1994, MOL GEN GENET, V244, P548, DOI 10.1007/BF00583906; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MATZKE MA, 1995, PLANT PHYSIOL, V107, P579; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 2002, MOL CLONING LAB MANU	32	25	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12150	12158		10.1074/jbc.271.21.12150	http://dx.doi.org/10.1074/jbc.271.21.12150			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647807	hybrid			2022-12-27	WOS:A1996UL66000009
J	Yamakita, Y; Ono, S; Matsumura, F; Yamashiro, S				Yamakita, Y; Ono, S; Matsumura, F; Yamashiro, S			Phosphorylation of human fascin inhibits its actin binding and bundling activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMUSCLE CALDESMON; CULTURED-CELLS; PROTEIN; LOCALIZATION; TROPOMYOSIN; ACTIVATION; KINASE	Human fascin is an actin-bundling protein that is thought to be involved in the assembly of actin filament bundles present in microspikes as well as in membrane ruffles and stress fibers. We have found that human fascin is phosphorylated in vivo upon treatment with 12-O-tetradecanoylphorbol-13-acetate, a tumor promoter. The in vivo phosphorylation is gradually increased from 0.13 to 0.30 mol/mol during 2 h of treatment, concomitant with the disappearance of human fascin from stress fibers, membrane ruffles, and microspikes. Human fascin can also be phosphorylated in vitro by protein kinase C at the same sites as observed in vivo as judged by phosphopeptide mapping. The extent of phosphorylation depends on pH: the stoichiometries are 0.05, 0.38, and 0.6 mol of phosphate/mol of protein at pH 7.0, 6.0, and 5.0, respectively. Phosphorylation greatly reduces actin binding of human fascin, while lowering the pH to 6.0 alone does not affect fascin-actin binding. With the incorporation of 0.25 mol of phosphate/mol of protein, the actin binding affinity is reduced from 6.7 x 10(6) to 1.5 x 10(6) m(-1). The actin bundling activity is also decreased. These results suggest that phosphorylation of fascin plays a role in actin reorganization after treatment with 12-O-tetradecanoylphorbol-13-acetate.			Yamakita, Y (corresponding author), RUTGERS STATE UNIV, DEPT MOLEC BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA.		Ono, Shoichiro/A-6475-2015; Yamakita, Yoshihiko/A-3003-2016	Ono, Shoichiro/0000-0002-4763-0398; Matsumura, Fumio/0000-0002-8204-153X; Yamashiro, Shigeko/0000-0001-7207-9406	NATIONAL CANCER INSTITUTE [R37CA042742] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA42742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; CASSIDY P, 1979, J BIOL CHEM, V254, P1148; DUH FM, 1994, DNA CELL BIOL, V13, P821, DOI 10.1089/dna.1994.13.821; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HOAR PE, 1979, SCIENCE, V204, P503, DOI 10.1126/science.432654; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KANE RE, 1976, J CELL BIOL, V71, P704, DOI 10.1083/jcb.71.3.704; MAHOWALD AP, 1980, GENET BIOL DROSOPHIL, P141; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; PATTERSON J, 1991, GENETICS, V129, P1073; POODRY CA, 1980, GENET BIOL DROSOPHIL, P443; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; YAMASHIROMATSUMURA S, 1985, J BIOL CHEM, V260, P5087	22	110	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12632	12638		10.1074/jbc.271.21.12632	http://dx.doi.org/10.1074/jbc.271.21.12632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647875	hybrid			2022-12-27	WOS:A1996UL66000077
J	Dolis, D; deKroon, IPM; deKruijff, B				Dolis, D; deKroon, IPM; deKruijff, B			Transmembrane movement of phosphatidylcholine in mitochondrial outer membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PHOSPHOLIPID ASYMMETRY; TRANSFER PROTEIN; TRANSLOCATION	One of the steps in the import of phosphatidylcholine (PC) in mitochondria is transmembrane movement across the outer membrane, This process was investigated in vitro using isolated mitochondrial outer membrane vesicles (OMV) from rat liver. C-14-Labeled PC was introduced into the OMV from small unilamellar vesicles by a PC-specific transfer protein (PCTP). The membrane topology of the newly introduced PC was determined from its accessibility to phospholipase A(2). Under conditions where the OMV stay intact, externally added phospholipase A(2) is able to hydrolyze up to 50% of both the introduced [C-14]PC and the endogenous PC. Pool size calculations showed that close to 100% of the PC in the OMV can be exchanged by PCTP. A back-exchange experiment revealed that the introduction of the labeled PC is reversible. The results demonstrate that newly introduced PC molecules readily equilibrate over both leaflets of the OMV membrane. The kinetics of the PCTP-mediated exchange process indicate that the t(1/2) of the transmembrane movement at 30 degrees C is 2 min or less.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT BIOCHEM MEMBRANES,INST BIOMEMBRANES,3584 CH UTRECHT,NETHERLANDS	Utrecht University			de Kroon, Anton I/O-4119-2016	de Kroon, Anton/0000-0003-1209-756X				AKEROYD R, 1981, EUR J BIOCHEM, V114, P385, DOI 10.1111/j.1432-1033.1981.tb05158.x; ANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOK MC, 1971, BIOCHIM BIOPHYS ACTA, V233, P61, DOI 10.1016/0005-2736(71)90358-0; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; JOHNSON LW, 1975, BIOCHIM BIOPHYS ACTA, V375, P176, DOI 10.1016/0005-2736(75)90187-X; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NICOLAY K, 1990, BIOCHIM BIOPHYS ACTA, V1025, P49, DOI 10.1016/0005-2736(90)90189-U; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; ROSE HG, 1965, J LIPID RES, V6, P428; ROTHMAN JE, 1976, BIOCHEMISTRY-US, V15, P2361, DOI 10.1021/bi00656a018; ROUSSELET A, 1976, BIOCHIM BIOPHYS ACTA, V426, P372, DOI 10.1016/0005-2736(76)90383-7; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SPERKAGOTTLIEB CDM, 1988, BIOCHIM BIOPHYS ACTA, V946, P227, DOI 10.1016/0005-2736(88)90397-5; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VAN MEER G, 1980, EUR J BIOCHEM, V103, P283; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANDENBESSELAAR AMHP, 1978, BIOCHIM BIOPHYS ACTA, V510, P242, DOI 10.1016/0005-2736(78)90024-X; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; WESTERMAN J, 1983, METHOD ENZYMOL, V98, P581; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOJTCZAK L, 1969, BIOCHIM BIOPHYS ACTA, V193, P64, DOI 10.1016/0005-2736(69)90059-5; YAFFE MP, 1983, BIOCHEMISTRY-US, V22, P1497, DOI 10.1021/bi00275a026	31	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11879	11883		10.1074/jbc.271.20.11879	http://dx.doi.org/10.1074/jbc.271.20.11879			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662651	hybrid			2022-12-27	WOS:A1996UL25000048
J	Mutskov, VJ; Russanova, VR; Dimitrov, SI; Pashev, IG				Mutskov, VJ; Russanova, VR; Dimitrov, SI; Pashev, IG			Histones associated with non-nucleosomal rat ribosomal genes are acetylated while those bound to nucleosome-organized gene copies are not	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; RNA GENES; XENOPUS-LAEVIS; DROSOPHILA-MELANOGASTER; PSORALEN-CROSSLINKING; NUCLEOLAR CHROMATIN; LASER IRRADIATION; DNA CROSSLINKING; CELL-CYCLE; EXPRESSION	Acetylation of histones bound to rat rRNA genes has been studied relative to their organization in chromatin, either as canonical nucleosomes, containing the inactive copies, or as anucleosomal nonrepeating structures, corresponding to the transcribed genes (Conconi, A., Widmer, R. M., Koller, T., and Sogo, J. M. (1989) Cell 57, 753-761). Nuclei from butyrate-treated rat tumor cells were irradiated with a UV laser to cross-link proteins to DNA, and the purified covalent complexes were immunofractionated by an antibody that specifically recognized the acetylated histones. Upon probing with sequences coding for mature rat 28 S RNA, DNA of the antibody-bound complexes was 5-20-fold enriched relative to the total rat DNA. Since the laser cross-links histones to DNA in both active and inactive genes, one cannot distinguish which one of them, or both, are bound to acetylated histones. Alternatively, purified mononucleosomes were immunofractionated, but DNA from the antibody bound monosomes was not enriched in coding rDNA. Taken together, these results suggest that nucleosome organized rRNA genes are bound to nonmodified histones and that the acetylated histones are associated with the active, anucleosomal gene copies.	BULGARIAN ACAD SCI, INST MOLEC BIOL, BU-1113 SOFIA, BULGARIA	Bulgarian Academy of Sciences			dimitrov, stefan/M-7697-2013	dimitrov, stefan/0000-0002-1326-3630				AMERO SA, 1988, J BIOL CHEM, V263, P10734; ANGELOV D, 1988, NUCLEIC ACIDS RES, V16, P4525, DOI 10.1093/nar/16.10.4525; BELIKOV SV, 1990, FEBS LETT, V273, P205, DOI 10.1016/0014-5793(90)81085-3; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; BRAGA EA, 1985, GENE, V36, P249, DOI 10.1016/0378-1119(85)90180-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; COLAVITOSHEPANSKI M, 1983, J BIOL CHEM, V258, P5944; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CONCONI A, 1984, J MOL BIOL, V178, P920, DOI 10.1016/0022-2836(84)90319-X; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; CULOTTA V, 1988, CELL, V52, P585, DOI 10.1016/0092-8674(88)90471-0; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DIMITROV SI, 1990, NUCLEIC ACIDS RES, V18, P6393, DOI 10.1093/nar/18.21.6393; DIMITROV SI, 1987, EMBO J, V6, P2387, DOI 10.1002/j.1460-2075.1987.tb02516.x; DIMITROV SI, 1992, EUR J BIOCHEM, V204, P977, DOI 10.1111/j.1432-1033.1992.tb16719.x; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON EM, 1987, J BIOL CHEM, V262, P6943; JUDELSON HS, 1982, MOL CELL BIOL, V2, P211, DOI 10.1128/MCB.2.3.211; LABHART P, 1982, CELL, V28, P279, DOI 10.1016/0092-8674(82)90346-4; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1992, CELL BIOL INT REP, V16, P1177, DOI 10.1016/S0309-1651(05)80045-1; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NESS PJ, 1983, J MOL BIOL, V166, P361, DOI 10.1016/S0022-2836(83)80090-4; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; PASHEV IG, 1991, TRENDS BIOCHEM SCI, V16, P323, DOI 10.1016/0968-0004(91)90133-G; PASHEV IG, 1983, EUR J BIOCHEM, V133, P379, DOI 10.1111/j.1432-1033.1983.tb07473.x; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; REEVES R, 1976, SCIENCE, V194, P529, DOI 10.1126/science.973136; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; SPADAFORA C, 1984, NUCLEIC ACIDS RES, V12, P2691, DOI 10.1093/nar/12.6.2691; STEFANOVSKY VY, 1989, BIOCHEM BIOPH RES CO, V164, P304, DOI 10.1016/0006-291X(89)91718-X; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSANEV R, 1993, REPLICATION TRANSCRI, P137; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1991, J CELL SCI, V99, P13; UDVARDY A, 1984, J MOL BIOL, V175, P113, DOI 10.1016/0022-2836(84)90470-4	46	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11852	11857		10.1074/jbc.271.20.11852	http://dx.doi.org/10.1074/jbc.271.20.11852			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662629	hybrid			2022-12-27	WOS:A1996UL25000044
J	Xia, Y; Buja, LM; McMillin, JB				Xia, Y; Buja, LM; McMillin, JB			Change in expression of heart carnitine palmitoyltransferase I isoforms with electrical stimulation of cultured rat neonatal cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE GAMMA-SUBUNIT; MYOSIN HEAVY-CHAIN; MALONYL-COA; GENE-EXPRESSION; SKELETAL-MUSCLE; HYPERTROPHY; GROWTH; LIVER; CDNA; ADAPTATION	Electrical stimulation of neonatal rat cardiac myocytes in culture produces increases in myocyte size (hypertrophy) and organization of actin into myofibrillar arrays. The maturation of the cells is associated with enhanced contractile parameters and cellular calcium content. The numbers and intensity of cellular mitochondrial profiles increase, as measured by scanning laser confocal microscopy. Consistent with the hypertrophic response is increased cellular content of beta-myosin heavy chain and cytochrome oxidase subunit Va messages, as well as increases in cytochrome oxidase activity in the stimulated cardiac myocytes. Myocyte contractile capacity is associated with increased expression of the muscle carnitine palmitoyltransferase (CPT-I) isoform as measured by Northern analysis, immunoblotting, and altered sensitivity of CPT-I activity to malonyl-CoA in the stimulated cells. The data suggest that a switch from the liver isoform of CPT-I, prominent in the neonatal rat heart, to the muscle CPT-I which predominates in adult rat heart, takes place in the neonatal cardiac myocytes over the same time period as the hypertrophic-mediated changes in myofibrillar assembly and increased contractile activity.	UNIV TEXAS, HLTH SCI CTR, SCH MED, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston				Buja, Louis Maximilian/0000-0001-8386-7029	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-38863] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COOK GA, 1987, J BIOL CHEM, V262, P2050; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HENNIG B, 1975, EUR J BIOCHEM, V55, P167, DOI 10.1111/j.1432-1033.1975.tb02149.x; HILENSKI LL, 1991, CELL TISSUE RES, V264, P577, DOI 10.1007/BF00319047; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; HUDSON EK, 1996, IN PRESS AM J PHYSL; IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCMILLIN JB, 1994, ARCH BIOCHEM BIOPHYS, V312, P375, DOI 10.1006/abbi.1994.1322; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; MERLE PL, 1995, J BIOL CHEM, V270, P17361, DOI 10.1074/jbc.270.29.17361; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; SCHNEIDER MD, 1991, MOL BIOL MED, V8, P167; SEDAN RS, 1996, J BIOL CHEM, V271, P2112; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G	46	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12082	12087		10.1074/jbc.271.20.12082	http://dx.doi.org/10.1074/jbc.271.20.12082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662650	hybrid			2022-12-27	WOS:A1996UL25000075
J	Baier, LJ; Bogardus, C; Sacchettini, JC				Baier, LJ; Bogardus, C; Sacchettini, JC			A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINE CACO-2; DIFFERENTIATION; METABOLISM; INSULIN; GLUCOSE; EXPRESSION	The human intestinal fatty acid binding protein (IFABP) binds long-chain fatty acids in vitro, but its intracellular function has remained speculative. A poly morphism in the gene that encodes IFABP results in an alanine (Ala(54)) to threonine (Thr(54)) substitution at codon 54 that alters the in vitro binding affinity of the protein for long-chain fatty acids. To identify potential functional variability between Ala(54) and Thr(54) IFABP, we established permanently transfected Caco-2 cell lines that express either Ala(54) or Thr(54) IFABP. We found that Caco-2 cells expressing Thr(54) IFABP transport long-chain fatty acids and secrete triglycerides to a greater degree than Caco-2 cells expressing Ala(54) IFABP. These results provide the first demonstration that IFABP participates in the intracellular transport of long-chain fatty acids. In addition, the observed increase in transport of fatty acids across cells expressing Thr(54) IFABP suggests a plausible physiologic mechanism for our prior observation that Pima Indians with a Thr(54) IFABP genotype have increased post-absorptive lipid oxidation rates and are more insulin-resistant than Pimas with a Ala(54) IFABP genotype.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Baier, LJ (corresponding author), NIDDK, NATL INST HLTH, 4212 N 16TH ST, PHOENIX, AZ 85016 USA.							ABBOTT WGH, 1987, DIABETES, V36, P897, DOI 10.2337/diabetes.36.8.897; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; HUGHES TE, 1987, J BIOL CHEM, V262, P3762; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; LEVIN MS, 1992, J LIPID RES, V33, P9; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; LILLIOJA S, 1985, J CLIN INVEST, V75, P1106, DOI 10.1172/JCI111804; LOWE JB, 1987, J BIOL CHEM, V262, P5931; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; PIATTI PM, 1995, METABOLISM, V44, P883, DOI 10.1016/0026-0495(95)90241-4; PINTO M, 1983, BIOL CELL, V47, P323; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRABER MG, 1987, J LIPID RES, V28, P1350; TROTTER PJ, 1993, J BIOL CHEM, V268, P10017; TROTTER PJ, 1991, J LIPID RES, V32, P293; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250	27	145	150	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10892	10896		10.1074/jbc.271.18.10892	http://dx.doi.org/10.1074/jbc.271.18.10892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631905				2022-12-27	WOS:A1996UJ34200073
J	Graziani, A; Galimi, F; Medico, E; Cottone, E; Gramaglia, D; Boccaccio, C; Comoglio, PM				Graziani, A; Galimi, F; Medico, E; Cottone, E; Gramaglia, D; Boccaccio, C; Comoglio, PM			The HIV-1 Nef protein interferes with phosphatidylinositol 3-kinase activation 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GROWTH-FACTOR RECEPTOR; SIGNAL TRANSDUCTION; TRANSGENIC MICE; GENE	nef is a human immunodeficiency virus (HIV) gene encoding a 27-kDa myristoylated protein with structural features of a signal transducing molecule, but whose functions are largely unknown. We studied the interactions of Nef with the signal transduction pathways triggered by the platelet-derived growth factor (PDGF) receptor. The association of phosphatidylinositol (PI) S-kinase with the activated receptor was severely impaired by nef expression. Conversely, PDGF-induced receptor tyrosine phosphorylation, binding to phospholipase C-gamma and to Res-GAP were not modified. Microtubule-associated protein kinase activation and intracellular calcium influx in response to PDGF were either unaffected or only slightly enhanced. Nef significantly reduced the proliferative response to the growth factor, white the chemotactic response was unchanged. These data show that Nef affects selectively the PI 3-kinase signaling pathway and suggest that this interference results in some of the HIV adverse effects on host cell functions.	UNIV TURIN,SCH MED,INST CANC RES & TREATMENT,I-10126 TURIN,ITALY	University of Turin			Graziani, Andrea/AAB-6301-2022; Medico, Enzo/AAC-3185-2021; GRAMAGLIA, DANIELA/A-6354-2012; Galimi, Francesco/J-4238-2012; graziani, andrea/B-2554-2009; Boccaccio, Carla/AHE-7875-2022	Graziani, Andrea/0000-0002-6302-2317; Medico, Enzo/0000-0002-3917-2438; graziani, andrea/0000-0002-6302-2317; Boccaccio, Carla/0000-0003-2620-9083; Comoglio, Paolo/0000-0002-7056-5328; Gramaglia, Daniela/0000-0001-6259-0059				BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; CONNOR JA, 1987, J BIOL CHEM, V262, P2919; DE SK, 1994, J BIOL CHEM, V269, P6656; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; NEIDERMAN TM, 1993, VIROLOGY, V197, P420; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZAZOPOULOS E, 1993, VIROLOGY, V194, P20, DOI 10.1006/viro.1993.1230; ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634	32	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6590	6593		10.1074/jbc.271.12.6590	http://dx.doi.org/10.1074/jbc.271.12.6590			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636073	hybrid			2022-12-27	WOS:A1996UB15700008
J	Bennett, BD; Jetton, TL; Ying, GT; Magnuson, MA; Piston, DW				Bennett, BD; Jetton, TL; Ying, GT; Magnuson, MA; Piston, DW			Quantitative subcellular imaging of glucose metabolism within intact pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; B-CELLS; ELECTRICAL-ACTIVITY; INSULIN-SECRETION; GLUCOKINASE; HETEROGENEITY; STIMULATION; CHANNELS; SENSOR; CA2+	Studies of dispersed beta cells have been used to infer their behavior in the intact pancreatic islet. When dispersed, beta cells exhibit multiple metabolic glucose-response populations with different insulin secretion properties, This has led to a model for glucose-dependent insulin secretion hom the islet based on a step-wise recruitment of individual beta cells. However, previously reported synchronous and uniform Ca2+ activity and electrical responses indicate that beta cell behavior within intact islets is more uniform. Therefore, uncertainty remains whether beta cell metabolic heterogeneity is functionally important in intact islets. We have used two-photon excitation microscopy to measure and compare the glucose-induced NAD(P)H autofluorescence response in dispersed beta cells and within intact islets, Over 90% of beta cells in intact islets responded to glucose with significantly elevated NAD(P)H levels, compared with less than 70% of dispersed beta cells, In addition, all responding beta cells within intact islets exhibited a sigmoidal glucose dose response behavior with inflection points of similar to 8 mM glucose, These results suggest that beta cell heterogeneity may be functionally less important in the intact islet than has been predicted hom studies of dispersed beta cells and support the role of glucokinase as the rate-limiting enzyme in the beta cell glucose response.	VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University			Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499	NIDDK NIH HHS [DK42502, DK42612] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balaban R. S., 1990, NONINVASIVE TECHNIQU, P213; COORE HG, 1964, BIOCHEM J, V93, P66, DOI 10.1042/bj0930066; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Denk Winfried, 1995, P445; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; MALAISSE WJ, 1991, ENDOCRINE PANCREAS, P73; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEDA P, 1984, Q J EXP PHYSIOL CMS, V69, P719; PIPELEERS D, 1994, DIABETOLOGIA, V37, pS57, DOI 10.1007/BF00400827; PISTON DW, 1995, J MICROSC SOC AM, V1, P25; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; Sandison David R., 1995, P39; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SHARP DW, 1973, TRANSPLANTATION, V16, P686; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344	23	156	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3647	3651						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631975				2022-12-27	WOS:A1996TV72400049
J	Larson, PJ; StanfieldOakley, SA; VanDusen, WJ; Kasper, CK; Smith, KJ; Monroe, DM; High, KA				Larson, PJ; StanfieldOakley, SA; VanDusen, WJ; Kasper, CK; Smith, KJ; Monroe, DM; High, KA			Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLATION RECOGNITION SITE; K-DEPENDENT PROTEINS; X ACTIVATION SYSTEM; HEMOPHILIA-B; MONOCLONAL-ANTIBODIES; MOLECULAR-BASIS; PROPEPTIDE; PROTHROMBIN; INVITRO; METAL	This report describes the analysis of a novel mutant human factor IX protein from a patient with hemophilia B (factor IX activity <1%; factor IX antigen 45%), Enzymatic amplification of all eight exons of the factor IX gene followed by direct sequence analysis reveals a single nucleotide change (a guanine --> adenine transition) in exon 2 at nucleotide 6409 which results in a glycine --> arginine substitution at amino acid 12 in the gamma-carboxyglutamic acid rich (Gla) domain of the mature protein. Factor IX was isolated by immunoaffinity chromatography from plasma obtained from the proband, The purified protein is indistinguishable from normal factor IX by polyacrylamide gel electrophoresis, Characterization of the variant in purified component assays reveals that it is activated normally by its physiologic activator factor XIa, but its phospholipid-dependent activation by the factor VIIa-tissue factor complex is diminished, In the presence of phospholipid and 5 mar Ca2+, the activities of variant and normal plasma-derived factor IX are similar; however, in the presence of activated factor VIIIa (intrinsic tenase complex), the normal augmentation of the cleavage of the specific substrate of factor IX factor X, is not observed. The determination of the association constants for normal and variant factor IXa with factor VIIIa shows that the affinity of the activated variant factor IX for the cofactor factor VIIIa is 172-fold lower than normal, Competition studies using active site-inactivated factor IXas in the intrinsic tenase complex confirm that the defect in the variant protein is in its binding to factor VIIIa. We conclude that the structural integrity of the Gla domain of human factor IX is critical for the normal binding of factor IXa to factor VIIIa in the intrinsic tenase complex, In addition, a glycine at amino acid 12 is necessary for normal activation of factor IX by the factor VIIa-tissue factor complex.	UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; MERCK & CO INC,W POINT,PA 19486; UNIV NEW MEXICO,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV SO CALIF,ORTHOPED HOSP,LOS ANGELES,CA 90007	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; Merck & Company; University of New Mexico; University of New Mexico; University of Southern California	Larson, PJ (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,324 S 34TH ST,PHILADELPHIA,PA 19104, USA.		High, Katherine A./AAB-9322-2020	Monroe, Dougald/0000-0002-0493-2943	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048322, P01HL006350, F32HL008510] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL48322, NRSA HL08510, P01 HL06350] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEALS JM, 1989, ARCH BIOCHEM BIOPHYS, V268, P485, DOI 10.1016/0003-9861(89)90316-0; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; BRAUNSTEIN KM, 1981, J CLIN INVEST, V68, P1420, DOI 10.1172/JCI110393; CHAN V, 1991, BRIT J HAEMATOL, V79, P63, DOI 10.1111/j.1365-2141.1991.tb08008.x; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FRAZIER D, 1989, BLOOD, V74, P971; FURIE B, 1990, BLOOD, V75, P1753; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; GRIFFITH MJ, 1982, THROMB RES, V27, P289, DOI 10.1016/0049-3848(82)90076-7; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBER P, 1990, J BIOL CHEM, V265, P12467; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOZIER JN, 1990, BLOOD, V75, P1097; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; ORSTAVIK KH, 1975, THROMB RES, V7, P373, DOI 10.1016/0049-3848(75)90031-6; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; SUGIMOTO M, 1988, BRIT J HAEMATOL, V72, P216; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; WALLMARK A, 1991, BLOOD S1, V78, pA60; WARE J, 1989, J BIOL CHEM, V264, P11401; WATZKE HH, 1990, J BIOL CHEM, V265, P11982; WU SM, 1990, J BIOL CHEM, V265, P13124; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHANG L, 1992, BLOOD, V80, P942	46	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3869	3876						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632006				2022-12-27	WOS:A1996TV72400080
J	Liu, YS; Guyton, KZ; Gorospe, M; Xu, QB; Kokkonen, GC; Mock, YD; Roth, GS; Holbrook, NJ				Liu, YS; Guyton, KZ; Gorospe, M; Xu, QB; Kokkonen, GC; Mock, YD; Roth, GS; Holbrook, NJ			Age-related decline in mitogen-activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DNA-SYNTHESIS; PHOSPHATASE; COMPLEX; JUN; FOS	A number of studies have demonstrated that the proliferative capacity of cells declines with aging. In particular, epidermal growth factor (EGF)-stimulated DNA synthesis is reduced in hepatocytes from aged rats relative to young rats. Growth factor stimulation activates a genetic program in large part regulated by a family of mitogen-activated protein kinases (MAPK) that phosphorylate and thereby activate transcription factors involved in controlling the expression of proliferation-associated genes. In the present study, we compared the activation of the extracellular signal-regulated kinase 2 (ERK2) and c-Jun N-terminal kinase 1 (JNK1) MAPK in EGF-stimulated hepatocytes derived from young (6-month) and aged (24-month) rats. JNK activity was not appreciably altered by EGF treatment of cells from either age group, In contrast, ERK2 was highly activated by EGF treatment, but the magnitude of activation was significantly lower in hepatocytes of aged animals compared to those of young animals (7-fold versus 20-fold, respectively). The reduced ERK2 activity in response to EGF was associated with decreased c-fos and c-jun mRNA expression and lower levels of AP-1 transcription factor DNA binding activity in the aged hepatocytes. Finally, the basal expression of MAPK phosphatase 1, a MAPK-regulated gene involved in regulating MAPK activity, was higher in aged hepatocytes. Taken together, these findings suggest that an alteration in the balance between MAP kinase-phosphatase activities could con tribute to the age-related decline in proliferative capacity.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224; NIA,MOLEC PHYSIOL & GENET SECT,CELLULAR & MOLEC BIOL LAB,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				ABDELHAFIZ HAM, 1992, MOL ENDOCRINOL, V16, P2079; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BUCHER NLR, 1964, CANCER RES, V24, P509; CHARLES CH, 1992, ONCOGENE, V7, P187; COSCO OA, 1995, CELL, V81, P1137; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENSLER PJ, 1995, AM J PATHOL, V147, P1; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIGAMI A, 1993, BIOCHEM BIOPH RES CO, V196, P181, DOI 10.1006/bbrc.1993.2232; ISHIGAMI A, 1994, J CELL PHYSIOL, V158, P231, DOI 10.1002/jcp.1041580204; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798	36	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3604	3607						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631968				2022-12-27	WOS:A1996TV72400042
J	Kochetkova, M; Shannon, MF				Kochetkova, M; Shannon, MF			DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HELIX FORMATION; GM-CSF; FORMING-OLIGONUCLEOTIDES; BINDING-PROTEINS; AUTOCRINE GROWTH; TRANSCRIPTION; SEQUENCE; RECOGNITION; PROMOTERS	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hemopoietic growth factor that is expressed in activated T cells, fibroblasts, macrophages, and endothelial cells. Although GM-CSF does not appear to be essential for normal hemopoiesis, overexpression of GM-CSF has been implicated in the pathogenesis of some diseases such as myeloid leukemia and chronic inflammation, An NF-kappa B/Rel binding site within the GMCSF promoter, termed the kappa B element appears to be important for controlling expression in reporter gene assays in response to a number of stimuli in T cells, We investigated oligonucleotide-directed triple helix formation across this regulatory sequence as a potential tool to inhibit GM-CSF gene transcription. A 15-base oligonucleotide, GM3, was targeted to a purine-rich region in the GM-CSF proximal promoter, which overlaps the kappa B element. Gel mobility shift assays and DNase I footprinting demonstrated that GM3 formed a sequence-specific collinear tripler with its double-stranded DNA target, Tripler formation by GM3 blocked recombinant and nuclear NF-kappa B proteins binding to the GM-CSF element. GM3 also caused selective inhibition of the human T-cell lymphotrophic virus-1 Tax transactivator-induced luciferase activity from a reporter construct driven by the GM-CSF promoter in Jurkat T cells, Finally, GM3 greatly reduced the concentration of endogenous GM-CSF mRNA induced by different stimuli in Jurkat T cells but did not affect interleukin 3 mRNA levels in the same cells. We conclude that the kappa B element in the GM-CSF promoter plays a central role in the transcriptional activation of the endogenous GM-CSF gene, Colinear tripler formation acts as a selective transcriptional repressor of the GM-CSF gene and may have potential therapeutic application in cases of undesirable overexpression of this protein.	INST MED & VET SCI, DIV HUMAN IMMUNOL, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Institute Medical & Veterinary Science Australia				Kochetkova, Marina/0000-0002-0599-7378				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BUDEL LM, 1989, BLOOD, V74, P565; CHENG AJ, 1994, NUCLEIC ACIDS RES, V22, P4742, DOI 10.1093/nar/22.22.4742; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; ESTROV Z, 1992, EXP HEMATOL, V20, P558; FREEDMAN MH, 1992, BRIT J HAEMATOL, V80, P40, DOI 10.1111/j.1365-2141.1992.tb06398.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HENDERSON B, 1992, TRENDS PHARMACOL SCI, V13, P145, DOI 10.1016/0165-6147(92)90052-8; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HIMES SR, 1993, ONCOGENE, V8, P3189; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JENKINS F, 1995, J IMMUNOL, V155, P1240; JMASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518; KATO M, 1992, LYMPHOKINE CYTOK RES, V11, P287; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P7587, DOI 10.1021/bi00148a021; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MAYFIELD C, 1994, NUCLEIC ACIDS RES, V22, P1909, DOI 10.1093/nar/22.10.1909; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; METCALF D, 1986, BLOOD, V67, P257; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1993, BLOOD, V82, P1724, DOI 10.1182/blood.V82.6.1724.bloodjournal8261724; OLIVAS WM, 1995, BIOCHEMISTRY-US, V34, P278, DOI 10.1021/bi00001a034; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PEBUSQUE MJ, 1988, EXP HEMATOL, V16, P360; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; ROY C, 1994, EUR J BIOCHEM, V220, P493, DOI 10.1111/j.1432-1033.1994.tb18648.x; RUSSELL NH, 1992, BLOOD REV, V6, P149, DOI 10.1016/0268-960X(92)90026-M; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STULL RA, 1995, PHARM RES-DORDR, V12, P465, DOI 10.1023/A:1016281324761; SUN JS, 1991, CR ACAD SCI III-VIE, V313, P585; THOMAS TJ, 1995, NUCLEIC ACIDS RES, V23, P3594, DOI 10.1093/nar/23.17.3594; TU GC, 1995, J BIOL CHEM, V270, P28402; VELLENGA E, 1987, EXP HEMATOL, V15, P652; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WILLIAMSON DJ, 1988, CLIN EXP IMMUNOL, V72, P67; WILSON WD, 1993, BIOCHEMISTRY-US, V32, P10614, DOI 10.1021/bi00091a011; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; YOUNG DC, 1986, BLOOD, V68, P1178	59	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14438	14444		10.1074/jbc.271.24.14438	http://dx.doi.org/10.1074/jbc.271.24.14438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662666	hybrid			2022-12-27	WOS:A1996UQ66000074
J	Nemoto, Y; Terajima, M; Shoji, W; Obinata, M				Nemoto, Y; Terajima, M; Shoji, W; Obinata, M			Regulatory function of delta/YY-1 on the locus control region-like sequence of mouse glycophorin gene in erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; PUTATIVE ONCOGENE; FINGER PROTEIN; POLYMERASE-II; ENHANCER; EXPRESSION; ELEMENTS	The far upstream region (-1.2-0.9 kilobase pairs) of the mouse glycophorin gene contains the locus control region (LCR)-like region, which acts as an erythroid-specific enhancer dependent on chromosomal integration in murine erythroleukemia (MEL) cells. In the present study, we demonstrated that this region binds six nuclear factors, The binding of GATA-1 to corresponding sites did not show any change before or after induction with dimethyl sulfoxide, but the binding of Spi-1/PU.1 and an unidentified factor called glycophorin regulatory element binding factor (GRBF) showed a change during induction. While binding activity of Spi-1/PU.1 dropped soon after induction, the GRBF activity increased after induction when expression of the glycophorin gene began, After identification of the consensus binding site of GRBF, we cloned cDNA for that factor by Southwestern method, and it was Identified as a previously reported transcription factor, delta, a murine form of YY-1 which is a versatile transcription factor, Mutation analysis in the delta/YY-1 binding site within the LCR-like region indicated that delta/YY-1 acts as a regulatory protein in combination with the E-box-binding protein that binds to the neighboring sequence.	TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University			Watanabe, Mamoru/AHE-0489-2022					ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRUCE AH, 1992, NUCLEIC ACIDS RES, V20, P5771; CHANG JC, 1992, P NATL ACAD SCI USA, V89, P3107, DOI 10.1073/pnas.89.7.3107; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; JARMAN AP, 1991, MOL CELL BIOL, V11, P679; KILIANG L, 1990, P NATL ACAD SCI USA, V87, P8207; KLEMENZ M, 1990, CELL, V60, P113; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1992, BLOOD, V80, P575; PANDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SHRIVASTAVA A, 1993, SCIENCE, V262, P889; SIGH H, 1986, NATURE, V19, P154; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TERAJIMA M, 1995, J BIOCHEM-TOKYO, V118, P593, DOI 10.1093/oxfordjournals.jbchem.a124951; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13542	13548		10.1074/jbc.271.23.13542	http://dx.doi.org/10.1074/jbc.271.23.13542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662744	hybrid			2022-12-27	WOS:A1996UP38500037
J	Ajiro, K; Yoda, K; Utsumi, K; Nishikawa, Y				Ajiro, K; Yoda, K; Utsumi, K; Nishikawa, Y			Alteration of cell cycle-dependent histone phosphorylations by okadaic acid - Induction of mitosis-specific H3 phosphorylation and chromatin condensation in mammalian interphase cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; PROTEIN PHOSPHATASE INHIBITOR; CHINESE-HAMSTER CELLS; TUMOR PROMOTER; M-PHASE; KINASE; H1; STARFISH; P34CDC2; OOCYTE	Effects of okadaic acid (OA), a protein phosphatase inhibitor, on chromatin structure and phosphorylation of histones were examined using HeLa and N18 cells. The chromatin condensation in HeLa cells was mild and resemble prometaphase nuclei, while the condensation in N18 cells was extensive and chromatin became a compact body, H2A in HeLa cells was extensively and consistently phosphorylated at the same site throughout the cell cycle, and H3 was demonstrated to be phosphorylated at the mitosis-specific site Ser(10). In contrast, H1 phosphorylation was rapidly decreased in most sites within 3 h. The reduction of H1 phosphorylation was accompanied by a quantitative change in the set of H1 phosphopeptides. During the early phase of the OA treatment, H1 phosphorylation was transiently elevated in tandem, whereas H3 phosphorylation reached a maximum somewhat later, The results suggest that mitosis-specific events (cdc2/H1 kinase activation, H1 super-phosphorylation, mitosis-specific H3 phosphorylation and chromatin condensation) induced by OA are sequentially associated, The changes appear to reflect a molecular mechanism similar to that operating in normal mitosis.	AICHI CANC CTR, RES INST, CELL BIOL LAB, LAB ULTRASTRUCT RES, NAGOYA, AICHI 464, JAPAN; NAGOYA UNIV, FAC SCI, INST MOLEC BIOL, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Nagoya University	Ajiro, K (corresponding author), AICHI CANC CTR, RES INST, CELL BIOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN.							AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1454, DOI 10.1021/bi00509a008; BALHORN R, 1972, BIOCHEMISTRY-US, V11, P1094, DOI 10.1021/bi00756a023; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; DOLBY TW, 1979, BIOCHEMISTRY-US, V18, P1333, DOI 10.1021/bi00574a033; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HANKS SK, 1983, EXP CELL RES, V148, P293, DOI 10.1016/0014-4827(83)90153-2; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KINOSHITA N, 1991, COLD SH Q B, V56, P621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PAULSON JR, 1994, J CELL SCI, V107, P267; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; RIEBER MS, 1992, CANCER RES, V52, P6397; RIME H, 1990, DEV BIOL, V141, P115, DOI 10.1016/0012-1606(90)90106-S; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SHIBATA K, 1993, J BIOL CHEM, V268, P18431; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SZOLLOSI MS, 1993, J CELL SCI, V104, P861; THNG JPH, 1994, J BIOL CHEM, V269, P9568; van Holde K.E., 1988, CHROMATIN; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZHENG B, 1991, J BIOL CHEM, V266, P10031; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	48	126	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13197	13201		10.1074/jbc.271.22.13197	http://dx.doi.org/10.1074/jbc.271.22.13197			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662672	hybrid			2022-12-27	WOS:A1996UN47400078
J	Herwald, H; Dedio, J; Kellner, R; Loos, M; MullerEsterl, W				Herwald, H; Dedio, J; Kellner, R; Loos, M; MullerEsterl, W			Isolation and characterization of the kininogen-binding protein p33 from endothelial cells - Identity with the gC1q receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; EXPRESSION; PLATELETS; PREKALLIKREIN; ACTIVATION; PLASMA; SITE; BRADYKININ; KALLIKREIN; CLEAVAGE	Kininogens, the precursor proteins of the vasoactive kinins, bind specifically, reversibly, and saturably to platelets, neutrophils, and endothelial cells. Two domains of the kininogens expose major cell binding sites: domain D3 that is shared by H- and L-kininogen and domain D5(H) that is exclusively present in H-kininogen. Previously we have mapped the kininogen cell binding sites to 27 residues of D3 (''LDC27'') and 20 residues of D5(H) (''HKH20''), respectively (Herwald, H., Hasan, A. A. K., Godovae-Zimmermann, J., Schmaier, A. H., and Muller-Esterl, W. (1995) J. Biol. Chem. 270, 14634-14642; Hasan, A. A. K., Cines, D. B., Herwald, H., Schmaier, A. H., and Muller-Esterl, W. (1995) J. Biol. Chen. 270, 19256-19261). The corresponding kininogen acceptor site(s) exposed by the cell surfaces are still poorly defined. Using a non-ionic detergent, Nonidet P-40, we have been able to solubilize kininogen binding sites from an endothelial cell line, EA.hy926, in their functionally active form. Affinity chromatography of the solubilized kininogen binding sites on HKH20, a synthetic peptide representing the D5(H) cell binding site, allowed us to isolate a 33-kDa protein (''p33'') that binds specifically and reversibly to H-kininogen with a K-D (apparent dissociation constant) of 9 +/- 2 nM. Preparative SDS electrophoresis followed by NH2-terminal amino acid sequence analysis identified the kininogen-binding protein p33 as the gC1q receptor (''gC1qR''), an extrinsic membrane protein that interacts with the globular domains of the complement component C1q. The purified p33 binds C1q with moderate affinity, K-D = 240 +/- 10 nM. Recombinant expression of the corresponding cDNA in Escherichia coli demonstrated that p33 binds H-kininogen, but not L-kininogen. Peptide HKH20 but not peptide LDC27 inhibited binding of H-kininogen to the recombinant p33 in a concentration-dependent manner, indicating that H-kininogen binds to p33 via domain D5(H). Recombinant p33 efficiently inhibited the binding of H-kininogen to EA.hy926 cells. Factor XII, but not prekallikrein, competed with H-kininogen binding to p33. These findings suggest that an endothelial binding protein mediates the assembly of critical components of the kinin-generating pathway on the surface of endothelial cells, thereby linking the early events of kinin formation and complement activation.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-55099 MAINZ, GERMANY; UNIV MAINZ, INST MED MICROBIOL & HYG, D-55099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz			Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842				ABDALLA S, 1993, J BIOL CHEM, V268, P17277; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EGGLETON P, 1994, BLOOD, V84, P1640; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GHEBREHIWET B, 1995, J IMMUNOL, V155, P2614; GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/jem.153.3.665; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GREENGARD JS, 1992, METHOD ENZYMOL, V215, P369; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1995, J BIOL CHEM, V270, P14634; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIKAWA K, 1992, BLOOD, V80, P1980; PEERSCHKE EIB, 1994, J IMMUNOL, V152, P5896; REDDIGARI SR, 1993, J BIOL CHEM, V268, P11982; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; STEMMER F, 1984, J IMMUNOL METHODS, V74, P9, DOI 10.1016/0022-1759(84)90361-2; Stewart J.M., 1980, BRADYKININ KALLIDIN, P227; TAIT JF, 1987, J BIOL CHEM, V262, P11651; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; ZINI JM, 1993, BLOOD, V81, P2936	41	200	209	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13040	13047		10.1074/jbc.271.22.13040	http://dx.doi.org/10.1074/jbc.271.22.13040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662673				2022-12-27	WOS:A1996UN47400056
J	Neddermann, P; Gallinari, P; Lettieri, T; Schmid, D; Truong, O; Hsuan, JJ; Wiebauer, K; Jiricny, J				Neddermann, P; Gallinari, P; Lettieri, T; Schmid, D; Truong, O; Hsuan, JJ; Wiebauer, K; Jiricny, J			Cloning and expression of human G/T mismatch-specific thymine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE METHYLATION; NUCLEAR EXTRACTS; MAMMALIAN-CELLS; G.T MISPAIRS; POLYMERASE; DEAMINATION; PROTEINS; INVITRO	Hydrolytic deamination of 5-methylcytosine leads to the formation of G/T mismatches. We have shown previously that these G/T mispairs are corrected to G/C pairs by a mismatch-specific thymine-DNA glycosylase, TDG, which we subsequently purified from human cells. Here we describe the cloning of the human cDNA encoding TDG. We have identified two distinct cDNA species that differ by 100 nucleotides at the 3'-untranslated region. These cDNAs contain a 410-amino acid open reading frame that encodes a 46-kDa polypeptide. The G/T glycosylase, expressed both in vitro and in Escherichia coli, migrated in denaturing polyacrylamide gels with an apparent size of 60 kDa. The substrate specificity of the recombinant protein corresponded to that of the cellular enzyme, and polyclonal antisera raised against the recombinant protein neutralized both activities. We therefore conclude that the cDNA described below encodes human TDG. Data base searches identified a serendipitously cloned mouse cDNA sequence that could be shown to encode the murine TDG homologue. No common amino acid sequence motifs between the G/T-specific enzyme and other DNA glycosylases could be found, suggesting that TDG belongs to a new class of base-excision repair enzymes.	IST RIC BIOL MOLEC P ANGELETTI, DEPT BIOCHEM, I-00040 POMEZIA, ITALY; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London			Hsuan, Justin/C-8825-2009; Gallinari, Paola/ABE-8238-2021	Hsuan, Justin/0000-0001-6083-7564; Lettieri, Teresa/0000-0002-3363-9666				[Anonymous], 1982, MOL CLONING LAB MANU; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P108; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; Harlow E., 1988, ANTIBODIES LAB MANUA; HERGERSBERG M, 1991, EXPERIENTIA, V47, P1171, DOI 10.1007/BF01918381; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SIBGHATULLAH, 1992, BIOCHEMISTRY-US, V31, P7998, DOI 10.1021/bi00149a034; SIBGHATULLAH, 1993, NUCLEIC ACIDS RES, V21, P1281, DOI 10.1093/nar/21.5.1281; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	30	233	248	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12767	12774		10.1074/jbc.271.22.12767	http://dx.doi.org/10.1074/jbc.271.22.12767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662714	hybrid			2022-12-27	WOS:A1996UN47400014
J	Ceresa, BP; Pessin, JE				Ceresa, BP; Pessin, JE			Insulin stimulates the serine phosphorylation of the signal transducer and activator of transcription (STAT3) isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; INTERFERON-ALPHA; GROWTH-FACTOR; GAMMA; INDUCTION; PROTEINS	Insulin stimulation of Chinese hamster ovary cells expressing the human insulin receptor and differentiated 3T3L1 adipocytes resulted in a time-dependent reduction in the SDS polyacrylamide gel electrophoretic mobility of STATS. The decreased STAT3 mobility initially occurred by 2 min and was quantitative by 5 min. In addition, the change in STAT3 mobility was concentration-dependent and was detectable at 0.3 nM insulin with maximal effect between 1 and 3 nM. Although both these cell types also express the STAT1 alpha, STAT1 beta, STAT5, and STAT6 isoforms, only STAT3 was observed to undergo an insulin dependent reduction in mobility. Immunoprecipitation of STAT1 and STAT3 from P-32-labeled cells demonstrated that only STAT3 was phosphorylated in response to insulin whereas phosphoamino acid analysis indicated that this phosphorylation event occurred exclusively on serine residues. Furthermore, treatment of cell extracts with alkaline phosphatase reversed the insulin-stimulated decrease in STAT3 mobility. Together, these data demonstrate that insulin is a specific activator of STAT3 serine phosphorylation without affecting the other STAT isoforms.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK25295, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, P30DK025295, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TIAN SS, 1994, BLOOD, V84, P1760; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	36	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12121	12124		10.1074/jbc.271.21.12121	http://dx.doi.org/10.1074/jbc.271.21.12121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647800	hybrid			2022-12-27	WOS:A1996UL66000002
J	Daly, RJ; Sanderson, GM; Janes, PW; Sutherland, RL				Daly, RJ; Sanderson, GM; Janes, PW; Sutherland, RL			Cloning and characterization of GRB14, a novel member of the GRB7 gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; EXPRESSION CLONING; SH3 DOMAIN; PROTEIN; PURIFICATION; POLYPEPTIDES; CELLS; IDENTIFICATION	Screening of a human breast epithelial cell cDNA library with the tyrosine-phosphorylated C terminus of the epidermal growth factor receptor identified a novel member of the GRB7 gene family, designated GRB14. In addition to a pleckstrin homology domain-containing central region homologous to the Caenorhabditis elegans protein F10E9.6/mig 10 and a C-terminal Src homology 2 (SH2) domain, a conserved N-terminal motif, P(S/A)IPNPFPEL, can now be included as a hallmark of this family. GRB14 mRNA was expressed at high levels in the liver, kidney, pancreas, testis, ovary, heart, and skeletal muscle. Anti-Grb14 antibodies recognized a protein of approximately 58 kDa in a restricted range of human cell lines. Among those of breast cancer origin, GRB14 expression strongly correlated with estrogen receptor positivity, and differential expression was also observed among human prostate cancer cell lines. A GST-Grb14 SH2 domain fusion protein exhibited strong binding to activated platelet-derived growth factor (PDGF) receptors (PDGFRs) in vitro, but association between Grb14 and beta-PDGFRs could not be detected in vivo. In serum-starved cells, Grb14 was phosphorylated on serine residues, which increased with PDGF, but not EGF, treatment. Grb14 is therefore a target for a PDGF-regulated serine kinase, an interaction that does not require PDGFR-Grb14 association.			Daly, RJ (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA.		Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008	Daly, Roger/0000-0002-5739-8027				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNOLLY JM, 1989, PROSTATE, V15, P177, DOI 10.1002/pros.2990150211; DALY RJ, 1995, BREAST CANCER RES TR, V34, P85, DOI 10.1007/BF00666495; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JANES PW, 1994, ONCOGENE, V9, P3601; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	44	112	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12502	12510		10.1074/jbc.271.21.12502	http://dx.doi.org/10.1074/jbc.271.21.12502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647858	hybrid			2022-12-27	WOS:A1996UL66000060
J	Galan, JM; Moreau, V; Andre, B; Volland, C; HaguenauerTsapis, R				Galan, JM; Moreau, V; Andre, B; Volland, C; HaguenauerTsapis, R			Ubiquitination mediated by the Npi1p/Rsp5p ubiquitin-protein ligase is required for endocytosis of the yeast uracil permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; HALF-LIFE; GENE; INVIVO; PATHWAY; ACTIN; CELLS	Uracil uptake by Saccharomyces cerevisiae is mediated by the FUR4-encoded uracil permease. This permease undergoes endocytosis and subsequent degradation in cells subjected to adverse conditions. The data presented here show that uracil permease also undergoes basal turnover under normal growth conditions. Both basal and induced turnover depend on the essential Npi1p/Rsp5p ubiquitin-protein ligase. Epitope-tagged ubiquitin variants have been used to show that uracil permease is ubiquitinated in vivo. The ubiquitin-permease conjugates that are readily demonstrated in wild type cells were barely detectable in npi1 mutant cells, indicating that uracil permease may be a physiological substrate of the Npi1p ubiquitin ligase. The lack of ubiquitination of the permease in npi1 cells resulted in an increase in active, i.e. plasma membrane-located, permease, suggesting that there is a direct relationship between ubiquitination and removal of the permease from the plasma membrane. The accumulation of ubiquitin-permease conjugates in thermosensitive act1 mutant cells, deficient in the internalization step of endocytosis is consistent with this idea. On the other hand, the degradation of uracil permease does not require a functional proteasome since the permease was not stabilized in either pre1 pre2 or cim3 and cim5 mutant cells that have impaired catalytic (pre) or regulatory (cim) proteasome subunits. In contrast, both basal and stress-stimulated turnover rates were greatly reduced in pep4 mutant cells having defective vacuolar protease activities. We therefore propose that ubiquitination of uracil permease acts as a signal for endocytosis of the protein that is subsequently degraded in the vacuole.	UNIV PARIS 07, INST JACQUES MONOD, CNRS, F-75251 PARIS 05, FRANCE; CNRS, INST BIOL MOLEC & CELLULAIRE, F-67084 STRASBOURG, FRANCE; FREE UNIV BRUSSELS, LAB PHYSIOL CELLULAIRE & GENET LEVURES, B-1050 BRUSSELS, BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Libre de Bruxelles; Vrije Universiteit Brussel			André, Bruno/D-1725-2010; Haguenauer-Tsapis, Rosine/C-5446-2012	Moreau, Violaine/0000-0002-4513-7022				ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GALAN JM, 1994, BIOCHEM BIOPH RES CO, V201, P769, DOI 10.1006/bbrc.1994.1767; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MCGRAW P, 1995, YEAST S, V11, pS405; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SHORTLE D, 1984, P NATL ACAD SCI-BIOL, V81, P4889, DOI 10.1073/pnas.81.15.4889; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; URBANGRIMAL D, 1995, BIOCHEM J, V308, P847, DOI 10.1042/bj3080847; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VOLLAND C, 1994, FOLIA MICROBIOL, V39, P554, DOI 10.1007/BF02814106; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZOLADEK T, 1995, MOL CELL BIOL, V15, P6884; [No title captured]	56	260	263	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10946	10952		10.1074/jbc.271.18.10946	http://dx.doi.org/10.1074/jbc.271.18.10946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631913	hybrid			2022-12-27	WOS:A1996UJ34200081
J	ChavesOlarte, E; Florin, I; Boquet, P; Popoff, M; vonEichelStreiber, C; Thelestam, M				ChavesOlarte, E; Florin, I; Boquet, P; Popoff, M; vonEichelStreiber, C; Thelestam, M			UDP-glucose deficiency in a mutant cell line protects against glucosyltransferase toxins from Clostridium difficile and Clostridium sordellii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIN; METABOLISM; INVIVO; GRP78	We have previously isolated a fibroblast mutant cell with high resistance to the two Rho-modifying glucosyltransferase toxins A and B of Clostridium difficile. We demonstrate here a low level of UDP-glucose in the mutant, which explains its toxin resistance since: (i) to obtain a detectable toxin B-mediated Rho modification in lysates of mutant cells, addition of UDP-glucose was required, and it promoted the Rho modification dose-dependently; (ii) high pressure liquid chromatography analysis of nucleotide extracts of cells indicated that the level of UDP-glucose in the mutant (0.8 nmol/10(6) cells) was lower than in the wild type (3.7 nmol/10(6) cells); and (iii) sensitivity to toxin B was pestered upon microinjection of UDP-glucose, Using the mutant as indicator cell we also found that the related Clostridium sordellii lethal toxin is a glucosyltransferase which requires UDP-glucose as a cofactor. Like toxin B it glucosylated 21-23-kDa proteins in cell lysates, but Rho was not a substrate for lethal toxin.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; UNIV COSTA RICA,FAC MICROBIOL,INST CLODOMIRO PICADO,SAN JOSE,COSTA RICA; FAC MED NICE,INSERM,F-06107 NICE 2,FRANCE; INST PASTEUR,UNITE TOXINES MICROBIENNES,F-75724 PARIS 15,FRANCE; UNIV MAINZ,VERFUGUNGSGEBAUDE FORSCH & ENTWICKLUNG,INST MED MIKROBIOL & HYG,D-55101 MAINZ,GERMANY	Karolinska Institutet; Universidad Costa Rica; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johannes Gutenberg University of Mainz								CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; FLORIN I, 1983, BIOCHIM BIOPHYS ACTA, V763, P383, DOI 10.1016/0167-4889(83)90100-3; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; FLORIN I, 1994, ZBL BAKT S, V24, P406; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; GRUBB MF, 1994, BIOCHEM MOL BIOL INT, V30, P819; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KEPPLER D, 1965, METHOD ENZYMAT AN, P2225; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHLIN MR, 1988, J BIOL CHEM, V263, P2285; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MITCHELL MJ, 1987, INFECT IMMUN, V55, P1610, DOI 10.1128/IAI.55.7.1610-1615.1987; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PAOPFF MR, 1996, IN PRESS J BIOL CHEM, V271; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Selzer J., 1994, Naunyn-Schmiedeberg's Archives of Pharmacology, V349, pR15; SHOSHAN MC, 1990, EUR J CELL BIOL, V53, P357; SWEENEY C, 1993, BIOCHEM J, V290, P563, DOI 10.1042/bj2900563; THELESTAM M, 1980, SCAND J INFECT DIS S, V22, P16; VONEICHELSTREIB.C, 1996, MOL MICROBIOL, V17, P313; VONEICHELSTREIBER C, 1994, ZBL BAKT S, V24, P51; WEHRLI SL, 1992, ANAL BIOCHEM, V202, P105, DOI 10.1016/0003-2697(92)90214-R	30	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6925	6932		10.1074/jbc.271.12.6925	http://dx.doi.org/10.1074/jbc.271.12.6925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636120	hybrid			2022-12-27	WOS:A1996UB15700055
J	Gu, HH; Wall, S; Rudnick, G				Gu, HH; Wall, S; Rudnick, G			Ion coupling stoichiometry for the norepinephrine transporter in membrane vesicles from stably transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; SENSITIVE DOPAMINE TRANSPORTER; BRAIN GABA TRANSPORTER; RAT-BRAIN; SEROTONIN TRANSPORTER; PLASMA-MEMBRANE; PLATELET 5-HYDROXYTRYPTAMINE; ACTIVE-TRANSPORT; CLONING; EXPRESSION	We prepared membrane vesicles from stable LLC-PK1 cells expressing serotonin (5-HT) gamma-aminobutyric acid (GABA) and norepinephrine (NE) transporters (SERT, GAT-1, and NET), These vesicles accumulate transport substrates when the appropriate transmembrane ion gradients are imposed, For NET, accumulation of [H-3]dopamine (DA) was stimulated by imposition of Na+ and Cl- gradients (out > in) and of a K+ gradient (in > out), The presence of Na+ or Cl-, even in the absence of a gradient, stimulated DA accumulation by NET, but K+ had little or no effect in the absence of a K+ gradient, Stimulation by a K+ gradient was markedly enhanced by increasing the K+ permeability with valinomycin, suggesting that net positive charge is transported together with DA. Cationic DA is likely to be the major substrate for NET, since varying pH did not affect K-m. We estimated the Na+:DA stoichiometry by measuring the effect of the transmembrane Na+ gradient on peak DA accumulation, The results suggest a 1:1 cotransport of Na+ with DA. Taken together, the results suggest that NET catalyzes cotransport of one cationic substrate molecule with one Na+ ion, and one Cl- ion, and that K+ does not participate directly in the transport process.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BROWN CDA, 1984, BIOCHIM BIOPHYS ACTA, V769, P471, DOI 10.1016/0005-2736(84)90332-8; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; CAMMACK JN, 1993, J PHYSIOL-LONDON, V472, P81, DOI 10.1113/jphysiol.1993.sp019938; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GALLI A, 1995, J EXP BIOL, V198, P2197; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1992, MOL PHARMACOL, V42, P383; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARDER R, 1985, J NEUROCHEM, V45, P1154, DOI 10.1111/j.1471-4159.1985.tb05536.x; HEDIGER M, 1995, J PHYSL P, V452, pS7; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUMPHREYS CJ, 1991, BIOCHEM SOC T, V19, P95, DOI 10.1042/bst0190095; Iversen L., 1967, UPTAKE STORAGE NORAD; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1994, J EXP BIOL, V196, P237; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KNOTH J, 1981, J BIOL CHEM, V256, P6541; KOBOLD G, 1985, N-S ARCH PHARMACOL, V331, P209, DOI 10.1007/BF00634240; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LEE CM, 1982, J NEUROSCI, V2, P1515; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; Lin Fan, 1995, Society for Neuroscience Abstracts, V21, P781; LINGJAERDE O, 1969, FEBS LETT, V3, P103, DOI 10.1016/0014-5793(69)80108-0; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; NELSON N, 1994, J EXP BIOL, V196, P213; NELSON PJ, 1979, J BIOL CHEM, V254, P84; NELSON PJ, 1982, J BIOL CHEM, V257, P6151; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1189, DOI 10.1152/ajpcell.1992.262.5.C1189; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; RUDNICK G, 1986, PLATELET FUNCTION ME, V2, P119; SCHERMAN D, 1981, EUR J BIOCHEM, V116, P535, DOI 10.1111/j.1432-1033.1981.tb05369.x; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SNEDDON JM, 1969, BRIT J PHARMACOL, V37, P680, DOI 10.1111/j.1476-5381.1969.tb08506.x; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; UHL GR, 1994, J EXP BIOL, V196, P229; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	53	54	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6911	6916		10.1074/jbc.271.12.6911	http://dx.doi.org/10.1074/jbc.271.12.6911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636118	hybrid			2022-12-27	WOS:A1996UB15700053
J	Matera, KM; Takahashi, S; Fujii, H; Zhou, H; Ishikawa, K; Yoshimura, T; Rousseau, DL; Yoshida, T; IkedaSaito, M				Matera, KM; Takahashi, S; Fujii, H; Zhou, H; Ishikawa, K; Yoshimura, T; Rousseau, DL; Yoshida, T; IkedaSaito, M			Oxygen and one reducing equivalent are both required for the conversion of alpha-hydroxyhemin to verdoheme in heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADATION; SYSTEM; PURIFICATION; MICROSOMES; FEATURES; IRON; FORM	Heme oxygenase is a central enzyme of heme degradation and associated carbon monoxide biosynthesis. We have prepared the alpha-hydroxyheme-heme oxygenase complex, which is the first intermediate in the catalytic reaction. The active site structure of the complex was examined by optical absorption, EPR, and resonance Raman spectroscopies. In the ferric form of the enzyme complex, the heme iron is five coordinate high spin and the alpha-hydroxyheme group in the complex assumes a structure of an oxophlorin where the alpha-meso hydroxy group is deprotonated. In the ferrous form, the alpha-hydroxy group is protonated and consequently the prosthetic group assumes a porphyrin structure. The alpha-hydroxyheme group undergoes a redox-linked conversion between a keto and an enol form. The ferric alpha-hydroxyheme reacts with molecular oxygen to form a radical species. Reaction of the radical species with a reducing equivalent yields the verdoheme-heme oxygenase complex. Reaction of the ferrous alpha-hydroxyheme-heme oxygenase complex with oxygen also yields the verdoheme-enzyme complex. We conclude that the catalytic conversion of ferric alpha-hydroxyheme to verdoheme by heme oxygenase requires molecular oxygen and one reducing equivalent.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; AT&T BELL LABS,MURRAY HILL,NJ 07974; YAMAGATA TECHNOPOLIS FDN,INST LIFE SUPPORT TECHNOL,YAMAGATA 990,JAPAN; YAMAGATA UNIV,SCH MED,DEPT BIOCHEM,YAMAGATA 99023,JAPAN	Case Western Reserve University; AT&T; Nokia Corporation; Nokia Bell Labs; Yamagata University			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NIGMS NIH HHS [GM39492, GM48714, GM51588] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588, R01GM048714, R01GM039492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH AL, 1993, J AM CHEM SOC, V115, P1422, DOI 10.1021/ja00057a027; BOGUMIL R, 1995, BIOCHEMISTRY-US, V34, P10483, DOI 10.1021/bi00033a021; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; FUJII H, 1990, THESIS KYOTO U; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; ISOGAI Y, 1995, J BIOL CHEM, V270, P7853, DOI 10.1074/jbc.270.14.7853; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KIKUCHI G, 1980, TRENDS BIOCHEM SCI, V5, P323, DOI 10.1016/0968-0004(80)90141-3; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MASUOKA N, 1987, BIOCHEMISTRY-US, V26, P3672, DOI 10.1021/bi00386a062; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MORISHIMA I, 1995, INORG CHEM, V34, P1528, DOI 10.1021/ic00110a035; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SHRAGALEVINE Z, 1994, BIOCHEMISTRY-US, V33, P14656, DOI 10.1021/bi00253a002; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003	38	98	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6618	6624		10.1074/jbc.271.12.6618	http://dx.doi.org/10.1074/jbc.271.12.6618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636077	hybrid			2022-12-27	WOS:A1996UB15700012
J	Bonay, P; Munro, S; Fresno, M; Alarcon, B				Bonay, P; Munro, S; Fresno, M; Alarcon, B			Intra-Golgi transport inhibition by megalomicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROAD-SPECIFICITY ALPHA-1->2; H+-TRANSLOCATING ATPASE; BREFELDIN-A; ENDOPLASMIC-RETICULUM; ORGANELLE STRUCTURE; SECRETORY PROTEINS; VESICLE MEMBRANES; MUTANT DEFICIENT; RAT-LIVER; APPARATUS	Megalomicin (MGM) is a macrolide antibiotic which has been demonstrated previously to cause an anomalous glycosylation of viral proteins. Here we show that MGM produces profound alterations on Golgi morphology and function. The addition of MGM at 50 mu M for 1 h caused a dilation of the Golgi detected by immunofluorescence staining for medial- and trans-Golgi markers. The effect of MGM was clearly more intense on the trans-side of the Golgi, as evidenced in electron microscope preparations. The effect on Golgi morphology was reversible and correlated with an impairment of glycoprotein processing in the trans-Golgi. Thus, although the vesicular stomatitis virus G protein was processed in the presence of MGM to an endoglycosidase H-resistant form, it was poorly sialylated. The sialylation of cellular proteins was also inhibited, resulting in cells with low level of sialylation on the cell surface. However MGM did not inhibit the activities of the galactosyl- or sialyltransferase as measured in vitro. MGM inhibited cis- to medial-, and more strongly, medial- to trans-Golgi transport of vesicular stomatitis virus G protein in an in vitro system, suggesting that the impairment in glycoprotein maturation observed in vivo is the result of intra-Golgi transport inhibition.	UNIV AUTONOMA MADRID,CTR BIOL MOLEC SEVERO OCHOA,CSIC,E-28049 MADRID,SPAIN; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); MRC Laboratory Molecular Biology			Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070; Fresno Escudero, Manuel/0000-0002-9223-5477; Munro, Sean/0000-0001-6160-5773				ALARCON B, 1984, ANTIVIR RES, V4, P231, DOI 10.1016/0166-3542(84)90029-9; ALARCON B, 1988, FEBS LETT, V231, P207, DOI 10.1016/0014-5793(88)80732-4; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BECKERS CJM, 1992, METHOD ENZYMOL, V219, P5; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHAWLA D, 1991, BIOCHEM J, V279, P159, DOI 10.1042/bj2790159; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HEIMER GV, 1974, J CLIN PATHOL, V27, P254, DOI 10.1136/jcp.27.3.254; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KAKU H, 1993, J BIOL CHEM, V268, P13237; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MILLA M, 1989, BIOCHEM SOC T, V17, P447, DOI 10.1042/bst0170447; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MONIS E, 1987, EUR J BIOCHEM, V168, P287, DOI 10.1111/j.1432-1033.1987.tb13419.x; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; MOURELATOS Z, 1990, P NATL ACAD SCI USA, V87, P4393, DOI 10.1073/pnas.87.11.4393; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; SEOG DH, 1994, BIOCHEM BIOPH RES CO, V199, P1073, DOI 10.1006/bbrc.1994.1338; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; VARKI A, 1983, J BIOL CHEM, V258, P2808; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; WEINSTEIN MJ, 1972, Patent No. 3632750; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; XIE XS, 1986, J BIOL CHEM, V261, P2492; XU HX, 1994, J BIOL CHEM, V269, P22875; YILLA M, 1993, J BIOL CHEM, V268, P19092; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	54	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3719	3726						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631986				2022-12-27	WOS:A1996TV72400060
J	Yuan, L; Nelson, BA; Caryl, G				Yuan, L; Nelson, BA; Caryl, G			The catalytic cysteine and histidine in the plant acyl-acyl carrier protein thioesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; UMBELLULARIA-CALIFORNICA; IMMATURE COTYLEDONS; MUTAGENESIS	The plant acyl-acyl carrier protein (acyl-ACP) thioesterases (TEs) play an essential role in chain termination during de novo fatty acid synthesis and are of biochemical interest because of their utilities in the genetic engineering of plant seed oils, Biochemical data have shown the possible involvement of an active-site cysteine and a histidine in catalysis, suggesting that these enzymes activate the hydrolysis of the thioester bond using the same basic catalytic machinery as those of proteases and lipases, To identify the cysteine and histidine residues that are critical in catalysis we substituted, in a 12:0 ACP TE (Uc FatB1), a conserved cysteine (Cys-320) to an Ala or a Ser, and three conserved histidines (His-140, His-285, and His-345) to an Ala or an Arg, Each Ala mutation caused a substantial loss of enzyme activity, However, only C320A and H285A completely inactivated the enzyme, indicating that these two residues are essential for catalysis, Considerable activity (>60%) still remained when Cys-320 was converted to a Ser, but this mutant (C320S) displayed a reversed sensitivity toward thiol or serine hydroxyl inhibitors compared with the wild-type enzyme, A pH optimal study demonstrates that while the wild-type enzyme has the highest activity between pH 8.5 and 9.5, the mutant H285A shows a shifted optimum to higher pH and a significant increase of activity around pH 12, This result suggests that Arg-285 (pK(alpha) 12) is deprotonated at high pH thus partially mimicking the role of His-285 for proton abstraction in the wild-type enzyme, We conclude that the Cys-320 of the wild-type enzyme and Ser-320 of the mutant enzyme can attack the thioester bond of the substrate 12:0 ACP, assisted by His-285, Because plant TEs are highly conserved in length and sequence and the residues investigated here are completely conserved in all available TEs, it is reasonable to believe that homologues of Cys-320 and His-285 are present in the active sites of all plant acyl-ACP TEs.			Yuan, L (corresponding author), CALGENE INC,1920 5TH ST,DAVIS,CA 95616, USA.							BRANDEN C, 1991, INTRO PROTEIN STRUCT, P249; CHASAN R, 1995, PLANT CELL, V7, P235; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; FERRI SR, 1991, J BIOL CHEM, V266, P12852; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; KNUTZON DS, 1992, PLANT PHYSIOL, V100, P1751, DOI 10.1104/pp.100.4.1751; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; POLLARD MR, 1991, ARCH BIOCHEM BIOPHYS, V284, P306, DOI 10.1016/0003-9861(91)90300-8; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; YUAN L, 1995, P NATL ACAD SCI USA, V92, P10639, DOI 10.1073/pnas.92.23.10639	16	41	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3417	3419						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631942				2022-12-27	WOS:A1996TV72400016
J	Lippuner, V; Cyert, MS; Gasser, CS				Lippuner, V; Cyert, MS; Gasser, CS			Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; PHOSPHOPROTEIN PHOSPHATASES; IMPORTANT DETERMINANT; TRANSGENIC TOBACCO; SEQUENCE-ANALYSIS; PROTEIN-KINASE; ZINC FINGERS; GENES; EXPRESSION	The salt-sensitive phenotype of yeast cells deficient in the phosphoprotein phosphatase, calcineurin, was used to identify genes from the higher plant Arabidopsis thaliana that complement this phenotype, cDNA clones corresponding to two different sequences, designated STO (salt tolerance) and STZ (salt tolerance zinc finger), were found to increased tolerance of calcineurin mutants and of wild-type yeast to both Li+ and Na+ ions, STZ is related to Cys(2)/His(2)-type zinc-finger proteins found in higher plants, and STO is similar to the Arabidopsis CONSTANS protein in regions that may also be zinc fingers, Although neither protein has sequence similarity to any protein phosphatase, STO was able to at least partially compensate for all tested additional phenotypic effects of calcineurin deficiency, and STZ compensated for a subset of these effects, Salt tolerance produced by STZ appeared to be partially dependent on ENA1/PMR2, a P-type ATPase required for Li+ and Na+ efflux in yeast, whereas the effect of STO on salt tolerance was independent of ENA1/PMR2, STZ and STO were found to be expressed in Arabidopsis roots and leaves, whereas only STO message was detectable in flowers. An apparent increase in the level of STZ mRNA was observed in response NaCl exposure in Arabidopsis seedlings, but the level of STO mRNA was not altered by this treatment.	UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DIV BIOL SCI,DAVIS,CA 95616; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	University of California System; University of California Davis; Stanford University				Gasser, Charles/0000-0001-5735-8175; Cyert, Martha/0000-0003-3825-7437	NIGMS NIH HHS [GM-48729] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048729] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIERER BE, 1994, LYMPHOCYTE ACTIVATIO, P128; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHEN TC, 1995, J BIOL CHEM, V270, P7750, DOI 10.1074/jbc.270.13.7750; CROUSE GF, 1983, METHOD ENZYMOL, V101, P78; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GASSER CS, 1988, J BIOL CHEM, V263, P4280; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HOFFMAN CS, 1993, CURRENT PROTOCOLS MO; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KRANZ AR, 1987, ARABIDOPSIS INFORMAT, V24; LEHLE FR, 1992, PHYSIOL PLANTARUM, V84, P223, DOI 10.1111/j.1399-3054.1992.tb04657.x; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURGUIA JR, 1995, SCIENCE, V267, P232; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; PAVIETICH NP, 1991, SCIENCE, V252, P809; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROCHESTER DE, 1986, EMBO J, V5, P451, DOI 10.1002/j.1460-2075.1986.tb04233.x; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAKAMOTO A, 1993, EUR J BIOCHEM, V217, P1049, DOI 10.1111/j.1432-1033.1993.tb18336.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; TAKATSUJI H, 1994, PLANT CELL, V6, P947, DOI 10.1105/tpc.6.7.947; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	64	152	207	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12859	12866		10.1074/jbc.271.22.12859	http://dx.doi.org/10.1074/jbc.271.22.12859			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662738	hybrid			2022-12-27	WOS:A1996UN47400028
J	Sato, K; Aoto, M; Mori, K; Akasofu, S; Tokmakov, AA; Sahara, S; Fukami, Y				Sato, K; Aoto, M; Mori, K; Akasofu, S; Tokmakov, AA; Sahara, S; Fukami, Y			Purification and characterization of a Src-related p57 protein-tyrosine kinase from Xenopus oocytes - Isolation of an inactive form of the enzyme and its activation and translocation upon fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-DIVISION; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; VIRUS; SEQUENCE; LAEVIS; IDENTIFICATION; PP60SRC	In the previous study (Fukami, Y., Sate, K.-I., Ikeda, H., Kamisango, K., Koizumi, K., and Matsuno, T. (1993) J. Biol. Chem. 268, 1132-1140), we found that an antibody termed anti-pepY antibody causes a severalfold activation of bovine brain c-Src. The anti-pepY antibody was raised against a synthetic peptide corresponding to residues 410-428 of chicken c-Src, one of the most conserved regions among the Src family protein-tyrosine kinases. In this study, we have used this antibody as an in vitro activator and purified a c-Src-related protein-tyrosine kinase from the particulate fraction of Xenopus laevis oocytes. A synthetic peptide corresponding to residues 7-26 of fission yeast Cdc2 was used as substrate. Immunoreactivity toward the antibody was also monitored during the purification. The purified kinase displayed a single polypeptide of 57 kDa on SDS-gel electrophoresis and showed a specific activity of 2.37 and 20.1 nmol/min/mg protein in the absence and the presence of the anti-pepY antibody, respectively. The purified enzyme underwent autophosphorylation and phosphorylated actin and the Cdc2 peptide exclusively on tyrosine residues. Specific antibodies against c-Src, Fyn, c-Yes, c-Fgr, Lck, Lyn, Hck, and Blk proteins did not recognize the p57 Xenopus tyrosine kinase. The kinase activity of the Xenopus enzyme was not affected by oocyte maturation but was found to be elevated severalfold upon fertilization. Fertilization also caused a translocation of the activated enzyme from the particulate fraction to the cytosolic fraction. The activation and translocation was observed within 1 min after fertilization. These results suggest a possible involvement of the p57 Xenopus tyrosine kinase in the signal transduction of fertilization.	KOBE UNIV,GRAD SCH SCI & TECHNOL,NADA KU,KOBE 657,JAPAN	Kobe University	Sato, K (corresponding author), KOBE UNIV,BIOSIGNAL RES CTR,MOLEC BIOL LAB,NADA KU,KOBE 657,JAPAN.		SATO, Kan/G-1076-2013					ABASSI YA, 1994, DEV BIOL, V164, P430, DOI 10.1006/dbio.1994.1213; AZUMA K, 1991, J BIOL CHEM, V266, P4831; BARTH LG, 1959, J EMBRYOL EXP MORPH, V7, P210; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASNELLIE JE, 1984, P NATL ACAD SCI-BIOL, V81, P6676, DOI 10.1073/pnas.81.21.6676; CIAPA B, 1991, FEBS LETT, V295, P167, DOI 10.1016/0014-5793(91)81410-A; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; FEDER D, 1990, J BIOL CHEM, V265, P8205; FELLER SM, 1992, BIOCHEMISTRY-US, V31, P3044, DOI 10.1021/bi00127a003; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FUKAMI Y, 1985, P NATL ACAD SCI USA, V82, P321, DOI 10.1073/pnas.82.2.321; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAINAUT P, 1991, BIOCHEM J, V273, P673, DOI 10.1042/bj2730673; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HEDRICK JL, 1991, METHOD CELL BIOL, V36, P231; HESKETH R, 1994, ONCOGENE HDB, P448; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ENZYMES, V17, P191; ISLAM N, 1994, DNA CELL BIOL, V13, P719, DOI 10.1089/dna.1994.13.719; JONES SD, 1993, DEV GENET, V14, P185, DOI 10.1002/dvg.1020140305; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KINSEY WH, 1995, BIOCHEM BIOPH RES CO, V208, P204, DOI 10.1006/bbrc.1995.1324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; MOORE KL, 1995, DEV BIOL, V168, P1, DOI 10.1006/dbio.1995.1056; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEAUCELLIER G, 1988, J BIOL CHEM, V263, P13806; PEAUCELLIER G, 1993, DEV GROWTH DIFFER, V35, P199; SATO K, 1990, BIOCHEM BIOPH RES CO, V171, P1152, DOI 10.1016/0006-291X(90)90805-W; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SPIVACK JG, 1984, MOL CELL BIOL, V4, P1631, DOI 10.1128/MCB.4.8.1631; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEELE RE, 1990, ONCOGENE, V5, P369; STEELE RE, 1989, ONCOGENE RES, V1, P223; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; WATTS JD, 1992, J BIOL CHEM, V267, P901; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	47	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13250	13257		10.1074/jbc.271.22.13250	http://dx.doi.org/10.1074/jbc.271.22.13250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662722	hybrid			2022-12-27	WOS:A1996UN47400087
J	Nicholson, B; McGivan, JD				Nicholson, B; McGivan, JD			Induction of high affinity glutamate transport activity by amino acid deprivation in renal epithelial cells does not involve an increase in the amount of transporter protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM-A ACTIVITY; LINE NBL-1; RAT-BRAIN; EXPRESSION; LEADS	In renal epithelial cells amino acid deprivation in duces an increase in L-Asp transport with a doubling of the V-max and no change in K-m (4.5 mu M) in a cycloheximide-sensitive process. The induction of sodium-dependent L-aspartate transport was inhibited by single amino acids that are metabolized to produce glutamate but not by those that do not produce glutamate. The transaminase inhibitor aminooxyacetate in glutamine free medium caused a decrease in cell glutamate content and an induction of glutamate transport. In complete medium aminooxyacetate neither decreased cell glutamate nor increased transport activity. These results are consistent with a triggering of induction of transport by low intracellular glutamate concentrations. High affinity glutamate transport in these cells is mediated by the excitatory amino acid carrier 1 (EAAC1) gene product. Western blotting using antibodies to the C-terminal region of EAAC1 showed that there is no increase in the amount of EAAC1 protein on prolonged incubation in amino acid-free medium. Conversely, the induction of high affinity glutamate transport by hyperosmotic shock was accompanied by an increase in EAAC1 protein. It is proposed that low glutamate levels lead to the induction of a putative protein that activates the EAAC1 transporter. A model illustrating such a mechanism is described.			Nicholson, B (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Bernt E., 1963, METHOD ENZYMAT AN, P384; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DOYLE FA, 1992, BIOCHIM BIOPHYS ACTA, V1104, P55, DOI 10.1016/0005-2736(92)90131-5; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FELIPE A, 1992, BIOCHEM J, V284, P577, DOI 10.1042/bj2840577; FERRERMARTINEZ A, 1995, BIOCHEM J, V310, P689, DOI 10.1042/bj3100689; INOUE K, 1995, MOL BRAIN RES, V28, P343, DOI 10.1016/0169-328X(94)00244-9; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KILBERG MS, 1985, CURR TOP CELL REGUL, V25, P133; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MOFFETT J, 1984, MOL CELL BIOL, V4, P799, DOI 10.1128/MCB.4.4.799; NANDAN D, 1990, BIOCHEM CELL BIOL, V68, P1057, DOI 10.1139/o90-156; PEEKHAUS N, 1995, J BACTERIOL, V177, P5140, DOI 10.1128/jb.177.17.5140-5147.1995; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955	23	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12159	12164		10.1074/jbc.271.21.12159	http://dx.doi.org/10.1074/jbc.271.21.12159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647808	hybrid			2022-12-27	WOS:A1996UL66000010
J	Pratt, JC; Weiss, M; Sieff, CA; Shoelson, SE; Burakoff, SJ; Ravichandran, KS				Pratt, JC; Weiss, M; Sieff, CA; Shoelson, SE; Burakoff, SJ; Ravichandran, KS			Evidence for a physical association between the Shc-PTB domain and the beta(c) chain of the granulocyte-macrophage colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION; PROTEIN; INTERLEUKIN-3; REQUIRES; SUBUNIT	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates the growth and function of several myeloid cell types at different stages of maturation. The effects of GM-CSF are mediated through a high affinity receptor that is composed of two chains: a unique, ligand-specific alpha chain and a beta common chain (beta(c)) that is also a component of the receptors for interleukin 3 (IL-3) and IL-5, beta(c) plays an essential role in the transduction of extracellular signals to the nucleus through its recruitment of secondary messengers, Several downstream signaling events induced by GM CSF stimulation have been described, including activation of tyrosine kinases and tyrosine phosphorylation of cellular proteins (including beta(c)) and activation of the Ras/mitogen-activated protein kinase and the JAK/STAT pathways, A region within the beta(c) cytoplasmic tail (amino acids 517-763) has been reported to be necessary for tyrosine phosphorylation of the adapter protein, Shc, and for the subsequent GM-CSF-induced activation of Ras, In this paper, we describe a physical association between the tyrosine phosphorylated GM-CSF receptor (GMR)-beta(c) chain and Shc in vivo. Using a series of cytoplasmic truncation mutants of beta(c) and various mutant Shc proteins, we demonstrate that the N-terminal phosphotyrosine-binding (PTB) domain of Shc binds to a short region of beta(c) (amino acids 549-656) that contains Tyr(577). Addition of a specific phosphopeptide encoding amino acids surrounding this tyrosine inhibited the interaction between beta(c) and Shc. Moreover, mutation of a key residue within the phosphotyrosine binding pocket of the Shc-PTB domain abrogated its association with beta(c). These observations provide an explanation for the previously described requirement for Tyr(577) of beta(c) for GM-CSF-induced tyrosine phosphorylation of She and have implications for Ras activation through the GM-CSF, IL-3, and IL-5 receptors.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV MUNICH,CHILDRENS HOSP,DEPT PEDIAT,D-80337 MUNICH,GERMANY; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Munich; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Durstin M., 1995, Blood, V86, p257A; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; MIYAJIMA A, 1993, BLOOD, V82, P1960; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1996, IN PRESS P NATL ACAD; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Watanabe S., 1995, Blood, V86, p153A; WEISS M, 1993, BLOOD, V82, P3298; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU S, 1995, J BIOL CHEM, V270, P14863; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	32	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12137	12140		10.1074/jbc.271.21.12137	http://dx.doi.org/10.1074/jbc.271.21.12137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647804	hybrid			2022-12-27	WOS:A1996UL66000006
J	Bose, S; Feix, J; Seetharam, S; Seetharam, B				Bose, S; Feix, J; Seetharam, S; Seetharam, B			Dimerization of transcobalamin II receptor - Requirement of a structurally ordered lipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; BASOLATERAL MEMBRANES; PROTEIN INTERACTIONS; HUMAN-PLACENTA; BRUSH-BORDER; CHOLESTEROL; MODEL; BACTERIORHODOPSIN; PHOSPHOLIPIDS; THICKNESS	Transcobalamin II receptor (TC II-R) exists as a monomer and a dimer of molecular masses of 62 and 124 kDa in the microsomal and plasma membranes, respectively, and in vitro, pure TC II-R monomer dimerizes upon insertion into egg PC/cholesterol (molar ratio, 4:1) liposomes (Bose, S., Seetharam, S., and Seetharam, B. (1995) J. Biol. Chem. 270, 8152-8157 and Bose, S., Seetharam, S., Hammond, T., and Seetharam, B. (1995) Biochem. J. 310, 923-929). The current studies were carried out to define the mechanism of TC II-R dimerization. Both the mature TC II-R (62 kDa) and the enzymatically deglycosylated TC II-R (45-47 kDa) demonstrated optimal association and formed dimers of molecular masses of 95 and 124 kDa, respectively, at 22 degrees C when bound to egg PC vesicles containing at least 10 mol % of cholesterol, Mature TC II-R dimerized upon insertion into synthetic phosphatidylcholine vesicles of different fatty acyl chain length (dimyristoyl, dipalmitoyl, and disteroyl phosphatidylcholine) in the absence or the presence of cholesterol at temperatures below or above their transition temperatures, respectively, Dimerization of TC II-R also occurred with vesicles prepared using lipid extract from the plasma but not microsomal membranes, Cholesterol depletion of native intestinal plasma membranes or its enrichment in the microsomal membranes resulted in the in situ conversion of the 124-kDa dimer to the 62-kDa monomer or of the monomer into the dimer form, respectively, Treatment of plasma membranes with phospholipase A(2) resulted in the conversion of the dimer form of the receptor to the monomer form and spin label studies using 1-palmitoyl, 12 doxylsteroyl phosphatidylcholine revealed that interactions of TC II-R with PC vesicles increased order around the probe, Based on these results we suggest that dimerization of TC II-R is mediated by its interactions with a rigid more ordered lipid bilayer membrane, is regulated in plasma membranes by cholesterol levels, and is independent of glycosylation-mediated folding.	MED COLL WISCONSIN,DEPT BIOCHEM,MACC FUND CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOPHYS,MACC FUND CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT MED,MACC FUND CTR,MILWAUKEE,WI 53226; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	NIDDK NIH HHS [NIDDK-26638] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barlett G.R., 1959, J BIOL CHEM, V234, P466; Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; BUSH SF, 1980, BIOCHEMISTRY-US, V19, P4429, DOI 10.1021/bi00560a008; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CHAPELLE S, 1983, BIOCHIM BIOPHYS ACTA, V753, P269, DOI 10.1016/0005-2760(83)90017-6; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CHAPMAN D, 1979, FEBS LETT, V98, P211, DOI 10.1016/0014-5793(79)80186-6; CORTIJO M, 1982, J MOL BIOL, V157, P597, DOI 10.1016/0022-2836(82)90501-0; COURCHAINE AJ, 1959, CLIN CHEM, V5, P609; CRIADO M, 1984, J BIOL CHEM, V259, P9188; EAST JM, 1984, J BIOL CHEM, V259, P8070; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P5894, DOI 10.1073/pnas.77.10.5894; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P73; HUANG CH, 1977, LIPIDS, V12, P348, DOI 10.1007/BF02533637; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IPSEN JH, 1990, BIOPHYS J, V57, P405, DOI 10.1016/S0006-3495(90)82557-1; JOHANNSSON A, 1981, J BIOL CHEM, V256, P1643; KINNUNEN PKJ, 1991, CHEM PHYS LIPIDS, V57, P375, DOI 10.1016/0009-3084(91)90087-R; LADBROOK.BD, 1968, BIOCHIM BIOPHYS ACTA, V150, P333, DOI 10.1016/0005-2736(68)90132-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LOW MG, 1980, BIOCHEMISTRY-US, V19, P3913, DOI 10.1021/bi00558a004; MABREY S, 1978, BIOCHEMISTRY-US, V17, P2464, DOI 10.1021/bi00605a034; MOLITORIS BA, 1985, J MEMBRANE BIOL, V83, P207, DOI 10.1007/BF01868695; MOURITSEN OG, 1993, ANNU REV BIOPH BIOM, V22, P145, DOI 10.1146/annurev.bb.22.060193.001045; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; NEXO E, 1980, BIOCHIM BIOPHYS ACTA, V628, P190, DOI 10.1016/0304-4165(80)90366-9; OLDFIELD E, 1972, FEBS LETT, V23, P285, DOI 10.1016/0014-5793(72)80300-4; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; SACKMANN E, 1984, BIOL MEMBRANES, V0005, P00105; SANDERMANN H, 1978, BIOCHIM BIOPHYS ACTA, V515, P209, DOI 10.1016/0304-4157(78)90015-1; SEARMARK T, 1987, J MOL ENDOCRINOL, V4, P51; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; SHIMSHICK EJ, 1973, BIOCHEMISTRY-US, V12, P2351, DOI 10.1021/bi00736a026; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; WALTERS JRF, 1986, GASTROENTEROLOGY, V91, P34, DOI 10.1016/0016-5085(86)90435-X; WORCESTER DL, 1976, J MOL BIOL, V100, P359, DOI 10.1016/S0022-2836(76)80068-X; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11718	11725		10.1074/jbc.271.20.11718	http://dx.doi.org/10.1074/jbc.271.20.11718			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662615	hybrid			2022-12-27	WOS:A1996UL25000023
J	Bunting, KD; Townsend, AJ				Bunting, KD; Townsend, AJ			De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines - Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; CYCLOPHOSPHAMIDE; IDENTIFICATION; OXIDATION; ALDOPHOSPHAMIDE; ACROLEIN; 4-HYDROPEROXYCYCLOPHOSPHAMIDE; RETINALDEHYDE; METABOLISM; CATALYZE	Human class 1 aldehyde dehydrogenase (hALDH-1) can oxidize aldophosphamide, a key aldehyde intermediate in the activation pathway of cyclophosphamide and other oxazaphosphorine (GAP) anti-cancer alkylating agents. Overexpression of class 1 ALDH (ALDH-1) has been observed in cells selected for survival in the presence of OAPs. We used transfection to induce de novo expression of human ALDH-1 in V79/SD1 Chinese hamster cells to clearly quantitate the role of hALDH-1 expression in OAF resistance. Messenger RNA levels correlated well with hALDH-1 protein levels and enzyme activities (1.5-13.6 milliunits/mg with propionaldehyde/NAD(+) substrate, compared to < 1 milliunit/mg in controls) in individual clonal transfectant lines, and slot blot analysis confirmed the presence of the transfected cDNA. Expressed ALDH activity was closely correlated (r = 0.99) with resistance to mafosfamide, up to 21-fold relative to controls. Transfectants were cross-resistant to other OAPs but not to phosphoramide mustard, ifosfamide mustard, melphalan, or acrolein. Resistance was completely reversed by pretreatment with 25 mu m diethylaminobenzaldehyde, a potent ALDH inhibitor. Alkaline elution studies showed that expression of ALDH-1 reduced the number of DNA cross-links commensurate with mafosfamide resistance, and this reduction in cross-links was fully reversed by the inhibitor. Thus, overexpression of human class 1 ALDH alone is sufficient to confer GAP-specific drug resistance.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P187, DOI 10.1016/0891-5849(93)90058-3; BROCK N, 1982, THERAPIEWOCHE, V32, P4975; BUNTING KD, 1994, J BIOL CHEM, V269, P23197; Bunting KD, 1996, J BIOL CHEM, V271, P11891, DOI 10.1074/jbc.271.20.11891; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHANG TKH, 1993, CANCER RES, V53, P5629; COLVIN M, 1990, CANCER CHEMOTHERAPY, P276; COX PJ, 1979, BIOCHEM PHARMACOL, V28, P2045, DOI 10.1016/0006-2952(79)90222-3; DE GC, 1994, EUR J CANCER, V30, P2137; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HILL DL, 1972, CANCER RES, V32, P658; HILTON J, 1984, CANCER RES, V44, P5156; KANO T, 1987, CANCER RES, V47, P5626; KASTAN MB, 1990, BLOOD, V75, P1947; KOHN FR, 1985, BIOCHEM PHARMACOL, V34, P3465, DOI 10.1016/0006-2952(85)90719-1; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; MANTHEY CL, 1988, BIOCHEM PHARMACOL, V37, P2781, DOI 10.1016/0006-2952(88)90041-X; MANTHEY CL, 1990, CANCER RES, V50, P4991; MITCHELL DY, 1988, DRUG METAB DISPOS, V16, P37; MOREB J, 1992, CANCER RES, V52, P1770; NIEMEYER U, 1989, PROGR CLIN BIOCH MED, V9, P35; PASLEAU F, 1985, GENE, V38, P227, DOI 10.1016/0378-1119(85)90221-5; REKHA GK, 1994, BIOCHEM PHARMACOL, V48, P1943, DOI 10.1016/0006-2952(94)90593-2; RUSSO J, 1989, ENZYMOLOGY MOL BIOL, V2; SAHOVIC EA, 1988, CANCER RES, V48, P1223; SLADEK N, 1995, P AM ASSOC CANC RES, V35, P325; SLADEK NE, 1991, ADV EXP MED BIOL, V284, P97; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SLADEK NE, 1989, DRUG METAB REV, V20, P697, DOI 10.3109/03602538909103572; SREERAMA L, 1993, BIOCHEM PHARMACOL, V45, P2487, DOI 10.1016/0006-2952(93)90231-K; SREERAMA L, 1994, CANCER RES, V54, P2176; SREERAMA L, 1995, BIOCHEM PHARMACOL, V49, P669, DOI 10.1016/0006-2952(94)00503-E; SREERAMA L, 1993, ADV EXP MED BIOL, V328, P99; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	40	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11884	11890		10.1074/jbc.271.20.11884	http://dx.doi.org/10.1074/jbc.271.20.11884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662658	hybrid			2022-12-27	WOS:A1996UL25000049
J	Mineo, C; James, GL; Smart, EJ; Anderson, RGW				Mineo, C; James, GL; Smart, EJ; Anderson, RGW			Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to Caveolae membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MA104 CELLS; DEPENDENT ACTIVATION; NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; RAS; PROTEINS; FOLATE; KINASE; GRB2	An essential step in the epidermal growth factor (EGF)-dependent activation of MAP kinase is the recruitment of Raf-1 to the plasma membrane. Here we present evidence that caveolae are the membrane site where Raf-1 is recruited. Caveolae fractions prepared from normal Rat-1 cells grown in the absence of serum were highly enriched in both EGF receptors and Ras. Thirty seconds after EGF was added to these cells Raf-1 began to appear in caveolae but not in non caveolae membrane fractions. The maximum concentration was reached at 3 min followed by a decline over the next 60 min. During this time EGF receptors disappeared from the caveolae fraction while the concentration of Ras remained constant. The Raf-1 in this fraction was able to phosphorylate MAP kinase kinase, whereas cytoplasmic Raf-1 in the same cell was inactive. Elevation of cellular cAMP blocked the recruitment of Raf-1 to caveolae. Overexpression of Ha-Ras(V12) caused the recruitment of Raf-1 to caveolae independently of EGF stimulation, and this was blocked by the farnesyltransferase inhibitor BZA-5B. Finally, prenylation appeared to be required for localization of Ras to caveolae.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT NEUROSCI & MOL GENET, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169, GM 15631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169, F32GM015631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P799; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COCHET C, 1988, J BIOL CHEM, V263, P3290; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENHENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU P, 1994, J BIOL CHEM, V91, P11728; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PALADE GE, 1953, J APPL PHYS, V24, P1424; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	395	396	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11930	11935		10.1074/jbc.271.20.11930	http://dx.doi.org/10.1074/jbc.271.20.11930			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662667	hybrid			2022-12-27	WOS:A1996UL25000055
J	Johnson, MC; Kajikawa, O; Goodman, RB; Wong, VA; Mongovin, SM; Wong, WB; FoxDewhurst, R; Martin, TR				Johnson, MC; Kajikawa, O; Goodman, RB; Wong, VA; Mongovin, SM; Wong, WB; FoxDewhurst, R; Martin, TR			Molecular expression of the alpha-chemokine rabbit GRO in Escherichia coli and characterization of its production by lung cells in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1; MESSENGER-RNA EXPRESSION; ALVEOLAR MACROPHAGES; STIMULATORY ACTIVITY; HUMAN NEUTROPHIL; INTERLEUKIN-8; IL-8; FIBROBLASTS; ACTIVATION; CYTOKINES	GRO proteins are alpha-chemokine cytokines that attract neutrophils and stimulate the growth of a variety of cells, Previously, we observed that rabbit alveolar macrophages transcribe the genes for at least two GRO homologues. In order to study the role of GRO cytokines in lung inflammation, we cloned the predominant rabbit GRO cDNA (RabGRO) from alveolar macrophages, expressed bioactive recombinant protein (rRabGRO) in Escherichia coli, and developed a sensitive and specific enzyme-linked immunosorbent assay for RabGRO protein. We found that rabbit AM express and secrete GRO in vitro in response to both exogenous (e.g. lipopolysaccharide, heat-killed Staphylococcus aureus, and crystalline silica) and endogenous inflammatory stimuli (e.g. tumor necrosis factor-alpha) as determined by both radioimmunoprecipitation and enzyme-linked immunosorbent assay. Biologically significant amounts of GRO are present in vivo in the bronchoalveolar lavage fluid of rabbits with E. coli pneumonia; by in situ hybridization, GRO mRNA is detectable in infiltrating pulmonary leukocytes and bronchial epithelial cells. These results indicate that GRO chemokines are likely to be important mediators of the inflammatory response that accompanies acute infectious processes in the lungs.	VET AFFAIRS MED CTR, MED RES SERV, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, DIV PULM & CRIT CARE MED, SEATTLE, WA 98108 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542, F32HL009042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029103] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542, HL09042-01] Funding Source: Medline; NIAID NIH HHS [AI29103] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BECKER S, 1994, AM J PHYSIOL, V266, pL278, DOI 10.1152/ajplung.1994.266.3.L278; BECKER S, 1991, J IMMUNOL, V147, P4307; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; CAO Y, J EXP MED, V182, P2069; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; FREVERT CW, 1995, J IMMUNOL, V154, P335; GEISER T, 1993, J BIOL CHEM, V268, P15419; GOODMAN RB, 1994, CHEST, V105, pS99; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HASKILL S, 1988, J IMMUNOL, V140, P1690; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; JOHNSON MC, 1994, GENE, V151, P337, DOI 10.1016/0378-1119(94)90684-X; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSE PJ, 1991, BIOCHEM J, V278, P493, DOI 10.1042/bj2780493; KAJIKAWA O, 1993, AM REV RESPIR DIS, V147, pA751; KRIEGER M, 1992, J IMMUNOL, V149, P2662; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; KURDOWSKA A, 1994, CYTOKINE, V6, P124, DOI 10.1016/1043-4666(94)90033-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MARTIN TR, 1992, J CLIN INVEST, V90, P2209, DOI 10.1172/JCI116106; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NAKAGAWA H, 1994, BIOCHEM J, V301, P545, DOI 10.1042/bj3010545; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; OHMORI Y, 1994, J IMMUNOL, V153, P2204; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; RICHMOND A, 1985, CANCER RES, V45, P6390; ROGIVUE C, 1995, LAB INVEST, V72, P689; ROT A, 1991, CYTOKINE, V3, P21, DOI 10.1016/1043-4666(91)90006-Y; SCHWARTZ D, 1994, J CLIN INVEST, V94, P1968, DOI 10.1172/JCI117548; SEBOK K, 1993, J IMMUNOL, V150, P1524; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHOBERG DS, 1995, AM J RESP CRIT CARE, V151, pA454; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; THOMAS KM, 1994, J IMMUNOL, V152, P2496; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WATANABE K, 1989, J BIOL CHEM, V264, P19559; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470; YOSHIMURA T, 1991, J IMMUNOL, V146	47	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10853	10858		10.1074/jbc.271.18.10853	http://dx.doi.org/10.1074/jbc.271.18.10853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631900	hybrid			2022-12-27	WOS:A1996UJ34200068
J	Martys, JL; Wjasow, C; Gangi, DM; Kielian, MC; McGraw, TE; Backer, JM				Martys, JL; Wjasow, C; Gangi, DM; Kielian, MC; McGraw, TE; Backer, JM			Wortmannin-sensitive trafficking pathways in Chinese hamster ovary cells - Differential effects on endocytosis and lysosomal sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI FOREST VIRUS; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; JUXTAMEMBRANE REGION; TRANSFERRIN RECEPTOR; BINDING-SITE; SH2 DOMAINS; PROTEIN; ACTIVATION	Phosphatidylinositol (PI) 3'-kinases are a family of lipid kinases implicated in the regulation of cell growth by oncogene products and tyrosine kinase growth factor receptors. The catalytic subunit of the p85/p110 PI 3'kinase is homologous to VPS-34, a phosphatidylinositol-specific lipid kinase involved in the sorting of newly synthesized hydrolases to the yeast vacuole. This suggests that PI 3'-kinases may play analogous roles in mammalian cells. We have measured a number of secretory and endocytic trafficking events in Chinese hamster ovary cells in the presence of wortmannin, a potent inhibitor of PI S'-kinase. Wortmannin caused a 40-50% down-regulation of surface transferrin receptors, with a dose dependence identical to that required for maximal inhibition of the p85/p110 PI 3'-kinase in intact cells. The redistribution of transferrin receptors reflected a 60% increase in the internalization rate and a 35% decrease in the recycling rate. Experiments with fluorescent transferrin showed that entry of transferrin receptors into the recycling compartment and efflux of receptors out of the compartment were slowed by wortmannin. Wortmannin altered the morphology of the recycling compartment, which was more vesiculated than in untreated cells. Using Semliki Forest virus as a probe, we also found that delivery of the endocytosed virus to its lysosomal site of degradation was slowed by wortmannin, whereas endosomal acidification was unaffected. In contrast to these effects on endocytosis and recycling, wortmannin did not affect intracellular processing of newly synthesized viral spike proteins. Wortmannin did induce missorting of the lysosomal enzyme cathepsin D to the secretory pathway, but only at a dose 20-fold greater than that required to inhibit p85/p110 PI 3'kinase activity or to redistribute transferrin receptors. Our data demonstrate the presence of wortmannin-sensitive enzymes at three distinct steps of the endocytic cycle in Chinese hamster ovary cells: internalization, transit from early endosomes to the recycling and degradative compartments, and transit from the recycling compartment back to the cell surface. The wortmannin-sensitive enzymes critical for endocytosis and recycling are distinct from those involved in sorting newly synthesized lysosomal enzymes.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University				Kielian, Margaret/0000-0002-7395-4791	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052929] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44541] Funding Source: Medline; NIGMS NIH HHS [GM-52929] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BECK KA, 1991, J BIOL CHEM, V266, P4442; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DONG JM, 1989, J BIOL CHEM, V264, P7377; DUFFUS WA, 1995, J VIROL, V69, P2471, DOI 10.1128/JVI.69.4.2471-2479.1995; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KIELIAN M, 1990, J VIROL, V64, P4614, DOI 10.1128/JVI.64.10.4614-4624.1990; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; KODAKI T, 1994, EUR J BIOCHEM, V219, P775, DOI 10.1111/j.1432-1033.1994.tb18557.x; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PHALEN T, 1991, J CELL BIOL, V112, P615, DOI 10.1083/jcb.112.4.615; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POWIS G, 1994, CANCER RES, V54, P2419; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TOKER A, 1994, J BIOL CHEM, V269, P32358; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YANO H, 1993, J BIOL CHEM, V268, P25846; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZHANG J, 1993, J BIOL CHEM, V268, P22251	74	115	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10953	10962		10.1074/jbc.271.18.10953	http://dx.doi.org/10.1074/jbc.271.18.10953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631914				2022-12-27	WOS:A1996UJ34200082
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			Laminin interactions important for basement membrane assembly are promoted by zinc and implicate laminin zinc finger-like sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; AMINO-ACID SEQUENCE; DENSITY-LIPOPROTEIN-RECEPTOR; COLLAGEN TYPE-IV; NUCLEOTIDE-SEQUENCE; A-CHAIN; MULTIDOMAIN PROTEIN; BINDING-SITES; CELL-ADHESION	Laminin is an abundant basement membrane (BM) glycoprotein which regulates specific cellular functions and participates in the assembly and maintenance of the BM superstructure. The assembly of BM is believed to involve the independent polymerization of collagen type IV and laminin, as well as high affinity interactions between laminin, entactin/nidogen, perlecan, and collagen type IV. We report here that Zn2+ can influence laminin binding activity, in vitro. Laminin contains 42 cysteine-rich repeats of which 12 contained nested zinc finger consensus sequences. Recently, the entactin binding site was mapped to one of these zinc finger-containing repeats on the laminin gamma chain (Mayer, U., Nischt, R., Poschl, E., Mann, K., Fukuda, K., Gerl, M., Yamada, Y., and Timpl, R. (1993) EMBO J. 12, 1879-1885), Based on these observations, the effect of a series of essential ions (Ca2+, Cd2+, CU2+, Mg2+, Mn2+, and Zn2+) on laminin binding activity was evaluated, Zn2+ was found to be the most effective at enhancing laminin-entactin and laminin collagen type IV binding. Laminin-bound Zn2+ was detected by flame atomic absorption spectroscopy at a maximum of 8 mol/mol of laminin, Furthermore, Ca2+ dependent laminin polymerization was unaffected by Zn2+. an observation consistent with the lack of zinc finger-containing repeats in the terminal globular domains required fbr polymerization, We conclude that Zn2+-laminin complexes may generate high affinity binding sites which contribute to BM cross-linking important for its assembly and homeostasis. Zinc is likely a cofactor for 2 kinds of cross-linking interactions; one involving direct binding between laminin and collagen type IV and the other a ternary complex of lamininentactin-collagen type IV.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada								APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHI HC, 1989, J BIOL CHEM, V264, P1543; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT D, 1992, BIOCHEM J, V287, P849, DOI 10.1042/bj2870849; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HUDSON BG, 1989, LAB INVEST, V61, P256; KALB E, 1991, J BIOL CHEM, V266, P19047; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LYON AW, 1991, LAB INVEST, V64, P785; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1995, LAB INVEST, V72, P272; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; PALM SL, 1983, J CELL BIOL, V96, P1218, DOI 10.1083/jcb.96.5.1218; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PERLMUTTER LS, 1990, BRAIN RES BULL, V24, P677, DOI 10.1016/0361-9230(90)90007-M; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SIPERSTEIN MD, 1988, AM J MED, V85, P119, DOI 10.1016/0002-9343(88)90404-4; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YAMAMOTO T, 1985, BIOCHEM BIOPH RES CO, V132, P605, DOI 10.1016/0006-291X(85)91176-3; YURCHENCO PD, 1988, AM J PATHOL, V132, P278; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	66	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6845	6851		10.1074/jbc.271.12.6845	http://dx.doi.org/10.1074/jbc.271.12.6845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636109	hybrid			2022-12-27	WOS:A1996UB15700044
J	Kordula, T; Ripperger, J; Morella, KK; Travis, J; Baumann, H				Kordula, T; Ripperger, J; Morella, KK; Travis, J; Baumann, H			Two separate signal transducer and activator of transcription proteins regulate transcription of the serine proteinase inhibitor-3 gene in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; ALPHA-1-ACID GLYCOPROTEIN GENE; 3 C/EBP ISOFORMS; STIMULATING FACTOR; PROTEASE INHIBITORS; MOLECULAR-CLONING; BINDING-PROTEIN; GM-CSF; EXPRESSION; RECEPTOR	The serine proteinase inhibitor (SPI-3) gene expression is transcriptionally regulated by interleukin (IL)-6 and glucocorticoids in hepatic cells. To identify the transcription factors involved in regulation of the SPI-3 promoter-chloramphenicol acetyltransferase constructs we overexpressed Signal Transducer and Activator of Transcription (STAT) proteins (STAT1, STAT3, STAT5B, and STAT6) and CAAT enhancer-binding protein beta. Specific: signaling pathways were activated by cointroduced receptors for growth hormone, IL-3, IL-4, or chimeric receptors containing the cytoplasmic domain of gp130. STAT3 and STAT5B induced transcription via the SPI-3 promoter. The STAT5B response was substantially enhanced by truncation of the 5'-flanking region from -1021 to -148. The responsiveness to STAT3 and STAT5B required the STAT binding element at -132 to -124. This element was sufficient to confer regulation onto a heterologous promoter gene construct. In contrast, overexpression of CAAT enhancer-binding protein beta reduced the transcriptional activity of the SPI-3 promoter, presumably by interfering with STAT protein binding to the promoter element. The SPI-3 gene is the first example of an acute phase gene that is responsive to both STAT3 and STAT5B.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA; JAGIELLONIAN UNIV, INST MOLEC BIOL, PL-31120 KRAKOW, POLAND; UNIV ERLANGEN NURNBERG, D-91068 ERLANGEN, GERMANY	Roswell Park Cancer Institute; University System of Georgia; University of Georgia; Jagiellonian University; University of Erlangen Nuremberg					NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline; NHLBI NIH HHS [HL26148] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1993, J BIOL CHEM, V268, P15681; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORDULA T, 1994, BIOCHEM BIOPH RES CO, V201, P222, DOI 10.1006/bbrc.1994.1692; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; KORDULA T, 1995, BIOCHEM J, V309, P63, DOI 10.1042/bj3090063; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LECAM A, 1994, J BIOL CHEM, V269, P21532; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LECAM G, 1987, FEBS LETT, V210, P1, DOI 10.1016/0014-5793(87)81286-3; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORELLA KK, 1995, BLOOD, V86, P557, DOI 10.1182/blood.V86.2.557.bloodjournal862557; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PAGES G, 1990, GENE, V94, P273, DOI 10.1016/0378-1119(90)90398-B; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZIEGLER SF, 1995, EUR J IMMUNOL, V25, P399, DOI 10.1002/eji.1830250214; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6752	6757		10.1074/jbc.271.12.6752	http://dx.doi.org/10.1074/jbc.271.12.6752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636096	hybrid			2022-12-27	WOS:A1996UB15700031
J	Sapru, MK; Gao, JP; Walke, W; Burmeister, M; Goldman, D				Sapru, MK; Gao, JP; Walke, W; Burmeister, M; Goldman, D			Cloning and characterization of a novel transcriptional repressor of the nicotinic acetylcholine receptor delta-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ELECTRICAL-ACTIVITY; IMMEDIATE EARLY GENE; DNA-BINDING; Y-BOX; MYOGENIC FACTORS; EXPRESSION; PROTEINS; ENHANCER; PROMOTER; MOTIF	We have identified a negative cis-acting regulatory element in the nicotinic acetylcholine receptor delta-subunit gene's promoter. This element resides within a previously identified 47-base pair activity dependent enhancer. Proteins that bind this region of DNA were cloned from a lambda gt11 innervated muscle expression library. Two cDNAs (MY1 and MY1a) were isolated that encode members of the Y-box family of transcription factors. MY1/1a RNAs are expressed at relatively high levels in heart, skeletal muscle, testis, glia, and specific regions of the central nervous system, MY1/1a are nuclear proteins that bind specifically to the coding strand of the 47-base pair enhancer and suppress delta-promoter activity in a sequence-specific manner. These results suggest a novel mechanism of repression by MY1/1a, which may contribute to the low level expression of the delta- subunit gene in innervated muscle. Finally, the gene encoding MY1/1a, Yb2, maps to the mid-distal region of mouse chromosome 6.	UNIV MICHIGAN,MENTAL HLTH RES INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PSYCHIAT & HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Burmeister, Margit/A-3157-2013	Burmeister, Margit/0000-0002-1914-2434				BEECHEY CV, 1992, MOUSE GENOME, V90, P670; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ELLIOTT RW, 1994, MAMM GENOME, V5, pS79; EVANS S, 1987, J BIOL CHEM, V262, P4911; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FABER M, 1990, J BIOL CHEM, V265, P22243; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HASAN S, 1994, J BIOL CHEM, V269, P25042; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LOCK LF, 1994, GENOMICS, V20, P354, DOI 10.1006/geno.1994.1188; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OZER J, 1990, J BIOL CHEM, V265, P22143; PRODY CA, 1991, J BIOL CHEM, V266, P22588; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P847; SAKURA H, 1988, GENE, V73, P499; SAMBROOK J, 1989, MOL CLONING LABORATO, P122; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TANG JC, 1994, DEVELOPMENT, V120, P1799; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKE W, 1994, J BIOL CHEM, V269, P19447; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; WOLFFE AP, 1992, NEW BIOL, V4, P290	53	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7203	7211		10.1074/jbc.271.12.7203	http://dx.doi.org/10.1074/jbc.271.12.7203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636158	hybrid			2022-12-27	WOS:A1996UB15700093
J	Hensold, JO; Stratton, CA; Barth, D; Galson, DL				Hensold, JO; Stratton, CA; Barth, D; Galson, DL			Expression of the transcription factor, Spi-1 (PU.1), in differentiating murine erythroleukemia cells is regulated post-transcriptionally - Evidence for differential stability of transcription factor mRNAs following inducer exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; PUTATIVE ONCOGENE SPI-1; DNA-BINDING PROTEIN; C-FOS; GENE; ACTIVATION; GLOBIN; CLONING; VIRUS; DEADENYLATION	Increased expression of the transcription factor Spi-1 (PU.1) results from retroviral insertion in nearly all Friend spleen focus-forming virus-transformed murine erythroleukemia cell lines and exposure of these cells to Me(2)SO, induces their differentiation and decreases Spi-1 mRNA level by 4-5-fold. While these results suggest that alterations in Spi-1 expression have significant effects on erythroblast growth and differentiation, neither the cause nor the effect of the decrease in Spi-1 expression that follows Me(2)SO exposure has been established. The experiments described here demonstrate that the effect of inducers on Spi-1 expression is regulated post-transcriptionally. Nuclear run-off transcriptions demonstrated that Spi-1 transcription was not decreased following Me(2)SO exposure. Additionally, expression of a recombinant Spi-1 mRNA under transcriptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to endogenous Spi-1 mRNA. The ability of Me(2)SO to destabilize Spi-1 mRNA was selective, as the stability of the erythroid transcription factors GATA-1 and NF-E2 were not similarly effected. The effect of Me(2)SO on the stability of Spi-1 mRNA provides a novel means of altering gene expression in these cells and is likely to have significance for the differentiation of these cells.	CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH 44106; DEPT VET AFFAIRS MED CTR,CLEVELAND,OH 44106; MASSACHUSETTS GEN HOSP,ARTHRIT UNIT,BOSTON,MA 02129	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Harvard University; Massachusetts General Hospital			Galson, Deborah L./E-9370-2010	Galson, Deborah L./0000-0002-2045-8807	NIDDK NIH HHS [DK43414] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; EBERT PS, 1976, CANCER RES, V36, P1809; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HENSOLD JO, 1991, BLOOD, V77, P1362; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAUB O, 1980, P NATL ACAD SCI-BIOL, V77, P3297, DOI 10.1073/pnas.77.6.3297; LAVIGEUR A, 1990, NEW BIOL, V2, P1015; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PEACOCK J, 1990, MOL CELL BIOL, V10, P3307; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STOECKLE MY, 1993, BIOTECHNIQUES, V15, P227; TILGHMAN SM, 1977, P NATL ACAD SCI USA, V74, P4406, DOI 10.1073/pnas.74.10.4406; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZHENG DE, 1994, MOL CELL BIOL, V14, P373	49	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3385	3391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631937				2022-12-27	WOS:A1996TV72400011
J	Hill, A; Nantel, A; Rock, CD; Quatrano, RS				Hill, A; Nantel, A; Rock, CD; Quatrano, RS			A conserved domain of the viviparous-1 gene product enhances the DNA binding activity of the bZIP protein EmBP-1 and other transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; ZIPPER PROTEIN; TAX PROTEIN; MAIZE; ACTIVATOR; EMBRYOGENESIS; EXPRESSION; RECOGNIZES; SEQUENCE; PROMOTER	The maize VP1 protein is a seed-specific regulator of gene expression that effects the expression of a subset of abscisic acid (ABA)-regulated genes that are expressed during the maturation program of the seed. In addition, VP1 has pleiotropic effects on seed development that are not related to ABA. In transient expression assays, VP1 has been shown to transactivate gene expression through at least two distinct promoter elements: the G boxes from the ABA-inducible wheat Em gene and the SphI box from the maize C1 gene. We have investigated how VP1 can transactivate gene expression through diverse promoter elements by analyzing its association in vitro with EmBP-1, a factor that binds the Em promoter. We demonstrate that VP1 can greatly enhance the DNA binding activity of EmBP-1 in a gel retardation assay. This enhancing activity has also been observed on transcription factors as diverse as Opaque-2, Max, Sp1, and NF-kappa B. Deletion of a small but highly conserved region (BR2) in VP1 eliminates the enhancement in vitro as well as the ability of VP1 to transactivate Em gene expression in a transient expression assay. A 40-amino acid fragment from VP1 sandwiched between the maltose-binding protein and LacZ can confer the enhancement function to this fusion protein in vitro. A weak and relatively nonspecific interaction between BR2 and DNA is demonstrated by UV cross-linking. The in vitro properties we observe for VP1 might explain the regulatory effects of VP1 on a diverse set of genes and why mutations in the vp1 locus have pleiotropic effects.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill				, Christopher/0000-0002-2090-0650	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013588] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44288, GM14752, GM13588-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BANNISTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3523, DOI 10.1093/nar/20.13.3523; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; DOONER HK, 1985, PLANT PHYSIOL, V77, P486, DOI 10.1104/pp.77.2.486; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; Fujisawa J, 1993, Hum Cell, V6, P266; GALAU GA, 1991, PHYSIOL PLANTARUM, V81, P280; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HATTORI T, 1995, PLANT J, V7, P913, DOI 10.1046/j.1365-313X.1995.07060913.x; HATTORI T, 1994, PLANT MOL BIOL, V24, P805, DOI 10.1007/BF00029862; HATTORI T, 1992, GENE DEV, V6, P609, DOI 10.1101/gad.6.4.609; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIDOU SI, 1994, DNA SEQUENCE, V5, P125, DOI 10.3109/10425179409039714; Litts J C, 1991, DNA Seq, V1, P263, DOI 10.3109/10425179109020781; LITTS JC, 1992, PLANT MOL BIOL, V19, P335, DOI 10.1007/BF00027357; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1989, DEV GENET, V10, P473, DOI 10.1002/dvg.1020100608; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCCARTY DR, 1989, PLANT CELL, V1, P523, DOI 10.1105/tpc.1.5.523; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAIVA R, 1994, PLANTA, V192, P332, DOI 10.1007/BF00198568; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PLA M, 1991, MOL GEN GENET, V230, P394, DOI 10.1007/BF00280296; RIVIN CJ, 1991, PLANT PHYSIOL, V95, P358, DOI 10.1104/pp.95.2.358; ROCK CD, 1994, CURR BIOL, V4, P1013, DOI 10.1016/S0960-9822(00)00229-3; Rock Christopher D., 1995, P671; Scandalios J G, 1990, Adv Genet, V28, P1; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WILLIAMS B, 1991, PLANT MOL BIOL, V16, P919, DOI 10.1007/BF00015086; WILLIAMS BA, 1994, DEV GENET, V15, P415, DOI 10.1002/dvg.1020150504; WILLIAMSON JD, 1992, P NATL ACAD SCI USA, V89, P8842, DOI 10.1073/pnas.89.18.8842	46	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3366	3374						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631935	hybrid, Green Published			2022-12-27	WOS:A1996TV72400009
J	Pall, EA; Bolton, KM; Ervasti, JM				Pall, EA; Bolton, KM; Ervasti, JM			Differential heparin inhibition of skeletal muscle alpha-dystroglycan binding to laminins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; EXTRACELLULAR-MATRIX; PROTEOGLYCANS; AGRIN; PROTEINS; LOCALIZATION; SARCOLEMMA; COMPONENT; ISOFORMS; SUBUNITS	The laminin binding properties of alpha-dystroglycan purified from rabbit skeletal muscle membranes were examined, In a solid phase microtiter assay, I-125-laminin (laminin-1) bound to purified alpha-dystroglycan in a specific and saturable manner with a half-maximal concentration of 8 nM, The binding of I-125-alpha-dystroglycan to native laminin and merosin (a mixture of laminin-2 and -4) was also compared using the solid phase assay, The absolute binding of I-125-alpha-dystroglycan to laminin (6955 +/- 250 cpm/well) was similar to that measured for merosin (7440 +/- 970 cpm/well). However, inclusion of 1 mg/ml heparin in the incubation medium inhibited I-125-alpha-dystroglycan binding to laminin by 84 +/- 4.3% but inhibited I-125-alpha-dystroglycan binding to merosin by only 17 +/- 5.2%, Similar results were obtained with heparan sulfate, while de-N-sulfated heparin, hyaluronic acid, and chondroitin sulfate had no differential effect, These results were confirmed by iodinated laminin and merosin overlay of electrophoretically separated and blotted dystrophin-glycoprotein complex. In contrast to the results obtained with skeletal muscle alpha-dystroglycan, both laminin and merosin binding to purified brain alpha-dystroglycan was significantly inhibited by heparin, Our data support the possibility that one or more heparan sulfate proteoglycans may specifically modulate the interaction of alpha-dystroglycan with different extracellular matrix proteins in skeletal muscle.	UNIV WISCONSIN,DEPT PHYSIOL,SCH MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Ervasti, James/AAZ-4786-2020		NIAMS NIH HHS [AR42423] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042423] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; BROWN JC, 1994, J CELL SCI, V107, P329; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARRINO DA, 1984, J BIOL CHEM, V259, P2419; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; DOW KE, 1994, EXP NEUROL, V128, P233, DOI 10.1006/exnr.1994.1132; DOW KE, 1991, CELL TISSUE RES, V265, P345, DOI 10.1007/BF00398082; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FRITZ VK, 1988, MED SCI SPORT EXER, V20, P354, DOI 10.1249/00005768-198808000-00005; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; HAYASHI YK, 1993, J NEUROL SCI, V119, P53, DOI 10.1016/0022-510X(93)90191-Z; HIGUCHI I, 1994, J CLIN INVEST, V94, P601, DOI 10.1172/JCI117375; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; NAGASAVA K, 1980, METHODS CARBOHYDR CH, V8, P291; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PACIFICI M, 1980, EXP CELL RES, V126, P143, DOI 10.1016/0014-4827(80)90479-6; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WANG LS, 1992, NEURON, V8, P701, DOI 10.1016/0896-6273(92)90091-Q; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	49	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3817	3821						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631999				2022-12-27	WOS:A1996TV72400073
J	Sabourin, JC; Kern, AS; Gregori, C; Porteu, A; Cywiner, C; Chatelet, FP; Kahn, A; Pichard, AL				Sabourin, JC; Kern, AS; Gregori, C; Porteu, A; Cywiner, C; Chatelet, FP; Kahn, A; Pichard, AL			An intronic enhancer essential for tissue-specific expression of the aldolase B transgenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GENE-EXPRESSION; PYRUVATE-KINASE; RAT-LIVER; METABOLIC ZONATION; MESSENGER-RNAS; PROMOTER; POSITION; MICE; TRANSCRIPTION; CELLS	Expression in mice of transgenes directed by regulatory regions of the rat aldolase B gene requires the presence of a B element located in the first intron, while constructs devoid of this intronic enhancer are silent. Histo- and immunochemical staining of transgenic tissue sections showed that the longer transgene was expressed in the proximal tubular cells of the kidney, enterocytes located in small intestine villi and liver parenchymal cells. In the liver, a maximal expression was observed in perivenous hepatocytes, while the transgene was weakly active in periportal hepatocytes, which reproduced the pattern of functional zonation already reported for other glycolytic and gluconeogenic genes in the liver. We also established that the transgene retained the necessary elements for a correct chronological expression during development but was lacking elements necessary for activation by high carbohydrate diet. Instead, transgene expression was paradoxically stimulated in fasted animals, suggesting that the endogenous gene, which must be active under both glycolytic and gluconeogenic conditions, could possess distinct elements activating it in fasted as well as in carbohydrate-fed animals; the former element might be conserved in the transgene and the latter one might be lost.	INSERM, U129, INST COCHIN GENET MOLEC, F-75014 PARIS, FRANCE; CHU ST ANTOINE, LAB BIOL MOLEC MORPHOL, F-75012 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; GREGORI C, 1991, BIOCHEM BIOPH RES CO, V176, P722, DOI 10.1016/S0006-291X(05)80244-X; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUDER WG, 1984, KIDNEY INT, V26, P101, DOI 10.1038/ki.1984.143; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Hildebrand R, 1980, Adv Anat Embryol Cell Biol, V60, P1; JUNGERMANN K, 1988, SEMIN LIVER DIS, V8, P329, DOI 10.1055/s-2008-1040554; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; KATZ N, 1977, FEBS LETT, V83, P272, DOI 10.1016/0014-5793(77)81021-1; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; MIETHKE H, 1985, BIOL CHEM H-S, V366, P493, DOI 10.1515/bchm3.1985.366.1.493; MISKIMINS R, 1992, DEV BRAIN RES, V65, P217, DOI 10.1016/0165-3806(92)90182-V; MUNNICH A, 1985, J CLIN INVEST, V75, P1045, DOI 10.1172/JCI111766; NUMAZAKI M, 1984, EUR J BIOCHEM, V142, P165, DOI 10.1111/j.1432-1033.1984.tb08265.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; SCHAPIRA F, 1975, ISOZYMES, V3, P987; SHIH HM, 1994, J BIOL CHEM, V269, P9380; TRUS M, 1980, J HISTOCHEM CYTOCHEM, V28, P579, DOI 10.1177/28.6.7391551; VAULONT S, 1986, J BIOL CHEM, V261, P7621; WEBER A, 1984, J BIOL CHEM, V259, P1798; WELSH FA, 1972, J HISTOCHEM CYTOCHEM, V20, P107, DOI 10.1177/20.2.107	37	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3469	3473						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631949	hybrid			2022-12-27	WOS:A1996TV72400023
J	Schwientek, T; Narimatsu, H; Ernst, JF				Schwientek, T; Narimatsu, H; Ernst, JF			Golgi localization and in vivo activity of a mammalian glycosyltransferase (human beta 1,4-galactosyltransferase) in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLYCOSYLATION; RETENTION; OLIGOSACCHARIDES; TOPOGRAPHY; APPARATUS; SIGNAL; DOMAIN	Gene fusions encoding the membrane anchor region of yeast alpha 1,2-mannosyltransferase (Mnt1p) fused to human beta 1,4-galactosyltransferase (Gal-Tf) were constructed and expressed in the yeast Saccharomyces cerevisiae, Fusion proteins containing 82 or only 36 N-terminal residues of Mnt1p were produced and quantitatively N-glycosylated; glycosyl chains were shown to contain alpha 1,6-, but not alpha 1,3-mannose determinants, a structure typical for an early Golgi compartment, A final Golgi localization of both fusions was confirmed by sucrose gradient fractionations, in which Gal-Tf activity cofractionated with Golgi Mnt1p activity, as well as by immunocytological localization experiments using a monoclonal anti-Gal-Tf antibody, In an in vitro Gal-Tf enzymatic assay the Mnt1/Gal-Tf fusion and soluble human Gal-Tf had comparable K-m values for UDP-Gal (about 45 mu M). To demonstrate in vivo activity of the Mnt1/Gal-Tf fusion the encoding plasmids were transformed in an alg1 mutant, which at the non-permissive temperature transfers short (GlcNAc)(2) glycosyl chains to proteins. Using specific lectins the addition of galactose to several yeast proteins in transformants could be detected, These results demonstrate that Gal-Tf, a mammalian glycosyltransferase, is functional in the molecular environment of the yeast Golgi, indicating conservation between yeast and human cells, The in vivo function of human Gal-Tf indicates that the yeast Golgi is accessible for UDP-Gal and suggests strategies for the construction of yeast strains, in which desired glycoforms of heterologous proteins are produced.	UNIV DUSSELDORF, INST MIKROBIOL, D-40225 DUSSELDORF, GERMANY; SOKA UNIV, DIV CELL BIOL, INST LIFE SCI, HACHIOJI, TOKYO 192, JAPAN	Heinrich Heine University Dusseldorf; Soka University								ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; AOKI D, 1990, EMBO J, V9, P371; AOKI D, 1992, P NATL ACAD SCI USA, V89, P439; BEGGS JD, 1981, A BENZON S, V16, P383; BERGER EG, 1986, FEBS LETT, V203, P64, DOI 10.1016/0014-5793(86)81437-5; BORSIG L, 1995, BIOCHEM BIOPH RES CO, V210, P14, DOI 10.1006/bbrc.1995.1621; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; ERNST LK, 1989, J BIOL CHEM, V264, P3436; GOMEZ L, 1994, P NATL ACAD SCI USA, V91, P1829, DOI 10.1073/pnas.91.5.1829; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; JONES EW, 1990, METHOD ENZYMOL, V185, P372; KLEENE R, 1994, BIOCHEM BIOPH RES CO, V201, P160, DOI 10.1006/bbrc.1994.1683; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON KGI, 1988, TRENDS BIOTECHNOL, V6, P256, DOI 10.1016/0167-7799(88)90058-3; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; SCHWIENTEK T, 1995, J BIOL CHEM, V270, P5483, DOI 10.1074/jbc.270.10.5483; SCHWIENTEK T, 1994, GENE, V145, P299, DOI 10.1016/0378-1119(94)90024-8; Sherman F., 1986, METHODS YEAST GENETI; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; STROUS GJ, 1985, J CELL BIOL, V97, P723; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; UEMURA M, 1992, CANCER RES, V52, P6153; VERDON B, 1983, METHOD ENZYMAT AN, V3, P374; YOUAKIM A, 1994, ANN NY ACAD SCI, V745, P331	36	25	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3398	3405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631939				2022-12-27	WOS:A1996TV72400013
J	Ito, M; Komori, H				Ito, M; Komori, H			Homeostasis of cell-surface glycosphingolipid content in B16 melanoma cells - Evidence revealed by an endoglycoceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-GLYCANASE; PLASMA-MEMBRANE; SPHINGOSINE; OLIGOSACCHARIDE; SPHINGOMYELIN; PROLIFERATION; PURIFICATION; HYDROLYSIS; ACTIVATOR; PATHWAY	This paper describes the homeostasis of glycosphingolipid (GSL) on the cell surface as revealed for the first time by an application of endoglycoceramidase (EGCase) capable of hydrolyzing the linkage between the oligosaccharide and the ceramide of various GSLs. When cell-surface GSLs of B16 melanoma cells were hydrolyzed by the action of EGCase, the synthesis of GSLs was found to increase transiently, possibly due to the activation of UDP-glucose:ceramide glucosyltransferase. As a result, the cell-surface GSL content was restored quickly to exactly the same level found without the EGCase treatment, if EGCase was removed from the cell culture. Treatment of erythrocytes with EGCase was found to increase the ceramide content of the plasma membrane. Surprisingly, however, in B16 cells the increase of membrane ceramide by EGCase caused the suppression of de novo ceramide production, resulting in maintenance of the ceramide content of B16 cells at the same level even after EGCase treatment. The signal for homeostatic regulation could be the ceramide released by the action of EGCase, since C-2-ceramide was found to mimic in part the action of EGCase; it suppressed de novo production of ceramide and was directly converted to GSL, NeuAc alpha 2,3Gal beta 1,4Glc beta 1,1 N-acetylsphingosine (C-2-ceramide GM(3)). Our finding demonstrates a novel form of homeostatic regulation coupled to the GSL-synthesizing system in mammalian cells for maintaining the contents of both cell-surface GSLs and free ceramide. Since many opportunistic pathogens were found to produce EGCase extracellularly, this restoration mechanism could also be present as a defense mechanism against microbial EGCase.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN		Ito, M (corresponding author), KYUSHU UNIV,FAC AGR,MARINE BIOCHEM LAB,HIGASHI KU,6-10-1 HAKOZAKI,FUKUOKA 812,JAPAN.			ito, Makoto/0000-0003-3159-7818				ASIDA H, 1992, EUR J BIOCHEM, V205, P729; BASU M, 1995, GLYCOCONJUGATE J, V12, P439; BASU S, 1990, INDIAN J BIOCHEM BIO, V27, P386; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1993, EUR J BIOCHEM, V218, P645, DOI 10.1111/j.1432-1033.1993.tb18418.x; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; ITO M, 1991, J BIOCHEM-TOKYO, V110, P328, DOI 10.1093/oxfordjournals.jbchem.a123580; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; KOK JW, 1989, P NATL ACAD SCI USA, V86, P9896, DOI 10.1073/pnas.86.24.9896; KOMORI H, 1995, FEBS LETT, V374, P299, DOI 10.1016/0014-5793(95)01137-4; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; MIKAWA T, 1987, MITSUBISHI CHEM R D, V1, P34; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V202, P398, DOI 10.1006/bbrc.1994.1941; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; RADIN NS, 1991, TRENDS GLYCOSCI GLYC, V3, P200; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRUM JC, 1995, J BIOL CHEM, V270, P13541, DOI 10.1074/jbc.270.22.13541; YAGER JA, 1991, VET MICROBIOL, V28, P363, DOI 10.1016/0378-1135(91)90071-M; ZHANG H, 1990, J BIOL CHEM, V265, P76	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12655	12660		10.1074/jbc.271.21.12655	http://dx.doi.org/10.1074/jbc.271.21.12655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647878	hybrid			2022-12-27	WOS:A1996UL66000080
J	Maas, S; Melcher, T; Herb, A; Seeburg, PH; Keller, W; Krause, S; Higuchi, M; OConnell, MA				Maas, S; Melcher, T; Herb, A; Seeburg, PH; Keller, W; Krause, S; Higuchi, M; OConnell, MA			Structural requirements for RNA editing in glutamate receptor pre-mRNAs by recombinant double-stranded RNA adenosine deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNELS; CELLS	Pre-mRNAs for brain expressed ionotropic glutamate receptor subunits undergo RNA editing by site-specific adenosine deamination, which alters codons for molecular determinants of channel function. This nuclear process requires double-stranded RNA structures formed by exonic and intronic sequences in the pre-mRNA and is likely to be catalyzed by an adenosine deaminase that recognizes these structures as a substrate, DRADA, a double-stranded RNA adenosine deaminase, is a candidate enzyme for L-glutamate-activated receptor channel (GluR) pre-mRNA editing. We show here that DRADA indeed edits GluR pre-mRNAs, but that it displays selectivity for certain editing sites, Recombinantly expressed DRADA, both in its full-length form and in an N-terminally truncated version, edited the Q/R site in GluR6 pre-mRNA and the R/G site but not the Q/R site of GluR-B pre-mRNA, This substrate selectivity correlated with the base pairing status and sequence environment of the editing-targeted adenosines. The Q/R site of GluR-B pre-mRNA was edited by an activity partially purified from HeLa cells and thus differently structured editing sites in GluR pre-mRNAs appear to be substrates for different enzymatic activities.	UNIV HEIDELBERG,CTR MOLEC BIOL,LAB MOL NEUROENDOCRINOL,D-69120 HEIDELBERG,GERMANY; UNIV BASEL,DEPT CELL BIOL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg; University of Basel			OConnell, Mary Anne/G-4740-2015; Krause, Sabine/AAJ-1163-2020; O'Connell, Mary Anne/U-7693-2019	OConnell, Mary Anne/0000-0003-3844-6174; Krause, Sabine/0000-0002-3141-886X; O'Connell, Mary Anne/0000-0003-3844-6174				BASS BL, 1995, CURR BIOL, V5, P598, DOI 10.1016/S0960-9822(95)00119-9; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BERNARD A, 1994, J NEUROCHEM, V62, P2057, DOI 10.1046/j.1471-4159.1994.62052057.x; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PASCHEN W, 1994, J NEUROCHEM, V63, P1596, DOI 10.1046/j.1471-4159.1994.63051596.x; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Seeburg PH, 1996, J NEUROCHEM, V66, P1; SHARMEEN L, 1991, P NATL ACAD SCI USA, V88, P8096, DOI 10.1073/pnas.88.18.8096; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	39	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12221	12226		10.1074/jbc.271.21.12221	http://dx.doi.org/10.1074/jbc.271.21.12221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647818	hybrid			2022-12-27	WOS:A1996UL66000020
J	Williams, JP; Blair, HC; McKenna, MA; Jordan, SE; McDonald, JM				Williams, JP; Blair, HC; McKenna, MA; Jordan, SE; McDonald, JM			Regulation of avian osteoclastic H+-ATPase and bone resorption by tamoxifen and calmodulin antagonists - Effects independent of steroid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; ESTROGEN-RECEPTOR; PHOSPHODIESTERASE; CELLS; ANTIESTROGENS; MEMBRANE; WOMEN; ACID	We used highly purified avian osteoclasts and isolated membranes from osteoclasts to study effects of tamoxifen, 4-hydroxytamoxifen, calmodulin antagonists, estrogen, diethylstilbestrol, and the anti-estrogen ICI 182780 on cellular degradation of H-3-labeled bone in vitro and on membrane HCl transport. Bone resorption was reversibly inhibited by tamoxifen, 4-hydroxytamoxifen, and trifluoperazine with IC50 values of similar to 1 mu M. Diethylstilbestrol and 17-beta-estradiol had no effects on bone resorption at receptor-saturating concentrations, while ICI 182780 inhibited bone resorption at concentrations greater than 1 mu M. At these concentrations ICI 182780, like tamoxifen, inhibits calmodulin stimulated cyclic nucleotide phosphodiesterase activity. Membrane HCl transport, assessed by ATP-dependent acridine orange uptake, was unaffected by 17-beta-estradiol and diethylstilbestrol at concentrations up to 10 mu M, while ICI 182780 inhibited HCl transport at concentrations greater than 1 mu M. In contrast HCl transport was inhibited by tamoxifen, 4-hydroxytamoxifen, and the calmodulin antagonists, trifluoperazine and calmidazolium, with IC50 values of 0.25-1.5 mu M. These results suggested the presence of a membrane-associated non steroid receptor for tamoxifen in osteoclasts. Tamoxifen binding studies demonstrated saturable binding in the osteoclast particulate fraction, but not in the nuclear or cytosolic fractions. Membranes enriched in ruffled border by differential centrifugation following nitrogen cavitation showed binding consistent with one site, K-d similar to 1 mu M. Our findings indicate that tamoxifen inhibits osteoclastic HCl transport by binding membrane-associated target(s), probably similar or related to calmodulin antagonist targets. Further, effects of estrogens or highly specific anti-estrogens on bone turnover do not support the hypothesis of a direct effect on osteoclasts by these compounds in this species.	UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294; VET AFFAIRS MED CTR,LAB SERV,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAMS NIH HHS [AR43225] Funding Source: Medline; NIA NIH HHS [AG12951] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012951] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BEKKER PJ, 1990, J BONE MINER RES, V5, P557; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BLAIR HC, 1993, CLIN ORTHOP RELAT R, V294, P7; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BOUHOUTE A, 1992, BIOCHEM BIOPH RES CO, V184, P1432, DOI 10.1016/S0006-291X(05)80043-9; BOUHOUTE A, 1994, BIOCHEM PHARMACOL, V47, P748, DOI 10.1016/0006-2952(94)90140-6; BRUBAKER KD, 1994, BIOCHEM BIOPH RES CO, V200, P899, DOI 10.1006/bbrc.1994.1535; CARANO A, 1993, AM J PHYSIOL, V264, pC694, DOI 10.1152/ajpcell.1993.264.3.C694; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; DAUVOIS S, 1993, J CELL SCI, V106, P1377; FANIDI A, 1989, ENDOCRINOLOGY, V125, P1187, DOI 10.1210/endo-125-3-1187; JOHNSON JD, 1987, ANAL BIOCHEM, V162, P291, DOI 10.1016/0003-2697(87)90039-X; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LERNER LJ, 1990, CANCER RES, V50, P4177; LIPPMAN SM, 1993, CANCER, V72, P984, DOI 10.1002/1097-0142(19930801)72:3+<984::AID-CNCR2820721306>3.0.CO;2-0; LISKOVA M, 1976, CALC TISS RES, V22, P207; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LYMAN SD, 1985, BIOCHEM PHARMACOL, V34, P2221, DOI 10.1016/0006-2952(85)90425-3; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; OURSLER MJ, 1985, J CELL BIOL, V100, P1592, DOI 10.1083/jcb.100.5.1592; PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822; RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; TOBIAS JH, 1991, ACTA ENDOCRINOL-COP, V124, P121, DOI 10.1530/acta.0.1240121; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VEIGL ML, 1989, PHARMACOL THERAPEUT, V44, P181, DOI 10.1016/0163-7258(89)90066-1; WILLIAMS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P119, DOI 10.1006/abbi.1994.1479; WRIGHT CDP, 1994, J BONE MINER RES, V9, P153; WRIGHT CDP, 1993, BRIT MED J, V306, P429, DOI 10.1136/bmj.306.6875.429-a	34	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12488	12495		10.1074/jbc.271.21.12488	http://dx.doi.org/10.1074/jbc.271.21.12488			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647856	hybrid			2022-12-27	WOS:A1996UL66000058
J	Bunting, KD; Townsend, AJ				Bunting, KD; Townsend, AJ			Protection by transfected rat or human class 3 aldehyde dehydrogenases against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines - Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT L1210 CELLS; CYCLOPHOSPHAMIDE; IDENTIFICATION; EXPRESSION; OXIDATION; RETINALDEHYDE; LEUKEMIA; CATALYZE; ACID; CDNA	Expression of class 3 aldehyde dehydrogenase (ALDH-3) has been associated with acquired or inherent resistance to oxazaphosphorine (OAP) antineoplastic alkylating agents (e.g. cyclophosphamide). We previously demonstrated that expression of transfected rat ALDH-3 can confer GAP-specific resistance in human MCF-7 cells (Bunting, K. D., Lindahl, R., and Townsend, A. J. (1994) J. Biol. Chem. 269, 23197-23203). However, the aldophosphamide intermediate inactivated by human class 1 ALDH (hALDH-1) has not proven to be a good substrate for the purified hALDH-3. We have examined the ability of transfected human or rat ALDH-3 to confer OAF resistance in V79/SD1 cells, Clones expressing elevated human (386-5938 milliunits/mg) or rat (4-597 milliunits/mg, benzaldehyde/NADP(+) substrate) ALDH-3 activity were 1.3- to 12-fold resistant to mafosfamide relative to control cells (<1 milliunit/mg). Resistance was correlated with hALDH-3 activity, and was reversed by pretreatment with the ALDH inhibitor diethylaminobenzaldehyde. Transfectants were cross resistant to 4-hydroperoxycyclophosphamide and 4-hydroperoxyifosfamide but not to phosphoramide mustard, ifosfamide mustard, melphalan, or acrolein. DNA interstrand cross-links were reduced commensurately with the fold resistance to mafosfamide in the highest activity clone. A key finding was the detection of a metabolite, most likely carboxyphosphamide, that is formed only by cytosols from cells expressing either class 3 or class 1 ALDH.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BUNTING KD, 1994, J BIOL CHEM, V269, P23197; Bunting KD, 1996, J BIOL CHEM, V271, P11884, DOI 10.1074/jbc.271.20.11884; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; DOEHMER J, 1988, P NATL ACAD SCI USA, V85, P5769, DOI 10.1073/pnas.85.16.5769; HADIDI AHFA, 1988, J CHROMATOGR-BIOMED, V427, P121, DOI 10.1016/0378-4347(88)80110-5; HILL DL, 1972, CANCER RES, V32, P658; HILTON J, 1984, BIOCHEM PHARMACOL, V33, P1867, DOI 10.1016/0006-2952(84)90541-0; HILTON J, 1984, CANCER RES, V44, P5156; HSU LC, 1992, J BIOL CHEM, V267, P3030; KOELLING TM, 1990, BLOOD, V76, P1209; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LIN KH, 1986, IN VITRO CELL DEV B, V22, P263; LINDAHL R, 1976, BIOCHIM BIOPHYS ACTA, V452, P345, DOI 10.1016/0005-2744(76)90184-4; MANTHEY CL, 1988, BIOCHEM PHARMACOL, V37, P2781, DOI 10.1016/0006-2952(88)90041-X; REKHA GK, 1994, BIOCHEM PHARMACOL, V48, P1943, DOI 10.1016/0006-2952(94)90593-2; RUSSO JE, 1988, CANCER RES, V48, P2963; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SLADEK N, 1995, P AM ASSOC CANC RES, V35, P325; SLADEK NE, 1991, ADV EXP MED BIOL, V284, P97; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SREERAMA L, 1994, BIOCHEM PHARMACOL, V48, P617, DOI 10.1016/0006-2952(94)90294-1; SREERAMA L, 1993, BIOCHEM PHARMACOL, V45, P2487, DOI 10.1016/0006-2952(93)90231-K; SREERAMA L, 1994, CANCER RES, V54, P2176; SREERAMA L, 1995, BIOCHEM PHARMACOL, V49, P669, DOI 10.1016/0006-2952(94)00503-E; SREERAMA L, 1993, ADV EXP MED BIOL, V328, P99; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; VONEITZEN U, 1994, CANCER LETT, V76, P45, DOI 10.1016/0304-3835(94)90132-5	28	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11891	11896		10.1074/jbc.271.20.11891	http://dx.doi.org/10.1074/jbc.271.20.11891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662659	hybrid			2022-12-27	WOS:A1996UL25000050
J	Liang, YX; Robinson, DF; Dennig, J; Suske, G; Fahl, WE				Liang, YX; Robinson, DF; Dennig, J; Suske, G; Fahl, WE			Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; GROWTH-FACTOR PDGF; RNA POLYMERASE-II; V-SIS; CELLULAR-TRANSFORMATION; IDENTIFICATION; EXPRESSION; COEXPRESSION; ACTIVATION; RECEPTORS	Expression of PDGF-B, the gene encoding the platelet-derived growth factor B chain, has been implicated as a participant in an autocrine growth loop in the human osteosarcoma cell line U2-OS. In previous work, we identified a primary site in the PDGF-B promoter, the SIS proximal element (SPE), which is critical for transcription of the PDGF-B gene in U2-OS cells. We also identified Spl as one of the SPE-binding proteins in U2-OS nuclear extracts. In the present work, we have identified another SPE-binding protein to be Sp3. Gel mobility shift assays showed that both Spl and Sp3 require the CACCC motif within the SPE for binding. In vitro transcription assays showed that Sp1 or/and Sp3 is necessary for transcription of the PDGF-B gene. Cotransfection experiments functionally demonstrated that Sp1 and Sp3 can independently or additively activate the PDGF-B promoter through the SPE as well as a synthetic promoter. However, the CACCC motif within the SPE is not the only site within the minimal PDGF-B promoter through which Sp1/Sp3 acts; additional nested deletion analyses showed that multiple cis-acting elements within the minimal promoter are required for full level transcription of the PDGF-B gene in U2-OS cells.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	University of Wisconsin System; University of Wisconsin Madison; Philipps University Marburg				Suske, Guntram/0000-0002-4807-0513				ANTONIADES HN, 1991, BAILLIERE CLIN ENDOC, V5, P595, DOI 10.1016/S0950-351X(10)80005-9; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5591; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; PERES R, 1987, CANCER RES, V47, P3425; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P18255; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Sherf BA, 1994, PROMEGA NOTES, V49, P14; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	35	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11792	11797		10.1074/jbc.271.20.11792	http://dx.doi.org/10.1074/jbc.271.20.11792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662647	hybrid			2022-12-27	WOS:A1996UL25000035
J	Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK				Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK			Purification and characterization of the vnf-encoded apodinitrogenase from Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; 2ND ALTERNATIVE NITROGENASE; DINITROGENASE REDUCTASE; VANADIUM NITROGENASE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; INVITRO SYNTHESIS; STRUCTURAL GENES; FEMO-COFACTOR; PROTEIN	The unf-encoded apodinitrogenase (apodinitrogenase 2) has been purified from Azotobacter vinelandii strain CA117.30 (Delta nifKDB), and is an alpha(2) beta(2) delta(2) hexamer. Apodinitrogenase 2 can be activated in vitro by the addition of the iron-vanadium cofactor (FeV-co) to form holodinitrogenase 2, which functions in C2H2, H+, and N-2 reduction. Under certain conditions, the alpha(2) beta(2) delta(2) hexamer dissociates to yield the free delta subunit (the VNFG protein) and a form of apodinitrogenase 2 that exhibits no C2H2, H+, or N-2 reduction activities in the in vitro FeV-co activation assay; however, these activities can be restored upon addition of VNFG to the FeV-co activation assay system. No other vnf-, nif-, or non-nif-encoded proteins were able to replace the function of VNFG in the in vitro processing of alpha(2) beta(2) apodinitrogenase 2 (in the presence of FeV-co) to a form capable of substrate reduction, Apodinitrogenase 2 is also activable in vitro by the iron-molybdenum cofactor to form a hybrid enzyme with unique properties, most notably the inability to reduce N-2 and insensitivity to CO inhibition of C2H2 reduction.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1996, IN PRESS J BIOL CHEM, V271; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURRIS RH, 1957, METHOD ENZYMOL, V4, P355, DOI 10.1016/0076-6879(57)04064-1; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; DAVIS R, 1996, IN PRESS J BACTERIOL, V178; DILWORTH MJ, 1987, NATURE, V327, P167, DOI 10.1038/327167a0; EADY RR, 1991, ADV INORG CHEM RAD, V36, P77; GOLLAN U, 1993, EUR J BIOCHEM, V215, P25, DOI 10.1111/j.1432-1033.1993.tb18003.x; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HALES BJ, 1986, BIOCHEMISTRY-US, V25, P7253, DOI 10.1021/bi00371a001; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOERGER RD, 1989, J BACTERIOL, V171, P1075, DOI 10.1128/jb.171.2.1075-1086.1989; KENNEDY C, 1986, MOL GEN GENET, V205, P318, DOI 10.1007/BF00430445; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOORE VG, 1994, J AM CHEM SOC, V116, P12101, DOI 10.1021/ja00105a080; PAU RN, 1993, BIOCHEM J, V293, P101, DOI 10.1042/bj2930101; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995	36	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6819	6826		10.1074/jbc.271.12.6819	http://dx.doi.org/10.1074/jbc.271.12.6819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636105	hybrid			2022-12-27	WOS:A1996UB15700040
J	Liu, MY; Qin, Y; Liu, J; Tanswell, AK; Post, M				Liu, MY; Qin, Y; Liu, J; Tanswell, AK; Post, M			Mechanical strain induces pp60(src) activation and translocation to cytoskeleton in fetal rat lung cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INSOLUBLE CELLULAR MATRIX; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY; STABLE ASSOCIATION; FOCAL ADHESIONS; 2ND MESSENGERS; PHOSPHORYLATION; SUBSTRATE	We have previously shown that mechanical strain-induced fetal rat lung cell proliferation is transduced via the phospholipase C-gamma-protein kinase C pathway. In the present study, we found that protein-tyrosine kinase activity of fetal lung cells increased after a short period of strain, which was accompanied by tyrosine phosphorylation of proteins of similar to 110-130 kDa. Several components of this complex were identified as pp60(src) substrates. Strain increased pp60(src) activity in the cytoskeletal fraction, which coincided with a shift in subcellular distribution of pp60(src) hom the Triton-soluble to the cytoskeletal fraction. Strain-induced pp60(src) translocation did not appear to be mediated via the focal adhesion kinase-paxillin pathway. In contrast, strain increased the association between pp60(src) and the actin filament-associated protein of 110 kDa. Preincubation of cells with herbimycin A, a tyrosine kinase inhibitor, abolished strain-induced phospholipase C-gamma 1 tyrosine phosphorylation and its coimmunoprecipitation with pp60(src). It also inhibited strain-induced DNA synthesis. These results suggest that activation of pp60(src) is an upstream event of the phospholipase C-gamma-protein kinase C pathway that may represent an important mechanism by which mechanical perturbations are converted to biological reactions in fetal lung cells.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PEDIAT,MED RES COUNCIL,GRP LUNG DEV,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PEDIAT,NEONATAL RES DIV,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Liu, Mingyao/0000-0002-9188-8417				BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BRIGHTON CT, 1992, J ORTHOPAED RES, V10, P385, DOI 10.1002/jor.1100100311; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DHAR A, 1994, J BIOL CHEM, V269, P9123; DOWNING JR, 1991, ONCOGENE, V6, P607; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRANGOS JA, 1993, PHYSICAL FORCES MAMM; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Harding R., 1991, LUNG SCI F, P1655; HISHIKAWA K, 1994, J CLIN INVEST, V93, P1975, DOI 10.1172/JCI117189; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KITTERMAN JA, 1988, CAN J PHYSIOL PHARM, V66, P1122, DOI 10.1139/y88-184; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; LIU M, 1992, AM J PHYSIOL, V263, pL376; LIU MY, 1995, AM J PHYSIOL-LUNG C, V268, pL729, DOI 10.1152/ajplung.1995.268.5.L729; LIU MY, 1995, AM J PHYSIOL-LUNG C, V269, pL178, DOI 10.1152/ajplung.1995.269.2.L178; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; RANKIN S, 1994, J BIOL CHEM, V269, P704; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RILEY DJ, 1990, AM REV RESPIR DIS, V142, P910, DOI 10.1164/ajrccm/142.4.910; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIMPSON LL, 1985, AM J ANAT, V172, P31, DOI 10.1002/aja.1001720103; SKINNER SJM, 1989, RES PERINATAL MED, V8, P133; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDENBURGH HH, 1993, J CELL PHYSIOL, V155, P63, DOI 10.1002/jcp.1041550109; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	48	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7066	7071		10.1074/jbc.271.12.7066	http://dx.doi.org/10.1074/jbc.271.12.7066			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636139	hybrid			2022-12-27	WOS:A1996UB15700074
J	Sheff, D; Lowe, M; Kreis, TE; Mellman, I				Sheff, D; Lowe, M; Kreis, TE; Mellman, I			Biochemical heterogeneity and phosphorylation of coatomer subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-COP; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; COATED VESICLES; BREFELDIN-A; KINASE-C; TRANSPORT; COMPLEX	The coat protomer complex I (COPI) family of coat proteins are involved in the assembly of membrane-associated coats thought to mediate vesicular transport between the endoplasmic reticulum and the Golgi complex, between adjacent Golgi cisternae, and possibly in the endocytic pathway. We investigated whether this heterogeneity in the sites of COPI action might be reflected in biochemical heterogeneity of one or more COPI subunits. A simplified method was devised to purify the cytosolic COPI precursor complex, coatomer, from rat liver cytosol, The individual subunits were analyzed by high resolution two dimensional gel electrophoresis and mass spectroscopic analysis of tryptic peptides. Considerable charge heterogeneity was observed, particularly for the beta-COP and delta-COP subunits. The multiple species detected, however, did not appear to reflect the presence of distinct translation products but rather a significant degree of protein phosphorylation. The observed pI of beta-COP was sensitive to alkaline phosphatase digestion. Moreover, isolation of coatomer from metabolically labeled tissue culture cells demonstrated directly that both beta-COP and delta-COP, but no other coatomer subunits, were serine-phosphorylated. COPI phosphorylation may regulate coatomer assembly, membrane recruitment, or the specificity of coatomer-organelle interaction.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	Yale University; University of Geneva			Sheff, David/A-1269-2007; Mellman, Ira/ABG-5896-2020		NIGMS NIH HHS [GM29765, F32GM16339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016339, R01GM029765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CELIS JE, 1993, ELECTROPHORESIS, V14, pU1091, DOI 10.1002/elps.11501401178; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; FABBRI M, 1994, J BIOL CHEM, V269, P26848; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; GRIFFITHS G, 1996, IN PRESS J CELL SCI; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KREIS TE, 1996, IN PRESS ANN REV CEL; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LOWE M, 1995, J BIOL CHEM, V270, P3164; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703	41	35	36	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7230	7236		10.1074/jbc.271.12.7230	http://dx.doi.org/10.1074/jbc.271.12.7230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636162				2022-12-27	WOS:A1996UB15700097
J	Vaandrager, AB; Ehlert, EME; Jarchau, T; Lohmann, SM; deJonge, HR				Vaandrager, AB; Ehlert, EME; Jarchau, T; Lohmann, SM; deJonge, HR			N-terminal myristoylation is required for membrane localization of cGMP-dependent protein kinase type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; GUANYLYL CYCLASE; MECHANISM; STABILITY; RECEPTOR	The apical membrane of intestinal epithelial cells harbors a unique isozyme of cGMP-dependent protein kinase (cGK type II) which acts as a key regulator of ion transport systems, including the cystic fibrosis transmembrane conductance regulator (CFTR)-chloride channel. To explore the mechanism of cGK II membrane-anchoring, recombinant cGK II was expressed stably in HEK 293 cells or transiently in COS-1 cells, In both cell lines, cGK II was found predominantly in the particulate fraction, Immunoprecipitation of solubilized cGK II did not reveal any other tightly associated proteins, suggesting a membrane binding motif within cGK II itself. The primary structure of cGK II is devoid of hydrophobic transmembrane domains; cGK II does, however, contain a penultimate glycine, a potential acceptor for a myristoyl moiety, Metabolic labeling showed that cGK II was indeed able to incorporate [H-3]myristate. Moreover, incubation of cGK II expressing 293 cells with the myristoylation inhibitor 2-hydroxymyristic acid (1 mM) significantly increased the proportion of cGK II in the cytosol from 10 +/- 5 to 35 +/- 4%. Furthermore, a nonmyristoylated cGK II Gly(2) --> Ala mutant was localized predominantly in the cytosol after transient expression in COS-1 cells, The absence of the myristoyl group did not affect the specific enzyme activity or the K-alpha for cGMP and only slightly enhanced the thermal stability of cGK II. These results indicate that N-terminal myristoylation fulfills a crucial role in directing cGK II to the membrane.	ERASMUS UNIV ROTTERDAM,FAC MED & HLTH SCI,DEPT BIOCHEM,CARDIOVASC RES INST COEUR,3000 DR ROTTERDAM,NETHERLANDS; UNIV WURZBURG,MED CLIN,LAB CLIN BIOCHEM,D-97080 WURZBURG,GERMANY	Erasmus University Rotterdam; University of Wurzburg			Ehlert, Erich M/A-4054-2012	Vaandrager, Arie/0000-0001-9394-9239				BERGER HA, 1993, J BIOL CHEM, V268, P2037; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1984, BIOCHEM SOC T, V12, P180, DOI 10.1042/bst0120180; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FIELD M, 1989, NEW ENGL J MED, V321, P800; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager A B, 1994, Adv Pharmacol, V26, P253, DOI 10.1016/S1054-3589(08)60057-5; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	27	75	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7025	7029		10.1074/jbc.271.12.7025	http://dx.doi.org/10.1074/jbc.271.12.7025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636133	hybrid, Green Published			2022-12-27	WOS:A1996UB15700068
J	Best, A; Ahmed, S; Kozma, R; Lim, L				Best, A; Ahmed, S; Kozma, R; Lim, L			The Ras-related GTPase Rac1 binds tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; KINASE; RAF-1; RHO	The Ras-related Rho family are involved in controlling actin-based changes in cell morphology. Microinjection of Rac1, RhoA, and Cdc42Hs into Swiss 3T3 cells induces pinocytosis and membrane ruffling, stress fiber formation, and filopodia formation, respectively. To identify target proteins involved in these signaling pathways cell extracts immobilized on nitrocellulose have been probed with [gamma-P-32]GTP-labeled Rac1, RhoA, and Gdc42Hs. We have identified two 55-kDa brain proteins which bind Rac1 but not RhoA or Cdc42Hs. These 55-kDa proteins were abundant, had pI values of around 5.5, and could be purified by Q-Sepharose chromatography. The characteristics on two dimensional gel analysis suggested the proteins comprised alpha- and P-tubulin. Indeed, beta-tubulin specific antibodies detected one of the purified 55-kDa proteins. Rad bound pure tubulin (purified by cycles of polymerization and depolymerization) only in the GTP-bound state. The GTPase negative Rac1 point mutants, G12V and Q61L, did not significantly affect the ability of Rac1 to interact with tubulin while the ''effector-site'' mutant D38A prevented interaction. These results suggest that the Rac1-tubulin interaction may play a role in Rac1 function.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, GLAXO IMCB GRP, SINGAPORE 0411, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Best, A (corresponding author), INST NEUROL, DEPT NEUROCHEM, 1 WAKEFIELD ST, LONDON WC1N 1PJ, ENGLAND.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1995, METHOD ENZYMOL, V256, P114; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SERRANO L, 1986, METHOD ENZYMOL, V134, P179; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOTJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	31	108	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3756	3762						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631991				2022-12-27	WOS:A1996TV72400065
J	Buccione, R; Bannykh, S; Santone, I; Baldassarre, M; Facchiano, F; Bozzi, Y; DiTullio, G; Mironov, A; Luini, A; DeMatteis, MA				Buccione, R; Bannykh, S; Santone, I; Baldassarre, M; Facchiano, F; Bozzi, Y; DiTullio, G; Mironov, A; Luini, A; DeMatteis, MA			Regulation of constitutive exocytic transport by membrane receptors - A biochemical and morphometric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BASOPHILIC LEUKEMIA-CELLS; IMMATURE SECRETORY GRANULES; HETEROTRIMERIC G-PROTEIN; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; GOLGI MEMBRANES; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; PHORBOL ESTERS	Biochemical and morphometric approaches were combined to examine whether constitutive secretory transport might be controlled by plasma membrane receptors, as this possibility would have significant physiological implications. Indeed, IgE receptor stimulation in rat basophilic leukemia cells potently increased the rate of transport of soluble pulse-labeled S-35-sulfated glycosaminoglycans from distal Golgi compartments to the cell surface. This effect was largely protein kinase C (PKC)-dependent. Direct activation of PKC also stimulated constitutive transport of glycosaminoglycans, as indicated by the use of agonistic and antagonistic PKC Ligands. PKC ligands also had potent, but different, effects on the exocytic transport from distal Golgi compartments to the plasma membrane of a membrane-bound protein (vesicular stomatitis virus glycoprotein), which was slightly stimulated by activators and profoundly suppressed by inhibitors of PKC, Morphological analysis showed impressive changes of the organelles of the secretory pathway in response to IgE receptor stimulation and to direct PKC activation (enhanced number of buds and vesicles originating from the endoplasmic reticulum and Golgi and increase in surface and volume of Golgi compartments), suggestive of an overall activation of exocytic movements. These results show that rapid and large changes in constitutive transport fluxes and in the morphology of the exocytic apparatus can be induced by membrane receptors (as well as by direct PHC stimulation).	IST RIC FARMACOL MARIO NEGRI, CONSORZIO MARIO NEGRI SUD, PHYSIOPATHOL SECRET UNIT, I-66030 SANTA MARIA IMBARO, CHIETI, ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Buccione, R (corresponding author), IST RIC FARMACOL MARIO NEGRI, CONSORZIO MARIO NEGRI SUD, MOLEC NEUROBIOL LAB, I-66030 SANTA MARIA IMBARO, CHIETI, ITALY.		Baldassarre, Massimiliano/E-6236-2011; Baldassarre, Massimiliano/AAI-6581-2021; Facchiano, Francesco/K-8716-2016; Luini, Alberto/L-1372-2013	Baldassarre, Massimiliano/0000-0002-2498-4767; Baldassarre, Massimiliano/0000-0002-2498-4767; Facchiano, Francesco/0000-0003-4313-0617; Luini, Alberto/0000-0002-8729-2549; Buccione, Roberto/0000-0001-9210-5261; De Matteis, Maria Antonietta/0000-0003-0053-3061				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKITA Y, 1994, J BIOL CHEM, V269, P4653; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRION C, 1992, J BIOL CHEM, V267, P1477; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DVORAK AM, 1992, AM J PATHOL, V141, P1309; EKER P, 1994, J BIOL CHEM, V269, P18607; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; Luini Alberto, 1993, Trends in Cell Biology, V3, P290, DOI 10.1016/0962-8924(93)90002-I; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MORI K, 1993, CELL, V74, P743; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SLACK BE, 1993, J BIOL CHEM, V268, P21097; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; TURNER MD, 1992, BIOCHEM J, V286, P13, DOI 10.1042/bj2860013; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; YU KT, 1991, J BIOL CHEM, V266, P22564	72	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3523	3533						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631957				2022-12-27	WOS:A1996TV72400031
J	Ozcelebi, F; Rao, RV; Holicky, E; Madden, BJ; McCormick, DJ; Miller, LJ				Ozcelebi, F; Rao, RV; Holicky, E; Madden, BJ; McCormick, DJ; Miller, LJ			Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells - Similarities and differences relative to native pancreatic acinar cell receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL; KINASES; ELECTROPHORESIS; PURIFICATION; PROTEINS; PEPTIDES; CA-2+	Phosphorylation of G protein-coupled receptors is an established mechanism for desensitization in response to agonist stimulation, We previously reported phosphorylation of the pancreatic acinar cell cholecystokinin (CCK) receptor and the establishment of two-dimensional phosphopeptide mapping of its sites of phosphorylation (Ozcelebi, F,, and Miller, L, J, (1995) J, Biol, Chem, 270, 3435-3441), Here, we use similar techniques to map sites of phosphorylation of the same receptor expressed on a stable receptor-bearing Chinese hamster ovary (CHO)-CCKR cell line, Like the native cell, the CHO-CCKR cell receptor was phosphorylated in response to agonist stimulation in a concentration-dependent manner; however, the time course was quite different, CHO-CCKR cell receptor phosphorylation in creased progressively to a plateau after 15 min, while in the acinar cell it peaks within 2 min and returns to baseline over this interval, There were distinct qualitative and quantitative differences in the sites of phosphorylation of the two receptor systems, One site previously attributed to action of a staurosporine-insensitive kinase in the acinar cell was absent in the CHO-CCKR cell, Site-directed mutagenesis was utilized to eliminate pre dieted sites of protein kinase C action, but only two of four such sites affected the phosphopeptide map of this receptor, Chemical and radiochemical sequencing were performed on these and other phosphopeptides which were present in both the CHO-CCKR cells and agonist stimulated pancreatic acinar cells to provide direct evidence for the phosphorylation sites actually utilized, Thus, these data support the usefulness and limitations of a model cell system in studying receptor phosphorylation and desensitization.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BRUZZONE R, 1988, AM J PHYSIOL, V255, pG33, DOI 10.1152/ajpgi.1988.255.1.G33; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HADAC EM, 1996, IN PRESS PANCREAS; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; MADDEN BJ, 1995, PROTEIN SCI S2, V4, P153; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MILLER LJ, 1992, BIOCHEM BIOPH RES CO, V183, P396, DOI 10.1016/0006-291X(92)90494-6; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; OZCELEBI F, 1995, J BIOL CHEM, V270, P3435, DOI 10.1074/jbc.270.7.3435; POLLO DA, 1994, BBA-MOL CELL RES, V1224, P127, DOI 10.1016/0167-4889(94)90120-1; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302	26	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3750	3755						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631990				2022-12-27	WOS:A1996TV72400064
J	Gingras, D; White, D; Garin, J; Multigner, L; Job, D; Cosson, J; Huitorel, P; Zingg, H; Dumas, F; Gagnon, C				Gingras, D; White, D; Garin, J; Multigner, L; Job, D; Cosson, J; Huitorel, P; Zingg, H; Dumas, F; Gagnon, C			Purification, cloning, and sequence analysis of a M(r)=30,000 protein from sea urchin axonemes that is important for sperm motility - Relationship of the protein to a dynein light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; FLAGELLAR MICROTUBULES; MONOCLONAL-ANTIBODIES; MUTANTS; TUBULIN; ARMS	We have generated a series of monoclonal antibodies against axonemal proteins from sea urchin spermatozoa in order to identify novel proteins involved in the regulation of flagellar motility. The monoclonal antibody D405-14 inhibited the motility of demembranated-reactivated sperm models at low concentrations and recognized a single polypeptide of 33 kDa (p33) on immuno blots of sea urchin axonemal proteins. Fractionation of the axonemes with high salt solutions, heat, and detergent resulted in the selective extraction of p33 into a 0.6 M NaCl-soluble and a 0.5% sodium lauryl sarcosinate (Sarkosyl)-soluble form. Both forms of p33 were purified to apparent homogeneity by immunoaffinity chromatography on monoclonal antibody D405-14-Sepharose. We have also isolated and sequenced a full-length cDNA clone encoding the 33-kDa protein. The sequence predicts a polypeptide of 260 amino acids having a mass of 29,730 Da and an isoelectric point of 9.3. Sequence comparison indicates that p33 is 66% identical (74% similar) to the p28 light chain of axonemal inner dynein arm of Chlamydomonas reinhardtii. Taken together, these results suggest that we have identified a p28 light chain homolog in sea urchin sperm axoneme and that this protein may play a dynamic rob in flagellar motility.	MCGILL UNIV, ROYAL VICTORIA HOSP, UROL RES LAB, MONTREAL, PQ H3A 1A1, CANADA; CEA GRENOBLE, DEPT BIOL MOLEC & STRUCT, F-38054 GRENOBLE 9, FRANCE; UNIV PARIS 06, OBSERV OCEANOL, STN MARINE, URA 671 CNRS, F-06230 VILLEFRANCHE SUR MER, FRANCE; MCGILL UNIV, FAC MED, MONTREAL, PQ, CANADA; BIOTECHNOL RES INST, MONTREAL, PQ H4P 2R2, CANADA	McGill University; Royal Victoria Hospital; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; McGill University; National Research Council Canada			Zingg, Hans/GPS-9984-2022; Multigner, Luc/AAA-6214-2020; Multigner, Luc/I-2926-2015	Multigner, Luc/0000-0003-3205-8568; Multigner, Luc/0000-0003-3205-8568				ADAMS GMW, 1981, J CELL BIOL, V91, P69, DOI 10.1083/jcb.91.1.69; ADESSIC, 1995, J CELL SCI, V108, P3331; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAI DJ, 1982, CELL MOTIL CYTOSKEL, V2, P599, DOI 10.1002/cm.970020608; ASAI DJ, 1980, J CELL BIOL, V87, P114, DOI 10.1083/jcb.87.1.114; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; CURRY AM, 1993, CELL MOTIL CYTOSKEL, V24, P224, DOI 10.1002/cm.970240403; GAGNON C, 1994, MOL BIOL CELL, V5, P1051, DOI 10.1091/mbc.5.9.1051; GIBBONS BH, 1976, J CELL BIOL, V71, P823, DOI 10.1083/jcb.71.3.823; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARROW E, 1988, ANTIBODIES LAB MANUA, P511; HUANG B, 1979, J BIOL CHEM, V254, P3091; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDIZET M, 1995, MOL BIOL CELL, V6, P713, DOI 10.1091/mbc.6.6.713; LEDIZET M, 1995, MOL BIOL CELL, V6, P697, DOI 10.1091/mbc.6.6.697; MULTIGNER L, 1992, NATURE, V360, P33, DOI 10.1038/360033a0; MURRAY JM, 1991, INT REV CYTOL, V125, P47, DOI 10.1016/S0074-7696(08)61216-4; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OKUNO M, 1981, J CELL BIOL, V91, P689, DOI 10.1083/jcb.91.3.689; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; PIPERNO G, 1992, J CELL BIOL, V118, P1455, DOI 10.1083/jcb.118.6.1455; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; Sale W.S., 1989, CELL MOVEMENT, P89; STEPHENS R E, 1970, Journal of Molecular Biology, V47, P353, DOI 10.1016/0022-2836(70)90307-4; TIJSSEN P, 1985, PRACTICE THEORY ENZY, P329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS BD, 1986, J CELL BIOL, V101, P2085; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74	31	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12807	12813		10.1074/jbc.271.22.12807	http://dx.doi.org/10.1074/jbc.271.22.12807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662724	hybrid			2022-12-27	WOS:A1996UN47400020
J	Vasilyeva, E; Forgac, M				Vasilyeva, E; Forgac, M			3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate inhibits activity of the vacuolar (H+)-ATPase from bovine brain clathrin-coated vesicles by modification of a rapidly exchangeable, noncatalytic nucleotide binding site on the B subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; BEEF-HEART F1-ATPASE; H+-ATPASE; PROTON PUMP; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; CDNA SEQUENCE; ALPHA-SUBUNIT; V-ATPASES	It was previously observed that the B subunit of the tonoplast V-ATPase is modified by the photoactivated nucleotide analog 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate (BzATP) (Manolson, M. F., Rea, P. A., and Poole, R. J. (1985) J. Biol. Chem. 260, 12273-12279). We have further characterized the nucleotide binding sites on the V-ATPase and the interaction between BzATP and the B subunit. We observe that the V-ATPase isolated from bovine clathrin coated vesicles possesses approximately 1 mol of endogenous, tightly bound ATP/mol of V-ATPase complex. BzATP is not a substrate for the V-ATPase, but does act as a noncovalent inhibitor in the absence of irradiation changing the kinetic characteristics of ATP hydrolysis. Irradiation of the V-ATPase in the presence of [H-3]BzATP results primarily in modification of the 58-kDa B subunit, with complete inhibition of V-ATPase activity occurring upon modification of one B subunit per V-ATPase complex. Inhibition occurs as the result of modification of a rapidly (t(1/2) < 2 min) exchangeable site, and yet this site does not correspond to a catalytic site, as indicated by the effects of cysteine-modifying reagents which react with Cys(254) located at the catalytic sites on the A subunit. Thus, the noncatalytic nucleotide binding site modified by BzATP appears to be rapidly exchangeable. The site of [H-3]BzATP modification of the B subunit was localized to the region Ile(164) to Gln(171), which from the x-ray crystal structure of the homologous F-ATPase alpha subunit, is within 10 Angstrom of the ribose ring of ATP bound to the noncatalytic nucleotide binding site. Thus, despite the absence of a glycine-rich loop region in the B subunit, these data are consistent with a similar overall folding pattern for the V-ATPase B subunit and the F-ATPase alpha subunit.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1987, J BIOL CHEM, V262, P13765; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CROSS RL, 1982, J BIOL CHEM, V257, P2874; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HARRIS D A, 1973, Biochimica et Biophysica Acta, V314, P149, DOI 10.1016/0005-2728(73)90130-8; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1994, J BIOL CHEM, V269, P319; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V114, P171, DOI 10.1093/oxfordjournals.jbchem.a124150; KAMBOURIS NG, 1985, P NATL ACAD SCI USA, V82, P1950, DOI 10.1073/pnas.82.7.1950; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LEIMGRUBER RM, 1976, J BIOL CHEM, V251, P7103; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; LIU Q, 1994, J BIOL CHEM, V269, P31592; MAEDA M, 1976, BIOCHEM BIOPH RES CO, V70, P228, DOI 10.1016/0006-291X(76)91132-3; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; UCHIDA E, 1988, J BIOL CHEM, V263, P45; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEBER J, 1994, J BIOL CHEM, V269, P11261; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	61	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12775	12782		10.1074/jbc.271.22.12775	http://dx.doi.org/10.1074/jbc.271.22.12775			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662754	hybrid			2022-12-27	WOS:A1996UN47400015
J	Meng, HP; Leddy, JJ; Frank, J; Holland, P; Tuana, BS				Meng, HP; Leddy, JJ; Frank, J; Holland, P; Tuana, BS			The association of cardiac dystrophin with myofibrils/Z-disc regions in cardiac muscle suggests a novel role in the contractile apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; DILATED CARDIOMYOPATHY; EXCHANGE PROTEIN; HEART-MUSCLE; SARCOLEMMA; LOCALIZATION; MEMBRANE; HAMSTERS	Dystrophin serves a variety of roles at the cell membrane through its associations, and defects in the dystrophin gene can give rise to muscular dystrophy and genetic cardiomyopathy. We investigated localization of cardiac dystrophin to determine potential intracellular sites of association. Subcellular fractionation revealed that while the majority of dystrophin was associated with the sarcolemma, about 35% of the 427-kDa form of dystrophin was present in the myofibrils. The dystrophin homolog utrophin was detectable only in the sarcolemmal membrane and was absent from the myofibrils as were other sarcolemmal glycoproteins such as adhalin and the sodium-calcium exchanger. Extraction of myofibrils with KCl and detergents could not solubilize dystrophin. Dystrophin could only be dissociated from the myofibrillar protein complex in 5 M urea followed by sucrose density gradient centrifugation where it co-fractionated with one of two distinctly sedimenting peaks of actin. Immunoelectron microscopy of intracellular regions of cardiac muscle revealed a selective labeling of Z-discs by dystrophin antibodies. In the genetically determined cardiomyopathic hamster, strain CHF 147, the time course of development of cardiac insufficiency correlated with an overall 75% loss of myofibrillar dystrophin. These findings collectively show that a significant pool of the 427-kDa form of cardiac dystrophin was specifically associated with the contractile apparatus at the Z-discs, and its loss correlated with progression to cardiac insufficiency in genetic cardiomyopathy. The loss of distinct cellular pools of dystrophin may contribute to the tissue specific pathophysiology in muscular dystrophy.	UNIV OTTAWA, DEPT PHARMACOL, OTTAWA, ON K1H 8M5, CANADA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL & MED, LOS ANGELES, CA 90024 USA; MCGILL UNIV, MONTREAL NEUROL INST, MONTREAL, PQ H3A 2B4, CANADA	University of Ottawa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McGill University								AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BELCASTRO AN, 1991, MOL CELL BIOCHEM, V103, P113; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FRANK JS, 1994, AM J PHYSIOL-CELL PH, V267, pC1707, DOI 10.1152/ajpcell.1994.267.6.C1707; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0; HUNTER EG, 1984, CAN J PHYSIOL PHARM, V62, P1423, DOI 10.1139/y84-236; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, BIOCHEM BIOPH RES CO, V190, P589, DOI 10.1006/bbrc.1993.1089; JASMIN G, 1982, MUSCLE NERVE, V5, P20, DOI 10.1002/mus.880050105; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LI K, 1993, CARDIOVASC RES, V27, P968, DOI 10.1093/cvr/27.6.968; MAN NT, 1991, J CELL BIOL, V115, P1695; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MESSINA DA, 1994, J MOL CELL CARDIOL, V26, P937, DOI 10.1006/jmcc.1994.1111; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; NIGRO G, 1994, NEUROMUSCULAR DISORD, V4, P371, DOI 10.1016/0960-8966(94)90073-6; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PERENNEC J, 1992, BASIC RES CARDIOL, V87, P54, DOI 10.1007/BF00795390; PERI V, 1994, MOL CELL BIOCHEM, V130, P57, DOI 10.1007/BF01084268; PERI V, 1992, THESIS U OTTAWA; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SALVIATI G, 1989, BIOCHEM J, V258, P837, DOI 10.1042/bj2580837; SATO O, 1992, J BIOCHEM-TOKYO, V112, P631, DOI 10.1093/oxfordjournals.jbchem.a123951; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SEILER S, 1988, METHOD ENZYMOL, V157, P26; SOLE MJ, 1988, AM J CARDIOL, V62, pG20; TUANA BS, 1987, MOL CELL BIOCHEM, V76, P173; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; YOSHIDA K, 1993, MUSCLE NERVE, V16, P1161, DOI 10.1002/mus.880161104; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	51	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12364	12371		10.1074/jbc.271.21.12364	http://dx.doi.org/10.1074/jbc.271.21.12364			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647839	hybrid			2022-12-27	WOS:A1996UL66000041
J	Unzai, S; Hori, H; Miyazaki, G; Shibayama, N; Morimoto, H				Unzai, S; Hori, H; Miyazaki, G; Shibayama, N; Morimoto, H			Oxygen equilibrium properties of chromium(III)-iron(II) hybrid hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ELECTRON-PARAMAGNETIC RESONANCE; STATE HUMAN-HEMOGLOBIN; PROTOPORPHYRIN-IX; VALENCY HYBRIDS; LIGHT-ABSORPTION; LIGATION STATES; CARBON-MONOXIDE; LIGAND-BINDING; KINETICS	Cr(III)-Fe(II) hybrid hemoglobins, alpha(2)(Cr)beta(2)(Fe) and alpha(2)(Fe)beta(2)(Cr), in which hemes in either the alpha- or beta-subunits were substituted with chromium(III) protoporphyrin IX (Cr(III)PPIX), were prepared and characterized by oxygen equilibrium measurements. Because Cr(III)PPM binds neither oxygen molecules nor carbon monoxide, the oxygen equilibrium properties of Fe(II) subunits within these hybrids can be analyzed by a two-step oxygen equilibrium scheme. The oxygen equilibrium constants for both hybrids at the second oxygenation step agree with those for human adult hemoglobin at the last oxygenation step (at pH 6.5-8.4 with and without inositol hexaphosphate at 25 degrees C). The similarity between the effects of the Cr(III)PPM and each subunits' oxyheme on the oxygen equilibrium properties of the counterpart Fe(II) subunits within hemoglobin indicate the utility of Cr(III)PPM as a model for a permanently oxygenated heme within the hemoglobin molecule. We found that Cr(III)-Fe(II) hybrid hemoglobins have several advantages over cyanomet valency hybrid hemoglobins, which have been frequently used as a model system for partially oxygenated hemoglobins. In contrast to cyanomet heme, Cr(III)PPM within hemoglobin is not subject to reduction with dithionite or enzymatic reduction systems. Therefore, we could obtain more accurate and reasonable oxygen equilibrium curves of Cr(III)-Fe(II) hybrids in the presence of an enzymatic reduction system, and we could obtain single crystals of deoxy-alpha(2)(Cr)beta(2)(Fe) when grown in low salt solution in the presence of polyethylene glycol 1000 and 50 mM dithionite.	JICHI MED SCH,DEPT PHYS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University	Unzai, S (corresponding author), OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN.			Shibayama, Naoya/0000-0002-2208-1126				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALSTON K, 1984, HEMOGLOBIN, V8, P47, DOI 10.3109/03630268408996960; BANERJEE R, 1973, J MOL BIOL, V73, P455, DOI 10.1016/0022-2836(73)90093-4; BANERJEE R, 1969, J MOL BIOL, V42, P351, DOI 10.1016/0022-2836(69)90048-5; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1970, J MOL BIOL, V49, P461, DOI 10.1016/0022-2836(70)90257-3; BUCHLER JW, 1975, PORPHYRINS METALLOPO, P191; CASSOLY R, 1972, J BIOL CHEM, V247, P7332; CASSOLY R, 1971, BIOCHEM BIOPH RES CO, V44, P1015, DOI 10.1016/S0006-291X(71)80187-0; DAUGHERTY MA, 1994, BIOCHEMISTRY-US, V33, P10345, DOI 10.1021/bi00200a015; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P11182, DOI 10.1021/bi00160a032; EARLEY JE, 1965, TRANSITION METAL CHE, V1, P34; FIECHTNER MD, 1980, BIOCHEM BIOPH RES CO, V92, P277, DOI 10.1016/0006-291X(80)91549-1; FRONTICELLI C, 1993, BIOCHEMISTRY-US, V32, P1235, DOI 10.1021/bi00056a006; FUJII M, 1993, J BIOL CHEM, V268, P15386; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HOARD JL, 1971, SCIENCE, V174, P1295, DOI 10.1126/science.174.4016.1295; HORI H, 1991, BIOCHIM BIOPHYS ACTA, V1077, P392, DOI 10.1016/0167-4838(91)90556-F; IMAI K, 1977, J MOL BIOL, V109, P83, DOI 10.1016/S0022-2836(77)80047-8; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; Imai K, 1981, Methods Enzymol, V76, P470; Imai K, 1981, Methods Enzymol, V76, P438; KILMARTIN JV, 1971, BIOCHEM J, V124, P31, DOI 10.1042/bj1240031; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; LUISI B, 1989, J MOL BIOL, V206, P723, DOI 10.1016/0022-2836(89)90579-2; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; MAEDA T, 1972, BIOCHEMISTRY-US, V11, P3685, DOI 10.1021/bi00770a004; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; NAGAI K, 1977, J MOL BIOL, V111, P41, DOI 10.1016/S0022-2836(77)80130-7; OGAWA S, 1972, J MOL BIOL, V70, P315, DOI 10.1016/0022-2836(72)90542-6; OGAWA S, 1971, BIOCHEM BIOPH RES CO, V42, P9, DOI 10.1016/0006-291X(71)90354-8; PERRELLA M, 1994, BIOCHEMISTRY-US, V33, P10358, DOI 10.1021/bi00200a016; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PHILO JS, 1990, J BIOL CHEM, V265, P139; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; SCHEIDT WR, 1977, ACCOUNTS CHEM RES, V10, P339, DOI 10.1021/ar50117a005; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHIBAYAMA N, 1993, BIOCHEMISTRY-US, V32, P8792, DOI 10.1021/bi00085a009; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHIBAYAMA N, 1995, BIOCHEMISTRY-US, V34, P4773, DOI 10.1021/bi00014a035; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SHIBAYAMA N, 1991, BIOCHEMISTRY-US, V30, P8158, DOI 10.1021/bi00247a010; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SUMMERVILLE DA, 1977, J AM CHEM SOC, V99, P8195, DOI 10.1021/ja00467a012; SZABO A, 1975, BIOCHEMISTRY-US, V14, P931, DOI 10.1021/bi00676a009; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P17049; WARD KB, 1975, J MOL BIOL, V98, P161, DOI 10.1016/S0022-2836(75)80107-0; WATERMAN MR, 1970, J BIOL CHEM, V245, P5847; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493	54	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12451	12456		10.1074/jbc.271.21.12451	http://dx.doi.org/10.1074/jbc.271.21.12451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647851	hybrid			2022-12-27	WOS:A1996UL66000053
J	Chitnis, VP; Jung, YS; Albee, L; Golbeck, JH; Chitnis, PR				Chitnis, VP; Jung, YS; Albee, L; Golbeck, JH; Chitnis, PR			Mutational analysis of photosystem I polypeptides - Role of PsaD and the Lysyl 106 residue in the reductase activity of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; SUBUNIT; PROTEIN; FERREDOXIN; BINDING; GENE; SPINACH; IDENTIFICATION; BIOTINYLATION; PLASTOCYANIN	The ADC4 mutant of the cyanobacterium Synechocystis sp. PCC 6803 was studied to determine the structural and functional consequences of the absence of PsaD in photosystem I. Isolated ADC4 membranes were shown to be deficient in ferredoxin-mediated NADP(+) reduction, even though charge separation between P700 and F-A/F-B occurred with high efficiency. Unlike the wild type, F-B became preferentially photoreduced when ADC4 membranes were illuminated at 15 K, and the EPR line shapes were relatively broad. Membrane fragments oriented in two dimensions on thin mylar films showed that the g tensor axes of F-A(-) and F-B(-) were identical in the ADC4 and wild type strains, implying that PsaC is oriented similarly on the reaction center. PsaC and the F-A/F-B iron-sulfur clusters are lost more readily from the ADC4 membranes after treatment with Triton X-100 or chaotropic agents, implying a stabilizing role for PsaD. The specific role of Lys(106) of PsaD, which can be crosslinked to Glu(93) of ferredoxin (Lelong et al. (1994) J. Biol. Chem. 269, 10034-10039), was probed by site-directed mutagenesis. Chemical cross-linking and protease treatment experiments did not reveal any drastic alterations in the conformation of the mutant PsaD proteins. The EPR spectra of F-A and F-B in membranes of the Lys(106) mutants were similar to those of the wild type. Membranes of all Lys(106) mutants showed wild type rates of flavodoxin reduction and flavodoxin-mediated NADP(+) reduction, but had 10-54% decrease in the ferredoxin-mediated NADP(+) reduction rates. This implies that Lys(106) is a dispensable component of the docking site on the reducing side of photosystem I and an ionic interaction between Lys(106) of PsaD and Glu(93) of ferredoxin is not essential for electron transfer to ferredoxin. These results demonstrate that PsaD serves distinct roles in modulating the EPR spectral characteristics of F-A and F-B in stabilizing PsaC on the reaction center, and in facilitating ferredoxin-mediated NADP(+) photoreduction on the reducing side of photosystem I.	KANSAS STATE UNIV,DIV BIOL,MANHATTAN,KS 66506; UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	Kansas State University; University of Nebraska System; University of Nebraska Lincoln								ADMAN ET, 1973, J BIOL CHEM, V248, P3987; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; BEARDEN AJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P456, DOI 10.1016/0005-2728(72)90262-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; FRANKEL LK, 1992, BIOCHEMISTRY-US, V31, P11059, DOI 10.1021/bi00160a015; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V321, P229; HERVAS M, 1992, PHOTOCHEM PHOTOBIOL, V56, P319, DOI 10.1111/j.1751-1097.1992.tb02166.x; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; LELONG C, 1994, J BIOL CHEM, V269, P10034; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SETIF PQY, 1994, BIOCHEMISTRY-US, V33, P8495, DOI 10.1021/bi00194a014; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, J BIOL CHEM, V269, P21512; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1994, PLANT MOL BIOL, V2624, P294; XU QA, 1994, J BIOL CHEM, V269, P3205; XU QA, 1994, PLANT PHYSIOL, V106, P617, DOI 10.1104/pp.106.2.617; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	36	45	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11772	11780		10.1074/jbc.271.20.11772	http://dx.doi.org/10.1074/jbc.271.20.11772			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662633	hybrid			2022-12-27	WOS:A1996UL25000032
J	Gora, M; Grzybowska, E; Rytka, J; LabbeBois, R				Gora, M; Grzybowska, E; Rytka, J; LabbeBois, R			Probing the active-site residues in Saccharomyces cerevisiae ferrochelatase by directed mutagenesis - In vivo and in vitro analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FERROCHELATASE; MOLECULAR-CLONING; YEAST; GENE; SEQUENCE; DISRUPTION; EXPRESSION; VECTORS; MUTANT	Ferrochelatase is a mitochondrial inner membrane-bound enzyme that catalyzes the insertion of ferrous iron into protoporphyrin, the terminal step in protoheme biosynthesis. The functional/structural roles of 10 invariant amino acid residues were investigated by site-directed mutagenesis in the yeast Saccharomyces cerevisiae ferrochelatase. The mutant enzymes were expressed in a yeast strain lacking the ferrochelatase gene HEM15 and in Escherichia coli. The kinetic parameters of the mutant enzymes were determined for the enzymes associated with the yeast membranes and the enzymes in the bacterial soluble fraction, They were compared with the in vivo functioning of the mutant enzymes. The main conclusions are the following, Glu-314 is critical for catalysis, and we suggest that it is the base responsible for abstracting the N-pyrrole proton(s). His-235 is essential for metal binding, Asp-246 and Tyr-248 are also involved in metal binding in a synergistic manner. The K-m for protoporphyrin was also increased in the H235L, D246A, and Y248L mutants, suggesting that the binding sites of the two substrates are not independent of each other. The R87A, Y95L, Q111E, Q273E, W282L, and F308A mutants had 1.2-2-fold increased V-m and 4-10-fold increased K-m values for protoporphyrin, but the amount of heme made in vivo was 10-100% of the normal value. These mutations probably affected the geometry of the active center, resulting in improper positioning of protoporphyrin.	UNIV PARIS 07,INST JACQUES MONOD,LAB BIOCHIM PORPHYRINES,F-75251 PARIS,FRANCE; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02106 WARSAW,POLAND	UDICE-French Research Universities; Universite Paris Cite; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences			Gora, Monika/AAB-9577-2020; Grzybowska, Ewa/F-2711-2013	Gora, Monika/0000-0002-8554-663X; 				ABBAS A, 1993, J BIOL CHEM, V268, P8541; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DAILEY HA, 1986, J BIOL CHEM, V261, P7902; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; DAILEY HA, 1985, BIOCHEMISTRY-US, V24, P1287, DOI 10.1021/bi00327a003; DAILEY HA, 1984, J BIOL CHEM, V259, P2711; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P221, DOI 10.1007/BF02110037; FRANCO R, 1995, J BIOL CHEM, V270, P26352, DOI 10.1074/jbc.270.44.26352; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORA M, 1996, IN PRESS BIOCHIMIE P; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; Hansson M, 1995, PROTEINS, V23, P607, DOI 10.1002/prot.340230419; HANSSON M, 1994, EUR J BIOCHEM, V220, P201, DOI 10.1111/j.1432-1033.1994.tb18615.x; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KOHNO H, 1994, BBA-PROTEIN STRUCT M, V1209, P95, DOI 10.1016/0167-4838(94)90142-2; Labbe-Bois Rosine, 1994, V11, P413; LABBEBOIS R, 1977, MOL GEN GENET, V156, P177, DOI 10.1007/BF00283490; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavallee DK, 1988, MECH PRINCIPLES ENZY, P279; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, PLANT PHYSIOL, V105, P769, DOI 10.1104/pp.105.2.769; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; PERELLA FW, 1988, ANAL BIOCHEM, V174, P437; Rose MD., 1990, METHODS YEAST GENETI; RYTKA J, 1984, BIOCHEM J, V218, P405, DOI 10.1042/bj2180405; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH AG, 1994, J BIOL CHEM, V269, P13405; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1993, TOHOKU J EXP MED, V170, P1	39	51	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11810	11816		10.1074/jbc.271.20.11810	http://dx.doi.org/10.1074/jbc.271.20.11810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662602	hybrid			2022-12-27	WOS:A1996UL25000038
J	Poppleton, H; Sun, H; Fulgham, D; Bertics, P; Patel, TB				Poppleton, H; Sun, H; Fulgham, D; Bertics, P; Patel, TB			Activation of G(s alpha) by the epidermal growth factor receptor involves phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC ADENYLATE-CYCLASE; REGULATORY PROTEIN; TYROSINE KINASE; EGF RECEPTOR; GS-ALPHA; BINDING; IDENTIFICATION; SITE; RECONSTITUTION; PURIFICATION	Previous studies from our laboratory have shown that epidermal growth factor (EGF) stimulates cAMP accumulation in the heart via a process involving G(s alpha) and the EGF receptor (EGFR) protein tyrosine kinase activity (Nair, B. G., Parikh, B., Milligan, G., and Patel, T. B. (1990) J. Biol. Chem. 265, 21317-21322; Nair, B. G., and Patel, T. B. (1993) Biochem. Pharmacol. 46, 1239-1245). Therefore, studies were performed to investigate the hypothesis that the EGFR protein tyrosine kinase phosphorylates G(s alpha) and activates this protein. Employing purified EGFR and G(s alpha), we have demonstrated that the EGFR kinase phosphorylates G(s alpha) in a time-dependent manner with a stoichiometry of 2 mol of phosphate incorporated/mol of G(s alpha). As determined by phosphoamino acid analysis, the phosphorylation of G(s alpha) by the EGFR kinase was exclusively on tyrosine residues. Interestingly, GDP and guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) inhibited the phosphorylation of G(s alpha) without altering EGFR autophosphorylation, However, G protein beta gamma subunits protected against GDP- and GTP gamma S-mediated inhibition of phosphorylation of G(s alpha). In functional studies, phospho-G(s alpha) demonstrated a greater GTPase activity and also a greater capacity to bind GTP gamma S as compared to the nonphosphorylated G(s alpha). Moreover, the phospho-G(s alpha) augmented adenylyl cyclase activity in S49 cyc(-) cell membranes to a greater extent than its nonphosphorylated counterpart. Therefore, we conclude that phosphorylation of G(s alpha) on tyrosine residues by the EGFR kinase activates this G protein and increases its ability to stimulate adenylyl cyclase.	UNIV TENNESSEE, CTR HLTH SCI, DEPT PHARMACOL, MEMPHIS, TN 38163 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL 48308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BUSHFIELD M, 1991, EUR J BIOCHEM, V192, P537; CADENA DL, 1994, J BIOL CHEM, V269, P260; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; HART MJ, 1990, J BIOL CHEM, V265, P5990; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; MUMBY S, 1988, J BIOL CHEM, V263, P2020; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1993, BIOCHEM PHARMACOL, V46, P1239, DOI 10.1016/0006-2952(93)90473-A; NAIR BG, 1993, GROWTH FACTORS, V8, P41, DOI 10.3109/08977199309029133; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	32	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6947	6951		10.1074/jbc.271.12.6947	http://dx.doi.org/10.1074/jbc.271.12.6947			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636123	hybrid			2022-12-27	WOS:A1996UB15700058
J	Streicher, R; Kotzka, J; MullerWieland, D; Siemeister, G; Munck, M; Avci, H; Krone, W				Streicher, R; Kotzka, J; MullerWieland, D; Siemeister, G; Munck, M; Avci, H; Krone, W			SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; LEUCINE ZIPPER PROTEIN; MESSENGER-RNA; LDL-RECEPTOR; HUMAN-LIVER; GENE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; SEQUENCE	Transcription of the low density lipoprotein (LDL) receptor gene is regulated by intracellular cholesterol concentration, hormones, and growth factors. We studied the mechanisms by which insulin and estradiol stimulate promoter activity of the LDL receptor gene. Hormonal effects were analyzed in HepG2 cells after transient transfection with promotor reporter gene constructs. Successive 5' deletions of the LDL receptor promoter fragment from -537 to +88 revealed the sterol regulatory element 1 (SRE-1) between -65 and -56 as an insulin- and estradiol-sensitive cis-element. If the SRE-1 is point mutated at position -59 (C to G), which abolishes the binding of the SRE binding proteins (SREBP-1 and SREBP-2), no insulin or estradiol stimulatory effect on reporter gene expression was observed, indicating a role of SRE binding proteins in this regulatory mechanism, The concentration of the 125-kDa membrane-integrated SREBP-1 precursor protein in LDL repressed HepG2 cells is not altered by hormone treatment. Concentrations of SREBP-1 mRNA and precursor protein are reduced significantly by high and stable expression of an SREBP-1 antisense cDNA fragment in HepG2 cells (SREBP1(-) cells). Transfection of SREBP1(-) cells with promoter construct phLDL4 (-105 to +88) reduces induction of reporter gene activity by insulin and insulin-like growth factor-I to 35 and 17%, respectively, compared with HepG2 cells. The stimulatory effect of estradiol remains unchanged, and the inductions by pravastatin are enlarged. We conclude that different regulatory effects converge at SRE-1, but that SREBP-1 is selectively involved in the signal transduction pathway of insulin and insulin-like growth factor-I leading to LDL receptor gene activation.	UNIV COLOGNE,KLIN 2,D-50924 COLOGNE,GERMANY; UNIV COLOGNE,POLIKLIN INNERE MED,D-50924 COLOGNE,GERMANY	University of Cologne; University of Cologne				Kotzka, Jorg/0000-0003-1173-9372; , Gerhard/0000-0002-4712-0531				ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KRONE W, 1988, DIABETES, V37, P1386, DOI 10.2337/diabetes.37.10.1386; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; NANJEE MN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P151, DOI 10.1016/0005-2760(90)90182-W; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; Sambrook J., 2002, MOL CLONING LAB MANU; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STAELS B, 1990, J LIPID RES, V31, P1211; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; WADE DP, 1989, EUR J BIOCHEM, V181, P727, DOI 10.1111/j.1432-1033.1989.tb14784.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WINDLER EET, 1980, J BIOL CHEM, V255, P464; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	27	132	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7128	7133		10.1074/jbc.271.12.7128	http://dx.doi.org/10.1074/jbc.271.12.7128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636148	hybrid			2022-12-27	WOS:A1996UB15700083
J	Fukunaga, BN; Hankinson, O				Fukunaga, BN; Hankinson, O			Identification of a novel domain in the aryl hydrocarbon receptor required for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN-RESPONSIVE ENHANCER; LIGANDED AH RECEPTOR; LOOP-HELIX PROTEIN; GENE-TRANSCRIPTION; DROSOPHILA; SEQUENCE; MOUSE; RECOGNITION; ACTIVATION; REGULATOR	The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that binds DNA in the form of a heterodimer with the AHR nuclear translocator protein (ARNT). Both proteins possess basic helix-loop-helix motifs. ARNT binds to the side of the xenobiotic responsive element (XRE) that resembles an E-box (the sequence recognized by the majority of other basic helix-loop-helix proteins), whereas ABR binds to the side of the XRE that does not conform to the E-box sequence, The basic region of ARNT closely resembles those of other E-box-binding proteins, whereas the ''nominal basic region'' of AHR (amino acids 27-39), although required for XRE binding, deviates from this consensus. By extensive mutational analysis it is shown here that an additional block of amino acids of AHR (from tyrosine 9 to lysine 20) that contains a highly basic segment is required for XRE binding and transcriptional activation, Deletion of the first nine amino acids negates XRE binding. Substitution of either tyrosine 9 or arginine 14 with alanine eliminates XRE binding, whereas alanine substitutions at certain other sites within the block reduce but do not eliminate binding. The reported absence of the first nine amino acids in the purified protein may therefore be artifactual. These results suggest that the amino acids of AHR involved in binding to the XRE constitute a novel DNA-binding domain, comprising amino acids located within and amino-terminal to the nominal basic region.	UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, LAB STRUCT BIOL & MOLEC MED, LOS ANGELES, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; BACSI SG, 1995, MOL PHARMACOL, V47, P432; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HS, 1994, J BIOL CHEM, V269, P27554; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JORDAN KL, 1994, ONCOGENE, V9, P1177; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MAHON MJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P166, DOI 10.1006/abbi.1995.1217; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHAFER MW, 1993, ARCH BIOCHEM BIOPHYS, V307, P267, DOI 10.1006/abbi.1993.1589; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	45	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3743	3749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631989				2022-12-27	WOS:A1996TV72400063
J	Ye, XH; Robinson, MB; Batshaw, ML; Furth, EE; Smith, I; Wilson, JM				Ye, XH; Robinson, MB; Batshaw, ML; Furth, EE; Smith, I; Wilson, JM			Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-TRANSPLANTATION; GENE; MOUSE; EXPRESSION; MUTATION; HEPATOCYTES; TOXICITY	A murine model of ornithine transcarbamylase (OTC) deficiency was used in this study to evaluate the efficacy of recombinant adenoviruses for correcting the metabolic defect in liver. Recombinant adenoviruses deleted in E1 and containing a human OTC cDNA expressed little functional OTC enzyme in vivo and had no observable impact on the underlying metabolic abnormalities of the OTC-deficient mouse (i.e. elevated urinary orotate and serum glutamine). E1-deleted vectors were improved through the use of the strong constitutive promoter from cytomegalovirus driving the normal murine homolog of OTC cDNA and the ablation of E2a with a temperature-sensitive mutation. Infusion of this improved vector into the mouse model was associated with a complete normalization of liver OTC enzyme activity that persisted for at least 2 months with complete but transient correction in serum glutamine and urine erotic acid. These studies illustrate the utility of improved adenoviral vectors in the treatment of liver metabolic disease.	UNIV PENN,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104; CHILDRENS HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Ye, XH (corresponding author), UNIV PENN,MED CTR,WISTAR INST,INST HUMAN GENE THERAPY,RM 204,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009031, P30DK047757] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32649] Funding Source: Medline; NIDDK NIH HHS [DK09031, DK47757] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batshaw ML, 1995, GENE THER, V2, P743; BATSHAW ML, 1982, NEW ENGL J MED, V306, P1387, DOI 10.1056/NEJM198206103062303; BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015; BRUSILOW SW, 1989, J CHROMATOGR-BIOMED, V493, P388, DOI 10.1016/S0378-4347(00)82746-2; BRUSILOW SW, 1995, METABOLIC BASIS INHE, V1, P1187; CAVARD C, 1988, NUCLEIC ACIDS RES, V16, P2099, DOI 10.1093/nar/16.5.2099; CROMBLEHOLME TM, 1994, SEMIN PERINATOL, V18, P376; DOOLITTLE DP, 1974, J HERED, V65, P194, DOI 10.1093/oxfordjournals.jhered.a108500; ENGELHARDT JF, 1994, HUM GENE THER, V5, P1217, DOI 10.1089/hum.1994.5.10-1217; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENSINGER MJ, 1972, J VIROL, V10, P328, DOI 10.1128/JVI.10.3.328-339.1972; GOLDMAN MJ, 1995, HUM GENE THER, V6, P839, DOI 10.1089/hum.1995.6.7-839; GROSSMAN M, 1992, HUM GENE THER, V3, P501, DOI 10.1089/hum.1992.3.5-501; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HODGES PE, 1989, P NATL ACAD SCI USA, V86, P4142, DOI 10.1073/pnas.86.11.4142; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JONES SN, 1990, J BIOL CHEM, V265, P14684; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LARGILLIERE C, 1989, J PEDIATR-US, V115, P415, DOI 10.1016/S0022-3476(89)80843-1; LEE JT, 1989, J CLIN INVEST, V84, P1762, DOI 10.1172/JCI114360; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MIZUTANI A, 1968, J HISTOCHEM CYTOCHEM, V16, P172, DOI 10.1177/16.3.172; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; NAGATA N, 1991, AM J MED GENET, V39, P228, DOI 10.1002/ajmg.1320390226; QURESHI IA, 1979, PEDIATR RES, V13, P807, DOI 10.1203/00006450-197907000-00003; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; TODO S, 1992, HEPATOLOGY, V15, P419, DOI 10.1002/hep.1840150311; TUCHMAN M, 1989, NEW ENGL J MED, V320, P1498; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; YANG Y, 1996, IN PRESS GENE THER; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, P NATL ACAD SCI USA, V92, P7257, DOI 10.1073/pnas.92.16.7257; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4	39	131	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3639	3646						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631974				2022-12-27	WOS:A1996TV72400048
J	Boffa, LC; Morris, PL; Carpaneto, EM; Louissaint, M; Allfrey, VG				Boffa, LC; Morris, PL; Carpaneto, EM; Louissaint, M; Allfrey, VG			Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nucleosome containing a unique AR gene sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-SUBSTITUTED POLYAMIDE; CONSERVED CORE DOMAIN; AFFINITY-CHROMATOGRAPHY; STRAND-DISPLACEMENT; SODIUM BUTYRATE; C-FOS; DNA; ACTIVATION; CHROMATIN; PNA	The DNA sequence of the genes for the androgen receptor (AR) and TATA-binding protein (TBP), like many other genes encoding transcription factors, contains a series of tandem CAG repeats, Here we explore the capacity of complementary peptide nucleic acids (PNAs) to invade the CAG triplets of the AR and TBP genes in human prostatic cancer cells and show that the PNAs readily entered the nuclei of lysolecithin-permeabilized cells and effectively inhibited sense transcription of unique AR and TBP DNA sequences downstream of the site of PNA;DNA hybridization, but not upstream of that site, These PNAs had Little or no effect on transcription of the c-myc gene, which lacks a CAG triplet domain. Conversely, a PNA complementary to a unique sequence of the c-myc gene did not inhibit transcription of the AR or TBP genes but did inhibit c-myc transcription. Comparisons of PNA effects on sense and antisense transcription of the AR, TBP, and c-myc genes confirm that progression of the RNA polymerase complex beyond the site of PNA DNA hybridization is impaired in both directions. Suppression of the AR gene results in refolding of a transcriptionally active nucleosome containing a unique 17-mer AR DNA sequence.	IST,IST NAZL RIC CANC,DEPT EXPTL ONCOL,I-16132 GENOA,ITALY; ROCKEFELLER UNIV,POPULAT COUNCIL,NEW YORK,NY 10021; ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021	University of Genoa; IRCCS AOU San Martino IST; Population Council; Rockefeller University; Rockefeller University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA014908] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA14908] Funding Source: Medline; NICHD NIH HHS [R01 HD16149] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P7518, DOI 10.1073/pnas.90.16.7518; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BOFFA LC, 1995, P NATL ACAD SCI USA, V92, P1901, DOI 10.1073/pnas.92.6.1901; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3182; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P23409; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; DAHLE CE, 1993, BIOTECHNIQUES, V15, P1102; DEMIDOV VV, 1995, P NATL ACAD SCI USA, V92, P2637, DOI 10.1073/pnas.92.7.2637; DEMIDOV VV, 1994, NUCLEIC ACIDS RES, V22, P5218, DOI 10.1093/nar/22.24.5218; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; GASPAR ML, 1990, MOL ENDOCRINOL, V4, P1600, DOI 10.1210/mend-4-10-1600; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; LINDZEY J, 1994, VITAM HORM, V49, P383; MAHTRE AN, 1993, NAT GENET, V5, P184; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PRIOR CP, 1983, CELL, V34, P1038; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENBERG MP, 1994, BIOCHEM BIOPH RES CO, V198, P74, DOI 10.1006/bbrc.1994.1011; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TILLEY WD, 1990, CANCER RES, V50, P5382; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; WALKER J, 1990, J BIOL CHEM, V265, P5736; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	45	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13228	13233		10.1074/jbc.271.22.13228	http://dx.doi.org/10.1074/jbc.271.22.13228			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662737				2022-12-27	WOS:A1996UN47400083
J	Groupp, ER; DonovanPeluso, M				Groupp, ER; DonovanPeluso, M			Lipopolysaccharide induction of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the tissue factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR EGR-1; NF-KAPPA-B; MONOCYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODY; BLOOD MONOCYTES; FACTOR GENE; FOS; EXPRESSION; PHOSPHORYLATION	These studies examine the molecular basis for increased transcription of tissue factor (TF) in THP-1 cells stimulated with lipopolysaccharide (LPS). DNase I footprinting identified six sites of protein-DNA interaction between -383 and the cap site that varied between control and induced extracts. Four footprints show qualitative differences in nuclease sensitivity. Footprints I (-85 to -52) and V (-197 to -175) are induction-specific and localize to regions of the promoter that mediate serum, phorbol ester, partial LPS response (-111 to +14), and the major LPS inducible element (-231 to -172). Electrophoretic mobility shift assays with the -231 to -172 probe demonstrate JunD and Fos binding in both control and induced nuclear extracts; however, binding of c-Jun is only detected following LPS stimulation. Antibody inhibition studies implicate binding of Ets-1 or Ets-2 to the consensus site between -192 and -177, a region that contains an induction-specific footprint. The proximal region (-85 to -52), containing the second inducible footprint, binds Egr-1 following induction. These data suggest that LPS stimulation of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the TF promoter and implicates these factors in the transcriptional activation of TF mRNA synthesis.	UNIV PITTSBURGH, DEPT PATHOL, SCH MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCRR NIH HHS [1P41RR06009] Funding Source: Medline; NHLBI NIH HHS [1R29HL45621-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045621] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHILES TC, 1991, J IMMUNOL, V146, P1730; CONKLING PR, 1988, BLOOD, V72, P128; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GENG Y, 1993, J IMMUNOL, V151, P6692; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HROMAS R, 1994, INT J HEMATOL, V59, P257; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LYBERG T, 1981, BIOCHEM J, V194, P699, DOI 10.1042/bj1940699; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MORRISSEY JH, 1989, OXFORD SURVEYS EUKAR, P67; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIEMETZ J, 1977, BLOOD, V49, P947; NIEMETZ J, 1971, NATURE-NEW BIOL, V232, P247, DOI 10.1038/newbio232247a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RYSECK RP, 1991, ONCOGENE, V6, P533; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SETH A, 1993, ONCOGENE, V8, P1783; SLAPAK CA, 1993, J BIOL CHEM, V268, P12267; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TERNISIEN C, 1993, THROMB HAEMOSTASIS, V70, P800; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VOT PK, ADV CANCER RES, V55, P1; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	66	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12423	12430		10.1074/jbc.271.21.12423	http://dx.doi.org/10.1074/jbc.271.21.12423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647847	hybrid			2022-12-27	WOS:A1996UL66000049
J	Hailman, E; Albers, JJ; Wolfbauer, G; Tu, AY; Wright, SD				Hailman, E; Albers, JJ; Wolfbauer, G; Tu, AY; Wright, SD			Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN CONVERSION; ACUTE PHASE REACTANT; LPS BINDING-PROTEIN; HUMAN-PLASMA; POLYMYXIN-B; CD14; ENDOTOXIN; COMPLEXES; SERUM; CELLS	Phospholipid transfer protein (PLTP) and lipopolysaccharide-binding protein (LBP) are lipid transfer proteins found in human plasma. PLTP shares 24% sequence similarity with LBP. PLTP mediates the transfer and exchange of phospholipids between lipoprotein particles, whereas LBP transfers bacterial lipopolysaccharide (LPS) either to lipoprotein particles or to CD14, a soluble and cell-surface receptor for LPS, We asked whether PLTP could interact with LPS and mediate the transfer of LPS to lipoproteins or to CD14, PLTP was able to bind and neutralize LPS: incubation of LPS with purified recombinant PLTP (rPLTP) resulted in the inhibition of the ability of LPS to stimulate adhesive responses of neutrophils, and addition of rPLTP to blood inhibited cytokine production in response to LPS. Transfer of LPS by rPLTP was examined using fluorescence dequenching experiments and native gel electrophoresis. The results suggested that rPLTP was able to mediate the exchange of LPS between micelles and the transfer of LPS to reconstituted HDL particles, but it did not transfer LPS to CD14. Consonant with these findings, rPLTP did not mediate CD14-dependent adhesive responses of neutrophils to LPS. These results suggest that while PLTP and LBP both bind and transfer LPS, PLTP is unable to transfer LPS to CD14 and thus does not mediate responses of cells to LPS.	ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA; UNIV WASHINGTON, DEPT MED, NW LIPID RES LABS, SEATTLE, WA 98103 USA	Rockefeller University; University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30086] Funding Source: Medline; NIAID NIH HHS [AI 30556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; DAY JR, 1994, J BIOL CHEM, V269, P9388; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1994, J BIOL CHEM, V269, P8172; HAZIOT A, 1994, J ENDOTOXIN RES, V1, P73; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; KUSUNOKI T, 1995, J EXP MED, V182, P1673, DOI 10.1084/jem.182.6.1673; LARRICK JW, 1994, J IMMUNOL, V152, P231; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; MASSEY JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P124, DOI 10.1016/0005-2760(85)90038-4; MASUCCIMAGOULAS L, 1995, J CLIN INVEST, V95, P1587, DOI 10.1172/JCI117832; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RIBI E, 1966, J BACTERIOL, V92, P1493, DOI 10.1128/JB.92.5.1493-1509.1966; Rietschel E T, 1991, Infect Dis Clin North Am, V5, P753; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; THEOFAN G, 1994, J IMMUNOL, V152, P3623; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; WAECHTER DE, 1982, P NATL ACAD SCI-BIOL, V79, P1106, DOI 10.1073/pnas.79.4.1106; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yu B, 1996, J BIOL CHEM, V271, P4100	41	151	157	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12172	12178		10.1074/jbc.271.21.12172	http://dx.doi.org/10.1074/jbc.271.21.12172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647810	hybrid			2022-12-27	WOS:A1996UL66000012
J	Hansen, LH; Wang, XZ; Kopchick, JJ; Bouchelouche, P; Nielsen, JH; Galsgaard, ED; Billestrup, N				Hansen, LH; Wang, XZ; Kopchick, JJ; Bouchelouche, P; Nielsen, JH; Galsgaard, ED; Billestrup, N			Identification of tyrosine residues in the intracellular domain of the growth hormone receptor required for transcriptional signaling and stat5 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; FACTOR-I; CELLS; KINASE; PROTEIN; PHOSPHORYLATION; PROLACTIN; TISSUE; FAMILY; LIVER	The binding of growth hormone (GH) to its receptor results in its dimerization followed by activation of Jak2 kinase and tyrosine phosphorylation of the GH receptor itself, as well as Jak2 and the transcription factors Stat1, -3, and -5. In order to study the role of GH receptor tyrosine phosphorylation in intracellular signaling, we constructed GH receptors in which combinations of tyrosines were mutated to phenylalanines. We identified three tyrosine residues at positions 534, 566, and 627 that were required for activation of GH-stimulated transcription of the serine protease inhibitor (Spi) 2.1 promoter. Any of these three tyrosines is able to independently mediate GH-induced transcription, indicating redundancy in this part of the GH receptor. Tyrosine phosphorylation was not required for GH stimulation of mitogen-activated protein (MAP) kinase activity or for GH-stimulated Ca2+ channel activation since these pathways were normal in cells expressing a GH receptor in which all eight intracellular tyrosines were mutated to phenylalanines. Activation of Stat5 by GH was, however, abolished in cells expressing the GH receptor lacking intracellular tyrosines. This study demonstrates that specific tyrosines in the GH receptor are required for transcriptional signaling possibly by their role in the activation of transcription factor Stat5.	HAGEDORN RES INST, DK-2820 GENTOFTE, DENMARK; OHIO UNIV, EDISON BIOTECHNOL INST, ATHENS, OH 45701 USA; UNIV COPENHAGEN, GENTOFTE HOSP, DEPT CLIN CHEM, DK-2820 GENTOFTE, DENMARK	Novo Nordisk; Hagedorn Research Institute; University System of Ohio; Ohio University; University of Copenhagen; Herlev & Gentofte Hospital				Bouchelouche, Pierre/0000-0002-0441-8194; Nielsen, Jens Hoiriis/0000-0001-8252-3048; Billestrup, Nils/0000-0002-4968-8067				ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ILONDO MM, 1994, BIOCHEM BIOPH RES CO, V202, P391, DOI 10.1006/bbrc.1994.1940; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LOBIE PE, 1995, J BIOL CHEM, V270, P21745, DOI 10.1074/jbc.270.37.21745; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG XZ, 1993, MOL CELL ENDOCRINOL, V94, P89, DOI 10.1016/0303-7207(93)90055-O; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; YOON JB, 1987, J BIOL CHEM, V262, P4284; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12669	12673		10.1074/jbc.271.21.12669	http://dx.doi.org/10.1074/jbc.271.21.12669			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647880	hybrid			2022-12-27	WOS:A1996UL66000082
J	Kojima, R; Randall, J; Brenner, BM; Gullans, SR				Kojima, R; Randall, J; Brenner, BM; Gullans, SR			Osmotic stress protein 94 (Osp94) - A new member of the Hsp110/SSE gene subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE BINDING DOMAIN; HSP70 PROTEIN; ATPASE DOMAIN; CELL-LINE; EXPRESSION	Preservation of cell viability and function in the hyperosmolar environment of the renal medulla is a complex process that requires selective gene expression. We have identified a new member of the heat shock protein (hsp) 70 superfamily that is up regulated in renal inner medullary collecting duct cells (mIMCD3 cells) during exposure to hyperosmotic NaCl stress. Known as osmotic stress protein 94, or Osp94, this 2935-base pair cDNA encodes an 838-amino acid protein that shows greatest homology to the recently discovered hsp110/SSE gene subfamily. Like the hsps, Osp94 has a putative amino-terminal ATP-binding domain and a putative carboxyl-terminal peptide-binding domain. The in vitro translated Osp94 product migrated as a 105-110-kDa protein on SDS-polyacrylamide gel electrophoresis. In mIMCD3 cells, Osp94 mRNA expression was greatly upregulated by hyperosmotic NaCl or heat stress. In mouse kidney, Osp94 mRNA expression paralleled the known corticomedullary osmolality gradient showing highest expression in the inner medulla. Moreover, inner medullary Osp94 expression was increased during water restriction when osmolality is known to increase. Thus, Osp94 is a new member of the hsp110/SSE stress protein subfamily and likely acts as a molecular chaperone.	BRIGHAM & WOMENS HOSP,DIV RENAL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MEIJO UNIV,FAC PHARM,DEPT PHARMACOL,NAGOYA,AICHI 468,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Meijo University					NIDDK NIH HHS [DK35930, DK36031] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, R01DK035930] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BURG MB, 1992, J AM SOC NEPHROL, V3, P121; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1993, CELLULAR MOL PHYSL C, P363; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; FATHALLAH DM, 1993, J IMMUNOL, V151, P810; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MUKAI H, 1993, GENE, V132, P57; NAKAI K, 1992, GENOMICS, V14, P89; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; PARFETT CLJ, 1989, GENE, V82, P291, DOI 10.1016/0378-1119(89)90054-1; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TANAKA K, 1988, BIOCHIM BIOPHYS ACTA, V950, P138, DOI 10.1016/0167-4781(88)90006-1; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANCEY PH, 1988, J COMP PHYSIOL B, V158, P369, DOI 10.1007/BF00695336	31	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12327	12332		10.1074/jbc.271.21.12327	http://dx.doi.org/10.1074/jbc.271.21.12327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647834	hybrid			2022-12-27	WOS:A1996UL66000036
J	Redowicz, MJ; Korn, ED; Rau, DC				Redowicz, MJ; Korn, ED; Rau, DC			Nucleotides increase the internal flexibility of filaments of dephosphorylated Acanthamoeba myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSECOND ROTATIONAL MOTIONS; ACTIVATED ATPASE ACTIVITY; 3 PHOSPHORYLATION SITES; RABBIT PSOAS MUSCLE; HEAVY-CHAIN; ELECTRIC BIREFRINGENCE; STRUCTURAL DIFFERENCE; INTEGRAL-EQUATIONS; SKINNED FIBERS; ACTIN	The actin-activated Mg2+-ATPase activity of Acanthamoeba myosin II minifilaments is dependent both on Mg2+ concentration and on the state of phosphorylation of three serine sites at the C-terminal end of the heavy chains. Previous electric birefringence experiments on minifilaments showed a large dependence of signal amplitude on the phosphorylation state and Mg2+ concentration, consistent with large changes in filament flexibility. These observations suggested that minifilament stiffness was important for function. We now report that the binding of nucleotides to dephosphorylated minifilaments at Mg2+ concentrations needed for optimal activity increases the flexibility by about 10-fold, as inferred from the birefringence signal amplitude increase. An increase in flexibility with nucleotide binding is not observed for dephosphorylated minifilaments at lower Mg2+ concentrations or for phosphorylated minifilaments at any Mg2+ concentration examined. The relaxation times for minifilament rotations that are sensitive to the conformation myosin heads are also observed to depend on phosphorylation, Mg2+ concentration, and nucleotide binding. These latter experiments indicate that the actin activated Mg2+-ATPase activity of Acanthamoeba myosin II correlates with both changes in myosin head conformation and the ability of minifilaments to cycle between stiff and flexible conformations coupled to nucleotide binding and release.	NIDDK,OFF DIRECTOR,NIH,BETHESDA,MD 20892; NHLBI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Redowicz, Maria Jolanta/AAM-8020-2020; Korn, Edward D/F-9929-2012; Redowicz, Maria Jolanta/R-4083-2016	Redowicz, Maria Jolanta/0000-0001-5834-471X; Korn, Edward/0000-0003-3867-6295				ATKINSON MAL, 1989, J BIOL CHEM, V264, P4127; BRENNER B, 1991, J PHYSIOL-LONDON, V441, P703, DOI 10.1113/jphysiol.1991.sp018774; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COLLINS JH, 1981, J BIOL CHEM, V256, P2586; COTE GP, 1984, J BIOL CHEM, V259, P2781; COTE GP, 1981, J BIOL CHEM, V256, P2811; EADS TM, 1984, J MOL BIOL, V179, P55, DOI 10.1016/0022-2836(84)90306-1; EDEN D, 1995, BIOPHYS J S, V68, P372; Fisher A. J., 1995, Biophysical Journal, V68, P19; GANGULY C, 1992, J BIOL CHEM, V267, P20905; GANGULY C, 1990, J BIOL CHEM, V265, P9993; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P2237, DOI 10.1021/bi00356a058; HIGHSMITH S, 1993, BIOCHEMISTRY-US, V32, P2455, DOI 10.1021/bi00061a001; HIGHSMITH S, 1985, BIOCHEMISTRY-US, V24, P4917, DOI 10.1021/bi00339a029; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KINOSITA K, 1984, BIOCHEMISTRY-US, V23, P5963, DOI 10.1021/bi00320a012; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LUDESCHER RD, 1988, J MOL BIOL, V200, P89, DOI 10.1016/0022-2836(88)90335-X; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; OSTAP EM, 1993, BIOCHEMISTRY-US, V32, P6712, DOI 10.1021/bi00077a026; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAU DC, 1993, J BIOL CHEM, V268, P4612; RAU DC, 1993, J BIOL CHEM, V268, P4622; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REDOWICZ MJ, 1994, J BIOL CHEM, V269, P13558; REDOWICZ MJ, 1996, BIOPHYS J, V70, P160; ROOPNARINE O, 1995, BIOPHYS J, V68, P1461, DOI 10.1016/S0006-3495(95)80319-X; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; TRYBUS KM, 1994, J MUSCLE RES CELL M, V15, P587, DOI 10.1007/BF00121066; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WIJMENGA SS, 1987, J BIOL CHEM, V262, P15803; XU SE, 1993, J PHYSIOL-LONDON, V461, P283, DOI 10.1113/jphysiol.1993.sp019514	40	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12401	12407		10.1074/jbc.271.21.12401	http://dx.doi.org/10.1074/jbc.271.21.12401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647844	hybrid			2022-12-27	WOS:A1996UL66000046
J	Kim, YS; Jo, YY; Chang, IM; Toida, T; Park, Y; Linhardt, RJ				Kim, YS; Jo, YY; Chang, IM; Toida, T; Park, Y; Linhardt, RJ			A new glycosaminoglycan from the giant African snail Achatina fulica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANOMALOCARDIA-BRASILIANA; FLAVOBACTERIUM-HEPARINUM; ANTICOAGULANT ACTIVITY; HEPARAN-SULFATE; OLIGOSACCHARIDE; ELECTROPHORESIS; PROTEOGLYCANS; GLYCOPROTEIN	A new glycosaminoglycan has been isolated from the giant African snail Achatina fulica. This polysaccharide had a molecular weight of 29,000, calculated based on the viscometry, and a uniform repeating disaccharide structure of -->4)-2-acetyl,2-deoxy-alpha-D-glucopyranose (1-->4)-2-sulfo-alpha-L-idopyranosyluronic acid (1-->. This polysaccharide represents a new, previously undescribed glycosaminoglycan. It is related to the heparin and heparan sulfate families of glycosaminoglycans but is distinctly different from all known members of these classes of glycosaminoglycans. The structure of this polysaccharide, with adjacent N-acetylglucosamine and 2-sulfo-iduronic acid residues, also poses interesting questions about how it is made in light of our current understanding of the biosynthesis of heparin and heparan sulfate. This glycosaminoglycan represents 3-5% of the dry weight of this snail's soft body tissues, suggesting important biological roles for the survival of this organism, and may offer new means to control this pest. Snail glycosaminoglycan tightly binds divalent cations, such as copper(II), suggesting a primary role in metal uptake in the snail. Finally, this new polysaccharide might be applied, like the Escherichia coli K5 capsular polysaccharide, to the study of glycosaminoglycan biosynthesis and to the semisynthesis of new glycosaminoglycan analogs having important biological activities.	UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242; SEOUL NATL UNIV,INST NAT PROD RES,SEOUL 110460,SOUTH KOREA	University of Iowa; Seoul National University (SNU)			Wang, Lingchong/G-8417-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52622] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AL-HAKIM A, 1991, Applied and Theoretical Electrophoresis, V1, P305; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BURSON SL, 1972, BIOL BULL, V143, P506; DESAI UR, 1993, ANAL BIOCHEM, V213, P120, DOI 10.1006/abio.1993.1394; DIETRICH CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P1, DOI 10.1016/0304-4165(85)90041-8; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLIHER PM, 1981, APPL ENVIRON MICROB, V41, P360, DOI 10.1128/AEM.41.2.360-365.1981; GODAN D, 1983, PEST SLUGS SNAILS, P3; GOUDSMIT EM, 1972, CHEM ZOOLOGY, V7; GRENON JF, 1980, COMP BIOCHEM PHYS B, V66, P451; GRENON JF, 1981, J EXP MAR BIOL ECOL, V54, P277, DOI 10.1016/0022-0981(81)90162-3; GRIFFIN CC, 1995, CARBOHYD RES, V276, P183, DOI 10.1016/0008-6215(95)00166-Q; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HELLER E, 1976, BIOCHEMISTRY-US, V15, P1194, DOI 10.1021/bi00651a002; HOVINGH P, 1986, BIOCHEM J, V237, P573, DOI 10.1042/bj2370573; IRELAND MP, 1992, J MOLLUS STUD, V58, P157, DOI 10.1093/mollus/58.2.157; JORDAN RE, 1986, ARCH BIOCHEM BIOPHYS, V248, P690, DOI 10.1016/0003-9861(86)90524-2; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi S., 1964, Bulletin of the Japanese Society of Scientific Fisheries, V30, P893; LIBERTI PA, 1967, ARCH BIOCHEM BIOPHYS, V119, P510, DOI 10.1016/0003-9861(67)90485-7; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; Linhardt R., 1992, CARBOHYDRATESSYNTHET, P385; LINHARDT R, 1994, CURRENT PROTOCOLS MO; LINHARDT RJ, 1992, BIOCHEMISTRY-US, V31, P12441, DOI 10.1021/bi00164a020; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINHARDT RJ, 1996, LAB GUIDE GLYCOCONJU; LINHARDT RJ, 1996, CARBOHYDRATES DRUGS; Liu J, 1995, GLYCOBIOLOGY, V5, P765, DOI 10.1093/glycob/5.8.765; LIVINGSTONE DR, 1993, MULUSCA, V1; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Mathews M. B., 1975, CONNECTIVE TISSUE MA; MITRA D, 1987, BIOCHEM J, V242, P331, DOI 10.1042/bj2420331; MUNIAPPAN R, 1987, PLANT PROT B, V35, P127; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; OTSUKAFUCHINO H, 1992, COMP BIOCHEM PHYS C, V101, P607, DOI 10.1016/0742-8413(92)90094-N; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; PERVIN A, 1994, ANAL BIOCHEM, V221, P182, DOI 10.1006/abio.1994.1395; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; ROSETT W, 1980, J CLIN MICROBIOL, V11, P30, DOI 10.1128/JCM.11.1.30-34.1980; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; Toida T, 1996, ELECTROPHORESIS, V17, P341, DOI 10.1002/elps.1150170209; TOIDA T, 1995, GLYCOCONJUGATE, V12, P419; TRUEMAN ER, 1993, MULUSCA, V1; VANKUIK JA, 1986, EUR J BIOCHEM, V160, P621; WILBUR KM, 1993, MULUSCA, V1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919	53	101	106	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11750	11755		10.1074/jbc.271.20.11750	http://dx.doi.org/10.1074/jbc.271.20.11750			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662607	hybrid			2022-12-27	WOS:A1996UL25000028
J	Liu, SC; Smith, SE; Julian, J; Rohde, LH; Karin, NJ; Carson, DD				Liu, SC; Smith, SE; Julian, J; Rohde, LH; Karin, NJ; Carson, DD			cDNA cloning and expression of HIP, a novel cell surface heparan sulfate/heparin-binding protein of human uterine epithelial cells and cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SULFATE PROTEOGLYCAN; RIBOSOMAL-PROTEIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-STRUCTURE; MOUSE EMBRYOS; RECEPTOR; ATTACHMENT; MECHANISM; ADHESION	Heparan sulfate proteoglycans and their corresponding binding sites have been suggested to play an important role during the initial attachment of murine blastocysts to uterine epithelium and human trophoblastic cell lines to uterine epithelial cell lines. Previous studies on RL95 cells, a human uterine epithelial cell line, had characterized a single class of cell surface heparin/heparan sulfate (HP/HS)-binding sites. Three major HP/HS-binding peptide fragments were isolated from cell surfaces by tryptic digestion, and partial amino-terminal amino acid sequence for each peptide fragment was obtained (Raboudi, N., Julian, J., Rohde, L. H., and Carson, D. D. (1992) J. Biol. Chem. 267, 11930-11939). In the current study, using approaches of reverse transcription-polymerase chain reaction and cDNA library screening, we have cloned and expressed a novel, cell surface HP/HS-binding protein, named HP/HS interacting protein (HIP), from RL95 cells. The full-length cDNA of HIP encodes a protein of 159 amino acids with a calculated molecular mass of 17,754 Da and pI of 11.75. Transfection of HIP full-length cDNA into NIH 3T3 cells demonstrated cell surface expression and a size similar to that of HIP expressed by human cells. Predicted amino acid sequence indicates that HIP lacks a membrane spanning region and has no consensus sites for glycosylation. Northern blot analysis detected a single transcript of 1.3 kilobases in both total RNA and poly(A(+)) RNA. Examination of human cell lines and normal tissues using both Northern blot and Western blot analyses revealed that HIP is expressed at different levels in a variety of human cell lines and normal tissues but absent in some cell lines and some cell types of normal tissues examined. HIP has relatively high homology (similar to 80% both at the levels of nucleotide and protein sequence) to a rodent ribosomal protein L29. Thus, members of the L29 family may be displayed on cell surfaces where they may participate in HP/HS binding events.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DEPT INTEGRAT BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025235, R01HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; NOMURA M, 1982, TRENDS BIOCHEM SCI, V7, P92, DOI 10.1016/0968-0004(82)90154-2; OSTVOLD AC, 1992, FEBS LETT, V298, P219, DOI 10.1016/0014-5793(92)80061-K; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; RUDERT F, 1993, GENE, V133, P249, DOI 10.1016/0378-1119(93)90647-L; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SVOBODA M, 1992, EUR J BIOCHEM, V203, P341, DOI 10.1111/j.1432-1033.1992.tb16555.x; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Weber K., 1975, PROTEINS, VI, P179; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	39	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11817	11823		10.1074/jbc.271.20.11817	http://dx.doi.org/10.1074/jbc.271.20.11817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662616	hybrid			2022-12-27	WOS:A1996UL25000039
J	Fleming, I; Fisslthaler, B; Busse, R				Fleming, I; Fisslthaler, B; Busse, R			Interdependence of calcium signaling and protein tyrosine phosphorylation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P-450 INHIBITORS; KINASE INHIBITORS; HUMAN PLATELETS; T-CELLS; INFLUX; ENTRY; MOBILIZATION; BRADYKININ; INCREASE	The signal transduction cascade which initiates trans membraneous influx of Ca2+ into endothelial cells in response to the discharge of intracellular Ca2+ stores is thought to involve a step sensitive to tyrosine kinase inhibition. We investigated the interrelationship between Ca2+ signaling and protein tyrosine phosphorylation following cell stimulation with either the receptor-dependent agonist, bradykinin, or the protein-tyrosine phosphatase inhibitor, phenylarsine oxide. In cultured human endothelial cells phenylarsine oxide instigated a concentration-dependent increase in the intracellular concentration of free Ca2+ ([Ca2+](i)). This increase in [Ca2+](i) was not associated with the tyrosine phosphorylation of phospholipase C gamma, enhanced formation of inositol 1,4,5-trisphosphate, or the rapid depletion of intracellularly stored Ca2+ but was coincident with the enhanced and prolonged tyrosine phosphorylation of a number of cytoskeletal proteins. In bradykinin-stimulated cells the tyrosine phosphorylation of the same cytoskeletal proteins (most notably 85- and 100-kDa proteins) was transient when cells were stimulated in the presence of extracellular Ca2+, was maintained under Ca2+-free conditions, and was reversed following readdition of extracellular Ca2+. These data suggest that the tyrosine phosphorylation of 2 cytoskeletal proteins is determined by the level of Ca2+ present in intracellular stores thus indicating a critical role for tyrosine phosphorylation in the control of capacitative Ca2+ entry in endothelial cells.			Fleming, I (corresponding author), UNIV FRANKFURT KLINIKUM,ZENTRUM PHYSIOL,THEODOR STERN KAI 7,D-60590 FRANKFURT,GERMANY.		Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635				ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ALVAREZ J, 1991, BIOCHEM J, P274; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; BERVEN LA, 1994, FEBS LETT, V346, P235, DOI 10.1016/0014-5793(94)00481-1; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; LEE KM, 1993, J BIOL CHEM, V268, P9945; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1992, CELL CALCIUM, V13, P553, DOI 10.1016/0143-4160(92)90035-Q; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; YATOMI Y, 1992, BIOCHEM BIOPH RES CO, V186, P1480, DOI 10.1016/S0006-291X(05)81573-6; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130	24	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11009	11015		10.1074/jbc.271.18.11009	http://dx.doi.org/10.1074/jbc.271.18.11009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631922	hybrid			2022-12-27	WOS:A1996UJ34200090
J	Miano, JM; Olson, EN				Miano, JM; Olson, EN			Expression of the smooth muscle cell calponin gene marks the early cardiac and smooth muscle cell lineages during mouse embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; TATA-LESS PROMOTERS; HUMAN ELASTIN GENE; 5'-FLANKING REGION; VASCULAR INJURY; Z-DNA; TRANSCRIPTION; PROTEIN; BINDING; ACTIVATION	Although several genes are considered markers for vascular smooth muscle cell (SMC) differentiation, few have been rigorously tested for SMC specificity in mammals, particularly during development where considerable overlap exists between different muscle gene programs. Here we describe the temporospatial expression pattern of the SMC calponin gene (formerly hi or basic calponin) during mouse embryogenesis and in adult mouse tissues and cell lines. Whereas SMC calponin mRNA expression is restricted exclusively to SMCs in adult tissues, during early embryogenesis, SMC calponin transcripts are expressed throughout the developing cardiac tube as well as in differentiating SMCs. Transcription of the SMC calponin gene initiates at two closely juxtaposed sites in the absence of a consensus TATAA or initiator element. Transient transfection assays in cultured SMC demonstrated that high level SMC calponin promoter activity required no more than 549 nucleotides of 5' sequence. In contrast to the strict cell type-specificity of SMC calponin mRNA expression, the SMC calponin promoter showed activity in several cell lines that do not express the endogenous SMC calponin gene. These results demonstrate that SMC calponin responds to cardiac and smooth muscle gene regulatory programs and suggest that the cardiac and smooth muscle cell lineages may share a common gene regulatory program early in embryogenesis, which diverges as the heart matures. The finding that the isolated SMC calponin promoter is active in a wider range of cells than the endogenous SMC calponin gene also suggests that long-range repression or higher order regulatory mechanism(s) are involved in cell-specific regulation of SMC calponin expression.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207	NCI NIH HHS [CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BIRUKOV KG, 1991, CELL TISSUE RES, V266, P579, DOI 10.1007/BF00318599; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANK RS, 1995, CIRC RES, V76, P742, DOI 10.1161/01.RES.76.5.742; BLANK RS, 1992, J BIOL CHEM, V267, P984; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EB, 1995, DEV MECHANISMS HEART; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8553; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI DH, 1993, TRENDS CARDIOVAS MED, V3, P184, DOI 10.1016/1050-1738(93)90004-P; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KATOH Y, 1994, J BIOL CHEM, V269, P30538; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LECAIN E, 1991, J NEUROSCI RES, V28, P601, DOI 10.1002/jnr.490280417; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LI L, 1995, IN PRESS J CELL BIOL; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MIANO JM, 1993, AM J PATHOL, V142, P715; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1988, NUCLEIC ACIDS RES, V16, P10374, DOI 10.1093/nar/16.21.10374; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NISHIDA W, 1993, GENE, V130, P297, DOI 10.1016/0378-1119(93)90435-6; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; REILLY CF, 1989, J BIOL CHEM, V264, P6990; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STRASSER P, 1993, FEBS LETT, V330, P13, DOI 10.1016/0014-5793(93)80909-E; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKAHASHI K, 1993, CIRCULATION, V88, P174; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x	57	109	112	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7095	7103		10.1074/jbc.271.12.7095	http://dx.doi.org/10.1074/jbc.271.12.7095			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636144	hybrid			2022-12-27	WOS:A1996UB15700079
J	Yano, M; Marinelli, RA; Roberts, SK; Balan, V; Pham, L; Tarara, JE; deGroen, PC; LaRusso, NF				Yano, M; Marinelli, RA; Roberts, SK; Balan, V; Pham, L; Tarara, JE; deGroen, PC; LaRusso, NF			Rat hepatocytes transport water mainly via a non-channel-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CHIP28 PROTEIN; XENOPUS OOCYTES; MESSENGER-RNA; GLUCOSE TRANSPORTERS; EPITHELIAL-CELLS; PLASMA-MEMBRANES; BILE FORMATION; EXPRESSION; PERMEABILITY; KIDNEY	During bile formation by the liver, large volumes of water are transported across two epithelial barriers consisting of hepatocytes and cholangiocytes (i.e. intrahepatic bile duct epithelial cells), Tire recently reported that a water channel, aquaporin-channel-forming integral protein of 28 kDa, is present in cholangiocytes and suggested that it plays a major role in water transport by these cells, Since the mechanisms of water transport across hepatocytes remain obscure, we performed physiological, molecular, and biochemical studies on hepatocytes to determine if they also contain water channels. Water permeability was studied by exposing isolated rat hepatocytes to buffers of different osmolarity and measuring cell volume by quantitative phase contrast, fluorescence and laser scanning confocal microscopy, Using this method, hepatocytes exposed to hypotonic buffers at 23 degrees C increased their cell volume in a time and osmolarity-dependent manner with an osmotic water permeability coefficient of 66.4 x 10(-4) cm/s, In studies done at 10 degrees C, the osmotic water permeability coefficient decreased by 55% (p < 0.001, at 23 degrees C; t test), The derived activation energy from these studies was 12.8 kcal/mol. After incubation of hepatocytes with amphotericin B at 10 degrees C, the osmotic water permeability coefficient increased by 198% (p < 0.001) and the activation energy value decreased to 3.6 kcal/mol, consistent with the insertion of artificial water channels into the hepatocyte plasma membrane, Reverse transcriptase polymerase chain reaction with hepatocyte RNA as template did not produce cDNAs for three of the known mater channels. Both the cholesterol content and the cholesterol/phospholipid ratio of hepatocyte plasma membranes were significantly (p < 0.005) less than those of cholangiocytes; membrane fluidity of hepatocytes estimated by measuring steady-state anisotropy was higher than that of cholangiocytes. Our data suggests that the osmotic flow of water across hepatocyte membranes occurs mainly by diffusion via the lipid bilayer (not by permeation through water channels as in cholangiocytes).	MAYO CLIN & MAYO FDN,MAYO MED SCH,CTR BASIC RES DIGEST DIS,DEPT INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED SCH,CTR BASIC RES DIGEST DIS,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK024031, R01DK024031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 24031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; ALPINI G, 1986, AM J PHYSIOL, V251, pC872, DOI 10.1152/ajpcell.1986.251.6.C872; BOYER JL, 1979, YALE J BIOL MED, V52, P61; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; ECHEVARRIA M, 1992, J GEN PHYSIOL, V99, P573, DOI 10.1085/jgp.99.4.573; ECKLOFF BW, 1994, INT J SYST BACTERIOL, V44, P320, DOI 10.1099/00207713-44-2-320; Erlinger Serge, 1994, P769; Finkelstein A., 1987, WATER MOVEMENT LIPID; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; LAYDEN TJ, 1978, J CLIN INVEST, V62, P1375, DOI 10.1172/JCI109258; Lenzen Romana, 1993, P539; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MYERS BM, 1991, J CLIN INVEST, V88, P1207, DOI 10.1172/JCI115423; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; SCHACHTER D, 1984, HEPATOLOGY, V4, P140, DOI 10.1002/hep.1840040124; SCHARSCHMIDT BF, 1990, HEPATOLOGY TXB LIVER, P303; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; TIETZ P, 1994, GASTROENTEROLOGY, V106, pA998; TRIPATHI S, 1989, Q J EXP PHYSIOL CMS, V74, P385, DOI 10.1113/expphysiol.1989.sp003288; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; ZAHREBELSKI G, 1995, HEPATOLOGY, V21, P1361, DOI 10.1002/hep.1840210521; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26; ZHANG R, 1990, J BIOL CHEM, V265, P15375	36	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6702	6707		10.1074/jbc.271.12.6702	http://dx.doi.org/10.1074/jbc.271.12.6702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636089	hybrid			2022-12-27	WOS:A1996UB15700024
J	Lyczak, JB; Zhang, K; Saxon, A; Morrison, SL				Lyczak, JB; Zhang, K; Saxon, A; Morrison, SL			Expression of novel secreted isoforms of human immunoglobulin E proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 MESSENGER-RNAS; IGE; CHAIN; FORMS	Four human IgE isoforms produced by alternative splicing of the epsilon primary transcript were expressed as chimeric mouse/human anti 5-dimethylamino-1-naphthalenesulfonyl antibodies in the murine myeloma cell line Sp2/0, The four isoforms include the classic secreted form and three novel isoforms with altered carboxyl termini, All of these isoforms lack the transmembrane region encoded by the M1/M1' exon and are therefore predicted to be secreted proteins, When expressed in Sp2/0 cells, three of the IgE isoforms are assembled into complete molecules of two Ig heavy chains and two Ig light chains, whereas the fourth isoform is predominately assembled into half-molecules of one Ig heavy chain and one Ig light chain. All four isoforms are secreted with similar kinetics. In contrast, when the isoform containing the C epsilon 4 domain joined directly to the M2' exon (IgE grande) is expressed in the J558L cell line, it is degraded intracellularly, suggesting a cell line-dependent regulation of secretion. These data show that these novel isoforms of human IgE, predicted to occur from in vivo and in vitro mRNA analysis, can be produced and secreted by mammalian cells. The differ ent forms of IgE may have physiologically relevant but distinct roles in human IgE-mediated immune inflammation. The availability of purified recombinant human IgE isoforms makes it possible to analyze the functional differences among them.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV CLIN IMMUNOL, HART & LOUISE LYON LAB, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI-15251, AI-34567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, U01AI034567, U19AI034567, R21AI015251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATISTA FD, 1995, J IMMUNOL, V154, P209; DIAZSANCHEZ D, 1995, J IMMUNOL, V155, P1930; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; HELLMAN L, 1993, EUR J IMMUNOL, V23, P159, DOI 10.1002/eji.1830230126; MACDONALD SM, 1991, INT ARCH ALLER A IMM, V94, P144, DOI 10.1159/000235347; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MEGUR KE, 1994, J IMMUNOL, V153, P5549; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; OI VT, 1986, BIOTECHNIQUES, V4, P214; PENG C, 1992, J IMMUNOL, V148, P129; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; SARFATI M, 1992, IMMUNOLOGY, V76, P662; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1990, P NATL ACAD SCI USA, V87, P5322, DOI 10.1073/pnas.87.14.5322; YU LM, 1990, J IMMUNOL, V145, P3932; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233; ZHANG K, 1994, J BIOL CHEM, V269, P456	18	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3428	3436						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631944				2022-12-27	WOS:A1996TV72400018
J	Miyazawa, K; Shimomura, T; Kitamura, N				Miyazawa, K; Shimomura, T; Kitamura, N			Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CHAIN FORM; SCATTER FACTOR; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; SERINE-PROTEASE; LIVER; PURIFICATION; IDENTIFICATION; REGENERATION; PRECURSOR	Hepatocyte growth factor (HGF) is a potent mitogen, motogen, and morphogen for epithelial cells in vitro. It appears likely that HGF participates in tissue regeneration following hepatic and renal injury in vivo. The activity of HGF is localized to the injured tissues by a proteolytic activation system; HGF remains as an inactive single-chain form in the normal state and is converted to an active heterodimeric form in response to tissue injury. A protease responsible for this conversion is induced in the injured liver, but it has not yet been identified. We have previously purified and characterized HGF activator (HGFA), a serum-derived serine protease that efficiently activates single-chain HGF in vitro. In this study, we found that the HGF-converting activity in the injured liver was inhibited by an anti-HGFA antibody. We also found that the active form of HGFA was generated exclusively in the injured tissues. Thus, it appears likely that HGFA is the key enzyme that regulates the activity of HGF in the injured tissues. We also analyzed the heparin binding properties of the precursor and mature forms of HGFA. HGFA had a weak affinity for heparin near the physiological salt concentration in its precursor form but acquired a strong affinity for heparin upon activation that is linked to blood coagulation. This property may ensure the local action of this enzyme at the site of tissue injury.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN; MITSUBISHI KASEI CORP, RES CTR, AOBA KU, YOKOHAMA, KANAGAWA 227, JAPAN; TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, DEPT LIFE SCI, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN	Kansai Medical University; Tokyo Institute of Technology			MIYAZAWA, KEIJI/I-9713-2014					ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IGAWA T, 1993, AM J PHYSIOL, V265, pF61, DOI 10.1152/ajprenal.1993.265.1.F61; KAPLAN AP, 1988, METHOD ENZYMOL, V163, P3; LIU KX, 1992, AM J PHYSIOL, V263, pG642, DOI 10.1152/ajpgi.1992.263.5.G642; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARS WM, 1993, AM J PATHOL, V143, P949; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZARNEGAR R, 1989, CANCER RES, V49, P3314	34	188	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3615	3618						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631970				2022-12-27	WOS:A1996TV72400044
J	Osada, S; Yamamoto, H; Nishihara, T; Imagawa, M				Osada, S; Yamamoto, H; Nishihara, T; Imagawa, M			DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEINS; TRANSFERASE-P GENE; CASEIN KINASE-II; NUCLEAR-PROTEIN; SIGNAL TRANSDUCTION; C/EBP FAMILY; ALBUMIN GENE; PROMOTER; NF-IL6; MEMBER	CCAAT/enhancer-binding protein (C/EBP) transcription factor family members are related by a high degree of amino acid sequence identity to the basic leucine zipper DNA-binding domain and show distinct but overlapping patterns of tissue- and stage-restricted expression. Although C/EBP alpha and C/EBP beta have been shown to recognize a consensus sequence derived from regulatory elements in virus and acute-phase response genes, the potential for more subtle differences in the binding preference of the C/EBP family has not been previously addressed. The consensus sequence of C/EBP delta has not been reported. By using the method of polymerase chain reaction-mediated random site selection to assess the DNA binding specificity of the C/EBP family in an unbiased manner, we demonstrated the sequence preferences for C/EBP family members. With small variations, these C/EBP family members showed similar sequence preferences, and the consensus sequence was identified as RTTGCGYAAY (R = A or G, and Y = C or T). The phosphorylation of C/EBP delta by casein kinase II increased the binding activity, but did not affect the binding specificity, whereas it was reported that the phosphorylation of C/EBP alpha and C/EBP beta decreased the binding affinity. The specificity of action of C/EBP family members may be derived from the characteristics of each factor, including the expression profiles, the DNA binding affinities, the cofactors, and so on, in addition to the DNA binding specificities.	OSAKA UNIV,FAC PHARMACEUT SCI,DEPT ENVIRONM BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; INOUE S, 1991, NUCLEIC ACIDS RES, V19, P4091, DOI 10.1093/nar/19.15.4091; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NISHIKAWA J, 1994, NUCLEIC ACIDS RES, V22, P2902, DOI 10.1093/nar/22.15.2902; NISHIZAWA M, 1991, FEBS LETT, V282, P95, DOI 10.1016/0014-5793(91)80452-9; NSHIO Y, 1993, MOL CELL BIOL, V13, P1854; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	35	262	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3891	3896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632009				2022-12-27	WOS:A1996TV72400083
J	Tsytsykova, AV; Tsitsikov, EN; Geha, RS				Tsytsykova, AV; Tsitsikov, EN; Geha, RS			The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; IDENTIFICATION; CALCINEURIN; ELEMENTS; ENHANCER; PROTEIN; FOS; JUN	Four nuclear factor of activated T cells (NF-AT) binding motifs were found in the murine CD40 ligand promoter. Electrophoretic mobility shift assays using 18-base pair (bp) long oligonucleotides corresponding to the proximal site and nuclear extracts from activated T cells revealed two complexes which were inhibited by cyclosporin A and contained NF-ATc and NF-ATp. Neither complex contained AP-1 proteins. Multimers of the 18-bp oligonncleotides were not active in transient transfection assays using luciferase reporter gene constructs. In contrast, a 30-bp long oligonucleotide bound AP-1 proteins in addition to NP-AT proteins and its multimers strongly induced luciferase gene expression. These results suggested that NF-AT proteins play an important role in the expression of the CD40L gene and that their transcriptional activity requires AP-1 binding.	CHILDRENS HOSP,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-31541, AI-28046] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028046, U01AI031541, U19AI031541] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BRUGNONI D, 1994, EUR J IMMUNOL, V24, P1919, DOI 10.1002/eji.1830240831; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; FULEIHAN R, 1994, EUR J IMMUNOL, V24, P1925, DOI 10.1002/eji.1830240832; FULEIHAN R, 1995, CLIN IMMUNOL IMMUNOP, V76, P52, DOI 10.1006/clin.1995.1087; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; ISRAEL A, 1994, NATURE, V369, P443, DOI 10.1038/369443a0; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RAMESH N, 1994, IMMUNOL REV, V138, P87, DOI 10.1111/j.1600-065X.1994.tb00848.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TSITSIKOV EN, 1994, MOL IMMUNOL, V31, P895, DOI 10.1016/0161-5890(94)90009-4; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	33	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3763	3770						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631992				2022-12-27	WOS:A1996TV72400066
J	Verma, AK; Enyedi, A; Filoteo, AG; Strehler, EE; Penniston, JT				Verma, AK; Enyedi, A; Filoteo, AG; Strehler, EE; Penniston, JT			Plasma membrane calcium pump isoform 4a has a longer calmodulin-binding domain than 4b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP; CA-2+ PUMP	Alternate splicing of human plasma membrane calcium pump isoform 4 (hPMCA4) transcripts causes the expression of two variants, hPMCA4a and hPMCA4b, which have different downstream regulatory regions, Of the two, hPMCA4a has a lower affinity for calmodulin and a lower effective affinity for Ca2+ (Enyedi, A, Verma, A. K., Helm, R,, Adamo, H. P,, Filoteo, A. G,, Strehler, E, E,, and Penniston, J. T, (1994) J, Biol, Chem. 269, 41-43), Additional consequences of the alternate splice were studied by analyzing the characteristics of constructs (expressed in COS-1 cells) containing different portions of the carboxyl terminus of hPMCA4a, Our results show striking differences in the structure of the calmodulin-binding and autoinhibitory domains of the two variants, The calmodulin-binding region of hPMCA4b is a region of about 28 residues, whereas that of hPMCA4a is about 49 residues long and is probably interrupted by a region not involved in the binding, The autoinhibitory region of hPMCA4b (a part of the downstream region that keeps the molecule inactive in the absence of Ca2+-calmodulin) is divided between the 28-residue calmodulin-binding region and a downstream region, whereas in hPMCA4a, all of it is contained within the 49-residue calmodulin-binding region.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55901	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Enyedi A., 1995, Biophysical Journal, V68, pA318; JAMES P, 1988, J BIOL CHEM, V263, P2905; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SARKADI B, 1986, J BIOL CHEM, V261, P9552; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	18	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3714	3718						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631985				2022-12-27	WOS:A1996TV72400059
J	Gurgueira, SA; Meneghini, R				Gurgueira, SA; Meneghini, R			An ATP-dependent iron transport system in isolated rat liver nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; FERRITIN; INHIBITION; CALCIUM; SUBUNIT; MODEL	A concerted translational control is responsible for maintaining an iron level in the cytosol that is both adequate for the synthesis of iron-containing proteins and does not represent a danger to the cell. However, little is known about how iron level is controlled in the nucleus. Nuclei of rat liver take up iron from ferric citrate by a process that is dependent on ATP. This system shares several properties with known P-type ATPases, suggesting that a P-type ATPase in the nuclear membrane in responsible for iron transport, (i) Adenosine 5'-(beta,gamma-iminodiphosphate), a non-hydrolyzable ATP analogue, does not support iron uptake; (ii) the uptake is strongly inhibited by vanadate; (iii) there is an absolute requirement for Mg2+; and (iv) reagents that oxidize SH groups inhibit uptake, and this inhibition can be prevented by dithiothreitol. The energy of activation for the uptake (11.5 kcal/mol) and the K-m for ATP (0.4 mM) are similar to values for other known cation transport ATPases. Inhibitors of Na+, K+-ATPase, sarcoplasmic reticulum Ca2+-ATPase, proton V-ATPase, and nuclear Ca2+-ATPase have no effect on uptake. Ferric citrate can be replaced by Fe-ATP as a source of iron for the transport system; however, two other stronger iron chelators, Tiron and desferrioxamine, completely inhibit the uptake. Taken together, these data strongly suggest that an Fe-ATPase, distinct from other known P-type ATPase, distinct from other known P-type ATPase, is responsible for iron transport in the nucleus.	UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, BR-05599970 SAO PAULO, BRAZIL	Universidade de Sao Paulo			GURGUEIRA, SONIA A/G-8775-2012; Meneghini, Rogério/I-2961-2015	Gurgueira, Sonia/0000-0003-2928-1937				AISEN P, 1994, ADV EXP MED BIOL, V356, P31; ANNER BM, 1983, FEBS LETT, V158, P7, DOI 10.1016/0014-5793(83)80665-6; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BAKKEREN DL, 1985, INT J BIOCHEM, V17, P925, DOI 10.1016/0020-711X(85)90177-6; BINGHAM MJ, 1995, J PHYSIOL-LONDON, V482, P583, DOI 10.1113/jphysiol.1995.sp020542; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; DEMEIS L, 1980, SARCOPLASMIC RETICUL; FALLER B, 1994, J AM CHEM SOC, V116, P3860, DOI 10.1021/ja00088a022; FENG Y, 1992, J BIOL CHEM, V267, P5817; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; INESI G, 1973, J MOL BIOL, V81, P483, DOI 10.1016/0022-2836(73)90518-4; INESI G, 1994, J MEMBRANE BIOL, V141, P1; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZLOV AV, 1992, FREE RADICAL BIO MED, V13, P9, DOI 10.1016/0891-5849(92)90159-E; KUHN LC, 1994, ADV EXP MED BIOL, V356, P101; KUKIELKA E, 1994, ARCH BIOCHEM BIOPHYS, V308, P70, DOI 10.1006/abbi.1994.1010; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEINHARD GE, 1973, J BIOL CHEM, V248, P1121; LI CY, 1994, J BIOL CHEM, V269, P10242; LI CY, 1995, BIOCHEMISTRY-US, V34, P5130, DOI 10.1021/bi00015a025; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MENEGHINI R, 1995, CANCER J - FRANCE, V8, P109; MOORE L, 1975, J BIOL CHEM, V250, P4562; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; OCONNELL M, 1986, BIOCHEM J, V234, P727, DOI 10.1042/bj2340727; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P153; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SMITH AG, 1990, HEPATOLOGY, V12, P1399, DOI 10.1002/hep.1840120622; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x	40	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13616	13620		10.1074/jbc.271.23.13616	http://dx.doi.org/10.1074/jbc.271.23.13616			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662653	hybrid			2022-12-27	WOS:A1996UP38500048
J	Lewis, JA; Huq, A; Najarro, P				Lewis, JA; Huq, A; Najarro, P			Inhibition of mitochondrial function by interferon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC GLYCOLYSIS; THYROID-HORMONE; CYTO-TOXICITY; TUMOR-CELLS; HELA-CELLS; EXPRESSION; GENES; MECHANISM; NUCLEAR; GROWTH	We showed previously that type I interferon causes a down-regulation of mitochondrial gene expression, We show here that IFN treatment leads to functional impairment of mitochondria, Western blot analysis indicated that interferon treatment reduces the steady-state level of cytochrome b in murine L-929 cells. Interferon produced a reduction in cytochrome c oxidase and NADH-cytochrome c reductase activities of isolated mitochondria as well as inhibiting electron transport in isolated mitochondria and in intact cells. Several mitochondrial mRNAs are affected by interferon treatment in human Daudi lymphoblastoid cells, which are highly sensitive to the antiproliferative effects of interferon, Electron transport in Daudi cells was also inhibited by interferon both in intact cells and isolated mitochondria with a dose response identical to that for the antiproliferative response, In contrast, a Daudi strain resistant to the antiproliferative effects of interferon showed no down-regulation of mRNA expression and no inhibition of electron transport; Possibly as a consequence of the inhibitory effect on mitochondrial gene expression, treatment with interferon causes a reduction in cellular ATP levels, The inhibition of cellular growth by interferon may thus be partly a consequence of a reduction in cellular ATP levels.			Lewis, JA (corresponding author), SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.				NIGMS NIH HHS [GM4697703] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1975, J GEN VIROL, V28, P207, DOI 10.1099/0022-1317-28-2-207; BERRY MJ, 1985, J BIOL CHEM, V260, P1240; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1988, TRENDS BIOCHEM SCI, V13, P144, DOI 10.1016/0968-0004(88)90073-4; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DEGUCHI M, 1995, J INTERF CYTOK RES, V15, P977, DOI 10.1089/jir.1995.15.977; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HEINE UI, 1991, CELL REGUL, V2, P467, DOI 10.1091/mbc.2.6.467; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HILFENHAUS J, 1976, ARCH VIROL, V51, P87, DOI 10.1007/BF01317837; Hovanessian A G, 1981, Methods Enzymol, V79, P184; LEWIS JA, 1987, LYMPHOKINES INTERFER, P73; LEWIS JA, 1991, INTERFERON PRINCIPLE, P251; LEWIS JA, 1995, CYTOKINES PRACTICAL, P129; LOU J, 1994, J INTERFERON RES, V14, P33, DOI 10.1089/jir.1994.14.33; MINKS MA, 1979, J BIOL CHEM, V254, P5058; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NELSON BD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P275, DOI 10.1016/0005-2728(90)90266-7; PARSA AT, 1995, HUMAN CHROMOSOMES PR, P292; RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429; SCHATZ G, 1964, BIOCHIM BIOPHYS ACTA, V81, P448, DOI 10.1016/0926-6569(64)90130-0; SCHOLNICK P, 1973, J BIOL CHEM, V248, P5175; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAN B, 1989, VIROLOGY, V170, P277; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739	33	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13184	13190		10.1074/jbc.271.22.13184	http://dx.doi.org/10.1074/jbc.271.22.13184			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662694	hybrid			2022-12-27	WOS:A1996UN47400076
J	Szumilo, T; Zeng, YC; Pastuszak, I; Drake, R; Szumilo, H; Elbein, AD				Szumilo, T; Zeng, YC; Pastuszak, I; Drake, R; Szumilo, H; Elbein, AD			Purification to homogeneity and properties of UDP-GlcNAc (GalNAc) pyrophosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION; GLYCOPROTEINS	The pyrophosphorylase that condenses UTP and GlcNAc-1-P was purified 9500-fold to near homogeneity from the soluble fraction of pig liver extracts. At the final stage of purification, the enzyme was quite stable and could be kept for at least 4 months in the freezer with only slight loss of activity. On native gels, the purified enzyme showed a single protein band, and this band was estimated to have a molecular mass of similar to 125 kDa on Sephacryl S-300. SDS-polyacrylamide gel electrophoresis analysis of the enzyme gave three protein bands of 64, 57, and 49 kDa, but these polypeptides are all closely related based on the following, 1) All three polypeptides show strong cross-reactivity with antibody prepared against the 64-kDa band, 2) All three proteins become labeled with either the UDP-GlcNAc photoaffinity probe azido-I-125-salicylate-allylamine-UDP-GlcNAc or a similar UDP-GalNAc photoaffinity probe, and either labeling was inhibited in a specific and concentration-dependent manner by unlabeled UDP-GlcNAc or UI)PGalNAc. Thus, the enzyme is probably a homodimer composed of two 64-kDa subunits, The purified enzyme had an unusual specificity in that, at higher substrate concentrations, it utilized UDP-GalNAc as a substrate as well as UDP-GlcNAc in the reverse direction and GalNAc-1-P as well as GlcNAc-1-P in the forward direction, However, the K-m for the GalNAc substrates was considerably higher than that for GlcNAc derivatives. This activity for synthesizing UDP-GalNAc was not due to epimerase activity since no UDP-GalNAc could be detected when the enzyme was incubated with UDP-GlcNAc for various periods of time. The pyrophosphorylase required a divalent cation, with Mn2+ being best at 0.5-1 mM, and the pH optimum was between 8.5 and 8.9.	UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences					NHLBI NIH HHS [HL-17783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLOU C, 1982, MOL BIOL YEAST SACCH, P361; CARDINI CE, 1953, ARCH BIOCHEM BIOPHYS, V45, P55, DOI 10.1016/0003-9861(53)90404-4; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; DAVIDSON EA, 1966, AMINOSUGARS, P2; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; FUKUDA M, 1992, GLYCOCONJUGATES COMP, P379; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; Harlow E., 1988, ANTIBODIES LABORATOR, P63; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HEMMING FW, 1974, BIOCH LIPIDS, P39; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KAUSHAL GP, 1990, BIOCHEMISTRY-US, V29, P2168, DOI 10.1021/bi00460a030; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; MUNCHPETERSEN A, 1956, ACTA CHEM SCAND, V10, P928, DOI 10.3891/acta.chem.scand.10-0928; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V50, P129, DOI 10.1016/0006-3002(61)91068-X; REISSIG JL, 1955, J BIOL CHEM, V217, P959; SRERE P, 1994, TRENDS BIOCHEM SCI, V19, P519, DOI 10.1016/0968-0004(94)90048-5; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; SZUMILO T, 1993, J BIOL CHEM, V268, P17943; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; WHEAT RW, 1966, METHOD ENZYMOL, V8, P60	27	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13147	13154		10.1074/jbc.271.22.13147	http://dx.doi.org/10.1074/jbc.271.22.13147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662687	hybrid			2022-12-27	WOS:A1996UN47400071
J	Beard, WA; Minnick, DT; Wade, CL; Prasad, R; Won, RL; Kumar, A; Kunkel, TA; Wilson, SH				Beard, WA; Minnick, DT; Wade, CL; Prasad, R; Won, RL; Kumar, A; Kunkel, TA; Wilson, SH			Role of the ''helix clamp'' in HIV-1 reverse transcriptase catalytic cycling as revealed by alanine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; MECHANISM; TEMPLATE; KINETICS; DNA; TERMINATION; INHIBITOR; SEQUENCE; BINDING	Residues 259-284 of HIV-1 reverse transcriptase exhibit sequence homology with other nucleic acid polymerases and have been termed the ''helix clamp'' (Hermann, T., Meier, T., Gotte, M., and Heumann, H. (1994) Nucleic Acids Res, 22, 4625-4633), since crystallographic evidence indicates these residues are part of two alpha-helices (alpha H and alpha I) that interact with DNA. Alanine-scanning mutagenesis has previously demonstrated that several residues in alpha H make important interactions with nucleic acid and influence frameshift fidelity. To define the role of alpha I (residues 278-286) during catalytic cycling, we performed systematic site directed mutagenesis from position 277 through position 287 by changing each residue, one by one, to alanine, Each mutant protein was expressed and, except for L283A and T286A, was soluble. The soluble mutant enzymes were purified and characterized, In contrast to alanine mutants of alpha H, alanine substitution in alpha I did not have a significant effect on template . primer (T . P) binding as revealed by a lack of an effect on K-m,K-T . P, K-i for 3'-azido-2',3'-dideoxythymidine 5'-triphosphate, k(off,T . P), and processivity. Consistent with these observations, the fidelity of the mutant enzymes was not influenced. However, alanine mutagenesis of alpha I lowered the apparent activity of every mutant relative to wild-type enzyme, Titration of two mutants exhibiting the lowest activity with T . P (L282A and R284A) demonstrated that these mutant enzymes could bind T . P stoichiometrically and tightly, In contrast, active site concentrations determined from ''burst'' experiments suggest that the lower activity is due to a smaller population of enzyme bound productively to T . P. The putative electrostatic interactions between the basic side chains of the helix clamp and the DNA backbone are either very weak or kinetically silent, In contrast, interactions between several residues of alpha H and the DNA minor groove, 3-5 nucleotides from the 3'-primer terminus, are suggested to be critical for DNA binding and fidelity.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; NIEHS, GENET MOLEC LAB, NIH, RES TRIANGLE PK, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BAILLON JG, 1991, NEW BIOL, V3, P1015; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MISRA VK, 1995, P NATL ACAD SCI USA, V92, P4691, DOI 10.1073/pnas.92.10.4691; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	36	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12213	12220		10.1074/jbc.271.21.12213	http://dx.doi.org/10.1074/jbc.271.21.12213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647817	hybrid			2022-12-27	WOS:A1996UL66000019
J	Lamberg, A; Helaakoski, T; Myllyharju, J; Peltonen, S; Notbohm, H; Pihlajaniemi, T; Kivirikko, KI				Lamberg, A; Helaakoski, T; Myllyharju, J; Peltonen, S; Notbohm, H; Pihlajaniemi, T; Kivirikko, KI			Characterization of human type III collagen expressed in a baculovirus system - Production of a protein with a stable triple helix requires coexpression with the two types of recombinant prolyl 4-hydroxylase subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE; BETA-SUBUNIT; INSECT CELLS; PROCOLLAGEN; BIOSYNTHESIS; SECRETION; ENZYMES; CHAIN; GENE	An efficient expression system for recombinant collagens would have numerous scientific and practical applications. Nevertheless, most recombinant systems are not suitable for this purpose, as they do not have sufficient amounts of prolyl 4-hydroxylase activity. Pro-alpha 1 chains of human type III collagen expressed in insect cells by a baculovirus vector are reported here to contain significant amounts of 4-hydroxyproline and to form triple-helical molecules, although the T-m of the triple helices was only about 32-34 degrees C. Coexpression of the pro-alpha 1(III) chains with the alpha and beta subunits of human prolyl 4-hydroxylase increased the T-m to about 40 degrees C, provided that ascorbate was added to the culture medium. The level of expression of type III procollagen was also increased in the presence of the recombinant prolyl 4-hydroxylase, and the pro-alpha 1(III) chains and alpha 1(III) chains were found to be present in disulfide-bonded molecules. Most of the triple-helical collagen produced was retained within the insect cells and could be extracted from the cell pellet. The highest expression levels were obtained in High Five cells, which produced up to about 80 mu g of cellular type III collagen (120 mu g of procollagen) per 5 x 10(6) cells in monolayer culture and up to 40 mg/liter of cellular type III collagen (60 mg/liter procollagen) in suspension. The 4-hydroxyproline content and T-m of the purified recombinant type III collagen were very similar to those of the nonrecombinant protein, but the hydroxylysine content was slightly lower, being about 3 residues/1000 in the former and 5/1000 in the latter.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND; UNIV LUBECK, INST MED MOL BIOL, D-23538 LUBECK, GERMANY	University of Oulu; University of Oulu; University of Lubeck			Peltonen, Sirkku/C-3133-2008	Peltonen, Sirkku/0000-0003-0990-1430; Pihlajaniemi, Taina/0000-0002-1664-9045				ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; BOOTH BA, 1981, BIOCHIM BIOPHYS ACTA, V675, P117, DOI 10.1016/0304-4165(81)90076-3; BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CAVALLARO JF, 1994, BIOTECHNOL BIOENG, V43, P781, DOI 10.1002/bit.260430813; CHUNG E, 1974, SCIENCE, V183, P1200, DOI 10.1126/science.183.4130.1200; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MAPLES JA, 1985, AM J CLIN PATHOL, V83, P356, DOI 10.1093/ajcp/83.3.356; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; TROMP G, 1989, J BIOL CHEM, V264, P1349; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VERNET T, 1990, J BIOL CHEM, V265, P16661; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WEINER HL, 1994, P NATL ACAD SCI USA, V91, P10762, DOI 10.1073/pnas.91.23.10762	37	100	102	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11988	11995		10.1074/jbc.271.20.11988	http://dx.doi.org/10.1074/jbc.271.20.11988			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662631	hybrid			2022-12-27	WOS:A1996UL25000062
J	Ohta, Y; Hartwig, JH				Ohta, Y; Hartwig, JH			Phosphorylation of actin-binding protein 280 by growth factors is mediated by p90 ribosomal protein S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MAP KINASES; PLATELET; FILAMIN; PROTEOLYSIS; FILAMENTS; PATHWAYS	Although Ras-related small GTPases are believed to control cell proliferation and motility through activation of protein kinase cascades, little is known about the intracellular protein targets of activated kinases. Here we show that the p90 ribosomal S6 kinase 2 (RSK2) phosphorylates actin-binding protein (ABP-280) in intact rat 3Y1 fibroblasts. Growth factors such as fetal calf serum, epidermal growth factor, phorbol 12-myristate 13-acetate, and lysophosphatidic acid stimulate the phosphorylation of serine residues in ABP-280 in quiescent 3Y1 cells. Extracts from 3Y1 cells prepared after stimulation by lysophosphatidic acid, fetal calf serum, and epidermal growth factor retain activated protein kinase activity(s) toward ABP-280 in vitro. ABP kinase activities in lysates from lysophosphatidic acid-stimulated 3Y1 cells can be fractionated by MonoQ anion exchange column chromatography into three peaks having ABP kinase activities. One (ABP kinase peak 1) coelutes with the peak of RSK2 as judged by immunoblotting and S6 peptide kinase assays. Two-dimensional phosphopeptide maps show RSK2 phosphorylated ABP-280 to be phosphorylated at the same site(s) as those stimulated by growth factors in vivo. Incubation of ABP kinase peak 1 fractionated from unstimulated cells with activated ERK2 activates latent ABP kinase activity. These results show RSK2 to phosphorylate ABP-280 in vivo.	BRIGHAM & WOMENS HOSP, DIV EXPTL MED, LONGWOOD MED RES CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL 56252, HL-19429] Funding Source: Medline; NIDDK NIH HHS [DK38452] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056252, R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL RC, 1982, BLOOD, V59, P466; CHEN M, 1989, J BIOL CHEM, V264, P14282; DAVIES P, 1977, BIOCHEM BIOPH RES CO, V74, P300, DOI 10.1016/0006-291X(77)91408-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V118, P736, DOI 10.1016/0006-291X(84)91456-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OHTA Y, 1988, J BIOL CHEM, V263, P11540; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SEGER R, 1994, J BIOL CHEM, V269, P25699; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; UEDA M, 1992, EUR J BIOCHEM, V203, P347, DOI 10.1111/j.1432-1033.1992.tb16556.x; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WALLACH D, 1978, J BIOL CHEM, V253, P4739; YADA Y, 1990, BIOCHEM BIOPH RES CO, V172, P256, DOI 10.1016/S0006-291X(05)80202-5; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020; ZHANG Z, 1988, BIOCHEM BIOPH RES CO, V151, P355, DOI 10.1016/0006-291X(88)90601-8	37	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11858	11864		10.1074/jbc.271.20.11858	http://dx.doi.org/10.1074/jbc.271.20.11858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662682	hybrid			2022-12-27	WOS:A1996UL25000045
J	Sorby, M; Ostman, A				Sorby, M; Ostman, A			Protein-tyrosine phosphatase-mediated decrease of epidermal growth factor and platelet-derived growth factor receptor tyrosine phosphorylation in high cell density cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PHOSPHOTYROSINE PHOSPHATASE; FACTOR-I	Contact-induced growth inhibition is a characteristic feature of normal cells grown in monolayer. The importance of reversible tyrosine phosphorylation in mitogenic signaling, together with earlier reports of increased levels of protein-tyrosine phosphatases (PTPs) in densely cultured cells, has led to the proposal that PTPs may be involved in mediating contact inhibition of cell growth. We have compared net levels of ligand-induced tyrosine phosphorylation of the epidermal growth factor (EGF) receptor in mink lung epithelial cells cultured under sparse or dense conditions. The levels of net tyrosine phosphorylation of the stimulated EGF receptor was found to be more than 4-fold higher in sparse cultures. This difference was greatly reduced when cells were pretreated with the PTP inhibitor phenyl arsine oxide. Monitoring of dephosphorylation rates in vivo of the stimulated EGF receptors revealed increased EGF receptor-directed PTP activity in dense cultures. The platelet-derived growth factor beta-receptor, expressed in stably transfected porcine aortic endothelial cells, also displayed lower levels of ligand induced net tyrosine phosphorylation in cells from dense cultures. This density-dependent difference in tyrosine phosphorylation was reduced by pretreatment of cultures with the PTP inhibitor orthovanadate. A PTP-mediated decrease of the in vivo net levels of ligand induced tyrosine phosphorylation of EGF and platelet-derived growth factor receptors in cells at high density have thus been demonstrated. Loss of this previously unnoticed regulatory pathway may be involved in cellular transformation.	LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; CELLER JW, 1995, BIOCHEM BIOPH RES CO, V209, P614, DOI 10.1006/bbrc.1995.1544; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSBRIDGE JN, 1992, J CELL PHYSIOL, V151, P433, DOI 10.1002/jcp.1041510302; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MORI S, 1991, J BIOL CHEM, V266, P21158; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; SAP J, 1994, MOL CELL BIOL, V14, P1; SOUTHEY MC, 1995, BIOCHEM J, V305, P485, DOI 10.1042/bj3050485; WAY BA, 1993, J BIOL CHEM, V268, P26409	17	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10963	10966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631915				2022-12-27	WOS:A1996UJ34200083
J	Balsinde, J; Dennis, EA				Balsinde, J; Dennis, EA			Distinct roles in signal transduction for each of the phospholipase A(2) enzymes present in P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A(2); RAT MESANGIAL CELLS; CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; ARACHIDONIC-ACID RELEASE; SWISS 3T3 CELLS; TRANSFORMING GROWTH-FACTOR-BETA-2; ACTIVATION; INHIBITION; SECRETION; PROSTAGLANDIN-E(2)	Receptor-stimulated arachidonic acid (AA) mobilization in P388D(1) macrophages consists of a transient phase in which AA accumulates in the cell and a sustained phase in which AA accumulates in the incubation medium. We have shown previously that a secretory group II phospholipase A(2) (sPLA(2)) is the enzyme responsible for most of the AA released to the incubation medium. By using selective inhibitors for each of the PLA(2)s present in P388D(1) macrophages, we demonstrate herein that the cytosolic group IV PLA(2) (cPLA(2)) mediates accumulation of cell-associated AA during the early steps of P388D(1) cell activation. The contribution of both cPLA(2) and sPLA(2) to AA release can be distinguished on the basis of the different spatial and temporal characteristics of activation and substrate preferences of the two phospholipase A(2)s (PLA(2)s). Furthermore, the results suggest the possibility that a functionally active cPLA, may be necessary for sPLA(2) to act. cPLA(2) action precedes that of sPLA(2), and overcoming cPLA(2) inhibition by artificially increasing intracellular free AA levels restores extracellular AA release. Although this suggests cross-talk between cPLA(2) and sPLA(2), selective inhibition of one other PLA(2) present in these cells, namely the Ca2+-independent PLA(2), does not block, but instead enhances receptor-coupled AA release. These data indicate that Ca2+-independent PLA(2), does not mediate AA mobilization in P388D(1) macrophages. Collectively, the results of this work suggest that each of the PLA(2) present in P388D(1) macrophages serves a distinct role in cell activation and signal transduction.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AMIS R, 1994, BIOCHEM J, V298, P543; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DOMIN J, 1993, J BIOL CHEM, V268, P8927; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FONTEH AN, 1993, J IMMUNOL, V150, P563; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GLASER KB, 1990, J BIOL CHEM, V265, P8658; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; JOO F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P231, DOI 10.1016/0005-2736(93)90206-F; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PLESNIAK LA, 1993, BIOCHEMISTRY-US, V32, P5009, DOI 10.1021/bi00070a006; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S	35	332	337	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6758	6765		10.1074/jbc.271.12.6758	http://dx.doi.org/10.1074/jbc.271.12.6758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636097	hybrid, Green Published			2022-12-27	WOS:A1996UB15700032
J	Buton, X; Morrot, G; Fellmann, P; Seigneuret, M				Buton, X; Morrot, G; Fellmann, P; Seigneuret, M			Ultrafast glycerophospholipid-selective transbilayer motion mediated by a protein in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL-MEMBRANES; RAT-LIVER; PHOSPHOLIPID-BILAYER; ERYTHROCYTE-MEMBRANE; ISOTROPIC MOTION; PHOSPHATIDYLCHOLINE; VESICLES; MOVEMENT; LIPIDS; PHOSPHATIDYLETHANOLAMINE	A relatively rapid transbilayer motion of phospholipids in the microsomal membrane seems to be required due to their asymmetric synthesis in the cytoplasmic leaflet, Marked discrepancies exist with regard to the rate and specificity of this flip-flop process, To reinvestigate this problem, we have used both spin-labeled and radioactively labeled long chain phospholipids with a new fast translocation assay, Identical results were obtained with both types of probes, Transbilayer motion of glycerophospholipids was found to be much more rapid than previously reported (half-time less than 25 s) and to occur identically for phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine. Such transport is nonvectorial and leads to a symmetric transbilayer distribution of phospholipids, In contrast, transverse diffusion of sphingomyelin was 1 order of magnitude slower, Phospholipid flip-flop appears to occur by a protein-mediated transport process displaying saturable and competitive behavior, Proteolysis, chemical modification, and competition experiments suggest that this transport process may be related to that previously described in the endoplasmic reticulum for short-chain phosphatidylcholine (Bishop, W. R,, and Bell, R, M, (1985) Cell 42, 51-60), The relationship between phospholipid flip-flop and nonbilayer structures occurring in the endoplasmic reticulum was also investigated by P-31-NMR. Several conditions were found under which the (31)p isotropic NMR signal previously attributed to nonbilayer structures is decreased or abolished, whereas transbilayer diffusion is unaffected, suggesting that the flip-flop process is independent of such structures, It is concluded that flip-flop in the endoplasmic reticulum is mediated by a bidirectional protein transporter with a high efficiency for glycerophospholipids and a low efficiency for sphingomyelin. lie vivo, the activity of this transporter would be able to redistribute all changes in phospholipid composition due to biosynthetic processes between the two leaflets of the endoplasmic reticulum membranes within a time scale of seconds.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; UNIV DENIS DIDEROT,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite	Buton, X (corresponding author), LAB BIOPHYS CELLULAIRE,URA 526,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							BAKER JM, 1981, NATURE, V327, P341; BALLAS LM, 1981, BIOCHIM BIOPHYS ACTA, V665, P586, DOI 10.1016/0005-2760(81)90274-5; BELLEAU B, 1968, J AM CHEM SOC, V90, P1651, DOI 10.1021/ja01008a045; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BOLLEN IC, 1980, BIOCHEM J, V189, P475, DOI 10.1042/bj1890475; CLASSEN J, 1987, BIOCHEMISTRY-US, V26, P6604, DOI 10.1021/bi00395a007; COLEMAN R, 1978, J CELL BIOL, V76, P245, DOI 10.1083/jcb.76.1.245; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V600, P343, DOI 10.1016/0005-2736(80)90438-1; DEKRUIJFF B, 1978, BIOCHIM BIOPHYS ACTA, V507, P38, DOI 10.1016/0005-2736(78)90372-3; DEKRUIJFF B, 1978, BIOCHIM BIOPHYS ACTA, V514, P1, DOI 10.1016/0005-2736(78)90072-X; FELLMANN P, 1994, METHODS MOL BIOL 2, V27; GERRITSEN WJ, 1980, BIOCHIM BIOPHYS ACTA, V598, P554, DOI 10.1016/0005-2736(80)90035-8; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HIGGINS JA, 1981, BIOCHIM BIOPHYS ACTA, V640, P1, DOI 10.1016/0005-2736(81)90527-7; HIGGINS JA, 1987, J LIPID RES, V28, P268; HIGGINS JA, 1977, BIOCHIM BIOPHYS ACTA, V470, P342, DOI 10.1016/0005-2736(77)90126-2; HIGGINS JA, 1979, BIOCHIM BIOPHYS ACTA, V558, P48, DOI 10.1016/0005-2736(79)90314-6; HIGGINS JA, 1987, BIOL MEMBRANES PRACT, V2, P125; HUSTON JL, 1982, BIOCHIM BIOPHYS ACTA, V687, P247; KAWASHIMA Y, 1987, J BIOL CHEM, V262, P16495; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAMUEL NKP, 1985, J AM CHEM SOC, V107, P42, DOI 10.1021/ja00287a008; SEIGNEURET M, 1984, BIOCHEMISTRY-US, V23, P4271, DOI 10.1021/bi00314a002; STIER A, 1978, FEBS LETT, V91, P109, DOI 10.1016/0014-5793(78)80028-3; VANDENBESSELAAR AMHP, 1978, BIOCHIM BIOPHYS ACTA, V510, P242, DOI 10.1016/0005-2736(78)90024-X; VANDUIJN G, 1986, BIOCHIM BIOPHYS ACTA, V863, P193, DOI 10.1016/0005-2736(86)90259-2; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZILVERSMIT DB, 1977, BIOCHIM BIOPHYS ACTA, V469, P99, DOI 10.1016/0005-2736(77)90329-7	30	93	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6651	6657		10.1074/jbc.271.12.6651	http://dx.doi.org/10.1074/jbc.271.12.6651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636082				2022-12-27	WOS:A1996UB15700017
J	Kim, JH; Ryan, MG; Knaut, H; Hille, R				Kim, JH; Ryan, MG; Knaut, H; Hille, R			The reductive half-reaction of xanthine oxidase - The involvement of prototropic equilibria in the course of the catalytic sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-ATOM TRANSFER; ELECTRON-PARAMAGNETIC-RESONANCE; RELEVANT ANALOG COMPLEXES; DIFFERENT REDUCED FORMS; MOLYBDENUM CENTER; REACTION SYSTEM; ACTIVE-SITES; MOLYBDOENZYMES; MECHANISM; KINETICS	The pH dependence and solvent isotope sensitivity of three discrete steps in the reductive half-reaction of xanthine oxidase have been investigated, The pH dependence of both K-cat/K-m from steady-state experiments and k(red)/K-d from rapid reaction experiments with xanthine as substrate indicate that enzyme reacts preferentially with the neutral form of substrate and that an ionizable group in the active site having a pK(alpha) of similar to 6.6 must be unprotonated for reaction to take place. The solvent kinetic isotope effect on k(red)/K-d is 2.4, once a uniform shift on going to D2O of similar to 1 unit for both pK(alpha) values is taken into account. The pH dependence of the formation and decay of E(red)-P formed in the course the reaction of xanthine oxidase with lumazine has also been examined, Formation of this complex exhibits bell-shaped pH dependence, with pK(alpha) values of 6.5 and 7.8, consistent with the results obtained with xanthine. Decay of the E(red)-P complex is base-catalyzed with a pK(alpha) > 11 and exhibits a small solvent kinetic isotope effect of 1.7 at pH/D 8.5. By contrast, the catalytic intermediate giving rise to the ''very rapid'' EPR signal that is transiently observed in the course of the reaction of enzyme with the substrate 2-hydroxy-6-methylpurine is found to undergo acid-catalyzed breakdown with an associated pK(alpha) < 6. Formation and decay of this species exhibit solvent kinetic isotope effects of 2.0 and 3.5 at pH 10. The results are discussed in the context of a specific reaction mechanism for the reductive half-reaction of xanthine oxidase, in which discrete ionizations associated with the molybdenum center of the active site play critical roles in determining the magnitude of the rate constants by which the Mo(IV)-P and Mo(V)-P intermediates form and decay.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University				Knaut, Holger/0000-0002-8399-8720	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038917] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERT A, 1954, J CHEM SOC, P2060, DOI 10.1039/jr9540002060; BAZELYANSKY M, 1986, BIOCHEMISTRY-US, V25, P125, DOI 10.1021/bi00349a019; BERG JM, 1985, J AM CHEM SOC, V107, P917, DOI 10.1021/ja00290a029; BERG JM, 1984, J AM CHEM SOC, V106, P3035, DOI 10.1021/ja00322a050; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; BRAY RC, 1969, BIOCHEM J, V114, P725, DOI 10.1042/bj1140725; BRAY RC, 1985, BIOCHEM SOC T, V13, P560, DOI 10.1042/bst0130560; CARADONNA JP, 1988, J AM CHEM SOC, V110, P2139, DOI 10.1021/ja00215a022; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; DAVIS MD, 1982, J BIOL CHEM, V257, P4730; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; DOWERAH D, 1987, J AM CHEM SOC, V109, P5655, DOI 10.1021/ja00253a016; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; GHELLER SF, 1992, J AM CHEM SOC, V114, P6934, DOI 10.1021/ja00043a059; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTFREUND H, 1977, ENZYMES PHYSICAL PRI, P173; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; GUTTERIDGE S, 1980, BIOCHEM J, V189, P615, DOI 10.1042/bj1890615; GUTTERIDGE S, 1978, BIOCHEM J, V175, P869, DOI 10.1042/bj1750869; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1989, INORG CHEM, V28, P4018, DOI 10.1021/ic00320a016; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; JANCSO G, 1974, CHEM REV, V74, P689, DOI 10.1021/cr60292a004; KARSTEN WE, 1995, J AM CHEM SOC, V117, P5914, DOI 10.1021/ja00127a002; KIM JH, 1993, J BIOL CHEM, V268, P44; KURZ LC, 1983, BIOCHEMISTRY-US, V22, P382, DOI 10.1021/bi00271a023; LORIGAN GA, 1994, BBA-BIOENERGETICS, V1185, P284, DOI 10.1016/0005-2728(94)90243-7; MALTHOUSE JPG, 1981, BIOCHEM J, V199, P629, DOI 10.1042/bj1990629; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MASSEY V, 1973, IRON SULFUR PROTEINS, P301; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MOORE JW, 1981, KINETICS MECHANISM, P290; MORRISON M, 1963, J BIOL CHEM, V238, P2847; OERTLING WA, 1990, J BIOL CHEM, V265, P17446; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PALMER G, 1964, J BIOL CHEM, V239, P2657; ROBERTS SA, 1990, INORG CHEM, V29, P3650, DOI 10.1021/ic00344a007; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SCHULTZ BE, 1993, INORG CHEM, V32, P4244, DOI 10.1021/ic00072a016; SKIBO EB, 1986, BIOCHEMISTRY-US, V26, P3032; Stiefel E. I., 1977, PROG INORG CHEM, V21, P1; STIEFEL EI, 1973, P NATL ACAD SCI USA, V70, P988, DOI 10.1073/pnas.70.4.988; Tanner SJ, 1978, BIOCHEM SOC T, V6, P1328, DOI 10.1042/bst0061328; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WILSON GL, 1991, J AM CHEM SOC, V113, P6803, DOI 10.1021/ja00018a014; XIAO ZG, 1992, J AM CHEM SOC, V114, P9194, DOI 10.1021/ja00049a065	52	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6771	6780		10.1074/jbc.271.12.6771	http://dx.doi.org/10.1074/jbc.271.12.6771			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636099	hybrid			2022-12-27	WOS:A1996UB15700034
J	Wang, JA; Morris, AJ; Tolan, DR; Pagliaro, L				Wang, JA; Morris, AJ; Tolan, DR; Pagliaro, L			The molecular nature of the F-actin binding activity of aldolase revealed with site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MUSCLE ALDOLASE; GLYCOLYTIC-ENZYMES; CONTAINING-FILAMENTS; SKELETAL-MUSCLE; 3T3 CELLS; PROTEINS; CYTOPLASM; DEHYDROGENASE; ORGANIZATION; METABOLISM	We used site-directed mutagenesis of rabbit muscle aldolase, falling ball viscometry, co sedimentation binding assays, and negative stain electron microscopy, to identify specific residues involved in the aldolase-actin interaction, Three mutants, R42A (Arg --> Ala), K107A (Lys --> Ala), and R148A (Arg --> Ala), had minimal actin binding activity relative to wild type (wt) aldolase, and one mutant, K229A (Lys --> Ala), had intermediate actin binding activity, A mutant with similar to 4,000-fold reduced catalytic activity, D33S (Asp --> Ser), had normal actin binding activity, The aldolase substrates and product, fructose 1,6-bisphosphate, fructose 1-phosphate, and dihydroxyacetone phosphate, reversed the gelling of wt aldolase and F-actin, consistent with at least partial overlap of catalytic and actin-binding sites on aldolase, Molecular modeling reveals that the actin-binding residues we have identified are clustered in or around the catalytic pocket of the molecule. These data confirm that the aldolase-actin interaction is due to specific binding, and they suggest that electrostatic interactions between specific residues, rather than net charge, mediate this interaction. Low concentration of wt and D33S aldolase caused formation of high viscosity actin gel networks, while high concentrations of wt and D33S aldolase resulted in solation of the gel by bundling actin filaments, consistent with a potential role for this enzyme in the regulation of cytoplasmic structure.	UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195; BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	University of Washington; University of Washington Seattle; Boston University				Tolan, Dean/0000-0002-0598-7241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043521] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK17017, DK43521] Funding Source: Medline; NIGMS NIH HHS [GM08291] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; ARNOLD H, 1971, EUR J BIOCHEM, V22, P121, DOI 10.1111/j.1432-1033.1971.tb01522.x; ARNOLD H, 1968, EUR J BIOCHEM, V6, P163, DOI 10.1111/j.1432-1033.1968.tb00434.x; BARANOWSKI T, 1949, J BIOL CHEM, V180, P543; BAUER AC, 1964, FED PROC, V23, P310; BEERNINK PT, 1994, PROTEIN SCI, V3, P1383, DOI 10.1002/pro.5560030904; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; CLARK DL, 1986, ADV TEACHER ED, V2, P1; CLARKE FM, 1985, CELL MOTILITY MECHAN, P235; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; DEDUVE C, 1984, GUIDED TOUR LIVING C, P17; DON M, 1988, MOL CELL BIOCHEM, V81, P145; GAMBLIN SJ, 1991, J MOL BIOL, V219, P573, DOI 10.1016/0022-2836(91)90650-U; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; HARRIS SJ, 1987, BIOCHIM BIOPHYS ACTA, V911, P121, DOI 10.1016/0167-4838(87)90279-2; HARTMAN FC, 1976, J BIOL CHEM, V251, P3057; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HUMPHREYS L, 1986, INT J BIOCHEM, V18, P7, DOI 10.1016/0020-711X(86)90003-0; KELETI T, 1977, ADV ENZYME REGUL, V15, P233, DOI 10.1016/0065-2571(77)90019-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CY, 1975, ARCH BIOCHEM BIOPHYS, V166, P358, DOI 10.1016/0003-9861(75)90398-7; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; MASTERS C, 1984, J CELL BIOL, V99, pS222, DOI 10.1083/jcb.99.1.222s; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PAGLIARO L, 1989, J CELL SCI, V94, P333; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; Pagliaro L., 1995, ADV MOL CELL BIOL, V11, P93, DOI [10.1016/S1569-2558(08)60249-0, DOI 10.1016/S1569-2558(08)60249-0]; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PENHOET EE, 1971, J BIOL CHEM, V246, P318; PETERS RA, 1930, T FARADAY SOC, V26, P767; PETTE D, 1962, BIOCHEM BIOPH RES CO, V9, P367, DOI 10.1016/0006-291X(62)90056-6; RACKER E, 1952, J BIOL CHEM, V196, P347; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; RYAZANOV AG, 1988, FEBS LETT, V237, P1, DOI 10.1016/0014-5793(88)80159-5; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STRYER L, 1995, BIOCHEMISTRY-US, P181; TAKASAKI Y, 1990, PROG CLIN BIOL RES, V344, P935; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TELLAM RL, 1989, TRENDS BIOCHEM SCI, V14, P130, DOI 10.1016/0968-0004(89)90142-4; WALSH TP, 1977, BIOCHEM J, V165, P165, DOI 10.1042/bj1650165; WALSH TP, 1980, BIOCHEM J, V186, P89, DOI 10.1042/bj1860089; WALTER H, 1995, FEBS LETT, V361, P135, DOI 10.1016/0014-5793(95)00159-7; WANG J, 1994, J BIOCHEM BIOPH METH, V28, P251, DOI 10.1016/0165-022X(94)90001-9; WELCH GR, 1977, PROG BIOPHYS MOL BIO, V32, P103; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2	51	107	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6861	6865		10.1074/jbc.271.12.6861	http://dx.doi.org/10.1074/jbc.271.12.6861			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636111	hybrid			2022-12-27	WOS:A1996UB15700046
J	Andersson, LA; Bylkas, SA; Wilson, AE				Andersson, LA; Bylkas, SA; Wilson, AE			Spectral analysis of lactoperoxidase - Evidence for a common heme in mammalian peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; HOG THYROID PEROXIDASE; SPECTROSCOPIC PROPERTIES; PROSTHETIC GROUP; ACTIVE-SITE; RESONANCE SPECTROSCOPY; BOVINE LACTOPEROXIDASE; MILK LACTOPEROXIDASE; LIGAND COMPLEXES; IRON-PORPHYRIN	The identity of the non extractable heme of mammalian lactoperoxidase (LPO) has remained unsolved for over 40 years, Accepted possibilities include a constrained heme b or an 8-thiomethylene-modified heme b. Recent studies of myeloperoxidase (MPO) (Fenna, R., Zeng, J., and Davey, C. (1995) Arch. Biochem. Biophys. 316, 653-656; Taylor, K. L., Strobel, F., Yue, K. T., Ram, P., Pohl, J., Woods, A. S., and Kinkade, J. M., Jr. (1995) Arch. Biochem. Biophys. 316, 635-642) suggest possible prosthetic group similarities between MPO and LPO, To address heme identity for LPO, we used comparative magnetic circular dichroism (MCD) spectroscopy of LPO versus myoglobin (Mb), horseradish peroxidase (HRP), and MPO. MCD spectra of native Fe3+-LPO and Fe3+-CN--LPO are similar to 10 nm red shifted from analogous forms of Mb and HRP, including the formate-Mb adduct. MCD spectra of native LPO and MPO are opposite in sign, and MCD spectra of their cyanoadducts also differ, These data indicate the LPO heme is distinct from heme b of Rib and HRP as well as from ''heme m'' of MPO. From this work and literature analysis, we suggest that the nonextractable ''heme l'' of LPO has the two vinyl groups of heme b but lacks the 2-sulfonium-vinyl linkage of heme m. The observed red shifts in LPO spectra may derive from ester linkages to protein as for MPO. Strong spectral analogies between LPO and mammalian peroxidases (e.g. from saliva, eosinophils, thyroid, intestine) indicate similar prosthetic heme moieties.			Andersson, LA (corresponding author), KANSAS STATE UNIV,DEPT BIOCHEM,103 WILLARD HALL,MANHATTAN,KS 66506, USA.							ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDERSSON LA, 1995, BIOCHEM BIOPH RES CO, V211, P389, DOI 10.1006/bbrc.1995.1826; ANDERSSON LA, 1995, FEBS LETT, V370, P97, DOI 10.1016/0014-5793(95)00651-O; ANDERSSON LA, 1984, XENOBIOTICA, V14, P49, DOI 10.3109/00498258409151398; BEHERE DV, 1985, BIOCHEM BIOPH RES CO, V131, P607, DOI 10.1016/0006-291X(85)91280-X; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CHANG CS, 1993, BIOCHEMISTRY-US, V32, P2780, DOI 10.1021/bi00062a007; Dawson J. H., 1989, IRON PORPHYRINS 3, P1; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1992, NEW J CHEM, V16, P577; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DEROPP JS, 1985, J AM CHEM SOC, V107, P8268, DOI 10.1021/ja00312a080; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; GOFF HM, 1985, BIOCHEM BIOPH RES CO, V133, P794, DOI 10.1016/0006-291X(85)90974-X; HASHIMOTO S, 1989, FEBS LETT, V248, P205, DOI 10.1016/0014-5793(89)80462-4; HORI H, 1990, BIOCHEMISTRY-US, V29, P7106, DOI 10.1021/bi00482a023; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; IKEDASAITO M, 1990, ARCH BIOCHEM BIOPHYS, V283, P351, DOI 10.1016/0003-9861(90)90653-G; KIMURA S, 1978, ARCH BIOCHEM BIOPHYS, V189, P14, DOI 10.1016/0003-9861(78)90108-X; KITAGAWA T, 1983, BIOCHEMISTRY-US, V22, P2788, DOI 10.1021/bi00281a003; LANGBAKK B, 1989, BIOCHEM J, V259, P627, DOI 10.1042/bj2590627; LUKAT GS, 1988, BIOCHIM BIOPHYS ACTA, V954, P265, DOI 10.1016/0167-4838(88)90081-7; LUKAT GS, 1987, BIOCHEMISTRY-US, V26, P6927, DOI 10.1021/bi00396a011; LUKAT GS, 1993, J INORG BIOCHEM, V15, P157; MANSSONRAHEMTULLA B, 1988, BIOCHEMISTRY-US, V27, P233, DOI 10.1021/bi00401a035; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; METODIEWA D, 1989, BIOCHEM BIOPH RES CO, V160, P1183, DOI 10.1016/S0006-291X(89)80128-7; MODI S, 1990, J INORG BIOCHEM, V38, P17, DOI 10.1016/0162-0134(90)85003-F; MORRISON M, 1957, J BIOL CHEM, V228, P767; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; NICHOL AW, 1987, BIOCHEM J, V247, P147, DOI 10.1042/bj2470147; OHTAKI S, 1982, J BIOL CHEM, V257, P761; PRUITT KM, 1985, LACTOPEROXIDASE SYST; SHIRO Y, 1986, BIOCHEMISTRY-US, V25, P5844, DOI 10.1021/bi00368a002; SIEVERS G, 1983, BIOCHIM BIOPHYS ACTA, V742, P659, DOI 10.1016/0167-4838(83)90285-6; SIEVERS G, 1979, BIOCHIM BIOPHYS ACTA, V579, P181, DOI 10.1016/0005-2795(79)90097-7; SONO M, 1986, BIOCHEMISTRY-US, V25, P347, DOI 10.1021/bi00350a011; SONO M, 1982, J BIOL CHEM, V257, P8308; SONO M, 1991, P NATL ACAD SCI USA, V88, P11148, DOI 10.1073/pnas.88.24.11148; SONO M, 1986, BIOCHIM BIOPHYS ACTA, V873, P62, DOI 10.1016/0167-4838(86)90190-1; SPIRO TG, 1995, METHODS ENZYMOL, V246, P416; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; THANABAL V, 1989, BIOCHEMISTRY-US, V28, P7038, DOI 10.1021/bi00443a039; THOMAS EL, 1991, PEROXIDASES CHEM BIO, V1, P123; VICKERY L, 1975, J AM CHEM SOC, V98, P343; WEVER R, 1991, J BIOL CHEM, V266, P24308; [No title captured]	49	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3406	3412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631940	hybrid			2022-12-27	WOS:A1996TV72400014
J	Brooke, JS; Valvano, MA				Brooke, JS; Valvano, MA			Biosynthesis of inner core lipopolysaccharide in enteric bacteria identification and characterization of a conserved phosphoheptose isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PERFORMANCE LIQUID-CHROMATOGRAPHY; SALMONELLA-TYPHIMURIUM; MASS-SPECTROMETRY; SEQUENCE-ANALYSIS; RFAC GENE; DNA; CHROMOSOME; GLYCOPROTEINS; CONSTRUCTION	The lpcA locus has been identified in Escherichia coli K12 novobiocin-supersensitive mutants that produce a short lipopolysaccharide (LPS) core which lacks glyc eromannoheptose and terminal hexoses. We have characterized lpcA as a single gene mapping around 5.3 min (246 kilobases) on the E. coli K12 chromosome and encoding a 22.6-kDa cytosolic protein. Recombinant plasmids containing only lpcA restored a complete core LPS in the E. coli strain chi 711. We show that this strain has an IS5-mediated chromosomal deletion of 35 kilobases that eliminates lpcA. The LpcA protein showed discrete similarities with a family of aldose/ketose isomerases and other proteins of unknown function. The isomerization of sedoheptulose 7-phosphate, into a phosphosugar presumed to be D-glycero-D-mannoheptose 7-phosphate, was detected in enzyme reactions with cell extracts of E. coli lpcA(+) and of lpcA mutants containing the recombinant lpcA gene. We concluded that LpcA is the phosphoheptose isomerase used in the first step of glyceromannoheptose synthesis. We also demonstrated that lpcA is conserved among enteric bacteria, all of which contain glyceromannoheptose in the inner core LPS, indicating that LpcA is an essential component in a conserved biosynthetic pathway of inner core LPS.			Brooke, JS (corresponding author), UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,DENT SCI BLDG,RM 3003,LONDON,ON N6A 5C1,CANADA.		Valvano, Miguel A/G-8759-2012	Valvano, Miguel A/0000-0001-8229-3641				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECK KF, 1993, BIOTECHNIQUES, V14, P375; BIRKENBIHL RP, 1989, MOL GEN GENET, V220, P147, DOI 10.1007/BF00260869; CHEN L, 1993, J BACTERIOL, V175, P2534, DOI 10.1128/JB.175.9.2534-2540.1993; COLEMAN WG, 1979, J BACTERIOL, V139, P899, DOI 10.1128/JB.139.3.899-910.1979; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; CURTISS R, 1968, BACTERIOL REV, V32, P320, DOI 10.1128/MMBR.32.4_Pt_1.320-348.1968; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUBRAY G, 1982, ANAL BIOCHEM, V119, P325, DOI 10.1016/0003-2697(82)90593-0; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EIDELS L, 1971, P NATL ACAD SCI USA, V68, P1673, DOI 10.1073/pnas.68.8.1673; EIDELS L, 1974, J BIOL CHEM, V249, P5642; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLINELLIPIMPANEAU B, 1989, J AM CHEM SOC, V111, P3029, DOI 10.1021/ja00190a042; Hancock REW, 1994, BACTERIAL CELL WALL, P263; HAVEKES LM, 1976, MOL GEN GENET, V146, P43, DOI 10.1007/BF00267981; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; HOWARTH GB, 1969, CAN J CHEMISTRY, V47, P75, DOI 10.1139/v69-009; KASSAVETIS GA, 1982, J BIOL CHEM, V257, P5779; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KWON H, 1993, ANAL BIOCHEM, V215, P243, DOI 10.1006/abio.1993.1582; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; Maniatis T., 1982, MOL CLONING; MAROLDA CL, 1990, J BACTERIOL, V172, P3590, DOI 10.1128/jb.172.7.3590-3599.1990; POOLE K, 1988, J BACTERIOL, V170, P3177, DOI 10.1128/jb.170.7.3177-3188.1988; QURESHI N, 1988, J BIOL CHEM, V263, P11971; REEVES P, 1994, BACTERIAL CELL WALL, P281; RICK PD, 1987, ESCHERICHIA COLI SAL, P647; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SELVARAJ G, 1984, GENE, V32, P235, DOI 10.1016/0378-1119(84)90051-9; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; TABATA S, 1989, J BACTERIOL, V171, P1214, DOI 10.1128/jb.171.2.1214-1218.1989; TAMAKI S, 1971, J BACTERIOL, V105, P968, DOI 10.1128/JB.105.3.968-975.1971; TAYLOR PW, 1983, MICROBIOL REV, V47, P46, DOI 10.1128/MMBR.47.1.46-83.1983; UJEJSKI L, 1955, CAN J CHEM, V33, P687, DOI 10.1139/v55-082; UMEDA M, 1990, J MOL BIOL, V213, P229, DOI 10.1016/S0022-2836(05)80186-X; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; WOOD T, 1970, Archives of Biochemistry and Biophysics, V141, P440, DOI 10.1016/0003-9861(70)90160-8; WOOD T, 1985, PENTOSE PHOSPHATE PA; YAO ZJ, 1994, J BACTERIOL, V176, P4133, DOI 10.1128/JB.176.13.4133-4143.1994; YAO ZJ, 1992, J BACTERIOL, V174, P7500, DOI 10.1128/JB.174.23.7500-7508.1992; YARDLEY HJ, 1963, BIOCHEM J, V86, P101, DOI 10.1042/bj0860101; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	52	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3608	3614						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631969				2022-12-27	WOS:A1996TV72400043
J	Hirose, F; Yamaguchi, M; Kuroda, K; Omori, A; Hachiya, T; Ikeda, M; Nishimoto, Y; Matsukage, A				Hirose, F; Yamaguchi, M; Kuroda, K; Omori, A; Hachiya, T; Ikeda, M; Nishimoto, Y; Matsukage, A			Isolation and characterization of cDNA for DREF, a promoter-activating factor for Drosophila DNA replication-related genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA; ESCHERICHIA-COLI; GROWTH-REGULATION; BUDDING YEAST; EXPRESSION; CYCLE; TRANSCRIPTION; PROTEIN; BINDING	DREF, a transcription regulatory factor which specifically binds to the promoter-activating element DRE (DNA replication related element) of DNA replication-related genes, was purified to homogeneity from nuclear extracts of Drosophila Kc cells, cDNA for DREF was isolated with the reverse-transcriptase polymerase chain reaction method using primers synthesized on the basis of partial amino acid sequences and following screening of cDNA libraries, Deduced from the nucleotide sequences of cDNA, DREF is a polypeptide of 701 amino acid residues with a molecular weight of 80,096, which contains three characteristic regions, rich in basic amino acids, proline, and acidic amino acids, respectively, Deletion analysis of bacterially expressed DREF fused with glutathione S-transferase (GST-DREF) indicated that a part of the N-terminal basic amino acid region (16-115 amino acids) is responsible for the specific binding to DRE, A polyclonal and four monoclonal antibodies were raised against the GST-DREF fusion protein, The antibodies inhibited specifically the transcription of DNA polymerase alpha promoter in vitro. Cotransfection experiments using Kc cells demonstrated that overproduction of DREF protein overcomes the re repression of the proliferating cell nuclear antigen gene promoter by the zerknullt gene product. These results confirmed that DREF is a trans activating factor for DNA replication-related genes. Immunocytochemical analysis demonstrated the presence of DREF polypeptide in nuclei after the eighth nuclear division cycle, suggesting that nuclear accumulation of DREF is important for the coordinate zygotic expression of DNA replication-related genes carrying DRE sequences.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; MITSUBISHI KAGAKU INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; MED BIOL LAB,INA,NAGANO 396,JAPAN	Aichi Cancer Center; Mitsubishi Kagaku Institute of Life Sciences (MITILS)				Yamaguchi, Masamitsu/0000-0002-6321-9750				Ashburner M., 1989, DROSOPHILA LAB MANUA, P214; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOE VE, 1989, DEVELOPMENT, V107, P1; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1994, J BIOL CHEM, V269, P2937; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; Kornberg A, 1992, DNA REPLICATION, P471; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LI R, 1993, P NATL ACAD SCI USA, V90, P3554; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATSUKAGE A, 1986, DEV BIOL, V117, P226, DOI 10.1016/0012-1606(86)90365-9; MATSUKAGE A, 1995, GENE AMST, V116, P233; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; YAMAGUCHI M, 1991, J CELL SCI, V100, P729	47	118	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3930	3937						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632015				2022-12-27	WOS:A1996TV72400089
J	Poster, JB; Dean, N				Poster, JB; Dean, N			The yeast VRG4 gene is required for normal Golgi functions and defines a new family of related genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANADATE-RESISTANT MUTANTS; SACCHAROMYCES-CEREVISIAE; PROTEIN GLYCOSYLATION; SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; OUTER CHAIN; TRANSPORT; CELLS; PMR1; DNA	Sodium vanadate is an effective agent for the enrichment of yeast mutants with defects in glycosylation steps that occur in the Golgi complex (Ballou, L., Hitzeman, R. A. Lewis, M. S., and Ballou, C. E. (1991) Proc. Natl. Acad. Sci. U. S. A, 88, 3209-3212). We isolated and screened vanadate-resistant glycosylation mutants in the budding yeast, Saccharomyces cerevisiae, to identify any that may be defective in the secretory pathway, since changes in normal glycosylation may reflect defects within the secretory pathway. We identified one such mutant, allelic to vrg4/van2, that is defective in processes that occur specifically in the Golgi complex, Protein secreted from vrg4 mutants lacks the outer chain glycosylation that is normally extended during passage through the Golgi, This mutant fails to retrieve soluble endoplasmic reticulum proteins from the Golgi and accumulates the Golgi-specific biosynthetic intermediate of the vacuolar protein, carboxypeptidase Y. Analyses of intracellular membranes by staining with the fluorescent lipophilic dye, DiOC(6), and by electron microscopy reveals a dramatic alteration in the membrane morphology of vrg4 mutant cells. The VRG4 gene encodes a 36.9-kDa membrane protein that is essential for cell viability. A sequence homology search has identified five related genes, establishing that VRG4 is a founding member of a family of structurally similar genes. Taken together, these results suggest that the VRG4 gene plays an important role in regulating Golgi functions and in maintaining the normal organization of intracellular membranes.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48467] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BALLOU L, 1980, J BIOL CHEM, V255, P5986; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; DEAN N, 1996, IN PRESS GLYCOBIOLOG; DENA N, 1990, J CELL BIOL, V111, P369; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; GRAHAM TR, 1992, YEAST, V8, pS458; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAYAT MA, 1981, FIXATION ELECTRON MI, P184; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL K, 1992, GENETICS, V130, P273; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KANIKENNULAT C, 1995, GENETICS, V140, P933; KANIKENNULAT C, 1990, MOL CELL BIOL, V10, P898, DOI 10.1128/MCB.10.3.898; KANIKENNULAT C, 1995, MOL CELL BIOL, V140, P933; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; WILLSKY GR, 1985, J BACTERIOL, V164, P611, DOI 10.1128/JB.164.2.611-617.1985; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	44	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3837	3845						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632002				2022-12-27	WOS:A1996TV72400076
J	Shima, DT; Kuroki, M; Deutsch, U; Ng, YS; Adamis, AP; DAmore, PA				Shima, DT; Kuroki, M; Deutsch, U; Ng, YS; Adamis, AP; DAmore, PA			The mouse gene for vascular endothelial growth factor - Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PERMEABILITY FACTOR; TRANSFERRIN RECEPTOR; FACTOR FAMILY; GM-CSF; EXPRESSION; ANGIOGENESIS; TUMOR; CELLS; VEGF	We describe the genomic organization and functional characterization of the mouse gene encoding vascular endothelial growth factor (VEGF), a polypeptide implicated in embryonic vascular development and postnatal angiogenesis. The coding region for mouse VEGF is interrupted by seven introns and encompasses approximately 14 kilobases. Organization of exons suggests that, similar to the human VEGF gene, alternative splicing generates the 120-, 164-, and 188-amino acid isoforms, but does not predict a fourth VEGF isoform corresponding to human VEGF(206). Approximately 1.2 kilobases of 5'-flanking region have been sequenced, and primer extension analysis identified a single major transcription initiation site, notably lacking TATA or CCAT consensus sequences. The 5'-flanking region is sufficient to promote a 7-fold induction of basal transcription. The genomic region encoding the 3'-untranslated region was determined by Northern and nuclease mapping analysis. Investigation of mRNA sequences responsible for the rapid turnover of VEGF mRNA (mRNA half-life, <1 h) (Shima, D. T., Deutsch, U., and D'Amore, P. A (1995) FEES Lett. 370, 203-208) revealed that the 3'-untranslated region was sufficient to trigger the rapid turnover of a normally long-lived reporter mRNA in vitro. These data and reagents will allow the molecular and genetic analysis of mechanisms that control the developmental and pathological expression of VEGF.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP,SURG RES LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02115; MAX PLANCK INST PHYSIOL & CLIN RES,W-6350 BAD NAUHEIM,GERMANY	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Max Planck Society	Shima, DT (corresponding author), HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115, USA.		Ng, Wing Yin/HHN-1743-2022; D'Amore, Patricia/G-5660-2017	Ng, Yin Shan/0000-0002-4982-1999; D'Amore, Patricia/0000-0001-9652-8974; Deutsch, Urban/0000-0003-4265-6262	NEI NIH HHS [EY05985] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ADAMIS AP, 1995, IN PRESS ARCH OPHTHA; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BREIER G, 1992, DEVELOPMENT, V114, P521; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER JW, 1994, AM J PATHOL, V145, P574; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Sambrook J, 1989, MOL CLONING LABORATO; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; TISCHER E, 1991, J BIOL CHEM, V266, P11947; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	48	299	318	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3877	3883						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632007	hybrid			2022-12-27	WOS:A1996TV72400081
J	Tiberi, M; Nash, SR; Bertrand, L; Lefkowitz, RJ; Caron, MG				Tiberi, M; Nash, SR; Bertrand, L; Lefkowitz, RJ; Caron, MG			Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; HETEROLOGOUS DESENSITIZATION; ADENYLYL CYCLASE; CELLS; STRIATUM; ARRESTIN; RETINA	The role of G protein-coupled receptor kinases (GRKs) in the regulation of dopamine D1A receptor responsiveness is poorly understood, To explore the potential role played by the GRKs in the regulation of the rat dopamine D1A receptor, we performed whole cell phosphorylation experiments and cAMP assays in 293 cells cotransfected with the receptor alone or with various GRKs (GRK2, GRK3, and GRK5). The agonist-dependent phosphorylation of the rat D1A receptor was substantially increased in cells overexpressing GRK2, GRK3, or GRK5. Moreover, we report that cAMP formation upon receptor activation was differentially regulated in cells overexpressing either GRK2, GRK3, and GRK5 under conditions that elicited similar levels of GRK-mediated receptor phosphorylation, Cells expressing the rat D1A receptor with GRK2 and GRK3 displayed a rightward shift of the dopamine dose-response curve with little effect on the maximal activation when compared with cells expressing the receptor alone, In contrast, cells expressing GRK5 displayed a rightward shift in the EC(50) value with an additional 40% reduction in the maximal activation when compared with cells expressing the receptor alone, Thus, we show that the dopamine D1A receptor can serve as a substrate for various GRKs and that GRK-phosphorylated D1A receptors display a differential reduction of functional coupling to adenylyl cyclase, These results suggest that the cellular complement of G protein-coupled receptor kinases may determine the properties and extent of agonist-mediated responsiveness and desensitization.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021		NINDS NIH HHS [NS-15976] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMLAIKY N, 1987, MOL PHARMACOL, V31, P129; AMLAIKY N, 1985, J BIOL CHEM, V260, P1983; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BALMFORTH AJ, 1990, J NEUROCHEM, V55, P2111, DOI 10.1111/j.1471-4159.1990.tb05803.x; BARTON AC, 1990, MOL PHARMACOL, V38, P531; BATES MD, 1991, AM J PHYSIOL, V260, pF937, DOI 10.1152/ajprenal.1991.260.6.F937; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHNEIWEISS H, 1990, EUR J PHARM-MOLEC PH, V189, P287, DOI 10.1016/0922-4106(90)90121-D; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DJAMGOZ MBA, 1992, NEUROCHEM INT, V20, P139, DOI 10.1016/0197-0186(92)90166-O; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GINGRICH JA, 1988, BIOCHEMISTRY-US, V27, P3907, DOI 10.1021/bi00411a003; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HAGA T, 1994, J NEUROCHEM, V63, P400; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JARVIE KR, 1994, DOPAMINE RECEPTORS T, P133; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESTLER EJ, 1994, CELL, V79, P923, DOI 10.1016/0092-8674(94)90022-1; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OFORI S, 1993, J PHARMACOL EXP THER, V266, P350; OLSON MF, 1992, MOL ENDOCRINOL, V6, P1095, DOI 10.1210/me.6.7.1095; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Sokal R. R, 1981, BIOMETRY; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TIBERI M, 1994, J BIOL CHEM, V269, P27925; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU X-M, 1991, Molecular and Cellular Neuroscience, V2, P464	49	144	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3771	3778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631993				2022-12-27	WOS:A1996TV72400067
J	BrownAugsburger, P; Hartshorn, K; Chang, D; Rust, K; Fliszar, C; Welgus, HG; Crouch, EC				BrownAugsburger, P; Hartshorn, K; Chang, D; Rust, K; Fliszar, C; Welgus, HG; Crouch, EC			Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D - Expression of a trimeric protein with altered anti-viral properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-A VIRUSES; ALVEOLAR MACROPHAGES; HUMAN NEUTROPHIL; DOMAIN; CELLS; LOCALIZATION; PURIFICATION; LECTINS; CLONING; OPSONIN	Surfactant protein D (SP-D) molecules are preferentially assembled as dodecamers consisting of trimeric subunits associated at their amino termini, The NH2-terminal sequence of each monomer contains two conserved cysteine residues, which participate In interchain disulfide bonds, In order tea study the roles of these residues in SP-D assembly and function, we employed site-directed mutagenesis to substitute serine for cysteine 15 and 20 in recombinant rat SP-D (RsSP-D), lad have expressed the mutant (RrSP-Dser15/20) in Chinese hamster ovary (CRO-RP) cells, The mutant, which was efficiently secreted, bound to maltosyl-agarose, but unlike RrSP-D, was assembled exclusively as trimers. The constituent monomers showed a decreased mobility on SDS-polyacrylamide gel electrophoresis resulting from an increase in the size and sialylation of the N-linked oligosaccharide at Asn-70. Although RrSP-Dser15/20 contained a pepsin-resistant triple helical domain, it showed a decreased T-m, and acquired susceptibility to proteolytic degradation, Like RrSP-D, RrSP-Dser15/20 hound to the hemagglutinin of influenza A. However, it showed no viral aggregation and did not enhance the binding of influenza A to neutrophils (PMN), augment PMN respiratory burst, or protect PMNs from deactivation, These studies indicate that amino-terminal disulfides are required to stabilize dodecamers, and support our hypothesis that the oligomerization of trimeric subunits contributes to the anti-microbial properties of SP-D.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118	Washington University (WUSTL); Washington University (WUSTL); Boston University; Boston University				Hartshorn, Kevan/0000-0002-7196-7433	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594, HL44015] Funding Source: Medline; NIAMS NIH HHS [AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; HARTSHORN KL, 1993, J IMMUNOL, V151, P6265; HARTSHORN KL, 1988, J IMMUNOL, V141, P1295; Hartshorn KL, 1996, BLOOD, V87, P3450, DOI 10.1182/blood.V87.8.3450.bloodjournal8783450; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HARTSHORN KL, 1990, BLOOD, V75, P218; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LIM BL, 1994, J BIOL CHEM, V269, P11820; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; REID KBM, 1993, BIOCHEM SOC T, V21, P464, DOI 10.1042/bst0210464; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SPISSINGER T, 1991, EUR J BIOCHEM, V199, P65, DOI 10.1111/j.1432-1033.1991.tb16092.x; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590	40	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13724	13730		10.1074/jbc.271.23.13724	http://dx.doi.org/10.1074/jbc.271.23.13724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662732	hybrid			2022-12-27	WOS:A1996UP38500064
J	Cohen, DM; Gullans, SR; Chin, WW				Cohen, DM; Gullans, SR; Chin, WW			Urea inducibility of egr-1 in murine inner medullary collecting duct cells is mediated by the serum response element and adjacent Ets motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; PROTEIN-BINDING SITE; C-FOS EXPRESSION; REGULATORY FACTOR; IONIZING-RADIATION; TERNARY COMPLEX; MDCK CELLS; GENE; TRANSCRIPTION	The renal medullary solute urea increases transcription and protein expression of the zinc finger-containing transcription factor Egr-1 in a renal epithelial cell-specific fashion, Transient transfection of mIMCD3 cells with a luciferase reporter gene driven by 1.2 kilobases of the murine egr-1 5'-flanking sequence showed 4-fold increase in reporter gene activity with 200 mM urea treatment. The effect of impermeant solutes such as NaCl was much less pronounced, whereas the permeant solute glycerol had no effect, In addition, this same sequence, minus the egr-1 minimal promoter, conferred urea responsiveness to a heterologous (thymidine kinase) promoter. Whereas deletion of two putative AP-1 sites from the sequence had no effect upon urea inducibility, elimination of the five putative serum response elements (SREs) abolished the urea effect. Progressive deletion of the SREs caused a corresponding diminution in urea effect, Two key tandem SREs (SRE-3 and SRE-4), in conjunction with their two adjacent clusters of Ets motifs, were sufficient to confer urea responsiveness to a reporter gene. This response was markedly attenuated in the absence of either cluster of Ets motifs and was abolished if both clusters were deleted. By electrophoretic mobility shift assay, formation of the ternary complex was constitutive and was demonstrable in vitro despite the presence of 200 mosm urea or NaCl. Therefore urea-inducible egr-1 transcription in renal medullary cells is mediated through the SRE and adjacent Ets motifs; ternary complex formation is not inhibited even in the presence of physiological hyperosmolality.	OREGON HLTH SCI UNIV, VET AFFAIRS MED CTR, PORTLAND, OR 97201 USA; BRIGHAM & WOMENS HOSP, DIV RENAL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV GENET, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Cohen, DM (corresponding author), OREGON HLTH SCI UNIV, DIV NEPHROL, PP262, 3314 SW US VET HOSP RD, PORTLAND, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, K08DK002188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36031, DK-02188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1994, J BIOL CHEM, V269, P25865; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RIM M, 1992, ONCOGENE, V7, P2065; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1992, TRANSCRIPTIONAL REGU, V2, P881; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	53	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12903	12908		10.1074/jbc.271.22.12903	http://dx.doi.org/10.1074/jbc.271.22.12903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662677	hybrid			2022-12-27	WOS:A1996UN47400035
J	Fournier, E; Rosnet, O; Marchetto, S; Turck, CW; Rottapel, R; Pelicci, PG; Birnbaum, D; Borg, JP				Fournier, E; Rosnet, O; Marchetto, S; Turck, CW; Rottapel, R; Pelicci, PG; Birnbaum, D; Borg, JP			Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; GRB2; RAS; PROTEINS; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; CELLS	The FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which belongs to the family of receptors for vascular endothelial growth factor. As the result of an alternative processing of primary mRNA transcripts, the long isoform differs from the short isoform by an additional stretch of 65 amino acid residues located at the C terminus and containing three tyrosine residues, Tyr(1333), Tyr(1337), and Tyr(1363). Only the long isoform is endowed with a transforming capacity in fibroblasts. We show that this activity is related to the capacity of the tyrosine 1337-containing sequence to interact with the phosphotyrosine binding domain of the SHC protein. This demonstrates that a functional. property of this newly described domain includes relay of mitogenic signals. In addition, it shows that the same receptor can mediate different functions through the optional binding of the phosphotyrosine binding domain and that the alternative use of this domain is sufficient to direct the signal toward different pathways.	INSERM,U119,MOLEC ONCOL LAB,F-13009 MARSEILLE,FRANCE; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; WELLESLEY HOSP,RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Rosnet, Olivier/G-3536-2013; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Rosnet, Olivier/0000-0002-3020-910X; Rottapel, Robert/0000-0002-6024-5558				BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORG JP, 1995, ONCOGENE, V10, P973; BORG JP, 1996, IN PRESS MOL ANAL MA; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CRAPARO A, 1995, J BIOL CHEM, V270, P15689; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOURNIER E, 1995, ONCOGENE, V11, P921; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25248; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PARK JE, 1994, J BIOL CHEM, V269, P25646; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEETHARAM L, 1995, ONCOGENE, V10, P135; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TRUB T, 1995, J BIOL CHEM, V270, P18205; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	71	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12956	12963		10.1074/jbc.271.22.12956	http://dx.doi.org/10.1074/jbc.271.22.12956			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662748	hybrid			2022-12-27	WOS:A1996UN47400044
J	Gerhartz, C; Heesel, B; Sasse, J; Hemmann, U; Landgraf, C; SchneiderMergener, J; Horn, F; Heinrich, PC; Graeve, L				Gerhartz, C; Heesel, B; Sasse, J; Hemmann, U; Landgraf, C; SchneiderMergener, J; Horn, F; Heinrich, PC; Graeve, L			Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130 .1. Definition of a novel phosphotyrosine motif mediating STAT1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA RECEPTOR; MOLECULAR-CLONING; EXPRESSION; BINDING; IDENTIFICATION; CELLS	Interleukin-6 (IL-6) and gamma-interferon (IFN gamma) activate an overlapping set of genes via the Jak/STAT pathway, However, at least in human cells, a differential activation of STAT transcription factors was observed: IL-6 activates both acute phase response factor (APRF)/STAT3 and STAT1, whereas IFN gamma leads only to STAT1 activation, All STATs cloned so far contain SH2 domains, Since all cytokine receptors using the Jak/STAT pathway were found to be tyrosine-phosphorylated after ligand binding, it has been proposed that specific phosphotyrosine modules within the cytoplasmic domain of the receptor chains recruit different STAT factors. We have analyzed by mutational studies and by phosphopeptide competition assays which of the tyrosine modules of the IL-6 signal transducer gp130 are capable of recruiting either APRF or STAT1, We found that two of the four tyrosine modules that are important for APRF activation also activate STAT1. For these modules, we propose the new consensus sequence YXPQ. We further present evidence that STAT1 is activated independently from APRF suggesting that gp130 contains multiple independent STAT binding sites, We compare the APRF and STAT1 activation motifs of gp130 with the STAT1 activation moth of the IFN gamma receptor and demonstrate that the specificity of activation can be changed from APRF to STAT1 and vice versa by only two point mutations within a tyrosine module. These data strongly support the concept that the activation of a specific STAT is determined mainly by the phosphotyrosine module, The significance of these findings for other receptor systems is discussed.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY	RWTH Aachen University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHUA AO, 1994, J IMMUNOL, V153, P128; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSHCIN D, 1995, EMBO J, V14, P1421; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; LIU Y, 1994, J IMMUNOL, V152, P1821; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; Sambrook J., 2002, MOL CLONING LAB MANU; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	46	225	229	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12991	12998		10.1074/jbc.271.22.12991	http://dx.doi.org/10.1074/jbc.271.22.12991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662591	hybrid			2022-12-27	WOS:A1996UN47400049
J	Liu, L; Rannels, SR; Falconieri, M; Phillips, KS; Wolpert, EB; Weaver, TE				Liu, L; Rannels, SR; Falconieri, M; Phillips, KS; Wolpert, EB; Weaver, TE			The testis isoform of the phosphorylase kinase catalytic subunit (PhK-gamma T) plays a critical role in regulation of glycogen mobilization in developing lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL LUNG; SKELETAL-MUSCLE; MESSENGER-RNA; RAT LUNG; SURFACTANT; EXPRESSION; SEQUENCE; LIVER; IDENTIFICATION; CLONING	In order to identify the form of phosphorylase kinase catalytic subunit expressed in developing lung, degenerate polymerase chain reaction primers were designed based on conserved domains of the two known catalytic subunits, expressed primarily in muscle and testis, Amplification of cDNA from day 19 fetal rat lung followed by cloning and sequence analyses indicated that only the testis isoform of phosphorylase kinase (PhK-gamma T) was detectable in fetal lung. In situ hybridization analyses indicated that expression of PhK-gamma T RNA in developing lung tissue was widespread and not restricted to Type II epithelial cells; PhK-gamma T protein expression was temporally and spatially correlated with expression of PhK-gamma T RNA, PhK-gamma T RNA and protein expression was also characterized in the PhK-deficient glycogen storage dis ease (gsd) rat, PhK-gamma T RNA levels were similar in Type II cells isolated from wild type and gsd/gsd fetuses; in contrast, PhK-gamma T protein was virtually undetectable in gsd/gsd Type II cells and enzyme activity was very low. These results suggest that PhK-gamma T plays a critical role in mobilization of glycogen during fetal lung development and that failure to catabolize glycogen in the gsd/gsd rat is related to an untranslatable PhK-gamma T RNA or unstable protein.	CHILDRENS HOSP, MED CTR, DIV PULM BIOL, TCHRF, CINCINNATI, OH 45229 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Cincinnati Children's Hospital Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NICHD NIH HHS [HD20748] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD020748] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENDER PK, 1987, J BIOL CHEM, V262, P8799; BRESLIN JS, 1993, AM J RESP CELL MOL, V9, P533, DOI 10.1165/ajrcmb/9.5.533; CALALB MB, 1992, J BIOL CHEM, V267, P1455; CAWLEY KC, 1988, NUCLEIC ACIDS RES, V16, P2355, DOI 10.1093/nar/16.5.2355; CAWLEY KC, 1993, J BIOL CHEM, V268, P1194; CHAMBERLAIN JS, 1987, P NATL ACAD SCI USA, V84, P2886, DOI 10.1073/pnas.84.9.2886; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK D, 1988, CURR TOP CELL REGUL, V29, P217; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COHEN P, 1983, METHOD ENZYMOL, V99, P243; DAVIDSON JJ, 1992, P NATL ACAD SCI USA, V89, P2096, DOI 10.1073/pnas.89.6.2096; FARRELL PM, 1986, BIOCHIM BIOPHYS ACTA, V878, P159, DOI 10.1016/0005-2760(86)90142-6; HANKS SK, 1989, MOL ENDOCRINOL, V3, P110, DOI 10.1210/mend-3-1-110; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARMANN B, 1991, J BIOL CHEM, V266, P15631; ITO T, 1990, J HISTOCHEM CYTOCHEM, V38, P691, DOI 10.1177/38.5.2332626; KIKKAWA Y, 1971, AM J PATHOL, V64, P423; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTHUS R, 1980, BIOCHEM J, V188, P99, DOI 10.1042/bj1880099; MANISCALCO WM, 1978, BIOCHIM BIOPHYS ACTA, V530, P333, DOI 10.1016/0005-2760(78)90153-4; NEWGARD CB, 1991, BIOCHIM BIOPHYS ACTA, V1090, P333, DOI 10.1016/0167-4781(91)90198-U; Pickett-Gies CA., 1986, ENZYMES, V17, P395; RANNELS SR, 1991, AM J PHYSIOL, V260, pL419, DOI 10.1152/ajplung.1991.260.6.L419; RANNELS SR, 1994, CELL BIOL LAB HDB, P116; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLHASE DE, 1989, PEDIATR RES, V26, P167, DOI 10.1203/00006450-198909000-00001; SILVA EFD, 1987, FEBS LETT, V220, P36, DOI 10.1016/0014-5793(87)80871-2; VORBROKER DK, 1995, AM J PHYSIOL-LUNG C, V268, pL647, DOI 10.1152/ajplung.1995.268.4.L647; WEAVER TE, 1988, J APPL PHYSIOL, V65, P982, DOI 10.1152/jappl.1988.65.2.982; Zuker M, 1994, Methods Mol Biol, V25, P267	32	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11761	11766		10.1074/jbc.271.20.11761	http://dx.doi.org/10.1074/jbc.271.20.11761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662648	hybrid			2022-12-27	WOS:A1996UL25000030
J	Lougheed, M; Steinbrecher, UP				Lougheed, M; Steinbrecher, UP			Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HERITABLE HYPERLIPIDEMIC RABBIT; MOUSE PERITONEAL-MACROPHAGES; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; LIPID-PEROXIDATION; MODIFIED LDL; LIGAND-BINDING; KUPFFER CELLS	Several investigators have reported nonreciprocal cross-competition between unlabeled acetyl low density lipoprotein (LDL) and oxidized LDL for the degradation of the corresponding labeled LDLs. The failure of acetyl LDL to compete fully for the degradation of oxidized LDL has been interpreted as evidence for additional receptor(s) specific for oxidized LDL. In the present study, it is demonstrated that the ability of oxidized LDL to compete for the degradation of acetyl LDL is determined largely by its extent of oxidation. Extensively oxidized LDL competed for 90% of acetyl LDL degradation in murine macrophage, and hence there appears to be no pathway in these cells that is specific for acetyl LDL but not oxidized LDL. The reciprocal situation (competition by acetyl LDL for uptake and degradation of oxidized LDL) proved to be more complicated. Oxidized LDL is known to be susceptible to aggregation, and less than half of the aggregates found in the present experiments were large enough to be removed by filtration or centrifugation at 10,000 x g. When oxidized LDL was prepared under conditions that resulted in minimal aggregation, acetyl LDL competed for greater than 80% of oxidized LDL degradation. With more extensive oxidation and aggregation of LDL, acetyl LDL only competed for about 45% of oxidized LDL degradation, while polyinosinic acid remained an effective competitor. Individual preparations of oxidized LDL that differed in degree of oxidation were separated into aggregated and nonaggregated fractions, and it was shown that both fractions were competed to a similar degree by acetyl LDL in mouse peritoneal macrophages and in Chinese hamster ovary cells transfected with human scavenger receptor type I cDNA, Hence, aggregation by itself did not alter the apparent rate of uptake by the scavenger receptor pathway. These results indicate that the extent of oxidation of LDL affects its mechanism of uptake and that about half of the uptake of very extensively oxidized LDL appears to be via a pathway distinct from the scavenger receptor type I/II. The uptake of very extensively oxidized LDL was not affected by cytochalasin D, an inhibitor of phagocytosis. As well, it was not affected by an antibody to CD36 in human monocyte-derived macrophages or in THP-1 cells, suggesting that this alternate pathway does not involve CD36.	UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 4E3,CANADA	University of British Columbia								ACTON S, 1995, J BIOL CHEM, V269, P21003; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; ASHKENAS J, 1993, J LIPID RES, V34, P983; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; DOI T, 1993, J BIOL CHEM, V268, P2126; EMI M, 1993, J BIOL CHEM, V268, P2120; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; FOX PL, 1987, J BIOL CHEM, V262, P6046; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; FROSTEGARD J, 1991, ATHEROSCLEROSIS, V90, P119, DOI 10.1016/0021-9150(91)90106-D; FROSTEGARD J, 1992, ARTERIOSCLER THROMB, V12, P461, DOI 10.1161/01.ATV.12.4.461; HABERLAND M, 1988, SCIENCE, V24, P215; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HOFF HF, 1992, J BIOL CHEM, V267, P602; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; KAMPS JAAM, 1992, ARTERIOSCLER THROMB, V12, P1079, DOI 10.1161/01.ATV.12.9.1079; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1990, J LIPID RES, V31, P645; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1990, NATURE, V343, P532; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LEPAGE G, 1986, J LIPID RES, V27, P114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NICHOLSON A, 1995, THROMB VASC BIOL, V15, P269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UEDA Y, 1993, ATHEROSCLEROSIS, V101, P25, DOI 10.1016/0021-9150(93)90098-F; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	60	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11798	11805		10.1074/jbc.271.20.11798	http://dx.doi.org/10.1074/jbc.271.20.11798			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662601	hybrid			2022-12-27	WOS:A1996UL25000036
J	Yen, PM; Liu, Y; Sugawara, A; Chin, WW				Yen, PM; Liu, Y; Sugawara, A; Chin, WW			Vitamin D receptors repress basal transcription and exert dominant negative activity on triiodothyronine-mediated transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC-ACID RECEPTOR; DNA-BINDING; RESPONSE ELEMENTS; V-ERBA; GENE; 1,25-DIHYDROXYVITAMIN-D3; RESISTANCE; EXPRESSION; DOMAIN	We have examined vitamin D receptor (VDR), thyroid hormone receptor (TR), and retinoid X receptor beta (RXR beta) binding to vitamin D (VDREs), two thyroid hormone (TREs) (DR4 and F2), and a retinoic acid response element (DR5). VDR/RXR bound well to the VDREs and to DR4 and DR5 using the electrophoretic mobility shift assay. Surprisingly, VDR/RXR also bound well to F2, which contains half-sites arranged as an inverted palindrome. In co-transfection experiments using CV-1 cells, we observed that VDR repressed basal transcription in the absence of ligand on DR3 and osteopontin VDREs and F2, but had no effect on DR4 or DR5, VDR selectively mediated ligand-dependent transcription on only VDREs. VDR also exhibited dominant negative activity as it blocked triiodothyronine (T-3)-mediated transcriptional activity on DR4 and F2. These results demonstrate that VDR/RXR heterodimers can bind promiscuously to a wide range of hormone response elements, including inverted palindromes. Moreover, they show that unliganded VDRs, similar to TRs and retinoic acid receptors, can repress basal transcription. Last, they also suggest a novel repressor function of VDR on T-3 mediated transcription which may be significant in tissues where VDR and TR are co-expressed.	TOHOKU UNIV,DEPT INTERNAL MED 2,SENDAI,MIYAGI 980,JAPAN	Tohoku University	Yen, PM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,GW THORN RES BLDG,RM 907,20 SHATTUCK ST,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Sugawara, Akira/0000-0003-4511-8101; Yen, Paul/0000-0002-3790-8114	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002186] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08DK-02186] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; BRENT G A, 1989, New Biologist, V1, P329; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN DJ, 1995, NATURE, V377, P454; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FREEDMAN LP, 1994, MOL ENDOCRINOL, V8, P265, DOI 10.1210/me.8.3.265; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; IKEDA M, 1995, END SOC M WASH JUN; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KAJI H, 1989, ENDOCRINOLOGY, V124, P930, DOI 10.1210/endo-124-2-930; KATZ D, 1993, J BIOL CHEM, V268, P20905; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LENG XK, 1994, J BIOL CHEM, V50, P31435; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SONE T, 1989, J BIOL CHEM, V264, P20230; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; SUGAWARA A, 1994, ENDOCRINOLOGY, V135, P1956, DOI 10.1210/en.135.5.1956; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; YANG YZ, 1995, 11 INT THYR C TOR; YEN PM, 1994, J BIOL CHEM, V269, P12704; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3; YEN PM, 1994, J BIOL CHEM, V269, P903; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; YEN PM, 1992, J BIOL CHEM, V267, P23248; YEN PM, 1993, ENDOCR J, V1, P461; ZHANG XK, 1991, NEW BIOL, V3, P169	57	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10910	10916		10.1074/jbc.271.18.10910	http://dx.doi.org/10.1074/jbc.271.18.10910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631908	hybrid			2022-12-27	WOS:A1996UJ34200076
J	Callan, OH; So, OY; Swinney, DC				Callan, OH; So, OY; Swinney, DC			The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TIME-DEPENDENT INHIBITION	We present here for the first time a method for determining the rate constants associated with slow binding inhibition of prostaglandin H synthase (PGHS), The rate constants were determined by a method using initial steady-state conditions, which minimize the impact of catalytic autoinactivation of the enzyme, The currently available methods for determining the kinetic constants associated with slow binding enzyme inhibition do not distinguish between rate decreases due to enzyme inhibition or due to autoinactivation of the enzyme. A mathematical model was derived assuming a rapid reversible formation of an initial enzyme-inhibitor complex (EI) followed by a slow reversible formation of a second enzyme-inhibitor complex (EI*). The two enzyme inhibitor complexes are assumed to be in slow equilibrium, This method was used to evaluate the kinetic parameters associated with the binding and selectivity of the nonsteroidal antinflammatory drugs (NSAIDs), flurbiprofen and indomethacin. The K-1 values associated with the formation of the first reversible complex (EI) for flurbiprofen with PGHS1 and PGHS2 were 0.53 +/- 0.06 and 0.61 +/- 0.08 mu M, respectively; the rate constants for the forward isomerization, k(2), into the second reversible complex (EI*) were 0.97 +/- 0.99 and 0.11 +/- 0.01 s(-1), respectively, and rates of the reverse isomerization from EI* k(-2), were 0.031 +/- 0.004 and 0.0082 +/- 0.0008 s(-1), respectively. Indomethacin was estimated to form the EI complex with the same affinity for both PGHS1 and PGHS2, 10.0 +/- 2.8 mu M and 11.2 +/- 2.0 mu M, respectively, and dissociate from EI* at approximately the same rate 0.0011 +/- 0.0002 s(-1) and 0.0031 +/- 0.0003 s(-1), respectively. However, the rate of isomerization into EI* from EI was much greater for PGHS1 than PGHS2, 0.33 +/- 0.08 s(-1) as compared with 0.034 +/- 0.004 s(-1). These results show that the overall affinity for the inhibition of PGHS1 versus PGHS2 was 30-fold greater for indomethacin (K-I* = 0.032 +/- 0.005 and 1.02 +/- 0.08 mu M, respectively) and 3-fold greater for flurbiprofen (K-I* = 0.017 +/- 0.002 and 0.045 +/- 0.004 mu M, respectively). The results also show that for both PGHS1 and PGHS2, flurbiprofen was bound tighter to the initial EI* complex than indomethacin; however, the rate of dissociation from EI* was slower for indomethacin than flurbiprofen. The rate of the forward isomerization to EI* is primarily responsible for the selectivity of both NSAIDs for PGHS1. This analysis shows the quantitative importance of the different kinetic parameters upon the overall binding affinity of these NSAIDs and should greatly assist in our understanding of the structural interactions that promote enzyme-inhibitor binding.	ROCHE BIOSCI,DEPT ENZYMOL,PALO ALTO,CA 94304; ROCHE BIOSCI,DEPT BIOMATH,PALO ALTO,CA 94304	Roche Holding; Roche Holding								BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BARTLETT PA, 1987, BIOCHEMISTRY-US, V26, P8553, DOI 10.1021/bi00400a009; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CHO YK, 1994, BIOCHEMISTRY-US, V33, P9637, DOI 10.1021/bi00198a032; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; GLASER K, 1995, EUR J PHARMACOL, V281, P107, DOI 10.1016/0014-2999(95)00302-2; IZQUIERDOMARTIN M, 1994, BIOCHEMISTRY-US, V33, P1356, DOI 10.1021/bi00172a011; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Quellet M., 1995, BIOCHEM J, V306, P247; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WALENGA RW, 1986, PROSTAGLANDINS, V31, P625, DOI 10.1016/0090-6980(86)90170-X; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402	22	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3548	3554						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631960				2022-12-27	WOS:A1996TV72400034
J	Weber, J; Senior, AE				Weber, J; Senior, AE			Binding and hydrolysis of TNP-ATP by Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING; CATALYTIC SITES; BETA-SUBUNIT; F1-ATPASE; TRYPTOPHAN; MECHANISM; LOCATION	It had previously been suggested that V-max hydrolysis rate of 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP) by F-1-ATPase required filling of only two catalytic sites on the enzyme (Grubmeyer, C., and Penefsky, H. S. (1981) J. Biol. Chem. 256, 3718-3727), whereas recently it was shown that V-max rate of ATP hydrolysis requires that all three catalytic sites are filled (Weber, J., Wilke-Mounts, S., Lee, R. S. F., Grell, E., and Senior, A. E. (1993) J. Biol. Chem. 268, 20126-20133), To resolve this apparent discrepancy, we measured equilibrium binding and hydrolysis of MgTNP-ATP under identical conditions, using beta Y331W mutant Escherichia coli F-1-ATPase, in which the genetically engineered tryptophan provides a direct fluorescent probe of catalytic site occupancy, We found that MgTNP-ATP hydrolysis at V-max rate did require filling of all three catalytic sites, but in contrast to the situation with MgATP, ''bisite hydrolysis'' of MgTNP-ATP amounted to a substantial fraction (similar to 40%) of V-max. Binding of MgTNP-ATP to the three catalytic sites showed strong binding cooperativity (K-d1 < 1 nM, K-d2 = 23 nM, K-d3 = 1.4 mu M). Free TNP-ATP (i.e. in presence of EDTA) bound to all three catalytic sites with lower affinity but was not hydrolyzed, These data emphasize that the presence of Mg2+ is critical for cooperativity of substrate binding, formation of the very high affinity first catalytic site, and hydrolytic activity in F-1-ATPases and that these three properties are strongly correlated.			Weber, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1982, J BIOL CHEM, V257, P2101; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; GRYCZYNSKI I, 1989, BIOCHEMISTRY-US, V28, P3490, DOI 10.1021/bi00434a051; HAUGHTON MA, 1995, J BIOL CHEM, V270, P20568, DOI 10.1074/jbc.270.35.20568; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; RAO R, 1988, J BIOL CHEM, V263, P5569; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TIEDGE H, 1986, BIOL CHEM H-S, V367, P689, DOI 10.1515/bchm3.1986.367.2.689; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1994, J BIOL CHEM, V269, P11261; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; [No title captured]	25	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3474	3477						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631950				2022-12-27	WOS:A1996TV72400024
J	Riewald, M; Schleef, RR				Riewald, M; Schleef, RR			Human cytoplasmic antiproteinase neutralizes rapidly and efficiently chymotrypsin and trypsin-like proteases utilizing distinct reactive site residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; MOLECULAR CHARACTERIZATION; NEUTROPHIL ELASTASE; ESCHERICHIA-COLI; ALPHA-2-ANTIPLASMIN; SERPIN; EXPRESSION; OVALBUMIN; MECHANISM	Human cytoplasmic antiproteinase (CAP) is an intracellular serpin that has been reported to utilize Arg(341) as the reactive site P-1 residue to neutralize a broad variety of extracellular serine proteases with trypsin-like specificity. Both native CAP and recombinant CAP purified from Escherichia coli were observed to form SDS-stable complexes not only with I-125-thrombin and I-125-urokinase, but also with I-125-chymotrypsin. Kinetic studies indicated that the amidolytic activity of chymotrypsin is inhibited efficiently and rapidly by CAP in a two-step process with a dissociation constant K-i of an initial loose complex of 3.3 nM, a forward isomerization rate constant k(2) to the tight complex of 0.014 s(-1), and an overall second order association rate constant of 6 x 10(6) M(-1) s(-1) similar to the kinetic constants obtained for the formation of the trypsin-CAP complex. N-terminal amino acid sequencing and mass spectrometry indicated that chymotrypsin interacts with CAP at Met(340), in contrast to thrombin, which interacts as expected at Arg(341). Thus, CAP is the first serpin that has been shown to be capable to inhibit efficiently and with similar association rate constants different proteases at distinct reactive site residues, strongly supporting the notion of a highly mobile and flexible serpin reactive site loop and suggesting that this inhibitor may have evolved separate reactive sites for the specific regulation of different proteolytic activities.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL49563, HL45954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049563, R01HL045954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1980, J BIOL CHEM, V255, P3931; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; CREIGHTON TE, 1989, TRENDS BIOCHEM SCI, V14, P319, DOI 10.1016/0968-0004(89)90159-X; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; GOGSTAD GO, 1983, THROMB RES, V31, P387, DOI 10.1016/0049-3848(83)90339-0; HAHM B, 1995, J VIROL, V69, P2534, DOI 10.1128/JVI.69.4.2534-2539.1995; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOPKINS PCR, 1994, SCIENCE, V265, P1893; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; KEZDY FJ, 1970, METHOD ENZYMOL, V19, P3; KIRSCHNER RJ, 1980, J BIOL CHEM, V255, P5468; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NACHMAN RL, 1976, J BIOL CHEM, V251, P4514; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Riewald M, 1996, J BIOL CHEM, V271, P7160, DOI 10.1074/jbc.271.12.7160; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scott FL, 1996, J BIOL CHEM, V271, P1605, DOI 10.1074/jbc.271.3.1605; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; SHARMA SK, 1981, BIOORG CHEM, V10, P357, DOI 10.1016/0045-2068(81)90049-3; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; SUN JR, 1995, BBA-PROTEIN STRUCT M, V1252, P28, DOI 10.1016/0167-4838(95)00108-7; SUN JR, 1995, J BIOL CHEM, V270, P16089, DOI 10.1074/jbc.270.27.16089; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; YE RD, 1987, J BIOL CHEM, V262, P3718; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	51	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14526	14532		10.1074/jbc.271.24.14526	http://dx.doi.org/10.1074/jbc.271.24.14526			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662739	hybrid			2022-12-27	WOS:A1996UQ66000087
J	Oliver, JD; Hresko, RC; Mueckler, M; High, S				Oliver, JD; Hresko, RC; Mueckler, M; High, S			The glut 1 glucose transporter interacts with calnexin and calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; GLYCOPROTEINS; TRANSCRIPTION; CHAPERONE; MEMBRANE; CELL; IP90	Calnexin is an integral membrane protein that acts as a chaperone during glycoprotein folding in the endoplasmic reticulum. Cross-linking studies were carried out with the aim of investigating the interactions of calnexin with glycoproteins in vitro, A truncated version of the integral membrane glycoprotein Glut 1 (GT(155)) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes, Following immunoprecipitation with an anti-calnexin antiserum, a cross-linker-independent association was observed between GT(155) and calnexin. In addition, the anti-calnexin antiserum immunoprecipitated a W-dependent cross-linking product consisting of GT(155) and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa), Both the GT(155)-calnexin and the GT(155)-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT(155), a characteristic of many calnexin interactions, A GT(155) mutant that was not glycosylated (AGGT(155)) did not associate with calnexin or CAP-60, Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT(155) only when the protein bore a correctly modified oligosaccharide group, Thus, our data show that both calnexin and calreticulin with Glut 1 in a glycosylation-dependent manner.	UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	University of Manchester; Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012	High, Stephen/0000-0002-4532-8152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	36	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13691	13696		10.1074/jbc.271.23.13691	http://dx.doi.org/10.1074/jbc.271.23.13691			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662691	hybrid			2022-12-27	WOS:A1996UP38500060
J	Teckman, JH; Perlmutter, DH				Teckman, JH; Perlmutter, DH			The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha 1-antitrypsin Z and S is distinct from that for an unassembled membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; DIRECTED MUTAGENESIS; BREFELDIN-A; RECEPTOR; VARIANT	We have theorized that a subset of PiZZ alpha 1-antitrypsin (alpha 1-AT)-deficient individuals is more susceptible to liver injury by virtue of second inherited trait(s) or environmental factor(s), which exaggerate the accumulation of mutant alpha 1-AT Z within the endoplasmic reticulum (ER) of Liver cells, Using a complementation approach in which cell Lines from PiZZ individuals with liver disease (''susceptible'' hosts) and from PiZZ individuals without liver disease (''protected'' hosts) are transduced with the mutant alpha 1-AT Z gene, we have recently shown that there is a delay in ER degradation of mutant alpha 1-AT Z protein that is only present in cell lines from susceptible hosts and correlates with the liver disease phenotype. In the present study we examined the specificity of this ER degradation pathway to determine if it is responsible for degrading other misfolded mutants of alpha 1-AT and/or for unassembled membrane proteins. The S mutant of alpha 1-AT and H2a subunit of the asialoglycoprotein receptor (ASGPR H2a) were expressed in skin fibroblast cell lines from susceptible and protected hosts. The results showed in both susceptible and protected hosts that alpha 1-AT S was associated with a delay in secretion as compared with wild type alpha 1-AT. The alpha 1-AT S mutant was retained in ER, albeit to a lesser extent than the alpha 1-AT Z mutant, There was, however, a significant increase in retention of alpha 1-AT S in the ER of susceptible as compared with protected host cells. The same host cell lines were transduced to express an unassembled membrane protein, ASGPR H2a, There was no difference in the kinetics of ER degradation of ASGPR H2a in susceptible as compared with protected hosts, Taken together, the results show that alpha 1-AT S is associated with a defect in biogenesis, intracellular retention, which is similar to but milder than alpha 1-AT Z. Like alpha 1-AT Z, alpha 1-AT S is degraded by a pathway in the ER, which is relatively inefficient in PiZZ individuals with the liver disease phenotype. However, this pathway appears to be different from that previously described for a model unassembled membrane protein.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110; CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital				Teckman, Jeffrey/0000-0002-4870-2621	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002379] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37784] Funding Source: Medline; NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [K11DK02379] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRODBECK RM, 1993, J BIOL CHEM, V268, P6771; CARLSON JA, 1988, J CLIN INVEST, V83, P1183; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CURIEL DT, 1989, J BIOL CHEM, V264, P10477; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOUE S, 1992, J BIOL CHEM, V267, P9080; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LE AQ, 1992, J BIOL CHEM, V267, P1072; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OWEN MC, 1976, BRIT MED J, V1, P130; Perlmutter D H, 1993, Prog Liver Dis, V11, P139; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SMITH GH, 1987, METHOD ENZYMOL, V151, P534; SVEGER T, 1995, HEPATOLOGY, V22, P514, DOI 10.1002/hep.1840220221; SVEGER T, 1976, NEW ENGL J MED, V294, P1216; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; YUNG ST, 1992, J CELL BIOL, V116, P57	30	73	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13215	13220		10.1074/jbc.271.22.13215	http://dx.doi.org/10.1074/jbc.271.22.13215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662752	hybrid			2022-12-27	WOS:A1996UN47400081
J	Ding, M; Vandre, DD				Ding, M; Vandre, DD			High molecular weight microtubule-associated proteins contain O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; IMMUNOCYTOCHEMICAL LOCALIZATION; CYTOPLASMIC PROTEINS; NERVOUS-TISSUE; GLYCOSYLATION; PHOSPHORYLATION; INHIBITION; FILAMENTS; NUCLEAR; BRAIN	We have examined the post-translational modification of high molecular weight microtubule-associated proteins (MAPs) and have shown that MAP1, MAP2, and MAP4 are glycosylated. The presence of carbohydrate residues on these proteins was indicated by labeling with biotin hydrazide following periodate oxidation, a specific and well established method for detecting saccharide moieties on proteins. Both MAP2 and MAP4 were also labeled in vitro by UDP-[H-3]galactose in the presence of galactosyltransferase. Labeling by galactosyltransferase indicated that MAP2 and MAP4 contained terminal nonreducing GlcNAc residues, and they appeared to be O-linked to the proteins as shown by their sensitivity to beta-elimination. Chromatographic analysis showed that the GlcNAc residues were directly linked to the proteins as monosaccharides. Thus, we have added MAP2 and MAP4 to the list of intracellular O-GlcNAc-modified proteins, which includes other cytoskeletal proteins such as cytokeratins 8, 13, and 18 and neurofilament proteins NF-L and NF-M. We further characterized the O-GlcNAc modification of MAP2, and stoichiometric analysis indicated that nearly 10% of the MAP2 isolated from rat brain is modified by O-GlcNAc. However, this estimate is thought to reflect the minimal level of O-GlcNAc modification present on MAP2. We have also shown that both the O-GlcNAc and biotin hydrazide-reactive carbohydrate moieties are located on the projection domain of MAP2. Three O-GlcNAc-containing peaks were observed following fast protein liquid chromatography of a tryptic digest of MAP2, suggesting that multiple modification sites exist. The specific modification sites and functional significance of the O-GlcNAc glycosylation on the high M(r) MAPs remain to be determined.	OHIO STATE UNIV,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210; OHIO STATE UNIV,PROGRAM MOL CELLULAR & DEV BIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031777] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31777] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; BRIONES E, 1985, P NATL ACAD SCI USA, V82, P5776, DOI 10.1073/pnas.82.17.5776; BURG MA, 1994, J NEUROBIOL, V25, P1, DOI 10.1002/neu.480250102; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hyams J. S., 1994, MICROTUBULES; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOBATA A, 1994, METHOD ENZYMOL, V230, P200; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V205, P1467, DOI 10.1006/bbrc.1994.2830; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SCHAFER IA, 1993, EXP CELL RES, V207, P213, DOI 10.1006/excr.1993.1185; SOLTYS BJ, 1992, BIOCHEM CELL BIOL, V70, P1174, DOI 10.1139/o92-163; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VALLEE RB, 1986, METHOD ENZYMOL, V134, P124; VANDRE DD, 1991, J CELL SCI, V98, P577; WILCHEK M, 1987, METHOD ENZYMOL, V138, P429; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	34	56	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12555	12561		10.1074/jbc.271.21.12555	http://dx.doi.org/10.1074/jbc.271.21.12555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647865	hybrid			2022-12-27	WOS:A1996UL66000067
J	Kashiwagi, K; Pistocchi, R; Shibuya, S; Sugiyama, S; Morikawa, K; Igarashi, K				Kashiwagi, K; Pistocchi, R; Shibuya, S; Sugiyama, S; Morikawa, K; Igarashi, K			Spermidine-preferential uptake system in Escherichia coli - Identification of amino acids involved in polyamine binding in PotD protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTRESCINE TRANSPORT-SYSTEM; CHROMOSOME; GROWTH; GENES; MAPS	Spermidine-binding sites on PotD protein, a substrate-binding protein in periplasm, in the spermidine-preferential uptake system in Escherichia coli were studied by measuring polyamine transport activities of right-side-out membrane vesicles with mutated PotD proteins prepared by site-directed mutagenesis of the potD gene and by measuring polyamine binding activities of these mutated PotD proteins. Polyamine transport activities of the mutated PotD proteins paralleled their polyamine binding activities. It was found that Trp-34, Thr-35, Glu-36, Tyr-37, Ser-83, Tyr-85, Asp-168, Glu-171, Trp-229, Trp-255, Asp-257, Tyr-293, and Gln-327 of PotD protein were involved in the binding to spermidine. When spermidine uptake activities were measured in intact cells expressing the mutated PotD proteins, it was found that Glu-171, Trp-255, and Asp-257 were more strongly involved in the binding of spermidine to PotD protein than the other amino acids listed above. The dissociation constants of spermidine for the mutated PotD proteins at Glu-171, Trp-255, and Asp-257 increased greatly in comparison with those for the other mutated PotD proteins. Since these three amino acids clearly interact with the diaminopropane moiety of spermidine, the results are in accordance with the finding that PotD protein has a higher affinity for spermidine than for putrescine. Putrescine was found to bind at the position of the diaminobutane moiety of spermidine.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187; PISTOCCHI, ROSSELLA/0000-0003-1304-6270				ADAMS MD, 1989, J BIOL CHEM, V264, P15739; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; FRYDMAN L, 1992, P NATL ACAD SCI USA, V89, P9186, DOI 10.1073/pnas.89.19.9186; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MATSUO Y, 1994, FEBS LETT, V345, P23, DOI 10.1016/0014-5793(94)00435-8; OH BH, 1994, J BIOL CHEM, V269, P4135; OH BH, 1994, J BIOL CHEM, V269, P26323; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; PEGG AE, 1988, CANCER RES, V48, P759; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SCATCHARD G, 1949, ANN NY ACAD SCI, V84, P4767; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sugiyama S, 1996, ACTA CRYSTALLOGR D, V52, P416, DOI 10.1107/S0907444995011498; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	34	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12205	12208		10.1074/jbc.271.21.12205	http://dx.doi.org/10.1074/jbc.271.21.12205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647815	hybrid			2022-12-27	WOS:A1996UL66000017
J	Khoo, KH; Chatterjee, D; Dell, A; Morris, HR; Brennan, PJ; Draper, P				Khoo, KH; Chatterjee, D; Dell, A; Morris, HR; Brennan, PJ; Draper, P			Novel O-methylated terminal glucuronic acid characterizes the polar glycopeptidolipids of Mycobacterium habana strain TMC 5135	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLIPID ANTIGENS; IDENTIFICATION; TUBERCULOSIS; XENOPI; AVIUM; MICE	Mycobacterium ''habana'' strain TMC 5135, which has been proposed as a vaccine against both leprosy and tuberculosis, is considered to be a strain of serotype I of the recognized species Mycobacterium simiae. We have now shown that each of these strains possesses characteristic polar glycopeptidolipids (GPL) which are sufficiently different to allow unequivocal strain identification. Thin layer chromatographic analysis demonstrated that M. habana synthesizes a family of apolar GPLs and three distinct polar GPLs (pGPL-I to -III) which exhibited migration patterns different from those of M. simiae serotype I (pGPL-Sim). Using a combination of chemical, mass spectrometric, and proton-NMR analyses, the GPLs from M. habana were determined to be based on the same generic structure as those from the M. avium complex, namely N-fatty acyl-D-Phe-(O-saccharide)-D-allo-Thr-D-Ala-L-alaninyl-O-monosaccharide. The de-O-acetylated apolar GPLs contain a 3-O-Me-6-deoxy-Tal attached to the allo-Thr and either a 3-O-Me-Rha or a 3,4-di-O-Me-Rha attached to the alaninol. In the pGPLs, oligosaccharides were found to be attached to the allo-Thr. The oligoglycosyl alditol reductively released from the least polar pGPL-I was fully characterized as L-Fucp alpha 1-->3-(6-O-Me)-D-Glcp beta 1-->3-(4-O-Me)-L-Rhap alpha 1-->3-L-Rhap alpha 1-->2-(3-O-Me)-6-deoxy-Tal. In pGPL-II and -III, the terminal Fuc residue is further 3-O-methylated and 4-O-substituted with an additional 2,4-di-O-Me-D-GlcA and 4-O-Me-D-GlcA, respectively. The corresponding oligosaccharide from pGPL-Sim was shown to be of identical molecular weight 60 pGPL-II but terminating with a 3,4-di-O-Me-GlcA. Enzyme-linked immunosorbent assay-based serological studies using anti-M. habana and anti-M. simiae sera against whole cells and purified pGPLs firmly established the polar GPLs as important antigens and indicated that the terminal epitopes L-Fuc-, 2,4-di-O-Me-D-GlcA, and 4-O-Me-D-GlcA uniquely present in pGPL-I, II, and -III, respectively, confer sufficient specificity for the identification of M. habana as a distinct serotype of M. simiae.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Imperial College London; Colorado State University; MRC National Institute for Medical Research			Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R37AI018357, R01AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18357] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ANZ W, 1969, ZBL BAKT 1 ORIG, V221, P530; Aspinall GO, 1995, ADV CARBOHYD CHEM BI, V51, P169, DOI 10.1016/S0065-2318(08)60194-8; BAESS I, 1982, ACTA PATH MICRO IM B, V90, P101; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BESRA GS, 1994, ZBL BAKT-INT J MED M, V281, P415; BESRA GS, 1993, BIOCHEMISTRY-US, V32, P347, DOI 10.1021/bi00052a043; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1979, J BIOL CHEM, V254, P4205; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; CHATTERJEE D, 1988, J BIOL CHEM, V263, P4092; CHATTERJEE D, 1987, J BIOL CHEM, V262, P3528; DELL A, 1994, METHOD ENZYMOL, V230, P108; DENNER JC, 1992, J CLIN MICROBIOL, V30, P473, DOI 10.1128/JCM.30.2.473-478.1992; FINE PEM, 1995, CLIN INFECT DIS, V20, P11, DOI 10.1093/clinids/20.1.11; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GUPTA HP, 1979, INDIAN J EXP BIOL, V17, P1190; JOLLES P, 1961, B SOC CHIM BIOL, V43, P177; KHOO KH, 1995, CARBOHYD RES, V276, P449, DOI 10.1016/0008-6215(95)00184-U; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; Lopez Marin L M, 1993, Eur J Biochem, V215, P859, DOI 10.1111/j.1432-1033.1993.tb18103.x; MACKENZIE SL, 1975, J CHROMATOGR, V111, P413, DOI 10.1016/S0021-9673(00)99292-6; MARIN LML, 1991, BIOCHEMISTRY-US, V30, P10536, DOI 10.1021/bi00107a024; MARIN LML, 1992, BIOCHEMISTRY-US, V31, P11106, DOI 10.1021/bi00160a021; MEISSNER G, 1975, AM REV RESPIR DIS, V111, P196; NOORDEEN SK, 1994, INT J LEPROSY, V62, P278; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIVIERE M, 1993, EUR J BIOCHEM, V214, P395, DOI 10.1111/j.1432-1033.1993.tb17935.x; SCHAEFER WB, 1967, AM REV RESPIR DIS, V96, P115; Singh N B, 1985, Indian J Lepr, V57, P278; SINGH NB, 1991, INT J LEPROSY, V59, P317; SINGH NB, 1989, INFECT IMMUN, V57, P653, DOI 10.1128/IAI.57.2.653-655.1989; VALDIVIA JA, 1971, B HIGIENE EPIDEMIOLO, V9, P65; YANAGHIHARA DL, 1985, J CLIN MICROBIOL, V21, P569, DOI 10.1128/JCM.21.4.569-574.1985	33	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12333	12342		10.1074/jbc.271.21.12333	http://dx.doi.org/10.1074/jbc.271.21.12333			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647835	hybrid			2022-12-27	WOS:A1996UL66000037
J	Luescher, IF; Romero, P; Kuznetsov, D; Rimoldi, D; Coulie, P; Cerottini, JC; Jongenee, CV				Luescher, IF; Romero, P; Kuznetsov, D; Rimoldi, D; Coulie, P; Cerottini, JC; Jongenee, CV			HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; ANTIGENIC PEPTIDES	Melanoma-associated genes (MAGEs) encode tumor-specific antigens that can be recognized by CD8(+) cytotoxic T lymphocytes. To investigate the interaction of the HLA-Al-restricted MAGE-1 peptide 161-169 (EADPT-GHSY) with HLA class I molecules, photoreactive derivatives were prepared by single amino acid substitution with N-beta-[iodo-4-azidosalicyloyl]-L-2,3-diaminopropionic acid. These derivatives were tested for their ability to bind to, and to photoaffinity-label, HLA-A1 on C1R.A1 cells. Only the derivatives containing the photoreactive amino acid in position 1 or 7 fulfilled both criteria. Testing the former derivative on 14 lymphoid cell lines expressing over 44 different HLA class I molecules indicated that it efficiently photoaffinity-labeled not only KLA-A1, but possibly also HLA-A29 and HLA-B44. MAGE peptide binding by HLA-A29 and HLA-B44 was confirmed by photoaffinity labeling with photoreactive MAGE-3 peptide derivatives on C1R.A29 and C1R.B44 cells, respectively. The different photoaffinity labeling systems were used to assess the ability of the homologous peptides derived from MAGE 1, -2, -3, -4a, -4b, -6, and -12 to bind to HLA-A1, KLA-A29, and HLA-B44. All but the MAGE-2 and MAGE-12 nonapeptides efficiently inhibited photoaffinity labeling of HLA-A1, which is in agreement with the known HLA-A1 peptide-binding motif (acidic residue in P3 and C-terminal tyrosine). In contrast, photoaffinity labeling of HLA-A29 was efficiently inhibited by these as well as by the MAGE-3 and MAGE-6 nonapeptides. Finally, the HLA-B44 photoaffinity labeling, unlike the HLA-A1 and HLA-A29 labeling, was inhibited more efficiently by the corresponding MAGE decapeptides, which is consistent with the reported HLA-B44 peptide-binding motif (glutamic acid in P2, and C-terminal tyrosine or phenylalanine). The overlapping binding of homologous MAGE peptides by HLA-A1, A29, and B44 is based on different binding principles and may have implications for immunotherapy of MAGE-positive tumors.	LUDWIG INST CANC RES,BRUSSELS BRANCH,B-1200 BRUSSELS,BELGIUM	Ludwig Institute for Cancer Research	Luescher, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CHEMIN BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.		Romero, Pedro/S-6015-2017	Romero, Pedro/0000-0002-9688-2882; Jongeneel, Cornelis Victor/0000-0002-3922-1906; Kuznetsov, Dmitry/0000-0002-9972-947X				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANJUERE F, 1995, ANAL BIOCHEM, V229, P61, DOI 10.1006/abio.1995.1379; BARBER LD, 1995, CURR BIOL, V5, P179, DOI 10.1016/S0960-9822(95)00039-X; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; BRODSKY FM, 1982, J IMMUNOL, V128, P129; DELGUERCIO MF, 1995, J IMMUNOL, V154, P685; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; DESMET C, 1994, IMMUNOGENETICS, V39, P121, DOI 10.1007/BF00188615; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1995, BIOCHEMISTRY-US, V34, P10130, DOI 10.1021/bi00032a005; DUPONT B, 1987, IMMUNOBIOLOGY HLA, V1; FALK K, 1994, IMMUNOGENETICS, V40, P238, DOI 10.1007/BF00167086; FLEISCHHAUER K, 1994, TISSUE ANTIGENS, V44, P311, DOI 10.1111/j.1399-0039.1994.tb02401.x; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; KUBO RT, 1994, J IMMUNOL, V152, P3913; LEVINE JE, 1994, TISSUE ANTIGENS, V44, P174, DOI 10.1111/j.1399-0039.1994.tb02376.x; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SIDNEY J, 1995, J IMMUNOL, V154, P247; SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8; TRAVERSARI C, 1992, J EXP MED, V176, P1453, DOI 10.1084/jem.176.5.1453; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P2134; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; YOUNG ACM, 1995, FASEB J, V9, P26, DOI 10.1096/fasebj.9.1.7821756	30	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12463	12471		10.1074/jbc.271.21.12463	http://dx.doi.org/10.1074/jbc.271.21.12463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647853	hybrid			2022-12-27	WOS:A1996UL66000055
J	Manzella, SM; Hooper, LV; Baenziger, JU				Manzella, SM; Hooper, LV; Baenziger, JU			Oligosaccharides containing beta 1,4-linked N-acetylgalactosamine, a paradigm for protein-specific glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; EQUINE CHORIONIC-GONADOTROPIN; STRUCTURAL ELUCIDATION; SIALYLATED OLIGOSACCHARIDES; BOVINE LUTROPIN; FOLLITROPIN; THYROTROPIN; TRANSFERASE; EXPRESSION		WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R01CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; BEYER TA, 1979, J BIOL CHEM, V254, P2531; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; CROWLEY WF, 1985, EPISODIC SECRETION H, P121; DAMM JBL, 1990, EUR J BIOCHEM, V189, P175, DOI 10.1111/j.1432-1033.1990.tb15474.x; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; EASTON EW, 1993, BLOOD, V81, P2978; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GYVES PW, 1990, P NATL ACAD SCI USA, V87, P3792, DOI 10.1073/pnas.87.10.3792; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LOCHNIT G, 1995, EUR J BIOCHEM, V228, P805, DOI 10.1111/j.1432-1033.1995.tb20326.x; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; MATSUI T, 1994, BIOCHEMISTRY-US, V33, P14039, DOI 10.1021/bi00251a012; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; QUERAT B, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P27; REED DK, 1991, J BIOL CHEM, V266, P14251; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VELDHUIS JD, 1988, AM J PHYSIOL, V255, pE749, DOI 10.1152/ajpendo.1988.255.6.E749; WEISSHAAR G, 1990, EUR J BIOCHEM, V192, P741, DOI 10.1111/j.1432-1033.1990.tb19285.x; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	54	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12117	12120		10.1074/jbc.271.21.12117	http://dx.doi.org/10.1074/jbc.271.21.12117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647799	hybrid			2022-12-27	WOS:A1996UL66000001
J	Fourcin, M; Chevalier, S; Guillet, C; Robledo, O; Froger, J; PouplardBarthelaix, A; Gascan, H				Fourcin, M; Chevalier, S; Guillet, C; Robledo, O; Froger, J; PouplardBarthelaix, A; Gascan, H			gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; MOLECULAR-CLONING; ONCOSTATIN-M; DA CELLS; HEMATOPOIETIC PROGENITORS; GROWTH-FACTOR; STEM-CELLS; FACTOR LIF	gp130 transducing receptor is involved in the formation of high affinity receptors for the cytokines of the interleukin-6 (IL-6) family. Recruitment of gp130 by IL-6 associated to its receptor leads to the dimerization of the transducing component, In the present study we did characterize the B-S12 monoclonal antibody raised against gp130 and able to elicit IL-6 type biological activities. B-S12 antibody triggered strongly the proliferation of TF1 and XG1 hematopoietic cell lines and was able to increase the synthesis of acute phase proteins in HepG2 hepatoma cell line. B-S12 also behaved as a synergistic factor with granulocyte-macrophage colony-stimulating factor for both proliferation and differentiation of CD34-positive hematopoietic cell progenitors. By using a symmetric enzyme-linked immunosorbent assay, allowing the detection of dimeric forms of soluble gp130, we found that addition of B-S12 to gp130 led to its dimerization. Analysis of the tyrosine phosphorylation events in gp130 and Jak kinase family members revealed that B-S12 quickly induced the phosphorylation of gp130 in a neural derived cell line, and that Jak1 and Jak2 were also recruited. In conclusion, we show that gp130 cross-linking with the B-S12 monoclonal antibody was sufficient to generate functional IL-6 type responses in hematopoietic, neural, and hepatic cells.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers								ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CHEREL M, 1995, BLOOD, V86, P2534; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P465; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEIN B, 1989, BLOOD, V73, P517; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LEARY AG, 1990, BLOOD, V75, P1960; LECRON JC, 1993, CLIN EXP IMMUNOL, V92, P23; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUSASHI M, 1991, BLOOD, V78, P1448; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VERFAILLIE C, 1991, BLOOD, V77, P263; WARD LD, 1994, J BIOL CHEM, V269, P23286; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P826; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	52	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11756	11760		10.1074/jbc.271.20.11756	http://dx.doi.org/10.1074/jbc.271.20.11756			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662709	hybrid			2022-12-27	WOS:A1996UL25000029
J	Kramer, JA; Krawetz, SA				Kramer, JA; Krawetz, SA			Nuclear matrix interactions within the sperm genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SPERMATOZOA; ATTACHMENT REGIONS; DNA; GENES; LOOPS; REPLICATION; DOMAIN; SITES; CHROMATIN; ANCHORAGE	Analysis of the haploid expressed human PRM1 --> PRM2 --> TNP2 genic domain has revealed two regions of attachment to the sperm nuclear matrix. These sperm nuclear matrix attachment regions delimit the DNase I-sensitive domain of this haploid expressed locus. The domain is intermediately associated with but not attached to the nuclear matrix. DNase I-sensitive genes within the mature sperm nucleus, such as protamine 1, protamine 2, transition protein 2, alpha-globin, and beta-actin, display this intermediate affinity for the sperm nuclear matrix. This may denote their role in templating the male genome prior to fertilization, thus ensuring the formation of a viable male pronucleus during early embryonic development.	WAYNE STATE UNIV, SCH MED, CS MOTT CTR HUMAN GROWTH & DEV, DETROIT, MI 48102 USA	Wayne State University	Kramer, JA (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT OBSTET & GYNECOL, CTR MOL MED & GENET, DETROIT, MI 48102 USA.		krawetz, stephen/GQQ-3308-2022		NICHD NIH HHS [1R01HD2850401A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARONE JG, 1994, J ANDROL, V15, P139; BASKIN Y, 1995, SCIENCE, V268, P1564, DOI 10.1126/science.7777854; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CHOUDHARY SK, 1995, J BIOL CHEM, V270, P8755, DOI 10.1074/jbc.270.15.8755; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DALTON S, 1986, NUCLEIC ACIDS RES, V14, P6507, DOI 10.1093/nar/14.16.6507; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; DOGGETT NA, 1995, NATURE, V377, P335; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GREENSTEIN RJ, 1988, DNA-J MOLEC CELL BIO, V7, P601, DOI 10.1089/dna.1988.7.601; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KALANDADZE AG, 1990, BIOCHEM BIOPH RES CO, V168, P9, DOI 10.1016/0006-291X(90)91667-H; KRAMER JA, 1995, MAMM GENOME, V6, P677, DOI 10.1007/BF00352382; KRAMER JA, 1996, IN PRESS GENOMICS; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; NELSON JE, 1994, J BIOL CHEM, V269, P31067; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; WARD WS, 1990, BIOCHEM BIOPH RES CO, V173, P20, DOI 10.1016/S0006-291X(05)81015-0; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; WARD WS, 1993, BIOL REPROD, V48, P1193, DOI 10.1095/biolreprod48.6.1193; ZLATANOVA J S, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P211	30	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11619	11622		10.1074/jbc.271.20.11619	http://dx.doi.org/10.1074/jbc.271.20.11619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662749	hybrid			2022-12-27	WOS:A1996UL25000007
J	Rehrauer, WM; Kowalczykowski, SC				Rehrauer, WM; Kowalczykowski, SC			The DNA binding site(s) of the Escherichia coli RecA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENETIC-RECOMBINATION; NEUTRON-SCATTERING; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; AMINO-ACIDS; RAS PROTEIN; EF-TU; COMPLEXES; LOCATION	Photochemical cross-linking has been used to identify residues in the Escherichia coli RecA protein that are proximal to and may directly mediate binding of DNA. Ultraviolet irradiation promotes specific and efficient cross-linking of the RecA protein to poly(deoxythymidylic) acid. Cross-linked peptides remaining covalently attached to the polynucleotide following proteolytic digestion with trypsin correspond to amino acids 61-72, 178-183, and 233-243 of the RecA protein primary sequence. Their location and surface accessibility in the crystal structure, along with the behavior of various recA mutants, support the assignment of the cross-linked regions to the DNA binding site(s) of the RecA protein. Functional overlap of amino acids 61-72 with an element of the ATP binding site suggests a structural mechanism by which nucleotide cofactors allosterically affect the RecA nucleoprotein filament.	UNIV CALIF DAVIS, MICROBIOL SECT, DIV BIOL SCI, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SECT MOL & CELL BIOL, DIV BIOL SCI, DAVIS, CA 95616 USA; NORTHWESTERN UNIV, SCH MED, DEPT MOLEC BIOL, CHICAGO, IL 60611 USA	University of California System; University of California Davis; University of California System; University of California Davis; Northwestern University					NIAID NIH HHS [AI-18987] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENIGHT AS, 1991, BIOCHIMIE, V73, P143, DOI 10.1016/0300-9084(91)90197-9; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CASSUTO E, 1980, P NATL ACAD SCI-BIOL, V77, P3962, DOI 10.1073/pnas.77.7.3962; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DICAPUA E, 1989, BIOCHEMISTRY-US, V28, P3287, DOI 10.1021/bi00434a025; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; JONG EAM, 1989, J MOL BIOL, V206, P133; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KARLIN S, 1996, IN PRESS J BACTERIOL; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KONOLA JT, 1995, J BIOL CHEM, V270, P8411, DOI 10.1074/jbc.270.15.8411; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P772, DOI 10.1111/j.1432-1033.1995.0772m.x; MORIMATSU K, 1995, ADV BIOPHYS, V31, P23, DOI 10.1016/0065-227X(95)99381-X; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PRASAD BVV, 1987, J MOL BIOL, V193, P579; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P125, DOI 10.1111/j.1751-1097.1984.tb03417.x; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILSON DH, 1990, J BIOL CHEM, V265, P7351; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363; YU X, 1990, BIOPHYS J, V57, P555, DOI 10.1016/S0006-3495(90)82571-6	58	43	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11996	12002		10.1074/jbc.271.20.11996	http://dx.doi.org/10.1074/jbc.271.20.11996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662640	hybrid			2022-12-27	WOS:A1996UL25000063
J	Krook, A; Moller, DE; Dib, K; ORahilly, S				Krook, A; Moller, DE; Dib, K; ORahilly, S			Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate-1 (IRS-1) but fail to mediate the biological effects of insulin - Evidence that IRS-1 phosphorylation is not sufficient for normal insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; PROTEIN; ACTIVATION; MUTATIONS; CELLS; ASSOCIATION; RESISTANCE; 3'-KINASE	Two naturally occurring mutant insulin receptors, Arg-1174 --> Gln and Leu-1178 --> Pro, found in patients with dominantly inherited Type A insulin resistance, showed unusual signaling properties when stably expressed in Chinese hamster ovary (CHO) cells. Both mutant receptors were expressed on the cell surface and bound insulin normally, but showed markedly impaired autophosphorylation in response to insulin. In addition, the in vitro tyrosine kinase activity of both mutant receptors toward an artificial substrate was also severely impaired. Despite these defects of kinase activity, antiphosphotyrosine immunoblotting of whole cell lysates and anti-phosphotyrosine immunoprecipitation of P-32-labeled cells showed insulin-stimulated tyrosine phosphorylation of a protein of similar to 185 kDa to an extent comparable to that seen in CHO cells expressing wild-type human insulin receptors. Anti-insulin receptor substrate-1 (IRS-1) immunoprecipitation followed by antiphosphotyrosine immunoblotting confirmed that this tyrosine-phosphorylated protein was IRS-1. In contrast, CHO cells expressing an insulin receptor mutated at the ATP binding site (Lys-1030 --> Arg) showed no insulin-stimulated autophosphorylation or phosphorylation of IRS-1. Despite exhibiting apparently normal insulin stimulation of IRS-1 tyrosine-phosphorylation, cells expressing the Arg-1174 --> Gln or Pro-1178 --> Leu receptors showed marked impairment in insulin stimulation of glycogen synthesis, thymidine incorporation, and activation of MAP kinase. The inability of these mutant receptors to signal normally to metabolic and mitogenic responses suggests that insulin-stimulated tyrosine phosphorylation of IRS-1 alone is insufficient to fully mediate insulin action.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Krook, A (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020; Krook, Anna/K-1192-2015	O'Rahilly, Stephen/0000-0003-2199-4449; Krook, Anna/0000-0002-0891-0258	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45874] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		ACCILI D, 1995, 77 ANN M END SOC WAS; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BACKER JM, 1990, BIOCHEMISTRY-US, V30, P6366; CAMA A, 1992, J BIOL CHEM, V267, P8383; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; GUSTAFSON TA, 1995, DIABETES, V44, pA49; ISAKOFF SJ, 1995, DIABETES, V44, pA19; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MORITZ W, 1994, FEBS LETT, V351, P276, DOI 10.1016/0014-5793(94)00876-0; MURKAMI MS, 1991, J BIOL CHEM, V266, P22653; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PATTI ME, 1995, DIABETES, V44, pA31; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1995, DIABETES, V44, pA49; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1988, CELL, V54, P642; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	46	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7134	7140		10.1074/jbc.271.12.7134	http://dx.doi.org/10.1074/jbc.271.12.7134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636149	hybrid			2022-12-27	WOS:A1996UB15700084
J	Maruyama, S; Kurosaki, T; Sada, K; Yamanashi, Y; Yamamoto, T; Yamamura, H				Maruyama, S; Kurosaki, T; Sada, K; Yamanashi, Y; Yamamoto, T; Yamamura, H			Physical and functional association of cortactin with Syk in human leukemic cell line K562	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ERYTHROID-DIFFERENTIATION; TYROSINE-PHOSPHORYLATION; GENE-EXPRESSION; HUMAN CARCINOMAS; SUBSTRATE; IDENTIFICATION; INDUCTION; ACTIVATION; GLOBIN	Human leukemic cell line K562 is induced to differentiate into the megakaryocytic lineage by stimulation with 12-O-tetradecanoylphorbol-18-acetate (TPA). We demonstrate here that TPA stimulation increases tyro sine phosphorylation of an 80-kDa protein at an early stage of megakaryocytic differentiation and that this 80-kDa protein is identical with cortactin. Since tyrosine kinase Syk, was activated by TPA stimulation, we examined the possibility that cortactin is a potential substrate of Syk in K562 cells. TPA-induced tyrosine phosphorylation of cortactin was decreased profoundly by overexpression of dominant-negative Syk. Furthermore, cortactin was associated with Syk even before TPA stimulation. Since cortactin was previously referred as an 80/85-kilodalton pp60(src) substrate, we examined the association between Src and cortactin, whereas its association could not be detected. These data suggest that Syk phosphorylates cortactin in K562 cells upon TPA treatment.	KOBE UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,KOBE 650,JAPAN; FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Kobe University; University of Fukui; University of Tokyo; Yale University			Sada, Kiyonao/H-7373-2015; Kurosaki, Tomohiro/D-1306-2009	Sada, Kiyonao/0000-0001-6124-3100; Kurosaki, Tomohiro/0000-0002-6352-304X				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BENHAMOU LE, 1994, EUR J IMMUNOL, V24, P1993, DOI 10.1002/eji.1830240909; BINSPAHR KJ, 1990, J IMMUNOL, V145, P971; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FORCE T, 1991, J BIOL CHEM, V266, P6650; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HOFFMAN R, 1991, CANCER CHEMOTH PHARM, V28, P102, DOI 10.1007/BF00689696; HONMA Y, 1989, CANCER RES, V49, P331; KATAGIRI K, 1993, J IMMUNOL, V150, P585; KATAYAMA N, 1989, BLOOD, V73, P123; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Leary J F, 1987, J Biol Regul Homeost Agents, V1, P73; LI WQ, 1994, J BIOL CHEM, V269, P2349; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUISIDELUCA C, 1984, J CLIN INVEST, V74, P821, DOI 10.1172/JCI111498; MAA MC, 1992, ONCOGENE, V7, P2429; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKAJIMA M, 1989, BIOCHEM BIOPH RES CO, V158, P958, DOI 10.1016/0006-291X(89)92815-5; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; Siebert P D, 1985, Prog Clin Biol Res, V191, P233; SUTHERLAND JA, 1986, J BIOL RESP MODIF, V5, P250; TABILIO A, 1983, CANCER RES, V43, P4569; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TONKONOW BL, 1982, BLOOD, V59, P738; VAINCHENKER W, 1981, BLOOD CELLS, V7, P357; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; YEN A, 1993, CANCER RES, V53, P3085; YU G, 1989, J BIOL CHEM, V264, P10276; ZHAN X, 1994, J BIOL CHEM, V269, P20221	47	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6631	6635		10.1074/jbc.271.12.6631	http://dx.doi.org/10.1074/jbc.271.12.6631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636079	hybrid			2022-12-27	WOS:A1996UB15700014
J	Martire, G; Mottola, G; Pascale, MC; Malagolini, N; Turrini, I; SerafiniCessi, F; Jackson, MR; Bonatti, S				Martire, G; Mottola, G; Pascale, MC; Malagolini, N; Turrini, I; SerafiniCessi, F; Jackson, MR; Bonatti, S			Different fate of a single reporter protein containing KDEL or KKXX targeting signals stably expressed in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; HUMAN CD8 GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; INTERMEDIATE COMPARTMENT; DISULFIDE-ISOMERASE; MEMBRANE-PROTEINS; SECRETORY PATHWAY; PLASMA-MEMBRANE; GOLGI-COMPLEX	In mammalian cells, resident luminal and type I transmembrane proteins of the endoplasmic reticulum usually contain KDEL and KKXX at the carboxyl terminus. These sequences induce retrieval hom compartments located downstream in the secretory pathway. It has been suggested that the retrieval may occur from multiple sites, ranging from the intermediate compartment to the trans-Golgi network. To compare the retrieval of luminal and type I membrane proteins, we have used different forms of a single reporter, the human CD8 glycoprotein, stably expressed in FRT cells. Metabolic labeling and oligosaccharide analysis show that the mechanism based on the KDEL signal is leaky. With time, the KDEL-containing CD8 form reaches the trans/trans-Golgi network compartments, where the protein is terminally glycosylated. At this stage, the retrieval mechanism stops being effective and the protein is consequently secreted. Conversely, the mechanism based on the KKXX signal guarantees that most of the KKXX-containing CD8 form resides in the endoplasmic reticulum, little in the Golgi complex and undetectable levels at the plasma membrane. The O-glycosylation of this protein comprises for the vast majority the sole addition of peptide-bound GalNAc that occurs in an early Golgi compartment.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV BOLOGNA, DIPARTIMENTO PATOL SPERIMENTALE, I-40126 BOLOGNA, ITALY; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA	University of Naples Federico II; University of Bologna; Johnson & Johnson; Johnson & Johnson USA			Pascale, Maria/B-4273-2012; Mottola, Giovanna/Y-7540-2019	Mottola, Giovanna/0000-0002-7541-0472				BONATTI S, 1989, J BIOL CHEM, V264, P12590; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DAHLLOF B, 1991, J BIOL CHEM, V266, P1804; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MALAGOLINI N, 1994, GLYCOCONJUGATE J, V11, P89, DOI 10.1007/BF00731148; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PETER F, 1992, J BIOL CHEM, V267, P10631; PILLER V, 1990, J BIOL CHEM, V265, P9264; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SARASTE J, 1991, J CELL SCI, V100, P415; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINICESSI F, 1995, ADV EXP MED BIOL, V376, P135; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; TANG BL, 1994, EUR J CELL BIOL, V65, P298; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VASSARD C, 1995, GLYCOCONJ J, V12, P447; VERDE V, 1995, EUR J CELL BIOL, V67, P267; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	56	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3541	3547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631959				2022-12-27	WOS:A1996TV72400033
J	Oda, N; Saxena, JK; Jenkins, TM; Prasad, R; Wilson, SH; Ackerman, EJ				Oda, N; Saxena, JK; Jenkins, TM; Prasad, R; Wilson, SH; Ackerman, EJ			DNA polymerases alpha and beta are required for DNA repair in an efficient nuclear extract from Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCISION REPAIR; MAMMALIAN-CELLS; DELTA; COMPLEMENTATION; PHOTOPRODUCTS; SEQUENCES; EPSILON; DIMERS	Xenopus oocytes and an oocyte nuclear extract efficiently repair the bulky DNA lesions cyclobutane pyrimidine dimers, (6-4) photoproducts, and N-acetoxy-2-aminofluorene (AAF) adducts by san excision repair mechanism. Nearly all (>95%) of the input damaged DNA was repaired within 5 h in both infected cells and extracts with no significant incorporation of label into control undamaged DNA. Remarkably, more than 10(10) cyclobutane pyrimidine dimers or (6-4) photoproducts are repaired/nuclei. The extracts are free from nuclease activity, and repair is independent of exogenous light. Both the high efficiency and DNA polymerase requirements of this system appear to be different from extracts derived from human cells. We demonstrated a requirement for DNA polymerases alpha and beta in repair of both photoproducts and AAF by inhibiting repair with several independent antibodies specific to either DNA polymerases alpha or beta and then restoring repair by adding the appropriate purified polymerase. Repair is inhibited by aphidicolin at concentrations specific for blocking DNA polymerase alpha and dideoxynucleotide triphosphates at concentrations specific for inhibiting DNA polymerase beta.	NIDDK, NIH, OFF SCI DIRECTOR, BETHESDA, MD 20892 USA; UNIV TEXAS, MED BRANCH, SCALY CTR MOL SCI, GALVESTON, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; AHOUSSEKHRA A, 1995, CELL, V80, P859; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BURZIO LO, 1981, MOL APPROACHES GENE, P149; Davidson E. H., 1986, GENE ACTIVITY EARLY; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DOREE M, 1993, CELL CYCLE PRACTICAL, P285; FRIEDBERG EC, 1995, DNA REPAIR; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOENJE H, 1978, J BIOL CHEM, V253, P2640; JONES CJ, 1992, NUCLEIC ACIDS RES, V20, P991, DOI 10.1093/nar/20.5.991; KEENEY S, 1990, MUTAT RES, V236, P239, DOI 10.1016/0921-8777(90)90008-S; KUMAR A, 1990, J BIOL CHEM, V265, P2124; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PROTICSABLJIC M, 1986, MOL CELL BIOL, V6, P3349, DOI 10.1128/MCB.6.10.3349; ROSENSTEIN BS, 1980, BIOPHYS J, V31, P196; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P16402, DOI 10.1074/jbc.270.27.16402; SWACK JA, 1985, ANAL BIOCHEM, V147, P10, DOI 10.1016/0003-2697(85)90003-X; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TANG MS, 1989, J BIOL CHEM, V264, P14455; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIST E, 1979, BIOCHIM BIOPHYS ACTA, V562, P62, DOI 10.1016/0005-2787(79)90126-6; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	38	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13816	13820		10.1074/jbc.271.23.13816	http://dx.doi.org/10.1074/jbc.271.23.13816			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662731	hybrid			2022-12-27	WOS:A1996UP38500077
J	Mateu, MG; Valero, ML; Andreu, D; Domingo, E				Mateu, MG; Valero, ML; Andreu, D; Domingo, E			Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GLYCOPROTEIN-IIB-IIIA; GLYCINE-ASPARTIC ACID; MAJOR ANTIGENIC SITE; SEROTYPE-C; RGD; ADHESION; FIBRONECTIN; BINDING; SEQUENCE	The conserved Arg-Gly-Asp (RGD) motif found in a hypervariable, mobile antigenic loop of foot-and-mouth disease virus (FMDV) is critically involved in virus attachment to cells by binding to an integrin, probably related to alpha(nu)beta(3). Here we describe (i) the synthesis of 241 15-mer peptides, which represent this loop of FMDV (isolate C-S8c1) and single variants in which each amino acid residue was replaced by 16 others and (ii) the inhibitory activity of these peptides on the ability of FMDV C-S8c1 to recognize and infect susceptible cells. This approach has allowed a first detailed evaluation of the specificity of each residue within a RGD containing protein loop on cell recognition. The results indicate that, in addition to the exquisitely specific RGD triplet, two highly conserved Leu residues located at positions +1 and +4 downstream of the RGD and, to a lesser extent, the residue at position +2 are the only critical and specific determinants within the loop in promoting cell recognition of a viral ligand. The results support the proposal that, in spite of their involvement in antibody recognition, RGD and other FMDV loop residues are remarkably conserved because of their essential role in cell recognition.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV BARCELONA,DEPT QUIM ORGAN,E-08028 BARCELONA,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona			Mateu, Mauricio/ABF-2146-2021; Andreu, David/I-4359-2014; Domingo, Esteban/K-3937-2014	Mateu, Mauricio/0000-0002-2915-1529; Andreu, David/0000-0002-6317-6666; Domingo, Esteban/0000-0002-0573-1676				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ALBERICIO F, 1990, J ORG CHEM, V55, P3730, DOI 10.1021/jo00299a011; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BAXT B, 1990, Virus Genes, V4, P73, DOI 10.1007/BF00308567; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; BOOTHROYD JC, 1982, GENE, V17, P153, DOI 10.1016/0378-1119(82)90068-3; BORREGO B, 1993, J VIROL, V67, P6071, DOI 10.1128/JVI.67.10.6071-6079.1993; CAMARERO JA, 1993, FEBS LETT, V328, P159, DOI 10.1016/0014-5793(93)80985-4; CHANG KH, 1992, J GEN VIROL, V73, P621, DOI 10.1099/0022-1317-73-3-621; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; Domingo E., 1990, Applied Virology Research, V2, P233; DOMINGO E, 1992, CURR TOP MICROBIOL, V176, P33; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Feigelstock DA, 1996, VACCINE, V14, P97, DOI 10.1016/0264-410X(95)00180-9; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Harber J, 1995, VIROLOGY, V214, P559, DOI 10.1006/viro.1995.0067; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Hernandez J, 1996, J GEN VIROL, V77, P257, DOI 10.1099/0022-1317-77-2-257; HERNANDEZ J, 1992, J GEN VIROL, V73, P213, DOI 10.1099/0022-1317-73-1-213; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; MARTINEZ MA, 1991, VIROLOGY, V184, P695, DOI 10.1016/0042-6822(91)90439-I; MASON PW, 1994, P NATL ACAD SCI USA, V91, P1932, DOI 10.1073/pnas.91.5.1932; MATEU MG, 1995, VIROLOGY, V210, P120, DOI 10.1006/viro.1995.1323; MATEU MG, 1992, EUR J IMMUNOL, V22, P1385, DOI 10.1002/eji.1830220609; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; MATEU MG, 1990, J GEN VIROL, V71, P629, DOI 10.1099/0022-1317-71-3-629; MATEU MG, 1989, P NATL ACAD SCI USA, V86, P5883, DOI 10.1073/pnas.86.15.5883; MEYER RF, 1994, VIRUS RES, V32, P299, DOI 10.1016/0168-1702(94)90079-5; NOVELLA IS, 1993, FEBS LETT, V330, P253, DOI 10.1016/0014-5793(93)80883-V; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; Pereira H.G., 1981, VIRUS DISEASES FOOD, P333; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; RIEDER E, 1994, J VIROL, V68, P5296, DOI 10.1128/JVI.68.8.5296-5299.1994; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; ROWE CA, 1993, THESIS U READING; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SEKIGUCHI K, 1982, ARCH VIROL, V74, P53, DOI 10.1007/BF01320782; SOBRINO F, 1983, VIROLOGY, V128, P310, DOI 10.1016/0042-6822(83)90258-1; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; SUROVOI AY, 1988, SOVIET J BIOORG CHEM, V14, P965; TRANQUI L, 1989, J CELL BIOL, V108, P2519, DOI 10.1083/jcb.108.6.2519; Valero M L, 1995, Biomed Pept Proteins Nucleic Acids, V1, P133; VERDAGUER N, 1995, EMBO J, V14, P1690, DOI 10.1002/j.1460-2075.1995.tb07158.x; VOSLOO W, 1992, EPIDEMIOL INFECT, V109, P547, DOI 10.1017/S0950268800050536; VOSLOO W, 1995, EPIDEMIOL INFECT, V114, P203, DOI 10.1017/S0950268800052055; WHITE JM, 1993, CURR BIOL, V3, P596, DOI 10.1016/0960-9822(93)90007-B; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413	67	112	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12814	12819		10.1074/jbc.271.22.12814	http://dx.doi.org/10.1074/jbc.271.22.12814			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662712	hybrid			2022-12-27	WOS:A1996UN47400021
J	Modur, V; Zimmerman, GA; Prescott, SM; McIntyre, TM				Modur, V; Zimmerman, GA; Prescott, SM; McIntyre, TM			Endothelial cell inflammatory responses to tumor necrosis factor alpha - Ceramide-dependent and -independent mitogen-activated protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; FAMILY MEMBERS; SPHINGOMYELINASE; MONOCYTOGENES; INTERLEUKIN-8; RESISTANT; INFECTION; CYTOKINES	Ceramide generation by stimulated sphingomyelinase activity has been implicated in tumor necrosis factor alpha (TNF) signaling of apoptosis and differentiation. We examined the role of ceramide in a major action of TNF: the initiation of inflammatory events. Sphingomyelinase C at high levels induced inflammatory protein expression in endothelial cells resulting in leukocyte adhesion, but the pattern of induction of adhesion molecules (E-selectin, ICAM-1, VCAM-1) and cytokines (interleukins 6 and 8) differed from that induced by TNF. TNF induced only a small increase in ceramide: using lower doses of sphingomyelinase to mimic this we found that small amounts of ceramide did not induce protein expression, but still rapidly activated Raf-1, mitogen-activated protein/extracellular regulated kinase (ERK) kinase (MEK) and ERKs. TNF additionally caused rapid p38 and JNK-1 mitogen-activated protein kinase activation and efficient NF-kappa B translocation, which could not be achieved even by high levels of ceramide. Thus activation of the ERK: cascade alone is an incomplete endothelial cell stimulus, and the TNF receptor generates at least two signals: Raf-1 activation, which could be ceramide-dependent; and ceramide-independent efficient NF-kappa B translocation and activation of p38 and JNK-1 mitogen-activated kinases.	UNIV UTAH,NE HARRISON CARDIOVASC RES & TRAINING INST,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PATHOL,SALT LAKE CITY,UT 84112; UNIV UTAH,PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCI NIH HHS [CCSG 3P30 CA 42014-09] Funding Source: Medline; NHLBI NIH HHS [HL 50513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CRUZ R, 1995, FASEB J, V9, pA127; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FENNELL DF, 1991, ARTERIOSCLER THROMB, V11, P97, DOI 10.1161/01.ATV.11.1.97; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mollby R., 1978, BACTERIAL TOXINS CEL, P367; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PATEL KD, 1994, J CLIN INVEST, V94, P631, DOI 10.1172/JCI117379; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINES MA, 1993, J BIOL CHEM, V268, P14572; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SALEEM A, 1995, J IMMUNOL, V154, P4150; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAN MH, 1994, NATURE, V372, P798; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1993, AM J RESP CELL MOL, V9, P573, DOI 10.1165/ajrcmb/9.6.573; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	55	211	214	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13094	13102		10.1074/jbc.271.22.13094	http://dx.doi.org/10.1074/jbc.271.22.13094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662702	hybrid			2022-12-27	WOS:A1996UN47400063
J	DeMaria, CT; Brewer, G				DeMaria, CT; Brewer, G			AUF1 binding affinity to A+U-rich elements correlates with rapid mRNA degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; SEQUENCES; POLY(A); PROTEIN; INVITRO; REGION	Rapid degradation of many labile mRNAs is regulated in part by an A+U-rich element (ARE) in their 3'-untranslated regions. Extensive mutational analyses of various AREs have identified important components of the ARE, such as the nonamer motif UUAUUUAUU, two copies of which serve as a potent mRNA destabilizer. To investigate the roles of trans-acting factors in ARE-directed mRNA degradation, we previously purified and molecularly cloned the RNA binding protein AUF1 and demonstrated that both cellular and recombinant AUF1 bind specifically to AREs as shown by UV cross-linking assays in vitro. In the present work, we have examined the in vitro RNA-binding properties of AUF1 using gel mobility shift assays with purified recombinant His(6)-AUF1 fusion protein. We find that ARE binding affinities of AUF1 correlate with the potency of an ARE to direct degradation of a heterologous mRNA, These results support a role for AUF1 in ARE directed mRNA decay that is based upon its affinity for different AREs.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT IMMUNOL & MICROBIOL, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER; NCI NIH HHS [CA12197] Funding Source: Medline; NIAID NIH HHS [T32-AI07401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKASHI M, 1994, BLOOD, V83, P3182; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARTER BZ, 1991, LAB INVEST, V65, P610; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KENAN DJ, 1994, TRENDS BIOCHEM SCI, V19, P57, DOI 10.1016/0968-0004(94)90033-7; KOEFFLER HP, 1980, BLOOD, V56, P344; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TREMMEL KD, 1996, KEYSTONE S MOL BIOL, P47; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	31	235	239	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12179	12184		10.1074/jbc.271.21.12179	http://dx.doi.org/10.1074/jbc.271.21.12179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647811	hybrid			2022-12-27	WOS:A1996UL66000013
J	Longo, VD; Gralla, EB; Valentine, JS				Longo, VD; Gralla, EB; Valentine, JS			Superoxide dismutase activity is essential for stationary phase survival in Saccharomyces cerevisiae - Mitochondrial production of toxic oxygen species in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; YEAST; GENE; METALLOTHIONEIN; BIOSYNTHESIS; SENSITIVITY; DEHYDRATASE; METABOLISM; EVOLUTION; MUTATION	Yeast lacking copper-zinc superoxide dismutase (CuZnSOD), manganese superoxide dismutase (SOD), catalase T, or metallothionein were studied using long term stationary phase (10-45 days) as a simple model system to study the roles of antioxidant enzymes in aging. In well aerated cultures, the lack of either SOD resulted in dramatic loss of viability over the first few weeks of culture, with the CuZnSOD mutant showing the more severe defect. The double SOD mutant died within a few days. The severity reversed in low aeration; the CuZnSOD mutant remained viable longer than the manganese SOD mutant. To test whether reactive oxygen species generated during respiration play an important role in the observed cellular death, growth in nonfermentable carbon sources was measured, All strains grew under low aeration, indicating respiratory competence, High aeration caused much reduced growth in single SOD mutants, and the double mutant failed to grow. However, removal of respiration via another mutation dramatically increased short term survival and reversed the known air-dependent methionine and lysine auxotrophies. Our results suggest strongly that mitochondrial respiration is a major source of reactive oxygen species in vivo, as has been shown in vitro, and that these species are produced even under low aeration.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles			Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; BENOV L, 1995, ARCH BIOCHEM BIOPHYS, V322, P291, DOI 10.1006/abbi.1995.1465; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DO TQ, 1996, IN PRESS P NATL ACAD; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HEIKKILA RE, 1985, CRC HDB METHODS OXYG, P233; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLIDAY R, 1995, UNDERSTANDING AGING, P41; IMLAY JA, 1991, MOL GEN GENET, V228, P410, DOI 10.1007/BF00260634; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KONO Y, 1982, J BIOL CHEM, V257, P5751; KUO CF, 1987, J BIOL CHEM, V262, P4724; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LIU XF, 1992, J BIOL CHEM, V267, P18298; Luck H., 1974, ESTIMATION CATALASE, V885; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; NISHIDA CR, 1994, P NATL ACAD SCI USA, V91, P9906, DOI 10.1073/pnas.91.21.9906; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; THIELE DJ, 1986, MOL CELL BIOL, V6, P1158, DOI 10.1128/MCB.6.4.1158; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993	42	437	447	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12275	12280		10.1074/jbc.271.21.12275	http://dx.doi.org/10.1074/jbc.271.21.12275			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647826	hybrid			2022-12-27	WOS:A1996UL66000028
J	Tiffany, HL; Handen, JS; Rosenberg, HF				Tiffany, HL; Handen, JS; Rosenberg, HF			Enhanced expression of the eosinophil-derived neurotoxin ribonuclease (RNS2) gene requires interaction between the promoter and intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE DEFICIENCY; 1ST INTRON; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; CATIONIC PROTEIN; COLLAGEN GENE; HL-60 CELLS; ELEMENTS; SEQUENCE; CONTAINS	The eosinophil-derived neurotoxin (EDN/RNS2) is a member of the mammalian ribonuclease gene family and is one of four proteins found in the large specific granules of human eosinophilic leukocytes. The gene encoding EDN consists of two exons, including a noncoding exon 1, separated by a single intron from the coding sequence in exon 2. We have identified a functional promoter of the EDN gene and shown that optimal expression depends on interaction between the pro meter and one or more sequence elements found in the single intron. Cells of the clone 15 eosinophilic variant of the human promyelocytic HL-60 cell line were transfected with constructs that included the promoter region of the EDN gene alone, promoter with exon 1, and promoter with both exon 1 and the intron positioned 5' to the chloramphenicol acetyltransferase (CAT) reporter gene (constructs referred to as PrCAT, PrExCAT, and PrExInCAT, respectively). Although reporter gene activity from either PrCAT or PrExCAT was only 2-3 fold higher than baseline (CAT alone), inclusion of the single intron (PrExInCAT) resulted in a 28-fold increase in reporter gene activity in uninduced clone 15 cells, and an 80-fold in activity when clone 15 cells were induced to differentiate toward eosinophils with butyric acid. The intron-mediated enhancer activity was reproduced in other human hematopoietic cell lines (K562, Jurkat, U937, and HL-60), but was not found in human 293 kidney cells, suggesting that the function of the enhancer element(s) may be tissue-specific. A significant portion of the observed enhancer activity resides in the first 60 base pairs the the intron, which includes consensus binding sites for both AP-1 and NF-ATp transcription factors, and a 15-base pair segment that is identical to a sequence found in the promoter of the gene encoding the neutrophil granule protein, lactoferrin. The noncoding exon 1/single intron/coding exon 2 genomic structure is a common feature among the mammalian ribonucleases; this finding suggests the possibility of a conserved mechanism of regulation in this gene family.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,GRAD PROGRAM GENET,WASHINGTON,DC 20052	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); George Washington University								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BAINTON DF, 1992, INFLAMMATION BASIC P, P303; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GALLIN JI, 1982, BLOOD, V59, P1317; GALLIN JI, 1985, ANNU REV MED, V36, P263; GOMOLIN HI, 1993, BLOOD, V82, P1868; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HENKEL G, 1992, J IMMUNOL, V149, P3239; HIGUCHI R, 1990, PCR PROTOCOLS, pCH2; JOHNSTON JJ, 1992, BLOOD, V79, P2998; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LI MS, 1995, BIOCHEM J, V305, P921, DOI 10.1042/bj3050921; LOMAX KJ, 1989, J CLIN INVEST, V83, P514, DOI 10.1172/JCI113912; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NAKANO T, 1992, ONCOGENE, V7, P527; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; POGULIS RJ, 1993, J BIOL CHEM, V268, P2493; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROSENBERG HF, 1993, BLOOD, V82, P268, DOI 10.1182/blood.V82.1.268.bloodjournal821268; SAMUELSON LC, 1991, NUCLEIC ACIDS RES, V19, P6935, DOI 10.1093/nar/19.24.6935; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Spry CJ, 1988, EOSINOPHILS COMPREHE; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TIFFANY HL, 1995, J LEUKOCYTE BIOL, V58, P49; TOURMENTE S, 1993, INSECT BIOCHEM MOLEC, V23, P137, DOI 10.1016/0965-1748(93)90092-7; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410	39	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12387	12393		10.1074/jbc.271.21.12387	http://dx.doi.org/10.1074/jbc.271.21.12387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647842	hybrid			2022-12-27	WOS:A1996UL66000044
J	Lin, AW; Chang, CC; McCormick, CC				Lin, AW; Chang, CC; McCormick, CC			Molecular cloning and expression of an avian macrophage nitric-oxide synthase cDNA and the analysis of the genomic 5'-flanking region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; INTERFERON-GAMMA; PURIFICATION; CALMODULIN; FERREDOXIN; REDUCTASE; BINDING; GENE; LIPOPOLYSACCHARIDE; OXIDOREDUCTASE	We report the first nonmammalian inducible nitric-oxide synthase (NOS) cDNA obtained from chicken macrophages. It exhibits an open reading frame encoding 1,136 amino acid residues, predicting a protein of 129,648-Da molecular mass. The deduced NOS protein sequence showed 66.6%, 70.4%, 54.2%, and 48.7% sequence identity to mouse and human inducible NOS and to two constitutive NOSs from rat brain and bovine endothelium. Overall, NOS appears to be a moderately conserved protein. Northern analysis showed that chicken iNOS mRNA is approximately 4.5 kilobases (kb), a size similar to mammalian inducible NOS. Analysis of 3.2 kb of 5'-flanking sequence of the chicken iNOS gene showed a putative TATA box at 30 base pairs (bp) upstream of the transcription initiation site. The functional importance of the upstream region was determined by transient expression of deletion constructs, An endotoxin regulatory region was located exclusively within 300 bp upstream of the transcription initiation site, This is in contrast to the two distinct sites identified in the mouse macrophage NOS promoter. Transcription factor binding sites such as NF-kappa B, PEA1, PEA3, and C/EBP were identified. Using a NF-kappa B inhibitor, we showed that NF-kappa B is indeed involved in the induction of chicken iNOS gene by lipopolysaccharide. Our results suggest that NF-kappa B is a common regulatory component in the expression of both mammalian and nonmammalian iNOS genes.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853	Cornell University								ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BACHMANN S, 1995, AM J PHYSIOL-RENAL, V268, pF885, DOI 10.1152/ajprenal.1995.268.5.F885; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BILLIAR TR, 1992, J LAB CLIN MED, V120, P192; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CATTELL V, 1993, EXP NEPHROL, V1, P265; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; COYLE P, 1995, BIOCHEM J, V309, P25, DOI 10.1042/bj3090025; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DIMMITT SB, 1995, CLIN EXP PHARMACOL P, V22, P204, DOI 10.1111/j.1440-1681.1995.tb01981.x; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FELDMAN PL, 1993, CHEM ENG NEWS, V20, P26; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GIBALDI M, 1993, J CLIN PHARMACOL, V33, P488, DOI 10.1002/j.1552-4604.1993.tb04694.x; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; HOFFMAN M, 1991, SCIENCE, V253, P1788; HOLMQVIST BI, 1994, NEUROSCI LETT, V171, P205, DOI 10.1016/0304-3940(94)90640-8; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARCINKIEWICZ J, 1995, EUR J IMMUNOL, V25, P947, DOI 10.1002/eji.1830250414; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MCCORMICK CC, 1988, P NATL ACAD SCI USA, V85, P309, DOI 10.1073/pnas.85.2.309; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; RADOMSKI MW, 1993, ADV EXP MED BIOL, V344, P251; REGULASKI M, 1996, P NATL ACAD SCI USA, V92, P9072; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SUNG YJ, 1991, J LEUKOCYTE BIOL, V50, P49, DOI 10.1002/jlb.50.1.49; TAMIR H, 1963, ARCH BIOCHEM BIOPHYS, V102, P249, DOI 10.1016/0003-9861(63)90178-4; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	67	112	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11911	11919		10.1074/jbc.271.20.11911	http://dx.doi.org/10.1074/jbc.271.20.11911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662618	hybrid			2022-12-27	WOS:A1996UL25000053
J	Gorman, C; Skinner, RH; Skelly, JV; Neidle, S; Lowe, PN				Gorman, C; Skinner, RH; Skelly, JV; Neidle, S; Lowe, PN			Equilibrium and kinetic measurements reveal rapidly reversible binding of ras to raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ONCOGENIC P21(RAS); GROWTH-FACTORS; KINASE-KINASE; HA-RAS; P21; IDENTIFICATION; EXPRESSION; SEQUENCE; C-RAF-1	Raf is a serine/threonine kinase that binds through its amino-terminal regulatory domain to the GTP form of Ras and thereby activates the mitogen activated protein kinase pathway, In this study, we have characterized the interaction of the Ras-binding domain of Raf with Ras using equilibrium binding methods (scintillation proximity assay and fluorescence anisotropy), rather than with more widely used nonequilibrium procedures (such as enzyme-linked immunosorbent assay and affinity precipitation). Initial studies using glutathione S-transferase fusion proteins with either residues 1-257 or 1-190 of Raf showed that although it was possible to detect Ras binding using an enzyme-linked immunosorbent assay or affinity precipitation, it was substoichiometric; under equilibrium conditions with only a small excess of Raf almost no binding was detected, This difference was probably due to the presence of a high percentage of inactive Raf protein, Further studies used protein containing residues 51-131 of Raf, which expressed in Escherichia coli as a stable glutathione S-transferase fusion, With this protein, binding with Ras could readily be measured under equilibrium conditions. The catalytic domain of neurofibromin inhibited binding of Ras to Raf, and Raf inhibited the binding of Ras to neurofibromin showing that Raf and neurofibromin cannot be bound simultaneously to Ras, The affinities of interaction of neurofibromin and Raf with Barvey-Ras(Leu-61) were similar, The rate constant for dissociation of Raf from Ras was estimated to be >1 min-l, suggesting that Ras, Raf, and neurofibromin may be in rapid equilibrium in the cell. In contrast to previous reports, under equilibrium conditions there was no evidence for a difference in affinity between the minimal Ras binding domain of Raf (residues 51-131) and a region containing an additional 16 carboxyl-terminal amino acids, suggesting that residues 132-147 do not form a critical binding determinant.	WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND; INST CANC RES, CANC RES CAMPAIGN, BIOMOLEC STRUCT UNIT, SUTTON SM2 5NG, SURREY, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; University of London; Institute of Cancer Research - UK								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ISHIKAWA F, 1988, ONCOGENE, V3, P653; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LOWE PN, 1991, J BIOL CHEM, V266, P1672; LOWE PN, 1994, CELL SIGNAL, V6, P109, DOI 10.1016/0898-6568(94)90067-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; RAPP UR, 1988, HDB ONCOGENES, P213; REY I, 1994, ONCOGENE, V9, P685; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SKINNER RH, 1994, ANAL BIOCHEM, V223, P259, DOI 10.1006/abio.1994.1582; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6713	6719		10.1074/jbc.271.12.6713	http://dx.doi.org/10.1074/jbc.271.12.6713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636091	hybrid			2022-12-27	WOS:A1996UB15700026
J	Kramer, A; Carstens, CP; Fahl, WE				Kramer, A; Carstens, CP; Fahl, WE			A novel CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription at the G(1)/S boundary is sequestered by a retinoblastoma-like protein in G(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; CELL-CYCLE; COMPLETE TRANSFORMATION; FOCUS FORMATION; 3T3 CELLS; EXPRESSION; KINASE; FIBROBLASTS; ONCOGENE; PROMOTER	Loss of adhesion leads to cell cycle arrest at the G(1)/S boundary in normal, adhesion-dependent, mesenchymal cells. This arrest is accompanied by the inability to produce cyclin A. Using deletional and mutational analysis of the cyclin A promoter, we have identified a CCAAT element that mediates the adhesion; dependent transcriptional activation of cyclin A in late G, phase of the cell cycle, Specific binding of a novel 40/115-kDa heterodimeric protein complex, which we have named CBP/cycA, to this CCAAT element was detectable in growing but not in G(0)-arrested or nonadherent normal rat kidney fibroblasts, During G(0) CBP/cycA appears to be present but sequestered by a retinoblastoma family member. These results suggest that expression of cyclin A, which controls cell cycle progression by adhesion at the G(1)/S boundary, is regulated by CBP/cycA and the phosphorylation status of the retinoblastoma protein dr a retino blastoma-related protein.	UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R37CA042024] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1979, CANCER RES, V39, P1504; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAYHURST GP, 1995, J VIROL, V69, P182, DOI 10.1128/JVI.69.1.182-188.1995; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HURLIN PJ, 1987, CANCER RES, V47, P5752; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KATO J, 1993, GENE DEV, V7, P331; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTINELLI R, 1994, MOL CELL BIOL, V14, P8322, DOI 10.1128/MCB.14.12.8322; MCCLURE DB, 1983, CELL, V32, P999, DOI 10.1016/0092-8674(83)90084-3; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; SCHLAEPFER DD, 1994, NATURE, V372, P786; STEELE C, 1992, CANCER RES, V52, P4706; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	45	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6579	6582						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636070				2022-12-27	WOS:A1996UB15700005
J	McCarthy, TL; Casinghino, S; Mittanck, DW; Ji, CH; Centrella, M; Rotwein, P				McCarthy, TL; Casinghino, S; Mittanck, DW; Ji, CH; Centrella, M; Rotwein, P			Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E(2) in primary rat osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BONE-FORMATION; FACTOR-BETA; CELLS; IDENTIFICATION; STIMULATION; SERUM; ACID; MITOGENESIS; FIBROBLASTS	Insulin-like growth factor (IGF) action is mediated by high affinity cell surface IGF receptors and modulated by a family of secreted IGF binding proteins (IGFBPs), IGFBP-5, the most conserved of six IGFBPs characterized to date, uniquely potentiates the anabolic actions of IGF-I for skeletal cells, In osteoblasts, IGFBP-5 production is stimulated by prostaglandin E(2) (PGE(2)), a local factor that mediates certain effects induced by parathyroid hormone, cytokines such as interleukin-1 and transforming growth factor-beta, and mechanical strain, In this study, we show that transcriptional and post-transcriptional events initiated by PGE(2) collaborate to enhance IGFBP-5 gene expression in primary fetal rat osteoblast cultures, PGE(2) treatment stimulated up to a 7-fold rise in steady-state levels of IGFBP-5 mRNA throughout 32 h of incubation, Analysis of nascent IGFBP-5 mRNA suggested that PGE(2) had only a modest stimulatory effect on IGFBP-5 gene transcription, and transient transfection studies with IGFBP-5 promoter-reporter genes confirmed that PGE, enhanced promoter activity by similar to 2-fold. Similar stimulatory effects were seen with forskolin. A DNA fragment with only 51 base pairs of the 5'-flanking sequence retained hormonal responsiveness, which may be mediated by a binding site for transcription factor AP-2 located at positions -44 to -36 in the proximal LGFBP-5 promoter, Incubation of osteoblasts with the mRNA transcriptional inhibitor 5,6-dichforo-1-beta-D-ribofilranosylbenzimidazole demonstrated that PGE(2) enhanced IGFBP-5 mRNA stability by 2-fold, increasing the t(1/2) from 9 to 18 h. The effects of PGE(2) on steady-state IGFBP-5 transcripts were abrogated by preincubating cells with cycloheximide, indicating that the effects of PGE(2) on both gene transcription and mRNA stability required ongoing protein synthesis, Therefore, both promoter-dependent and -independent pathways converge to enhance IGFBP-5 gene expression in response to PGE(2) in osteoblasts.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	McCarthy, TL (corresponding author), YALE UNIV, SCH MED, SECT PLAST SURG, POB 208041, NEW HAVEN, CT 06520 USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [DK47421, R01 DK042748, DK42748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421, R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; ARAI T, 1994, J BIOL CHEM, V269, P20388; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1996, IN PRESS ANN NY ACAD; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287; CHYUN YS, 1984, PROSTAGLANDINS, V27, P97, DOI 10.1016/0090-6980(84)90223-5; CLAUSSEN M, 1994, ENDOCRINOLOGY, V134, P1964, DOI 10.1210/en.134.4.1964; CLEMMONS DR, 1991, INSULIN LIKE GROWTH, V1; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GABBITAS B, 1995, ENDOCRINOLOGY, V136, P2397, DOI 10.1210/en.136.6.2397; JEE WSS, 1990, BONE MINER, V15, P175; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KLEINNULEND J, 1990, ENDOCRINOLOGY, V126, P1070, DOI 10.1210/endo-126-2-1070; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1993, ADV EXP MED BIOL, V343, P407; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; NGAN P, 1990, ARCH ORAL BIOL, V35, P717, DOI 10.1016/0003-9969(90)90094-Q; NICOLETTI VG, 1993, BIOTECHNIQUES, V14, P532; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527	44	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6666	6671		10.1074/jbc.271.12.6666	http://dx.doi.org/10.1074/jbc.271.12.6666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636084	hybrid			2022-12-27	WOS:A1996UB15700019
J	Qi, XY; Qin, W; Sun, Y; Kondoh, K; Grabowski, GA				Qi, XY; Qin, W; Sun, Y; Kondoh, K; Grabowski, GA			Functional organization of saposin C - Definition of the neurotrophic and acid beta-glucosidase activation regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; AMINO-ACID; PROTEIN-2 SAP-2; INVESTIGATE; SEQUENCE; PATIENT; VARIANT; SPLEEN; GLUCOCEREBROSIDASE; BIOSYNTHESIS	Saposin C is an essential co-factor for the hydrolysis of glucosylceramide by acid beta-glucosidase in mammals, In addition, prosaposin promotes neurite outgrowth in vitro via sequences in saposin C. The regional organization of these neurotrophic and activation properties of saposin C was elucidated using recombinant or chemically synthesized saposin Cs from various regions of the molecule. Unreduced and reduced proteins were analyzed by electrospray-mass spectrometry to establish the complement of disulfide bonds in selected saposin Cs. Using saposin B as a unreactive backbone, chimeric saposins containing various length segments of saposin B and C localized the neurotrophic and acid beta-glucosidase activation properties to the carboxyl- and NH2-terminal 50% of saposin C, respectively. The peptide spanning residues 22-31 had neurotrophic effects. Molecular modeling and site-directed mutagenesis localized the activation properties of saposin C to the region spanning residues 47-62. Secondary structure was needed for retention of this property. Single substitutions of R and S at the conserved cysteines at 47 or 78 diminished but did not obliterate the activation properties. These results indicate the segregation of neurotrophic and activation properties of saposin C to two different faces of the molecule and suggest a topographic sequestration of the activation region of prosaposin for protection of the cell from adverse hydrolytic activity of acid beta-glucosidase.	CHILDRENS HOSP,MED CTR,RES FDN,DIV HUMAN GENET,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; EHIME UNIV,SCH MED,DEPT NEUROPSYCHIAT,MATSUYAMA,EHIME 79001,JAPAN	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Ehime University					NIDDK NIH HHS [DK 36729] Funding Source: Medline; NINDS NIH HHS [NS 34071] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034071] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GARRETT KO, 1985, ARCH BIOCHEM BIOPHYS, V238, P344, DOI 10.1016/0003-9861(85)90173-0; GAVRIELIRORMAN E, 1989, GENOMICS, V5, P486; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; IYER SS, 1983, BIOCHIM BIOPHYS ACTA, V748, P1, DOI 10.1016/0167-4838(83)90020-1; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OSIECKINEWMAN K, 1987, BIOCHIM BIOPHYS ACTA, V915, P87, DOI 10.1016/0167-4838(87)90128-2; PRENCE E, 1985, ARCH BIOCHEM BIOPHYS, V236, P98, DOI 10.1016/0003-9861(85)90609-5; QI XY, 1994, J BIOL CHEM, V269, P16746; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; REINER O, 1989, J MOL NEUROSCI, V1, P225; SANO A, 1988, J BIOL CHEM, V263, P19597; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SUN Y, 1994, AM J PATHOL, V145, P1390; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; UEMURA KL, 1991, J BIOCHEM-TOKYO, V1100, P96; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; WEILER S, 1995, PROTEIN SCI, V4, P756	40	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6874	6880		10.1074/jbc.271.12.6874	http://dx.doi.org/10.1074/jbc.271.12.6874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636113	hybrid			2022-12-27	WOS:A1996UB15700048
J	Wolfe, PC; Chang, EY; Rivera, J; Fewtrell, C				Wolfe, PC; Chang, EY; Rivera, J; Fewtrell, C			Differential effects of the protein kinase C activator phorbol 12-myristate 13-acetate on calcium responses and secretion in adherent and suspended RBL-2H3 mucosal mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; 2H3 CELLS; TYROSINE PHOSPHORYLATION; CROSS-LINKING; RECEPTOR; INFLUX; EXOCYTOSIS; SIGNALS	Adhesion of RBL-2H3 mucosal mast cells to fibronectin-coated surfaces has been linked to changes in secretion and tyrosine kinase activity, me now show that adhesion affects the sensitivity of RBL cells to the protein kinase C activator phorbol 12-myristate 13-acetate (PMA). In suspended cells, PMA inhibited antigen-induced calcium influx (as measured by manganese influx) and changes in intracellular free calcium and had complex effects on antigen-stimulated secretion, However, in adherent cells PMA had little effect on these responses, Suspended cells only secreted in response to thapsigargin if they were co-treated with PMA, while adherent cells secreted in response to thapsigargin alone, The thapsigargin-induced secretion in adherent cells was inhibited by protein kinase C down-regulation and by the protein kinase C inhibitor GF 109203X, but not by calphostin C, We suggest that protein kinase C is constitutively activated in adherent cells, possibly due to modification of the regulatory domain of the enzyme.	NIAMS,NIH,SECT CHEM IMMUNOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Wolfe, PC (corresponding author), CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853, USA.		Wan, Daniel/F-4689-2010		NIAID NIH HHS [AI 19910] Funding Source: Medline; NIGMS NIH HHS [GM 08210] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008210] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; CLEVELAND PL, 1993, CELL CALCIUM, V14, P1, DOI 10.1016/0143-4160(93)90013-V; CREWS FT, 1981, ARCH BIOCHEM BIOPHYS, V212, P561, DOI 10.1016/0003-9861(81)90399-4; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEN HN, 1959, J EXP MED, V110, P187, DOI 10.1084/jem.110.2.187; FALCONE D, 1995, J CELL PHYSIOL, V164, P205, DOI 10.1002/jcp.1041640125; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FEWTRELL C, 1981, BIOCH ACUTE ALLERGIC, P295; GERMANO P, 1994, J BIOL CHEM, V269, P23102; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HOGG N, 1993, CURR OPIN IMMUNOL, V5, P383, DOI 10.1016/0952-7915(93)90057-Y; KANNER BI, 1984, J BIOL CHEM, V259, P188; KILEY SC, 1992, CARCINOGENESIS, V13, P1997, DOI 10.1093/carcin/13.11.1997; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LIU FT, 1980, J IMMUNOL, V124, P2728; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1991, FASEB J, V5, pA1044; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SAGIEISENBERG R, 1984, IMMUNOL LETT, V8, P237, DOI 10.1016/0165-2478(84)90002-6; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TAUROG JD, 1979, J IMMUNOL, V122, P2150; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WHITE KN, 1988, J IMMUNOL, V141, P942; YAMADA K, 1992, J IMMUNOL, V149, P1031	44	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6658	6665		10.1074/jbc.271.12.6658	http://dx.doi.org/10.1074/jbc.271.12.6658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636083	hybrid			2022-12-27	WOS:A1996UB15700018
J	Kiefer, PM; Varughese, KI; Su, Y; Xuong, NH; Chang, CF; Gupta, P; Bray, T; Whiteley, JM				Kiefer, PM; Varughese, KI; Su, Y; Xuong, NH; Chang, CF; Gupta, P; Bray, T; Whiteley, JM			Altered structural and mechanistic properties of mutant dihydropteridine reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURES; SUBSTRATE BINDING; HYDRIDE TRANSFER; RESOLUTION; CATALYSIS; COMPLEX	Nine single genetic mutants of rat dihydropteridine reductase (EC 1.6.99.7), D37I, W86I, Y146F, Y146H, K150Q, K150I, K150M, N186A, and A133S and one double mutant, Y146F/K150Q, have been engineered, overexpressed in Escherichia coli and their proteins purified. Of these, five, W86I, Y146F, Y146H, Y146F/K150Q, and A133S, have been crystallized and structurally characterized. Kinetic constants for each of the mutant enzyme forms, except N186A, which was too unstable to isolate in a homogeneous form, have been derived and in the five instances where structures are available the altered activities have been interpreted by correlation with these structures. It is readily apparent that specific interactions of the apoenzyme with the cofactor, NADH, are vital to the integrity of the total protein tertiary structure and that the generation of the active site requires bound cofactor in addition to a suitably placed W86. Thus when the three major centers for hydrogen bonding to the cofactor are mutated, i.e. 37, 150, and 186, an unstable partially active enzyme is formed. It is also apparent that tyrosine 146 is vital to the activity of the enzyme, as the Y146F mutant is almost inactive having only 1.1% of wild-type activity. However, when an additional mutation, K150Q, is made, the rearrangement of water molecules in the vicinity of Lys(150), accompanied by the recovery of 50% of the wild-type activity. It is suggested that the involvement of a water molecule compensates for the loss of the tyrosyl hydroxyl group. The difference between tyrosine and histidine groups at 146 is seen in the comparably unfavorable geometry of hydrogen bonds exhibited by the latter to the substrate, reducing the activity to 15% of the wild type. The mutant A133S shows little alteration in activity; however, its hydroxyl substituent contributes to the active site by providing a possible additional proton sink. This is of little value to dihydropteridine reductase but may be significant in the sequentially analogous short chain dehydrogenases/reductases, where a serine is the amino acid of choice for this position.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA011778] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052699] Funding Source: NIH RePORTER; NCI NIH HHS [CA11778] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NIGMS NIH HHS [GM52699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMAREGO WLF, 1979, BIOCHEM BIOPH RES CO, V89, P246, DOI 10.1016/0006-291X(79)90970-7; ARMAREGO WLF, 1982, J CHEM SOC P2, V21, P1227; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BENKOVIC SJ, 1985, J AM CHEM SOC, V107, P3706, DOI 10.1021/ja00298a048; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, X PLOR V 3 1 SYSTEM; BURKE JR, 1993, BIOCHEMISTRY-US, V32, P13220, DOI 10.1021/bi00211a034; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; DEPOUPLANA LR, 1994, BIOCHEMISTRY-US, V33, P7047, DOI 10.1021/bi00189a005; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KIM YH, 1992, J AM CHEM SOC, V114, P7116, DOI 10.1021/ja00044a024; KORRI KK, 1977, CAN J BIOCHEM CELL B, V55, P1145, DOI 10.1139/o77-171; KUHN DM, 1985, FOLATES PTERINS, V2, P353; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maniatis T., 1982, MOL CLONING; MATTHEWS DA, 1986, J BIOL CHEM, V261, P3891; MATTHEWS DA, 1991, ARCH BIOCHEM BIOPHYS, V287, P234, DOI 10.1016/0003-9861(91)90412-C; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; SHAHBAZ M, 1987, J BIOL CHEM, V262, P16412; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SU Y, 1993, J BIOL CHEM, V268, P26836; SWANSON BA, 1993, BIOCHEMISTRY-US, V32, P13231, DOI 10.1021/bi00211a035; VARUGHESE KI, 1994, P NATL ACAD SCI USA, V91, P5582, DOI 10.1073/pnas.91.12.5582; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WEBBER S, 1978, ANAL BIOCHEM, V84, P491, DOI 10.1016/0003-2697(78)90068-4; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105; YOU KS, 1985, CRC CR REV BIOCH MOL, V17, P313, DOI 10.3109/10409238509113625	38	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3437	3444						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631945				2022-12-27	WOS:A1996TV72400019
J	Schaefer, A; Magocsi, M; Stocker, U; Fandrich, A; Marquardt, H				Schaefer, A; Magocsi, M; Stocker, U; Fandrich, A; Marquardt, H			Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells - The role of calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYCLOSPORINE-A; PHOSPHATASE-ACTIVITY; PROTEIN PHOSPHATASE; SIGNALING PATHWAYS; GENE-TRANSCRIPTION; DIFFERENTIATION; CALCIUM; EXPRESSION; ACTIVATION	Down-regulation of c-myb mRNA levels by [Ca2+](i)-increasing agents (A23187, thapsigargin, cyclopiazonic acid) and erythropoietin-responsive murine erythroleukemia cell line, ELM-I-1. The Ca2+-induced suppression of c-myb trifluoperazine and calmidazolium, as well as by cyclosporin A, an inhibitor of the Ca2+/calmodulin-dependent protein phosphatase 2B (calcineurin). KN-62, an inhibitor of Ca2+/calmodulin-dependent protein kinases, did not antagonize the Ca2+-mediated decrease in c-myb mRNA. In cyclosporin A-treated ELM-I-1, cells, a close correlation could by demonstrated between the antagonization of the calcineurin phophatase activity. On the other hand, FK506, which did not inhibit calcineurin activity in ELM-I-1 cells, failed to prevent the Ca2+-mediated decrease in c-myb mRNA. The erythropoietin-induced down-regulation of c-myb mRNA levels could be demonstrated also in the presence of EGTA and was resistant to calmodulin antagonists and cyclosporin A. In addition, no increase in [Ca2+](i), was observed in ELM-I-1 cells in response to erythropoietin. Cyclosporin A inhibited the Ca2+-induced hemoglobin production, while the erythropoietin-mediated increase in hemoglobin synthesis was not affected. The results indicate that the Ca2+-induced decrease in c-myb mRNA and increase in hemoglobin synthesis is mediated by calcineurin, while these effects of erythropoietin occur independently of Ca2+ in ELM-I-1 cells. Calcineurin may be involved in the regulation of c-myb expression in erythroid precursor cells and Ca2+ signals via calcineurin may positively modulate the differentiation inducing action of erythropoietin.	FRAUNHOFER DEPT TOXICOL & ENVIRONM MED,D-20146 HAMBURG,GERMANY; NATL INST HEMATOL BLOOD TRANSFUS & IMMUNOL,H-1113 BUDAPEST,HUNGARY		Schaefer, A (corresponding author), UNIV HAMBURG,DEPT TOXICOL,SCH MED,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.							ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BUSFIELD SJ, 1992, BLOOD, V80, P412; CHERN Y, 1990, J BIOL CHEM, V266, P2009; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KUBO M, 1994, SCHWIMMUNOL, V5, P179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MILLER BA, 1989, BLOOD, V73, P1188; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OSTERTAG W, 1972, NATURE-NEW BIOL, V239, P231, DOI 10.1038/newbio239231a0; PATEL HR, 1992, J BIOL CHEM, V267, P21300; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; REN HY, 1994, J BIOL CHEM, V269, P19633; SAWADA T, 1992, EXP HEMATOL, V20, P629; SCHAEFER A, 1993, J BIOL CHEM, V268, P10876; SCHAEFER A, 1994, J BIOL CHEM, V269, P8786; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; SPIVAK JL, 1992, EXP HEMATOL, V20, P283; SYTKOWSKI AJ, 1993, ERYTHROPOIETIN MOL P, P254; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WATSON RJ, 1988, ONCOGENE, V2, P267; ZOBEL A, 1991, ONCOGENE, V6, P1397	52	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13484	13490		10.1074/jbc.271.23.13484	http://dx.doi.org/10.1074/jbc.271.23.13484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662717	hybrid			2022-12-27	WOS:A1996UP38500029
J	Silva, JC; Minto, RE; Barry, CE; Holland, KA; Townsend, CA				Silva, JC; Minto, RE; Barry, CE; Holland, KA; Townsend, CA			Isolation and characterization of the versicolorin B synthase gene from Aspergillus parasiticus - Expansion of the aflatoxin B-1 biosynthetic gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORSOLORINIC ACID; DIHYDROBISFURAN FORMATION; SACCHAROMYCES-CEREVISIAE; VERSICONAL ACETATE; CRYSTAL-STRUCTURE; GLUCOSE-OXIDASE; LIVER-CANCER; CELL-FREE; CONVERSION; STERIGMATOCYSTIN	Versicolorin B synthase catalyzes the side chain cyclizatian of racemic versiconal hemiacetal (7) to the bisfuran ring: system of (-)-versicolorin B (8), an essential transformation in the aflatoxin biosynthetic pathway of Aspergillus parasiticus. The dihydrobisfuran an is key to the mutagenic nature of aflatoxin B-1 (1), The protein, which skews 58% similarity and 38% identity with glucose oxidase from Aspergillus niger, possesses an amino-terminal sequence homologous to the ADP-binding region of other flavoenzymes. However, this enzyme does not require flavin or nicotinamide cofactors for its cyclase activity, The 643-amino acid native enzyme contains three potential sites for W-linked glycosylation, Asn-Xaa-Thr or Asn-Xaa-Ser. The cDNA and genomic clones of versicolorin B synthase were isolated by screening the respective libraries with random-primed DNA probes generated from an exact copy of an internal vbs sequence. This probe was created through polymerase chain reaction by using nondegenerate polymerase chain reaction primers derived from the amino acid sequences of peptide fragments of the enzyme. The 1985-base genomic rbs DNA sequence is interrupted by one intron of 53 nucleotides. Southern blotting, nucleotide sequencing, and detailed restriction mapping of the vbs-containing genomic clones revealed the presence of omtA, a methyltransferase active in the biosynthesis, 3.3 kilobases upstream of vbs and oriented in the opposite direction from vbs. The presence of omtA in close proximity to obs supports the theory that the genes encoding the aflatoxin biosynthetic enzymes in A, parasiticus are clustered.	JOHNS HOPKINS UNIV, DEPT CHEM, BALTIMORE, MD 21218 USA	Johns Hopkins University			Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X; Minto, Robert/0000-0001-7070-6832	NIEHS NIH HHS [ES 01670] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001670] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADYE J, 1964, BIOCHIM BIOPHYS ACTA, V86, P418, DOI 10.1016/0304-4165(64)90077-7; AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON JA, 1990, MYCOPATHOLOGIA, V110, P31, DOI 10.1007/BF00442767; ANDERSON JA, 1994, MYCOPATHOLOGIA, V126, P169, DOI 10.1007/BF01103771; ASPLIN F. D., 1961, Veterinary Record, V73, P1215; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAERTSCHI SW, 1988, J AM CHEM SOC, V110, P7923; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BENNETT JW, 1980, CAN J MICROBIOL, V26, P706, DOI 10.1139/m80-121; BENNETT JW, 1975, AGR FOOD CHEM, V23, P1132; BHATNAGAR D, 1988, BIOCHIMIE, V70, P743, DOI 10.1016/0300-9084(88)90103-4; BOEL E, 1984, EMBO J, V3, P1581, DOI 10.1002/j.1460-2075.1984.tb02014.x; BROLST SW, 1993, CAN J CHEM, V72, P200; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; CHANG PK, 1993, APPL ENVIRON MICROB, V59, P3273, DOI 10.1128/AEM.59.10.3273-3279.1993; CHATTERJEE M, 1994, J ORG CHEM, V59, P4424, DOI 10.1021/jo00095a016; CIHLAR RL, 1980, NUCLEIC ACIDS RES, V8, P793; CLEVELAND TE, 1987, APPL ENVIRON MICROB, V53, P1711, DOI 10.1128/AEM.53.7.1711-1713.1987; CLEVELAND TE, 1967, CAN J MICROBIOL, V33, P1108; Cole R. J., 1981, HDB TOXIC FUNGAL MET, P1; Dickens J, 1977, MYCOTOXINS HUMAN ANI, P99; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1970; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; GELBOIN HV, 1966, SCIENCE, V154, P1205, DOI 10.1126/science.154.3753.1205; GOPALAKRISHNAN S, 1990, BIOCHEMISTRY-US, V29, P10438, DOI 10.1021/bi00498a002; GURR SJ, 1990, GENE STRUCTURE EUKAR, P93; HATSUDA Y, 1971, AGR BIOL CHEM TOKYO, V35, P411; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORNG JS, 1989, APPL ENVIRON MICROB, V55, P2561, DOI 10.1128/AEM.55.10.2561-2568.1989; HSIEH DPH, 1973, BIOCHEM BIOPH RES CO, V52, P992, DOI 10.1016/0006-291X(73)91035-8; HSIEH DPH, 1976, J AGR FOOD CHEM, V24, P1170, DOI 10.1021/jf60208a018; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KELLER NP, 1993, APPL ENVIRON MICROB, V59, P479, DOI 10.1128/AEM.59.2.479-484.1993; KELLER NP, 1995, APPL ENVIRON MICROB, V61, P3628, DOI 10.1128/AEM.61.10.3628-3632.1995; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LEE LS, 1971, J AM OIL CHEM SOC, V48, P93, DOI 10.1007/BF02635696; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; Lillehoj E.B., 1977, MYCOTOXINS HUMAN ANI, P107; LIN BK, 1992, ARCH BIOCHEM BIOPHYS, V293, P67, DOI 10.1016/0003-9861(92)90366-5; LLOYD AT, 1991, MOL GEN GENET, V230, P288, DOI 10.1007/BF00290679; LOECHLER EL, 1988, J BIOMOL STRUCT DYN, V5, P1237, DOI 10.1080/07391102.1988.10506467; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maniatis T., 1982, MOL CLONING; MARTIN CN, 1977, NATURE, V267, P863, DOI 10.1038/267863a0; MCGUIRE SM, 1989, J AM CHEM SOC, V111, P8308, DOI 10.1021/ja00203a058; MCGUIRE SM, 1993, BIOORG MED CHEM LETT, V3, P653, DOI 10.1016/S0960-894X(01)81247-6; NEAL GE, 1973, NATURE, V244, P432, DOI 10.1038/244432a0; NIELSON KB, 1994, STRATEGIES MOL BIOL, V7, P27; PAPA KE, 1982, J GEN MICROBIOL, V128, P1345; PAPA KE, 1978, MYCOLOGIA, V70, P766, DOI 10.2307/3759356; PAPA KE, 1984, CAN J MICROBIOL, V30, P68, DOI 10.1139/m84-012; PEERS FG, 1976, INT J CANCER, V17, P167, DOI 10.1002/ijc.2910170204; RAMBOSEK J, 1987, CRIT REV BIOTECHNOL, V6, P357, DOI 10.3109/07388558709089387; SAUNDERS FC, 1972, CANCER RES, V32, P2487; SKORY CD, 1993, APPL ENVIRON MICROB, V59, P1642, DOI 10.1128/AEM.59.5.1642-1646.1993; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; STEYN PS, 1979, J CHEM SOC P1, V1, P451; TOWNSEND CA, 1988, J AM CHEM SOC, V110, P318, DOI 10.1021/ja00209a066; TOWNSEND CA, 1989, TETRAHEDRON, V45, P2263, DOI 10.1016/S0040-4020(01)83431-1; TOWNSEND CA, 1982, J AM CHEM SOC, V104, P6154, DOI 10.1021/ja00386a070; TOWNSEND CA, 1988, J CHEM SOC CHEM COMM, P726, DOI 10.1039/c39880000726; TOWNSEND CA, 1988, J ORG CHEM, V53, P2472, DOI 10.1021/jo00246a015; TOWNSEND CA, 1992, ENVIR SCI R, V44, P141; TRAIL F, 1994, APPL ENVIRON MICROB, V60, P4078, DOI 10.1128/AEM.60.11.4078-4085.1994; van Rensburg S J, 1990, J Environ Pathol Toxicol Oncol, V10, P11; VIDALCROS A, 1994, EUR J BIOCHEM, V219, P985, DOI 10.1111/j.1432-1033.1994.tb18581.x; Watanabe CMH, 1996, J ORG CHEM, V61, P1990, DOI 10.1021/jo952056v; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; YABE K, 1989, APPL ENVIRON MICROB, V55, P2172, DOI 10.1128/AEM.55.9.2172-2177.1989; YABE K, 1991, APPL ENVIRON MICROB, V57, P1340, DOI 10.1128/AEM.57.5.1340-1345.1991; YABE K, 1993, APPL ENVIRON MICROB, V59, P2486, DOI 10.1128/AEM.59.8.2486-2492.1993; YABE K, 1991, AGR BIOL CHEM TOKYO, V55, P1907, DOI 10.1080/00021369.1991.10870849; YU JJ, 1993, APPL ENVIRON MICROB, V59, P3564, DOI 10.1128/AEM.59.11.3564-3571.1993; YU JJ, 1995, APPL ENVIRON MICROB, V61, P2365, DOI 10.1128/AEM.61.6.2365-2371.1995	83	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13600	13608		10.1074/jbc.271.23.13600	http://dx.doi.org/10.1074/jbc.271.23.13600			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662689	hybrid			2022-12-27	WOS:A1996UP38500046
J	Eytan, GD; Regev, R; Oren, G; Assaraf, YG				Eytan, GD; Regev, R; Oren, G; Assaraf, YG			The role of passive transbilayer drug movement in multidrug resistance and its modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; TRANSMEMBRANE CHANNEL; PLASMA-MEMBRANE; TRANSPORT; CELLS; GRAMICIDIN; VERAPAMIL; PROGESTERONE; LIPOSOMES	The successful lowering of the intracellular concentration of multidrug resistance (MDR)-type drugs by P-glycoprotein (Pgp) relies on its ability to overcome the passive influx rate of each MDR-type drug, Thus, the aim of the present work was to study the effect of passive transbilayer drug movement on the multidrug resistance and its modulation, Fluorescence quenching studies indicated that whereas the Pgp substrate rhodamine 123 traverses an artificial lipid membrane with a lifetime of 3 min, the transbilayer movement rate of the MDR modulators, quinidine and quinine, was too fast to be detected with present methods. Transbilayer movement rates of drugs and modulators were estimated from their equilibration rate throughout artificial multilamellar vesicles, The equilibration rate of five selected modulators was faster than the equilibration rate of five representative MDR-type drugs tested, which was comparable with the rate of rhodamine 123 equilibration, Moreover, the carrier-type peptide ionophore, valinomycin, which is freely mobile in the membrane, inhibited Pgp-mediated efflux of rhodamine 123 from MDR cells, In contrast, the channel-forming ionophore gramicidin D, a Pgp substrate that flip-flops slowly across the membrane, did not modulate cellular Pgp activity, Pgp, with a turnover number of about 900 min(-1) can keep pace with the influx of an MDR-drug like rhodamine 123 exhibiting a transbilayer movement with a lifetime of minutes, On the other hand, Pgp would fail to protect MDR cells against cytotoxic drugs that are freely mobile through biological membranes and that re-enter cells faster than their Pgp-mediated active efflux rate, The relatively fast transbilayer movement exhibited by MDR modulators suggest that in contrast to MDR-type drugs, MDR modulators traverse the plasma membrane faster than the maximal expulsion rate of Pgp.			Eytan, GD (corresponding author), TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL.							BENZ R, 1976, J MEMBRANE BIOL, V27, P171, DOI 10.1007/BF01869135; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; BROXTERMAN HJ, 1989, FEBS LETT, V247, P405, DOI 10.1016/0014-5793(89)81380-8; CABRAL DJ, 1987, BIOCHEMISTRY-US, V26, P1801, DOI 10.1021/bi00381a002; CHABNER BA, 1990, CANC CHEMOTHERAPY PR; COLLANDER RUNAR, 1933, ACTA BOT FENNICA, V11-, P1; DROI S, 1995, EUR J BIOCHEM, V228, P1020; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; EYTAN GD, 1994, J BIOL CHEM, V269, P26058; FREI E, 1985, CANCER RES, V45, P6523; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HORIO M, 1989, J BIOL CHEM, V264, P14880; JAIN MK, 1985, BIOCHIM BIOPHYS ACTA, V818, P356, DOI 10.1016/0005-2736(85)90010-0; NEYFAKH AA, 1988, EXP CELL RES, V178, P513, DOI 10.1016/0014-4827(88)90419-3; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Overton E, 1902, ARCH GESAMTE PHYSIOL, V92, P115, DOI 10.1007/BF01659618; RAMU A, 1983, CANCER RES, V43, P5533; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SCHWARTZ MA, 1978, BIOCHEMISTRY-US, V17, P837, DOI 10.1021/bi00598a014; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SKOVSGAARD T, 1978, CANCER RES, V38, P1783; SPEELMANS G, 1994, BIOCHEMISTRY-US, V33, P13761, DOI 10.1021/bi00250a029; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1992, J BIOL CHEM, V267, P24248; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; URRY DW, 1971, P NATL ACAD SCI USA, V68, P1907, DOI 10.1073/pnas.68.8.1907; WARR JR, 1988, CANCER RES, V48, P4477; YANG CPH, 1989, J BIOL CHEM, V264, P782; YUSA K, 1989, CANCER RES, V49, P5002	36	158	164	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12897	12902		10.1074/jbc.271.22.12897	http://dx.doi.org/10.1074/jbc.271.22.12897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662680	hybrid			2022-12-27	WOS:A1996UN47400034
J	Fujiwara, K; OkamuraIkeda, K; Motokawa, Y				Fujiwara, K; OkamuraIkeda, K; Motokawa, Y			Lipoylation of acyltransferase components of alpha-ketoacid dehydrogenase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; ESCHERICHIA-COLI; H-PROTEIN; DIHYDROLIPOAMIDE ACYLTRANSFERASES; MOLECULAR-CLONING; ACID; SEQUENCE; EXPRESSION; SITE; PURIFICATION	Lipoic acid is a prosthetic group of the acyltransferase components of the pyruvate, alpha-ketoglutarate, and branched chain alpha-ketoacid dehydrogenase complexes, protein X of the eukaryotic pyruvate dehydrogenase complex, and H-protein of the glycine cleavage system, We have purified lipoyl-AMP:N-epsilon-lysine lipoyltransferase I and II from bovine liver mitochondria employing apoH-protein as an acceptor of lipoic acid (Fyjiwara, K., Okamura-Ikeda, K,, and Motokawa, Y, (1994) J. Biol, Chem. 269, 16605-16609). In this study, we demonstrated the lipoylation of the lipoyl domains of the mammalian pyruvate (LE2p), alpha-ketoglutarate (LE2k), and branched chain alpha-keto acid (LE2b) dehydrogenase complexes using the purified lipoyltransferase I and II, Lipoyltransferase I and II lipoylated LE2p and LE2k as efficiently as H-protein, but the lipoylation rate of LE2b was extremely low, Comparison of amino acid sequences surrounding the lipoylation site of these proteins shows that the conserved glutamic acid residue situated 3 residues to the N-terminal side of the Lipoylation site is replaced by glutamine (Gln-41) in LE2b. When Gln-41 of LE2b was changed to Glu, the rate of lipoylation increased about 100-fold and became comparable to that of LE2p and LE2k The replacement of the glutamic acid residue of LE2p (Glu-169) and LE2k (Glu-40) by glutamine resulted in decrease in the lipoylation rate more than 100-fold, These results suggest that the glutamic acid residue plays an important role in the lipoylation reaction possibly functioning as a recognition signal, Gly-27 and Gly-54 of LE2k are also well conserved among the lipoyl domains of the alpha-ketoacid dehydrogenase complexes and H-protein, The mutagenesis experiments of these residues indicated that the glycine residue situated 11 residues to the C-terminal side of the Lipoylation site (Gly-54 of LE2k) is important for the folding of lipoyl domain, and that existence of a small residue such as Gly or Cys at the position is essential for the lipoylation of these proteins.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Tokushima University								BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; FUJIWARA K, 1995, METHOD ENZYMOL, V251, P340, DOI 10.1016/0076-6879(95)51137-7; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P856; MATUDA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P114, DOI 10.1016/0167-4781(92)90109-D; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; NAKANO K, 1991, J BIOL CHEM, V266, P19013; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; Sambrook J., 2002, MOL CLONING LAB MANU; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130	24	43	45	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12932	12936		10.1074/jbc.271.22.12932	http://dx.doi.org/10.1074/jbc.271.22.12932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662700	hybrid			2022-12-27	WOS:A1996UN47400040
J	Solis, D; Romero, A; Kaltner, H; Gabius, HJ; DiazMaurino, T				Solis, D; Romero, A; Kaltner, H; Gabius, HJ; DiazMaurino, T			Different architecture of the combining site of the two chicken galectins revealed by chemical mapping studies with synthetic ligand derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; AMINO-ACID-SEQUENCE; LACTOSE; SPECIFICITY; INTESTINE; TISSUES; CLONING; COMPLEX; PROTEIN; CDNA	The detailed comparison of the carbohydrate-binding properties of related galectins from one organism can be facilitated by the application of an array of deliberately tailored methyl beta-lactoside derivatives. Focusing on chicken due to its expression of two galectins as a model for this approach, the combining-site architecture of the lectin from adult liver (CL-16) is apparently homologous to that previously observed for bovine galectin-1 (Solis, D., Jimenez-Barbero, J., Martin-Lomas, M., and Diaz-Maurino, T. (1998) Eur. J. Biochem. 223, 107-114). Besides preservation of the key interactions and minor differences, the lectin from adult intestine (CL-14) is able to accommodate an axial HO-3 at the glucose moiety. Homology-based modeling enabled us to tentatively attribute the observed differences to a slightly different orientation of pivotal side chains in the binding pocket due to distinct substitutions of amino acid residues in the variable region within the carbohydrate-recognition domain. Thus, the results suggest-overlapping but distinct ranges of potential ligands for the two chicken lectins and provide new information on their relationship to mammalian galectins. The described approach is suggested to be of relevance to design pharmaceuticals with enhanced selectivity to a certain member within a family of related lectins.	UNIV MUNICH,TIERARZTL FAK,INST PHYSIOL CHEM,D-80539 MUNICH,GERMANY	University of Munich	Solis, D (corresponding author), CSIC,INST QUIM FIS ROCASOLANO,SERRANO 119,E-28006 MADRID,SPAIN.		Solís, Dolores/E-5992-2015; Romero, Antonio/K-5754-2014	Solís, Dolores/0000-0002-8148-1875; Romero, Antonio/0000-0002-6990-6973; Gabius, Hans-Joachim/0000-0003-3467-3900; Kaltner, Herbert/0000-0003-4680-8411				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; AHMED H, 1994, GLYCOBIOLOGY, V4, P545, DOI 10.1093/glycob/4.5.545; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEYER EC, 1982, J CELL BIOL, V92, P23, DOI 10.1083/jcb.92.1.23; BEYER EC, 1980, J BIOL CHEM, V255, P4236; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CASTAGNA LF, 1994, J NEUROSCI RES, V37, P750, DOI 10.1002/jnr.490370609; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; KAYSER K, 1995, ROUX ARCH DEV BIOL, V204, P344, DOI 10.1007/BF02179503; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; ODA Y, 1993, J BIOL CHEM, V268, P5929; OGUCHI H, 1990, CANCER COMMUN, V2, P311; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; RIVERASAGREDO A, 1991, EUR J BIOCHEM, V197, P217, DOI 10.1111/j.1432-1033.1991.tb15902.x; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SCHNELLER M, 1995, CELL IMMUNOL, V166, P35, DOI 10.1006/cimm.1995.0005; SOLIS D, 1993, EUR J BIOCHEM, V214, P677, DOI 10.1111/j.1432-1033.1993.tb17968.x; SOLIS D, 1994, EUR J BIOCHEM, V223, P107, DOI 10.1111/j.1432-1033.1994.tb18971.x; SOLIS D, 1996, IN PRESS GLYCOSCIENC; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; WOYNAROWSKA B, 1994, J BIOL CHEM, V269, P22797	27	79	81	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12744	12748		10.1074/jbc.271.22.12744	http://dx.doi.org/10.1074/jbc.271.22.12744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662681	hybrid			2022-12-27	WOS:A1996UN47400010
J	Wu, YY; Bradshaw, RA				Wu, YY; Bradshaw, RA			Induction of neurite outgrowth by interleukin-6 is accompanied by activation of Stat3 signaling pathway in a variant PC12 cell (E2) line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACUTE-PHASE RESPONSE; NEURONAL DIFFERENTIATION; INTERFERON-ALPHA; TYROSINE KINASE; PROTEIN; BINDING; GENE; COMPLEXES; ISGF-3	PC12-E2 cells, a stable variant subcloned from native cell populations, produce neurites in a rapid, transcription-independent manner upon exposure to nerve growth factor (NGF) or basic fibroblast growth factor (bFGF). They also give a similar morphological response to interleukin-6 (IL-6), which is, however, transcription-dependent and with a slower onset, a phenomenon basically not observed in native PC12 cells, The response profile of PC12-E2 cells to NGF and bFGF is similar to that observed for native PC12 cells pre-exposed (primed) to NGF, and such cells also respond to IL-6 in a fashion indistinguishable from PC12-E2 cells, Mechanistically, NGF and bFGF induce a sustained phosphorylation and activation of ERK1 and ERK2 in both cells, while IL-6 produces only a transient and weak tyrosine phosphorylation, However, it does stimulate a prolonged and biphasic tyrosine phosphorylation and nuclear translocation of Stat3 (signal transducers and activators of transcription 3; at least 24 h) and, to a lesser extent, Stat1. Gel shift and supershift analyses confirm that IL-6 predominantly activates Stat3 (and some Stat1) and stimulates sis-inducilble element binding activity, Other members of the same cytokine subfamily, including ciliary neurotrophic factor and leukemia inhibitory factor, also cause a transient initial phase of tyrosine phosphorylation and activation of Stat1 and Stat3 (up to 1 h) but fail to stimulate a second phase of response and do not produce significant neurites. These results suggest that sustained signaling of either STAT or ERK pathways in PC12-E2 cells leads to induction of neuronal differentiation. However, only the latter is effective in native PC12 cells as the activation of Stat3 and Stat1 in native PC12 cells by IL-6 fails to induce neuronal differentiation. Thus, the response of PC12-E2 cells to IL-6 suggests the constitutive expression of a required factor(s) for differentiation, that is induced in native PC12 cells by NGF or bFGF (possibly by ERK activation), but not by IL-6 via Janus kinase/STAT activation. This factor(s), which has a sufficient half-life to allow primed cells to remain responsive to IL-6 for several days, is necessary but not sufficient for differentiation (as measured by neurite proliferation) to occur.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG 09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURPHY PG, 1995, J NEUROSCI, V15, P5130; NAKAJIMA K, 1991, MOL CELL BIOL, V9, P4605; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1995, J BIOL CHEM, V270, P7568, DOI 10.1074/jbc.270.13.7568; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN A, 1995, CELL, V82, P241; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; WU YY, 1995, J CELL PHYSIOL, V164, P522, DOI 10.1002/jcp.1041640310; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13023	13032		10.1074/jbc.271.22.13023	http://dx.doi.org/10.1074/jbc.271.22.13023			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662645				2022-12-27	WOS:A1996UN47400054
J	Perelroizen, I; Didry, D; Christensen, H; Chua, NH; Carlier, MF				Perelroizen, I; Didry, D; Christensen, H; Chua, NH; Carlier, MF			Role of nucleotide exchange and hydrolysis in the function of profilin in actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; LOW-AFFINITY SITES; ATP HYDROLYSIS; F-ACTIN; ACANTHAMOEBA PROFILIN; ADP-ACTIN; POLYMERIZATION; FILAMENTS; BINDING; MECHANISM	Profilin, an essential G-actin-binding protein, has two opposite regulatory functions in actin filament assembly. It facilitates assembly at the barbed ends by lowering the critical concentration (Pantaloni, D., and Carlier, M.-F. (1993) Cell 75, 1007-1014); in contrast it contributes to the pool of unassembled actin when barbed ends are capped. We proposed that the first of these functions required an input of energy. How profilin uses the ATP hydrolysis that accompanies actin polymerization and whether the acceleration of nucleotide exchange on G-actin by profilin participates in its function in filament assembly are the issues addressed here. We show that 1) profilin increases the treadmilling rate of actin filaments in the presence of Mg2+ ions; 2) when filaments are assembled from CaATP-actin, which polymerizes in a quasireversible fashion, profilin does not promote assembly at the barbed ends and has only a G-actin-sequestering function; 3) plant profilins do not accelerate nucleotide exchange on G-actin, yet they promote assembly at the barbed end. The enhancement of nucleotide exchange by profilin is therefore not involved in its promotion of actin assembly, and the productive growth of filaments from profilin-actin complex requires the coupling of ATP hydrolysis to profilin-actin assembly, a condition fulfilled by Mg-actin, and not by Ca-actin.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021; INST MOL AGROBIOL,SINGAPORE,SINGAPORE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Rockefeller University; National University of Singapore			Christensen, Helen/F-5053-2012	Christensen, Helen/0000-0003-0435-2065; Christensen, Hans Erik Molager/0000-0002-9540-8679				BRENNER SL, 1988, J BIOL CHEM, V258, P5013; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1986, J BIOL CHEM, V261, P785; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1986, J BIOL CHEM, V261, P778; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, J BIOL CHEM, V261, P2041; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; GERSHMAN LC, 1984, BIOCHEMISTRY-US, V23, P2199, DOI 10.1021/bi00305a015; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; KARAKESISOGLOU I, 1996, IN PRESS CELL MOTIL; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAL AA, 1984, J BIOL CHEM, V259, P3061; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; MITCHISON TJ, 1992, MOL BIOL CELL, V3, P1309, DOI 10.1091/mbc.3.12.1309; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; WEGNER A, 1981, J MOL BIOL, V153, P681, DOI 10.1016/0022-2836(81)90413-7; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WRIGGERS W, 1995, BIOPHYS J, V68, P284	39	127	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12302	12309		10.1074/jbc.271.21.12302	http://dx.doi.org/10.1074/jbc.271.21.12302			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647830	hybrid			2022-12-27	WOS:A1996UL66000032
J	Vallone, B; Bellelli, A; Miele, AE; Brunori, M; Fermi, G				Vallone, B; Bellelli, A; Miele, AE; Brunori, M; Fermi, G			Probing the alpha(1)beta(2) interface of human hemoglobin by mutagenesis - Role of the FG-C contact regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SINGULAR VALUE DECOMPOSITION; RESOLUTION X-RAY; HUMAN DEOXYHEMOGLOBIN; ALLOSTERIC MECHANISM; SUBUNIT DISSOCIATION; ESCHERICHIA-COLI; LIGAND-BINDING; OXYGEN BINDING; INTERSUBUNIT	The allosteric transition of hemoglobin involves an extensive reorganization of the alpha(1) beta(2) interface, in which two contact regions have been identified. This paper concerns the effect of two mutations located in the ''switch'' (alpha C3 Thr --> Trp) and the ''flexible joint'' (beta C3 Trp --> Thr). We have expressed and characterized one double and two single mutants: Hb alpha T38W/beta W37T, Hb beta W37T, and Hb alpha T38W, whose structure has been determined by crystallography. We present data on: (i) the interface structure in the two contact regions, (ii) oxygen and CO binding kinetics and cooperativity, (iii) dissociation rates of deoxy tetramers and association rates of deoxy dimers, and (iv) the effect of NaI on deoxy tetramer dissociation rate constant. All the mutants are tetrameric and T-state in the deoxygenated derivative. Reassociation of deoxygenated dimers is not modified by interface mutations. DeoxyHb alpha T38W dimerizes 30% slower than HbA; Hb beta W37T and Hb alpha T38W/beta W37T dissociate much faster. We propose a binding site for I- at the switch region. The single mutants bind O-2 cooperatively; the double one is almost non-cooperative, a feature confirmed by CO binding. The functional data, analyzed with the two-state model, indicate that these mutations reduce the value of the allosteric constant L(0).	UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; MRC Laboratory Molecular Biology			Miele, Adriana E./F-4083-2011; Vallone, Beatrice/F-4174-2012; Bellelli, Andrea/D-2785-2009	Miele, Adriana E./0000-0002-4637-2606; VALLONE, Beatrice/0000-0003-0058-9049; Brunori, Maurizio/0000-0002-7795-1635				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AMICONI G, 1989, J BIOL CHEM, V264, P17745; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; ANTONINI E, 1968, J BIOL CHEM, V243, P1816; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BELLELLI A, 1994, METHOD ENZYMOL, V232, P56; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BRIEHL RW, 1970, J BIOL CHEM, V245, P544; Brunori M, 1981, Methods Enzymol, V76, P582; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; EDELSTEI.SJ, 1970, J BIOL CHEM, V245, P4372; FANELLI AR, 1958, ARCH BIOCHEM BIOPHYS, V77, P478; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FERMI G, 1981, ATLAS PROTEIN SEQUEN, V2; GACON G, 1977, FEBS LETT, V82, P243, DOI 10.1016/0014-5793(77)80593-0; GIBSON QH, 1967, J BIOL CHEM, V242, P4678; GIBSON QH, 1987, J BIOL CHEM, V262, P516; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GRAY R, 1975, J BIOL CHEM, V249, P2879; HASHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P13688, DOI 10.1021/bi00212a038; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HOPFIELD JJ, 1971, J MOL BIOL, V61, P424; HUISMAN THJ, 1992, INT INFORMATION CTR, V16, P127; IP SHC, 1976, BIOCHEMISTRY-US, V15, P654, DOI 10.1021/bi00648a032; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; JONES CM, 1992, BIOCHEMISTRY-US, V31, P6692, DOI 10.1021/bi00144a008; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P8640, DOI 10.1021/bi00151a034; KELLETT GL, 1970, NATURE, V227, P921, DOI 10.1038/227921a0; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGEL RL, 1972, BIOCHEM BIOPH RES CO, V48, P959, DOI 10.1016/0006-291X(72)90702-4; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2163, DOI 10.1021/bi00707a026; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; SASAKI J, 1978, J BIOL CHEM, V253, P87; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHAAD O, 1993, CR ACAD SCI III-VIE, V316, P564; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SZABO A, 1978, P NATL ACAD SCI USA, V75, P2108, DOI 10.1073/pnas.75.5.2108; SZABO A, 1972, J MOL BIOL, V251, P1533; VALLONE B, 1993, FEBS LETT, V324, P117, DOI 10.1016/0014-5793(93)81375-A; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P17049; WEBER RE, 1993, J APPL PHYSIOL, V75, P2646, DOI 10.1152/jappl.1993.75.6.2646; WIEDERMANN BL, 1975, J BIOL CHEM, V250, P5273; YAMAOKA K, 1971, BLOOD, V30, P730; ZHANG J, 1996, IN PRESS J MOL BIOL	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12472	12480		10.1074/jbc.271.21.12472	http://dx.doi.org/10.1074/jbc.271.21.12472			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647854	hybrid			2022-12-27	WOS:A1996UL66000056
J	Hudson, KR; Vernallis, AB; Heath, JK				Hudson, KR; Vernallis, AB; Heath, JK			Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; GROWTH-HORMONE RECEPTOR; ONCOSTATIN-M; HUMAN INTERLEUKIN-6; MOLECULAR-CLONING; COMPONENT GP130; LIF RECEPTOR; CELLS	Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity. The region of hLIF most important for binding to the hLIF-R is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop. This site forms a distinct surface at the end of the four-helix bundle in the tertiary structure of the closely related murine LIF. The two residues of hLIF that contribute the majority of free energy for hLIF-R binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact. This arrangement of a few key residues surrounded by less important ones is analogous to the functional binding epitope of human growth hormone for its receptor. A second region of hLIF that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on hLIF-R binding. Residues in hLIF from both the A- and C-helices are involved in binding the gp130 co-receptor. Abolition of the gp130 binding site in hLIF created antagonists of LIF action.	UNIV OXFORD,DEPT BIOCHEM,CRC GROWTH FACTOR GRP,OXFORD OX1 3QU,ENGLAND; UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Oxford; University of Birmingham								ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DU XX, 1994, BLOOD, V83, P2023; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1992, CIBA F SYMP, V167, P245; Harlow E., 1988, ANTIBODIES LAB MANUA; HEATH JK, 1992, NATURE, V359, P17, DOI 10.1038/359017a0; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; Metcalf D, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046921; MIYAJIMA A, 1993, BLOOD, V82, P1960; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MOTT HR, 1995, CURR OPIN STRUC BIOL, V5, P114, DOI 10.1016/0959-440X(95)80016-T; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PIQUETPELLORCE C, 1994, EXP CELL RES, V213, P340, DOI 10.1006/excr.1994.1208; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SIMMONS DL, 1993, CELLULAR INTERACTION; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH DB, 1989, GENE ASMT, V77, P5189; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; THOMA B, 1994, J BIOL CHEM, V269, P6215; WARD LD, 1994, J BIOL CHEM, V269, P23286; WARE CB, 1995, DEVELOPMENT, V121, P1283; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YIN TG, 1993, J IMMUNOL, V151, P2555	77	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11971	11978		10.1074/jbc.271.20.11971	http://dx.doi.org/10.1074/jbc.271.20.11971			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662595	Green Accepted, hybrid			2022-12-27	WOS:A1996UL25000060
J	Lee, MO; Dawson, MI; Picard, N; Hobbs, PD; Pfahl, M				Lee, MO; Dawson, MI; Picard, N; Hobbs, PD; Pfahl, M			A novel class of retinoid antagonists and their mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR-ALPHA; THYROID-HORMONE; X-RECEPTOR; RESPONSE PATHWAYS; CONFORMATIONAL-CHANGES; DNA-BINDING; CELLS; EXPRESSION; PROMOTER; ELEMENT	Retinoids regulate a broad range of biological processes through two subfamilies of nuclear retinoid receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Recently, we reported a novel type of retinoic acid antagonist (SR11335) and showed that this compound can inhibit retinoic acid (RA) induced activation of a human immunodeficiency virus type 1 (HIV-l) promoter construct that contains a special RA response element (RARE). We have now further characterized the antagonism mediated by SR11335 and of newly synthesized structurally related compounds, Two compounds, SR11330 and SR11334, which are poor transactivators, also showed antagonist activities, inhibiting all-trans RA (tRA) and g-cis-RA. The retinoids inhibited transcriptional activation of RAR/RXR heterodimers effectively, while inhibition of RXR homodimers was less efficient. Inhibition was observed on several RAREs, including the TREpal, beta RARE, apoAI-RARE, and CRBPI-RARE, In addition, the antag.nists inhibited tRA-induced differentiation of HL-60 cells, The antagonist did not interfere with DNA binding of the receptors. In limited proteolytic digestion assays, SR11335 induced resistance of the receptors to proteolysis, but the pattern of the degradation was not altered from that induced by tRA, suggesting that these antagonists induce their biological effects by competing with agonists for binding to RARs, thereby preventing the induction of conformational changes of the receptors necessary for transcriptional activation.	SIDNEY KIMMEL CANC CTR,LA JOLLA,CA 92037; SRI INT,DIV LIFE SCI,MENLO PK,CA 94025	SRI International								ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1226; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; DAWSON MI, 1993, RETINOIDS PROGR RES, P205; DAWSON MI, 1993, RETINOIDS BIOL CHEM; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HASHIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1046, DOI 10.1210/mend-3-7-1046; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KANEKO S, 1991, MED CHEM RES, V1, P220; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LARGMAN C, 1989, BLOOD, V74, P99; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAIO JJ, 1988, J VIROL, V62, P1398, DOI 10.1128/JVI.62.4.1398-1407.1988; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ORCHARD K, 1993, J ACQ IMMUN DEF SYND, V6, P440; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1990, METHOD ENZYMOL, V153, P256; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAKASHITA A, 1993, BLOOD, V81, P1009; SPORN MB, 1994, RETINOIDS, V2; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TURPIN JA, 1992, J IMMUNOL, V148, P2539; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZEICHNER SL, 1992, J VIROL, V66, P2268, DOI 10.1128/JVI.66.4.2268-2273.1992; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11897	11903		10.1074/jbc.271.20.11897	http://dx.doi.org/10.1074/jbc.271.20.11897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662628	hybrid			2022-12-27	WOS:A1996UL25000051
J	Leedman, PJ; Stein, AR; Chin, WW; Rogers, JT				Leedman, PJ; Stein, AR; Chin, WW; Rogers, JT			Thyroid hormone modulates the interaction between iron regulatory proteins and the ferritin mRNA iron-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA LEVELS; TRANSLATIONAL CONTROL; BINDING-PROTEIN; SERUM FERRITIN; RECEPTOR; CELLS; HYPERTHYROIDISM; DETERMINANT; DEGRADATION	The cytoplasmic iron regulatory protein (IRP) modulates iron homeostasis by binding to iron-responsive elements (IREs) in the transferrin receptor and ferritin mRNAs to coordinately regulate transferrin receptor mRNA stability and ferritin mRNA translational efficiency, respectively. These studies demonstrate that thyroid hormone (T-3) can modulate the binding activity of the IRP to an IRE in vitro and in vivo. T-3 augmented an iron-induced reduction in IRP binding activity to a ferritin IRE in RNA electrophoretic mobility shift assays using cytoplasmic extracts from human liver hepatoma (HepG2) cells. Hepatic IRP binding to the ferritin IRE also diminished after in vivo administration of T-3 with iron to rats. In transient transfection studies using HepG2 cells and a human ferritin IRE-chloramphenicol acetyltransferase (H-IRE-CAT) construct, T-3 augmented an iron-induced increase in CAT activity by similar to 45%. RNase protection analysis showed that this increase in CAT activity was not due to a change in the steady state level of CAT mRNA. Nuclear T-3-receptors may be necessary for this T-3-induced response, because the effect could not be reproduced by the addition of T-3 directly to cytoplasmic extracts and was absent in CV-1 cells which lack T-3-receptors. We conclude that T-3 can functionally regulate the IRE binding activity of the IRP. These observations provide evidence of a novel mechanism for T-3 to up-regulate hepatic ferritin expression, which may in part contribute to the elevated serum ferritin levels seen in hyperthyroidism.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Leedman, PJ (corresponding author), UNIV WESTERN AUSTRALIA,ROYAL PERTH HOSP,DEPT MED,BOX X2213 GPO,PERTH,WA 6001,AUSTRALIA.		Leedman, Peter J/O-4044-2014	Rogers, Jack/0000-0003-1262-8578				CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Constanzo F, 1986, NUCLEIC ACIDS RES, V14, P721; Deshpande U R, 1992, Thyroidology, V4, P93; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1994, J BIOL CHEM, V269, P24252; HASHIMOTO T, 1989, ENDOCRINOL JAPON, V36, P873; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; IWASA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1279, DOI 10.1016/0006-291X(90)90662-7; JUMP DB, 1982, BIOCHEM BIOPH RES CO, V104, P701, DOI 10.1016/0006-291X(82)90693-3; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRANE IM, 1991, MOL ENDOCRINOL, V5, P469, DOI 10.1210/mend-5-4-469; KUBOTA K, 1993, CLIN INVESTIGATOR, V72, P26; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LIEBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171; MACARON CI, 1982, ANN INTERN MED, V96, P617, DOI 10.7326/0003-4819-96-5-617; Maniatis T, 1989, DECONTAMINATION DILU; MANO H, 1994, J BIOL CHEM, V269, P1591; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAKAMATSU J, 1985, J CLIN ENDOCR METAB, V61, P672, DOI 10.1210/jcem-61-4-672; TANG CK, 1992, J BIOL CHEM, V267, P24466; VANDEVYVER FL, 1982, ANN INTERN MED, V97, P930, DOI 10.7326/0003-4819-97-6-930_3; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WINKELMANN JC, 1981, SCIENCE, V213, P569, DOI 10.1126/science.6166047; WOLFF EC, 1964, THYROID GLAND, V1, P237; YEN PM, 1993, ENDOCR J, V1, P461	44	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12017	12023		10.1074/jbc.271.20.12017	http://dx.doi.org/10.1074/jbc.271.20.12017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662626	hybrid			2022-12-27	WOS:A1996UL25000066
J	Kitagawa, H; Ujikawa, M; Sugahara, K				Kitagawa, H; Ujikawa, M; Sugahara, K			Developmental changes in serum UDP-GlcA:chondroitin glucuronyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; HEPARAN-SULFATE; PROTEOGLYCANS; BIOSYNTHESIS; CARTILAGE	Bovine, rat, and chicken UDP-GlcA:chondroitin glucuronyltransferase activities in sera during prenatal and postnatal development were systematically measured with polymeric chondroitin as an exogenous acceptor and with UDP-[C-14]GlcA as a donor. The results indicated that the activity changed markedly with develop ment in all species examined. Specifically, the activity was the highest at the middle prenatal stage in the bovine and chicken sera and at the late prenatal stage in the rat serum, and it decreased sharply thereafter in all three species. Although the origin of the serum enzyme has not yet been determined, these changes may reflect developmentally regulated biosynthesis of chondroitin sulfate and also suggest that the glucuronyltransferase could be a regulatory enzyme controlling the expression of chondroitin sulfate.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN	Kobe Pharmaceutical University			Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INEROT S, 1983, COLLAGEN REL RES, V3, P245; JOHNSTONE A, 1982, IMMUNOCHEMISTRY PRAC, P31; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; LIND T, 1993, J BIOL CHEM, V268, P20705; POOLE AR, 1986, BIOCHEM J, V236, P1; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RODEN L, 1980, BIOCH GLYCOPROTEINS, P491; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1987, ANAL BIOCHEM, V166, P404, DOI 10.1016/0003-2697(87)90591-4; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SWEET MBE, 1979, ARCH BIOCHEM BIOPHYS, V198, P439, DOI 10.1016/0003-9861(79)90518-6; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	18	19	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6583	6585		10.1074/jbc.271.12.6583	http://dx.doi.org/10.1074/jbc.271.12.6583			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636071	hybrid			2022-12-27	WOS:A1996UB15700006
J	Nakatani, Y; Bagby, S; Ikura, M				Nakatani, Y; Bagby, S; Ikura, M			The histone folds in transcription factor TFIID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA BOX-BINDING; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; INITIATION; PURIFICATION; DOWNSTREAM; PROTEIN; DNA	The transcription factor TFIID is a multimeric protein complex containing the TATA box-binding polypeptide (TBP) and TBP-associated factors. We have previously reported that the N-terminal regions of dTAF(II)62 and dTAF(II)42 have sequence similarities with histones H4 and H3. Here, we demonstrate that the histone-homologous regions of dTAF(II)62 and dTAF(II)42 form a heteromeric complex both in vitro and in a yeast two-hybrid system. Neither dTAF(II)62 nor dTAF(II)42 forms a homomeric complex, in agreement with a nucleosomal histone character. Moreover, circular dichroism measurements show that the heteromeric complex is dominated by cy-helical secondary structure. These results strongly suggest the existence of a histone-like surface on TFIID.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba	Nakatani, Y (corresponding author), NICHHD,NIH,LAB MOLEC GROWTH REGULAT,BLDG 6,RM 416,6 CTR DR,MSC 2753,BETHESDA,MD 20892, USA.			Ikura, Mitsuhiko/0000-0002-9524-1303; Bagby, Stefan/0000-0003-2302-9511				ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURLEY SK, 1996, IN PRESS ANN REV BIO; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; RAMAKRISHNAN V, 1994, CURR OPIN STRUC BIOL, V4, P44, DOI 10.1016/S0959-440X(94)90058-2; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; TJIAN R, 1995, SCI AM, V272, P54, DOI 10.1038/scientificamerican0295-54; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839	27	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6575	6578		10.1074/jbc.271.12.6575	http://dx.doi.org/10.1074/jbc.271.12.6575			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636069	hybrid			2022-12-27	WOS:A1996UB15700004
J	Shire, D; Calandra, B; Delpech, M; Dumont, X; Kaghad, M; LeFur, G; Caput, D; Ferrara, P				Shire, D; Calandra, B; Delpech, M; Dumont, X; Kaghad, M; LeFur, G; Caput, D; Ferrara, P			Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; CELLS; INHIBITION; RHODOPSIN	The antagonist SR 141716A has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships. From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A, Receptors were transiently expressed in COS-3 cells, and their binding characteristics were studied with SR 141716A and with CP 55,940, an agonist recognized equally well by the two receptors. The region delineated by the fourth and fifth transmembrane helices of CB1 proved to be crucial for high affinity binding of SR 141716A. The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants, The replacement of the conserved cysteine residues in e2 of CB2 by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm, The e2 domain thus plays some role in CP 55,940 binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.			Shire, D (corresponding author), SANOFI RECH,LABEGE INNOPOLE BP 137,F-31676 LABEGE,FRANCE.							BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBLETT RD, 1995, LIFE SCI, V56, P1971, DOI 10.1016/0024-3205(95)00178-9; BRAMBLETT RD, 1995, 1995 ICRS S CANN CAN; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FELDER CC, 1995, MOL PHARMACOL, V48, P443; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FONG TM, 1994, J BIOL CHEM, V269, P2728; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HILLARD CJ, 1995, J NEUROCHEM, V64, P677; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; LU RS, 1993, MOL CELL BIOCHEM, V121, P119, DOI 10.1007/BF00925970; LUPKER JH, 1983, GENE, V24, P281, DOI 10.1016/0378-1119(83)90088-4; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OLAH ME, 1994, J BIOL CHEM, V269, P24692; PAN Y, 1994, J BIOL CHEM, V269, P31933; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RINALDICARMONA M, 1995, 1995 ICRS S CANN CAN; SACHAIS BS, 1994, MOL PHARMACOL, V46, P122; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; XUE JC, 1994, J BIOL CHEM, V269, P30195; ZHOU W, 1994, MOL PHARMACOL, V45, P165	45	92	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6941	6946		10.1074/jbc.271.12.6941	http://dx.doi.org/10.1074/jbc.271.12.6941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636122	hybrid			2022-12-27	WOS:A1996UB15700057
J	Therien, AG; Nestor, NB; Ball, WJ; Blostein, R				Therien, AG; Nestor, NB; Ball, WJ; Blostein, R			Tissue-specific versus isoform-specific differences in cation activation kinetics of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; SODIUM-PUMP; ENZYMATIC-PROPERTIES; MOLECULAR-CLONING; NA+/K+-ATPASE; CROSS-LINKING; ALPHA-SUBUNIT; ION-TRANSPORT; BETA-SUBUNIT; POTASSIUM	The experiments described in this report reconcile some of the apparent differences in isoform-specific kinetics of the Na,K-ATPase reported in earlier studies. Thus, tissue-specific differences in Na+ and K+ activation kinetics of Na,K-ATPase activity of the same species (rat) were observed when the same isoform was assayed in different tissues or cells. In the case of alpha 1, alpha 1-transfected HeLa cell, rat kidney, and axolemma membranes were compared. For alpha 3, the ouabain-insensitive alpha 3*-transfected HeLa cell (cf.Jewell, E. A., and Lingrel, J.B. (1991) J. Biol. Chem. 266, 16925-16930), pineal gland, and axolemma (mainly alpha 3) membranes were compared. The order of apparent affinities for Na+ of alpha 1 pumps was axolemma approximate to rat alpha 1-transfected HeLa > kidney, and for K+, kidney approximate to HeLa > axolemma. For alpha 3, the order of apparent affinities for Na+ was pineal gland approximate to axolemma > alpha 3*-transfected HeLa, and for K+, alpha 3*-transfected HeLa > axolemma approximate to pineal gland. In addition, the differences in apparent affinities for Na+ of either kidney alpha 1 or HeLa alpha 3* as compared to the same isoform in other tissues were even greater when the K+ concentration was increased. A kinetic analysis of the apparent affinities for Na+ as a function of K+ concentration indicates that isoform-specific as well as tissue-specific differences are related to the apparent affinities for both Na+ and K+, the latter acting as a competitive inhibitor at cytoplasmic Na+ activation sites. Although the nature of the tissue-specific modulation of K+/Na+ antagonism remains unknown, an analysis of the nature of the beta isoform associated with alpha 1 or alpha 3 using isoform-specific immunoprecipitation indicates that the presence of distinct beta subunits does not account for differences of alpha 1 of kidney, axolemma, and HeLa, and of alpha 3 of axolemma and HeLa; in both instances beta 1 is the predominant beta isoform present or associated with either alpha 1 or alpha 3. However, a kinetic difference in K+/Na+ antagonism due to distinct beta s may apply to alpha 3 of axolemma (alpha 3 beta 1) and pineal gland (alpha 3 beta 2).	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL, CINCINNATI, OH 45267 USA	McGill University; University System of Ohio; University of Cincinnati			Therien, Alex/AAS-8437-2021					ABBOTT A, 1993, BIOCHEMISTRY-US, V32, P3511, DOI 10.1021/bi00064a040; AKERA T, 1985, EUR J PHARMACOL, V111, P147, DOI 10.1016/0014-2999(85)90751-4; BERREBIBERTRAND I, 1994, FEBS LETT, V348, P55, DOI 10.1016/0014-5793(94)00550-8; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; Blostein R, 1989, CURR OPIN CELL BIOL, V1, P746, DOI 10.1016/0955-0674(89)90044-6; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CENA V, 1987, J BIOL CHEM, V262, P14467; CHOW DC, 1995, J EXP BIOL, V198, P1; DUNHAM PB, 1992, COMP BIOCHEM PHYS A, V102, P625, DOI 10.1016/0300-9629(92)90715-3; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FOUSSARDGUILBERT F, 1982, BIOCHIM BIOPHYS ACTA, V692, P296, DOI 10.1016/0005-2736(82)90534-X; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1993, J BIOL CHEM, V268, P17930; LYTTON J, 1985, J BIOL CHEM, V260, P1177; Markwell M A, 1981, Methods Enzymol, V72, P296; MARTIN DW, 1992, J BIOL CHEM, V267, P23922; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; MUNZER JS, 1994, SODIUM PUMP, P464; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PERIYASAMY SM, 1983, J BIOL CHEM, V267, P23922; SACHS JR, 1977, J PHYSIOL-LONDON, V273, P489, DOI 10.1113/jphysiol.1977.sp012106; SACHS JR, 1986, J PHYSIOL-LONDON, V374, P221, DOI 10.1113/jphysiol.1986.sp016076; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, CAN J PHYSIOL PHARM, V70, pS255, DOI 10.1139/y92-269; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; XU ZC, 1992, AM J PHYSIOL, V263, pC1007	48	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7104	7112		10.1074/jbc.271.12.7104	http://dx.doi.org/10.1074/jbc.271.12.7104			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636145	hybrid			2022-12-27	WOS:A1996UB15700080
J	Baumgart, E; Fahimi, HD; Stich, A; Volkl, A				Baumgart, E; Fahimi, HD; Stich, A; Volkl, A			L-lactate dehydrogenase A(4)- and A(3)B isoforms are bona fide peroxisomal enzymes in rat liver - Evidence for involvement in intraperoxisomal NADH reoxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; MALATE-DEHYDROGENASE; HYPOLIPIDEMIC DRUG; PROTEINS; LOCALIZATION; OXIDASE; BEZAFIBRATE; ASSOCIATION; CLOFIBRATE; BIOGENESIS	The subcellular localization of L-lactate dehydrogenase (LDH) in rat hepatocytes has been studied by analytical subcellular fractionation combined with the immunodetection of LDH in isolated subcellular fractions and liver sections by immunoblotting and immunoelectron microscopy. The results clearly demonstrate the presence of LDH in the matrix of peroxisomes in addition to the cytosol, Both cytosolic and peroxisomal LDH subunits have the same molecular mass (35.0 kDa) and show comparable cross-reactivity with an anti-cytosolic LDH antibody. As revealed by activity staining or immunoblotting after isoelectric focussing, both intracellular compartments contain the same liver-specific LDH-isoforms (LDH-A(4) > LDH-A(3)B) with the peroxisomes comprising relatively more LDH-A(3)B than the cytosol. Selective KCl extraction as well as resistance to proteinase K and immunoelectron microscopy revealed that at least 80% of the LDH activity measured in highly purified peroxisomal fractions is due to LDH as a bona fide peroxisomal matrix enzyme. In combination with the data of cell fractionation, this implies that at least 0.5% of the total LDH activity in hepatocytes is present in peroxisomes, Since no other enzymes of the glycolytic pathway (such as phosphoglucomutase, phosphoglucoisomerase, and glyceraldehyde-3-phosphate dehydrogenase) were found in highly purified peroxisomal fractions, it does not seem that LDH in peroxisomes participates in glycolysis, Instead, the marked elevation of LDH in peroxisomes of rats treated with the hypolipidemic drug bezafibrate, concomitantly to the induction of the peroxisomal beta-oxidation enzymes, strongly suggests that intraperoxisomal LDH may be involved in the reoxidation of NADH generated by the beta-oxidation pathway. The interaction of LDH and the peroxisomal palmitoyl-CoA beta-oxidation system could be verified in a modified beta-oxidation assay by adding increasing amounts of pyruvate to the standard assay mixture and recording the change of NADH production rates, A dose dependent decrease of NADH produced was simulated with the lowest NADH value found at maximal LDH activity. The addition of oxamic acid, a specific inhibitor of LDH, to the system or inhibition of LDH by high pyruvate levels (up to 20 mM) restored the NADH values to control levels. A direct effect of pyruvate on palmitoyl-CoA oxidase and enoyl-CoA hydratase was excluded by measuring those enzymes individually in separate assays. An LDH-based shuttle across the peroxisomal membrane should pro vide an efficient system to regulate intraperoxisomal NAD(+)/NADH levels and maintain the flux of fatty acids through the peroxisomal beta-oxidation spiral.	UNIV HEIDELBERG,INST ANAT & CELL BIOL 2,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Baumgart-Vogt, Eveline/I-5945-2013	Baumgart-Vogt, Eveline/0000-0002-8265-3763				AGOSTINI A, 1966, NATURE, V200, P1024; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BAUMGART E, 1989, J CELL BIOL, V108, P2221, DOI 10.1083/jcb.108.6.2221; BAUMGART E, 1994, PEROXISOMES, P37; BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184; BEIER K, 1988, EUR J CELL BIOL, V46, P383; Bergmeyer HU, 1983, METHOD ENZYMAT AN, V2, P211; BRDICZKA D, 1973, BIOCHIM BIOPHYS ACTA, V297, P203, DOI 10.1016/0304-4165(73)90066-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CATTANEO A, 1985, EXP CELL RES, V161, P130, DOI 10.1016/0014-4827(85)90497-5; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DANSCHER G, 1983, J HISTOCHEM CYTOCHEM, V31, P1394, DOI 10.1177/31.12.6631001; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EVERS J, 1973, ADV ENZYMOL, V28, P61; FAHIMI HD, 1982, ANN NY ACAD SCI, V386, P111, DOI 10.1111/j.1749-6632.1982.tb21410.x; FINE IH, 1963, BIOCHEMISTRY-US, V2, P116, DOI 10.1021/bi00901a020; FRNACO R, 1988, BIOCH INT, V16, P689; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUKASAWA KM, 1986, MOL BIOL EVOL, V3, P330; GEE R, 1974, ARCH BIOCHEM BIOPHYS, V161, P187, DOI 10.1016/0003-9861(74)90250-1; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; KLINE ES, 1986, ARCH BIOCHEM BIOPHYS, V246, P673, DOI 10.1016/0003-9861(86)90323-1; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LI SSL, 1989, BIOCHEM SOC T, V17, P304, DOI 10.1042/bst0170304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; MANN VM, 1992, COMP BIOCHEM PHYS B, V102, P561, DOI 10.1016/0305-0491(92)90048-V; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MAYER RJ, 1980, IMMUNOCHEMICAL METHO, P126; MCGROARTY E, 1974, ARCH BIOCHEM BIOPHYS, V161, P194, DOI 10.1016/0003-9861(74)90251-3; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MIDDELKOOP E, 1993, BIOCHIM BIOPHYS ACTA, V1220, P15, DOI 10.1016/0167-4889(93)90091-3; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; OSMUNDSEN H, 1982, INT J BIOCHEM, V14, P905, DOI 10.1016/0020-711X(82)90074-X; OSMUNDSEN H, 1994, BIOCHEM SOC T, V22, P436, DOI 10.1042/bst0220436; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; REHFELD DW, 1972, J BIOL CHEM, V247, P4803; SAKURABA H, 1995, J BIOL CHEM, V270, P37, DOI 10.1074/jbc.270.1.37; SCHRADER M, 1994, EUR J CELL BIOL, V64, P281; Sies H., 1982, METABOLIC COMPARTMEN, P205; SMALL GM, 1985, BIOCHEM J, V227, P205, DOI 10.1042/bj2270205; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669; TSUJI S, 1994, P NATL ACAD SCI USA, V91, P9392, DOI 10.1073/pnas.91.20.9392; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; VOLKL A, 1988, J HISTOCHEM CYTOCHEM, V36, P329, DOI 10.1177/36.4.3346536; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WILCKE M, 1995, J BIOL CHEM, V270, P6949, DOI 10.1074/jbc.270.12.6949; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5260, DOI 10.1073/pnas.82.16.5260; ZHONG XH, 1990, MOL CELL BIOL, V10, P770, DOI 10.1128/MCB.10.2.770; SIGMA TECHNICAL B, V340; SIGMA TECHNICAL B, V104	54	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3846	3855						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632003				2022-12-27	WOS:A1996TV72400077
J	Saxena, S; Allon, M				Saxena, S; Allon, M			The role of cytosolic calcium in chronic adaptation to phosphate depletion in opossum kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR MECHANISMS; REABSORPTION; INHIBITION; EXPRESSION; EVOLUTION; TRANSPORT; GENE; CDNA; RNA; RAT	Chronic dietary phosphate restriction is associated with up-regulation of sodium-dependent phosphate (Na/P-i) cotransport by renal proximal tubular epithelial cells in association with increases in Na/P-i cotransporter mRNA and protein. We investigated whether changes in cytosolic calcium mediate this adaptive response in opossum kidney cells, a continuous line of renal epithelial cells, After 24 h of phosphate depletion, steady-state cytosolic calcium levels were increased; this increase was observed at physiologic levels of phosphate restriction and was prevented by the calcium channel blocker verapamil, Chronic phosphate depletion was also associated with parallel increases in Na/P-i cotransport activity, Na/P-i cotransporter mRNA, and Na/P-i cotransporter protein, all of which were blocked in verapamil-treated cells, Actinomycin D, at a dose that prevented the increase in NaPi-4 mRNA during phosphate depletion, also prevented the increase in Na/P-i cotransport activity, Incubation with the calcium ionophore ionomycin or A23187 reproduced the increase in Na/P-i cotransporter mRNA in phosphate-replete cells, Conversely, chelation of cytosolic calcium by quin-2/AM prevented the increase in Na/P-i cotransporter mRNA in phosphate-depleted cells, The effect of an increase in cytosolic calcium was specific for the Na/P-i cotransporter as mRNA levels for the sodium-dependent glucose transporter were not affected. Our observations suggest that chronic phosphate restriction increases steady-state cytosolic calcium, which, in turn, increases transcription of Na/P-i cotransporter mRNA, thereby stimulating Na/P-i cotransport activity.	UNIV ALABAMA,CTR NEPHROL RES & TRAINING,BIRMINGHAM,AL; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ALLON M, 1993, AM J PHYSIOL, V264, pF404, DOI 10.1152/ajprenal.1993.264.3.F404; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; HAYES G, 1994, J BIOL CHEM, V269, P24143; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KIERSZTEJN M, 1992, J AM SOC NEPHROL, V2, P1484; LEVI E, 1992, ENDOCRINOLOGY, V131, P2182, DOI 10.1210/en.131.5.2182; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; MASSRY SG, 1991, AM J PHYSIOL, V260, pF12, DOI 10.1152/ajprenal.1991.260.1.F12; MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; SAXENA S, 1995, BIOCHEM BIOPH RES CO, V216, P141, DOI 10.1006/bbrc.1995.2602; SMOGORZEWSKI M, 1995, KIDNEY INT, V47, P1182, DOI 10.1038/ki.1995.168; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEINSTOCK RS, 1993, AM J PHYSIOL, V264, pE519, DOI 10.1152/ajpendo.1993.264.4.E519; WEIR MR, 1992, TRANSPLANTATION, V54, P681, DOI 10.1097/00007890-199210000-00023; WERNER A, 1994, J BIOL CHEM, V269, P6637; YANG JP, 1993, MOL ENDOCRINOL, V7, P753, DOI 10.1210/me.7.6.753	21	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3902	3906						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632011				2022-12-27	WOS:A1996TV72400085
J	Sha, Q; Romano, C; Lopatin, AN; Nichols, CG				Sha, Q; Romano, C; Lopatin, AN; Nichols, CG			Spermidine release from Xenopus oocytes - Electrodiffusion through a membrane channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE RECEPTOR ACTIVATION; POLYAMINE-TRANSPORT-SYSTEM; ESCHERICHIA-COLI; ION CHANNELS; INVIVO; CELLS	The mechanism of spermidine release from Xenopus oocytes was examined by measuring release of radioactive [H-3]spermidine under different ionic conditions, and under voltage clamp. In normal solution (2 mM K+), the efflux rate is less than 1% per hour, and is stimulated similar to 2-fold by inclusion of Ca2+ (1 mM) in the incubation medium. Spermidine efflux is stimulated similar to 10-fold in high [K+] (KD98) solution, In KD98 solution, efflux is strongly inhibited by divalent cations (K-i for Ba2+ block of spermidine efflux is similar to 0.1 mM), but not by tetraethyl-ammonium ions or verapamil, Spermidine efflux rates were not different between control oocytes and those expressing HRK1 inward rectifier K+ (Kir) channels. When the membrane potential was clamped, either by changing external [K+] in oocytes expressing HRK1, or by 2-microelectrode voltage-clamp, spermidine efflux was shown to be strongly dependent on voltage, as expected for a simple electrodiffusive process, where spermidine(3+) is the effluxing species, This result argues against spermidine diffusing out as an uncharged species, or in exchange for similarly charged counterions. These results are the first conclusive demonstration of a simple electrodiffusive pathway for spermidine efflux from cells.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Nichols, Colin/D-6336-2012		NATIONAL EYE INSTITUTE [R01EY009370, P30EY002687] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER; NEI NIH HHS [EY02687, EY09370] Funding Source: Medline; NHLBI NIH HHS [HL54171] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BYERS TL, 1990, BIOCHEM J, V269, P35, DOI 10.1042/bj2690035; FAGE D, 1993, J NEUROCHEM, V61, P261; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GILAD GM, 1991, EUR J PHARMACOL, V193, P41, DOI 10.1016/0014-2999(91)90198-Y; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; IGARASHI K, 1995, J PHARMACOL EXP THER, V272, P1101; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; KANO K, 1976, J BIOL CHEM, V251, P2795; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KHAN NA, 1990, BIOCHEM INT, V21, P607; KHAN NA, 1991, CELL BIOL INT REP, V15, P9, DOI 10.1016/0309-1651(91)90078-W; KHAN NA, 1992, EXP CELL RES, V199, P378, DOI 10.1016/0014-4827(92)90448-H; KHAN NA, 1994, NEUROPHARMACOLOGY PO, P37; KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MACKAREL AJ, 1994, BIOCHEM SOC T, V22, pS388, DOI 10.1042/bst022388s; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MINOCHA SC, 1990, J CHROMATOGR, V511, P177, DOI 10.1016/S0021-9673(01)93283-2; NICOLAS C, 1994, J NEUROCHEM, V62, P1835; POULIN R, 1995, J BIOL CHEM, V270, P1695, DOI 10.1074/jbc.270.4.1695; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; SAUNDERS NA, 1989, J CELL PHYSIOL, V139, P624, DOI 10.1002/jcp.1041390324; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; SHAW GG, 1994, NEUROPHARMACOLOGY PO, P61; SMITH MA, 1985, PLANT PHYSIOL, V78, P89, DOI 10.1104/pp.78.1.89; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; USHERWOOD PNR, 1994, NEUROPHARMACOLOGY PO, P167; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; YANG XC, 1990, J PHYSIOL-LONDON, V431, P103, DOI 10.1113/jphysiol.1990.sp018322	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3392	3397						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631938				2022-12-27	WOS:A1996TV72400012
J	Wei, K; Huber, BE				Wei, K; Huber, BE			Cytosine deaminase gene as a positive selection marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-TRANSCARBAMYLASE; COLORECTAL-CARCINOMA; ANTITUMOR-ACTIVITY; MAMMALIAN-CELLS; N-(PHOSPHONACETYL)-L-ASPARTATE; THERAPY; 5-FLUOROCYTOSINE; MECHANISM	Cytosine deaminase (EC 3.5.4.1), a non-mammalian enzyme, catalyzes the deamination of cytosine and 5-fluorocytosine to form uracil and 5-fluorouracil, respectively. Eukaryotic cells have been genetically modified with a bacterial cytosine deaminase gene to express a functional enzyme, When the genetically modified cells are combined with 5-fluorocytosine, it creates a potent negative selection system, which may have important applications in cancer gene therapy, In this paper, we introduce a novel positive selection method based upon the expression of the cytosine deaminase gene, This method utilizes inhibitors in the pyrimidine de novo synthesis pathway to create a condition in which cells are dependent on the conversion of pyrimidine supplements to uracil by cytosine deaminase, Thus, only cells expressing the cytosine deaminase gene can be rescued in a positive selection medium.	WELLCOME RES LABS,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories								AUSTIN EA, 1993, MOL PHARMACOL, V43, P380; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DOMIN BA, 1993, BIOCHEM PHARMACOL, V46, P503, DOI 10.1016/0006-2952(93)90527-4; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; HOOGENRAAD NJ, 1974, ARCH BIOCHEM BIOPHYS, V161, P76, DOI 10.1016/0003-9861(74)90236-7; HUBER BE, 1993, CANCER RES, V53, P4619; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P3302; JOHNSON RK, 1977, BIOCHEM PHARMACOL, V26, P81, DOI 10.1016/0006-2952(77)90137-X; KARLE JM, 1981, P AM ASSOC CANC RES, V22, P204; KATSURAGI T, 1989, AGR BIOL CHEM TOKYO, V53, P1313, DOI 10.1080/00021369.1989.10869490; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MOORE CE, 1982, BIOCHEM PHARMACOL, V31, P3317; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; NOVICKI DL, 1983, IN VITRO CELL DEV B, V19, P191; PORTER DJT, 1993, J BIOL CHEM, V268, P24005; RICHARDS CA, 1995, HUM GENE THER, V6, P881, DOI 10.1089/hum.1995.6.7-881; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TSUBOI KK, 1977, CANCER RES, V37, P3080	22	14	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3812	3816						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631998	hybrid			2022-12-27	WOS:A1996TV72400072
J	Yockey, CE; Smith, G; Izumo, S; Shimizu, N				Yockey, CE; Smith, G; Izumo, S; Shimizu, N			cDNA cloning and characterization of murine transcriptional enhancer factor-1-related protein 1, a transcription factor that binds to the M-CAT motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; HEAVY-CHAIN GENE; FACTOR-I TEF-1; DNA-BINDING; BETA-GENE; MAMMALIAN-CELLS; ACTIVATION; DISTINCT; MOUSE; DOMAIN	The M-CAT motif is a cis-regulatory DNA sequence that is essential for muscle-specific transcription of several genes. Previously, we had shown that both muscle-specific (A1) and ubiquitous (A2) factors bind to an essential M-CAT motif in the myosin heavy chain beta gene and that the ubiquitous factor is transcriptional enhancer factor (TEF)-1. Here we report the isolation of mouse cDNAs encoding two forms (a and b) of a TEF-1-related protein, TEFR1. The TEFR1a cDNA encodes a 427-amino acid protein. The coding region of TEFR1b is identical to 1a in both nucleotide and predicted amino acid sequence except for the absence of 43 amino acids downstream of the TEA DNA-binding domain. Three TEFR1 transcripts (similar to 7, similar to 3.5, and similar to 2 kilobase pairs) are enriched in differentiated skeletal muscle (myotubes) relative to undifferentiated skeletal muscle (myoblasts) and non-muscle cells in culture. In situ hybridization analysis indicated that TEFR1 transcripts are enriched in the skeletal muscle lineage during mouse embryogenesis. Transient expression of fusion proteins of TEFR1 and the yeast GAL4 DNA-binding domain in cell lines activated the expression of chloramphenicol acetyltransferase (CAT) reporter constructs containing GAL4 binding sites, indicating that TEFR1 contains an activation domain. An anti-TEFR1 polyclonal antibody supershifted the muscle-specific M-CAT-A1 factor complex in gel mobility shift assays, suggesting that TEFR1 is a major component of this complex. Our results suggest that TEFR1 might play a role in the embryonic development of skeletal muscle in the mouse.	UNIV S CAROLINA,SCH MED,DEPT ANAT & DEV BIOL,COLUMBIA,SC 29208; BETH ISRAEL HOSP,DIV MOLEC MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041893] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41893] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRIGERIO JM, 1995, HUM MOL GENET, V4, P37, DOI 10.1093/hmg/4.1.37; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Miller J. H, 1972, EXPT MOL GENETICS; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEYDERT A, 1987, CELL, V49, P121, DOI 10.1016/0092-8674(87)90762-8; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; 1991, PROGRAM MANUAL GCG P	57	46	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3727	3736						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631987	hybrid			2022-12-27	WOS:A1996TV72400061
